2014 ACR/ARHP Program Book

Transcription

program
book
2 0 1 4
Pre-meeting Courses: Friday, November 14 – Saturday, November 15, 2014
Annual Scientific Sessions: Saturday, November 15 – Wednesday, November 19, 2014
Exhibits: Sunday, November 16 – Tuesday, November 18, 2014
IMPORTANT LOCATIONS
ACR Office . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 260; Telephone: (617) 954-3940
Attendee Lounge. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Ballroom Lobby
Business Center. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Level 1: North Lobby
Career Connection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Exhibit Hall A: Discovery Center (Booth #731)
Child Care. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Call for Location; Telephone: (617) 954-3451
Coat/Baggage Check. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Level 1: Northeast Lobby A (near 154)
Concierge Center. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Level 1: North Lobby
Discovery Center. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Exhibit Hall A (Booth #731)
Exhibit Hall. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Exhibit Hall A
First Aid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Level 1: North Lobby
Foundation Booth. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Exhibit Hall A: Discovery Center (Booth #731)
Foundation Donors’ Lounge. . . . . . . . . . . . . . . . . . . . . . . . . . . Boardroom (Suite 201)
Hotel Reservations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Exhibit Level: Registration
Industry-Supported Symposia Information . . . . . . . . . . . . . . Level 1: North Lobby
Innovation Theater . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Exhibit Hall A (Booths #139 and #1401)
Lost and Found . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ACR Office (260)
Membership Booth. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Exhibit Level: Registration
Newsroom . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 252; Telephone: (617) 954-3943
Nursing Mothers’ Room. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 162-A
Overflow Rooms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109, 204 and 259
Poster Hall . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Exhibit Hall B
Prayer Room . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106
Recharge Areas . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Attendee Lounge, Technology Center
and Wi-Fi Way
Registration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Exhibit Level: East Registration
Restaurant Reservations. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Level 1: North Lobby
Ribbon Distribution. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Exhibit Level: Registration
Shuttle Bus. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Level 1 (near 156)
Simple Tasks. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Exhibit Hall A: Discovery Center (Booth #731)
Speaker Ready Room . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 206
Technology Center. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Level 1: North Lobby
Visitor Information. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Level 1: North Lobby
Wheelchairs. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . O
rder through ScootAround, Inc.;
Telephone: (888) 441-7575
Wi-Fi Way . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Exhibit Hall A
Special Needs
If you require special arrangements, please contact the ACR Office (260); Telephone: (617) 954-3940.
Emergency Contact Information
Space is provided on the back of your badge to list name and telephone numbers of your emergency
contacts. Please complete this information before inserting your badge in your badge holder.
*All important locations are located in the Boston Convention
and Exhibition Center.
2 0 1 4
program
book
ABOUT THE ANNUAL MEETING
Participation Statement
This Annual Meeting is sponsored by the American College of Rheumatology for educational purposes only. The material
presented is not intended to represent the only or the best methods appropriate for the medical conditions being discussed,
but rather is intended to present the opinions of the authors or presenters, which may be helpful to other healthcare
professionals arriving at their own conclusions and consequent application. Attendees participating in this medical
education program do so with full knowledge that they waive any claim they may have against the College for reliance on
any information presented during these educational activities. The College does not guarantee, warrant or endorse any
commercial products or services.
The ACR’s CME purpose is to provide comprehensive education to improve the knowledge and performance of physicians,
scientists and other health professionals in order to improve the quality of care in those with or at risk for arthritis and
rheumatic and musculoskeletal diseases.
The Annual Meeting program’s content was developed through a planning process that included a practice gap analysis that
identified educational needs in knowledge, competence and/or performance. Planners took professional activities, practice
setting, ABIM recertification requirements and physician attributes into account and have designed this activity to obtain
desired outcomes in terms of improved physician competence and performance.
Global Learning Objectives
At the conclusion of the 2014 ACR/ARHP Annual Meeting, participants should be able to:
• Identify recent developments in the diagnosis and management of patients with rheumatic diseases;
• Outline new technologies for the treatment of rheumatologic problems;
• D
escribe potential challenges in the delivery of care to patients with rheumatic diseases and to specify possible
solutions;
• Utilize new research data to improve the quality of care of patients with rheumatic diseases; and
• Summarize recent rheumatology research findings.
Printing of this publication is supported by Amgen, Inc.
This publication was printed by an FSC validated printer on eco-friendly paper.
TABLE OF CONTENTS
POLICIES
Copyright Materials Policy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
Photographs and Video Recording Policy . . . . . . . . . . . . . . . . . . . . . . . . . . 11
Media. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
Embargo Policy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
Abstract Reprint Policy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
MEETING INFORMATION
Cell Phones, PDAs & Other Electronic Devices . . . . . . . . . . . . . . . . . . . . . . 13
Children . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
Child Care. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
Nursing Mothers’ Room . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
Exhibit Hall. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
Meeting Room Capacity/Imortant First Safety Information. . . . . . . . . . . . 13
Photoograpy and Videotaping . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
Name Badges. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
No Smoking . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
MEETING NAVIGATION GUIDE
Tracks and State CME Designations. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
Session Formats. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
Abstract Formats. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
ACR Basic Research Conference: Emerging Perspectives
on the Microbiome in the Rheumatic Diseases – Day One of Two. . . . . . 23
ACR Clinical Research Conference: Patient-Centered Outcomes
in Rheumatology – Day One of Two . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
ACR/ABIM Maintenance of Certification Learning Session –
2014 Update in Rheumatology. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
Saturday, November 15, 2014
Pre-Meeting Courses
ACR Musculoskeletal Ultrasound Course for Rheumatologists –
Day Two of Two. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
ACR Clinical Research Conference: Patient-Centered Outcomes
in Rheumatology – Day Two of Two . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
ACR Practice Management Pre-meeting Course. . . . . . . . . . . . . . . . . . . . . 27
ACR Review Course. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
ACR Basic Research Conference: Emerging Perspectives
on the Microbiome in the Rheumatic Diseases – Day Two of Two. . . . . . 29
ARHP Clinical Focus Course: Diagnostic Imaging Use in Differential
Diagnosis for Common Rheumatic and Musculoskeletal Conditions. . . . 30
AAMC Medical Education Research Certificate (MERC) Workshop. . . . . . 31
Scientific Sessions
Abstract Categories. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
ACR/ARHP Opening Lecture and Awards
MEETING SERVICES
Opening Lecture: P4 Medicine Is Transforming Health Care:
A Longitudinal, Framingham-like Study of 100,000 Well Patients
Over 20-25 Years. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
Annual Meeting App. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
Discovery Center. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
Membership Booth. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
Lost and Found. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
ACR/ARHP Opening Reception. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
Sunday, November 16, 2014
Newsroom . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
ACR Sessions
Attendee Lounge. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
Age Before Beauty: Colchicine, Aspirin, Methotrexate
and Their Mechanisms of Action. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
Concierge Center. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
Registration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
Pediatric Rheumatology Town Hall. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
Shuttle Bus. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
Year in Review . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
Speaker Ready Room. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
ACR/ARHP Networking Event
Wi-Fi Way and Recharge Access. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
ACR/ARHP First-time Attendee Orientation. . . . . . . . . . . . . . . . . . . . . . . . . 32
Rheumatology Research Foundation Donors’ Lounge . . . . . . . . . . . . . . . . 20
ACR Meet the Professor Sessions
SPECIAL OFFERS
Basic Immunology for Clinical Rheumatologists (001). . . . . . . . . . . . . . . . 32
SessionSelect. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
What Would Make the Meeting Better?. . . . . . . . . . . . . . . . . . . . . . . . . . . 20
Medical Bag. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
POSTER SESSIONS
Poster Session Presenter Instructions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
Poster Presenter No-shows. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
Guided Poster Tours. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
ACR/ARHP Annual Meeting Program
Pre-Meeting Program
Friday, November 14, 2014
Pre-Meeting Courses
Day One of Two. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
2
ACR Advanced Rheumatology Coding Course:
Developing Experts in Rheumatology Coding and ICD-10-CM. . . . . . . . . 23
2014 Program Book
Crystal: Diagnosis and Management of Gout (002) . . . . . . . . . . . . . . . . . . 32
Cutaneous Vasculitis (003) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
Fibromyalgia 2014: Update on Management (004) . . . . . . . . . . . . . . . . . . 33
Macrophage Activation Syndrome (005). . . . . . . . . . . . . . . . . . . . . . . . . . . 33
Pain: Evaluation and Treatment of Back Pain (006) . . . . . . . . . . . . . . . . . . 33
Psoriatic Arthritis (007). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
Reactive Arthritis: An Update (008). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
Rheumatoid Arthritis: Challenging Cases (009). . . . . . . . . . . . . . . . . . . . . . 33
Systemic Lupus Erythematosus: Difficult to Treat
Systemic Lupus Erythematosus (010). . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
ACR Workshops
Joint Injection Techniques (201). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
Nail Calicoscopy (202). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
Tai Chi in Rheumatic Disease (203). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
TABLE OF CONTENTS
ACR Sessions
Systemic Lupus Erythematosus: Novel Treatments (017). . . . . . . . . . . . . . 43
CARE: Maintenance of Certification
Session One of Three – Vasculitits. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
Vaccinations for Patients on Biologic Therapies (018) . . . . . . . . . . . . . . . . 43
Current Understanding of Malignancies
in Connective Tissue Diseases. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
What is Not Central Nervous Angiitis:
Making the Right Diagnosis (020). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
Ethics and Rheumatology. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
ACR Sessions
Informative and Critical Peer Review for the ACR Journals:
A Guide to Providing Excellent Peer Review of Manuscripts . . . . . . . . . . 34
Osteoporosis: Current Concepts for the Clinician. . . . . . . . . . . . . . . . . . . . 35
Practice Issues: Health Care Bounty Hunters:
A Closer Look at RACs, Audits and Medical Documentation. . . . . . . . . . . 35
The Microbiome in Health and Disease. . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
When Pills Are Not Enough: Multidisciplinary Approaches
to Pediaric Pain and Hyperrmobility. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
Vasculitis: Update (019). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
ACR Knowledge Bowl: Preliminary Round. . . . . . . . . . . . . . . . . . . . . . . . . . 42
Avoiding Electronic Health Record Errors
and Their (Sometimes) Critical Consequences. . . . . . . . . . . . . . . . . . . . . . 44
Axial Spondyloarthritis Guidelines. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
Gout Management in 2014. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
How the Gut Primes the Immune System. . . . . . . . . . . . . . . . . . . . . . . . . . 44
Practice Issues: The Road to I10. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
Abstracts (#1-814). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
Rheumatology Research Foundation Memorial Lectureship
to Honor Dr. Stephen E. Malawista, MD: Innate Immunity
at the Core of Rheumatic Disease. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
ACR Sessions
The Butterfly Effect: Lupus Rashes and Their Mimics. . . . . . . . . . . . . . . . . 45
ACR Immunology Update: New Immunology
of the Spondyloarthropathies. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
ACR Workshops
Advocacy: Meet the Expert. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
Sarcoidosis in 2014 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
Clinical Anatomy and Physical Exam: Essential Tools
in Lower Extremity Regional Pain Syndromes (209) . . . . . . . . . . . . . . . . . 45
ACR Poster Session A and Poster Tours
Advanced Musculoskeletal Ultrasound (208) . . . . . . . . . . . . . . . . . . . . . . . 45
Social Media Boot Camp: Twitter Basics . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
ACR Sessions
ARHP Sessions
Autoimmunity in Immunodeficiency. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
ARHP Keynote Address: Happiness From the Inside Out. . . . . . . . . . . . . . 37
Educator: Medical Education: The Year in Review . . . . . . . . . . . . . . . . . . . 45
Exhbits and Innovation Theater
New Frontiers in Osteoarthritis Treatment:
The Role of Weight Loss, Surgery
and Current Treatment Guidelines. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
See page 238 for the complete Innovation Theater Listing.
ACR Workshops
Beyond Musculoskeletal Ultrasound for Rheumatologists (204). . . . . . . . 37
Clinical Anatomy and Physical Exam:
Essential Tools in Upper Extremity Regional Pain Syndromes (205). . . . . 37
Histopathology of Rheumatic Lung Disease (206). . . . . . . . . . . . . . . . . . . .38
Synovial Fluid Analysis and Crystal Identification (207). . . . . . . . . . . . . . . 38
ACR Sessions
Bone Biology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
New ACR Recommendations for the Management
of Rheumatoid Arthritis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
ARHP Sessions
The Great Debate: Belimumab for the Treatment
of Systemic Lupus Erythematosus. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
ACR Concurrent Abstract Sessions
Epidemiology and Public Health I:
Drug and Vaccine Safety (#820-825). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
Metabolic and Crystal Arthropathies I:
Clinical Aspects (#826-831). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
Miscellaneous Rheumatic and Inflammatory Diseases (#832-837). . . . . . 47
Rheumatoid Arthritis – Clinical Aspects I:
Cardiovascular Disease Risk (#838-843). . . . . . . . . . . . . . . . . . . . . . . . . . . 48
Immunology Boot Camp I: The Basics of Targeted Therapies . . . . . . . . . . 38
Rheumatoid Arthritis – Small Molecules, Biologics
and Gene Therapy I: Safety of Biologics and Small Molecules
in Rheumatoid Arthritis – Malignancy and Infection (#844-849). . . . . . . 48
What Can Brain Imaging Tell Us About Pharmacologic
and Non-Pharmacologic Treatment of Chronic Pain?. . . . . . . . . . . . . . . . 38
Spondylarthropathies and Psoriatic Arthritis I –
Novel Treatments Axial Spondyloarthritis (#850-855). . . . . . . . . . . . . . . . 49
ACR Plenary Session I: Discovery 2014
Systemic Lupus Erythematosus – Animal Models (#856-861). . . . . . . . . . 50
Affordable Care Act. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
Abstracts (#815-819). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
ARHP Networking Event
ARHP Networking Forum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
Ankylosing Spondylitis: 2014 Update (011). . . . . . . . . . . . . . . . . . . . . . . . . 43
Ankylosing Spondylitis: Disease Modification (012). . . . . . . . . . . . . . . . . . 43
Dermatological Manifestations of Rheumatic Diseases (013). . . . . . . . . . 43
Systemic Lupus Erythematosus – Clinical Aspects and Treatment:
Cardiovascular Disease and Pregancy (#862-867). . . . . . . . . . . . . . . . . . . 50
Systemic Lupus Erythematosus – Human Etiology
and Pathogenesis I: Pathways of Inflammation/Injury (#868-873). . . . . . 51
Systemic Sclerosis, Fibrosing Syndromes and Raynaud’s –
Clinical Aspects and Therapeutics I: Systemic Sclerosis,
Advances in Therapy (#874-879). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
Vasculitis I (#880-885). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
Hereditary Angioedema Update (014). . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
ARHP Sessions
Pediatric Systemic Lupus Erythematosus (015). . . . . . . . . . . . . . . . . . . . . . 43
Google Minefield: Empowering Patients
to Evaluate Online Resources . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
Rheumatoid Arthritis: Biological Agents (016) . . . . . . . . . . . . . . . . . . . . . . 43
2014 Program Book
3
TABLE OF CONTENTS
Practical Practice Management Session One: Improve Quality
and Efficiency . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
Sports Medicine for the Rheumatology Provider. . . . . . . . . . . . . . . . . . . . 53
ACR/ARHP Combined Abstract Session:
Epidemiology and Public Health (#970-975) . . . . . . . . . . . . . . . . . . . . . . . 67
Young Adults with Rheumatic Disease: The Patient Perspective. . . . . . . . 54
ARHP Sessions
ARHP Concurrent Abstract Session
Exemplary Abstracts (#886-891). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
ACR Workshops
Magnetic Resonance Imaging in the Diagnosis
and Management of Spondyloarthritis: A Clinician’s Guide (210). . . . . . 55
“Say What?”: Implications of Adolescent Development
and Behavior in Communicating With Health Care Providers. . . . . . . . . .68
Current Trends in Self-Management and Rheumatologic Care:
mHealth, eHealth, Digital Technology and Emerging
Ethical Considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
Muscle Involvement in Rheumatic Diseases (211). . . . . . . . . . . . . . . . . . . 55
Multidisciplinary Management of Scleroderma. . . . . . . . . . . . . . . . . . . . . 68
Osteoporosis: Interpreting Dual Energy X-Ray Absorptiometry
and Clinical Risk Factors: The New Fracture Risk Assessment
Algorithm (212). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
Physical Examination Skills for Improved Detection
of Synovitis and Cervical Thoracolumbar Disorders (213). . . . . . . . . . . . . 55
ACR Sessions
Therapeutic Targeting of the Innate Immune System. . . . . . . . . . . . . . . . . 55
Thieves’ Market: Show Me Your Best Cases . . . . . . . . . . . . . . . . . . . . . . . . 55
Fibromyalgia, Soft Tissue Disorders, Regional and Specific
Clinical Pain Syndromes I: Research Perspectives (#892-897) . . . . . . . . . 56
Health Services Research: Risk Assessment and Outcomes
of Rheumatic Disease (#898-903). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56
Imaging of Rheumatic Diseases: Ultrasound (#904-909). . . . . . . . . . . . . . 57
Muscle Biology,Myositis and Myopathies (#910-915) . . . . . . . . . . . . . . . . 58
Osteoporosis and Metabolic Bone Disease – Clinical Aspects
and Pathogenesis: Clinical Osteoporosis: Treatment
and Safety (#916-921) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
Pain: Basic and Clinical Aspects I (#922-927). . . . . . . . . . . . . . . . . . . . . . . . 59
Pediatric Rheumatology – Clinical and Therapeutic Aspects:
Juvenile Idiopathic Arthritis (#928-933). . . . . . . . . . . . . . . . . . . . . . . . . . . 60
Practical Practice Management Session Two:
Navigate HIPAA and Prevent Audits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
Osteoarthritis (#976-981). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
Industry-Supported Post-Meeting Symposia. . . . . . . . . . . . . . . . . . . 69
Monday, November 17, 2014
ACR Sessions
Educator: Cultivating the Competent Medical Educator:
A Growing Concern. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
Meniscus Biology in Osteoarthritis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
Rheumatology Research Foundation Paul Klemperer, MD
Memorial Lectureship: Gene-Environment Interactions as a Basis
for Unravelling Adaptive Immunity and Preparing for Tolerizing
Therapies in Rheumatoid Arthritis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
ARHP Sessions
Stats Boot Camp: The Effect Size: What Is It
and How Can You Use It?. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
Update on Findings from Large Registries:
Emphasis on Health Disparities in Rheumatioid Arthritis. . . . . . . . . . . . . 70
What Are Biosimilars?. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
Rheumatoid Arthritis – Animal Models I (#934-939) . . . . . . . . . . . . . . . . . 61
Rheumatoid Arthritis – Clinical Aspects II: Remission
and De-escalation of Therapy (#940-945) . . . . . . . . . . . . . . . . . . . . . . . . . 61
Ankylosing Spondylitis: 2014 Update (031). . . . . . . . . . . . . . . . . . . . . . . . . 70
and Gene Therapy II: Novel Therapies in Rheumatoid Arthritis –
Early in Development (#946-951). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
Controversies in Sjögren’s Syndrome (033). . . . . . . . . . . . . . . . . . . . . . . . . 70
Spondylarthropathies and Psoriatic Arthritis II –
Novel Treatments Psoriatic Arthritis (#952-957). . . . . . . . . . . . . . . . . . . . 63
Systemic Lupus Erythematosus –
Clinical Aspects and Treatment: Lupus Nephritis (#958-963). . . . . . . . . . 63
Pathogenesis, Animal Models and Genetics I (#964-969). . . . . . . . . . . . . 65
Crystal: Diagnosis and Management of Gout (021) . . . . . . . . . . . . . . . . . . 66
Infections with Biologics (022). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66
Inflammatory Eye Disease/Uveitis (023). . . . . . . . . . . . . . . . . . . . . . . . . . . 66
Pediatrics: Difficult to Treat Juvenile Idiopathic Arthritis (024). . . . . . . . . 66
Polymyalgia Rheumatica (025). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66
Pulmonary Hypertension in the Rheumatic Diseases (026). . . . . . . . . . . . 66
Rheumatology Practice 101:
Starting Out in Practice for the Graduating Fellow (028) . . . . . . . . . . . . . 67
Systemic Lupus Erythematosus: Novel Treatments (029). . . . . . . . . . . . . . 67
Vitamin D and Bone Health (030). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67
4
ACR/ARHP Combined Abstract Session
2014 Program Book
Basic Immunology for Clinical Rheumatologists (032). . . . . . . . . . . . . . . . 70
Dermatological Manifestations of Rheumatic Diseases (034). . . . . . . . . . 70
Osteoarthritis: Update 2014 (035). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71
Pregnancy and Rheumatic Diseases (036). . . . . . . . . . . . . . . . . . . . . . . . . . 71
Reactive Arthritis: An Update (037). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71
Systemic Lupus Erythematosus:
Difficult to Treat Systemic Lupus Erythematosus (039). . . . . . . . . . . . . . . 71
Vasculitis: Update (040). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71
ACR/ARHP Workshops
Advanced Musculoskeletal Ultrasound (214) . . . . . . . . . . . . . . . . . . . . . . . 71
Complementary and Alternative Therapies
in Rheumatic Disease (215). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71
Osteoporosis: Interpreting Dual Energy X-Ray Absorptiometry
and Clinical Risk Factors: The New Fracture Risk Assessment
Algorithm (216). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72
The Rheumatologic Musculoskeletal Screening Exam,
with Emphasis on Objective Disease-Specific Measurements (217) . . . . 72
TABLE OF CONTENTS
ACR Sessions
Psoriatic Arthritis (043). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81
CARE: Maintenance of Certification Session Two of Three . . . . . . . . . . . . 72
Hot Topics in Rheumatoid Arthritis: Comparative Effectiveness
and Harms of Biologics, and Management of Disease-modifying
Antirheumatic Drugs (DMARDs) and Biologics in the
Perioperative Period. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72
Juvenile Dermatomyositis: Clinical, Pathogenic
and Therapeutic State of the Art. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72
Systemic Sclerosis: Disease Staging and Subsetting
in Clinical Practice (049). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82
Practical Use of Registries. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73
Practice Issues: Practice Success in an Environment of Transition . . . . . . 73
Strategies for Academic Success:
The Roadmap From Mentee to Mentor. . . . . . . . . . . . . . . . . . . . . . . . . . . 73
Systems Biology of Lupus Nephritis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73
The ACR Gout Management Guidelines:
Have They Gotten Us to Where We Want to Be?. . . . . . . . . . . . . . . . . . . . 74
Scleroderma Mimics (046) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82
Still’s Disease and Autoinflammatory Syndromes (047). . . . . . . . . . . . . . . 82
Systemic Lupus Erythematosus: Central Nervous System (048) . . . . . . . . 82
Vasculitis Mimics (050) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82
ACR Sessions
Classification Criteria for Gout. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82
Classification Criteria for Myositis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83
Neonatal Lupus: From Bench to Bedside. . . . . . . . . . . . . . . . . . . . . . . . . . . 83
Rheumatology On the Street . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83
Telomeres, Telomerase and the Aging Immune System. . . . . . . . . . . . . . . 83
ACR/ARHP Poster Session B, Thieves’ Market Posters
and Poster Tours
ACR Workshops
Abstracts (#982 – 1793) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74
Joint Injection Techniques (222). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83
ACR Sessions
Magnetic Resonance Imaging in the Diagnosis
and Management of Spondyloarthritis: A Clinician’s Guide (223). . . . . . 83
Functional Genomics of Rheumatoid Arthritis:
From Genes to Function to Therapy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75
Synovial Fluid Analysis and Crystal Identification (224). . . . . . . . . . . . . . . 83
Legislative Update: Chat with Congress. . . . . . . . . . . . . . . . . . . . . . . . . . . . 75
ACR Sessions
Prosthetic Device Infections, Or Infection as a Threat
to the Bionic Man. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75
Clinical Challenges in Sjögren’s Syndrome:
Neurological Complications and Lymphoma Risk . . . . . . . . . . . . . . . . . . . 84
Social Media Boot Camp: Blogging for Beginners. . . . . . . . . . . . . . . . . . . . 75
Forefronts in Lupus Nephritis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
ARHP Session
Insight into Lung Fibrosis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
ARHP Distinguished Lectuer: Maintaining Health
and Well-Being Despite Living with a Rheumatic Disease. . . . . . . . . . . . . 75
Epidemiology and Public Health II: Osteoarthritis,
Sedentary Behavior and more (#1800-1805). . . . . . . . . . . . . . . . . . . . . . . 84
See page 238 for the complete Innovation Theater Listing.
Health Services Research: Improving Clinical Practice (#1806-1811). . . . . . 85
ACR Workshops
Innate Immunity and Rheumatic Disease (#1812-1817) . . . . . . . . . . . . . . 85
Histopathology of Vasculitis (218) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76
Osteoarthritis – Clinical Aspects I: Imaging
in Osteoarthritis (#1818-1823) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86
Knee Braces, Foot Orthoses, and Shoe Gear
for Managing Knee Osteoarthritis (219). . . . . . . . . . . . . . . . . . . . . . . . . . . 76
Musculoskeletal Ultrasound (220). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76
Renal Histopathology in Systemic Lupus Erythematosus
and Vasculitis (221). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76
ACR Sessions
ACR Immunology Update: Innate Lymphoid Cells. . . . . . . . . . . . . . . . . . . . 76
ACR Knowledge Bowl: Final Round. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76
ARHP Sessions
Evidence of the Benefits and Risks of Cannabis
and Cannabinoids for Treating Chronic Pain. . . . . . . . . . . . . . . . . . . . . . . . 77
Immunology Boot Camp II: The Basics of Autoimmunity
and Immunodeficiency. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77
Stats Boot Camp: Statistical Analysis of Ordinal Data. . . . . . . . . . . . . . . . . 77
ACR Plenary Session II: Discovery 2014
Pediatric Systemic Lupus Erythematosus (#1824-1829). . . . . . . . . . . . . . 86
Quality Measures and Quality of Care (#1830-1835). . . . . . . . . . . . . . . . . 87
Rheumatoid Arthritis – Clinical Aspects III:
Malignancies, Vaccinations, Pregnancy and Surgery (#1836-1841). . . . . 88
and Gene Therapy III: Innovative Therapeutic Strategies
in Rheumatoid Arthritis (#1842-1847) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 89
Spondylarthropathies and Psoriatic Arthritis III –
Clinical Aspects Psoriatic Arthritis (#1848-1853). . . . . . . . . . . . . . . . . . . . 90
Complications of Systemic Lupus Erythematosus (#1854-1859) . . . . . . . 90
Vasculitis II (#1860-1865) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 91
Abstracts (#1794-1799). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77
Pediatric Rheumatology (#1866-1871). . . . . . . . . . . . . . . . . . . . . . . . . . . . 92
ARHP Networking Event
ARHP Sessions
ARHP Networking at Noon. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81
Alternative Medicine: Presenting the Evidence
for Rheumatic Conditions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92
Adult Inflammatory Myopathy (041). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81
Biomarkers in Rheumatic Care. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 93
Pediatric Rheumatology for Adult Rheumatologists (042). . . . . . . . . . . . . 81
2014 Program Book
5
TABLE OF CONTENTS
Stats Boot Camp: A Call to Aims for Researchers!
An Interactive Session to Obtain Feedback
on Your Specific Aims Section . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 93
ARHP Sessions
Thriving with Rheumatic Disease: Cultivating Resilience. . . . . . . . . . . . . . 93
ACR/ARHP Workshops
From Inflammation to Atherosclerosis:
The Case of Inflammatory Rheumatic Diseases. . . . . . . . . . . . . . . . . . . . 104
Dermatopathology of Rheumatic Diseases (225). . . . . . . . . . . . . . . . . . . . 93
Role of Nutrition in Rheumatic Diseases. . . . . . . . . . . . . . . . . . . . . . . . . . 104
Joint Injections (Knee, Ankle, Shoulder and Wrist) (226). . . . . . . . . . . . . . 93
The Emerging Demand for Medicinal Cannabis by Young Adults
and Beyond. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 104
MDHAQ/RAPID3 and RHEUMDOC: Quantitative,
Standard, Scientific Summaries of Patient History
and Physical Exam, toward Better Clinical Decisions
and Outcomes (227). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94
Musculoskeletal Ultrasonography: Basic (228). . . . . . . . . . . . . . . . . . . . . . 94
ACR Session
Clinicopathologic Conference. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94
ACR Sessions
Health Disparities/Social Determinants of Health (#1932-1937). . . . . . . 104
Study Groups
ACR Musculoskeletal Ultrasound Study Group. . . . . . . . . . . . . . . . . . . . . 105
Antiphospholipid Syndrome Task Force Study Group. . . . . . . . . . . . . . . . 105
Capillaroscopy in Rheumatic Diseases Study Group. . . . . . . . . . . . . . . . . 105
Childhood Vasculitis Study Group. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .106
Career Opportunities in Rheumatology: Making a Choice. . . . . . . . . . . . . 94
Clinical Anatomy Study Group . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106
Curbside Consults – Ask the Experts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94
Crystal Study Group. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106
Fibrotic Complications of Scleroderma . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95
Degos Disease Study Group . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106
The Role of Bone in the Pathogenesis of Osteoarthritis. . . . . . . . . . . . . . . 95
Hypermobility Study Group . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106
Treating Pain Doesn’t Have to Be a Pain:
Practical Approaches to Pain Management. . . . . . . . . . . . . . . . . . . . . . . . 95
Interstitial Lung Disease Group. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106
Myositis Study Group . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 107
Epidemiology and Public Health III:
Gout and Systemic Lupus Erythematosus (#1872-1877). . . . . . . . . . . . . . 95
Clinical Pain Syndromes II: Clinical Perspectives (#1878-1883). . . . . . . . . 96
Genetics, Genomics and Proteomics I:
Epigenetic Mechanisms in Autoimmunity (#1884-1889) . . . . . . . . . . . . . 96
Imaging of Rheumatic Diseases: X-Ray, MRI and CT (#1890-1895). . . . . . 97
Pediatric Rheumatology – Pathogenesis
and Genetics (#1896-1901). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 98
Macrophage Activation Syndrome (MAS) Study Group. . . . . . . . . . . . . . 107
Osteoarthritis Study Group. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 107
Pediatric Rheumatologists Interested in Medial Education
Study Group . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 107
The Why and How of Disease Criteria Study Group. . . . . . . . . . . . . . . . . 107
Veterans Affairs Rheumatology Study Group . . . . . . . . . . . . . . . . . . . . . . 107
Tuesday, November 18, 2014
ACR Sessions
Glycosylation and Glycan Binding Proteins in Immune Function. . . . . . . 108
Rheumatoid Arthritis – Clinical Aspects IV:
Promising Biomarkers (#1902-1907). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99
Hepatitis C in 2014. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 108
and Gene Therapy IV: Safety of Biologics and Small Molecules
in Rheumatoid Arthritis – Cardiovascular and Other
Systems (#1908-1913). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99
ARHP Sessions
Spondylarthropathies and Psoriatic Arthritis – Pathogenesis,
Etiology: From Genes to Cytokines (#1914-1919). . . . . . . . . . . . . . . . . . 100
Biomarkers in Systemic Lupus Erythematosus (#1920-1925). . . . . . . . . 100
Patient Access to Biologics Across the Globe . . . . . . . . . . . . . . . . . . . . . . 108
Clinical Features of Central Nervous System Lupus and Diagnosis
of Cognitive Deficits and Psychiatric Disorders . . . . . . . . . . . . . . . . . . . . 108
Muscle and Adipose Tissue in Rheumatic Diseases:
Location is Everything. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 108
Antiphospholipid Syndrome (061). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
Clinical Aspects and Therapeutics II: Approaches to Cardiac
and Vascular Manifestations in Systemic Sclerosis (#1926-1931). . . . . . 101
Controversies in Sjögren’s Syndrome (062). . . . . . . . . . . . . . . . . . . . . . . . 109
Pediatrics: Periodic Fevers in Children (065). . . . . . . . . . . . . . . . . . . . . . . 109
Rheumatoid Arthritis: Outcome Measures in Clinical Practice (066). . . . . 109
Behçet’s Syndrome (052) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102
Immunodeficiency Syndromes (053). . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102
Infections with Biologics (054). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103
Myopathy: Issues in Diagnosis and Treatment (055) . . . . . . . . . . . . . . . . 103
Pulmonary Manifestations of Rheumatic Disease (056). . . . . . . . . . . . . . 103
Footwear in Orthoarthritis (063) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
Osteoporosis: Novel Treatments (064) . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
Safety of Drugs Used to Treat Rheumatoid Arthritis (067). . . . . . . . . . . . 109
Systemic Lupus Erythematosus: Central Nervous System (068) . . . . . . . 109
Systemic Sclerosis: Disease Staging and Subsetting
in Clinical Practice (069). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
Vasculitis – Factors That Influence Disease Patterns (070). . . . . . . . . . . . 110
Raynaud’s and Digital Ischemia (057). . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103
ACR/ARHP Workshops
Safety of Drugs Used to Treat Rheumatoid Arthritis (058). . . . . . . . . . . . 103
Advanced Musculoskeletal Ultrasound: Image Optimization
and Pathology Recognition (229) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110
Systemic Lupus Erythematosus: Lupus Nephritis (059) . . . . . . . . . . . . . . 103
Vasculitis – Factors That Influence Disease Patterns (060). . . . . . . . . . . . 103
6
Best Practices of Total Knee Arthroplasty –
From Surgery to Rehabilitation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103
2014 Program Book
Basic Statistical Concepts for the Medical Researcher (230). . . . . . . . . . 110
TABLE OF CONTENTS
Joint Injections (Knee, Ankle, Shoulder and Wrist) (231). . . . . . . . . . . . . 110
Psoriatic Arthritis (076). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 119
Magnetic Resonance Imaging of Peripheral Joints
in Rheumatology Practice (232) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110
Spondylarthropathy: An Update (077). . . . . . . . . . . . . . . . . . . . . . . . . . . . 119
ACR Sessions
Temporal Arteritis (079) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 119
Bioenergetics and Energy Regulation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110
Vaccinations for Patients on Biologic Therapies (080) . . . . . . . . . . . . . . . 120
CARE: Maintenance of Certification Session Three of Three. . . . . . . . . . 110
ACR Sessions
Educator: Direct Observation of Clinical Skills:
Educationally Indicated, Therapeutically Required. . . . . . . . . . . . . . . . . 111
Clinical Issues Associated with the Use of Methotrexate. . . . . . . . . . . . . 120
Systemic Lupus Erythematosus: Lupus Nephritis (078) . . . . . . . . . . . . . . 119
Macrophages Gone Wild. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111
Hench Lectureship: Why Steroids Work
in Some Inflammatory Diseases But Not in Others. . . . . . . . . . . . . . . . . 120
Myositis Mimics: Clinical and Molecular Diagnosis. . . . . . . . . . . . . . . . . . 111
New Regulatory T Cells. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 120
Rheumatology Research Foundation: Special Session . . . . . . . . . . . . . . . 111
Uncovering the Role of Connective Tissues
in Chronic Low Back Pain: From Bedside to Bench to Bedside. . . . . . . . 120
Risk and Risk Management of Cardiovascular Disease in Patients
with Rheumatoid Arthritis and Other Systemic Rheumatic Diseases. . . 111
ACR/ARHP Poster Session C, Late-Breaking
and Thieves’ Market Posters and Poster Tours . . . . . . . . . . . . . . . . 112
ARHP Sessions
Etiology and Management of Peripheral Neuropathy
in Patients with Rheumatic Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 120
Abstracts (#1938 – 2780) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112
Pharmacotherapy: What’s New in Rheumatology . . . . . . . . . . . . . . . . . . 120
ACR Sessions
Study Groups
ACR-EULAR PMR Guidelines. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 113
ACR-EULAR Study Group: Toward A New Understanding
of Myositis Through International Collaboration. . . . . . . . . . . . . . . . . . . 121
Metainflammation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 113
Rheumatology Research Foundation Oscar S. Gluck Memorial
Lectureship: Emerging Therapies in Bone Diseases:
Cellular Basis and Challenges. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 113
Autoantibodies in Diagnosis and Follow-Up
of Rheumatic Diseases Study Group. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 121
ARHP Sessions
Biosimilars in Theumatology: Update Study Group . . . . . . . . . . . . . . . . . 121
Mycobacterium Infections in Immunocompromised Patients. . . . . . . . . 113
Closing the Gap – Psoriasis to Psoriatic Arthritis Study Group. . . . . . . . . 121
RheumChat. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 113
Global Musculoskeletal Health Initiatives Study Group. . . . . . . . . . . . . . 121
Stats Boot Camp: The Prevalence Ratio as an Alternative
to the Odds Ratio for Cross-Sectional Studies. . . . . . . . . . . . . . . . . . . . . 114
High-Resolution Peripheral Quantitative Computed Tomography
(HR-pQCT) Imaging in Arthritis Study Group . . . . . . . . . . . . . . . . . . . . . . 122
Juvenile Arthritis Workgroup (JAW) Study Group. . . . . . . . . . . . . . . . . . . 122
See page 238 for the complete Innovation Theater Listing
Latin American Study Group. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 122
ACR Workshops
Neuroendocrine Immunology. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 122
Behçet’s Disease Study Group . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 121
Musculoskeletal Ultrasound (233). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 114
Pediatric Rheumatology Imaging Study Group. . . . . . . . . . . . . . . . . . . . . 122
Renal Histopathology in Systemic Lupus Erythematosus
and Vasculitis (234). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 114
Polymyalgia Rheumatica Study Group. . . . . . . . . . . . . . . . . . . . . . . . . . . . 122
Sjögren’s Syndrome Study Group. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 123
X-Ray Challenges in Rheumatic Diseases (235). . . . . . . . . . . . . . . . . . . . . 114
ACR/ARHP Workshops
ACR Sessions
Mesenchymal Stem Cells: Biology and Use in Rheumatic Diseases. . . . .114
Protecting Bone Health in Pediatric Rheumatic Diseases. . . . . . . . . . . . . 114
ARHP Sessions
Immunology Boot Camp III: Applying Principles of Immunology
to Treatment Decisions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 115
Pathways to Resilience: Biopsychosocial Mechanisms
for the Generation of Positive Affect in Chronic Pain . . . . . . . . . . . . . . . 115
Providing Evidence for Mid-Level Providers
in Rheumatology Practice . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 115
ACR Plenary Session III: Discovery 2014
Abstracts (#2781-2786). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 115
Challenging Cases in Osteoporosis Management (072). . . . . . . . . . . . . . 119
Crystal: Diagnosis and Management of Gout (073) . . . . . . . . . . . . . . . . . 119
Non-surgical Treatments for Osteoarthritis (074). . . . . . . . . . . . . . . . . . . 119
Osteoarthritis: Update 2014 (075). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 119
Dermatopathology of Rheumatic Diseases (236). . . . . . . . . . . . . . . . . . . 123
Magnetic Resonance Imaging of Peripheral Joints
in Rheumatology Practice (237) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 123
Musculoskeletal Ultrasonography: Basic (238). . . . . . . . . . . . . . . . . . . . . 123
The Rheumatologic Musculoskeletal Screening Exam,
with Emphasis on Objective Disease-specific Measurements (239). . . . . 123
ACR Session
ACR Business Meeting. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 124
ACR Sessions
Educator: Innovative Educators, Novel Techniques:
A Rheumatology Research Foundation Special Session. . . . . . . . . . . . . . 124
Novel Regulatory Cell Subsets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 124
Psoriatic Arthritis: Skin, Entheses and Joints. . . . . . . . . . . . . . . . . . . . . . . 124
ACR Late-Breaking Abstract Session. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 124
2014 Rheumatology Research Foundation Edmond L. Dubois, MD
Memorial Lectureship (#2787-2791) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 125
Biology and Pathology of Bone and Joint I: Bone Remodeling
in Inflammation and Arthritis (#2792-2797). . . . . . . . . . . . . . . . . . . . . . . 125
2014 Program Book
7
TABLE OF CONTENTS
Cytokines, Mediators, Cell-cell Adhesion,
Cell Trafficking and Angiogenesis I (#2798-2803). . . . . . . . . . . . . . . . . . . 126
Miscellaneous Pediatric Rheumatic Diseases (#2899-2904). . . . . . . . . . 140
Miscellaneous Rheumatic and Inflammatory Diseases/Innate
Immunity and Rheumatic Disease: Assessing Outcomes
of Infections in Rheumatic Disease (#2804-2809). . . . . . . . . . . . . . . . . . 126
Rheumatoid Arthritis – Animal Models II (#2905-2910). . . . . . . . . . . . . . 140
Rheumatoid Arthritis – Clinical Aspects V: Mortality
and Other Outcomes (#2810-2815) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 127
Rheumatoid Arthritis – Human Etiology and Pathogenesis II:
Citrullination, Autoantibodies and Genes (#2917-2922). . . . . . . . . . . . . 142
Rheumatoid Arthritis – Human Etiology and Pathogenesis I:
Mechanisms of Joint Damage – 2013 Lee C. Howley, Sr. Prize
(#2816-2820). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 127
and Gene Therapy VI: Biomarkers and Predictors
of Rheumatoid Arthritis Disease Response
and Outcomes (#2923-2928). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 142
and Gene Therapy V: Novel Therapies in Rheumatoid Arthritis –
Late in Development (#2821-2826). . . . . . . . . . . . . . . . . . . . . . . . . . . . . .128
Spondylarthropathies and Psoriatic Arthritis IV –
Clinical Aspects Axial Spondyloarthritis (#2827-2832) . . . . . . . . . . . . . . 129
Novel Therapies for Systemic Lupus Erythematosus (#2833-2838). . . . 129
and Pathogenesis II: Pathogenic Targets, Genetic Variants
and Apoptosis (#2839-2844). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 130
T cell Biology and Targets in Autoimmune Disease (#2845-2850). . . . . . 131
Vasculitis III (#2851-2856). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 131
Sjögren’s Syndrome I: Clinical Perspectives (#2929-2934). . . . . . . . . . . . 143
Spondylarthropathies and Psoriatic Arthritis V –
Clinical Aspects and Treatment (#2935-2940). . . . . . . . . . . . . . . . . . . . . 144
Adult Inflammatory Myopathy (081). . . . . . . . . . . . . . . . . . . . . . . . . . . . . 144
Behçet’s Syndrome (082) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 145
Calcium Crystal Arthritis (083) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 145
Juvenile Dermatomyositis (084). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 145
Myopathy: Issues in Diagnosis and Treatment (085) . . . . . . . . . . . . . . . . 145
Pregnancy and Rheumatic Diseases (086). . . . . . . . . . . . . . . . . . . . . . . . . 145
Pulmonary Manifestations of Rheumatic Disease (087). . . . . . . . . . . . . . 145
Rehabilitation (#2857-2862) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 133
Rheumatoid Arthritis: Challenging Cases (089). . . . . . . . . . . . . . . . . . . . . 145
ARHP Sessions
Brief Action Planning (BAP): A Motivational Interviewing (MI)
Technique to Enhance Patient Self-Management
and Improve Outcomes. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 133
Osteoporosis: Emerging Treatments Both Pharmacological
and Non-Pharmacological. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 134
The Psychosocial Impact and Treatment Options for Patients
with Neuropsychiatric Lupus and Their Caregivers. . . . . . . . . . . . . . . . . 134
Raynaud’s and Digital Ischemia (088). . . . . . . . . . . . . . . . . . . . . . . . . . . . . 145
Temporal Arteritis (090) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 145
ARHP Sessions
Multidisciplinary Management of the Juvenile Idiopathic
Arthritis Patient. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 146
Patient-Reported Outcomes Data for Comparative
Effectiveness Research in Arthritis Care. . . . . . . . . . . . . . . . . . . . . . . . . . 146
State-of-the-Art Interventional Recommendations
for Chronic Low Back Pain. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 146
Treatment Considerations in Chronic Pain. . . . . . . . . . . . . . . . . . . . . . . . . 134
Successful Aging in Rheumatic Disease. . . . . . . . . . . . . . . . . . . . . . . . . . . 146
ACR Workshops
Getting Electronic Health Records Right (240) . . . . . . . . . . . . . . . . . . . . . 134
Epidemiology/Public Health (#2941-2946). . . . . . . . . . . . . . . . . . . . . . . . 147
Systemic Sclerosis: How to Perform Skin Scores (241). . . . . . . . . . . . . . . 135
Industry-Supported Post-Meeting Symposia. . . . . . . . . . . . . . . . . . 147
Ultrasound Injection Guidance (242). . . . . . . . . . . . . . . . . . . . . . . . . . . . . 135
ACR Sessions
Autophagy in Rheumatic Diseases. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 135
Beyond Analgesics: State of the Evidence for Nutrition, Vitamins
and Exercise Prescriptions in Osteoarthritis Management. . . . . . . . . . . 135
Update on Safety Issues in the Treatment of Rheumatic Diseases –
From the FDA and Beyond. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 135
Antiphospholipid Syndrome (#2863-2868). . . . . . . . . . . . . . . . . . . . . . . . 135
B cell Biology and Targets in Autoimmune Disease (#2869-2874). . . . . . 137
Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking
and Angiogenesis II (#2875-2880). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 137
Education (#2881-2886) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 138
Epidemiology and Public Health IV:
Rheumatoid Arthritis Pathogenesis (#2887-2892). . . . . . . . . . . . . . . . . . 138
Osteoarthritis – Clinical Aspects II:
Osteoarthritis Risk Factors and Therapies (#2893-2898). . . . . . . . . . . . . 139
8
Rheumatoid Arthritis – Clinical Aspects VI:
Impact of Treatment and Other Interventions (#2911-2916). . . . . . . . . 141
2014 Program Book
Wednesday, November 19, 2014
ACR Sessions
Co-Stimulation Pathways: Therapeutic Opportunities
for the Rheumatic Diseases. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 147
Rheumatology Roundup: Highlights from the 2014 Annual Meeting . . . . 147
ARHP Sessions
Physical and Occupational Therapy for Juvenile Dermatomyositis:
Treatment Planning and Case Presentations. . . . . . . . . . . . . . . . . . . . . . 148
Rheumatic Manifestations of Malignancy. . . . . . . . . . . . . . . . . . . . . . . . . 148
ACR Sessions
Complement in Rheumatic Disease. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 148
Moving Toward Personalized Medicine for Systemic Lupus
Erythematosus Management: From Bench to Bedside. . . . . . . . . . . . . . 148
Primary Angiitis of the Central Nervous System and Its Mimics . . . . . . . 148
TABLE OF CONTENTS
Biology and Pathology of Bone and Joint II:
Cartilage Biology and Synovial Activation (#2947-2952). . . . . . . . . . . . . 149
Genetics, Genomics and Proteomics II: Genetics
of Autoimmunity (#2953-2958). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 149
Metabolic and Crystal Arthropathies II: Mechanisms
of Disease (#2959-2964) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 150
Pain: Basic and Clinical Aspects II/Orthopedics,
Low Back Pain and Rehabilitation (#2965-2970). . . . . . . . . . . . . . . . . . . 151
Rheumatoid Arthritis – Clinical Aspects VII: New Aspects
of Monitoring Disease (#2971-2976) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 152
Sjögren’s Syndrome II: Insights into Pathophysiology (#2977-2982). . . . 152
Spondylarthropathies and Psoriatic Arthritis VI –
Imaging and Biomarkers (#2983-2988). . . . . . . . . . . . . . . . . . . . . . . . . . . 153
CNS and Other Clinical Aspects (#2989-2994). . . . . . . . . . . . . . . . . . . . . 154
Clinical Aspects and Therapeutics III: Updates in Predictors
and Outcomes in Systemic Sclerosis (#2995-3000). . . . . . . . . . . . . . . . . 155
Pathogenesis, Animal Models and Genetics II (#3001-3006). . . . . . . . . 156
ARHP Sessions
Exercise Adherence in Arthritis: The Role of Technology. . . . . . . . . . . . . 156
Nothing About Us Without Us: Engaging Patients
in Rheumatology Research . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 157
ARHP Concurrent Abstract Sessions
Clinical Practice/Patient Care (#3007-3012) . . . . . . . . . . . . . . . . . . . . . . . 157
Innovations in Rheumatologic Care (#3013-3018). . . . . . . . . . . . . . . . . . 157
ACR Sessions
Inflammation and Atherothrombosis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 158
Advances in Molecular Profiling and Relevance
to Autoimmune Disease. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 158
Non-Radiographic Axial Spondyloarthritis:
The Controversy of Diagnosis and Optimal Treatment . . . . . . . . . . . . . . 159
ARHP Sessions
Work and Worker Health: Easy Accommodations
Keep People With Arthritis Employed. . . . . . . . . . . . . . . . . . . . . . . . . . . . 159
Industry-Supported Post-Meeting Symposia. . . . . . . . . . . . . . . . . . 159
ACR Poster Session A
Antiphospholipid Syndrome (#1-18) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 160
Biology and Pathology of Bone and Joint:
Osteoclasts, Osteoblasts and Bone Remodeling (#19-39). . . . . . . . . . . . 160
Epidemiology and Public Health: Osteoporosis,
Non-Inflammatory Arthritis and More (#40-73) . . . . . . . . . . . . . . . . . . . 161
Genetics, Genomics and Proteomics I (#74-93) . . . . . . . . . . . . . . . . . . . . 161
Health Services Research (#94-118). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 163
Imaging of Rheumatic Diseases: Ultrasound (#119-154). . . . . . . . . . . . . 163
Metabolic and Crystal Arthropathies: Clinical Aspects (#155-185). . . . . 165
Orthopedics, Low Back Pain and Rehabilitation (#186-199) . . . . . . . . . . 165
Osteoarthritis – Clinical Aspects: Imaging
and Biomechanics (#200-222). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 166
and Pathogenesis: Osteoporosis: Pathogenesis, Epidemiology
and Diagnosis (#223-240) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 167
Pain: Basic and Clinical Aspects (#241-268). . . . . . . . . . . . . . . . . . . . . . . . 167
Juvenile Idiopathic Arthritis (#269-304). . . . . . . . . . . . . . . . . . . . . . . . . . 168
Pediatric Rheumatology – Pathogenesis and Genetics (#305-321). . . . . 169
Rheumatoid Arthritis – Animal Models (#322-347) . . . . . . . . . . . . . . . . . 170
Rheumatoid Arthritis – Clinical Aspects: Novel Biomarkers
and Other Measurements of Disease Activity (#348-432) . . . . . . . . . . . 170
Rheumatoid Arthritis – Human Etiology
and Pathogenesis (#433-456) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 173
and Gene Therapy: Safety of Biologics and Small Molecules
in Rheumatoid Arthritis (#457-519) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 174
Sjögren’s Syndrome: Pathophysiology (#520-535). . . . . . . . . . . . . . . . . . 176
Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects
and Treatment I (#536-602). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 177
Spondylarthropathies and Psoriatic Arthritis –
Pathogenesis, Etiology (#603-633) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 179
Systemic Lupus Erythematosus – Animal Models (#634-664). . . . . . . . . 180
Treatment and Management Studies (#665-719). . . . . . . . . . . . . . . . . . 181
Clinical Aspects and Therapeutics: Systemic Sclerosis Measures
and Outcomes (#720-743). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 182
Pathogenesis, Animal Models and Genetics (#744-774). . . . . . . . . . . . . 183
Vasculitis (#775-814). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 184
ACR/ARHP Poster Session B
B cell Biology and Targets in Autoimmune Disease:
Rheumatoid Arthritis and Related Diseases (#982-1000). . . . . . . . . . . . 185
Biology and Pathology of Bone and Joint: Cartilage,
Synovium and Osteoarthritis (#1001-1026). . . . . . . . . . . . . . . . . . . . . . . 186
and Angiogenesis (#1027-1050) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 187
Epidemiology and Public Health (ACR): Rheumatoid Arthritis
and Systemic Lupus Erythematosus Outcomes (#1051-1082) . . . . . . . . 187
Epidemiology and Public Health (ARHP): Epidemiology
and Public Health (#1083-1092). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 188
Fibromyalgia, Soft Tissue Disorders, Regional
and Specific Clinical Pain Syndromes: Clinical Focus (#1093-1120). . . . 189
Genetics, Genomics and Proteomics II (#1121-1140). . . . . . . . . . . . . . . . 189
Health Services Research (ACR) (#1141-1165) . . . . . . . . . . . . . . . . . . . . . 190
Health Services Research (ARHP):
Health Services Research (#1166-1168). . . . . . . . . . . . . . . . . . . . . . . . . . 191
Imaging of Rheumatic Diseases:
Magnetic Resonance Imaging (MRI) (#1169-1193). . . . . . . . . . . . . . . . . 191
Innate Immunity and Rheumatic Disease:
Signaling Mechanisms (#1194-1213) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 192
Metabolic and Crystal Arthropathies:
Mechanisms of Disease (#1214-1224) . . . . . . . . . . . . . . . . . . . . . . . . . . . 192
Miscellaneous Rheumatic
and Inflammatory Diseases (#1225-1254). . . . . . . . . . . . . . . . . . . . . . . . 193
2014 Program Book
9
TABLE OF CONTENTS
Muscle Biology, Myositis and Myopathies:
Myositis Autoantibodies and Disease Phenotype (#1255-1273) . . . . . . 194
Osteoarthritis – Clinical Aspects: Epidemiology
and Pathogenesis (#1274-1293) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 194
Pediatric Rheumatology – Clinical and Therapeutic Aspects (ARHP):
Pediatrics (#1294-1329). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 195
Pediatric Lupus, Scleroderma and Myositis (ACR) (#1330-1331). . . . . . 196
Psychology/Social Sciences (ARHP) (#1332-1339) . . . . . . . . . . . . . . . . . . 196
Quality Measures and Quality of Care (#1340-1361). . . . . . . . . . . . . . . . 196
Rheumatoid Arthritis – Clinical Aspects (ACR):
Comorbidities, Treatment Outcomes and Mortality (#1362-1443) . . . . . 197
Rheumatoid Arthritis – Clinical Aspects (ARHP):
Clinical Practice/Patient Care (#1444-1453). . . . . . . . . . . . . . . . . . . . . . . 200
and Gene Therapy: Novel therapies, Biosimilars, Strategies
and Mechanisms in Rheumatoid Arthritis (#1478-1541) . . . . . . . . . . . . 201
Clinical Aspects and Treatment II (#1542-1603). . . . . . . . . . . . . . . . . . . . 203
Biomarker, Translational and Nephritis Studies (#1604-1626). . . . . . . . 205
and Pathogenesis: Autoimmune Disease Transition,
Disease Subsets and Prediction of Flares, Cytokines
and Autoantibodies (#1627-1673) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 206
Clinical Aspects and Therapeutics: Systemic Sclerosis, Diagnostic
and Therapeutic Aspects (#1674-1703) . . . . . . . . . . . . . . . . . . . . . . . . . . 207
Pathogenesis, Animal Models and Genetics (#1704-1732). . . . . . . . . . . 208
T cell Biology in Rheumatoid Arthritis
and Other Arthritis (#1733-1753). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 209
Vasculitis (#1754-1793). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 209
ACR/ARHP Poster Session C
B cell Biology and Targets in Autoimmune Disease:
Systemic Lupus Erythematosus and Related Diseases (#1938-1956). . . 211
and Angiogenesis (#1957-1980) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 211
Education (ACR) (#1981-2005). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 212
Education (ARHP): Education/Community Programs (#2006-2013). . . . 213
Epidemiology and Public Health (ACR):
Rheumatoid Arthritis Pathogenesis and Treatment (#2014-2044). . . . . 214
Epidemiology and Public Health (ARHP) (#2045-2054) . . . . . . . . . . . . . . 214
and Specific Clinical Pain Syndromes:
Research Focus (#2056-2083). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 214
Genetics, Genomics and Proteomics (#2084-2102). . . . . . . . . . . . . . . . . 215
Health Services Research (#2103-2125) . . . . . . . . . . . . . . . . . . . . . . . . . . 216
Imaging of Rheumatic Diseases:
Various Imaging Techniques (#2126-2150). . . . . . . . . . . . . . . . . . . . . . . . 217
Infections, Infection-related Biomarkers and Impact
of Biologic Therapies (#2151-2163) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 217
Innate Immunity and Rheumatic Disease: Mediators,
Cells and Receptors (#2164-2185). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 218
Miscellaneous Rheumatic and Inflammatory Diseases (#2186-2209). . . . 218
10
2014 Program Book
Muscle Biology, Myositis and Myopathies:
Immunological Aspects of Inflammatory Myopathy (#2210-2229) . . . . . 219
Osteoarthritis – Clinical Aspects: Therapeutics (#2230-2252). . . . . . . . . 220
and Pathogenesis: Osteoporosis: Treatment, Safety,
and Long Term Outcomes (#2253-2268) . . . . . . . . . . . . . . . . . . . . . . . . . 221
Systemic Juvenile Idiopathic Arthritis, Spondyloarthropathy
and Miscellaneous Pediatric Rheumatic Diseases (#2269-2304). . . . . . 221
Quality Measures and Quality of Care (#2305-2324). . . . . . . . . . . . . . . . 222
Rehabilitation Sciences (ARHP) (#2325-2334). . . . . . . . . . . . . . . . . . . . . . 223
Research Methodology (ARHP) (#2335-2338). . . . . . . . . . . . . . . . . . . . . . 223
Rheumatoid Arthritis – Animal Models (#2339-2364). . . . . . . . . . . . . . . 223
Rheumatoid Arthritis – Clinical Aspects (ACR): Impact of Various
Interventions and Therapeutic Approaches (#2365-2429). . . . . . . . . . . 224
Rheumatoid Arthritis – Clinical Aspects (ARHP):
Clinical Practice/Patent Care (#2430-2444) . . . . . . . . . . . . . . . . . . . . . . . 226
and Gene Therapy: Therapeutic Strategies, Biomarkers
and Predictors of Outcomes in Rheumatoid Arthritis (#2467-2530) . . . . 227
Sjögren’s Syndrome: Clinical Science (#2531-2552). . . . . . . . . . . . . . . . . 230
Clinical Aspects and Treatment III (#2553-2618). . . . . . . . . . . . . . . . . . . 230
Systemic Lupus Erythematosus – Clinical Aspects
and Treatment: Epidemiology, Women’s Health,
Cardiovascular and CNS (#2619-2672). . . . . . . . . . . . . . . . . . . . . . . . . . . 232
Systemic Lupus Erythematosus – Human Etiology and Pathogenesis:
T and B Cell Signaling and Genetic Variants (#2673-2696). . . . . . . . . . . 234
Clinical Aspects and Therapeutics: Determinants of Disease,
Classification and Response (#2697-2721). . . . . . . . . . . . . . . . . . . . . . . . 235
T cell Biology in Lupus, Vasculitis, Myositis
and Other Autoimmunity (#2722-2743). . . . . . . . . . . . . . . . . . . . . . . . . . 235
Vasculitis (#2744-2780). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 236
INNOVATION THEATER LISTING. . . . . . . . . . . . . . . . 238
INDUSTRY-SUPPORTED
POST MEETING SYMPOSIA. . . . . . . . . . . . . . . . . . . . . . . 239
CERTIFICATES OF CME CREDIT
OR PARTICIPATION
Accredidation Statements. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 246
Evaluations, CME Credit and Cerfiticates. . . . . . . . . . . . . . . . . . . . . . . . . . 246
When Claiming CME Credit. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 246
Conflict of Interest and Disclosure. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 246
RECOGNITIONS
ACR/ARHP Annual Meeting Leadership. . . . . . . . . . . . . . . . . . . . . . . . . . . 248
Exhibitors. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 252
Supporter Acknowledgements. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 256
INDICIES
ACR/ARHP Annual Meeting Planning Committee Disclosures. . . . . . . . . 258
ACR/ARHP Abstract Category Chair and Reviwer Disclosures. . . . . . . . . 260
Invited Speaker Moderator Index. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 268
ACR/ARHP Abstract Author Index. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 288
ACR/ARHP Abstract Moderator Disclosure Index. . . . . . . . . . . . . . . . . . . 346
The most comprehensive
online collection of
rheumatology-related images.
Serving as a centralized resource for clinicians, researchers
and health care professionals, the Rheumatology Image Bank
provides invaluable assistance in self-study or the education
of others.
Start your visual exploration of rheumatology today
at http://images.rheumatology.org!
Stop by the ACR’s Discovery Center, located in Exhibit Hall
A (Booth #731), or the Concierge Center, located in the
North Lobby, and speak with staff to learn more about
the Rheumatology Image Bank and all it can offer you.
The ACR would like to thank the following company for
their generous support of the Rheumatology Image Bank:
COPYRIGHT
MATERIALS POLICY
The Annual Meeting is a private
event. Programs presented at the
meeting are for the education
of attendees and purchasers of
recorded presentations as authorized
by the American College of
information Rheumatology. Information displayed
or presented at all sessions during
the Annual Meeting is the property of the ACR or the presenter.
Information may not be recorded, photographed, copied,
photocopied, transferred to electronic format, reproduced or
distributed without the written permission of the ACR and the
presenter. Any use of the program content, which includes but is
not limited to oral presentations, audiovisual materials used by
speakers and program handouts, without the written consent of
the ACR is prohibited. This policy applies before, during and after
the meeting. The ACR will enforce its intellectual property rights
and penalize those who infringe upon it.
general
Use of American College of Rheumatology’s Name
The names, insignias, logos and acronyms of the ACR, the ARHP
and the Rheumatology Research Foundation are proprietary
marks. Use of the names in any fashion, by any entity, for any
purpose, is prohibited without the written permission of the
College.
PHOTOGRAPHS AND VIDEO
RECORDING POLICY
As a courtesy to our presenters, ACR policy does not permit
photographs or recordings during educational sessions, including
poster sessions. The only exception to this is for registered
media, who should review their registration materials for more
information.
MEDIA
Credentialed media attend the Annual Meeting to cover stories
for consumer, trade and other media outlets, and are easily
identified by their black press ribbons. Media has access to
all general sessions and limited access (at the discretion of
speakers) to Meet the Professor and Workshop sessions. Media
may use hand-held audio recorders and still cameras; moving
video recording is also permitted with the permission of the
presenter(s). The exception to this policy is that no photos
or video are allowed in the Exhibit Hall. Press who would like
general photos of the Exhibit Hall can obtain these after the
meeting from the ACR. Attendees who have questions about the
ACR’s media policies should contact the ACR Public Relations
department at pr@rheumatology.org.
2014 Program Book
11
general information
EMBARGO POLICY
Accepted abstracts are made available to the public online
in advance of the meeting and are published in a special
supplement of Arthritis & Rheumatology. Information contained
in those abstracts may not be released until the abstracts
appear online. Academic institutions, private organizations and
companies with products whose value may be influenced by
information contained in an abstract may issue a press release
to coincide with the availability of an ACR abstract on the ACR
website. However, the ACR continues to require that information
that goes beyond that contained in the abstract (e.g., discussion
of the abstract done as part a scientific presentation or
presentation of additional new information that will be available
at the time of the meeting) is under embargo until 4:30 pm
Eastern Time on Saturday, November 15, 2014. Violation of
this policy may result in the abstract being withdrawn from the
meeting and other measures deemed appropriate. Authors are
responsible for notifying financial and other sponsors about this
policy.
ABSTRACT REPRINT POLICY
Copyright law covers all Annual Meeting abstracts published
by the American College of Rheumatology. All rights reserved.
No abstracts may be reproduced in any form or by any means,
except as permitted under section 107 and 108 of the United
States Copyright Act, without the prior permission of the
publisher.
For the purposes of this statement, the term “ACR abstracts”
refers to all Annual Meeting abstracts as published in Arthritis
& Rheumatology and posted online, including the abstracts
accepted for presentation during ARHP sessions and the latebreaking category.
For the purposes of this statement, the term “ACR posters”
refers to the accepted abstracts as presented during the Annual
Meeting. All ACR posters are the property of the ACR or the
presenting author and cannot be reproduced or distributed
without written permission from the ACR and the presenting
author.
For the purposes of this statement, the term “reproduce”
includes all forms of reproduction including, but not limited to,
print, electronic and photographed formats.
For the purposes of this statement, the term “presenting author”
refers to the author who is designated as the individual who will
present the work during the ACR Annual Meeting, as identified
through the abstract submission process.
Approval Process
Excerpts of ACR abstracts or ACR abstracts in their entirety may
not be reproduced without the prior written permission of the
publisher. Permission requests and other permission inquiries
should be addressed to:
Permissions Department
c/o John Wiley & Sons, Inc.
111 River Street
Hoboken, NJ 07030
Fax: (201) 748-6008
www.wiley.com/go/permissions
aa
!
Commercial entities seeking permission to
reprint must obtain all materials from the
author and/or publisher John Wiley & Sons,
Inc. ACR cannot provide any materials.
Reproducing ACR Abstracts and ACR Poster Presentations
for Dissemination During the Annual Meeting
Following approval (see approval process), an exhibiting
organization may:
• D
isseminate copies of individual ACR abstracts from its
exhibit space. Booklets of abstracts (e.g., two or more)
may not be produced.
• D
isseminate information summaries (title/date/time/
poster number) of ACR abstracts from its exhibit space.
Summaries may not reference company or product
names. Requests for approval must be submitted in
writing to abstractreprints@rheumatology.org.
Presenting authors may disseminate individual copies of their
ACR poster during their assigned poster presentation time.
Dissemination must be limited to the area directly in front of
their assigned poster space and may not interfere with other
poster presentations.
Reproducing ACR Abstracts and ACR Poster Presentations
for Dissemination After the Annual Meeting
Following approval (see approval process above), the ACR
permits ACR abstracts to be reprinted and disseminated
following the Annual Meeting.
Booklets of abstracts (e.g., two or more) must include the
following statement on the front of the booklet: Abstracts
reprinted from the ACR/ARHP Annual Meeting held November
14-19, 2014. The American College of Rheumatology does not
guarantee, warrant, or endorse any commercial products or
services. Reprinted by (insert name of supporting company).
Booklets cannot contain corporate or product logos or any
advertisements. No exceptions.
12
2014 Program Book
general information
ACR Posters
Following approval from the ACR and the presenting author,
copies of ACR poster presentation images may be reproduced.
IMPORTANT: The ACR does not retain and cannot provide
poster presentation images. Requests to reproduce individual
ACR posters or booklets of posters (e.g., two or more) must be
submitted via e-mail to abstractprints@rheumatology.org.
Poster reproduction requests must include the following:
Abstract ID Number
• Abstract title
• Presenting author’s name
• A copy of presenting author’s written approval
(Please Note: An e-mail approval from the presenting
author is acceptable).
The following statement must be listed under each poster
reprint:
Poster reprinted from the ACR/ARHP Annual Meeting held
November 14-19, 2014. The American College of Rheumatology
does not guarantee, warrant, or endorse any commercial
products or services. Reprinted by (insert name of supporting
company).
Use of the ACR Scientific Program Content
Information displayed or presented at all sessions during the
Annual Meeting is the property of the ACR or the presenter.
Information may not be recorded, photographed, copied,
photocopied, transferred to electronic format, reproduced or
distributed without the written permission of the ACR and the
presenter. Any use of the program content, which includes but is
not limited to oral presentations, audiovisual materials used by
speakers and program handouts, without the written consent of
the ACR is prohibited. This policy applies before, during and after
the meeting. The ACR will enforce its intellectual property rights
and penalize those who infringe upon it.
MEETING INFORMATION
Cell Phones, PDAs & Other Electronic Devices
As a courtesy to meeting attendees, electronic devices must be
operated in silent/vibrate mode within educational sessions;
devices that beep, ring, etc. are prohibited. Cell phone
conversations are not permitted in meeting rooms.
Children
For safety reasons, strollers are not permitted in the exhibit
hall and all children must be accompanied by an adult. Only
registered attendees will be permitted into meeting rooms.
Child Care
KiddieCorp is providing child care services for our attendees
during meeting hours. If you did not reserve space in
advance, you can inquire about space availability by calling
(617) 954-3451.
Nursing Mothers’ Room
During scientific session hours, a staffed Nursing Mothers’
room will be available in Room 162-A. This room will have a
private seating area, a refrigerator and a bulletin board for
information exchange, advice and suggestions.
Exhibit Hall
Located in Hall A, you will find the latest technology and services
demonstrated or on display in the exhibit hall. See page 252 for
more information.
Exhibit Hall hours:
Sunday, November 16. . . . . . . . . . . . . . . 10:00 AM – 5:00 PM
Monday, November 17. . . . . . . . . . . . . . 10:00 AM – 5:00 PM
Tuesday, November 18. . . . . . . . . . . . . . 10:00 AM – 2:30 PM
Meeting Room Capacity/Important Fire Safety Information
Attendance at scientific sessions is on a first-come, first-served
basis. Rooms which have reached the maximum capacity may be
closed according to local fire and safety regulations. Standing in
the aisle or against the walls is not permitted. If overcrowding
occurs, staff/security personnel will close the session.
Sessions closed due to overcrowding may be redirected to an
overflow room or made available on SessionSelect within 24
hours following the session. See page 19 for more information
on SessionSelect.
Photography and Videotaping
Photographers will be present at the meeting. Registration
and attendance at, or participation in, ACR meetings and other
activities constitutes an agreement by the registrant for the
ACR’s use and distribution (both now and in the future) of
the registrant or attendee’s image or voice in photographs,
videotapes, electronic reproductions and audio tapes of
such events and activities. Visual reproduction of sessions is
prohibited without prior written permission of the ACR. The ACR
reserves the rights to audio and video reproduction at the 2014
ACR/ARHP Annual Meeting. See copyrighted materials policy for
more information on page 11.
Name Badges
For security reasons, your badge will be required for admittance
to all sessions, exhibits, social events and shuttle buses. Please
wear your badge so it can be easily seen at all times. Lost badges
should be reported to the registration staff immediately.
No Smoking
All meeting facilities at the convention center, hotel meeting
rooms and other venues have been designated as non-smoking
areas.
2014 Program Book
13
M
Pd
PS
general information
MEETING NAVIGATION GUIDE
Use the following track icons to help you identify the most
relevant
PS based on your specialty.
PM content
PS
PRIMARY TRACKS
PS
PM
Basic Science
PS
PM
Business/Administration
Clinical Practice
PM
Ed
PrM
Pd
PS
Educators
PM
Ed
Pd
PS
FIT
Pediatrics
PrM
PrM
FIT
Fellows-In-Training
FIT
Practice Management
STATE CME DESIGNATIONS
PS Management
Pain
The ACR designates certain sessions for pain
PM
management credit as required by the Medical Board
of California (AB487). This designation is identified
by the icon shown and will be placed next to the
session title.
Patient Safety
The ACR designates certain sessions that will satisfy
PS
patient safety/risk management requirements of the
Medical Board of Pennsylvania. This designation is
identified by the icon shown and will be placed next
to the session title.
SESSION FORMATS
ACR Sessions provide an update on the most recent
developments in the field of rheumatology and provide
instruction to improve patient care. Developments from other
specialties and practical patient management skills will be
emphasized.
ARHP Sessions offer educational programs of interest to various
health professionals. Concurrent sessions include invited
speakers; peer-reviewed programs and lectures; and research
and special interest abstract sessions.
ACR and ARHP Concurrent Abstract Sessions provide a platform
for the presentation of the most up-to-date basic science and
clinical research data in the field of rheumatology. Sessions are
grouped by topic or theme and include short oral presentations
of high scoring accepted abstracts.
14
2014 Program Book
Meet the Professor Sessions provide an opportunity for
interaction and consultation with highly respected professionals
who have expertise in a particular area. A separate registration
is required.
Networking Events provide unique opportunities to socialize and
network with peers in smaller group settings.
Clinical Science
SECONDARY TRACKS
PM
Exhibits and Industry-Supported Sessions provide attendees
with an opportunity to learn about the latest technological
advances in the treatment of rheumatic diseases within the
exhibit hall via various exhibitions and non-CME sessions in
the Innovation Theater, as well as evening and post-meeting
symposia.
Poster Sessions include accepted abstracts not selected for oral
presentation. Poster sessions are arranged by topic/category.
Presenters are required to accompany their posters during
designated poster presentation times.
Pre-Meeting Courses offer attendees, with a specific interest, a
unique learning opportunity. A separate registration is required.
Study Groups bring together attendees with a common interest
in one disease, a group of related disorders or a specialized field
of study for discussion and dissemination of information.
Workshops foster Hands-On learning, and provide an
opportunity for interaction and consultation with highly
respected professionals who have expertise in a particular area.
A separate registration is required.
ABSTRACT FORMATS
Late-Breaking Session features truly late-breaking research.
Oral Presentations are the main forum for didactic presentation
of original research related to rheumatic diseases.
Plenary Sessions highlight abstracts of significant novelty and
importance. There will be three theme-based sessions offered.
Poster Presentations feature poster displays of abstracts, while
facilitating one-on-one interaction between the presenter and
the audience.
Poster Tours are small groups guided by experts in a particular
field. Each tour will highlight selected posters of novel or recent
developments within an abstract category. There is no additional
cost to participate, although a separate registration is required.
ABSTRACT CATEGORIES
ACR
Basic Science
1.B-cell Biology and Targets in Autoimmune Disease:
B-lymphocyte differentiation, B-cell subsets, plasma cells,
autoantigens, autoreactive B-cells and tissue injury.
2.Biology and Pathology of Bone and Joint: joint biology
and biochemistry, cartilage and chondrocyte biology, basic
studies of osteoarthritis, bone structure and function,
bone mineral and matrix, osteoblasts and osteoclasts.
general information
3.Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking
and Angiogenesis: cytokines, chemokines and their
receptors; downstream signaling effects and biologic
pathways; cell-cell recognition and adhesion molecules,
cell matrix interactions, matrix characteristics and
properties, lymphoid organogenesis.
ealth Services Research: delivery of care affecting
19. H
patients with rheumatic disease; health systems and health
care economic and ultization analysis.
4.Genetics, Genomics and Proteomics: techniques,
strategies and observations related to disease
susceptibility and expression; bioinformatics and systems
biology.
21.Infection-related Rheumatic Disease: musculoskeletal
manifestations of infectious disease, infectious arthritis
and pathogenesis.
5.
6.
I nnate Immunity and Rheumatic Disease: dendritic cells,
antigen presentation, auto-inflammatory pathogenesis,
pattern recognition receptors and their ligands, NK cells,
complement and Fc receptors.
P
ain – Basic Aspects: studies on pain mechanisms, animal
models of pain and pain physiology.
7.Pediatric Rheumatology – Pathogenesis and Genetics:
pathological, genetic and other laboratory-based aspects
of pediatric rheumatology conditions.
20. I maging of Rheumatic Diseases: radiography, nuclear
medicine, magnetic resonance imaging (MRI), ultrasound
and computed tomography (CT).
etabolic and Crystal Arthropathies: crystal-induced
22. M
arthritis, metabolic conditions including endocrine
abnormalities.
23.Miscellaneous Rheumatic and Inflammatory Diseases:
rheumatic manifestations and therapy of less common and
even rare illnesses not included in other categories (e.g.,
RS3PE, reticulohistiocytosis, SAPHO).
24.Muscle Biology, Myositis and Myopathies: muscle biology,
inflammatory and non-inflammatory muscle disease.
8.Rheumatoid Arthritis – Animal Models: animal models of
inflammatory synovitis, mechanisms and treatment.
25.Orthopedics, Low Back Pain and Rehabilitation:
orthopedic conditions and interventions, physical medicine
techniques and outcomes, sports medicine.
9.Rheumatoid Arthritis – Human Etiology and
Pathogenesis: genetics, susceptibility loci, etiology and
pathogenesis.
26.Osteoarthritis – Clinical Aspects: patient-oriented studies
of osteoarthritis, including treatment, diagnosis and
outcomes.
10.Spondylarthropathies Psoriatic Arthritis – Pathogenesis,
Etiology: etiology and pathogenesis, including genetics,
reactive arthritis and animal models.
27.Osteoporosis and Metabolic Bone Disease – Clinical
Aspects and Pathogenesis: patient-oriented studies of
bone structure and integrity and its change in various
disease states.
11. S ystemic Lupus Erythematosus – Animal Models: animal
models, mechanisms and treatment.
12. S ystemic Lupus Erythematosus – Human Etiology and
Pathogenesis: genetics, susceptibility loci, etiology and
pathogenesis.
13.Systemic Sclerosis, Fibrosing Syndromes and Raynaud’s –
Pathogenesis, Animal Models and Genetics: cellular and
molecular mechanisms, biomarkers.
14. T -cell Biology and Targets in Autoimmune Disease:
T-lymphocyte antigens and subpopulations, cognate
interactions, T-lymphocyte activation and proliferation.
CLINICAL
15.Antiphospholipid Syndrome: pathophysiology,
presentation and management.
16. E ducation: research on curriculum design and
implementation; educational research projects; and
outcomes research on physician and trainee education
including associated health training.
17.Epidemiology and Public Health: descriptive and/or
analytical studies of populations.
18.Fibromyalgia, Soft Tissue Disorders, Regional and Specific
Clinical Pain Syndromes: regional pain syndromes, local
diseases of muscle, ligament and tendon, fibromyalgia.
28. NEW! Pain – Clinical Aspects: studies on pain evaluation, pain management and pain-related functional imaging.
29.Pediatric Rheumatology – Clinical and Therapeutic
Aspects: clinical aspects and treatment of inflammatory
and non-inflammatory pediatric conditions.
30. NEW! Quality Measures and Quality of Care:
development and use of tools to measure or quantify
healthcare processes, outcomes, patient perceptions,
organizational structures and/or systems relating to
healthcare goals including safety, effectiveness, patient
centricity, equity and timeliness.
31.Rheumatoid Arthritis – Clinical Aspects: clinical aspects
of rheumatoid arthritis. Should not contain any treatment
studies.
32.Rheumatoid Arthritis – Small Molecules, Biologics and
Gene Therapy: treatment of human rheumatoid arthritis
including DMARDs, NSAIDs, glucocorticoids, new potential
small molecules, biologics and gene therapy approaches.
Human use only.
33.Sjögren’s Syndrome: pathophysiology, presentation and
treatment.
2014 Program Book
15
Stop by the Discovery Center
to learn what’s new at the College!
We’re located in the center of the Exhibit Hall (Booth #731).
L E A R N
• G
et details about our 2015
educational activities
• F ind answers to your
coding and billing
questions
• T alk with ACR staff about
The Lupus Initiative, CME
activities, registries, MOC
tools, and more
C O N N E C T
• “ Get Social” by meeting
with a social media
mentor
• S peak with key
representatives from the
ACR and ARHP journals
E N G A G E
S E E
• H
ear about the Foundation’s
programs and initiatives
• D
emo popular online tools
and resources
• L earn about the latest
advocacy efforts and
how you can get involved
iew and order the latest
• V
Rodnan Commemorative
Gout Print
• E nroll in the
ACR Rheumatology
Musculoskeletal Ultrasound
Certification Program
• C
ollect complimentary
product brochures,
publications and patient
education materials
Discovery Center Hours:
Sunday, November 16. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10:00 am – 5:00 pm
Monday, November 17. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10:00 am – 5:00 pm
Tuesday, November 18. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10:00 am – 2:30 pm
general information
34.Spondylarthropathies and Psoriatic Arthritis – Clinical
Aspects and Treatment: small molecule and biologic
therapies of spondyloarthropathies, reactive arthritis and
psoriatic arthritis.
35. S ystemic Lupus Erythematosus – Clinical Aspects and
Treatment: diagnosis, clinical manifestations, outcomes,
and treatment, including new small molecules, biologics
and gene therapy. Human lupus only.
36. S ystemic Sclerosis, Fibrosing Syndromes, and Raynaud’s –
Clinical Aspects and Therapeutics: clinical aspects of these
syndromes and of treatments.
37.
Vasculitis: genetics, etiology, pathogenesis, polygmatic
rheumatica, presentation and management.
ARHP
38.Clinical Practice/Patient Care: care of patients, practice
management, medication monitoring/adherence and
complementary and alternative strategies.
39. Education/Community Programs: patient education,
professional education, community-based programs and
public health programs.
40.Epidemiology and Public Health: descriptive and
analytical studies of health status and health outcomes of
populations and patient groups.
41.Health Services Research: health care systems and
delivery, economic evaluations, quality improvements and
analysis.
42.Pediatrics: pediatric practice and patient care.
43.Psychology/Social Sciences: social, emotional and
behavioral factors affecting patients, families and
providers.
44.Rehabilitation Sciences: physical therapy, occupational
therapy, exercise programs, splinting/orthotics and other
rehabilitation services.
45.Research Methodology: quantitative and qualitative
studies, new assessment tools and methodology, new
analytical techniques and research study management.
MEETING SERVICES
NEW! Annual Meeting App – Everything You Need, in One Place
Search the program, retrieve syllabi, view abstracts and access
recorded sessions on SessionSelect. See page 19 for more
information on SessionSelect.
Discovery Center – The Spot for All Things ACR, ARHP
and the Foundation!
Discovery Center Hours:
Sunday, November 16. . . . . . . . . . . . . . . 1
0:00 AM – 5:00 PM
Tuesday, November 18. . . . . . . . . . . . . . 10:00 AM – 2:30 PM
Located in the center of Exhibit Hall A, Booth #731, the Discovery
Center is designed to highlight all of the College’s exceptional
programs and services. ACR’s professional staff is on hand
to demonstrate online tools and resources, introduce new
initiatives of the College that are under way, provide information
and answer any questions you may have. The Discovery Center
has it all in one place! See page 16 for more information.
Look for these specific areas in the Discovery Center:
• Advocacy
Get the most up-to-date information on the legislative and
regulatory issues affecting your profession. We have talking
points on all ACR legislative priorities and tips on how to get
more involved with the ACR’s advocacy efforts. You can also
receive information on RheumPAC – the ACR’s political action
committee.
• E ducation
Learn about ACR/ARHP educational offerings and upcoming
meetings in 2015 and beyond. You can also demo online
products, tools and training programs like SessionSelect,
Advanced and Fundamentals of Rheumatology Courses and
the popular Rheumatology Image Bank.
• R
heumatology Research Foundation
Learn about the latest activities the Foundation is doing to
ensure the future of rheumatology. View and order the latest
poster in the Rodnan Commemorative Gout Print poster
series, and hear about Foundation programs and initiatives.
• P
ractice Management & Coding
Visit with ACR certified coders and practice management
experts for any coding, billing, insurance or practice
management questions. We have all the resources you need
for an efficient rheumatology practice. You can also pick up
the latest copy of the ACR’s monthly RheumWATCH.
Take advantage of the new
Annual Meeting App!
• P
ublications
The editorial office staff of the Arthritis & Rheumatology and
Arthritis Care & Research journals will be available to answer
questions concerning online article submission and article
review processes for the journals.
2014 Program Book
17
general information
• S imple Tasks
Learn how the ACR’s Simple Tasks campaign is educating
lawmakers and referring physicians and others who influence
rheumatology on the severity of inflammatory rheumatic
diseases and the importance of rheumatologists and
rheumatology health professionals in the treatment of those
diseases. You can also learn how you can get involved in the
Campaign in Action initiative.
• Q
uality & Informatics
Learn how enrollment in the Rheumatology Clinical Registry
can benefit you by providing Hands-On measurement tools
and reports that enable you to comparatively assess the
quality and outcome of rheumatologic care you provide. Plan
on attending interactive demonstrations of this tool offered
throughout the meeting.
• C
ertification
Need help navigating Maintenance of Certification? We have
answers to help steer your route to success with the American
Board of Internal Medicine’s Maintenance of Certification
program. An ABIM representative will be on site to help
answer your questions.
• M
usculoskeletal Ultrasound Certification
Interested in certifying in ultrasound? The ACR is providing
a voluntary pathway for physicians, physician assistants
and nurse practitioners who perform ultrasound as part of
their practice in rheumatology to demonstrate competence
to patients, peers and payers through its first certification
program.
Lost and Found
Found items should be returned to the ACR Office, Room 260.
If you are looking for a lost item, go to the ACR Office or call
(617) 954-3940.
Newsroom
Located in Room 252, use of the Newsroom is limited to media
representatives with press passes.
Attendee Lounge
Located in the Ballroom Lobby, attendees are welcome to relax
and enjoy seating while networking with colleagues, checking
e-mail and recharging their laptops or smartphones.
Concierge Center
Need directions to your next session or interested in discovering
all things ACR? Stop by the Concierge Center located in the
center of the North Lobby (Level 1). Staff is on hand to assist you
and answer general questions about the Annual Meeting, ACR/
ARHP events, programs, resources and services of the College—
and we’re happy to give directions to your next session, too.
Concierge Center Hours:
Friday, November 14. . . . . . . . . . . . . . . .
Saturday, November 15 . . . . . . . . . . . . .
Sunday, November 16. . . . . . . . . . . . . . .
Monday, November 17. . . . . . . . . . . . . .
Tuesday, November 18. . . . . . . . . . . . . .
Wednesday, November 19. . . . . . . . . . .
6:30 AM –6:00 PM
:30 AM –6:30 PM
6
6:30 AM –6:00 PM
6:30 AM –6:00 PM
6
:30 AM –6:00 PM
7:00 AM –1:00 PM
• C
areer Connection
Employers and candidates are encouraged to take advantage
of the online Career Connection to post position openings,
search nationwide rheumatology career opportunities and
much more.
Career Fair
On Friday, November 14 from 6:00 – 8:00 pm, potential
employers and candidates can meet in the Grand Ballroom
C-D-E at the Westin Boston Waterfront and enjoy
complimentary hors d’oeuvres and beverages while discussing
career opportunities. During this time, employers who have
registered for the Career Fair can distribute handouts, flyers
or business cards to potential candidates.
aa
A Take-Away Gift Just for You!
Come by the Discovery Center and take home
a meeting souvenir—get your picture taken with
one of the landmarks of Boston and discover
where the 2015 ACR/ARHP Annual Meeting
will be held!
Membership Booth
Located in Registration (Exhibit Level), this is the place to go
if you want to become a member, pay dues, reinstate your
membership, learn more about member benefits and awards
or volunteer to serve on a committee.
18
2014 Program Book
Registration
Registration counters are located in East Registration
(Exhibit Level).
Registration Hours:
Friday, November 14. . . . . . . . . . . . . . . .
Sunday, November 16. . . . . . . . . . . . . . .
Monday, November 17. . . . . . . . . . . . . .
:30 AM –6:00 PM
6
6:30 AM –6:30 PM
6:30 AM –6:00 PM
7:00 AM –6:00 PM
7:00 AM –6:00 PM
7:00 AM –1:00 PM
Get On-Demand Annual
Meeting Education with
SessionSelect!
ATTENDEE
BONUS!
Your Annu
al Meeting
registratio
n fee give
s
you FREE
acce
online con ss to the
tent of the
2014 Annu
al Meeting
in Session
Select for
one year!
Starting on Monday (November 17), you can view fully-synchronized presentations
online, complete with speaker slides and audio, within 24 hours from the completion
of the live session—just as if you were actually attending each session. Take advantage
of the most convenient way to experience education from the Annual Meeting at
your own pace.
With SessionSelect you can:
• S tay up to date on the most relevant information and research pertaining to
rheumatic diseases
pply session information to your practice to enhance your knowledge, competence
•A
and performance
atch and learn 24/7—View content on your mobile device or download MP3 files
•W
for listening to audio on-the-go
To learn more about SessionSelect or to view
a demo, be sure to stop by the ACR’s Discovery
Center, located in Exhibit Hall A (Booth #731), or
the Concierge Center, located in the North Lobby,
or go to www.ACRannualmeeting.org/SessionSelect.
www.rheumatology.org/SessionSelect
Recordings of individual sessions are subject to change. Ticketed sessions and pre-meeting courses are not included in complimentary access.
CME credit is not available for viewing 2014 sessions online.
general information
Shuttle Bus
Shuttle service will be provided to and from the Boston
Convention and Exhibition Center and ACR hotels that are
designated as non-walking hotels. On Friday, Saturday and
Wednesday, service operates continuously. On Sunday through
Tuesday, service operates from 6:30 - 10:30 am and 2:30 - 6:30
pm. Full shuttle service information will be posted in ACR hotel
lobbies and at the shuttle bus entrances of the convention
center.
This service is complimentary for attendees and registered
guests who booked their rooms through ACR Housing. Attendees
who have booked their rooms on their own in contracted or noncontracted ACR hotels may purchase an ACR shuttle bus pass at
the ACR registration counter for $50.
Speaker Ready Room
Located in Room 206, check-in is expected of all speakers and
oral abstract presenters (excluding Meet the Professor and
Workshop speakers, as well as poster presenters). Plan to check
in at least 3 hours prior to your presentation time. In the Speaker
Ready Room, you can review your presentation and approve the
file to be uploaded to the central server. Professional audiovisual
technicians will be available to assist you. Computers in the
Speaker Ready Room will be configured with hardware and
software exactly like the ones in the meeting rooms and will
allow you to preview your presentation, identify problems and
make corrections as necessary before your presentation.
Speaker Ready Room Hours:
Friday, November 14. . . . . . . . . . . . . . . .
Sunday, November 16. . . . . . . . . . . . . . .
Monday, November 17. . . . . . . . . . . . . .
Rheumatology Research Foundation Donors’ Lounge
Experience the perks of supporting the Rheumatology Research
Foundation while at the 2014 ACR/ARHP Annual Meeting
in Boston! Attendees with access are invited to enjoy a hot
breakfast every morning and gourmet coffee service throughout
the day. Located in the Boardroom, the Donors’ Lounge is a great
place to check your e-mail between sessions or catch up on work
at our private computer stations. Donors are also invited to
relax, watch television and network with their colleagues.
Eligible donors will be able to get into the lounge with the 2014
Donors’ Lounge Access Pass. Passes will be distributed on site
to individuals who have donated a total of $500 or more during
fiscal year 2014 (July 1, 2013 through June 30, 2014).
Donors’ Lounge Hours:
Saturday, November 15 . . . . . . . . . . . . . Noon – 5:00 PM
Sunday, November 16. . . . . . . . . . . . . . . 7:00 AM – 6:00 PM
Tuesday, November 18. . . . . . . . . . . . . . 7
:00 AM – 6:00 PM
Wednesday, November 19. . . . . . . . . . . 7:00 AM – 12:30 PM
SPECIAL OFFERS AT
THE ANNUAL MEETING
SessionSelect – no need to miss a session!
6:30 AM –6:00 PM
6:30 AM –6:30 PM
6:30 AM –6:00 PM
6:30 AM –8:00 PM
6
:30 AM –6:00 PM
7
:00 AM –12:30 PM
Wi-Fi Way and Recharge Access
Complimentary Wi-Fi access is available in all rooms of the
convention center. Recharge areas will be available in Wi-Fi Way
(Exhibit Hall A), the Attendee Lounge (Ballroom Lobby) and the
Technology Center (North Lobby).
Within 24 hours of virtually every live session at the Annual
Meeting, video recordings of the presentations, including oral
abstracts, will be available through SessionSelect. As an attendee
benefit, you get FREE online access for one year to hundreds of
hours of Annual Meeting content–over $500 of added value. See
page 19 for more information.
Please Note: Recordings of individual sessions are subject to
change. Ticketed sessions and pre-meeting courses are not
included in complimentary access. CME credit is not available for
viewing 2014 sessions through SessionSelect.
What Would Make This Meeting Better?
You’ve got ideas to share, and we’ve made it easy for you to
share them.
• Tweet your idea using the #ACR2014 hashtag.
• S ubmit your session proposal or topic idea for the 2015
meeting at ACRannualmeeting.org.
Medical Bag
Don’t forget to pick up a Medical Bag prior to visiting the
exhibits. Each bag contains special offers and invitations from
our exhibitors and will be distributed from the exhibition
entrance while supplies last.
20
2014 Program Book
general information
POSTER SESSIONS
Poster presentations facilitate one-on-one interaction between
the presenters and attendees. Posters are grouped by topic and
will remain displayed in the poster hall (Exhibit Hall B) from 9:00
am - 4:00 pm, Sunday, November 16 - Tuesday, November 18.
Poster presenters will be available at their poster from 9:00 11:00 am.
One poster session will be held each day; however, there is
no poster session on Wednesday. Poster presentations will be
unopposed during the 10:00 - 11:00 am hour. The number on the
poster boards refers to the abstract presentation number, and
this number will change for each poster session.
Late-breaking abstract posters will be available for viewing
Sunday, November 16 - Tuesday, November 18. Late-breaking
abstract presenting authors will be available at their posters on
Tuesday, November 18 from 9:00 am - 11:00 pm
Thieves’ Market posters will be presented on Monday,
November 17 and Tuesday, November 18.
NEW THIS YEAR!
• T wo new ACR clinical science abstract categories have
been introduced: “Pain: Clinical Aspects” and “Quality
Measures and Quality of Care.”
aa
!
The abstract supplement will no longer
be offered in the flash drive version. All
attendees will be able to easily access the
abstract supplement publication online.
Posters must be mounted by 8:30 am of the designated poster
session and dismantled after 4:00 pm as outlined in the abstract
acceptance notification. Posters not dismantled by 5:00 pm
each day will be recycled. Poster storage will not be available in
the poster hall.
In order to ensure a positive experience for both attendees and
poster presenters, it is important to make sure that all posters
are properly mounted and presenters are present from 9:00
- 11:00 am for poster presentations to answer questions from
attendees. Poster presenter ribbons will be available in the
Speaker Ready Room (Room 206).
Poster Presenter No-shows
Please Note: The ACR will be monitoring posters during the
presentation hours in an effort to make certain the College is
meeting the educational needs and expectations of attendees.
Poster Sessions - Sunday, November 16 through Tuesday,
November 18 from 9:00 am - 4:00 pm
Set Up: . . . . . . . . . . . . . . . . . . . . . . . . . . . 7:00 – 8:30 AM
Presentation: . . . . . . . . . . . . . . . . . . . . . 9:00 – 11:00 AM
Poster Tours: . . . . . . . . . . . . . . . . . . . . . . 9:00
– 9:45 AM
10:15 – 11:00 AM
Posters to remain up until 4:00 pm
Poster pick up:. . . . . . . . . . . . . . . . . . . . . 4:00 – 6:30 PM
ACR Removal: . . . . . . . . . . . . . . . . . . . . . 6:30 PM*
*The ACR will remove and promptly recycle all posters not picked
up by 6:30 pm each day.
Guided Poster Tours
Guided poster tours, led by experts in the field, will guide small
groups of attendees during the poster presentation times
to highlight novel or recent developments. Selected posters
from various abstract categories will be included in the tours.
Although there is no fee to participate, pre-registration is
required and each tour is limited to 20 registered scientific
attendees.
If you would like to participate and have not registered, you
can check tour availability and request a ticket at registration,
located in East Registration on the Exhibit Level. If you registered
in advance of the meeting, your ticket is located on the back
of your name badge. Once you have your ticket, it is important
that you collect your headset from the Poster Tour Kiosk and
meet your group 10 minutes before your tour departs from the
entrance of the poster hall, located in Exhibit Hall B. Poster tour
reservations will be released to stand-by attendees five minutes
before the tour.
2014 Program Book
21
FRIDAY
2 0 1 4
Great Meetings
n o v e m b e r
1 4 ,
Come from
Great Ideas!
Call for Proposals: Submit your session
idea or study group topic for the 2015 ACR/ARHP
Annual Meeting at ACRannualmeeting.org TODAY!
We are looking for proposals that:
• Reflect clinical innovation and cutting edge research.
• Convey best practices.
• Present evidence-based medicine.
• Stimulate discussion and challenge mind-sets.
Tell us about learning models that:
• Address challenges in your area of practice.
• Create opportunities to share information across
geographical demographics.
• Encourage collaboration between subspecialities
• Promote partnership among physicians and
health professionals.
Relevant topics may include:
• Technological advances impacting practice.
• World-wide trends in patient care.
• Outcomes assessment and holistic treatment.
Deadline for submissions is Friday, November 21, 2014
acr/arhp scientific sessions
FRIDAY, NOVEMBER 14, 2014
PRE-MEETING COURSES
PM
PS
ACR MUSCULOSKELETAL ULTRASOUND
COURSE FOR RHEUMATOLOGISTS – DAY ONE
OF TWO
7:45 am – 5:30 pm
109 A
Admission to the ACR Musculoskeletal Ultrasound Course for
Rheumatologists requires a separate registration. Registration
includes complimentary Continental Breakfast and a boxed lunch.
Upon completion of this session, participants should be able to:
• demonstrate proper ultrasound exam technique and
procedure guidance, applying standardized protocols
• identify and describe normal sonographic anatomy and
fundamental pathology for rheumatology indications
• explain the requirements for documentation related to
musculoskeletal ultrasound
Moderator: Eugene Y. Kissin, MD
22
2014 Program Book
Faculty: Catherine J. Bakewell, MD; Jurgen Craig-Muller, MD;
Paul J. DeMarco, MD; Amy M. Evangelisto, MD; Janak R. Goyal,
MD; Jay B. Higgs, MD; Gurjit S. Kaeley, MBBS, MRCP; Eugene Y.
Kissin, MD; Minna J. Kohler, MD; Gary A. Kunkel, MD; Clara Lin,
MD; Daniel G. Malone, MD; Bethany A. Marston, MD; Midori
Jane Nishio, MD; Anthony M. Reginato, PhD, MD; Johannes
Roth, MD; Jonathan Samuels, MD; Darren Tabechian, MD; Ralf
G. Thiele, MD, RhMSUS; Karina Marianne Torralba, MD, MMED;
Alicia Weeks, MD
7:00 – 7:45 am
Continental Breakfast
7:45 am
Introduction
Eugene Y. Kissin, MD
8:00 am
Principles of Musculoskeletal Ultrasound for Rheumatologists
Jay B. Higgs, MD
scientific sessions
9:30 am
Lecture: Standard Scans, Sonographic Anatomy and Basic
Sonographic Pathology
10:00 am
Live Demonstration: Hand and Wrist
5:00 pm
Hands-On Scanning: The Upper Extremity in Pediatrics
Bethany A. Marston, MD and Johannes Roth, MD
ACRPMADVANCED
RHEUMATOLOGY CODING
PS
COURSE: DEVELOPING EXPERTS IN
RHEUMATOLOGY CODING AND
ICD-10-CM
9:00 am – 5:00 pm
257 A
10:15 am
Hands-On Scanning: The Hand and Wrist
All Faculty
Admission to the ACR Certified Rheumatology Coder Course
requires a separate registration. Registration includes
complimentary Continental Breakfast and a boxed lunch.
This course is not eligible for CME credit.
11:30 am – 12:30 pm
Boxed Lunch
8:00 – 9:00 am
12:30 – 2:15 pm
Speakers: Antanya Chung, CPC, CPC-I, CRHC, CCS-P and
Melesia Tillman, CPC, CPC-I, CRHC, CHA
The Elbow
12:30 pm
Amy M. Evangelisto, MD
1:00 pm
Live Demonstration: Scanning of the Elbow
Amy M. Evangelisto, MD
1:15 pm
Hands-On Scanning: The Elbow
All Faculty
2:15 – 2:30 pm
Afternoon Break
2:30 – 4:30 pm
The Shoulder
2:30 pm
Gurjit S. Kaeley, MBBS, MRCP
3:00 pm
Live Demonstration: Scanning of the Shoulder
3:15 pm
Hands-On Scanning: The Shoulder
All Faculty
2 0 1 4
Hand and Wrist
4:30 pm
Lecture: Pediatric Anatomy in Musculoskeletal Ultrasound
Johannes Roth, MD
1 4 ,
9:30 – 11:30 am
Pediatrics
FRIDAY
9:15 – 9:30 am
Morning Break
4:30 – 5:30 pm
n o v e m b e r
8:30 am
Introduction to Typical Sonographic Findings and Tissue
Characteristics in Rheumatology
Clara Lin, MD
• exhibit proficiency in adjudicating claims for accurate medical
coding for diagnoses, procedures and services in physicianbased settings
• demonstrate knowledge of medical coding rules and
regulations including compliance and reimbursement
• evaluate, revise and focus physician educational efforts and
queries to meet documentation requirements for medical
necessity and ICD-10-CM
• identify the impact ICD-10-CM will have on organizations and
workflow
• implement strategies that will improve clinical documentation
and facilitate a smooth transition to ICD-10-CM
• recognize how ICD-10-CM documentation requirements
will affect principal diagnosis selection, additional diagnosis
reporting and diagnosis sequencing
ACR BASIC RESEARCH
CONFERENCE:
PS
PM
EMERGING PERSPECTIVES ON THE
MICROBIOME IN THE RHEUMATIC DISEASES –
DAY ONE OF TWO
1:00 – 6:10 pm
210 B
Admission to the Basic Research Conference requires a separate
registration.
• describe underlying principles and evidence demonstrating
how the microbiome may affect immune development and
thresholds of immune responsiveness
2014 Program Book
23
n o v e m b e r
1 4 ,
FRIDAY
2 0 1 4
scientific sessions
• e xamine the technologic and bioinformatics tools that are
used to provide quantitative data that enable correlations
with host phenotypes and alterations (or dysbioses) within
the microbiome
• describe disease states that may be affected by microbial
dysbioses
1:00 – 1:45 pm
Keynote Lecture: Microbiome and Host Immune
Defenses
Speaker: Dan Littmann, MD, PhD
1:45 – 4:00 pm
Session I: Overview of General Principles
Moderator: Heidi H. Kong, MD, MHSc
1:45 pm
Culture Independent Surveys of Microbiomes
Rob Knight, PhD
2:15 pm
Surveys of Human Populations and Families
Jack Gilbert, PhD
2:45 pm
Analysis and Models of Microbiomes
Eric A. Franzosa, PhD
3:15 pm
Multi-Omics
Janet Jansson, PhD
3:45 pm
Afternoon Break
4:00 – 6:10 pm
Session II: The Microbiome and Regional Immunity
Moderator: Susan A. Boackle, MD
4:00 pm
Microbial Molding of Mucosal Immunity
Hiroshi Kiyono, DDS, PhD
4:30 pm
Microbiome and Lung
Susan Lynch, PhD
5:00 pm
Microbial Regulation of Responses in the Skin
Heidi H. Kong, MD, MHSc
5:30 pm
Immunity at the Barriers
Yasmine Belkaid, PhD
6:00 pm
Questions and Answers
6:10 – 7:00 pm
Networking Reception
Reception combined with ACR Clinical Research Conference
participants.
24
2014 Program Book
ACR CLINICAL RESEARCH CONFERENCE:
PATIENT-CENTERED OUTCOMES IN
RHEUMATOLOGY – DAY ONE OF TWO
PM
PS
1:00 – 6:00 pm
205 B
Admission to the ACR Clinical Research Conference requires a
separate registration.
• define the role of patient-centered outcomes from the
perspectives of clinical researchers, patients, caregivers and
other stakeholders
• define the contribution of patient-centered outcomes in a
learning health care system
• describe the case for patient-reported outcomes in clinical
care and identify strategies to overcome barriers to use
• identify and select key variables to consider in selection of
patient-reported outcomes measures
• incorporate patient-reported outcomes results into shared
decision making in their respective clinical settings
1:00 – 4:00 pm
Session I: Methodology and Development
Moderators: Esi Morgan DeWitt, MD, MSCE
1:00 pm
Patient-Centered Outcome Research: Why Methods Matter
Sherine E. Gabriel, MD, MSc
1:15 pm
Modern Methods in Patient-Reported Outcomes Measure
Development
Karon Cook, PhD
2:00 pm
Advances in Comparative Effectiveness Research Methods in
Rheumatoid Arthritis
Jeffrey R. Curtis, MD, MPH, MS
2:30 pm
Patient-Centered Outcomes Research Institute (PCORI) and
Patients as Partners in Research
Joe V. Selby, MD, MPH
3:00 pm
“Nothing About Me Without Me”: Including the Patient in
Outcomes Research
Leslie Kelly-Hall
3:30 pm
3:45 pm
Afternoon Break
4:00 – 6:00 pm
Session II: Translating Patient-Centered Outcomes to
the Real World Setting
Moderator: Sherine E. Gabriel, MD, MSc
scientific sessions
4:00 pm
The Role of Patient-Centered Outcomes in a Learning Health
System
L. Charles Bailey, MD, PhD
2:40 – 3:00 pm
Afternoon Break
4:30 pm
How New Treatments Show They Are Working
Laure Gossec, MD, PhD
Speaker: Seetha U. Monrad, MD
Session II: Questions from 2014 Update
4:30 – 6:00 pm
Session III: Questions from 2014 Update
6:00 – 7:00 pm
Networking Reception
Reception combined with ACR Basic Research Conference
participants.
PM
PS
ACR/ABIM MAINTENANCE OF
CERTIFICATION LEARNING SESSION –
2014 UPDATE IN RHEUMATOLOGY
1:00 – 6:00 pm
258 B
Admission to the ACR/ABIM Maintenance of Certification
Learning Session requires a separate registration. Learn
in an interactive environment as clinical experts lead you
through 30 case-based questions from ABIM’s 2014 Update in
Rheumatology Module. After the session, submit your answers
online to the ABIM to receive 10 medical knowledge points for
the Maintenance of Certification program.
PRE-MEETING COURSES
PM
PS
ACR MUSCULOSKELETAL ULTRASOUND
COURSE FOR RHEUMATOLOGISTS – DAY TWO
OF TWO
7:15 am – 5:50 pm
109 A
Admission to the ACR Musculoskeletal Ultrasound Course for
Rheumatologists requires a separate registration. Registration
includes complimentary Continental Breakfast and a boxed
lunch.
Moderator: Eugene Y. Kissin, MD
Faculty: Catherine J. Bakewell, MD; Jurgen Craig-Muller, MD;
Paul J. DeMarco, MD; Amy M. Evangelisto, MD; Janak R. Goyal,
MD; Jay B. Higgs, MD; Gurjit S. Kaeley, MBBS, MRCP; Eugene Y.
Kissin, MD; Minna J. Kohler, MD; Gary A. Kunkel, MD; Clara Lin,
MD; Daniel G. Malone, MD; Bethany A. Marston, MD; Midori
Jane Nishio, MD; Anthony M. Reginato, PhD, MD; Johannes
Roth, MD; Jonathan Samuels, MD; Darren Tabechian, MD; Ralf
G. Thiele, MD, RhMSUS; Karina Marianne Torralba, MD, MMED;
Alicia Weeks, MD
• assess strengths and weaknesses in rheumatology medical
base knowledge
• state major developments in rheumatology over the past ten
years
• satisfy a self-evaluation requirement for the American Board
of Internal Medicine Maintenance of Certification program
• demonstrate proper ultrasound exam technique and
procedure guidance, applying standardized protocols
• identify and describe normal sonographic anatomy and
fundamental pathology for rheumatology indications
• explain the requirements for documentation related to
musculoskeletal ultrasound
1:00 pm
Introduction
Carol A. Langford, MD, MHS
6:45 – 7:15 am
1:10 – 2:40 pm
Session I: Questions from 2014 Update
Speaker: Carol A. Langford, MD, MHS
2 0 1 4
5:45 pm
Wrap-Up
Sherine E. Gabriel, MD, MSc and Esi Morgan DeWitt, MD, MSCE
1 5 ,
SATURDAY, NOVEMBER 17, 2014
5:30 pm
SATURDAY
Speaker: Erika H. Noss, MD, PhDSATURDAY, NOVEMBER 15,
2014
n o v e m b e r
5:00 pm
Learning Health System and Patient-Centered Outcomes in
Pediatric Rheumatology
Esi M. Morgan DeWitt, MD, MSCE
3:00 – 4:30 pm
7:15 am
Opening Remarks
7:30 – 9:15 am
The Hip
7:30 am
2014 Program Book
25
n o v e m b e r
1 5 ,
SATURDAY
2 0 1 4
scientific sessions
Midori Jane Nishio, MD
of Procedures
Janak R. Goyal, MD
8:00 am
Live Demonstration: Scanning of the Hip
Midori Jane Nishio, MD
3:45 pm
Panel Discussion – Implementing Musculoskeletal Ultrasound
in the Practice of Rheumatology
Catherine Bakewell, MD; Paul J. DeMarco, MD; Eugene Y. Kissin,
MD; and Ralf G. Thiele, MD, RhMSUS
8:15 am
Hands-On Scanning: The Hip
All Faculty
9:15 – 9:30 am
Morning Break
9:30 – 11:30 am
The Knee
9:30 am
Gary A. Kunkel, MD
10:00 am
Live Demonstration: Scanning of the Knee
Gary A. Kunkel, MD
10:15 am
Hands-On Scanning: The Knee
All Faculty
11:30 am – 12:30 pm
Boxed Lunch
12:30 pm – 2:30 pm
Foot and Ankle
12:30 pm
Ralf G. Thiele, MD, RhMSUS
1:00 pm
Live Demonstration: Scanning of Foot and Ankle
Ralf G. Thiele, MD, RhMSUS
1:15 pm
Hands-On Scanning: Foot and Ankle
All Faculty
2:30 pm
Billing, Coding and Report Generation
Paul J. DeMarco, MD
3:00 pm – 3:15 pm
Afternoon Break
3:15 pm – 5:00 pm
Ultrasound Needle Guidance
3:15 pm
Lecture: Evidence Base and Technique of Ultrasound Guidance
26
2014 Program Book
4:15 pm
Hands-On Scanning: Ultrasound Guidance of Procedures
All Faculty
5:00 – 5:50 pm
Pediatrics
5:00 pm
Lecture: The Lower Extremity in Pediatrics
Johannes Roth, MD
5:20 pm
Hands-On Scanning: Pediatrics
Bethany A. Marston, MD and Johannes Roth, MD
ACR CLINICAL RESEARCH CONFERENCE:
PATIENT-CENTERED OUTCOMES IN
RHEUMATOLOGY – DAY TWO OF TWO
PM
PS
7:45 am – 4:30 pm
205 B
Admission to the ACR Clinical Research Conference requires
a separate registration. Registration includes complimentary
Continental Breakfast and a boxed lunch.
• define the role of patient-centered outcomes from the
perspectives of clinical researchers, patients, caregivers and
other stakeholders
• define the contribution of patient-centered outcomes in a
learning health care system
• describe the case for patient-reported outcomes in clinical
care and identify strategies to overcome barriers to use
• identify and select key variables to consider in selection of
patient reported outcomes measures
• incorporate patient-reported outcomes results into shared
decision making in their respective clinical settings
7:00 – 7:45 am
7:45 – 8:00 am
Introduction
Speakers: Sherine E. Gabriel, MD, MSc and Esi Morgan DeWitt,
MD, MSCE
8:00 – 9:30 am
Session III: Research Perspective
Moderator: Kenneth G. Saag, MD, MSc
scientific sessions
8:00 am
Patient-Centered Outcomes Research in ANCA-Associated
Vasculitis
Peter A. Merkel, MD, MPH
2:00 – 4:30 pm
8:30 am
Patient-Centered Outcomes Research in Pediatrics
Angelo Ravelli, MD
2:00 pm
The Patient-Reported Outcomes Measurement Information
System in Rheumatology
James P. Witter, MD, PhD
Session VI: Patient-Reported Outcomes (PROs)
Measures in Research and Clinical Trials
Moderator: Dinesh Khanna, MD
9:30 am
Use of Patient-Reported Outcomes in Rheumatology Clinical
Practice
Clifton O. Bingham III, MD
3:20 pm
Abstract Presentations
3:50 pm
10:00 am
Passive Patient-Reported Outcomes: Biosensors and Social
Media to Track Patient Outcomes
Brennan Spiegel, MD, MSHS
10:45 am
Shared Decision Making: Incorporating Patient-Centered
Outcomes
Liana Fraenkel, MD, MPH
11:15 am
Family Communication – The Next Frontier for Improving
Patient Satisfaction
Richard Siegrist, Jr., MBA, MS, CPA
11:45 am
Big Data and the Point of Care
Kenneth D. Mandl, MD, MPH
12:15 – 1:00 pm
Boxed Lunch
1:00 – 2:00 pm
Session V: Patient Perspective
Moderator: Sherine E. Gabriel, MD, MSc
1:00 pm
Importance of Patient-Centered Outcomes From the Patient’s
Viewpoint
Kelly Young, BA
1:30 pm
Parent Engagement in Care and Research
Judy K. Crosby, JD
2 0 1 4
Moderator: Nora G. Singer, MD
1 5 ,
2:50 pm
Incorporating Patient-Centered Outcomes (PCOs) in Product
Development: Industry Perspective
Arijit X. Ganguli, MBA, PhD
Session IV: Clinical Care Perspective: Practical Tools
for Using Patient-Reported Outcomes (PROs)
SATURDAY
2:30 – 2:50 pm
Afternoon Break
9:30 am – 1:00 pm
10:30 – 10:45 am
Morning Break
n o v e m b e r
9:00 am
Patient-Centered Outcomes Research in Scleroderma
Dinesh Khanna, MD, MSc
4:00 pm
Wrap-Up
Sherine E. Gabriel, MD, MSc and Esi Morgan DeWitt, MD, MSCE
PS
PM
ACR PRACTICE MANAGEMENT PRE-MEETING
COURSE
8:00 am – 4:00 pm
257 A
Admission to the ACR Practice Management Pre-meeting
Course requires a separate registration. Registration includes
complimentary Continental Breakfast and a boxed lunch.
Moderator: Nilsa Cruz
7:00 – 8:00 am
8:00 – 9:00 am
Customer Service That Rocks: Boost Patient
Satisfaction
Speaker: Brandi Young, DNP
• identify steps to achieve outstanding patient satisfaction
results and discover reliable methods for dealing with
demanding patients
• outline breaking through ordinary communication and
outdated work habits and improve overall customer service
from check-in to check-out
• discuss specific techniques to implement for over-the-phone
or in-person communications to calm upset patients
9:00 – 9:30 am
Morning Break
2014 Program Book
27
scientific sessions
n o v e m b e r
1 5 ,
SATURDAY
2 0 1 4
9:30 – 10:30 am
Take Your Appeals to the Next Level
Speaker: Mark Painter
• identify how to customize appeal letters for Level II appeals so
no higher level appeals are rejected
• identify the steps to appeal for all carriers, which forms to use
and proven strategies for successful appeals
• discuss how to craft effective appeals letters and get your
PS
PM
claims paid
• discuss why it is important to move from a back-end
collections strategy to a front-end strategy
• identify all that should be collected at the time of service and
the difference it will make in collections (e.g., co-insurance,
co-pay, self-pay)
• define the practice collection process and what it means to
the practice bottom line
• identify tactics, tools and technologies to optimize collections
from self-pay patients and reduce days in accounts receivable
10:30 – 11:30 am
Managing Denials in a Complex Reimbursement
Environment
• identify how to set up a tracking mechanism to collect data
on denials
• improve front and back office processes to prevent future
denials
• determine root causes, patterns and process breakdowns
responsible for denials, and explaining how establishing
corrective steps may reduce the volume of denied claims
and write-offs
11:30 am – 12:30 pm
Boxed Lunch
12:30 – 1:30 pm
Ins and Outs of an Effective Compliance Plan
Speaker: Anita Henderson Sumpter, MBA, MHA, CPC, CMOM
• discuss how to structure an “effective” anti-corruption
compliance program.
• identify the vital elements of an effective compliance program
• discuss the role of a compliance office in fighting fraud and
implementing a compliance program
1:30 – 2:00 pm
Afternoon Break
2:00 – 3:00 pm
Increase Team Performance and Productivity
• discuss how to reduce staff conflict and build a team with a
common purpose and shared vision
• identify the elements of building a high-performance team
• discuss the key principles of team dynamics, such as balance,
conflict management and team alignment to provide practical
insight into productivity and team success
28
3:00 – 4:00 pm
Improve Time-of-Service Collections From the
Front End
2014 Program Book
Speaker: Jessica Farrell, PharmD
ACR REVIEW COURSE
8:00 am – 4:00 pm
Exhibit Hall C
Admission to the ACR Review Course requires a separate
registration. Registration includes complimentary Continental
Breakfast and a boxed lunch.
Moderators: Simon M. Helfgott, MD and Kristine M. Lohr, MD,
MS
6:30 – 8:00 am
8:00 – 8:45 am
Pregnancy Management and Outcome in Systemic
Lupus Erythematosus
Speaker: Lisa R. Sammaritano, MD
• review the key clinical issues related to pregnancy in the lupus
patient
• discuss some of the more common clinical challenges facing
the rheumatologist and obstetrician
• formulate some recommendations regarding the management
of pregnancy and the role of the rheumatologist
8:45 – 9:30 am
The Diagnosis and Management of Macrophage
Activation Syndrome
Speaker: Alexei A. Grom, MD
• identify the clinical features of macrophage activation
syndrome
• review the steps required to establish the diagnosis, using lab
and clinical criteria
• discuss treatment options for macrophage activation
syndrome
9:30 – 10:15 am
Interstitial Lung Disease in Rheumatic Disease: A
Focused Review
Speaker: Aryeh Fischer, MD
• evaluate patterns of interstitial lung disease (ILD) and the
clinical landscape of ILD disease in rheumatic diseases
scientific sessions
• r eview the evaluation of rheumatic patients with ILD and the
evaluation for occult rheumatic diseases in those presenting
with presumed idiopathic ILD
• outline the management of ILD in patients with rheumatic
disease
10:15 – 10:45 am
Morning Break
Speaker: Soumya Raychaudhuri, MD, PhD
Management of Salivary Gland Involvement in
Sjögren’s Syndrome
Speaker: Alan N. Baer, MD
• describe salivary gland anatomy and methods to assess
function and structure
• recognize symptoms and signs of salivary gland disease and
MALT lymphoma in Sjögren’s syndrome
• recommend management of salivary hypofunction and MALT
lymphoma in Sjögren’s syndrome
12:15 – 1:15 pm
Boxed Lunch
1:15 – 2:00 pm
Management of Pseudogout: Insights for Clinicians
Speaker: Geraldine M. McCarthy, MD
• describe the clinical features of calcium pyrophosphate
dihydrate (CPPD) crystal-associated arthropathy
• formulate a diagnostic approach to CPPD arthropathy and
screening for predisposing metabolic disease
• manage CPPD arthropathy
2:00 – 2:45 pm
Assessing Disease and Managing Large Vessel
Vasculitis
Speaker: Kenneth J. Warrington, MD
• recognize the presentations of Takayasu arteritis and giant cell
arteritis
• describe vascular involvement in large vessel vasculitis
• recommend short- and long-term management of large vessel
vasculitis
2:45 – 3:15 pm
Afternoon Break
ACR BASIC RESEARCH
CONFERENCE:
PS
PM
EMERGING PERSPECTIVES ON THE
MICROBIOME IN THE RHEUMATIC DISEASES –
DAY TWO OF TWO
2 0 1 4
11:30 am – 12:15 pm
• discuss interactions of medications used to treat rheumatoid
arthritis and malignancy
• discuss the risks and benefits of rheumatoid arthritis
treatment in the setting of malignancy
• modify rheumatoid arthritis treatment in the setting of
malignancy
1 5 ,
• review how genomics affects the clinician’s understanding of
specific rheumatic diseases such as rheumatoid arthritis
• discuss the future role of genomics and how it may fit into the
rheumatology practice of tomorrow
Speaker: Iain B. McInnes, PhD
SATURDAY
Genomics for the Clinician
Rheumatoid Arthritis Therapy After Diagnosis of
Malignancy
n o v e m b e r
10:45 – 11:30 am
3:15 – 4:00 pm
8:00 am – 4:30 pm
210 B
Admission to the ACR Basic Research Conference requires a
separate registration. Registration includes complimentary
Continental Breakfast and a boxed lunch.
• describe underlying principles and evidence demonstrating
how the microbiome can affect immune development and
thresholds of immune responsiveness
• examine the technologic and bioinformatics tools that are
used to provide quantitative data that enable correlations
with host phenotypes and alterations (or dysbioses) within
the microbiome
• describe disease states that may be affected by microbial
dysbioses
7:00 – 8:00 am
8:00 – 10:30 am
Session III: Mechanisms of Immune Activation and
Regulation
Moderator: Kevin D. Deane, MD, PhD
8:00 am
Mechanisms of Immune Activation and Regulation
Andrew Gewirtz, PhD
8:30 am
Microbiome and Gut T Cell Signaling
June L. Round, PhD
9:00 am
Microbiota and Tumor Immunity
Romina Goldszmid, PhD
9:30 am
The Microbiome as a Potential Risk Factor for Psoriatic
Arthritis
Anne Barton, PhD
2014 Program Book
29
scientific sessions
10:00 am
10:10 – 10:30 am
Morning Break
10:30 am – 1:30 pm
Session IV: Microbiome and Rheumatic Disease
n o v e m b e r
1 5 ,
SATURDAY
2 0 1 4
Moderator: Gregg J. Silverman, MD
10:30 am
Microbiome and Psoriatic Arthritis
James T. Rosenbaum, MD
11:00 am
Microbiome and Rheumatoid Arthritis
Jose U. Scher, MD
11:30 am
Microbiome and Inflammatory Bowel Disease
Jonathan Braun, MD, PhD
Noon
GALT Mediated Regulation of Immunologic Tolerance and
Systemic Lupus Erythematosus
Jo Spencer, PhD
12:30 pm
12:45 – 1:30 pm
Boxed Lunch
1:30 – 4:30 pm
Session V: Prospects for Manipulating Disease
Through the Microbiome
Moderator: Jose U. Scher, MD
1:30 pm
Consequences for Disease and Health of Shifting the
Microbiome: Antibiotics, Probiotics and Nutriceuticals
David A. Mills, MS, PHD
2:00 pm
Treatment of Inflammatory Bowel Disease With Nematodes
Joel Weinstock, MD
2:30 pm
Manipulating the Urogenital Microbiome of Women
Gregor Reid, PhD, MBA
30
ARHP CLINICAL FOCUS COURSE:
DIAGNOSTIC
PS
PM
IMAGING USE IN DIFFERENTIAL DIAGNOSIS
FOR COMMON RHEUMATIC AND
MUSCULOSKELETAL CONDITIONS
8:00 am – 4:30 pm
254 A
Admission to the ARHP Clinical Focus Course requires a separate
registration. Registration includes complimentary Continental
Breakfast and a boxed lunch.
Moderator: Karen Huisinga, MN, ARNP
• review the concepts of common, patient-specific rheumatic
differential diagnosis
• develop basic knowledge of diagnostic imaging focusing on
plain film, MRI and ultrasound
• define the role, utilization and limitations of diagnostic
imaging in plain film, MRI and ultrasound in the clinical setting
• identify the appropriate imaging modality to apply in the
clinical setting
7:00 – 8:00 am
8:00 am
Introduction
Karen Huisinga, MN, ARNP
8:15 – 9:00 am
Diagnostic Imaging: A Tool for Differential Diagnosis
Michael D. Ross, PT, DHSc, OCS
9:00 – 11:00 am
Plain Film
9:00 am
Outlining the Value of Plain Film
9:45 – 10:00 am
Morning Break
10:00 am
Plain Film Case Presentation
10:45 am
Plain Film Questions and Answer
3:00 – 3:15 pm
Afternoon Break
11:00 am – 1:30 pm
3:15 pm
Fecal Transplants
Michael J. Sadowsky, PhD
11:00 am
Outline the Value of Ultrasound
Patrick Astourian, MPAS, PA-C
3:45 pm
Abstract Presentations
11:45 am – 12:30 pm
Boxed Lunch
4:20 pm
Wrap-Up
Heidi H. Kong, MD, MHSc and Rob Knight, PhD
12:30 pm
Ultrasound Case Presentations
Patrick Astourian, MPAS, PA-C
2014 Program Book
Ultrasound
scientific sessions
1:15 pm
Ultrasound Case Questions and Answer
SCIENTIFIC SESSIONS
1:30 – 3:30 pm
ACR/ARHP OPENING LECTURE AND AWARDS
Magnetic Resonance Imaging (MRI)
4:30 – 6:15 pm
1:30 pm
Outlining the Value of MRI
Stacy Smith, MD
Exhibit Hall C
Moderators: Joseph Flood, MD, ACR President and
Karen L. Smarr, PhD, ARHP President
2:15 – 2:30 pm
Afternoon Break
4:30 pm
ACR Presidential Address
2:30 – 3:15 pm
MRI Case Presentations
Stacy Smith, MD
5:00 pm
Recognition of 2014 ACR Masters
3:15 – 3:30 pm
MRI Case Questions and Answer
Recognition of 2014 ARHP Merit Awards Recipients
Recognition of 2014 ACR Awards of Distinction Recipients
PM
PS
AAMC MEDICAL EDUCATION RESEARCH
CERTIFICATE (MERC) WORKSHOP
9:00 am – 4:00 pm
This workshop is not eligible for CME credit.
204 A
9:00 am – Noon
Formulating Research Questions and Designing
Studies
Speaker: Karen Richardson-Nassif, PhD
• write a FINER (feasible, interesting, novel, ethical, relevant)
educational research question
• specify an educational research area of interest
• evaluate whether they need Institutional Review Board
approval for their study
• select the correct design for their research question
5:30 – 6:15 pm
Measuring Educational Outcomes With Reliability
and Validity
Speaker: Karen Richardson-Nassif, PhD
• identify three types of reliability (inter-rater, test-retest and
internal consistency)
• match types of reliability with appropriate statistical measures
• describe the relationship between reliability and validity
• describe multiple forms of evidence for validity
• select an approach to reliability and validity assessment for a
particular study
PS
Speaker: Leroy Hood, MD, PhD
• review systems medicine and how its technologies and
strategies are changing medicine
• describe how P4 medicine differs from evidence-based
medicine
• explain the power of a longitudinal, Framingham-like 100,000
person wellness study for optimizing wellness for each
individual and for studying wellness to disease transitions at
the earliest stage
ACR/ARHP OPENING RECEPTION
6:15 – 9:00 pm
Ballroom East and West
Noon – 1:00 pm
Boxed Lunch
1:00 – 4:00 pm
PM
Opening Lecture: P4 Medicine Is Transforming Health
Care: A Longitudinal, Framingham-like Study of
100,000 Well Patients Over 20-25 Years
2 0 1 4
4:15 pm
Wrap-Up
1 6 ,
Recognition of 2014 Rheumatology Research Foundation
Corporate Roundtable Donors
SUNDAY
Audience Response Interactive Session
n o v e m b e r
Recognition of 2014 ACR Distinguished Fellows Awards
Recipients
3:30 – 4:30 pm
SUNDAY, NOVEMBER 16, 2014
ACR SESSIONS
7:30 – 8:30 am
253 B
PM
PS
Age Before Beauty: Colchicine, Aspirin, Methotrexate
and Their Mechanisms of Action
Moderator: Wael N. Jarjour, MD
Speaker: Bruce N. Cronstein, MD
2014 Program Book
31
scientific sessions
• review methotrexate-putative mechanisms of action
in rheumatoid arthritis and gene expression data in
methotrexate-naïve patients before and after treatment
• review hydroxychloroquine mechanisms of action including
discussion of effects on autophagy and TLR signaling in
rheumatoid arthritis and lupus
• review rituximab-recognized mechanisms of action and
immune phenotypic changes in rheumatoid
arthritis
PS
PM
104 B
Pediatric Rheumatology Town Hall
n o v e m b e r
1 6 ,
SUNDAY
2 0 1 4
Moderator: Anna Huttenlocher, MD
• delineate the American Board of Pediatrics Maintenance of
Certification program
• clarify the ACGME milestones for pediatrics • identify current work initiated for pediatric rheumatology
by the ACR
7:30 am
Update on the Modifications to the American Board of
Pediatrics Maintenance of Certification Program
C. Egla Rabinovich, MD, MPH
7:50 am
Update on Accreditation Council for Graduate Medical
Education Pediatric Milestones
Marilynn G. Punaro, MD
8:10 am
American College of Rheumatology Update and Pediatric
Awards
Polly J. Ferguson, MD
PM
PS
Exhibit Hall C
Year in Review
Moderator: Chester V. Oddis, MD
• discuss selected recent publications on the pathophysiological
basis of rheumatic diseases by literature review of important
publications
• describe selected treatment modalities for rheumatic diseases
from the recent published literature
• evaluate how these new advances may impact the practice of
rheumatology
7:30 am
Clinical Perspective
S. Louis Bridges Jr., MD, PhD
8:00 am
Basic Science Perspective
Cornelia M. Weyand, MD, PhD
32
2014 Program Book
NETWORKING EVENT
7:30 – 8:30 am
102 A
ACR/ARHP First-time Attendee Orientation
First-time annual meeting attendees are invited to an orientation
to learn the ‘ins and outs’ of the annual meeting. Dr. Audrey
Uknis, ACR Immediate Past President and Dr. Jan Richardson,
ARHP Immediate Past President, will assist you in planning how
to get the most out of your first annual meeting.
This session is not eligible for CME credit. Coffee and tea will be
provided.
Moderators: Audrey B. Uknis, MD and Jan K. Richardson, PT, PhD,
OCS
PS
PM
ACR MEET THE PROFESSOR SESSIONS
7:45 – 9:15 am
Admission to Meet the Professor sessions requires a separate
registration and ticket. To verify which session you registered for,
the registration code on your ticket needs to match the three-digit
code in parentheses below. If you are interested in participating
in one of these sessions or exchanging your ticket, visit the ACR
registration desk to check space availability. View the session
overview and learning objectives online in the Annual Meeting App.
Access and download the app at www.ACRannualmeeting.org.
* Sessions denoted with an asterisk were sold out as of August 30.
Westin – Paine (Lobby)
*Basic Immunology for Clinical Rheumatologists (001)
Speaker: John Atkinson, MD
• describe how the immune system functions in normal
individuals
• identify abnormalities of immune regulation that lead to
autoimmunity
Westin – Otis (Lobby)
Crystal: Diagnosis and Management of Gout (002)
PM
PS
Speaker: Theodore R. Fields, MD
• recall the various published guidelines for diagnosis of gout,
including the most recent and appreciate the input that, when
appropriate, can be added with ultrasound and Dual Energy
CT scanning
• appreciate the challenges in gout patient education and
medication adherence
• recall the 2012 ACR guidelines for gout management and
appreciate those issues that still remain controversial or
unresolved
• discuss the types of agents in the pipeline for future gout
therapy and potential future approaches to gout management
scientific sessions
Westin – Hancock (Lobby)
Westin – Alcott (Mezzanine)
Reactive Arthritis: An Update (008)
Cutaneous Vasculitis (003)
Speaker: Ruth Ann Vleugels, MD, MPH
Speaker: John D. Reveille, MD
• use the cutaneous exam to help distinguish between small
and medium-sized vasculitides
• observe the histopathological features of cutaneous vasculitis,
which lead directly to clinical disease observable on the skin
• identify vasculitis mimickers with cutaneous involvement
• define the role of dermatologists in the diagnosis, work-up
and management of cutaneous vasculitides
• identify various causes of reactive arthritis
• discuss mechanisms of disease pathogenesis
• describe current treatment options for reactive arthritis
Westin – Douglas (Mezzanine)
*Rheumatoid Arthritis: Challenging Cases (009)
Speaker: Daniel Furst, MD, MPH
Fibromyalgia 2014: Update on Management (004)
PM
PS
Speaker: Daniel J. Clauw, MD
Westin – Faneuil (Mezzanine)
2 0 1 4
Speaker: Maria Dall’Era, MD
• review established data from the medical literature in order to
improve clinical practice related to the treatment of systemic
lupus erythematosus
• examine management strategies for refractory cutaneous
manifestations of systemic lupus erythematosus
• discuss management of progressive or relapsing lupus
nephritis
PS
PM
• discuss management of severe cytopenias
*Macrophage Activation Syndrome (005)
Speaker: Alexei A. Grom, MD
• recognize the signs and symptoms of macrophage activation
syndrome (MAS) in rheumatology
• r ecognize markedly distinct nature of the systemic form
of juvenile idiopathic arthritis and the fact that MAS most
frequently occurs in patients with this disease
• discuss current treatment approaches in MAS
Pain: Evaluation and Treatment of Back Pain (006)
1 6 ,
*Systemic Lupus Erythematosus: Difficult-to-Treat
Systemic Lupus Erythematosus (010)
Westin – Stone (Lobby)
Westin – Webster (Lobby)
SUNDAY
• identify newly proposed biological mechanisms for
fibromyalgia and centralized pain
• discuss the role of central nervous system dysfunction in the
pathogenesis of fibromyalgia
• describe the drug and non-drug treatments that are effective
in fibromyalgia n o v e m b e r
• discuss the management of patients with refractory
rheumatoid arthritis
• identify novel treatment options for those failing conventional
therapies
• create effective management plans for complicated
rheumatoid arthritis patients
Westin – Revere (Lobby)
ACR WORKSHOPS
7:45 – 9:45 am
PM
PS
Speaker: Rajiv Dixit, MD
• describe the clinically relevant anatomy of the lumbar spine
• clinically evaluate a patient with acute or chronic back pain
or a patient with an associated nerve root compression
syndrome
• formulate a rational and cost effective management plan with
a clear understanding of surgical indications
Westin – Adams (Mezzanine)
*Psoriatic Arthritis (007)
Speaker: Dafna D. Gladman, MD
• discuss advances in diagnosis and classification of psoriatic
arthritis
• determine if patients with psoriatic arthritis should be treated
aggressively
• determine treatment options for patients with psoriatic
arthritis
Admission to Workshops requires a separate registration and ticket.
To verify which session you registered for, the registration code
on your ticket needs to match the three-digit code in parentheses
below. If you are interested in participating in one of these sessions
or exchanging your ticket, visit the ACR registration desk to
check space availability. View the session overview and learning
objectives online in the Annual Meeting App. Access and download
the app at www.ACRannualmeeting.org.
152
*Joint Injection Techniques (201)
Speaker: Atul A. Deodhar, MD and Kenneth S. O’Rourke, MD
• discuss indications and contraindications for joint aspirations
and injections
• identify and avoid common mistakes in joint injection
procedures
• perform common joint and soft tissue injections on upper and
lower extremities
2014 Program Book
33
scientific sessions
161
*Nailfold Capillaroscopy (202)
Speaker: Maurizio Cutolo, MD
154
n o v e m b e r
1 6 ,
SUNDAY
2 0 1 4
• distinguish between normal nailfold capillary array and
early/advanced microvascular changes that allows the
early differential diagnosis between primary and secondary
Raynaud’s phenomenon by using nailfold videocapillaroscopy
(NVC)
• identify the early scleroderma pattern, the predictive/
prognostic value of NVC for the SSc clinical complications (by
models/indexes) as linked to the NVC patterns
• quantify the microvascular lesions
• d istinguish between the difference of combined predictive
value of the NVC patterns and nuclear antibodies, the links
with peripheral blood changes, as well as the effects of
systemic sclerosis therapeutic treatments on NVC patterns
Tai Chi in Rheumatic Disease (203)
Speaker: Mary L. Jurisson, MD
• describe the practice of tai chi and qigong and advise patients
of its evidence-based benefits and risks
• practice 1 or 2 qigong exercises independently
• describe some of the simplified curricula
ACR SESSIONS
8:30 – 10:00 am
52 A
PM
PS
CARE: Maintenance of Certification Session One of
Three – Vasculitis
All annual meeting scientific attendees will receive access to the
CARE: MOC module on their ACR profiles. Successful completion
of the 30 case-based question online module with a score of 70%
or higher will enable submission to the ABIM to receive ten (10)
medical knowledge points for the Maintenance of Certification
program. Ten (10) vasculitis questions will be covered at
this session. Attendance at the session(s) is not required to
participate in the online module.
Moderator: Carol A. Langford, MD, MHS
Speaker: Carol A. Langford, MD, MHS
knowledge
• review the diagnosis, management and treatment of
rheumatic diseases that are part of the ABIM’s rheumatology
MOC examination blueprint
• satisfy a self-evaluation of medical knowledge requirement for
the ABIM MOC program
Ballroom East
PS
PM
Current Understanding of Malignancies in Connective
Tissue Diseases
Moderator: Dinesh Khanna, MD
• review the mechanisms of cancer-associated autoimmune
diseases
• discuss data related to associations of scleroderma and
idiopathic inflammatory myopathies with malignancy and
relationships with autoantibodies
8:30 am
Idiopathic Inflammatory Myopathies – Whom Should We
Screen for Malignancy?
Frederick W. Miller, MD, PhD
9:00 am
Scleroderma – Whom Should We Screen for Malignancy?
Ami A. Shah, MD, MHS
9:30 am
Cancers and Autoimmune Disease – What Is the Link?
Antony Rosen, MD
PM
PS
254 A
Ed
Ethics and RheumatologyPM
Pd
PS
PM
Ed
Eth
PM
PrM
Pd
PS
FIT
PrM
FIT
Moderators: Robert H. Shmerling, MD and Jane Kang, MD
• develop knowledge and skills to address ethical conflicts that
arise in rheumatologic practice and research
• recognize how social and cultural perspectives affect the
approach to ethical decision making
• identify key ethical issues concerning social media for health
professionals in general and rheumatologists in particular
8:30 am
Ethical Challenges in Rheumatologic Research
Arthur L. Caplan, PhD
9:00 am
Ethics Concerns of the ACR Membership
C. Ronald MacKenzie, MD
9:30 am
Ethical Challenges Posed By Social Media
Elizabeth A. Kitsis, MD, MBE
257 A
PM
PS
Informative and Critical Peer Review for the ACR
Journals: A Guide to Providing Excellent Peer Review
FIT
PrM
Pd
PS
PM
Ed
of Manuscripts
Moderators: Joan M. Bathon, MD, Editor, Arthritis &
Rheumatology and Marian T. Hannan, DSc, MPH, Editor, Arthritis
Care & Research
• p eer-review scientific manuscripts within a field of interest
• a ssess one’s own work prior to submission in terms of clarity
of message and importance of the findings
34
2014 Program Book
scientific sessions
• d
escribe the requirements and scientific preferences of the
journals of the ACR
8:30 am
Outline and Key Points of Conducting a Review
Joan M. Bathon, MD and Marian T. Hannan, DSc, MPH
8:50 am
Panel Presentation: Reviewing Clinical Science Articles
Karen H. Costenbader, MD, MPH
PM
9:00 am
Panel Presentation: Reviewing Translational Articles
Richard J. Bucala, MD, PhD
258 B
The Microbiome in Health and Disease
Moderator: Robert A. Colbert, MD, PhD
Exhibit Hall C
Osteoporosis: Current Concepts for the Clinician
Moderator: Margaret R. Wilkes, MD
• discuss etiologies, diagnosis and management of low bone
density in premenopausal women
• describe secondary causes of low bone density in men and
treatment strategies for male osteoporosis
• review current data for best practice regarding utilization of
bone turnover markers and duration of antiresorptive therapy
in the treatment of osteoporosis
8:30 am
The Skin Microbiome
Elizabeth A. Grice, PhD
2 0 1 4
PS
PM
1 6 ,
9:30 am
SUNDAY
9:20 am
Panel Presentation: Reviewing From a Biostatistics Perspective
Michael P. LaValley, PhD
• review the skin microbiome system and its role in
dermatologic and systemic diseases
• e valuate the interactions between the microbiome and host
gender in disease predisposition
• examine the role of the microbiome in inflammatory
arthritides
n o v e m b e r
9:10 am
Panel Presentation: Reviewing Genetics/Genome-Wide
Association Study Articles
9:00 am
Gender, Microbiome and Autoimmunity
Jayne Danska, PhD
9:30 am
The Microbiome in Inflammatory Arthritides
Jose U. Scher, MD
PM
104 B
PS
When Pills Are Not Enough: Multidisciplinary
Approaches to Pediatric Pain and Hypermobility
PM
PM
Ed
PS
Pd
PS
PrM
FIT
Moderators: Laura E. Schanberg, MD and Kenneth N. Schikler,
MD
8:30 am
Osteoporosis in Young Women
Elizabeth J. Shane, MD
9:00 am
Osteoporosis in Men
Benjamin Z. Leder, MD
9:30 am
Antiresorptive Therapies and Utilization of Bone Turnover
Markers in the Management of Osteoporosis
Karen E. Hansen, MD, MS
160 B
• e xplain how to effectively respond to allegations of
overpayments
• identify ways to improve workflow to handle the everincreasing number of multi-payer audits
• identify automated tools for tracking the status of individual
claims
• a ppraise the types of audits to expect and key areas that
each audit program may target (i.e., medical necessity,
documentation, etc.)
PS
PM
PS
Practice Issues: Health Care Bounty Hunters: A Closer
Look at RACs, Audits and Medical Documentation
Moderator: Douglas White, MD, PhD
Speaker: Anita Henderson Sumpter, MBA, MHA, CPC, CMOM
• discuss the scope and purpose of the RAC, ZIPC and CERT
contractors and audits trends for each program
• describe novel insights in juvenile fibromyalgia diagnosis and
prognosis
• effectively diagnose hypermobility syndromes and discuss
prognosis
• recognize the value and the role of medications in the
management of non-inflammatory musculoskeletal pains in
children and adolescents
8:30 am
Juvenile Fibromyalgia: Diagnosis, Severity and Prognosis
Susmita Kashikar-Zuck, PhD
9:00 am
The Spectrum of Pediatric Hypermobility – A Geneticist’s
Viewpoint
Brad Tinkle, MD, PhD
2014 Program Book
35
scientific sessions
9:30 am
Integrated Management of Non-Inflammatory Musculoskeletal
Pain in Children
Kenneth Goldschneider, MD
ACR POSTER SESSION A AND POSTER TOURS
8:30 am – 4:00 pm
Poster presenters will be available from 9:00 – 11:00 am
(abstracts # 1 – 814). Poster tours will be held 9:00 – 9:45 am
and 10:15 – 11:00 am. Morning snacks will be available from
9:00 – 10:30 am.
Poster Hall (Exhibit Hall B)
n o v e m b e r
1 6 ,
SUNDAY
2 0 1 4
Guided Poster Tours
Guided poster tours allow scientific attendees to ask questions
and gain insights from some of the best-known rheumatology
leaders. Tours are complimentary; however, registration
is required and is limited to scientific attendees. If you preregistered for a tour, you should have received a ticket with
your meeting materials. Once you have your ticket, check in
at the tour desk 15 minutes prior to the start of your tour to
receive your headset. Your reservation will be held only until
five minutes prior to the start of the tour. After this time, your
reservation is not guaranteed and may be released to standby
attendees. If you did not pre-register, tickets may be available
in the registration area (Exhibit Level: East Registration).
Alternatively, you may go directly to the poster tour desk and
wait for a standby ticket. Standby tickets will be assigned on a
first-come, first-served basis five minutes prior to the start of
each tour. Each tour participant will receive a wireless headset
which will be registered against the participants’ registration ID.
Participants will be charged $50 if the headset is not returned
within 15 minutes of the end of the tour.
9:00 – 9:45 am
Fellows Only: How to Navigate the Poster Hall (301)
Tour Guide: Calvin R. Brown, Jr, MD
Pain: Basic and Clinical Aspects (302)
Tour Guide: Anne-Marie Malfait, MD, PhD
Past President’s Picks Poster Tour (303)
Tour Guide: Mary K. Crow, MD
Tour Guide: Michael Weinblatt, MD
Rheumatoid Arthritis Treatment – Small Molecules, Biologics
and Gene Therapy Poster Tour (305)
Tour Guide: Iain B. McInnes, PhD
Systemic Lupus Erythematosus: Clinical Aspects Poster Tour
(306)
Tour Guide: Diane L. Kamen, MD, MS
10:15 – 11:00 am
Antiphospholipid Syndrome Poster Tour (307)
Tour Guide: Pier Luigi Meroni, MD
36
2014 Program Book
Metabolic and Crystal Arthropathies Poster Tour (308)
Tour Guide: N. Lawrence Edwards, MD
Tour Guide: David G. Borenstein, MD
Rheumatoid Arthritis: Clinical Aspects Poster Tour (310)
Tour Guide: Jennifer Barton, MD
(311)
Tour Guide: Megan E. B. Clowse, MD, MPH
Vasculitis Poster Tour (312)
Tour Guide: Robert F. Spiera, MD
ACR SESSIONS
9:00 – 10:00 am
PM
210 B
PS
ACR Immunology Update: New Immunology of the
Spondyloarthropathies
Moderator: Gregg J. Silverman, MD
Speaker: Christopher T. Ritchlin, MD, MPH
• review the demographics and common clinical presentations
for these conditions
• appraise insights gained from genetic surveys and evolving
insights into cellular and molecular pathogenesis
• discuss recent advances in clinical trials with new therapeutic
agents
102 A
PM
PS
Advocacy: Meet the Expert – A Senator’s Perspective
on Advocacy Best Practices
Moderator: William F. Harvey, MD, MSc
Speaker: The Honorable Tim Hutchinson (U.S. House 1993-1997;
U.S. Sen. 1997-2003)
• review how rheumatologists can interact with elected officials
locally
• review how rheumatologists can interact with elected officials
nationally
• a ppraise effective and ineffective ways of approaching
elected officials
PS
PM
Ballroom West
Sarcoidosis in 2014
Moderator: Elana J. Bernstein, MD, MSc
• discuss the diagnosis and management of cardiac sarcoidosis
• discuss the diagnosis and management of neurosarcoidosis
9:00 am
Cardiac Sarcoidosis
Daniel Culver, DO
scientific sessions
(Booths #139 and #1401)
9:30 am
Neurosarcoidosis
Nadera J. Sweiss, MD
Innovation Theater A and B
PM
Non-CME accredited presentations have been planned and
will be implemented in accordance with the requirements
of the FDA and applicable standards of the PhRMA Code on
Interactions with Healthcare Professionals. Innovation Theater A
presentations will be held from 10:30 – 11:15 am, 12:30 – 1:15
pm and 2:30 – 3:15 pm. Innovation Theater B presentations
will be held from 11:30 am – 12:15 pm, 1:30 – 2:15 pm and
3:30 – 4:15 pm. For a complete listing of Innovation Theater
presentations, see
PS 238.
PM page
PS
153 B
Social Media Boot Camp: Twitter Basics
Moderator: Paul Sufka, MD
ACR WORKSHOPS
10:30 am – 12:30 pm
9:30 am
How to Tweet
Christopher E. Collins, MD
159
• identify non-musculoskeletal uses of ultrasound in
rheumatology patients.
• recognize some common ultrasound abnormalities in patients
with rheumatic diseases.
• recognize the importance of proper ultrasound transducer
selection and system settings to obtain adequate ultrasound
images.
• apply introductory ultrasound scanning techniques for nonmusculoskeletal scanning.
• apply introductory ultrasound scanning techniques to assess
for vasculitis
ARHP SESSION
9:00 – 10:00 am
PS
ARHP Keynote Address: Happiness from the Inside
Out
Moderator: Afton L. Hassett, PsyD
Speaker: Cynthia Coney, MEd, CAPP
• identify the three stages patients may traverse after a
diagnosis of chronic illness
• list at least three personal strengths that resilient people
exhibit
• apply resiliency skills into personal and professional lives
EXHIBITS
10:00 am – 5:00 pm
Exhibit Hall A
Join your colleagues in the Exhibit Hall for morning and
afternoon refreshments from 10:00 – 11:00 am and
2:00 – 3:00 pm.
*Beyond Musculoskeletal Ultrasound for
Rheumatologists (204)
Speaker: Minna J. Kohler, MD
9:55 am
Question and Answer
107PM
B
2 0 1 4
9:05 am
Why Tweet?
Ronan Kavanagh, MD, MRCP
1 6 ,
9:00 am
Introduction
Paul Sufka, MD
SUNDAY
n o v e m b e r
• create an Twitter account
• recognize proper and improper usage of tweeting in
professional environments
• identify whom to follow, e.g., rheumatologists and other
interesting people in medicine
• identify and define a hashtag
• demonstrate how to tweet
• demonstrate how to retweet or favorite noteworthy
information
152
*Clinical Anatomy and Physical Exam: Essential Tools
in Upper Extremity Regional Pain Syndromes (205)
PM
PS
Speakers: Robert A. Kalish, MD and Pablo Villasenor Ovies, MD
• demonstrate clinical anatomy of the lower extremities in
performing the physical examination
• apply knowledge of clinical anatomy to better understanding
and diagnosis of the common regional pain syndromes
• administer the physical examination of the lower extremities
on healthy volunteers
2014 Program Book
37
scientific sessions
154
11:20 am
Presentation of the New ACR Rheumatoid Arthritis Guidelines
Jasvinder A. Singh, MD, MPH
Histopathology of Rheumatic Lung Disease (206)
Speakers: Allen Burke, MD and Fabio Tavora, MD, PhD
11:50 am
Kenneth G. Saag, MD, MSc
• a ppraise the basic patterns of lung injury as seen
microscopically
• c ompare pathologic findings in rheumatologic lung diseases
with their idiopathic counterparts
• d
istinguish histologic features of drug induced lung injury from
rheumatologic injury
ARHP SESSIONS
11:00 am – Noon
PS
PM
161
Synovial Fluid Analysis and Crystal Identification (207)
257 A
Affordable Care Act
n o v e m b e r
1 6 ,
SUNDAY
2 0 1 4
Speakers: Brian F. Mandell, MD, PhD; Gilda M. Clayburne, MLT
and Lan Chen, MD, PhD
Moderator: Daniel F. Battafarano, DO
Speaker: Angela K. Golden, DNP
• prepare synovial fluid samples for microscopic examination
• identify various components of synovial fluid
• identify crystals in synovial fluid
• describe the changes that the Affordable Care Act will have on
health care
• explain how reimbursement will be affected by the Affordable
Care Act
• summarize the changes of the Affordable Care Act that will
impact rheumatology directly
ACR SESSIONS
11:00 am – Noon
PM
PS
52 A
210 B
Bone Biology
Moderators: George C. Tsokos, MD and Steven R. Goldring, MD
Speaker: Laurie H. Glimcher, MD
PM
PS
New ACR Recommendations for the Management of
PS
PS
PM
PM
38
PS
Immunology Boot Camp I: The Basics of Targeted
Therapies
Moderators: Deborah McCloskey, RN, BSN and Brandi Young,
DNP, FNP-C
Speaker: Troy R. Torgerson, MD, PhD
• review how the skeleton remodels itself continuously through
bone formation and resorption
• establish familiarity with the signaling pathways that operate
in osteoblasts
• recognize the need for new therapeutics to treat low bone
mass
Ballroom East
PM
• describe the basic building blocks of the immune system
• summarize the components of innate immunity, including
sensing self and foreign
• explain the body’s immediate response to an antigen
254 A
PM
PS
What Can Brain Imaging Tell Us About Pharmacologic
and Non-Pharmacologic Treatment of Chronic Pain?
PM
PS
Moderators: S. Louis Bridges Jr., MD, PhD and Raveendhara R.
Bannuru, MD
Moderator: Daniel J. Clauw, MD
• describe the recommended treatment approach for patients
with rheumatoid arthritis
• outline the ACR’s recommendations for use of non-biologic
and biologic disease-modifying agents in the treatment of
• explain the ACR’s recommendations for use of corticosteroids
in the treatment of rheumatoid arthritis
• explain some of the basic principles of brain neurochemistry
and brain connectivity and how these are altered in chronic
pain
• describe how brain neurotransmitters and connectivity
patterns may be altered by pharmacologic and nonpharmacologic treatment
• recognize how neuroimaging outcomes can be used to guide
clinical decision making
11:00 am
Overview of Guideline Development, Including Methods and
Literature Review
Timothy E. McAlindon, MD, MPH, MRCP
11:00 am
Pharmacologic Neuroimaging in Chronic Pain
Richard E. Harris, PhD
2014 Program Book
scientific sessions
11:30 am
Neuroplastic Response to Non-Pharmacologic Treatment in
Chronic Pain
Vitaly Napadow, PhD
ACR PLENARY SESSION I – DISCOVERY 2014
11:00 am – 12:30 pm
Conclusion: We identify cH2B as an antigenic target of the ACPA
immune response and our findings suggest that intra-articular
histone citrullination can link innate immunity via NETosis
and adaptive immunity via generation of citrullinated histone
immune complexes. The generation of citrullinated histone
antigens during low grade articular inflammation provides a
potential mechanism for the conversion from asymptomatic
ACPA seropositivity to clinical RA.
Exhibit Hall C
ACR Plenary Session I: Discovery 2014
Moderators: Joseph Flood, MD and Chester V. Oddis, MD
11:00 am
Rheumatology Research Foundation Corporate Roundtable
Awards
SUNDAY
n o v e m b e r
11:15 am
815. Netosis Induced Histone Citrullination Facilitates Onset
and Propagation of Rheumatoid Arthritis
1 6 ,
Dong Hyun Sohn and Jeremy Sokolove, VA Palo Alto Healthcare
System and Stanford University, Palo Alto, CA
Methods: We performed proteomic analysis of human NETs to
identify all citrullinated proteins including those targeted as part
of the RA immune response. Using a combination of ELISA and
IHC we compared RA and OA serum, synovial fluid and synovial
tissue for levels of histone 2B (H2B), anti-H2B antibodies, as
well as H2B-containing immune complexes. Using macrophage
activation assays we assessed the effect of histone citrullination
on immunostimulatory capacity and evaluated the stimulatory
capacity of native and citrullinated H2B-containing immune
complexes. Finally, we immunized mice with citrullinated H2B
(cH2B) with and without the induction of low grade collagen
induced arthritis to assess the potential for anti-cH2B antibodies
to mediate arthritis in vivo.
Results: Proteomic interrogation of NET-derived proteins, RA
serum, synovium and synovial fluid identified robust targeting
of NET-derived citrullinated histones by the ACPA immune
response. Over 90% of RA patients have anti-cH2B antibodies
and over half have measurable levels of synovial fluid H2B
immune complexes. We observe that histone citrullination
increases innate immunostimulatory capacity and that immune
complexes containing citrullinated histones both activate
macrophage cytokine production and propagate NETosis. Finally,
we demonstrate that autoimmunity to cH2B is arthritogenic,
both by primary immunization as well as immune serum
transfer, but only in the setting of underlying low grade articular
inflammation.
2 0 1 4
Background/Purpose: Anti-citrullinated protein antibodies
(ACPAs) are characteristic of rheumatoid arthritis however,
their presence years before onset of clinical RA is perplexing.
Although multiple putative citrullinated antigens have been
identified, including citrullinated products of NETosis, no studies
have demonstrated the capacity of these antigens to initiate
inflammatory arthritis. We sought to identify citrullinated
products of NETosis targeted by the RA immune response and
with the capacity to drive inflammatory arthritis.
Disclosures: D. H. Sohn, None; J. Sokolove, None.
11:30 am
816. TRNT1 Missense Mutations Define a New Periodic Fever
Syndrome
Angeliki Giannelou, National Institute for Arthritis and
Musculoskeletal and Skin Diseases,Bethesda, MD
Background/Purpose: Two thirds of the 1700 patients seen
at our NIH clinic for autoinflammatory diseases do not have a
genetic diagnosis. Whole exome sequencing permits analysis of
most of the protein coding regions of the human genome.
Methods: With the use of whole exome sequencing and
candidate gene screening, we identified five children from four
unrelated families, who had unexplained autoinflammatory
disease and shared mutations in one common gene. One
family from Saudi Arabia was consanguineous with two
affected daughters. The second family of mixed Czech and
British background had one affected boy. The third and
fourth families were of mixed European ancestry from the
United States and each family had one affected daughter. We
performed additional experiments in patients samples including
flow cytometry, immunophenotyping, cytokine profiling,
mitochondria related function and ribosomal assembly assays.
Protein function was studied with morpholino knockdowns in
zebrafish embryos.
Results: All patients carried missense recessive mutations in
one common gene, the TRNT1 (tRNA Nucleotidyl Transferase,
2014 Program Book
39
scientific sessions
n o v e m b e r
1 6 ,
SUNDAY
2 0 1 4
CCA-Adding, 1), on chromosome 3. The two affected Saudi
Arabian sisters were homozygous for a p.H215R missense
mutation, while the other three children were compound
heterozygous for a missense mutation, p. I223T or p. R99W and
one shared mutation p.D163V. The p.H215R mutation was not
found in any public database neither in 1061 Arab control DNA
samples. From the three Caucasian mutations, the p.R99W was
novel whereas the p. I223T and p.D163V were found at a very
low allele frequency (<0.001) at the NHLBI exomedatabase. All
mutations affect highly conserved amino acid residues and are
predicted to be damaging to the protein function. All children
had recurrent episodes of high fevers with negative sepsis work
up that occurred in association with microcytic anemia and a
spectrum of multisystem features. Neurologic involvement
ranged from mild developmental delay to nystagmus, hypotonia,
optic nerve atrophy and sensorineural hearing loss.
Other variables manifestations include dysmorphic features,
musculoskeletal and gastrointestinal symptoms, B cell
immunodeficiency and hypogammaglobulinemia. Studies
performed so far, point towards a maturation defect of the B cell
lineage in the bone marrow, as a possible cause of the observed
immunodeficiency. Preliminary data from cytokine analysis in
two patients have shown elevated levels of the proinflammatory
cytokines interleukin 6 and type 1interferon, suggesting
possible therapeutic targets. Knockdown of the zebrafish TRNT1
homologue caused hydrocephaly, defects in tail development,
anemia and a reduction in the number of hair cells present in
the lateral line, that has function resembling human inner ear.
Conclusion: The CCA-adding TRNT1 enzyme catalyzes the
addition of the CCA terminus to the 3 prime end of all tRNAs
precursors, a step that is essential for tRNA aminoacylation
and protein synthesis. The discovery that missense mutations
in this essential and ubiquitously expressed gene cause a
newly defined periodic fever syndrome , will allow further
understanding of mechanisms underlying inflammation.
matched by age, gender and calendar year. Cox regression was
used to calculate hazard ratios (HR) to determine baseline risk
factors for increased mortality in the BeSt population.
Results: During 10 years, 72 of 508 patients died at a mean age
of 75 years. No difference in survival was observed between the
treatment strategies (p=0.805) (figure), with 16/126, 15/121,
21/133 and 20/128 deaths in arm 1 to 4, respectively. Based on
the general Dutch population, 62 deaths were expected and
72 deaths occurred, resulting in an overall SMR of 1.16 (95%
confidence interval, CI 0.92 – 1.46). Comparing the general
population to each of the treatment strategies resulted in a SMR
(95% CI) of 1.00 (0.61 – 1.64), 1.02 (0.61 – 1.69), 1.30 (0.85 –
1.99) and 1.32 (0.85 – 2.04) in arm 1 to 4, respectively.
In the BeSt population, baseline age (HR 1.13, 95% CI 1.101.16), male gender (HR 1.78, 95% CI 1.06-2.99), smoking at
baseline (HR 5.19, 95% CI 3.08-8.75) and health assessment
questionnaire at baseline (HR 1.89, 95% CI 1.29-2.76) were
associated with an increased risk of mortality. Randomization
arm was not associated with an increased risk of mortality (arm
1 as reference category; arm 2 HR 0.99, 95% CI 0.49 – 2.00; arm
3 HR 1.27, 95% CI 0.66 – 2.44; arm 4 HR 1.25, 95% CI 0.65 –
2.41).
Conclusion: After 10 years of continued tight controlled
treatment in patients with rheumatoid arthritis in the BeSt
study, the survival rate was comparable to the general Dutch
population, without differences between the treatment
strategies. Higher age, male gender, smoking and worse
functional ability were associated with an increased risk of
mortality within our study population. These results suggest that
treatment targeted at DAS ≤2.4 prevents increased mortality
previously associated with RA and that the medication used in
these strategies does not increase mortality.
Disclosures: A. Giannelou, None.
11:45 am
817. Mortality in a Large Cohort of Patients with Early
Rheumatoid Arthritis That Were Treated-to-Target for 10 Years
I.M. Markusse, Leiden University Medical Center, Leiden,
Netherlands
Background/Purpose: Recent studies showed diverging results
about mortality trends in patients with rheumatoid arthritis
(RA). Our aim was to determine survival after 10 years of treatto-target therapy in patients with early RA, to compare these
survival rates with the general population and to define risk
factors for mortality during the 10 years duration of the BeSt
study.
Methods: The BeSt study enrolled 508 Dutch patients with
recent-onset active RA (1987 criteria) who were randomized to:
sequential monotherapy, step-up therapy, initial combination
including either prednisone or infliximab. During 10 years, all
patients were treated-to-target, aiming at a disease activity
score (DAS) ≤2.4. Kaplan-Meier curves and the log-rank test
were used to compare survival rates in the four treatment
strategies. Standardized mortality ratios (SMR) were calculated
to compare the BeSt population to the general Dutch population,
40
2014 Program Book
Disclosures: I. M. Markusse, None.
Noon
818. Incident Rheumatoid Arthritis and Risk of Mortality
Among Women Followed Prospectively from 1976 to 2010 in
the Nurses’ Health Study
Jeffrey A. Sparks, Brigham and Women’s Hospital, Harvard
Medical School, Boston, MA
Background/Purpose: RA has been associated with increased
mortality compared to general population estimates. Previous
studies were limited due to the inability to directly compare RA
patients to controls, short follow-up and lack of detailed data on
clinical, lifestyle and serologic factors. We evaluated mortality
among women followed prospectively prior to RA diagnosis,
directly comparing to women without RA.
Methods: We conducted a study of RA and mortality among
121,700 women followed from 1976 to 2010 in the Nurses’
Health Study (NHS). Incident RA was validated by medical record
scientific sessions
review according to the 1987 ACR RA criteria and classified by
serostatus. Women who reported RA or other connective tissue
diseases before the start of NHS were excluded. Women were
followed from cohort entry to death or end of follow-up and
were censored for loss to follow-up. Deaths were validated by
the National Death Index; death certificate and medical record
review determined cause of death. Cox regression models
estimated hazard ratios (HRs) and 95% confidence intervals
(CIs) for all-cause, cardiovascular disease (CVD), cancer and
respiratory mortality for women with RA compared to women
without RA. We obtained HRs for mortality by RA duration
and serologic RA phenotype. Models were adjusted for age,
demographics and other mortality factors, including physical
activity, smoking, obesity, comorbidities and family history of
cancer, CVD and diabetes.
CVD-specific
mortality
Cancerspecific
mortality
Respiratoryspecific
mortality†
AgeMultivariable
Multivariable
adjusted HR
HR
HR (95% CI)*
(95% CI)
(95% CI)*
Multivariable
Multivariable HR
HR
(95% CI)*
(95% CI)*
No RA
1.00 (ref)
1.00 (ref)
1.00 (ref)
1.00 (ref)
1.00 (ref)
RA
1.42 (1.261.61)
2.07 (1.832.35)
1.87 (1.442.43)
1.35 (1.071.69)
4.50 (3.28-6.17)
No RA
1.00 (ref)
1.00 (ref)
1.00 (ref)
1.00 (ref)
1.00 (ref)
1.24 (1.151.33)
1.22 (1.141.30)
1.55 (1.42-1.69)
All RA
RA duration 1.16 (1.13- 1.32 (1.27(per 5 years) 1.20)
1.36)
Seropositive RA
No RA
1.00 (ref)
1.00 (ref)
1.00 (ref)
1.00 (ref)
1.00 (ref)
RA
1.54 (1.331.79)
2.33 (2.002.71)
1.80 (1.272.55)
1.25 (0.921.70)
6.23 (4.38-8.85)
1.00 (ref)
1.00 (ref)
1.26 (1.151.39)
1.23 (1.131.34)
1.69 (1.53-1.85)
Seronegative RA
No RA
1.00 (ref)
1.00 (ref)
1.00 (ref)
1.00 (ref)
1.00 (ref)
RA
1.15 (0.931.41)
1.60 (1.301.98)
1.84 (1.232.73)
1.40 (0.991.98)
1.97 (0.97-3.98)
No RA
1.00 (ref)
1.00 (ref)
1.00 (ref)
1.00 (ref)
1.00 (ref)
1.19 (1.062.73)
1.18 (1.061.31)
1.23 (1.00-1.51)
1.28)
*Adjusted for age, questionnaire period, US region, race/ethnicity, education, husband’s
education, body mass index (<18.5, 18.5-24.9, 25-29.9, ≥30), cigarette smoking pack-years
(never, 0-10, 10.1-20, >20), post-menopausal hormone use, physical activity, healthy eating
index, cancer, cardiovascular disease, diabetes mellitus, family history of diabetes, family
history of cancer, family history of myocardial infarction <60 years of age and aspirin use
through follow-up. Modifiable factors were adjusted up to RA diagnosis (cigarette smoking
pack-years, physical activity and body mass index).
†
Among women with RA, there were a total of 43 respiratory deaths that were due to
pneumonia (11), emphysema (8), chronic interstitial lung disease (5), asthma (1) and other
respiratory diseases (18).
Disclosures: J. A. Sparks, None.
12:15 pm
819. Secukinumab, a Monoclonal Antibody to Interleukin17A, Significantly Improves Signs and Symptoms of Active
Ankylosing Spondylitis: Results of a 52-Week Phase 3
Randomized Placebo-Controlled Trial with Intravenous Loading
and Subcutaneous Maintenance Dosing
2 0 1 4
All-cause
mortality
1.00 (ref)
1 6 ,
Table. Hazard ratios for all-cause and cause-specific mortality in RA serologic phenotypes
among women in the Nurses’ Health Study, 1976-2010 (n = 119,264).
1.00 (ref)
SUNDAY
Conclusion: In 34 years of prospective follow-up, women
diagnosed with RA had a two-fold increased risk of death
from any cause compared to women without RA. Respiratory
mortality was six-fold higher in seropositive RA and women with
RA were significantly more likely to die from CVD and cancer
than women without RA. Respiratory mortality appears to be
an important but understudied cause of death in RA. These
findings provide evidence of high RA mortality burden that is
unexplained by traditional mortality predictors.
1.00 (ref)
1.44)
n o v e m b e r
Results: We validated 960 incident RA cases and identified
25,699 deaths in 34 years of NHS follow-up. Of the 261 deaths
among women with RA, 75 (29%) were from cancer, 58 (22%)
were from CVD and 43 (16%) were from respiratory causes.
Compared to women without RA, women with RA had increased
all-cause mortality that remained significant after adjusting
for age and other mortality factors (HR 2.07, 95% CI 1.83-2.35,
Table). Mortality was significantly increased for seropositive
(HR 2.33, 95% CI 2.00-2.71) and seronegative RA (HR 1.60, 95%
CI 1.30-1.98) compared to non-RA women. Each five years
of RA duration conferred a 32% (95% CI 27-36%) increased
mortality compared to non-RA. Women with RA had significantly
increased risk for mortality from CVD (HR 1.87, 95% CI 1.442.43), cancer (HR 1.35, 95% CI 1.07-1.69) and respiratory (HR
4.50, 95% CI 3.28-6.17) causes compared to women without RA.
Respiratory mortality for women with seropositive RA was sixfold higher than non-RA women (HR 6.23, 95% CI 4.38-8.85).
No RA
Dominique L. Baeten, Department of Clinical Immunology and
Rheumatology and Department of Experimental Immunology,
Academic Medical Centre/University of Amsterdam, Amsterdam,
Netherlands
Background/Purpose: A phase 2, proof-of-concept study
indicated that secukinumab, an anti–IL-17A monoclonal
antibody, suppressed signs and symptoms of active ankylosing
spondylitis (AS) by Week (Wk) 6. We present Wk 16 and Wk
52 efficacy and safety data from MEASURE 1 (NCT01358175),
a phase 3 study assessing secukinumab vs. placebo (PBO) in
patients (pts) with AS.
Methods: Pts with active AS fulfilling modified New York Criteria
and BASDAI ≥ 4, despite current or previous therapy with
NSAIDs, DMARDs and/or anti-TNF agents, were randomized
to receive: i.v. secukinumab 10 mg/kg (Wk 0, 2, 4) followed
by s.c. secukinumab 75 mg every 4 wks (10 IV → 75 SC), s.c.
secukinumab 150 mg every 4 wks (10 IV → 150 SC), or PBO
on same i.v. and s.c. schedules. Endpoints included ASAS20 at
Wk 16 (primary), ASAS40, hsCRP, ASAS 5/6, BASDAI, SF-36 PCS,
ASQoL and ASAS partial remission. Statistical analyses followed a
pre-defined hierarchical hypothesis testing strategy to adjust for
multiplicity. PBO pts were re-randomized to secukinumab 75 mg
or 150 mg s.c. based on ASAS20 response at Wk 16, with nonresponders switched at Wk 16 and responders at Wk 24.
Results: Baseline characteristics of the 371 randomized pts were
similar between study arms: mean age 40.1-43.1 years, mean
disease duration 6.5-8.3 years, mean BASDAI 6.05-6.51, ~27%
inadequate response to anti-TNF agents (TNF-IR). The study met
its primary efficacy endpoint with a significantly higher ASAS20
response at Wk 16 in the 10 IV → 75 SC (59.7%) and 10 IV →
150 SC (60.8%) groups vs. PBO (28.7%; P < 0.01 for each dose);
ASAS20 response rates in TNF-naïve pts were 60.0%, 66.3% and
32.6% and in the TNF-IR pts were 58.8%, 45.5% and 18.2%, in
2014 Program Book
41
scientific sessions
n o v e m b e r
1 6 ,
SUNDAY
2 0 1 4
the 10 IV → 75 SC, 10 IV → 150 SC and PBO groups, respectively
(P< 0.01 vs. PBO). Significant improvements with both doses
of secukinumab vs. PBO were observed for all pre-specified
secondary endpoints at Wk 16 (Table), with responses sustained
through Wk 52. Onset of action of secukinumab was rapid, with
significant improvements in ASAS20, ASAS40, hsCRP, ASAS5/6
and BASDAI seen at Wk 1. Through to Wk 16, drug exposure
levels were similar in the secukinumab groups due to the i.v.
loading doses. Secukinumab was generally well tolerated. At
Wk 16, 66.9% of pts in the 10 IV → 75 SC group and 69.6% in
the 10 IV → 150 SC group experienced an AE, vs. 55.7% on PBO;
SAE rates were 1.6%, 2.4% and 4.1%, respectively. Through Wk
52 visit of the last pt (average exposure [range]: 451.7 [8–757]
days), AE/SAE rates were 76.5%/10.1% and 85.1%/9.4% for pts
receiving secukinumab 75 or 150 mg s.c., respectively, at any
point in the study.
Table. Summary of 16-week efficacy results
Week 16 Data
Secukinumab
10 mg/kg i.v. →
75 mg s.c.
(N = 124)
Secukinumab
10 mg/kg i.v. →
150 mg s.c.
(N = 125)
Placebo
(N = 122)
ASAS20 response
59.7%*
60.8%*
28.7%
ASAS40 response
33.1%*
41.6%*
13.1%
hsCRP, post-baseline to baseline
ratio (LSM±SE)
0.45 ± 1.092*
0.40 ± 1.090*
0.97 ± 1.095
ASAS5/6
45.2%*
48.8%*
13.1%
BASDAI, mean change from baseline score (LSM±SE)
-2.34 ± 0.175*
-2.32 ± 0.172*
-0.59 ± 0.180
5.64 ± 0.595*
5.57 ± 0.586*
0.96 ± 0.612
ASQoL, mean change from baseline
-3.61 ± 0.424*
score (LSM±SE)
-3.58 ± 0.420*
-1.04 ± 0.437
SF-36 PCS, mean change from
baseline score (LSM±SE)
ASAS partial remission
16.1%*
15.2%*
3.3%
*P<0.01 vs. placebo
Prespecified hierarchical statistical testing strategy used to account for multiplicity. Missing
data for categorical variables were imputed as nonresponse
ASAS, Assessment of SpondyloArthritis International Society Criteria; ASQoL, Ankylosing
Spondylitis Quality of Life; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; hsCRP,
high-sensitivity C-reactive protein; LSM, least square mean; SE, standard error; NS, not
significant; SF-36 PCS, short form 36 physical component summary
Conclusion: The selective IL-17A inhibitor secukinumab provided
rapid and significant improvement of signs and symptoms
in pts with active AS, regardless of prior anti-TNF exposure.
Improvements were observed from Wk 1 and sustained through
52 wks. Secukinumab was well tolerated through 52 wks with no
unexpected safety findings.
Disclosures: D. L. Baeten, Research grants from Boehringer
Ingelheim, Janssen, MSD, Novartis, Pfizer, 2, 9, Consulting fees
from AbbVie, Boehringer Ingelheim, BMS, Eli Lilly, Jannsen, MSD,
Novartis, Pfizer, Roche, UCB, 5.
ARHP NETWORKING EVENT
12:30 – 2:15 pm
Commonwealth Ballroom
Networking Forum
All ARHP attendees are invited to this kick-off forum for the annual
meeting. A box lunch will be provided for the first 250 people. You
will have an opportunity to meet and network with other health
professionals. Discipline tables will be arranged to help facilitate
connections. This session is not eligible for CME credit.
42
2014 Program Book
ACR SESSION
12:45 – 2:15 pm
PM
PS
Ballroom West
ACR Knowledge Bowl: Preliminary Round
Moderator: Rebecca L. Manno, MD, MHS
• identify key images that are important to recognize in clinical
practice
• describe factual information related to various rheumatic
diseases
• identify historical facts relevant to the field of rheumatology
Competing Teams:
Bourbon Street Bunions
Nirupa J. Patel, MD; Kenneth Van Dyke, DO and Joseph Martinez,
MD
“Complement”ary Medicine!
Sobia Hassan, BM BS, MRCP; Maria Antonelli, MD and Santosh
Bhusal, MD
Combat Rheumatology
Ramon Arroyo, MD; Joshua Scott, DO, MS, BS and Ian Ward, MD
Drugs ANCAnna Help Your GPA
Soumya Chatterjee, MD, MS; Piyush Poddar, MD and David Theis,
DO, BA
Healing Hinges
Kenneth J. Warrington, MD; Megan L. Krause, MD and Abha G.
Singh, MBBS
Motor City Road Runners
Alireza Meysami, MD; Reshma Khan, MD and Reshma Marri, BS,
MD
Rheumatology Research Unit
Rosa Daniela Grembiale, MD; Francesco Ursini, PhD, MD and
Saverio Naty, MD
Rheumawiz
Rohini Samant, MBBS, MD; Piyush Joshi, MBBS, MD and Yathish
GC, MBBS, MD
Sweet Bones Alabama
Laura B. Hughes, MD, MSPH; Xena Whittier, MD, MS, BA and
Jenny Lin, MD
Team Galveston
Vijaya Murthy, MD; Rajani Rudrangi, MD and Niharika Ganti, MD
Team Ireland
John J. Carey, CCD, MS; Richard Conway, BAO, BCh, MB, MRCPI
and Orla Ni Mhuircheartaigh, BAO, BCh, MB, MRCPI
The Bauer Rumble
Robert P. Friday, MD, PhD; Sara Schoenfeld, MD and Zachary
Wallace, MD
scientific sessions
The Brooklyn Rheuminators
Deana M. Lazaro, MD; Nina Ramessar, MBBS and Jigar Shah, MD
The Hawkeyes
Namrata Singh, MBBS; Bharat Kumar, MD and Vijay Aluri, MD
Triple Therapy: Triple Threat
Ted R. Mikuls, MD, MSPH; Manpreet Sethi, MBBS;
and Priyanka Vashisht, MD
The Honey Badgers
Andrew Östör, MD; Andra Negoescu, MD;
and Elena Nikiphorou, MRCP, MD (Res), PGCMEPM
Hereditary Angioedema Update (014)
Speaker: Peter Deane, MD
• discuss the pathophysiology of hereditary angioedema
• discuss the proper approach to the patient with angioedema
• discuss current treatment options
PS
12:45 – 2:15 pm
Speaker: Lianne S. Gensler, MD
• discuss the spectrum of axial spondyloarthritis, including
ankylosing spondylitis
• discuss the early diagnosis of ankylosing spondylitis and axial
spondyloarthritis
• describe clinical and radiographic outcome measures used in
clinical trials and practice
• summarize axial spondyloarthritis treatment options and
evaluate the impact of treatment on outcomes
*Ankylosing Spondylitis: Disease Modification (012)
Speaker: Joachim Sieper, MD
• outline what is known about the pathophysiology of disease
modification in spondyloarthritis
• review outcomes relevant to the concept of disease
modification in spondyloarthritis and assess their relevance to
clinical practice
• review therapeutic issues relevant to the concept of disease
modification
• discuss assessment of disease modification clinical trial
*Dermatological Manifestations of Rheumatic
Diseases (013)
• identify cutaneous findings associated with underlying
rheumatic disease
• construct a differential diagnosis for these conditions
• design a strategy for management of skin disease seen in
patients with rheumatic diseases
2 0 1 4
*Ankylosing Spondylitis: 2014 Update (011)
1 6 ,
• discuss the epidemiology of pediatric systemic lupus
erythematosus
• describe the differences in organ involvement between
pediatric and adult systemic lupus erythematosus
• discuss the management and treatment of pediatric systemic
lupus erythematosus
• review consensus treatment plans for the induction of
proliferative lupus nephritis in pediatric patients
• discuss novel biomarkers that in the future may be beneficial
in managing pediatric systemic lupus erythematosus
SUNDAY
Speaker: Kelly A. Rouster-Stevens, MD, MS
n o v e m b e r
*Pediatric Systemic Lupus Erythematosus (015)
*Rheumatoid Arthritis: Biological Agents (016)
Speaker: Edward C. Keystone, MD
• describe recent trends in the use of biologics to improve
outcomes and utility
• describe strategies to reduce costs of biologics
• discuss emerging biologics, including biosimilars and their
advantage for the therapeutic algorithm
*Systemic Lupus Erythematosus: Novel Treatments
(017)
Speaker: Susan Manzi, MD, MPH
• describe the history of therapeutic agents and the rationale
for further drug development in lupus
• review new data to support standard therapies for
management of lupus
• discuss the newest therapies approved for lupus and those
currently under investigation
*Vaccinations for Patients on Biologic Therapies (018)
Speaker: Jeffrey R. Curtis, MD, MPH, MS
• recognize the importance of appropriate vaccinations in
patients with autoimmune disease
• identify the different types of immunizations especially those
which are live viruses
• describe the effect of different classes of immunomodulatory
medications on vaccine efficacy and safety
2014 Program Book
43
scientific sessions
*Vasculitis: Update (019)
Speaker: Raashid A. Luqmani, DM
• describe the current definitions of vasculitis according to
affected vessel size
• discuss the role of simple clinical evaluation alongside the
various available laboratory and imaging tests, including antineutrophil cytoplasm antibodies
• identify current and novel therapeutic modalities
*What Is Not Central Nervous Angiitis: Making the
Right Diagnosis (020)
n o v e m b e r
1 6 ,
SUNDAY
2 0 1 4
Speaker: Leonard H. Calabrese, DO
• list and elaborate on the diagnostic criteria for primary angiitis
of the central nervous system
• discuss the test operating characteristic of commonly
employed neurodiagnostics, i.e., magnetic resonance,
angiography, cerebrospinal fluid analysis, etc.
• list and appraise diagnostic heuristics for the recognition and
diagnosis of primary angiitis of the central nervous system and
the separation of mimics that can confound the diagnosis
PS
PM
Avoiding Electronic Health Record Errors and Their
(Sometimes) Critical Consequences
Moderator: Salahuddin Kazi, MD
Speaker: Steven K. Magid, MD
• recognize common errors in electronic health record systems
and how to prevent these issues
• evaluate legal and social implications of unintended
consequences in electronic health records
• review approaches to mitigate electronic health record related
errors using a strategic set of solutionsPS
PM
157 B
Axial Spondyloarthritis Guidelines
PM
PM
PS
PS
Moderators: John D. Reveille, MD and Atul A. Deodhar, MD
• describe the ACR-SAA-SPARTAN recommendations for
management of patients with axial spondyloarthritis/
• review the process and methods used in the development of
the new ACR-SAA-SPARTAN guidelines
1:00 pm
Overview of Guidelines Development, Including Methods and
Literature Review
Liron Caplan, MD, PhD
2014 Program Book
PM
PS
Exhibit Hall C
PrM
Pd
PS
Edin 2014
Gout ManagementPM
FIT
PM
PS
Moderators: Jasvinder A. Singh, MD, MPH and Alan N. Baer, MD
• describe the effective management of gout in the setting of
chronic kidney disease
• discuss the current best treatment for tophaceous gout and
emerging therapies
1:00 pm
Effective Management of Gout in the Setting of Renal Disease
Lisa K. Stamp, PhD
1:30 pm
Tophaceous Gout: Past, Present and the Future of Therapeutics
Tuhina Neogi, MD, PhD
PM
PS
102 A
Speaker: Hilde Cheroutre, PhD
1:00 – 2:00 pm
44
1:50 pm
How the Gut Primes the Immune System
ACR SESSIONS
254 A
1:25 pm
Presentation of the Draft ACR-SAA-SPARTAN Axial
Spondyloarthritis/Ankylosing Spondylitis Guidelines
Michael M. Ward, MD
• examine the collaboration of the intestinal host-microbial
interface and the innate and adaptive immune system in
the detection and regulation of microbial populations and
maintaining homeostasis
• examine the effects of disruption of the intestinal-host
microbial interface and its contribution to chronic
inflammatory disease
PS
PM
151 A
Practice Issues: The Road to I10
Moderator: Douglas White, MD, PhD
• describe the challenges in the physician practice and the
workflow for staff and patients
• identify any productivity loss due to coding backlogs
• discuss delays in turnaround time due to training
• assess performance in the new environment
• discuss any reimbursement disruptions and the flow of denials
and/or adjustments for claims billed with ICD-9 codes for the
earlier part of the year
1:00 pm
The Advocacy Movement
William F. Harvey, MD, MSc
scientific sessions
1:20 pm
Physician’s Perspective of ICD-10
Jonathan Kay, MD
159
*Advanced Musculoskeletal Ultrasound (208)
Speaker: Jay B. Higgs, MD
1:40 pm
Process and Strategy From the Coder’s Viewpoint
Evan Gwilliam, DC, MBA, BS, CPC, NCICS, CCPC, CCCPC, CPC-I
MCS-P
104 B
PM
Rheumatology Research Foundation Memorial
PS
Lectureship to Honor Dr. Stephen E. Malawista, MD:
Innate Immunity at the Core of Rheumatic Disease
• d emonstrate improvement in their techniques for performing
selected musculoskeletal ultrasound examinations
• u
se practical knowledge of ultrasound technology to improve
image quality
152
Eth
PM
• identify mimics of lupus rashes
• distinguish between lupus rashes and their mimics
• discuss the management of lupus rashes, including the
PS
PM
treatment of rashes
refractory to initial therapy
ACR WORKSHOPS
1:15 – 3:15 pm
2 0 1 4
Moderators: Elana J. Bernstein, MD, MSc and Meenakshi Jolly,
MD, MS
Speaker: Bonnie T. Mackool, MD, MSPH
1 6 ,
The Butterfly Effect: Lupus Rashes and Their Mimics
ACR SESSIONS
SUNDAY
PS
Ballroom East
• demonstrate clinical anatomy of the lower extremities in
performing the physical examination
• apply knowledge of clinical anatomy to better understanding
and diagnosis of the common regional pain syndromes
• perform the physical examination of the lower extremities on
healthy volunteers
n o v e m b e r
PM
PS
Speakers: Robert A. Kalish, MD and Pablo Villasenor Ovies, MD
Moderator: Linda Bockenstedt, MD
Speaker: Robert Terkeltaub, MD
• evaluate novel translational vision and action in the science
and practice of rheumatology, by reviewing lucid examples of
Dr. Malawista’s seminal works and their evolving fate
• recognize the power of clinical observation and creative
thinking in fleshing out etiopathogenesis, epidemiology and
treatment of rheumatic diseases, exemplified by Lyme disease
and gout
• appraise phagocyte innate immune responses to exogenous
infectious and endogenous particulate danger signals
and how nuances in macrophage differentiation and
function orchestrate inflammatory responses and can be
therapeutically corralled in rheumatic disease
Clinical Anatomy and Physical Exam: Essential Tools in
Lower Extremity Regional Pain Syndromes (209) PM
2:30 – 4:00 pm
PS
PM
52 A
Autoimmunity in Immunodeficiency
Moderators: Nora G. Singer, MD and Jose Carlos Crispin Acuna,
MD
• describe the presence of autoimmune manifestations in
patients with primary immunodeficiency
• discuss the molecular basis for the development of
autoimmunity in primary immunodeficiency
• consider therapeutic approaches for autoimmune
manifestations in patients with primary immunodeficiency
2:30 pm
Autoimmunity and Autoimmune Diseases in Primary
Immunodeficiencies
Erin Janssen, MD, PhD
3:15 pm
The Abnormal Regulation of B-Cell Tolerance in Patients with
Autoimmune Disease and Primary Immunodeficiencies
Eric Meffre Sr., PhD
PM
PS
102 A
Educator: Medical Education: The Year in Review
PM
Ed
Pd
PS
PrM
FIT
Moderators: Deana M. Lazaro, MD and Michael J. Battistone,
MD
Speaker: Andrew R. Hoellein, MD
• recognize the major research reports and scholarship in the
field of medical education over the past year
2014 Program Book
45
scientific sessions
• t ranslate results of educational research to their own
educational programs
• formulate ideas for educational research at their own
institution
205 B
PM
PS
New Frontiers in Osteoarthritis Treatment: The
Role of Weight Loss, Surgery and Current Treatment
FIT
PrM
Pd
PS
PM
Ed
Guidelines
n o v e m b e r
1 6 ,
SUNDAY
2 0 1 4
Moderators: Jasvinder A. Singh, MD, MPH and Timothy E.
McAlindon, MD, MPH, MRCP
• summarize the evidence regarding weight loss in the
management of osteoarthritis
• assess the role of arthroscopic debridement in treatment of
osteoarthritis
• discuss how to reconcile differences between recent
osteoarthritis treatment guidelines from the ACR, AAOS and
other leading organizations
2:30 pm
Weight Loss in the Management of Osteoarthritis: Lessons
From Randomized Trials
Stephen P. Messier, PhD
3:00 pm
Arthroscopic Debridement and Meniscal Tear Surgery in
Osteoarthritis Patients: Who Needs It and When and When
Not to Do It
Jeffrey N. Katz, MD, MSc
3:30 pm
Recommendations for Management of Osteoarthritis: Can We
Reconcile Differences?
Marc C. Hochberg, MD, MPH, MACP
Exhibit Hall C
PM
PS
The Great Debate: Belimumab for the Treatment of
• identify predictors of response to belimumab
• discuss the efficacy of belimumab in the treatment of systemic
lupus erythematosus
• evaluate the limitations of belimumab in the treatment of
systemic lupus erythematosus
• describe the safety issues with belimumab
• discuss the outcomes and limitations of the BLISS-52 and
BLISS-76 trials
2:30 pm
Pro Perspective
Bevra H. Hahn, MD
3:05 pm
Pro Rebuttal
David A. Isenberg, MD
46
2014 Program Book
3:13 pm
Con Perspective
3:48 pm
Con Rebuttal
Bevra H. Hahn, MD
3:56 pm
Pro Final
Bevra H. Hahn, MD
3:58 pm
Con Final
ACR CONCURRENT ABSTRACT SESSIONS
2:30 – 4:00 pm
253 B
PM
PS
Epidemiology and Public Health I: Drug and Vaccine
Safety
Moderators: Kaleb Michaud, PhD and Cynthia S. Crowson, MS
2:30 pm
820. Herpes Zoster Infection Risk in Auto-Immune and
Inflammatory Diseases: Implications for Vaccination
Huifeng Yun1, Shuo Yang2, Lang Chen2, Fenglong Xie2, K. L.
Winthrop3, John Baddley2, Kenneth G. Saag4, Jasvinder Singh2
and Jeffrey R. Curtis2, 1University of Alabama at Birmingham
School of Public Health, Birmingham, AL, 2University of
Alabama at Birmingham, Birmingham, AL, 3Oregon Health and
Science University, Portland, OR, 4The University of Alabama at
Birmingham, Birmingham, AL
2:45 pm
821. Pregnancy Outcome in Women Treated with Adalimumab
for the Treatment of Rheumatoid Arthritis: An Update
Christina D Chambers1, Diana L Johnson2, Yunjun Luo2, Ronghui
Xu1 and Kenneth L Jones2, 1University of California San Diego
Department of Family and Preventive Medicine, La Jolla, CA,
2
University of California San Diego Department of Pediatrics,
La Jolla, CA Pharmaceuticals, 2, Sandoz, 2, Sanofi-Aventis
Pharmaceutical, 2, Teva Pharmaceuticals, 2, UCB, 2.
3:00 pm
822. Meloxicam and Risk of Myocardial Infarction: A
Population-Based Cohort Study
Deepan Dalal1, Maureen Dubreuil2, Yuqing Zhang2, Christine
Peloquin2, Tuhina Neogi2, Hyon Choi2 and David T. Felson2,
1
Boston Medical Center, Boston, MA, 2Boston University School
of Medicine, Boston, MA
3:15 pm
823. Risk of Active Tuberculosis in Patients with Arthritis
Receiving TNF-α Inhibitors: A Look Beyond the Baseline
Tuberculosis Screening Protocol
Alina Soare, Carina Mihai, Ana Maria Gherghe, Rucsandra
Dobrota, Raida Oneata, Simona Pintilie, Mihaela Milicescu,
scientific sessions
Ioan Ancuta, Andrei Martin, Mariana Sasu, Claudia Ciofu, Liviu
Macovei, Victor Stoica and Mihai Bojinca, Carol Davila University
of Medicine and Pharmacy & Cantacuzino Hospital, Bucharest,
Romania
Paloma Vela2 and Juan Miguel Ruiz-Nodar3, 1Hospital General
Universitario de Elda, Alicante, Spain, 2Universidad Miguel
Hernández, Alicante, Spain, 3Hospital General Universitario de
Alicante, Alicante, Spain
3:30 pm
824. Impact of Oral Glucocorticoid Therapy on Mortality in
Patients with Rheumatoid Arthritis and Diabetic Mellitus
Mohammad Movahedi and William G Dixon, Arthritis Research
UK Centre for Epidemiology, The University of Manchester,
Manchester, United Kingdom
3:30 pm
830. Profound Hypouricemia Induced in Human Subjects By
Novel Bifunctional Inhibitors of Xanthine Oxidase and URAT1
Raymond P. Warrell Jr.1, Anna Klukovits2, Keith Barnes3, Chitkala
Satyanarayana4, Chris Cheeseman5 and John Piwinski1, 1RelburnMetabolomics, Inc., Westfield, NJ, 2SOLVO Biotechnology,
Budapest, Hungary, 3AMRI, Albany, NY, 4AMRI, Singapore,
Singapore, 5University of Alberta, Alberta, AB
3:45 pm
825. Serious Infections on TNF Inhibitors: Have the Risks
Changed over Calendar Time and How High Are They?
Elizabeth V. Arkema, Karolinska Institutet, Stockholm, Sweden
Disclosures: E. V. Arkema, None.
PM
PS
2:45 pm
827. Gout and the Risk of Alzheimer’s Disease: A PopulationBased Cohort Study
Na Lu1, Yuqing Zhang1, Alberto Ascherio2, Miguel Hernan2,
Tuhina Neogi1, Maureen Dubreuil3 and Hyon Choi4, 1Boston
University School of Medicine, Boston, MA, 2Harvard School of
Public Health, Boston, MA, 3Boston University Medical Center,
Boston, MA, 4Harvard Medical School, Boston, MA
3:00 pm
828. Extent of Urate Deposition in Asymptomatic
Hyperuricemia and Symptomatic Gout: A Dual Energy
Computed Tomography Study
Nicola Dalbeth1, Meaghan House1, Opetaia Aati1, Paul Tan1,
Christopher Franklin1, Anne Horne1, Gregory Gamble1, Lisa K.
Stamp2, Anthony Doyle1 and Fiona M. McQueen1, 1University
of Auckland, Auckland, New Zealand, 2University of Otago,
Christchurch, New Zealand
3:15 pm
829. Asymptomatic Deposit of Monosodium Urate Crystals
Associates to a More Severe Coronary Calcification in
Hyperuricemic Patients with Acute Coronary Syndrome
Mariano Andrés1, María Amparo Quintanilla1, Francisca Sivera1,
PS
Miscellaneous Rheumatic and Inflammatory Diseases
Moderators: Mehrdad Maz, MD and Isabelle Koné-Paut, MD
2 0 1 4
2:30 pm
826. Comparison of Classification Criteria for Gout Using
Monosodium Urate Crystal Identification By a Certified
Examiner As the Gold-Standard in a Large Multi-National Study
William Taylor1, Nicola Dalbeth2, Jaap Fransen3, Tuhina Neogi4,
H. Ralph Schumacher Jr.5 and Tim Jansen6, 1University of Otago
Wellington, Wellington, New Zealand, 2University of Auckland,
Auckland, New Zealand, 3Radboud University, Nijmegen,
Netherlands, 4Boston University School of Medicine, Boston, MA,
5
University of Pennsylvania VA Medical Center, Philadelphia, PA,
6
Radboud University Medical Center, Nijmegen, Netherlands
PM
160 B
1 6 ,
Moderators: N. Lawrence Edwards, MD and Janitzia VazquezMellado, MD PhD
SUNDAY
Metabolic and Crystal Arthropathies I: Clinical
Aspects
n o v e m b e r
104 B
3:45 pm
831. Bisphosphonates and Risk of Acute Pseudogout: A CaseControl Study in the Clinical Practice Research Datalink (CPRD)
Edward Roddy, Sara Muller, Zoe Paskins, Samantha Hider, Milisa
Blagojevic-Bucknall and Christian Mallen, Keele University, Keele,
United Kingdom
2:30 pm
832. NOD2-Associated Autoinflammatory Disease: The Largest
Cohort Study
Qingping Yao, Min Shen, Christine McDonald, Felicitas Lacbawan
and Bo Shen, Cleveland Clinic, Cleveland, OH
2:45 pm
833. Canakinumab Use in Patients with Cryopyrin-Associated
Periodic Syndrome: Interim Safety and Efficacy Results from
Beta-Confident Registry
Hal M. Hoffman1, Jasmin B. Kuemmerle-Deschner2, Philip
N. Hawkins3, T. van der Poll4, Ulrich A. Walker5, Ken Abrams6
and Hugh H. Tilson7, 1University of California at San Diego, La
Jolla, CA, 2University Hospital Tuebingen, Tuebingen, Germany,
3
University College London Medical School, London, United
Kingdom, 4University of Amsterdam, Amsterdam, Netherlands,
5
Department of Rheumatology, University Hospital Basel, Basel,
Switzerland, Basel, Switzerland, 6Novartis Pharmaceutical
Corporation, East Hanover, NJ, 7University of North Carolina,
Chapel Hill, NC
3:00 pm
834. Interleukin-18 (IL-18) As a Biomarker for Diagnosis and
Evaluation of Disease Activity in Patients with Adult Onset
Still’s Disease and Systemic Onset Juvenile Idiopathic Arthritis
Holger Kudela1, Susanne Drynda2, Anke Lux3, Gerd Horneff4 and
Joern Kekow2, 1Univ of Magdeburg, Clinic for Rheumatology,
Vogelsang-Gommern, Germany, 2Univ of Magdeburg, Clinic
of Rheumatology, Vogelsang-Gommern, Germany, 3Univ of
Magdeburg, Institute for Biometry and Medical Informatics,
Magdeburg, Germany, 4Asklepios Clinic Sankt Augustin, Sankt
Augustin, Germany
2014 Program Book
47
scientific sessions
n o v e m b e r
1 6 ,
SUNDAY
2 0 1 4
3:15 pm
835. Relapsing Polychondritis Can Be Characterized By 3
Different Clinical Phenotypes: Analysis of a Series of 142
Patients
Jeremie Dion1, Nathalie Costedoat-Chalumeau1, Damien Sène2,
Judith Cohen-Bittan3, Gaëlle Leroux3, Charlotte Dion4, Camille
Francès5 and Jean-Charles Piette3, 1National Referral Center
for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–
HP, Université Paris Descartes, Paris, Paris, France, 2Hopital
Lariboisière, service de Médecine Interne, Paris, France, 3CHU
Pitié-Salpêtrière, Paris, France, 4Ecole des hautes études en
sciences sociales, Paris, France, 5Hôpital Tenon, Paris Cedex 20,
France
3:30 pm
836. Categorical Change in 6MWD in Patients with Connective
Tissue Disease Associated Pulmonary Arterial Hypertension
Receiving Ambrisentan over 3-Years
Aryeh Fischer1, Virginia D. Steen2, Steven Nathan3, Hunter Gillies4,
James Tislow4 and Chris Blair4, 1National Jewish Health, Denver,
CO, 2Georgetown University Medical Center, Washington, DC,
3
Inova Medical Group, Falls Church, VA, 4Gilead Sciences, Inc.,
Foster City, CA
3:45 pm
837. Progressive Multifocal Leukoencephalopathy Associated
with Biologic Therapy in Rheumatic Diseases: Strengthening
Association with Rituximab
Eamonn Molloy1 and Leonard H. Calabrese2, 1St Vincent
University Hospital, Dublin, Ireland, 2Cleveland Clinic Foundation,
Cleveland, OH
Ballroom East
PM
PS
Rheumatoid Arthritis – Clinical Aspects I:
Cardiovascular Disease Risk
Moderators: Grant H. Louie, MD, MHS and Jon Giles, MD, MPH
2:30 pm
838. The Impact of Rheumatoid Arthritis Disease Activity on
Cardiovascular Disease Risk: What Is the Role of the Flare?
Elena Myasoedova1, Arun K. Chandran1, Birkan İlhan2, Brittny
T. Major1, C. John Michet1, Eric L. Matteson1 and Cynthia S.
Crowson1, 1Mayo Clinic, Rochester, MN, 2Marmara University
School of Medicine, Istanbul, Turkey
2:45 pm
839. Cardiovascular Risk with NSAIDs in Rheumatoid Arthritis:
An Analysis Using Routinely Collected Data
Fowzia Ibrahim1, Antigoni Grigoriou2, Khaldoun Chaabo2, David
L. Scott2, Sophia Steer2 and James Galloway2, 1King’s College
London, Department of Rheumatology, London, United Kingdom,
2
King’s College Hospital, Department of Rheumatology, London,
London, United Kingdom
3:00 pm
840. Vascular Calcifications on Hand and Wrist Radiographs
Are Associated with Cardiovascular Risk Factors, AntigenSpecific Anti-Citrullinated Protein Antibodies and Mortality in
E. Blair Solow1, Fang Yu2, Geoffrey M. Thiele3, Jeremy Sokolove4,
48
2014 Program Book
William H. Robinson5, Zachary M. Pruhs3, Kaleb Michaud3, Alan
R. Erickson3, Harlan Sayles3, Gail S. Kerr6, Angelo L. Gaffo7,
Liron Caplan8, Lisa A. Davis8, Grant W. Cannon9, Andreas M.
Reimold10, Joshua Baker11, Pascale Schwab12, Daniel Anderson3
and Ted R. Mikuls3, 1UT Southwestern Medical Center, Dallas,
TX, 2University of Nebraska Medical Center, Omaha, NE,
3
Omaha VA Medical Center and University of Nebraska Medical
Center, Omaha, NE, 4VA Palo Alto Healthcare System and
Stanford University, Palo Alto, CA, 5VA Palo Alto Health Care
System and Stanford University, Palo Alto, CA, 6Washington DC
VAMC, Georgetown and Howard University, Washington, DC,
7
Birmingham VA Medical Center and University of Alabama
at Birmingham, Birmingham, AL, 8Denver VAMC and Univ of
Colorado School of Medicine, Aurora, CO, 9Salt Lake City VA and
University of Utah, Salt Lake City, UT, 10Dallas VA and University
of Texas Southwestern, Dallas, TX, 11University of Pennsylvania
and Philadelphia VAMC, Philadelphia, PA, 12Oregon Health &
Science University, Portland, OR
3:15 pm
841. Lipid Control and Cardiovascular Risk for Patients
with Rheumatoid Arthritis Compared with Matched NonRheumatoid Arthritis Patients
J An1, E Alemao2, K Reynolds3, H Kawabata2, D H Solomon4, K P
Liao4 and T C Cheetham3, 1Western University of Health Sciences,
Pomona, CA, 2Bristol-Myers Squibb, Princeton, NJ, 3Kaiser
Permanente Southern California, Pasadena, CA, 4Brigham and
Women’s Hospital, Boston, MA
3:30 pm
842. Is Rheumatoid Arthritis a Coronary Heart Disease Risk
Equivalent, Similar to Diabetes?
Jie Zhang1, Shuo Yang2, Lang Chen2, Fenglong Xie2, Huifeng Yun3,
Paul M. Muntner2, Emily Levitan2, Monica Safford2, Kenneth G.
Saag4, Jasvinder Singh2 and Jeffrey R. Curtis2, 1Univ. of Alabama
at Birmingham, Birmingham, AL, 2University of Alabama
at Birmingham, Birmingham, AL, 3University of Alabama at
Birmingham School of Public Health, Birmingham, AL, 4The
University of Alabama at Birmingham, Birmingham, AL
3:45 pm
843. Exercise Is Associated with Protective Cardiovascular Risk
Profile Including Increased HDL Particle Number in Patients
with Rheumatoid Arthritis
Kevin Byram, Annette Oeser, MacRae F. Linton, Sergio Fazio, C
Michael Stein and Michelle Ormseth, Vanderbilt University,
Nashville, TN
Ballroom West
PS
PM
and Gene Therapy I: Safety of Biologics and Small
Molecules in Rheumatoid Arthritis – Malignancy and
Infection
Moderators: Stephen A. Paget, MD and Peter C. Taylor, MD, PhD
2:30 pm
844. Frequency of Significant Infection in Patients with RA
Following Initiation of Rituximab with up to 5 Years of Followup in a US Observational Study
scientific sessions
Kenneth G. Saag1, Kevin L. Winthrop2, D E Furst3, Kimberly
Alexander4, Angelika Jahreis5, Carol Chung6 and Kurt Oelke7,
1
The University of Alabama at Birmingham, Birmingham, AL,
2
Oregon Health & Science University, Portland, OR, 3University
of California at Los Angeles, Los Angeles, CA, 4Genentech, Inc.,
South San Francisco, CA, 5Genentech, South San Francisco, CA,
6
Genentech, Inc, South San Francisco, CA, 7Rheumatic Disease
Center, Glendale, WI
3:45 pm
849. Tofacitinib, an Oral Janus Kinase Inhibitor, in the
Treatment of Rheumatoid Arthritis: Safety and Efficacy in
Open-Label, Long-Term Extension up to 6 Years
Spondyloarthropathies and Psoriatic Arthritis I –
Novel Treatments for Axial Spondyloarthritis
Moderators: Atul A. Deodhar, MD and Lianne S. Gensler, MD
2:30 pm
850. Targeting Synovial Mast Cells in Spondyloarthritis: A
Proof-of-Concept Study with the Tyrosine Kinase Inhibitor
Nilotinib
Jacqueline E. Paramarta1, Maureen C. Turina1, Tanja F. Heijda1,
Iris C. Blijdorp2, Troy Noordenbos1, Nataliya Yeremenko1 and
Dominique L. Baeten2, 1Academic Medical Center/University
of Amsterdam, Amsterdam, Netherlands, 2Department of
Clinical Immunology and Rheumatology and Department of
Experimental Immunology, Academic Medical Centre/University
of Amsterdam, Amsterdam, Netherlands
2 0 1 4
3:30 pm
848. Malignant Progression of Precancerous Lesions of the
Uterine Cervix Following DMARD Therapy in Female Arthritis
Patients
René Cordtz1, Lene Mellemkjær2, Bente Glintborg1, Merete Lund
Hetland3 and Lene Dreyer1, 1Copenhagen University Hospital
Gentofte, Hellerup, Denmark, 2The Danish Cancer Society,
Copenhagen, Denmark, 3Copenhagen University Hospital
Glostrup. On behalf of all departments of Rheumatology in
Denmark., Glostrup, Denmark
PS
1 6 ,
3:15 pm
847. Safety of TNF Inhibitor Therapy in Patients Who Have Had
a Prior Malignancy
Seung-Hyeon Bae, Doo-Ho Lim, Soo Min Ahn, Seokchan Hong,
Yong-Gil Kim, Chang-Keun Lee and Bin Yoo, University of Ulsan
College of Medicine, Asan Medical Center, Seoul, South Korea
PM
SUNDAY
3:00 pm
846. Rheumatoid Arthritis, Anti-Tumor Necrosis Factor Therapy
and Risk of Squamous Cell and Basal Cell Skin Cancer- a
Nationwide Population Based Prospective Cohort Study from
Sweden
Pauline Raaschou1, Julia F Simard2, Charlotte Asker-Hagelberg3,
Johan Askling4 and the ARTIS Study group5, 1Karolinska Institutet,
Stockholm, Sweden, 2Stanford School of Medicine, Stanford, CA,
3
Swedish Medical Products Agency, SE-751 03 Uppsala, Sweden,
4
Clinical Epidemiology Unit, Department of Medicine, Karolinska
Institutet, Stockholm, Sweden, 5Karolinska Institutet och Svensk
Reumatologisk förening, Solna, Sweden
210 B
n o v e m b e r
2:45 pm
845. The Risk of Cancer with Tumor Necrosis Factor Inhibitors
in Patients Concomitantly Exposed to Non-Biological
Immunosuppressants Differs According to the Indication
Layla Saliba1, Guillaume Moulis2, Malak Aboutaam3, Grégory
Pugnet2, Vanessa Rousseau1, Leila Chebane1, Nadine Petitpain4,
Bernadette Baldin5, Jean-Louis Montastruc1 and Haleh
Bagheri1, 1Toulouse University Hospital, Clinical Pharmacology
Department, University of Toulouse, Toulouse, France, 2Toulouse
University Hospital, Department of Internal Medicine, University
of Toulouse, INSERM UMR 1027, Toulouse, France, 3Reims
University Hospital, Pharmacovigilance Regional Center,
Reims, France, 4Nancy University Hospital, Pharmacovigilance
Regional Center, Nancy, France, 5Nice University Hospital,
Pharmacovigilance Regional Center, Nice, France
J. Wollenhaupt1, J. Silverfield2, E.B. Lee3, S.P. Wood4, K. Terry4,
H. Nakamura5, K. Kwok6, A. Anisfeld6, C. Nduaka4, R. Riese4 and
L. Wang4, 1Schoen-Klinik Hamburg-Eilbek Teaching Hospital of
the University of Hamburg, Hamburg, Germany, 2Healthpoint
Medical Group, Tampa, FL, 3Seoul National University, Seoul,
South Korea, 4Pfizer Inc, Groton, CT, 5Pfizer Inc, Tokyo, Japan,
6
Pfizer Inc, New York, NY
2:45 pm
851. A Tailored Approach to Reduce Dose of Anti-TNF Drugs Is
Equally Effective, but Substantially Less Costly Than Standard
Dosing in Patients with Ankylosing Spondylitis over One Year:
A Propensity Score-Matched Cohort Study
Jakub Zavada1, Michal Uher2, Katarina Sisol3, Sarka Forejtova3,
Katerina Jarosova3, Herman F. Mann4, Jiri Vencovsky5 and Karel
Pavelka6, 1Charles University, Prague, Czech Republic, 2Institute
of Biostatistics and Analyses, Masaryk University, Brno, Czech
Republic, 3Institute of Rheumatology, Prague, Czech Republic,
4
Institute of Rheumatology and Department of Rheumatology,
1st Faculty of Medicine, Charles University, Prague, Prague,
Czech Republic, 5Institute of Rheumatology and Clinic of
Rheumatology, 1st Faculty of Medicine, Charles University in
Prague, Prague, Czech Republic, 6Institute of Rheumatology,
Praha, Czech Republic
3:00 pm
852. Safety and Efficacy of Certolizumab Pegol over 96 Weeks
in Patients with Axial Spondyloarthritis, Including Ankylosing
Spondylitis and Non-Radiographic Axial Spondyloarthritis
Joachim Sieper1, Martin Rudwaleit2, Désirée M. van der
Heijde3, Walter P. Maksymowych4, Maxime Dougados5, Philip
Mease6, Jürgen Braun7, Atul A. Deodhar8, Bengt Hoepken9,
Tommi Nurminen9 and Robert B. M. Landewé10, 1Charité
Universitätsmedizin Berlin, Berlin, Germany, 2Endokrinologikum,
Berlin, Germany, 3Leiden University Medical Center, Leiden,
Netherlands, 4University of Alberta, Edmonton, AB, 5Université
Paris René Descartes and Hôpital Cochin, Paris, France, 6Swedish
Medical Center and University of Washington, Seattle, WA,
7
Ruhr-University Bochum, Herne, Germany, 8Oregon Health
and Sciences University, Portland, OR, 9UCB Pharma, Monheim,
Germany, 10Amsterdam Rheumatology Center, Amsterdam,
Netherlands
2014 Program Book
49
scientific sessions
n o v e m b e r
1 6 ,
SUNDAY
2 0 1 4
3:15 pm
853. Cancer Incidence in TNF Inhibitor Treated Patients with
Axial Spondyloarthritis and Psoriatic Arthritis – a Study from
the ARTIS and Danbio Registers Johan Askling1, Lene Dreyer2, Merete Lund Hetland3, Lennart
Jacobsson4, Lars-Erik Kristensen5, Bente Glintborg6, . ARTIS and
DANBIO study groups7 and Karin Hellgren1, 1Karolinska Institutet,
Stockholm, Sweden, 2Gentofte University Hospital, Hellreup,
Denmark, 3Glostrup University Hospital, Glostrup, Denmark,
4
Sahlgrenska Academy, Gothenburg, Sweden, 5Lund University,
Lund, Sweden, 6Gentofte University Hospital, Gentofte, Denmark,
7
Karolinska Institutet, Stockholm, Sweden
3:30 pm
860. Inhibition of G Protein βγ Signaling Inhibits Nephritis in
Lupus Prone Mice
Teresa Owen, Javier Rangel-Moreno, Jesi To, Bruce Goldman,
Alan Smrcka and Jennifer H. Anolik, University of Rochester,
Rochester, NY
3:45 pm
861. Ultraviolet B Generates Type 1 Interferon and Induces
Autoantibody-Mediated Disease in a Mouse Model of
Cutaneous Lupus
Clayton Sontheimer and Keith B. Elkon, University of Washington,
Seattle, WA
3:30 pm
854. Golimumab Versus Pamidronate for the Treatment of
Axial Spondyloarthropathy (SpA): A 48-Week Randomized
Controlled Trial
Chi Chiu Mok, Angela Li, Kar Li Chan and Ling Yin Ho, Tuen Mun
Hospital, Hong Kong, Hong Kong
3:45 pm
855. Active and Structural Lesions on MRI of the Sacroiliac
Joints Predict Major Clinical Responses in Patients with NonRadiographic Axial Spondyloarthritis Treated with Etanercept
WP Maksymowych1, S Wichuk1, H Jones2, A Szumski2, L Marshall2,
J Bukowski2 and RG Lambert1, 1University of Alberta, Edmonton,
AB, 2Pfizer Inc., Collegeville, PA
PM
153 B
Systemic Lupus Erythematosus – Animal Models
Moderators: Keith B. Elkon, MD and Ram P. Singh, PhD
2:30 pm
856. A Pathogenic Role for the Gut Microbiota in Murine
Antiphospholipid Syndrome and Lupus
Silvio M. Vieira, Andrew Yu, Michael Hiltesperger, Odelya E.
Pagovich, Eleni Tiniakou, William Ruff, John Sterpka and Martin
Kriegel, Yale School of Medicine, New Haven, CT
2:45 pm
857. Amelioration of Systemic Lupus Erythematosus (SLE) in
NZM 2328 Mice By Selectively Blocking Engagement of Two
BAFF Receptors
Chaim O. Jacob, Ning Yu and William Stohl, University of
Southern California Keck School of Medicine, Los Angeles, CA
3:00 pm
858. ABT-199, a Potent and Selective BCL-2 Inhibitor, Prevents
Lupus Nephritis in the Spontaneous NZB/W F1 Mouse Model
By Depleting Selective Lymphocyte Populations While Sparing
Platelets
Li Chun Wang1, Stuart Perper1, Annette Schwartz1, Christian
Goess1, Liz O’connor1, Dawna Hartman1, Candace Graff1, Andrew
Souers2, Joel Leverson2, Steven Elmore2 and Lisa Olson1, 1AbbVie
Inc, AbbVie Bioresearch Center, Worcester, MA, 2AbbVie Inc,
North Chicago, IL
3:15 pm
859. TGF-β3-Producing CD4+CD25-LAG3+ Regulatory T Cells
Control B Cell Responses
50
Tomohisa Okamura1, Kaoru Morita1, Mariko Inoue1, Toshihiko
Komai1, Yukiko Iwasaki1, Shuji Sumitomo1, Shinichiro Nakachi1,
Hirofumi Shoda2, Keishi Fujio2 and Kazuhiko Yamamoto1,
1
Graduate School of Medicine, the University of Tokyo, Tokyo,
Japan, 2The University of Tokyo, Tokyo, Japan
2014 Program Book
258 B
PM
PS
Systemic Lupus Erythematosus – Clinical Aspects and
Treatment: Cardiovascular Disease and Pregnancy
Moderators: Wendy Marder, MD and Eliza Chakravarty, MD, MS
PS
2:30 pm
862. Risk Factors for Changes in Subclinical Atherosclerosis As
Measured By Carotid Intima Media Thickness (IMT) and Plaque
over 5 Years in Women with Systemic Lupus Erythematosus
(SLE)
Apinya Lertratanakul1, Peggy W. Wu1, Alan Dyer1, William Pearce1,
Emma Barinas-Mitchell2, Trina Thompson2 and Rosalind RamseyGoldman3, 1Northwestern University, Chicago, IL, 2University
of Pittsburgh, Pittsburgh, PA, 3Northwestern University and
Feinberg School of Medicine, Chicago, IL
2:45 pm
863. Metabolic Syndrome in Young Premenopausal Female
Lupus Patients Is Mainly Influenced By Therapies
Luciana Muniz1, Rosa M.R. Pereira1, Thiago Silva1, Eloisa Bonfá2
and Eduardo Ferreira Borba1, 1University of São Paulo, São Paulo,
Brazil, 2Faculdade de Medicina da Universidade de São Paulo,
São Paulo, Brazil
3:00 pm
864. Association of Coronary Artery Calcification with Brown
and White Pericardial Adipose Tissue in SLE
Kelly J. Shields, Lupus Center of Excellence / Allegheny Health
Network, Pittsburgh, PA
3:15 pm
865. Cardiovascular Events Prior to or Early after Diagnosis of
SLE
Murray B. Urowitz1, Dafna D. Gladman1, Nicole Anderson1,
Dominique Ibanez1 and Systemic Lupus International
Collaborating Clinics (SLICC)2, 1University of Toronto, Toronto
Western Hospital, Toronto, ON, 2University of Toronto, Toronto
Western Hospital (Coordinating Center), Toronto, ON
scientific sessions
3:30 pm
866. Heart Rate Variability: An Inflammatory Biomarker in
Aikaterini Thanou1, Stavros Stavrakis2, John Dyer2, Stan Kamp1,
Melissa E. Munroe1, David Albert3, Judith A. James1 and Joan T.
Merrill1, 1Oklahoma Medical Research Foundation, Oklahoma
City, OK, 2University of Oklahoma Health Sciences Center,
Oklahoma City, OK, 3AliveCor, Inc., San Francisco, CA
3:30 pm
872. Interferon-α and Angiogenic Dysregulation in Pregnant
Lupus Patients Destined for Preeclampsia
Danieli Andrade1, Mimi Kim2, Luz P. Blanco3, S. Ananth
Karumanchi4, Gloria Koo1, Patricia M. Redecha1, Kyriakos A.
Kirou1, Angela M. Alvarez5, Melissa J. Mulla5, Mary K. Crow1,
Vikki Abrahams5, Mariana J. Kaplan3 and Jane E. Salmon1,
1
Hospital for Special Surgery, New York, NY, 2Albert Einstein
College of Medicine, Bronx, NY, 3National Institutes of Health,
Bethesda, MD, 4Beth Israel Deaconess Medical Center, Harvard
Medical School, Boston, MA, 5Yale School of Medicine, New
Haven, CT
3:45 pm
867. Specific SLE Disease Manifestations in the Six Months
Prior to Conception Predict Similar Manifestations during
Pregnancy
Sara K. Tedeschi, Hongshu Guan, Alexander Fine, Bonnie L.
Bermas and Karen H. Costenbader, Brigham and Women’s
Hospital, Harvard Medical School, Boston, MA
PM
Moderators: Robert M. Clancy, PhD and Susan Boackle, MD
3:00 pm
870. IRF1 Influences on Histone H4 Acetylation in Systemic
Lupus Erythematosus
Yiu Tak Leung1, Lihua Shi2, Kelly Maurer2, Li Song2, Zhe
Zhang3, Michelle Petri4 and Kathleen E. Sullivan2, 1University
of Pennsylvania, Philadelphia, PA, 2The Children’s Hospital
of Philadelphia, Philadelphia, PA, 3Bioinformatics, Children’s
Hospital of Philadelphia, Philadelphia, PA, 4Johns Hopkins
University School of Medicine, Baltimore, MD
3:15 pm
871. Antimalarials Regulate TLR7/8 Mediated Macrophage
Activation Via Epigenetic Modification at the TNFα Promoter
Androo J. Markham1, Mark Halushka2, Cristiana Guiducci3,
Robert M. Clancy1 and Jill P. Buyon1, 1New York University School
of Medicine, New York, NY, 2John Hopkins Pathology, Baltimore,
MD, 3Dynavax Technologies, Berkeley, CA
PS
2 0 1 4
2:45 pm
869. UBE2L3 genotype Influences Plasma Cell Proliferation in
Systemic Lupus Erythematosus By Regulation of NF-κB By the
Linear Ubiquitination Assembly Complex
Myles J. Lewis1, Simon Vyse1, Adrian M. Shields2, Sebastian
Boeltz2, Patrick Gordon2, Timothy D. Spector2, Paul J. Lehner3,
Henning Walczak4 and Timothy J. Vyse2, 1Queen Mary University
of London, London, United Kingdom, 2King’s College London,
London, United Kingdom, 3University of Cambridge, Cambridge,
United Kingdom, 4University College London, London, United
Kingdom
PM
Systemic Sclerosis, Fibrosing Syndromes and
Raynaud’s – Clinical Aspects and Therapeutics I:
Systemic Sclerosis, Advances in Therapy
1 6 ,
2:30 pm
868. Protein Phosphatase 5 (PP5) Regulates Methylation
Sensitive Gene Expression in CD4+ T Cells
Dipak R. Patel, Gabriela Gorelik and Bruce C. Richardson,
University of Michigan, Ann Arbor, MI
157 B
SUNDAY
Systemic Lupus Erythematosus – Human Etiology and
Pathogenesis I: Pathways of Inflammation/Injury
PS
n o v e m b e r
107 B
3:45 pm
873. The Second Messenger, Cyclic GMP-AMP Dinucleotide
(cGAMP) and the Enzyme, Cyclic GMP-AMP Synthase (cGAS),
Are Expressed in Systemic Lupus Erythematosus
Jie An, Joshua Woodward, Reynold Karr, Thomas H. Teal and
Keith B. Elkon, University of Washington, Seattle, WA
Moderators: Sindhu R. Johnson, MD, PhD and Christopher P.
Denton, MD, PhD
2:30 pm
874. Safety and Efficacy of Subcutaneous Tocilizumab in Adults
with Systemic Sclerosis: Week 24 Data from a Phase 2/3 Trial
Dinesh Khanna1, Christopher P. Denton2, Jacob M. van Laar3,
Angelika Jahreis4, Sabrina Cheng4, Helen Spotswood5, Jeffrey
Siegel4 and Daniel E. Furst on behalf of FaSScinate Clinical Trial
in Patients With SS6, 1University of Michigan Health System, Ann
Arbor, MI, 2University College London Medical School, London,
United Kingdom, 3University Medical Center Utrecht, Utrecht,
Netherlands, 4Genentech, South San Francisco, CA, 5Roche
Products Ltd., Welwyn Garden City, United Kingdom, 6University
of California, Los Angeles, CA
2:45 pm
875. Treatment-Related Outcomes in Connective Tissue
Disease-Associated Pulmonary Arterial Hypertension: A Pooled
Analysis of 12 Randomized Controlled Trials
Rennie L. Rhee1, Nicole B. Gabler1, Amy Praestgaard1, Peter
A. Merkel2 and Steven M. Kawut1, 1University of Pennsylvania,
Philadelphia, PA, 2Vasculitis Center, University of Pennsylvania,
Philadelphia, PA
3:00 pm
876. SAR100842, an Antagonist of Lysophosphatidic Acid
Receptor 1, As a Potential Treatment for Patients with Systemic
Sclerosis: Results from a Phase 2a Study
Dinesh Khanna1, Christopher P. Denton2, Alexandre
Jagerschmidt3, Martine Jasson4, Oliver Distler5 and Yannick
Allanore6, 1University of Michigan Scleroderma Program, Ann
Arbor, MI, 2UCL Medical School Royal Free Campus, London,
United Kingdom, 3Sanofi-Aventis, Chilly-Mazarin, France,
4
Sanofi-Aventis, Paris, France, 5Zurich University Hospital, Zurich,
2014 Program Book
51
scientific sessions
Switzerland, 6Department of Rheumatology, University Paris
Descartes and Cochin Hospital, Paris, France
n o v e m b e r
1 6 ,
SUNDAY
2 0 1 4
3:15 pm
877. Sildenafil Attenuates the Fibrotic Phenotype in
Scleroderma Skin Fibroblasts
Tomoaki Higuchi1, Yasushi Kawaguchi1, Kae Takagi1, Akiko
Tochimoto1, Yuko Ota1, Yasuhiro Katsumata1, Takahisa Gono1,
Masanori Hanaoka1, Yuko Okamoto1, Hidenaga Kawasumi1 and
Hisashi Yamanaka2, 1Tokyo Women’s Medical University, Tokyo,
Japan, 2Institute of Rheumatology, Tokyo Women’s Medical
University, Tokyo, Japan
3:30 pm
878. Luminex and Autoantigen Microarray Analysis of Sera
from Patients with Diffuse Cutaneous Systemic Sclerosis
Reveals Changes Associated with Imatinib Mesylate Treatment
D. James Haddon1, Hannah Wand1, Paul J. Utz1, Robert F. Spiera2,
Jessica K. Gordon2 and Lorinda Chung3, 1Stanford University
School of Medicine, Stanford, CA, 2Hospital for Special Surgery,
New York, NY, 3Stanford University School of Medicine, Palo Alto,
CA
3:45 pm
879. Efficacy of Autologous Hematopoietic Stem Cell
Transplantation in Rapidly Progressive Systemic Sclerosis:
Prolonged Remission of Disease Activity in a Long-Term Follow
up
Eleonora Zaccara1, Domenico Sambataro2, Wanda Maglione1,
Gianluca Sambataro1, Francesco Onida3, Claudio Annaloro3,
Giorgia Saporiti3, Elena Tagliaferri3, Agostino Cortelezzi3, Rosaria
Giordano3, Claudio Vitali4 and Nicoletta Del Papa2, 1Osp. G. Pini,
Milano, Italy, 2Istituto G.Pini, Milan, Italy, 3Fondazione IRCCS
Ca’ Granda Ospedale Maggiore Policlinico-University of Milan,
San Giuseppe, Lecco, Italy
Milano, Italy, 4Istituto
PS
PM
156 B
Vasculitis I
Moderators: Maria C. Cid, MD. PhD and Kenneth J. Warrington,
MD
2:30 pm
880. An Immunochip Study Confirms a Strong Contribution
of HLA Class I and II Genes in the Susceptibility to Giant Cell
Arteritis
Francisco David Carmona1, Sarah Mackie2, Jose Ezequiel
Martin1, John Taylor2, Augusto Vaglio3, Lara Bossini-Castillo1,
Santos Castañeda4, Maria C. Cid5, José Hernández-Rodríguez5,
Roser Solans6, Ricardo Blanco7, Lorenzo Beretta8, Claudio
Lunardi9, Marco A. Cimmino10, Cisca Wijmenga11, Torsten
Witte12, Julia Holle13, Frank Moosig13, Verena Schönau14,
Andre Franke15, Øyvind Palm16, Andreas P. Diamantopoulos17,
Benedicte A. Lie18, Simon Carette19, David Cuthbertson20, Gary
S. Hoffman21, Nader A. Khalidi22, Curry L. Koening23, Carol A.
Langford24, Carol McAlear25, Larry Moreland26, Paul A. Monach27,
Christian Pagnoux19, Philip Seo28, Antoine G. Sreih29, Kenneth
J. Warrington30, Steven R. Ytterberg30, Colin T. Pease31, Andrew
Gough32, Michael Green33, Lesley Hordon34, Stephen Jarrett35,
52
2014 Program Book
Richard Watts36, Sarah Levy37, Yusuf Patel38, Sanjeet Kamath39,
Bhaskar Dasgupta40, Paul IW. de Bakker41, Bobby P.C. Koeleman41,
Jennifer H. Barrett2, Carlo Salvarani42, Peter A. Merkel25, Miguel
A. Gonzalez-Gay7, Ann W. Morgan2 and Javier Martin1, 1Instituto
de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC,
Armilla (Granada), Spain, 2University of Leeds, Leeds, United
Kingdom, 3University Hospital of Parma, Parma, Italy, 4Hospital
Universitario de La Princesa, IISP, Madrid, Spain, 5Hospital Clínic
University of Barcelona, Institut d’Investigacions Biomèdiques
August Pi i Sunyer (IDIBAPS), Barcelona, Spain, 6Hospital Vall
d’Hebron, Autonomous University of Barcelona, Barcelona,
Spain, 7Hospital Universitario Marqués de Valdecilla, IFIMAV,
Santander, Spain, 8Referral Center for Systemic Autoimmune
Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore
Policlinico di Milano, Milan, Italy, 9Università degli Studi
di Verona, Verona, Italy, 10University of Genova, Genova,
Italy, 11University Medical Hospital Groningen, University
of Groningen, Groningen, Netherlands, 12Hannover Medical
School, Hannover, Germany, 13Vasculitis Clinic, Klinikum Bad
Bramstedt & University Hospital of Schleswig Holstein, Bad
Bramstedt, Germany, 14Universitätsklinikum Erlangen, Erlangen,
Germany, 15Christian-Albrechts-University of Kiel, Kiel, Germany,
16
Oslo University Hospital and University of Oslo, Oslo, Norway,
17
Hospital of Southern Norway Trust, Kristiansand, Norway,
18
University of Oslo and Oslo University Hospital, Oslo, Norway,
19
University of Toronto, Toronto, ON, 20University of South
Florida, Tampa, FL, 21Center for Vasculitis Care and Research,
Cleveland Clinic Foundation, Cleveland, OH, 22St. Joseph’s
Hospital, McMaster University, Hamilton, ON, 23University of
Utah, Salt Lake City, UT, 24Center for Vasculitis Care and Research,
Cleveland Clinic, Cleveland, OH, 25Vasculitis Center, University of
Pennsylvania, Philadelphia, PA, 26Vasculitis Center, of University
of Pittsburgh Medical Center, Pittsburgh, PA, 27Vasculitis Center,
Boston University School of Medicine, Boston, MA, 28Johns
Hopkins Vasculitis Center, Johns Hopkins University, Baltimore,
MD, 29The University of Pennsylvania, Philadelphia, PA, 30Mayo
Clinic, Rochester, MN, 31Leeds Teaching Hospitals NHS Trust,
Leeds, United Kingdom, 32Harrogate and District Foundation
Trust, Harrogate, United Kingdom, 33York Teaching Hospital
NHS Foundation Trust, York, United Kingdom, 34Mid Yorkshire
Hospitals NHS Trust, Dewsbury, United Kingdom, 35Mid Yorkshire
Hospitals NHS Trust, Wakefield, United Kingdom, 36Ipswich
Hospital NHS Trust, Ipswich, United Kingdom, 37Croydon Health
Service NHS Trust, Croydon, United Kingdom, 38Hull and East
Yorkshire NHS Trust, Hull East Yorkshire, United Kingdom,
39
Staffordshire and Stoke-on-Trent Partnership NHS Trust,
Staffordshire, United Kingdom, 40Southend University Hospital,
Essex, United Kingdom, 41University Medical Center Utrecht,
Utrecht, Netherlands, 42Azienda Ospedaliera ASMN, Istituto di
Ricovero e Cura a Carattere Scientifico, Reggio Emilia, Italy
2:45 pm
881. DNA Methylation Analysis of the Temporal Artery
Microenvironment Reveals a Robust T Cell Signature and
Suggests a Role for TNF-α in Giant Cell Arteritis
Patrick S. Coit, Lindsey B. De Lott, Bin Nan, Victor M. Elner and
Amr H. Sawalha, University of Michigan, Ann Arbor, MI
scientific sessions
3:00 pm
882. A Signature of microRNAs Overexpressed in Inflamed
Temporal Arteries of Patients with Giant Cell Arteritis
Stefania Croci, Alessandro Zerbini, Luigi Boiardi, Francesco
Muratore, Alessandra Bisagni, Giulia Pazzola, Luca Cimino,
Antonio Moramarco, Davide Nicoli, Enrico Farnetti, Bruno
Casali, Alberto Cavazza, Maria Parmeggiani and Carlo Salvarani,
Arcispedale S Maria Nuova, Reggio Emilia, Italy
ARHP SESSIONS
2:30 – 4:00 pm
255
education
• d
escribe process of online search for arthritis education
resources
• evaluate health literacy of online content to selectively
identify content that meets the needs of specific patients/
consumers
2:30 pm
Online Patient Resources for Arthritis and Strategies to Locate
Quality Information and Usability
Maura D. Iversen, BSc, DPT, SD, MPH
PM
2 0 1 4
256
1 6 ,
3:15 pm
Empowering Patients to Navigate the Google Minefield
Laura E. Ray, MA, MLS
SUNDAY
3:45 pm
885. A 2-Week Single-Blind, Randomized, 3-Arm Proof of
Concept Study of the Effects of Secukinumab (anti-IL17 mAb),
Canakinumab (anti-IL-1 b mAb), or Corticosteroids on Initial
Disease Activity Scores in Patients with PMR, Followed By an
Open-Label Extension to Assess Safety and Effect Duration
Eric L. Matteson1, Bhaskar Dasgupta2, Wolfgang A. Schmidt3,
Carlo Salvarani4, Nagui Gendi5, Mauro Galeazzi6, Sylvie Stitah7,
Yue Li7, Marie-Anne Valentin7, Bolan Linghu8 and Stephen
J. Oliver7, 1Mayo Clinic, Rochester, MN, 2Southend University
Hospital, Essex, United Kingdom, 3Immanuel Krankenhaus, Berlin,
Germany, 4Arcispedale-Santa-Maria-Nuova, Reggio Emilia, Italy,
5
Basildon & Thurroch University Hospitals NHS Trust, Basildon,
Essex, United Kingdom, 6Università di Siena, Siena, Italy,
7
Novartis Pharma AG, Basel, Switzerland, 8Novartis Pharma AG,
Cambridge, MA
Google Minefield: Empowering Patients to Evaluate
FIT
FIT
PrM
PrM
Pd
PS
Pd
PS
PM
Ed
PM
Ed
Online Resources
n o v e m b e r
3:30 pm
884. Interleukin 6 Does Not Upregulate Pro Inflammatory
Cytokine Expression in an Ex-Vivo Model of Giant Cell Arteritis
Lorraine O’Neill1, Jennifer McCormick2, Wei Gao2, Conor
Murphy3, Geraldine M. McCarthy4, Douglas J. Veale1, Ursula
Fearon2 and Eamonn S. Molloy1, 1St. Vincent’s University
Hospital, Dublin 4, Ireland, 2Translational Rheumatology
Research Group, Dublin, Ireland, 3Royal Victoria Eye and Ear
Hospital, Dublin, Ireland, 4Mater Misericordiae University
Hospital, Dublin 7, Ireland
PS
• identify quality resources for patients regarding arthritis
3:15 pm
883. Accuracy of High Resolution MRI of Scalp Arteries for the
Diagnosis of Giant Cell Arteritis: Results of a Prospective Study
Maxime Rhéaume1, Ryan Rebello2, Christian Pagnoux3, Simon
Carette3, Marie Clements-Baker4, Violette Cohen-Hallaleh2, David
Doucette-Preville2, B. Stanley Jackson5, Sam Salama6, George
Ioannidis7 and Nader A. Khalidi8, 1Division of Rheumatology,
St. Joseph’s Hospital, McMaster University, Hamilton, ON,
2
Department of Radiology, St. Joseph’s Hospital, McMaster
University, Hamilton, ON, 3University of Toronto, Toronto, ON,
4
Queens University, Kingston, ON, 5Department of Surgery,
St. Joseph’s Hospital, McMaster University, Hamilton, ON,
6
Department of Pathology, St. Joseph’s Hospital, McMaster
University, Hamilton, ON, 7St Joseph’s Healthcare Hamilton,
Hamilton, ON, 8St. Joseph’s Hospital, McMaster University,
Hamilton, ON
PM
PS
Practical Practice Management Session One: Improve
Quality and Efficiency
Moderators: Lee Anderson, BSN and Brandi Young, DNP
• recognize the links between quality improvement initiatives
and payment reform
• apply techniques in quality measurement to drive practice
improvement in rheumatology
• utilize tools created by the ACR, including the Rheumatology
Clinical Registry (RCR) and the Rheumatology Informatics
System for Effectiveness (RISE) Registry, to successfully report
quality measures for their practices
2:30 pm
Payment Reform: What’s Coming?
Robert Warren, MD, PhD, MPH
3:00 pm
Quality Improvement in Rheumatology
Jinoos Yazdany, MD, MPH
PM
PS
151 A
Sports Medicine for the Rheumatology Provider
Moderator: Judy Foxworth, PhD, PT
• identify mechanisms of injury of common sports medicine
injuries of both the shoulder and knee of the older athlete
• discuss medical/surgical management of common sports
medicine injuries of the knee and shoulder with special
consideration of athletes with osteoarthritis
• present evidence of best practices for rehabilitation for
older athletes with common shoulder and knee injuries with
rheumatic disease
2014 Program Book
53
scientific sessions
2:30 pm
Most Common Sports Medicine Injuries of the Older Athlete
Karl Fields, MD
3:15 pm
Special Considerations for Sports Participation for Those with
Rheumatic Disease
James J. Irrgang, ATC, PhD, PT
254 A
PM
PS
Young Adults with Rheumatic Disease: The Patient
FIT
PrM
Pd
PS
Ed
Perspective PM
n o v e m b e r
1 6 ,
SUNDAY
2 0 1 4
Moderator: Sandra Mintz, BSN
• enhance their knowledge of the multifaceted experiences of
living with a rheumatic disease
• discuss the importance of patient advocacy and how to help
develop it at any age
• employ tips towards engaging patients and providing them
opportunities to develop their toolset for living with a
rheumatic disease
2:30 pm
Patient Perspective
Jennifer R. Horonjeff, MS
3:15 pm
Young Adults with Rheumatic Disease: The Patient Perspective
Kiana Johnson, PhD
ARHP CONCURRENT ABSTRACT SESSION
2:30 – 4:00 pm
PM
PS
257 A
Exemplary Abstracts
Moderators: Scott Hasson, Pt, PhD and Robert M. McLean, MD
2:30 pm
886. Measuring Rheumatoid Arthritis Remission: Which Index
of Disease Activity Best Predicts Work Status?
Nancy A. Baker1, Heather Eng2, Juan (June) Feng2, Jason Lyons2,
Yong Gil Hwang1, Kimberly P. Liang1 and Larry W. Moreland1,
1
University of Pittsburgh, Pittsburgh, PA, 2University of Pittsburgh,
Graduate School of Public Health, Pittsburgh, PA
2:45 pm
887. The Impact of Inadequate Health Literacy on Disease
Activity in Patients with Rheumatoid Arthritis
Maria Celeste Orozco1, Maria Florencia Marengo1, Christian
A. Waimann1, Ana Inés Marcos2, Amelia Granel2, Sofia Velez3,
Federico Zazzetti3, Juan C. Barreira4, Paula Kohan5, Oscar L. Rillo6,
María Victoria Collado7, Graciela Gómez8, Ricardo V. Juárez9,
Veronica Lencina9, Andrea D’Orazio10, Gustavo Rodriguez
54
2014 Program Book
Gil10, Mariana Salcedo11 and Gustavo Citera1, 1Instituto de
Rehabilitación Psicofísica, Buenos Aires, Argentina, 2Hospital
San Roque de Gonnet, La Plata, La Plata, Argentina, 3Hospital
Britanico, Buenos Aires, Argentina, 4British Hospital, Buenos
Aires, Argentina, 5Hospital Gral. de agudos Dr. E. Tornú,
Buenos Aires, Argentina, 6Hospital General de Agudos Dr. E.
Tornú, Buenos Aires, Argentina, 7Instituto de Investigaciones
Medicas Alfredo Lanari, Buenos Aires, Argentina, 8Insituto de
Investigaciones Medicas de la UBA, Capital Federal, Argentina,
9
Hospital Señor del Milagro, Salta, Argentina, 10Hospital
Municipal de agudos Dr. Leonidas Lucero, Bahía Blanca,
Argentina, 11Consultorio Privado, San Nicolás, Argentina
3:00 pm
888. Annual Medical Care Expenditures Among US Adults with
Gout, 2005 – 2011
Miriam G. Cisternas1, Louise Murphy2, David J. Pasta3, Edward
H. Yelin4 and Charles Helmick2, 1MGC Data Services, Carlsbad,
CA, 2Centers for Disease Control and Prevention, Atlanta, GA,
3
DMA Corporation, Palo Alto, CA, 4University of California, San
Francisco, San Francisco, CA
3:15 pm
889. Exercise, Manual Therapy and Use of Booster Sessions
in Physical Therapy for Knee OA: A Multi-Center Randomized
Clinical Trial
G Kelley Fitzgerald1, Julie Fritz2, John Childs3, Gerard P. Brennan4,
Douglas P. Landsittel5, Brett Neilson6, Alexandra Gil1 and J. Haxby
Abbott7, 1University of Pittsburgh, Pittsburgh, PA, 2University of
Utah, Salt Lake City, UT, 3US Army-Baylor University, Schertz, TX,
4
Intermountain Healthcare, Murray, UT, 5University of Pittsburgh,
Center for Health Care Research Data Center, Pittsburgh, PA,
6
Henry M. Jackson Foundation, Bethesda, MD, 7University of
Otago, Dunedin, New Zealand
3:30 pm
890. Test of the NIH Patient-Reported Outcomes Measurement
Information System (PROMIS) 29-Item Profile in a Large Cohort
of Rheumatic Disease Patients
Patricia P. Katz1, Sofia Pedro2 and Kaleb Michaud3, 1University
of California, San Francisco, San Francisco, CA, 2National Data
Bank, Wichita, KS, 3University of Nebraska Medical Center and
National Data Bank, Omaha, NE
3:45 pm
891. Randomized Clinical Trial of Group Vs. Individual Physical
Therapy for Knee Osteoarthritis
Kelli D. Allen1, Dennis Bongiorni2, Hayden B. Bosworth3, Cynthia
Coffman3, Santanu Datta3, David Edelman3, Jennifer H. Lindquist2,
Eugene Oddone3 and Helen Hoenig3, 1Durham VA Medical
Center and University of North Carolina at Chapel Hill, Durham,
NC, 2Durham VA Medical Center, Durham, NC, 3Durham VA
Medical Center and Duke University Medical Center, Durham,
NC
PM
PS
scientific sessions
• d
emonstrate the mechanism leading to mechanical neck and
lumbar pain and the approach at the bedside to discerning
the mechanisms and its treatment
• demonstrate how to more easily determine joint swelling
particularly in the metacarpophalangeal joint, proximal
interphalangeal joint and wrists
ACR WORKSHOPS
4:00 – 6:00 pm
159
Muscle Involvement in Rheumatic Diseases (211)
Speaker: Sakir Humayun Gultekin, MD
• identify the histologic abnormalities of steroid myopathy,
polymyositis, dermatomyositis and inclusion body myositis
• examine the major differential diagnostic possibilities in
possible myositis cases
• interpret the findings in the muscle biopsy pathology report
154
*Osteoporosis: Interpreting Dual Energy X-Ray
Absorptiometry and Clinical Risk Factors: The New
Fracture Risk Assessment Algorithm (212)
Speaker: Stuart L. Silverman, MD
• use bone mineral density and clinical risk factors in
determination of absolute risk of fracture
• discuss the concept of intervention threshold
• assess limitations of the Fracture Risk Assessment Algorithm
in clinical practice
152
Physical Examination Skills for Improved Detection of
Synovitis and Cervical Thoracolumbar Disorders (213)
• describe the concept of referred pain and its presentation
with neck and lumbar disorders
Therapeutic Targeting of the Innate Immune System
Moderator: Betsy Barnes, PhD
• describe mechanisms and molecules involved in activation of
the innate immune system
• identify new potential therapeutic targets to maintain immune
tolerance
• recognize the multifunctional role of high mobility group box 1
(HMBG1) in inflammation
4:30 pm
High Mobility Group Box 1 as Chemokine and Cytokine
Helena E. Harris
2 0 1 4
161
PS
1 6 ,
• recognize typical active and structural lesions of
spondyloarthritis
• recognize complicated/subtle lesions of spondyloarthritis
• recognize lesions that may mimic spondyloarthritis
• recognize pitfalls in the interpretation of MRI in
spondyloarthritis
PM
SUNDAY
Speaker: Walter P. Maksymowych, MD
52 A
n o v e m b e r
Magnetic Resonance Imaging in the Diagnosis and
Management of Spondyloarthritis: A Clinician’s Guide
(210)
ACR SESSIONS
4:30 – 6:00 pm
5:00 pm
Dendric Cells in Tolerance and Immune Activation
Michel C. Nussenzweig, MD, PhD
5:30 pm
Activation of the Immune System by Intracellular Nucleic Acids
Tracy McGaha, PhD
PM
PS
Ballroom East
Thieves’ Market: Show Me Your Best Cases
Moderators: Rula Hajj-Ali, MD; N. Lawrence Edwards, MD and
Rebecca L. Manno, MD, MHS
• compare their diagnostic and management approaches of
selected clinical problems with those of other rheumatologists
and the presenters
• recognize unusual presentations of common diseases
• identify and recognize essential mimics of the rheumatic
diseases
4:30 pm
Image Competition Presentation
Erika H. Noss, MD
4:50 pm
Case Presentation 1: A Rapid Decline
Kevin Wei, MD PhD
5:00 pm
Case Presentation 2: An Uncommon Cause of a Common
Presentation
David McCormick, MB, BaO, BCh, MRCP
2014 Program Book
55
scientific sessions
5:10 pm
Case Presentation 3: Groundhog Day
P. W. James Russell, MB, BChir
5:20 pm
Case Presentation 4: It is Not a Simple Headache
Catherine E. Najem, MD
5:30 pm
Case Presentation 5: Lesions in the Spine – A Diagnostic
Dilemma
Mehwish Khan, MBBS, MD
n o v e m b e r
1 6 ,
SUNDAY
2 0 1 4
5:40 pm
Case Presentation 6: The Nose Knows
Sarah Goglin, MD
4:30 – 6:00 pm
104 B
PM
PS
and Specific Clinical Pain Syndromes I: Research
PS
PM
Perspectives
Moderators: Laurence A. Bradley, PhD and Leslie J. Crofford, MD
4:30 pm
892. Symptom Increase in Fibromyalgia Is Not Consistent
with the Central Sensitization or Central Hyperresponsiveness
Hypothesis
Frederick Wolfe1, Brian T. Walitt2, Johannes Rasker3, Robert S.
Katz4 and Winfried Häuser5, 1National Data Bank for Rheumatic
Diseases, Wichita, KS, 2Washington Hospital Center, Washington,
DC, 3University Twente, Enschede, Netherlands, 4Rush Medical
College, Chicago, IL, 5Klinikum Saarbrücken, Saarbrücken,
Germany
4:45 pm
893. Polysymptomatic Distress Categories for Clinical and
Research Use
Frederick Wolfe1, Brian T. Walitt2, Johannes Rasker3, Robert S.
Katz4 and Winfried Häuser5, 1National Data Bank for Rheumatic
Diseases, Wichita, KS, 2Washington Hospital Center, Washington,
DC, 3University Twente, Enschede, Netherlands, 4Rush Medical
College, Chicago, IL, 5Klinikum Saarbrücken, Saarbrücken,
Germany
5:00 pm
894. Small Fiber Neuropathy in Women with Fibromyalgia.
a Clinical-Pathological Correlation Using Confocal Corneal
Biomicroscopy
Manuel Ramírez-Fernández1, Laura-Aline Martinez-Martinez2,
Angelica Vargas-Guerrero2, Manuel Martínez-Lavín2, Everardo
Hernandez Quintela1 and Jorge Velazco-Caspia1, 1Asociación
para Evitar la Ceguera en México, Mexico City, Mexico, 2Instituto
Nacional de Cardiologia, Mexico City, Mexico
56
2014 Program Book
5:15 pm
895. The Fibromyalgia Syndrome and Widespread Pain
Frequency in Active Duty U.S. Service Members with
Posttraumatic Stress Disorder
Bernard Hildebrand Jr.1, Jay B. Higgs1, Douglas Williamson2, Edna
Foa3, Patricia Resick4, Jim Mintz2, Antoinette Brundige2, Kevin
Kelly5, Adam Borah5, Stacey Young-McCaughan2, Brett Litz6,
Elizabeth Hembree3 and Alan Peterson2, 1San Antonio Military
Medical Center, JBSA – Fort Sam Houston, TX, 2The University
of Texas Health Science Center at San Antonio, San Antonio, TX,
3
University of Pennsylvania, Philadelphia, PA, 4Duke University,
Durham, NC, 5Carl R. Darnall Army Medical Center, Fort Hood,
TX, 6VA Boston Healthcare System, Boston, MA
5:30 pm
896. Development of Fibromyalgia and Polysymptomatic
Distress Definitions in the National Health Interview Survey
Brian Walitt1, Richard Nahin2, Robert S. Katz3, Martin J. Bergman4
and Frederick Wolfe5, 1MedStar Health, Washington, DC,
2
National Institutes of Health, Bethesda, MD, 3Rush Medical
College, Chicago, IL, 4Taylor Hospital, Ridley Park, PA, 5National
Data Bank for Rheumatic Diseases, Wichita, KS
5:45 pm
897. Resting State Functional Connectivity Differs Between
Chronic Fatigue Syndrome Patients and Healthy Controls
Jason Craggs1, Charles Gay1, Andrew O’Shea1, Ricky Madhavan1,
Donald Price1, Michael Robinson1 and Roland Staud2, 1University
of Florida, Gainesville, FL, 2Univ of Florida Med Ctr/JHMHC,
Gainesville, FL
151 A
PM
PS
Health Services Research: Risk Assessment and
Outcomes of Rheumatic Disease
Moderators: Edward H. Yelin, PhD and Katherine Liao, MD, MPH
4:30 pm
898. Traditional Cardiovascular Risk-Factor Management in
Patients with Rheumatoid Arthritis Compared with Matched
Non-Rheumatoid Arthritis Patients in a US Managed Care
Setting
J An1, K Reynolds2, E Alemao3, H Kawabata3, D H Solomon4, K P
Liao4 and T C Cheetham2, 1Western University of Health Sciences,
Pomona, CA, 2Kaiser Permanente Southern California, Pasadena,
CA, 3Bristol-Myers Squibb, Princeton, NJ, 4Brigham and Women’s
Hospital, Boston, MA
4:45 pm
899. Insurance Status and U.S. Region Associated with
Placement of Permanent Vascular Access in Dialysis Patients
with End-Stage Renal Disease Secondary to Lupus Nephritis
Laura Plantinga1, Cristina M. Drenkard1, Rachel Patzer1, William
McClellan1, Stephen Pastan1 and S. Sam Lim2, 1Emory University,
Atlanta, GA, 2Emory University School of Medicine, Division of
Rheumatology, Atlanta, GA
scientific sessions
5:00 pm
900. Race and Sex Specific Incidence Rates and Predictors of
Total Knee Arthroplasty: Data from the Osteoarthritis Initiative,
7 Years Follow up
Jamie E. Collins, Bhushan Deshpande, Jeffrey N. Katz and Elena
Losina, Brigham and Women’s Hospital, Boston, MA
5:15 pm
901. Rate of Serum Uric Acid (SUA) Assessment in Gout
Patients Treated with Urate-Lowering Therapy: Treating to
Target?
Robert Morlock1, David M. Kern2, Ozgur Tunceli2, Siting Zhou2,
Laura Horne3, Sulabha Ramachandran3 and Hyon Choi4, 1Ardea
Biosciences, San Diego, CA, 2HealthCore, Inc., Wilmington, DE,
3
AstraZeneca, Wilmington, DE, 4Harvard Medical School, Boston,
MA
Imaging of Rheumatic Diseases: Ultrasound
Moderators: Jay B. Higgs, MD and Wolfgang A. Schmidt, MD
904. Ultrasound Synovitis Reflects Synovial Inflammation at a
Histopathological Level
Nora Ng, Stephen Kelly, Frances Humby, Maria DiCicco, Vidalba
Rocher, Rebecca Hands, Michele Bombardieri and Costantino
Pitzalis, William Harvey Research Institute, Queen Mary
University of London, London, United Kingdom
4:45 pm
905. First Step in the Development of an Ultrasound Joint
Inflammation Score for Rheumatoid Arthritis: A Data Driven
Approach
Anna-Birgitte Aga1, Hilde Berner Hammer1, Inge C. Olsen1,
Till Uhlig1, Tore K. Kvien1, Désirée van der Heijde2, Elisabeth
Lie1, Espen A. Haavardsholm1 and the Arctic study Group1,
1
Diakonhjemmet Hospital, Oslo, Norway, 2Leiden University
Medical Center, Leiden, Netherlands
2014 Program Book
2 0 1 4
210 B
1 6 ,
PM
5:30 pm
908. Ultrasound-Detected Tenosynovitis Independently
Associates with Flare in Patients with Rheumatoid Arthritis in
Clinical Remission
Emanuela Bellis1, Greta Carrara2, Carlo Alberto Scirè2, Alessandra
Bortoluzzi3, Alberto Batticciotto4, Antonella Adinolfi5, Giovanni
Cagnotto6, Marta Caprioli7, Marco Canzoni8, Francesco
Cavatorta9, Fulvia Ceccarelli10, Orazio De Lucia11, Valentina
Di Sabatino12, Antonella Draghessi13, Georgios Filippou12,
Ilaria Farina3, Maria Cristina Focherini14, Paola Frallonardo15,
Alessandra Gabba16, Angelica Gattamelata10, Marwin Gutierrez13,
Luca Idolazzi17, Filippo Luccioli18, Pierluigi Macchioni19, Marco
Massarotti20, Claudio Mastaglio21, Luana Menza21, Giulia
Mirabelli18, Maurizio Muratore22, Simone Parisi23, Valentina
Picerno12, Matteo Piga24, Roberta Ramonda25, Bernd Raffeiner15,
Daniela Rossi26, Paola Rossini27, Garifallia Sakellariou28,
Crescenzio Scioscia29, Carlo Venditti30, Annamaria Iagnocco10
and Marco Matucci-Cerinic31, 1Ospedale Mauriziano, Turin, Italy,
2
Italian Society for Rheumatology, Milan, Italy, 3A.O.U. S.Anna
di Cona, Ferrara, Italy, 4L.Sacco University Hospital, Milan,
Italy, 5Policlinico le Scotte, Siena, Italy, 6IRCCS Policlinico San
Matteo, Pavia, Italy, 7Istituto di Cura Città di Pavia, Pavia, Italy,
8
A.O. Sant’Andrea, Rome, Italy, 9A.O.U.P. Santa Chiara, Trento,
Italy, 10Sapienza University of Rome, Rome, Italy, 11Orthopedic
Institute Gaetano Pini, Milano, Italy, 12University of Siena, Siena,
Italy, 13Università Politecnica delle Marche, Jesi, Italy, 14Ospedale
Infermi, Rimini, Italy, 15University of Padova, Padova, Italy,
16
A.O.U. di Cagliari, Cagliari, Italy, 17Ospedale Civile Maggiore,
Verona, Italy, 18University of Perugia, Perugia, Italy, 19Arcispedale
S Maria Nuova, IRCCS, Reggio Emilia, Italy, 20Istituto Clinico
Humanitas, Rozzano, Italy, 21Moriggia-Pelascini, Gravedona, Italy,
22
Department of Rheumatology, Hospital Galateo, San Cesario
di Lecce, Italy, 23A.O. Città della Salute e della Scienza di Torino,
Turin, Italy, 24Unit and Chair of Rheumatology, University Hospital
of Cagliari, Cagliari, Italy, 25University of Padua, Padova, Italy,
26
University of Turin, Turin, Italy, 27P.O. “Destra Secchia”, Pieve
di Coriano, Italy, 28Rheumatology and Translational Immunology
Research Laboratories (LaRIT), Division of Rheumatology, IRCCS
Policlinico S. Matteo Foundation/University of Pavia, Pavia, Italy,
29
University of Bari, Bari, Italy, 30A.O. Rummo, Benevento, Italy,
31
University of Florence, Florence, Italy
SUNDAY
5:45 pm
903. Poor Adherence to Medications for Systemic Lupus
Erythematosus Predicts Higher Health Care Utilization in U.S.
Medicaid Beneficiaries
Jinoos Yazdany1, Candace H. Feldman2, Hongshu Guan3 and
Karen H. Costenbader3, 1University of California, San Francisco,
San Francisco, CA, 2Brigham and Women’s Hospital, Boston,
MA, 3Brigham and Women’s Hospital, Harvard Medical School,
Boston, MA
PS
5:15 pm
907. Ultrasonographic Tenosynovitis Score Is Responsive to
Biologic Treatment in Patients with Rheumatoid Arthritis
Hilde B. Hammer and Tore K. Kvien, Diakonhjemmet Hospital,
Oslo, Norway
n o v e m b e r
5:30 pm
902. Co-Management for Children with JIA: A Survey of
Primary Care Providers Regarding Current Practices and
Willingness to Provide Services
Amanda Mroczek, Gary Freed and Meredith Riebschleger,
University of Michigan, Ann Arbor, MI
5:00 pm
906. How Long Does Sonographic Joint Activity Continue
in Clinically Remittive Joints of Patients with Rheumatoid
Arthritis?
Miriam Gärtner, Farideh Alasthi, Gabriela Supp, Peter Mandl,
Josef Smolen and Daniel Aletaha, Medical University of Vienna,
Vienna, Austria
57
scientific sessions
5:45 pm
909. A Diagnostic Protocol for Giant Cell Arteritis (GCA) Using
Ultrasound Assessment
Jennifer Piper1, Ana Sofia Serafim1, Cristina Ponte1, Surjeet
Singh2, Bhaskar Dasgupta3, Wolfgang A. Schmidt4, Eugene
McNally5, Andreas P. Diamantopoulos6, Andrew Hutchings7
and Raashid Luqmani8, 1University of Oxford, Oxford, United
Kingdom, 2Sciences, Oxford, England, 3Southend University
Hospital, Essex, United Kingdom, 4Immanuel Krankenhaus, Berlin,
Germany, 5Oxford University, Oxford, United Kingdom, 6Hospital
of Southern Norway Trust, Kristiansand, Norway, 7London School
of Hygiene and Tropical Medicine, London, United Kingdom,
8
Oxford NIHR Musculoskeletal Biomedical Research Unit, Oxford,
United Kingdom
PS
PM
160 B
2 0 1 4
4:30 pm
910. The Selective Sphingosine-1-Phosphate Receptor 1/5
Modulator Siponimod (BAF312) Shows Beneficial Effects in
Patients with Active, Treatment Refractory Polymyositis and
Dermatomyositis: A Phase IIa Proof-of-Concept, Double-Blind,
Randomized Trial
Katalin Danko1, Jiri Vencovsky2, Ingrid E. Lundberg3, Anthony A
Amato4, Chester V. Oddis5, Maria Molnar6, Antonette Mallari
Moher7, Laurence Colin8, Florian Muellershausen9, David
Lee9 and Peter Gergely9, 1University of Debrecen, Hungary,
Debrecen, Hungary, 2Charles University, Prague, Czech
Republic, 3Rheumatology Unit, Karolinska University Hospital,
Solna, Karolinska Institutet, Stockholm, Sweden, 4Brigham
and Women’s Hospital and Harvard Medical School, Boston,
MA, 5University of Pittsburgh, Pittsburgh, PA, 6Institute of
Genomic Medicine and Rare Disorders, Semmelweis University,
Budapest, Hungary, 7Novartis Institutes for Biomedical Research
(former employee), Basel, Switzerland, 8Novartis Pharma, Basel,
Switzerland, 9Novartis Institutes for Biomedical Research, Basel,
Switzerland
n o v e m b e r
SUNDAY
1 6 ,
Muscle Biology, Myositis and Myopathies
Moderator: Megan Curran, MD
4:45 pm
911. Bioluminescent Imaging of Histidyl-Transfer RNA
Synthetase-Induced Myositis Reveals Early-Phase Involvement
of NF-Kb-Mediated Inflammation
Nicholas A. Young1, Lai-Chu Wu1, Michael Bruss1, Wael N.
Jarjour1 and Dana P. Ascherman2, 1The Ohio State University
Wexner Medical Center, Columbus, OH, 2Miami VAMC, Miami, FL
5:00 pm
912. A Consensus Hybrid Definition Using a Conjoint Analysis Is
the Proposed As Response Criteria for Minimal and Moderate
Improvement for Adult Polymyositis and Dermatomyositis
Clinical Trials
Rohit Aggarwal1, Lisa G. Rider2, Nicolino Ruperto3, Nastaran
Bayat2, Brian Erman4, Brian M. Feldman5, Adam M. Huber6,
Chester V. Oddis1, Ingrid E. Lundberg7, Anthony A. Amato,
MD8, Robert G. Cooper, MD, FRCP9, Hector Chinoy10, Maryam
Dastmalchi11, David Fiorentino12, David Isenberg13, James D.
58
2014 Program Book
Katz14, Andrew L. Mammen15, Marianne de Visser16, Steven R.
Ytterberg17, Katalin Danko18, Luca Villa19, Mariangela Rinaldi19,
Howard Rockette1, Peter A. Lachenbruch20, Frederick W.
Miller2 and Jiri Vencovsky, MD, DSc21, 1University of Pittsburgh,
Pittsburgh, PA, 2Environmental Autoimmunity Group, NIEHS,
NIH, Bethesda, MD, 3Istituto Giannina Gaslini, Genoa, Italy,
4
Social and Scientific Systems, Inc., Durham, NC, 5The Hospital
for Sick Children, Toronto, ON, 6IWK Health Centre, Halifax,
NS, 7Rheumatology Unit, Karolinska University Hospital, Solna,
Karolinska Institutet, Stockholm, Sweden, 8Brigham and
Women’s Hospital and Harvard Medical School, Boston, MA,
9
University of Liverpool, Liverpool, United Kingdom, 10Centre
for Musculoskeletal Research, University of Manchester,
Manchester, United Kingdom, 11Karolinska University Hospital
in Solna, Karolinska Institutet, Stockholm, Sweden, 12Stanford
University, Redwood City, CA, 13Arthritis Research UK Centre
for Adolescent Rheumatology, University College London,
London, United Kingdom, 14NIH, Bethesda, MD, 15Johns
Hopkins University, Baltimore, MD, 16Academic Medical
Centre, Amsterdam, Netherlands, 17Mayo Clinic, Rochester, MN,
18
University of Debrecen, Hungary, Debrecen, Hungary, 19IRCCS
Istituto G. Gaslini, Genova, Italy, 20NIEHS, NIH, Bethesda, MD,
21
Charles University, Prague, Czech Republic
5:15 pm
913. Long Term Outcomes of Patients with Moderate Creatine
Kinase (CK) Elevation Seen in a Rheumatology Clinic
Lyudmila Kirillova1, Abraham Tacang1, Andrea Berger2, Thomas
M. Harrington1 and Androniki Bili1, 1Geisinger Health System,
Danville, PA, 2Center for Health Research, Geisinger Health
System, Danville, PA
5:30 pm
914. A Predictive Model of Disease Outcome in RituximabTreated Myositis Patients Using Clinical Features,
Autoantibodies and Serum Biomarkers
Jeannette Olazagasti1, Cynthia S. Crowson1, Molly S. Hein1,
Consuelo Lopez de Padilla1, Rohit Aggarwal2, Chester V. Oddis2
and Ann M. Reed1, 1Mayo Clinic, Rochester, MN, 2University of
Pittsburgh, Pittsburgh, PA
5:45 pm
915. Increased Risk of Myocardial Infarction in
Dermatomyositis and Polymyositis: A General PopulationBased Cohort Study
Kateryna Vostretsova1, Erin Carruthers2, Eric C. Sayre2, John
Esdaile2 and J Antonio Avina-Zubieta3, 1University of British
Columbia, Vancouver, BC, 2Arthritis Research Centre of Canada,
Richmond, BC, 3University of British Columbia, Department of
Experimental Medicine, Vancouver, BC
153 B
PM
PS
Osteoporosis and Metabolic Bone Disease – Clinical
Aspects and Pathogenesis: Clinical Osteoporosis:
Treatment and Safety
Moderators: Simpson Bobo Tanner, MD and Chad Deal, MD
scientific sessions
4:30 pm
916. Effects of 2 Years of Treatment with Romosozumab
Followed By 1 Year of Denosumab or Placebo in
Postmenopausal Women with Low Bone Mineral Density
MR McClung1, A Chines2, JP Brown3, A Diez-Perez4, H Resch5,
J Caminis6, MA Bolognese7, S Goemaere8, HG Bone9, JR
Zanchetta10, J Maddox2, O Rosen2, S Bray11 and A Grauer2,
1
Oregon Osteoporosis Center, Portland, OR, 2Amgen Inc.,
Thousand Oaks, CA, 3Laval University and CHU de Québec
Research Centre, Quebec City, QC, 4Autonomous University of
Spain, Barcelona, Spain, 5St. Vincent Hospital, Vienna, Austria,
6
UCB, Raleigh, NC, 7Bethesda Health Research Center, Bethesda,
MD, 8Ghent University Hospital, Ghent, Belgium, 9Michigan Bone
and Mineral Clinic, Detroit, MI, 10Instituto de Investigaciones
Metabólicas, Buenos Aires, Argentina, 11Amgen Ltd., Cambridge,
United Kingdom
1 6 ,
156 B
Pain: Basic and Clinical Aspects I
PM
PS
2 0 1 4
5:15 pm
919. Glucocorticoid Exposure and Fracture Risk in a Large
Cohort of Commercially-Insured Rheumatoid Arthritis Patients
Under Age 65
Akhila Balasubramanian1, Sally Wade2, Robert A Adler3, Celia
Fang (Lin)4, Michael Maricic5, Cynthia O’Malley1, Kenneth G.
Saag6 and Jeffrey R. Curtis6, 1Amgen, Inc., Thousand Oaks, CA,
2
Wade Outcomes Research and Consulting, Salt Lake City, UT,
3
Hunter Holmes McGuire VA Medical Center, Richmond, VA,
4
Amgen, Thousand Oaks, CA, 5Catalina Pointe Rheumatology,
Tucson, AZ, 6The University of Alabama at Birmingham,
Birmingham, AL
PM
SUNDAY
5:00 pm
918. Findings from Denosumab (Prolia®) Postmarketing Safety
Surveillance for Serious Infections
W Golden1, DB Crittenden1, M Uhart1, RB Wagman1, C
Stehman-Breen1, S Papapoulos2 and NB Watts3, 1Amgen Inc.,
Thousand Oaks, CA, 2Leiden University Medical Center, Leiden,
Netherlands, 3Mercy Health Osteoporosis and Bone Health
Services, Cincinnati, OH
5:45 pm
921. Comparison of Infection Rates in Patients Receiving
Denosumab, Denosumab and Biologics and Biologics Alone in
a Suburban Rheumatology Clinic
Sajina Prabhakaran1 and Charles Pritchard2, 1Drexel University
College of Medicine, Philadelphia, PA, 2Drexel University College
of Medicine, Willow Grove, PA
PS
n o v e m b e r
4:45 pm
917. Evaluation of Invasive Oral Procedures and Events in
Women with Postmenopausal Osteoporosis Treated with
Denosumab: Results from the Pivotal Phase 3 Fracture Study
Extension
Nelson B. Watts1, John T. Grbic2, Michael McClung3, Socrates
Papapoulos4, David Kendler5, Christence S. Teglbjaerg6, Lawrence
O’Connor7, Rachel B. Wagman7, Eric Ng7, Nadia S. Daizadeh7
and Pei-Ran Ho7, 1Mercy Health Osteoporosis and Bone Health
Services, Cincinnati, OH, 2Columbia University, New York, NY,
3
Oregon Osteoporosis Center, Portland, OR, 4Leiden University
Medical Center, Leiden, Netherlands, 5University of British
Columbia, Vancouver, BC, 6Center for Clinical and Basic Research,
Ballerup, Denmark, 7Amgen Inc., Thousand Oaks, CA
5:30 pm
920. Randomized Controlled Trial to Assess the Safety
and Efficacy of Odanacatib in the Treatment of Men with
Osteoporosis
Eric Orwoll1, Silvano Adami2, Neil Binkley3, Roland Chapurlat4,
Bente Langdahl5, Steven Doleckyj6, Hilde Giezek7, Boyd Scott8
and Arthur Santora8, 1Oregon Health and Science University,
Portland, OR, 2Rheumatology Department, University of Verona,
Verona, Italy, 3University of Wisconsin, Madison, WI, 4Hopital
Edouard Herriot, Lyon, France, 5Aarhus University Hospital,
Aarhus, Denmark, 6Merck & Co., Inc., Whitehouse Station, NJ,
7
MSD Belgium, Brussels, Belgium, 8Merck Sharp & Dohme Corp.,
Whitehouse Station, NJ
Moderators: Yvonne C. Lee, MD and Martin K. Lotz, MD and
Camilla Svensson, PhD
4:30 pm
922. A Potential Role for TLR4 Activation in Osteoarthritis
Associated Pain
Rachel E. Miller1, Shingo Ishihara1, Phuong Tran1, Richard
J. Miller2 and Anne-Marie Malfait1, 1Rush University Medical
Center, Chicago, IL, 2Northwestern University, Chicago, IL
4:45 pm
923. Phenotypes of Osteoarthritis-Related Knee Pain and Their
Transitions over Time: The Osteoarthritis Initiative
Na Lu1, Tuhina Neogi1, K. Douglas Gross1, Jingbo Niu1, Hyon
Choi2 and Yuqing Zhang1, 1Boston University School of Medicine,
Boston, MA, 2Harvard Medical School, Boston, MA
5:00 pm
924. Characteristics of Pain Flares in Knee Osteoarthritis
Susan L. Murphy1, Angela K. Lyden1, Arnold Gammaitoni2, David
A. Williams3, Daniel J. Clauw1, J. Ryan Scott1 and Kristine Phillips1,
1
University of Michigan, Ann Arbor, MI, 2Zogenix, Inc, San Diego,
CA, 3Univ of MI Hlth System-Lobby M, Ann Arbor, MI
5:15 pm
925. Cortical Reorganization after Duloxetine TreatmentRelated Pain Decrease in Knee Osteoarthritis
Pascal Tetreault, Marwan Baliki, Etienne Vachon-Presseau,
Renita Evonne Yeasted, Thomas J. Schnitzer and A. Vania
Apkarian, Northwestern University, Chicago, IL
2014 Program Book
59
scientific sessions
n o v e m b e r
1 6 ,
SUNDAY
2 0 1 4
5:30 pm
926. Does a Family History of Total Knee Replacement for Knee
Osteoarthritis Influence Knee Pain and Structural Progression?
a Prospective Longitudinal Cohort Study
Feng Pan1, Hussain Khan1, Changhai Ding1, Tania Winzenberg1,
Johanne Martel-Pelletier2, Jean-Pierre Pelletier2, Flavia Cicuttini3
and Graeme Jones1, 1Menzies Research Institute Tasmania,
University of Tasmania, Hobart,7000, Australia, 2Osteoarthritis
Research Unit, University of Montreal Hospital Research Centre
(CRCHUM), Notre-Dame Hospital, Montreal, QC, 3School of
Public Health and Preventive Medicine, Monash University,
Melbourne, Australia
5:45 pm
927. Urate Crystal Induced Inflammation and Joint Pain Are
Reduced in Transient Receptor Potential Ankyrin 1 (TRPA1)
Deficient Mice – a New Potential Role for TRPA1 in Gout
Lauri J Moilanen, Mari Hämäläinen, Lauri Lehtimäki, Riina
Nieminen and Eeva Moilanen, The Immunopharmacology
Research Group, University of Tampere School of Medicine and
Tampere University Hospital, Tampere, Finland
253 B
PM
PS
Pediatric Rheumatology – Clinical and Therapeutic
PrM
Pd
PS
Ed
Aspects: Juvenile Idiopathic Arthritis PM
FIT
5:00 pm
930. An Exploratory Analysis of Predictors of Response from
12-Weeks of Canakinumab Therapy in Patients with Active
Systemic Juvenile Idiopathic Arthritis
Hermine I. Brunner1, Nicola Ruperto2, Isabelle Koné-Paut2, Bo
Magnusson2, Seza Ozen2, Flavio Sztajnbok2, Jordi Anton2, Judith
Barash2, Reinhard Berner2, Fabrizia Corona2, Karine Lheritier3,
Corine Gaillez3, Alberto Martini2 and Daniel Lovell1, 1PRCSG,
Cincinnati, OH, 2PRINTO-Istituto Gaslini, Genova, Italy, 3Novartis
Pharma AG, Basel, Switzerland
5:15 pm
931. Response to Canakinumab Treatment Is Maintained in
Systemic Juvenile Idiopathic Arthritis Patients
N.M. Wulffraat1, N. Ruperto2, H.I. Brunner3, S. Oliveira2, Y. Uziel2,
K. Nistala2, R. Cimaz2, M. Ferrandiz2, B. Flato2, M.L. Gamir2, I.
Koné-Paut2, C. Gaillez4, K. Lheritier4, K. Abrams5, A. Martini2
and D.J. Lovell3, 1UMC Utrecht, Utrecht, Netherlands, 2PRINTOIstituto Gaslini, Genova, Italy, 3PRCSG, Cincinnati, OH, 4Novartis
Pharma AG, Basel, Switzerland, 5Novartis Pharmaceuticals
Corporation, East Hanover, NJ
4:30 pm
928. A Multinational Study of the Epidemiology, Treatment and
Outcome of Childhood Arthriti: Preliminary Data from 6,940
Patients
Alessandro Consolaro1, Amita Aggarwal2, Troels Herlin3, Olga
Vougiouka4, Rubén Burgos-Vargas5, Ilonka Orban6, Nahid
Shafaie7, Maria Trachana8, Lidia Rutkowska-Sak9, Ingrida
Rumba-Rozenfelde10, Dimitrina Mihaylova11, Alberto Martini1
and Angelo Ravelli12, 1Istituto Giannina Gaslini, Genova, Italy,
2
Sanjay Gandhi Postgraduate Institute of Medical Sciences,
Lucknow, India, 3Aarhus University Hospital, Aarhus, Denmark,
4
P. A. Kyriakou Children’s Hospital of Athens University, Athens,
Greece, 5Hospital General de Mexico, Universidad Nacional
Autonoma de Mexico, Mexico City, Mexico, 6National Institute
of Rheumatology and Physiotherapy, Budapest, Hungary,
7
Tehran University of Medical Sciences, Tehran, Iran, 8Aristotle
University, Thessaloniki, Greece, 9Institute of Rheumatology,
Warsaw, Poland, 10University of Latvia, Riga, Latvia, 11University
Children Hospital, Sofia, Bulgaria, 12Istituto Giannina Gaslini and
University of Genova, Genova, Italy
5:30 pm
932. MRP8/14 Serum Level As Predictor of Response to
Starting and Stopping Anti-TNF Treatment in Non-Systemic
Juvenile Idiopathic Arthritis
Janneke Anink1, Marieke H. Otten1, Lisette W.A. van SuijlekomSmit1, Marion A.J. Van Rossum2, Koert M. Dolman3, Esther
P.A. Hoppenreijs4, Rebecca ten Cate5, Simona Ursu6, Lucy R
Wedderburn7, Gerd Horneff8, Thomas Vogl9, Dirk Föll10, Johannes
Roth9 and Dirk Holzinger11, 1Erasmus MC Sophia Children’s
Hospital, Rotterdam, Netherlands, 2Emma Kinderziekenhuis
Academic Medical Center, Amsterdam, Netherlands, 3St. Lucas
Andreas Hospital and Reade Institute, Amsterdam, Netherlands,
4
Radboud University Medical Center, Nijmegen, Netherlands,
5
Leiden University Medical Center, Leiden, Netherlands,
6
Arthritis Research UK Centre for Adolescent Rheumatology at
University College London, Great Ormond Street Hospital and
UCLH, University College London, London, United Kingdom,
7
Arthritis Research UK Centre for Adolescent Rheumatology,
University College London, London, United Kingdom, 8Asklepios
Klinik Sankt Augustin, Sankt Augustin, Germany, 9Institute
of Immunology University of Muenster, Muenster, Germany,
10
University Children’s Hospital Muenster, Muenster, Germany,
11
University Hospital Muenster, Muenster, Germany
4:45 pm
929. Antibiotic Exposure and the Development of Juvenile
Idiopathic Arthritis: A Population-Based Case-Control Study
Daniel B. Horton1, Frank I. Scott IV2, Kevin Haynes1, Mary E. Putt1,
Carlos D. Rose3, James D. Lewis1 and Brian L. Strom4, 1Center
for Clinical Epidemiology and Biostatistics, Perelman School of
Medicine, University of Pennsylvania, Philadelphia, PA, 2Division
of Gastroenterology, Hospital of the University of Pennsylvania,
Philadelphia, PA, 3Division of Rheumatology, Nemours A.I.
5:45 pm
933. A Multi-Center, Double-Blind, Randomized-Withdrawal
Trial of Subcutaneous Golimumab in Pediatric Patients with
Active Polyarticular Course Juvenile Idiopathic Arthritis Despite
Methotrexate Therapy: Week 48 Results
Hermine I. Brunner1, Nicolino Ruperto2, N Tzaribachev3, Gerd
Horneff4, Carine Wouters5, Violeta Vladislava Panaviene2,
Vyacheslav Chasnyk6, Carlos Abud-Mendoza7, Ruben Cuttica8,
Andreas Reiff9, M Maldonado-Velázquez1, Nadina Rubio-Pérez10,
Moderators: Murray H. Passo, MD and Andrew S. Zeft, MD,
MSCE
60
duPont Hospital for Children, Thomas Jefferson University,
Wilmington, DE, 4Rutgers Biomedical and Health Sciences,
Newark, NJ
2014 Program Book
scientific sessions
4:45 pm
935. Targeting Glycolysis in Rheumatoid Arthritis
Monica Guma1, Alessia Lodi2, Ajit Divakaruni1, Anne Murphy1,
Stefano Tiziani2 and Gary S. Firestein3, 1University of California,
San Diego, La Jolla, CA, 2University of Texas at Austin, Austin, TX,
3
University of California at San Diego School of Medicine, La
Jolla, CA
5:00 pm
936. Active Invasion of Periodontal Bacteria into Synovial Joint
Exacerbates Collagen-Induced Arthritis in Disease-Prone B10
Riii Mice
Sasanka Chukkapalli1, Mercedes Rivera-Kweh1, Irina Velsko1,
Indraneel Bhattacharyya1, S. John Calise2, Edward Chan1,
Minoru Satoh3 and Lakshmyya Kesavalu1, 1College of Dentistry,
University of Florida, Gainesville, FL, 2University of Florida,
Gainesville, FL, 3Univ. Occupational and Environmental Health,
Kitakyushu, Fukuoka, Japan
Exhibit Hall C
PM
2 0 1 4
4:30 pm
934. Amelioration of Inflammatory Arthritis By Anti-TNF
Therapy Is Associated with Restoration of Lymphatic
Contraction
Echoe M. Bouta1, Igor Kuzin2, Karen de Mesy-Bentley1, Ronald
Wood3, Homaira Rahimi4, Rui-Cheng Ji5, Christopher T. Ritchlin3,
Andrea Bottaro2, Lianping Xing1 and Edward M. Schwarz1,
1
University of Rochester, Rochester, NY, 2Cooper Medical School,
Camden, NJ, 3University of Rochester Medical Center, Rochester,
NY, 4University of Rochester/Golisano Children’s Hospital,
Rochester, NY, 5Oita University, Oita, Japan
5:45 pm
939. Prenatal Methyl-Rich Diet Decreases Inflammation in
Collagen Induced Arthritis
Sanjay Garg1, Dipak R. Patel2 and Raymond Yung2, 1University of
Michigan, Ann Arbor, MI, Ann Arbor, MI, 2University of Michigan,
Ann Arbor, MI
1 6 ,
Rheumatoid Arthritis – Animal Models I
Moderators: Peter A. Nigrovic, MD and Ewa Cairns, PhD
5:30 pm
938. C1q Is Mandatory for Disease Development in
Experimental Arthritis and Expression of Its Receptors
Correlates with Disease Activity in Patients
Matthieu Ribon1, Julie Mussard1, Roxane Herve1, Marina Botto2,
Marie-Christophe Boissier3 and Patrice Decker1, 1INSERM
UMR 1125, Li2P, University Paris 13, Sorbonne Paris Cité and
Rheumatology Department, Avicenne Hospital, Assistance
Publique-Hôpitaux de Paris (AP-HP), Bobigny, France, 2Imperial
College, London, United Kingdom, 3INSERM UMR 1125, Li2P,
University Paris 13, Sorbonne Paris Cité, Bobigny, France
SUNDAY
107 B
5:15 pm
937. A Unique Role for IL-18 Receptor-α in Monocyte Migration
in RA and K/BxN Serum Transfer Arthritis
W. Alexander Stinson1, Phillip L. Campbell1, Jeffrey Ruth1,
Gautam Edhayan1, Ray A. Ohara1, Nicholas Lepore1, Alisa
E. Koch2, David A. Fox1 and M. Asif Amin1, 1Division of
Rheumatology, University of Michigan Medical Center, Ann
Arbor, MI, 2Department of Veteran’s Affairs and University of
Michigan, Ann Arbor, MI
n o v e m b e r
Rik Joos11, V Keltsev12, Evgeny Nasonov13, Daniel Kingsbury14,
M Bandeira15, Earl Silverman16, F Weller-Heinemann10, A van
Royen-Kerkhof17, Alan M. Mendelsohn18, Lilianne Kim18, Daniel
Lovell19 and A Martini20, 1PRCSG, Cincinnati, OH, 2Istituto
Giannina Gaslini, Genoa, Italy, 3PRINTO & PRCSG, Bramstedt,
Germany, 4Asklepios Klinik Sankt Augustin, Sankt Augustin,
Germany, 5University Hosp Gasthuisberg, Leuven, Belgium,
6
Novartis Pharma, Saint-Petersburg, Russia, 7Hospital Central
& Facultad de Medicina, Universidad Autónoma de San Luis
Potosí, San Luis Potosí, Mexico, 8Hospital de Ninos Pedro de
Elizalde, Capital Federal, Argentina, 9Children’s Hospital of
Los Angeles, Los Angeles, CA, 10PRINTO, Genoa, Italy, 11UZ
Gent, Gent, Belgium, 12Paediatric Rheumatology International
Trials Organisation–IRCCS [PRINTO], Genoa, Italy, 13State
Institute of Rheumatology of RAMS, Moscow, Russia, 14Randall
Children’s Hospital at Legacy Emanuel, Portland, OR, 15Hospital
Infantil Pequeno Príncipe, Curitiba, Brazil, 16Hosp for Sick
Children, Toronto, ON, 17Department of Pediatric Immunology
& Rheumatology, Wilhelmina Children’s Hospital, University
Medical Center Utrecht, Utrecht, Netherlands, 18Janssen
Research & Development, LLC., Spring House, PA, 19Division of
Rheumatology, Cincinnati Children’s Hospital Medical Center,
Department of Pediatrics, University of Cincinnati, Cincinnati,
OH, 20Istituto Gaslini-PRINTO, Genova, Italy
PS
PM
PS
Rheumatoid Arthritis – Clinical Aspects II: Remission
and De-Escalation of Therapy
Moderators: Clifton O. Bingham III, MD and Kimme Hyrich, MD,
PhD
4:30 pm
940. Study of Reduction of Therapy in Patients with
Rheumatoid Arthritis in Ongoing Remission
Judith Haschka1, Jürgen Rech1, Matthias Englbrecht1, Stephanie
Finzel1, Michaela Reiser1, Axel J. Hueber1, Arnd Kleyer1, HansPeter Tony2, Martin Fleck3, Karin Manger4, Wolfgang Ochs5, Jörg
Wendler6, Hanns-Martin Lorenz7, Hubert Nüßlein8, Rieke Alten9,
Winfried Demary10 and Georg Schett1, 1University of ErlangenNuremberg, Erlangen, Germany, 2University Hospital Würzburg,
Würzburg, Germany, 3Asklepios Medical Center Bad Abbach,
Bad Abbach, Germany, 4Rheumatology Practice Bamberg,
Bamberg, Germany, 5Rheumatology Practice Bayreuth, Bayreuth,
Germany, 6Rheumatology Practice Erlangen, Erlangen, Germany,
7
University of Heidelberg, Heidelberg, Germany, 8Rheumatology
Practice Nuremberg, Nuremberg, Germany, 9Schlosspark-Klinik,
University Medicine Berlin, Berlin, Germany, 10Rheumatolgy
Practice Hildesheim, Hildesheim, Germany
4:45 pm
941. Biologic De-Escalation in Rheumatoid Arthritis: Cost
Savings and Clinical Success
Tarun S. Sharma1, Lyudmila Kirillova2, Andrea Berger3 and Eric
D. Newman2, 1Geisinger Medical Center, Danville, PA, 2Geisinger
Health System, Danville, PA, 3Center for Health Research,
Geisinger Health System, Danville, PA
2014 Program Book
61
scientific sessions
n o v e m b e r
1 6 ,
SUNDAY
2 0 1 4
5:00 pm
942. ACR/EULAR Remission in RA patients in Clinical Practice – Does Substitution of Patient Global with Pain Score Change
Remission Rates? Data from the Danish Danbio Registry
Merete Lund Hetland, The Danish Rheumatologic Database
(DANBIO), Glostrup Hospital., Copenhagen, Denmark
5:15 pm
943. Improvements in the Proportion of Patients Achieving
DAS, CDAI and SDAI Remission By Omitting the Patient
Global Assessment (PtGA): an Analysis from a Prospective,
Observational Registry
Philip Baer1, WG Bensen2, Carter Thorne3, Boulos Haraoui4, Denis
Choquette5, Regan Arendse6, John Kelsall7, Maqbool Sheriff8,
John S. Sampalis9, Emmanouil Rampakakis9, Francois Nantel10,
May Shawi10, Allen J Lehman10, Susan Otawa10 and Edward
Keystone11, 1Private Practice, Scarborough, ON, 2St Joseph’s
Hospital and McMaster University, Hamilton, ON, 3Southlake
Regional Health Centre, Newmarket, ON, 4University of Montreal
Hospital Centre, Montreal, QC, 5Institut de rhumatologie de
Montréal (IRM), Montréal, QC, 6University of Saskatchewan,
Saskatoon, SK, 7The Mary Pack Arthritis Centre, Vancouver, BC,
8
Nanaimo Regional General Hospital, Nanaimo, BC, 9JSS Medical
Research, Montreal, QC, 10Janssen Inc., Toronto, ON, 11Mount
Sinai Hospital, University of Toronto, Toronto, ON
5:30 pm
944. Predict the Chance of Remission for Your RA Patient in
Real Life
Till Uhlig1, Vibeke Norvang1, Elisabeth Lie1, Erik Rødevand2, Knut
Mikkelsen3, Åse S. Lexberg4, Synøve Kalstad5 and Tore K. Kvien1,
1
Diakonhjemmet Hospital, Oslo, Norway, 2St. Olavs Hospital,
Trondheim, Norway, 3Revmatismesykehuset, Lillehammer,
Norway, 4Vestre Viken Hospital, Drammen, Norway, 5University
Hospital of Northern Norway, Tromsø, Norway
5:45 pm
945. Disease Remission Reduces Risk of Heart Failure in
Rheumatoid Arthritis Patients Independent of Treatment
Strategy
Thomas Schau1, Michael Gottwald2, Christian Butter1 and
Michael Zaenker2, 1Cardiology Dept., Immanuel Klinikum Bernau
Heart Center Brandenburg, Bernau, Germany, 2Immanuel
Klinikum Bernau, Rheumatology Center Northern Brandenburg,
Bernau, Germany
Ballroom West
PM
PS
and Gene Therapy II: Novel Therapies in Rheumatoid
Arthritis – Early in Development
Moderators: Vivian P. Bykerk, MD and Iain B. McInnes, PhD
4:30 pm
946. Phase 1 Study of Immunotherapy Using AutoantigenLoaded Dendritic Cells in Patients with Anti-Citrullinated
Peptide Antigen Positive Rheumatoid Arthritis
Young Bin Joo1, Jun-Eui Park2, Chan-Bum Choi3, Jeongim Choi1,
Jin-ah Jang2, Minkyu Heo2, Hak-yeop Kim2, Hye-Soon Lee1, YongSoo Bae4 and Sang-Cheol Bae5, 1Hanyang University Hospital
62
2014 Program Book
for Rheumatic Diseases, Seoul, South Korea, 2JW CreaGene
Research Institute, JWCreaGene Inc., Seongnam-si, South Korea,
3
Hanyang University Hospital for Rheumatic Diseases, Clinical
Research Center for Rheumatoid Arthritis (CRCRA), Seoul,
South Korea, 4Sungkyunkwan University, Suwon, South Korea,
5
Department of Rheumatology, Hanyang University Hospital for
Rheumatic Diseases, Seoul, South Korea
4:45 pm
947. Efficacy and Safety of NNC01140006, an Anti-IL-21
Monoclonal Antibody, in Patients with Active Rheumatoid
Arthritis
Juan D. Cañete1, Piotr Leszczynski2, Rikke Riisbro3 and Klaus
S. Frederiksen3, 1Hospital Clínic of Barcelona, Barcelona, Spain,
2
Department of Rheumatology and Rehabilitation, Poznan
Medical University, Poznan, Poland, 3Novo Nordisk A/S, Søborg,
Denmark
5:00 pm
948. A Phase 2b, Randomized, Double-Blind, Parallel-Group,
Placebo-Controlled, Dose-Finding, Multi-Center Study to
Evaluate the Safety and Efficacy of ASP015K in Moderate
to Severe Rheumatoid Arthritis Subjects Who Have Had an
Inadequate Response to Methotrexate
Alan J. Kivitz1, Anna Zubrzycka-Sienkiewicz2, Sergio R. GutierrezUreña3, Jeffrey Poiley4, Rita Kristy5, Kathyjo Shay5 and Jay P. Garg5,
1
Altoona Center for Clinical Research, Duncansville, PA, 2ARS
Rheumatica sp. Zo.o, Reumatika, Warszawa, Poland, 3Hospital
Civil de Guadalajara FAA, CUCS UdG, Guadalajara, Mexico,
4
Arthritis Associates, Orlando, FL, 5Astellas Pharma Global
Development, Northbrook, IL
5:15 pm
949. Safety and Efficacy of CF101 in Rheumatoid Arthritis
Patients: A Phase II Study
Rumen M. Stoilov1, Rodina N. Licheva2, Mariyana K. Mihaylova3,
Tatiana Reitblat4, Emil A. Dimitrov1, Krasimira M. Shimbova1,
Girish Bhatia5, Amit Pispati6, Alexandra Gurman- Balbir7, B R
Bagaria5, Boytcho A. Oparanov2, Sari Fishman8, Zivit Harpaz8,
Motti Farbstein8, Shira Cohen8, Michael H. Silverman8 and Pnina
Fishman8, 1Multiprofile Hospital for Active Treatment “Sv. Ivan
Rilski” – EAD, Clinic of Rheumatology, Sofia, Bulgaria, 2Diagnostic
Consulting Center, Rheumatology office, Sofia, Bulgaria,
3
3Diagnostic Consulting Center, Rheumatology office, Sofia,
Bulgaria, 4Barzilai Medical Center,, Ashkelon, Israel, 5Malpani
Multispeciality Hospital, Mumbai, India, 6Bhatia Hospital
Medical Research Society, Mumbai, India, 7Rambam Medical
Center, Haifa, Israel, 8CanFite Biopharma Ltd, Petah Tikva, Israel
5:30 pm
950. Multiple Mechanisms of Tolerance Characterize the
Immune Response to Autologous Modified Dendritic Cells
Exposed to Citrullinated Peptides in Patients with Rheumatoid
Arthritis
Soi-Cheng Law1, Hendrik Nel2, Ahmed Mehdi2, Kim-Anh Le Cao2
and Ranjeny Thomas1, 1Univ of Queensland, Brisbane, Australia,
2
University of Queensland, Brisbane, Australia
scientific sessions
5:45 pm
951. Safety, Tolerability and Functional Activity of ABT-122, a
Dual TNF- and IL-17A–Targeted DVD-Ig™, Following Single-Dose
Administration in Healthy Subjects
Heikki Mansikka1, Melanie Ruzek2, Margaret Hugunin2, Alexander
Ivanov2, Alyssa Brito2, Anca Clabbers2, Carolyn Cuff2, Chung-Ming
Hsieh2, Martin Okun1, Renee Heuser1, David Carter1, Barbara
Hendrickson1, Dipak Pisal1, Sandra Goss1, Jia Liu1, Charles Locke1,
Nasser Khan1 and Robert Padley1, 1AbbVie, Inc, North Chicago, IL,
2
AbbVie, Inc, Worcester, MA
258 B
PM
PS
Spondyloarthropathies and Psoriatic Arthritis II –
Novel Treatments for Psoriatic Arthritis
Moderators: Philip Mease, MD and Eric Ruderman, MD
1 6 ,
2 0 1 4
5:00 pm
954. Secukinumab, a Monoclonal Antibody to Interleukin17A, Provides Significant and Sustained Inhibition of Joint
Structural Damage in Active Psoriatic Arthritis Regardless of
Prior TNF Inhibitors or Concomitant Methotrexate: A Phase 3
Randomized, Double-Blind, Placebo-Controlled Study
Désirée van der Heijde1, Robert B. M. Landewé2, Philip Mease3,
Iain B. McInnes4, Philip G. Conaghan5, Luminita Pricop6, Gregory
5:30 pm
956. Real-World Validation of the Minimal Disease Activity
Index in Psoriatic Arthritis: An Analysis from the Prospective,
Observational, Biological Treatment Registry Across Canada
Proton Rahman1, Saeed Shaikh2, Michael Starr3, William
Bensen4, Denis Choquette5, Wojciech Olszynski6, Maqbool
Sheriff7, Michel Zummer8, Emmanouil Rampakakis9, John S.
Sampalis9, Allen J Lehman10, Susan Otawa10, Francois Nantel10,
Vincent Letourneau10 and May Shawi10, 1Memorial University of
Newfoundland, St. John’s, NF, 2McMaster University, Hamilton,
ON, 3Montreal General Hospital, Montreal, QC, 4Division of
Rheumatology, McMaster University, Hamilton, ON, 5Notre
Dame Hospital, Montreal, QC, 6University of Saskatchewan,
Saskatoon, SK, 7Nanaimo Regional General Hospital, Nanaimo,
BC, 8Université de Montréal, Montreal, QC, 9JSS Medical
Research, Montreal, QC, 10Janssen Inc., Toronto, ON
SUNDAY
4:45 pm
953. Secukinumab, a Human Anti–Interleukin-17A Monoclonal
Antibody, Improves Active Psoriatic Arthritis and Inhibits
Radiographic Progression: Efficacy and Safety Data from a
Phase 3 Randomized, Multicenter, Double-Blind, PlaceboControlled Study
Philip Mease1, Iain B. McInnes2, Bruce Kirkham3, Arthur
Kavanaugh4, Proton Rahman5, Désirée van der Heijde6, Robert
Landewé7, Peter Nash8, Luminita Pricop9, Jiacheng Yuan9,
Hanno Richards10 and Shephard Mpofu10, 1Swedish Medical
Center and University of Washington, Seattle, WA, 2University
of Glasgow, Glasgow, United Kingdom, 3Guy’s and St Thomas’
NHS Foundation Trust, London, United Kingdom, 4UCSD
School of Medicine, La Jolla, CA, 5Memorial University of
Newfoundland, St. John’s, NF, 6Leiden University Medical Center,
Leiden, Netherlands, 7Academic Medical Center, University
of Amsterdam, Amsterdam, Netherlands, 8University of
Queensland, Brisbane, Australia, 9Novartis Pharmaceuticals
Corporation, East Hanover, NJ, 10Novartis Pharma AG, Basel,
Switzerland
5:15 pm
955. Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in
Patients with Psoriatic Arthritis: Pharmacodynamic Results of a
Phase 3, Randomized, Controlled Trial
Peter Schafer1, Peng Chen2, Lorraine Fang2, Andrew Wang2 and
Rajesh Chopra1, 1Celgene Corporation, Summit, NJ, 2Celgene
Corporation, Warren, NJ
n o v e m b e r
4:30 pm
952. A Phase IIb, Randomized, Double-Blind, PlaceboControlled, Dose-Ranging, Multicenter Study to Evaluate the
Efficacy and Safety of Clazakizumab, an Anti-IL-6 Monoclonal
Antibody, in Adults with Active Psoriatic Arthritis
Philip Mease1, A B Gottlieb2, A Berman3, E Drescher4, J Xing5, S
Banerjee5 and R Wong5, 1Swedish Medical Center and University
of Washington, Seattle, WA, 2Tufts Medical Center and Tufts
University School of Medicine, Boston, MA, 3Centro Médico
Privado de Reumatología, Tucuman, Argentina, 4Csolnoky Ferenc
Hospital, Veszprém, Hungary, 5Bristol-Myers Squibb, Princeton,
NJ
Ligozio6, Hanno Richards7 and Shephard Mpofu7, 1Leiden
University Medical Center, Leiden, Netherlands, 2Division of
Clinical Immunology and Rheumatology, Academic Medical
Center / University of Amsterdam & Atrium Medical Center,
Amsterdam, Netherlands, 3Swedish Medical Center, Seattle, WA,
4
University of Glasgow, Glasgow, United Kingdom, 5NIHR-Leeds
Musculoskeletal Biomedical Research Unit and Leeds Institute of
Rheumatic and Musculoskeletal Medicine, University of Leeds,
Leeds, United Kingdom, 6Novartis Pharmaceuticals Corporation,
East Hanover, NJ, 7Novartis Pharma AG, Basel, Switzerland
10:15 am
957. Long-Term Evaluation of NT-Probnp Levels in Ankylosing
Spondylitis Patients Under TNF Blockers: A Marker of
Persistent Disease Activity?
Debora Russo1, Carla G.S. Saad2, Ana C.M. Ribeiro1, Cláudia
Goldeinstein-Schainberg2, Percival D Sampaio-Barros2, Celio R.
Gonçalves2, Eloisa Bonfá1 and Julio C. B. Moraes2, 1University
of Sao Paulo, Sao Paulo, Brazil, 2Faculdade de Medicina da
Universidade de São Paulo, São Paulo, Brazil
205 B
PM
PS
Systemic Lupus Erythematosus – Clinical Aspects and
Treatment: Lupus Nephritis
Moderators: Maria Dall’Era, MD and Cynthia Aranow, MD
4:30 pm
958. The 10-Year Followup of a Trial Comparing Azathioprine
and Mycophenolate Mofetil for Longterm Immunosuppression
of Lupus Nephritis
Farah Tamirou1, David D’Cruz2, Shirish Sangle3, Philippe Remy4,
Carlos Vasconcelos5, Christoph Fiehn6, Maria del Mar Ayala
Gutierrez7, Inge-Margrethe Gilboe8, Maria Tektonidou9, Daniel
Blockmans10, Isabelle Ravelingien11, Véronique le Guern12,
2014 Program Book
63
scientific sessions
n o v e m b e r
1 6 ,
SUNDAY
2 0 1 4
Geneviève Depresseux1, Loïc Guillevin13, Ricard Cervera14 and
Frédéric A. Houssiau15, 1Institut de Recherche Expérimentale et
Clinique, Université catholique de Louvain, Bruxelles, Belgium,
2
Louis Coote Lupus Unit, St Thomas’ Hospital, London, United
Kingdom, 3St Thomas’ Hospital, London, United Kingdom,
4
Hôpital Henri Mondor, Créteil, France, 5Hospital Geral Santo
Antonio, Porto, Portugal, 6ACURA Centre for Rheumatic Diseases,
Baden-Baden, Germany, 7Hospital Regional Universitario Carlos
Haya, Malaga, Spain, Malaga, Spain, 8Oslo University Hospital
Rikshospitalet, Oslo, Norway, 9First Department of Internal
Medicine, Laikon Hospital, Athens University Medical School,
Athens, Greece, 10UZ Leuven, Leuven, Belgium, 11Onze-LieveVrouwzienkenhuis, Aalst, Belgium, 12Hôpital Cochin, Paris, France,
13
Hôpital Cochin, University Paris V Descartes, Paris, France,
14
Hospital Clínic of Barcelona, Barcelona, Spain, 15Université
catholique de Louvain, Brussels, Belgium
4:45 pm
959. Discoid Lupus Onset and Decrease Risk of Renal Disease
in Patients with Systemic Lupus Erythematosus: Data from a
Large Latin American Cohort
Guillermo J. Pons-Estel1, Gaobin Bao2, Bernado Pons-Estel3,
Daniel Wojdyla4, Veronica Saurit5, Alejandro J. Alvarellos6,
Francisco Caeiro7, Emilia I. Sato8, Enrique R. Soriano9,
Lilian Tereza Costallat10, Oscar Neira11, Antonio A. IglesiasGamarra12, Gil Reyes Llerena13, Mario Cardiel14, Eduardo M.
Acevedo-Vásquez15, Rosa Chacon16 and Cristina M. Drenkard2,
1
Department of Autoimmune Diseases, Institut Clìnic de
Medicina i Dermatologia, Hospital Clìnic, Barcelona, Spain,
2
Emory University, Atlanta, GA, 3Hospital Provincial de Rosario,
Rosario, Argentina, 4Universidad Nacional de Rosario, Argentina,
Rosario, Argentina, 5Hospital Privado de Córdoba, Córdoba,
Argentina, 6Hospital Privado Córdoba, Córdoba, Argentina,
7
Hospital Privado Centro Médico de Córdoba, Cordoba,
Argentina, 8Escola Paulista de Medicina – Universidade Federal
de São Paulo, Sao Paulo, Brazil, 9Rheumatology Unit, Internal
Medicine Service, Hospital Italiano de Buenos Aires, Instituto
Universitario Hospital Italiano de Buenos Aires and Fundacion
PM Catoggio, Buenos Aires, Argentina, 10Unicamp, Campinas,
Brazil, 11Univ of Chile Hosp Salvador, Santiago, Chile, 12ProfessorUniversidad Nacional de Colombia, Bogota, Colombia, 13Centro
de Investigaciones Médico Quirúrgicas (CIMEQ), La Habana,
Cuba, 14Secretaría de Salud de Michoacán, Morelia, Mexico,
15
Hospital Nacional “Guillermo Almenara Irigoyen”, Lima, Peru,
16
Hospital Universitario, Centro Nacional de Enfermedades
Reumáticas and Hospital de Clínicas Caracas, Caracas, Venezuela
5:00 pm
960. Allogeneic Mesenchymal Stem Cell Transplantation for
Lupus Nephritis Patients Refractory to Conventional Therapy
Dandan Wang, Huayong Zhang, Xuebing Feng and Lingyun
Sun, The Affiliated Drum Tower Hospital of Nanjing University
Medical School, Nanjing, China
5:15 pm
961. Outcome of Lupus Nephritis and Impact on Health Related
Quality of Life: Results from an International, Prospective,
Inception Cohort Study
John G. Hanly for the Systemic Lupus International Collaborating
64
2014 Program Book
Clinics1, Aidan O’Keeffe2, Li Su3, Murray B. Urowitz4, Juanita
Romero-Diaz5, Caroline Gordon6, Sang-Cheol Bae7, Sasha R
Bernatsky8, Ann E. Clarke9, Daniel J. Wallace10, Joan T. Merrill11,
David A. Isenberg12, Anisur Rahman13, Ellen M. Ginzler14, Paul
Fortin15, Dafna D. Gladman4, Jorge Sanchez-Guerrero16, Michelle
A. Petri17, Ian Bruce18, Mary Anne Dooley19, Rosalind RamseyGoldman20, Cynthia Aranow21, Graciela S. Alarcon22, Barri
Fessler22, Kristjan Steinsson23, Ola Nived24, Gunnar Sturfelt24,
Susan Manzi25, Munther A. Khamashta26, Ronald F. van
Vollenhoven27, Asad Zoma28, Manuel Ramos-Casals29, Guillermo
Ruiz-Irastorza30, S. Sam Lim31, Thomas Stoll32, Murat Inanc33,
Kenneth C. Kalunian34, Diane L. Kamen35, Peter Maddison36,
Christine A. Peschken37, Søren Jacobsen38, Anca Askanase39,
Jill P. Buyon40, Chris Theriault41, Kara Thompson41 and Vernon
Farewell3, 1Dalhousie University and Capital Health, Nova Scotia,
Canada, Halifax, NS, 2MRC Biostatistics Unit, Institute of Public
Heath, Cambridge, United Kingdom, 3MRC Biostatistics Unit,
Institute of Public Health, University Forvie Site, Cambridge,
United Kingdom, 4University of Toronto, Toronto Western
Hospital, Toronto, ON, 5Instituto Nacional de Ciencias Médicas
y Nutricion, Mexico City, Mexico, 6Rheumatology Research
Group, School of Immunity and Infection, College of Medical
and Dental Sciences, University of Birmingham, Birmingham,
United Kingdom, 7Hanyang University Hospital for Rheumatic
Diseases, Seoul, South Korea, 8Division of Rheumatology and
Clinical Epidemiology, McGill University, Montreal, Quebec,
QC, 9Division of Rheumatology, University of Calgary, Alberta,
Calgary, AB, 10Cedars-Sinai/David Geffen School of Medicine at
UCLA, Los Angeles, CA, 11Department of Clinical Pharmacology,
Oklahoma Medical Research Foundation, Oklahoma City, OK,
12
Centre for Rheumatology, Department of Medicine, University
College London, London, United Kingdom, 13University College
London, London, United Kingdom, 14SUNY-Downstate Medical
Center, Brooklyn, NY, 15Division of Rheumatology, Centre
Hospitalier Universitaire de Quebec et Universite Laval, Quebec,
QC, 16Centre for Prognosis Studies in the Rheumatic Diseases,
Toronto Western Hospital and University of Toronto, Toronto, ON,
17
Division of Rheumatology, Johns Hopkins University School of
Medicine, Baltimore, MD, 18Arthritis Research UK Epidemiology
Unit, Institution of Inflammation and Repair, University of
Manchester, NIHR Manchester Musculoskeletal Biomedical
Research Unit, Central Manchester University Hospitals,
Manchester Academic Health Sciences Centre, Manchester,
United Kingdom, 19Thurston Arthritis Research Center, University
of North Carolina, Chapel Hill, NC, 20Northwestern University
and Feinberg School of Medicine, Chicago, IL, 21Feinstein
Institute for Medical Research, Manhasset, NY, 22Department of
Medicine, University of Alabama at Birmingham, Birmingham,
AL, 23Center for Rheumatology Research, Landspitali University
Hospital, Reykjavik, Iceland, 24Department of Rheumatology,
University Hospital Lund, Lund, Sweden, 25Division of
Rheumatology, University of Pittsburgh School of Medicine,
Pittsburgh, PA, 26Lupus Research Unit, The Rayne Institute, St
Thomas Hospital, Kings College London School of Medicine,
London, United Kingdom, 27Unit for clinical therapy research
(ClinTrid), Karolinska Institute, Stockholm, Sweden, 28Lanarkshire
Centre for Rheumatology, Hairmyres Hospital, East Kilbride,
scientific sessions
PM
PS
Raynaud’s – Pathogenesis, Animal Models and
Genetics I
Moderators: Jessica K. Gordon, MD, MSc and Robert Lafyatis,
MD
4:30 pm
964. Skin Collagen Synthesis Rates Distinguish Between Early
and Late Diffuse Scleroderma Patients
Claire Emson1, Martin Decaris1, Michelle Gatmaitan1, Flora Luo1,
Dan Holochwost1, Simplicia FloraCruz1, Thomas Angel1, Kelvin
Li1, Marc Hellerstein1, Fredrick M. Wigley2, Scott Turner1 and
Francesco Boin2, 1KineMed Inc., Emeryville, CA, 2Johns Hopkins
2 0 1 4
157 B
5:15 pm
967. Mir-145 Protects Against Skin Fibrosis in Vivo by targeting
TGF-β Signaling
Serena Vettori1, Christian Beyer2, Matthias Brock1, Naoki
Iwamoto1, Britta Maurer1, Michelle Trenkmann1, Astrid Jüngel1,
Renate E. Gay1, Maurizio Calcagni3, Gabriele Valentini4, Steffen
Gay1, Joerg H. W. Distler2 and Oliver Distler1, 1Zurich University
Hospital, Zurich, Switzerland, 2Department of Internal Medicine
III and Institute for Clinical Immunology, University of ErlangenNuremberg, Erlangen, Germany, 3Division of Plastic Surgery and
Hand Surgery, University Hospital Zurich, Zurich, Switzerland,
4
Second University of Naples, Napoli, Italy
1 6 ,
5:45 pm
963. Reduction in Proteinuria and Normalization of C4
Complement Levels Predict Response to Treatment of Lupus
Nephritis with Low-Dose Pulse Cyclophosphamide and
Abatacept
Sarah Goglin1, David Wofsy1, Miriam G. Cisternas2 and Maria
Dall’Era1, 1University of California, San Francisco, San Francisco,
CA, 2MGC Data Services, Carlsbad, CA
5:00 pm
966. Adiponectin Is an Endogenous Anti-Fibrotic and Target
in Systemic Sclerosis: Novel Link Between Fibrosis and
Metabolism
Feng Fang1, Roberta G. Marangoni1, Xingchun Zhou2, Wen
Hong2, Boping Ye2, Asano Yoshihide3, Shinichi Sato3, Yuri
Masui3, Chengning Zhang1, Katja Lakota1, Jun Wei1, Monique
E. Hinchcliff1, Philipp Scherer4, Laszlo Otvos5 and John Varga6,
1
Northwestern University, Feinberg School of Medicine, Chicago,
IL, 2China Pharmaceutical University, Nanjing, China, 3University
of Tokyo, Tokyo, Japan, 4University of Texas Southwestern
Medical Center, Dallas, TX, 5Temple University, Philadelphia, PA,
6
Northwestern University Feinberg School of Medicine, Chicago,
IL
SUNDAY
5:30 pm
962. A Systematic Review and Network Meta-Analysis of the
Risk of Serious Infections with Immunosuppressives for Lupus
Nephritis
Jasvinder Singh1, Alomgir Hossain2, Ahmed Kotb2 and George
Wells3, 1University of Alabama at Birmingham, Birmingham, AL,
2
University of Ottawa, Ottawa, ON, 3University of Ottawa Heart
Institute, Ottawa, ON
Pharmaceutical Company Limited, Kanagawa, Japan,
3
IL
n o v e m b e r
United Kingdom, 29Josep Font Autoimmune Diseases Laboratory,
IDIBAPS, Department of Autoimmune Diseases, Hospital
Clinic, Barcelona, Spain, 30Autoimmune Diseases Research Unit,
Department of Internal Medicine, BioCruces Health Research
Institute, Hospital Universitario Cruces, University of the
Basque Country, Barakaldo, Spain, 31Emory University School of
Medicine, Division of Rheumatology, Atlanta, GA, 32Kantonsspital
Geissbergstr, Schaffhausen, Switzerland, 33Division of
Rheumatology, Department of Medicine, Istanbul Medical
Faculty, Istanbul University, Istanbul, Turkey, 34UCSD School of
Medicine, La Jolla, CA, 35Medical University of South Carolina,
Charleston, SC, 36Ysbyty Gwynedd Bangor, North Wales, United
Kingdom, 37University of Manitoba, Winnipeg, MB, 38Department
of Rheumatology, Rigshospitalet, Copenhagen University
Hospital, Copenhagen, Denmark, 39Columbia University Medical
Center, New York, NY, 40New York University School of Medicine,
New York, NY, 41Department of Medicine, Queen Elizabeth II
Health Sciences Centre and Dalhousie University, Halifax, NS
5:30 pm
968. Priming of WNT Signalling during Fibrosis Is Mediated By
TGF-β Induced Axin-2 Downregulation
Justin Gillespie1, Emma C. Derrett-Smith2, Michael McDermott1,
Paul Emery3, Christopher P Denton2 and Francesco Del Galdo3,
1
Leeds Institute of Rheumatic and Musculoskeletal Medicine,
University of Leeds, Leeds, United Kingdom, 2UCL Medical
School Royal Free Campus, London, United Kingdom, 3Leeds
Institute of Rheumatic and Musculoskeletal Medicine, University
of Leeds and NIHR Leeds Musculoskeletal Biomedical Research
Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United
Kingdom
5:45 pm
969. Caspase-8 Prevents Lung Fibrosis in a Murine SSc-like
Disease Model By Preventing Macrophage Differentiation
Alexander Misharin1, Carla M. Cuda2, Luisa Morales-Nebreda3,
Gokhan Mutlu1, GR Scott Budinger3 and Harris R. Perlman2,
1
Northwestern University, Chicago, IL, 2Northwestern University
Feinberg School of Medicine, Chicago, IL, 3Northwestern
University, Feinberg School of Medicine, Chicago, IL
4:45 pm
965. Blockade of TLR4 Signaling By TAK242 Ameliorates
Experimental Organ Fibrosis
Swati Bhattacharyya1, Wenxia Wang1, Zenshiro Tamaki1, Yasuhiro
Tsukimi2, Masashi Yamasaki2 and John Varga3, 1Northwestern
University, Feinberg School of Medicine, Chicago, IL, 2Takeda
2014 Program Book
65
scientific sessions
PM
PS
4:30 – 6:00 pm
n o v e m b e r
1 6 ,
SUNDAY
2 0 1 4
PM
PS
Speaker: Saima Chohan, MD
• review diagnostic criteria for gout
• assess treatment options for hyperuricemia, acute and chronic
gout
• assess the current ACR recommendations for the treatment of
acute and chronic manifestations of gout
*Infections with Biologics (022)
Speaker: Kathryn H. Dao, MD
• discuss the risk of infection related to inflammation and
disease
• discuss the risk factors for infection
• recognize the magnitude of risk imposed by steroids and
biologics
• determine the approach to risk reduction
*Inflammatory Eye Disease/Uveitis (023)
Speaker: Sergio Schwartzman, MD
• review the clinical manifestations of inflammatory eye disease
encountered by rheumatologists
• discuss diagnostic pearls for the evaluation of someone with
inflammatory eye disease
• discuss the treatment paradigms used for the inflammatory
eye diseases
Pediatrics: Difficult-to-Treat Juvenile Idiopathic
FIT
PrM
Pd
PS
PM
Ed
Arthritis (024)
Speaker: Thomas J. A. Lehman, MD
• discuss the differences in the treatment of the difficult
situations for the different subtypes of juvenile idiopathic
arthritis
66
2014 Program Book
• r ecognize some of the complications of the disease and
appropriate management
• explain the difficulties posed by non-adherence and
inadequate decision making
Polymyalgia Rheumatica (025)
Speaker: Antoine G. Sreih, MD
• distinguish the clinical subtleties of polymyalgia rheumatica
and outline an evaluative process that can help differentiate
it from other inflammatory conditions and identify
manifestations of giant cell arteritis
• discuss the new EULAR/ACR classification criteria and the
scoring algorithm for polymyalgia rheumatica
• review the therapeutic strategies used for the treatment of
polymyalgia rheumatica, including the range of glucocorticoid
regimens, other disease modifying therapies, “steroid-sparing”
approaches and new investigative drugs
Pulmonary Hypertension in the Rheumatic Diseases
(026)
Speaker: James R. Seibold, MD
• describe the World Health Organization classification of
pulmonary hypertension and how to recognize the frequent
overlap of these syndromes in the clinical setting of
connective tissue disease
• discuss the utility, sensitivity and specificity of non-invasive
screening tests and algorithms for determining which patients
are appropriate for right heart catheterization
• explain the benefits, risks, costs and effects on outcome of the
available therapies for pulmonary arterial hypertension
Speaker: Josef Smolen, MD
• describe similarities and differences between approved
biological agents in terms of efficacy and safety
• discuss issues around biosimilars
• assess the place of biologicals in the therapeutic
cascade according to the updated EULAR management
recommendations
• appraise the potential of induction therapy with biologics
followed by withdrawal of the biologic as a potential future
treatment approach
*Rheumatology Practice 101: Starting Out in Practice
FIT
PrM
Pd
PS (028)
PM
Ed
for the Graduating Fellow
Speakers: Alexandru F. Kimel, MD
• prepare for their first job search
scientific sessions
• a ssess expectation when starting out (perceptions versus
reality)
• adapt to new practice styles and build a referral base
• identify ways to ensure long term success and personal life
balance
*Systemic Lupus Erythematosus: Novel Treatments
(029)
Speaker: Liz Lightstone, MD, PhD
• state current Food and Nutrition Board recommendations for
vitamin D intake in older men and women
• recall evidence-based medicine conclusions regarding vitamin
D and osteoporotic fracture
• identify the range of serum 25(OH)D levels believed optimal
for bone health
ACR/ARHP COMBINED ABSTRACT SESSION
4:30 – 6:00 pm
109 A
PM
PS
ACR/ARHP Combined Abstract Session: Epidemiology
and Public Health
Moderator: Elizabeth G. Salt, PhD
4:30 pm
970. Risk of Developing Antiphospholipid Syndrome Following
Infection: A Systematic Review and Meta-Analysis of
Observational Studies
Noha Abdel-Wahab1, Maria A. Lopez-Olivo1, Saurabh Talathi2
and Maria E. Suarez-Almazor1, 1The University of Texas, MD
Anderson Cancer Center, Houston, TX, 2The University of Texas
Health Science Center at Houston, School of Public Health,
Houston, TX
2 0 1 4
Speaker: Nancy E. Lane, MD
5:15 pm
973. Relation of Pelvic Drop during Walking to Risk of Incident
Medial Knee Osteoarthritis: The Multicenter Osteoarthritis
Study
K. Douglas Gross1, Emily K. Quinn2, Michael C. Nevitt3, James C.
Torner4, Cora E. Lewis5 and David T. Felson1, 1Boston University
School of Medicine, Boston, MA, 2Boston University, Boston, MA,
3
UCSF (University of California, San Francisco), San Francisco, CA,
4
University of Iowa, Iowa City, Iowa City, IA, 5The University of
Alabama at Birmingham, Birmingham, AL
1 6 ,
Vitamin D and Bone Health (030)
SUNDAY
5:00 pm
972. Racial, Gender and Geographic Differences in Systemic
Lupus Erythematous and Lupus Nephritis Mortality Rates in
the Unites States, 1968-2010
Eric Y Yen1, Magda Shaheen2, Jennifer MP Woo1, Deborah
K. McCurdy1 and Ram Raj Singh3, 1UCLA Division of Pediatric
Rheumatology, Los Angeles, CA, 2Charles R. Drew University
of Medicine and Science, Los Angeles, CA, 3UCLA Division of
Rheumatology, Los Angeles, CA
n o v e m b e r
• review immunosuppressive therapy of lupus nephritis classes
II-V, including novel biologics
• discuss the management of lupus nephritis in pregnancy
• discuss novel approaches to improving adherence to therapy
in lupus nephritis
• describe the use of reno-protective and anti-proteinuria
therapies in lupus nephritis
• outline the future research agenda for clinical trials in lupus
nephritis
Dan Caspi7 and Ori Elkayam8, 1Tel Aviv medical center, Tel Aviv,
Israel, 2Tel Aviv Sourasky Medical Center and the Sackler Faculty
of Medicine, Tel Aviv University, Tel Aviv, Israel, 3Tel-Aviv Medical
Center, Sackler Faculty of Medicine, Tel-Aviv University, TelAviv, Israel, 4Tel Aviv Sourasky Medical Center and the Sackler
Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel, 5Tel
Aviv Sourasky Medical Ctr, Tel-Aviv University, Tel Aviv, Israel,
6
Department of rheumatology. Tel Aviv Medical Center, Tel Aviv,
Israel, 7Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 8Tel-Aviv
Medical Center, Sackler Faculty of Medicine, Tel-Aviv University,
Tel- Aviv, Israel
5:30 pm
974. Obesity Paradox in Osteoarthritis Progression – What
Effects Are We Measuring?
Qiong Louie-Gao1, Hyon K Choi1, David T. Felson2, Tuhina Neogi1,
Uyen Sa D.T. Nguyen1, Na Lu1 and Yuqing Zhang1, 1Boston
University School of Medicine, Boston, MA, 2University of
Manchester, Manchester, United Kingdom
5:45 pm
975. Chronic Pain Predicts Reduced Physical Activity in a Large
Population Cohort Study
Kathryn Remmes Martin, Marcus Beasley, Gary J. Macfarlane
and Daniel Whibley, University of Aberdeen, Aberdeen, United
Kingdom
4:45 pm
971. The Long-Term Efficacy of an Anti-Pneumococcal
Polysaccharide Vaccine (PPSV23, Pneumovax) Among
Autoimmune Inflammatory Rheumatic Patients
Adi Broyde1, Uri Arad2, Noa Madar-Balakinski2, Daphna Paran3,
Ilana Kaufman4, Ira Litinsky5, David Levartovsky6, Irena Wigler2,
2014 Program Book
67
scientific sessions
ARHP SESSIONS
• d
escribe the rehabilitation interventions used by occupational
and physical therapists to manage functional disability in
scleroderma
• discuss the management of psychosocial issues that can occur
in scleroderma
4:30 – 6:00 pm
255
PM
PS
“Say What?”: Implications of Adolescent Development
and Behavior in Communicating with Health Care
FIT
PrM
Pd
PS
Ed
Providers PM
4:30 pm
Targeted Therapy for Systemic Sclerosis
Virginia D. Steen, MD
n o v e m b e r
1 6 ,
SUNDAY
2 0 1 4
Moderator: Thuy T. Beam, BSN, RN
Speakers: Kiana Johnson, PhD and Courtney Wells, MPH, MSW
• evaluate the cultural competency skills of professionals
working with adolescents with rheumatic diseases
• recognize the developmental needs of adolescents with
rheumatic diseases
• use knowledge of adolescent development and behavior to
learn how to talk with adolescents
• develop comfort in speaking with adolescent patients
254 A
PS
PM
Current Trends in Self-Management and
Rheumatologic Care: mHealth, eHealth, Digital
Technology and Emerging Ethical Considerations
Eth
PM
Moderator: Catherine L. Backman, PhD
• define mobile health/eHealth and evaluate its utilization in
the care of people with arthritis
• examine mobile health applications and identify functionality
options to enhance consumer and health care provider
utilization
• outline potential and actual ethical situations that may arise in
the era of eHealth
4:30 pm
Take Two Apps and Call Me in the Morning: An Overview of
Mobile Health Applications to Improve Quality of Care
Elizabeth A. Breeden, PharmD
5:00 pm
State of the Science: A Conversation on Digital Resources to
Support Self-Management
Linda C. Li, PhD, PT and Maura D. Iversen, BSc, DPT, SD, MPH
5:30 pm
The e-Patient: Engaged, Empowered, Equipped, Enabled… and
Ethical?
Anne F. Townsend, MA, PhD
PM
PS
102 A
Multidisciplinary Management of Scleroderma
Moderator: Deborah McCloskey, RN, BSN
• explain the medical management for the skin, vascular and
organ involvement in scleroderma
68
2014 Program Book
5:00 pm
Rehabilitation Techniques to Improve Function in Scleroderma
Janet L. Poole, OTR, PhD
5:30 pm
Managing Psychosocial Challenges in Scleroderma
Vanessa L. Malcarne, PhD
256
PM
PS
Practical Practice Management Session Two: Navigate
HIPAA and Prevent Audits
• review the latest national HIPAA requirements
• evaluate current pre-audit preventive measures and strategies
for responding to audits
• develop an up-to-date small practice compliance plan
4:30 pm
HIPAA in 2014: Don’t Forget Research, Quality Measures and
Electronic Medical Records
Bruce Toppin, JD
5:15 pm
Audits, Affordable Care Act, ICD-10…I’m at the End of the Rope
Karen Zupko, BS
4:30 – 6:00 pm
PM
PS
257 A
Osteoarthritis
Moderators: Sara R. Piva, PhD, PT and Jan K. Richardson, PT, PhD
4:30 pm
976. Measurement Properties of the Health Assessment
Questionnaire Disability Index (HAQ-DI) in Patients with
Generalized Osteoarthritis (GOA)
Nienke Cuperus1, Elien A.M. Mahler1, Thea Vliet Vlieland2,
Thomas Hoogeboom3 and Cornelia H.M. van den Ende1, 1Sint
Maartenskliniek, Nijmegen, Netherlands, 2Leiden University
Medical Center, Leiden, Netherlands, 3CAPHRI school for public
health and primary care, CCTR centre for Care Technology
Research, Maastricht University, Maastricht, Netherlands
scientific sessions
4:45 pm
977. Randomized Clinical Trial of a Patient and Provider
Intervention for Managing Osteoarthritis in Veterans
Kelli D. Allen1, Hayden B. Bosworth2, Amy Jeffreys1, Cynthia
Coffman2, Santanu Datta2, Jennifer McDuffie3, Eugene Oddone2,
Jennifer Strauss3 and William S. Yancy Jr.3, 1Durham VA Medical
Center, Durham, NC, 2Durham VA Medical Center and Duke
University Medical Center, Durham, NC, 3Duke University
Medical Center, Durham, NC
5:00 pm
978. Socioeconomic Status Measures Are Associated with
Increasing Pain, Stiffness and Physical Function Among
Individuals with Knee and Hip Osteoarthritis
Rebecca Cleveland1, Jordan B. Renner2, Joanne M. Jordan3 and
Leigh F. Callahan4, 1University of North Carolina at Chapel Hill,
Chapel Hill, NC, 2University of North Carolina Department of
Radiology, Chapel Hill, NC, 3University of North Carolina Dept
of Epidemiology, Chapel Hill, NC, 4University of North Carolina,
Chapel Hill, NC
MONDAY, NOVEMBER 17, 2014
ACR SESSIONS
7:30 – 8:30 am
102 A
PM
PS
Educator: Cultivating the Competent Medical
PrM
Pd
PS
PM
Ed
Educator: A Growing Concern
FIT
Moderator: Kenneth S. O’Rourke, MD
Speaker: Kelley M. Skeff, MD, PhD
• discuss the major aspects of effective teaching in medical
school and clinical environments
• describe proposed competencies for medical educators based
on this framework
• describe personal goals for improving teaching PS
effectiveness
PM
Meniscus Biology in Osteoarthritis
2 0 1 4
104 B
1 7 ,
5:45 pm
981. The Effect of Compression Gloves in Hand Osteoarthritis:
A Pre-Post-Test Trial
Alison Hammond1, Yeliz Prior1, Vivienne Jones1, Mary Dooley2,
Yvonne Hough3 and Angela Jacklin4, 1University of Salford,
Greater Manchester, United Kingdom, 2Southport & Formby
District Hospital, Southport, United Kingdom, 3St Helens Hospital,
St Helens, United Kingdom, 4Stepping Hill Hospital, Stockport,
United Kingdom
These symposia are both CME-accredited and non-CME
company-directed programs. For CME-accredited symposia,
the sponsoring organization is responsible for planning and
providing CME credit. All non-CME programs are wholly
sponsored and supported by commercial entities. Please visit the
organization’s exhibit booth, the industry-supported symposia
booth or see page 239 for more information.
MONDAY
5:30 pm
980. Annual Medical Care Expenditures Among US Adults with
Osteoarthritis, 2008 – 2011
Miriam G. Cisternas1, Louise Murphy2, David J. Pasta3, Daniel H.
Solomon4 and Charles G. Helmick2, 1MGC Data Services, Carlsbad,
CA, 2Centers for Disease Control and Prevention, Atlanta, GA,
3
DMA Corporation, Palo Alto, CA, 4Brigham and Women’s
Hospital, Boston, MA
6:30 – 9:30 pm
n o v e m b e r
5:15 pm
979. Genome-Wide Association Study for Severe Radiographic
Knee Osteoarthritis
Youfang Liu1, Michelle Yau2, Laura Yerges-Armstrong3, Braxton
Mitchell3, Rebecca D. Jackson4, Marc C. Hochberg3, Shad Smith1,
William Maixner1, Luda Diatchenko5 and Joanne M. Jordan6,
1
University of North Carolina, Chapel Hill, NC, 2University of
Maryland, Baltimore,, MD, 3University of Maryland School of
Medicine, Baltimore, MD, 4The Ohio State University, Columbus,
OH, 5McGill University, Montreal, QC, 6University of North
Carolina Dept of Epidemiology, Chapel Hill, NC
INDUSTRY-SUPPORTED SYMPOSIA
Moderator: Richard F. Loeser, MD
Speaker: Robert Brophy, MD
• review the normal function of the meniscus in stabilizing the
joint
• appraise how meniscal injury contributes to osteoarthritis
pathogenesis
• describe the pro-inflammatory mediators produced by the
meniscus that could promote osteoarthritis
Ballroom East
Rheumatology Research Foundation Paul Klemperer,
MD Memorial Lectureship: Gene-Environment
PS
PM
Interactions as a Basis for Unravelling Adaptive
Immunity and Preparing for Tolerizing Therapies in
Moderator: David R. Karp, MD, PhD
Speaker: Lars Klareskog, MD, PhD
• critically evaluate studies on genetic and environmental/life
style risk factors for RA and other rheumatic diseases
• appraise the power of such studies for identifying subsets
of disease with different etiologies, molecular pathologies,
disease course and response to therapy
2014 Program Book
69
PM
scientific sessions
• r ecognize the effects of genes and environment/life style
in clinical practice to advise patients and their relatives in
avoiding and ameliorating disease
• critically evaluate the potentials of tolerizing therapies as
future options for prevention and treatment of rheumatoid
arthritis
ARHP SESSIONS
7:30 – 8:30 am
151 A
PM
PS
Stats Boot Camp: The Effect Size: What Is It and How
Can You Use It?
2 0 1 4
1 7 ,
MONDAY
n o v e m b e r
PM
PS
Update on Findings from Large Registries: Emphasis
on Health Disparities in Rheumatoid Arthritis
Moderator: Scott Hasson, PT, PhD
Speaker: Jeffrey D. Greenberg, MD, MPH
• discuss the incidence and prevalence of rheumatoid arthritis
in ethnic populations
• describe disease severity and clinical course of disease among
different ethnic groups
• discuss who are the medically underserved in this patient
population
PS
PM
153 B
What Are Biosimilars?
Moderator: Susan Chrostowski, MS, ANP-C, RN
• summarize the basic concept of biosimilar drugs
• discuss the development, clinical trial and approval process for
biosimilar drugs
• evaluate how the availability of biosimilars may affect their
rheumatology practice and patient care approaches
8:00 am
Where Are We Now with Biosimilars?
Vibeke Strand, MD
*Ankylosing Spondylitis: 2014 Update (031)
• distinguish between effect size and statistical significance
• define common effect sizes
• calculate and interpret common effect sizes
• discuss practical uses of effect sizes
7:30 am
What Are Biosimilars?
Lee S. Simon, MD
7:45 – 9:15 am
Moderator: Uyen Sa D.T. Nguyen, DSc, MPH
Speaker: Nancy A. Baker, MPH, OTR, OTR/L
255
PS
Speaker: Lianne S. Gensler, MD
• discuss the spectrum of axial spondyloarthritis, including
• discuss the early diagnosis of ankylosing spondylitis and axial
spondyloarthritis
• describe clinical and radiographic outcome measures used in
clinical trials and practice
• summarize axial spondyloarthritis treatment options and
understand the impact of treatment on outcomes
*Basic Immunology for Clinical Rheumatologists (032)
Speaker: John Atkinson, MD
• describe how the immune system functions in normal
individuals
• identify abnormalities of immune regulation that lead to
autoimmunity
Controversies in Sjögren’s Syndrome (033)
Speaker: Frederick Vinino, MD
• identify the best approach to establish a diagnosis of Sjögren’s
syndrome
• differentiate among various causes of salivary and/or lacrimal
gland swelling
• discuss current treatment algorithms for dry eyes, dry mouth
and systemic manifestations
• identify risk factors and markers for lymphoma in Sjögren’s
syndrome patients
Dermatological Manifestations of Rheumatic
Diseases (034)
• identify cutaneous findings associated with underlying
rheumatic disease
70
2014 Program Book
scientific sessions
• c onstruct a differential diagnosis for these conditions
• design a strategy for management of skin disease seen in
• e xamine management strategies for refractory cutaneous
manifestations of systemic lupus erythematosus
• discuss management of progressive or relapsing lupus
nephritis
• discuss management of severe cytopenias
Osteoarthritis: Update 2014 (035)
Speaker: Joanne M. Jordan, MD, MPH
*Vasculitis: Update (040)
• describe the pathogenesis of osteoarthritis including factors
that lead to its development and the underlying biology
responsible for the progression of osteoarthritis
• discuss advances in the management of osteoarthritis that
include non-pharmacologic interventions
• evaluate the potential benefits of new disease- or structuremodifying treatments for osteoarthritis
Speaker: Raashid A. Luqmani, DM
• describe the current definitions of vasculitis according to
affected vessel size
• discuss the role of simple clinical evaluation alongside the
various available laboratory and imaging tests, including antineutrophil cytoplasm antibodies
PS
PM
• identify current and novel
therapeutic modalities
*Pregnancy and Rheumatic Diseases (036)
Speaker: Eliza Chakravarty, MD, MS
159
• d emonstrate improvement in their techniques for performing
selected musculoskeletal ultrasound examinations
se practical knowledge of ultrasound technology to improve
• u
image quality
Rheumatoid Arthritis: Challenging Cases (038)
therapies
*Systemic Lupus Erythematosus: Difficult-to-Treat
Systemic Lupus Erythematosus (039)
Speaker: Maria Dall’Era, MD
*Advanced Musculoskeletal Ultrasound (214)
• identify various causes of reactive arthritis
• describe current treatment options for reactive arthritis
2 0 1 4
Reactive Arthritis: An Update (037)
Speaker: John D. Reveille, MD
1 7 ,
MONDAY
n o v e m b e r
• describe risk factors for adverse maternal and fetal outcomes
in systemic autoimmune diseases.
• describe key elements of preclinical risk assessment and
counseling for women who desire a future pregnancy
• discuss the impact of active maternal autoimmune disease
upon pregnancy outcomes
• discuss the risk-to-benefit analysis of common anti rheumatic
and immunosuppressive medications during pregnancy
ACR/ARHP WORKSHOPS
7:45 – 9:45 am
161
Complementary and Alternative Therapies in
Rheumatic Disease (215)
Speaker: Donald M. Marcus, MD
• describe the differences between the regulation of dietary
supplements and conventional medications and to inform
patients about current evidence concerning their efficacy and
safety
• inform patients about the efficacy of acupuncture and
chiropractic manipulation for relief of musculoskeletal pain
and osteoarthritis
• r eview established data from the medical literature in order
to improve clinical practice related to the treatment of
systemic lupus erythematosus including:
2014 Program Book
71
scientific sessions
154
Osteoporosis: Interpreting Dual Energy X-Ray
Absorptiometry and Clinical Risk Factors: The New
Fracture Risk Assessment Algorithm (216)
Speaker: Stuart L. Silverman, MD
• use bone mineral density and clinical risk factors in
determination of absolute risk of fracture
• discuss the concept of intervention threshold
• address limitations of the Fracture Risk Assessment Algorithm
in clinical practice
152
The Rheumatologic Musculoskeletal Screening
Exam, with Emphasis on Objective Disease-Specific
Measurements (217)
Speaker: Arthur M. Mandelin II, MD, PhD
Facilitators: Barbara A. Slusher, PA-C, MSW and Kori A. Dewing,
DNP, ARNP
n o v e m b e r
1 7 ,
MONDAY
2 0 1 4
• define the importance of using disease activity measurement
tools in daily practice, the barriers which hinder routine
widespread use and how these barriers can be overcome in
nearly any practice setting
• learn and practice several of the most common and wellrecognized disease activity measurement tools used in
rheumatology care, including the Disease Activity Score for 28
Joints (DAS-28) and Clinical Disease Activity Index (CDAI) for
rheumatoid arthritis; the Psoriatic Arthritis Response Criteria
(PsARC) for psoriatic arthritis; measurements of spine and hip
flexibility as well as the Ankylosing Spondylitis Disease Activity
Score (AS-DAS) for spondyloarthropathies; and the modified
Rodnan skin score for systemic sclerosis
ACR SESSIONS
8:30 – 10:00 am
52 A
PM
PS
CARE: Maintenance of Certification Session Two of
Three – Seronegative Spondyloarthropathies and
Infectious Diseases
program. Ten (10) seronegative spondyloarthropathies and
infectious diseases questions will be covered at this session.
Attendance at the session(s) is not required to participate in the
online module.
Speaker: Atul A. Deodhar, MD, MRCP
knowledge
72
2014 Program Book
• r eview the diagnosis, management and treatment of
Exhibit Hall C
Hot Topics in Rheumatoid Arthritis: Comparative
Effectiveness and Harms of Biologics and
PS
PM
Management of Disease-Modifying Antirheumatic
Drugs (DMARDs) and Biologics in the Perioperative
FIT
PrM
Pd
PS
PM
Ed Period
Moderators: Jasvinder A. Singh, MD, MPH and James R. O’Dell,
MD
• review the findings of comparative effectiveness of
biologics and oral small molecules from registries and direct
comparator trials for treatment
• discuss the comparative harms of biologics and oral small
molecules from registries and direct comparator trials for
treatment with biologics
• summarize how to manage biologics and traditional diseasemodifying antirheumatic drugs in the perioperative period
8:30 am
Comparative Efficacy and Effectiveness of Biologics: Head-toHead Trials vs. Registry Studies
Arthur Kavanaugh, MD
9:00 am
Comparative Harms of Biologics: How to Best Learn from the
Data?
William G. Dixon, MRCP, PhD
9:30 am
Perioperative Management of Biologics and Traditional
Disease-Modifying Antirheumatic Drugs
Susan M. Goodman, MD
107 B
PM
PS
Juvenile Dermatomyositis: Clinical, Pathogenic and
FIT
PrM
Pd
PS
Ed
Therapeutic State of the Art PM
Moderators: Kelly A. Rouster-Stevens, MD, MS and Angela
Robinson, MD, MPH
• review the latest information on the pathogenesis of juvenile
dermatomyositis
• review the different clinical phenotypes of juvenile
dermatomyositis
• r eview cutting-edge developments in treatments
and outcome measures for juvenile dermatomyositis
8:30 am
Pathogenesis of Juvenile Dermatomyositis
Ann M. Reed, MD
scientific sessions
9:00 am
The Clinical and Autoantibody Phenotypes of Juvenile Myositis
Lisa G. Rider, MD
9:30 am
Outcome Assessment and Advances in Therapies
Adam M. Huber, MD, MSc
PS
PM
204 A
Practical Use of Registries
Moderator: Melissa Francisco
• describe the importance of data collection and synthesis in
evidence-based care
• evaluate the importance of their role as a participant in the
Rheumatology Informatics System for Effectiveness registry
• develop strategies for participating in the registry and
accessing collective data as a part of improving patient care
8:30 pm
Rheumatology Informatics System for Effectiveness and Its
Applications
Salahuddin Kazi, MD
Practice Issues: Practice Success in an Environment of
Transition
Moderator: Suzanne Moore, MD
• review the next steps for Physician Quality Reporting System
(PQRS), Electronic Prescribing (eRx) and Electronic Health
Record (EHR) Incentive Programs
• discover how to avoid penalties
• r eview ways to avoid Health Insurance Portability and
Accountability Act (HIPAA) violations
Moderators: Flavia V. Castelino, MD and Darcy S. Majka, MD
• identify the necessary measures for a productive menteementor relationship
• develop time management and organizational skills for
academic success
• develop a strategy to transition from a mentored relationship
to independence
8:30 am
Your Role as a Mentee
8:50 am
Effective Time Management
Leena Sharma, MD
9:20 am
Transitioning to Independence
Liana Fraenkel, MD, MPH
9:40 am
Panel Discussion
PM
PS
253 B
Systems Biology of Lupus Nephritis
Moderators: Shu Man Fu, MD, PhD and Vasileios C. Kyttaris, MD
• review how a systems analysis of mouse and human renal
gene expression analysis can lead to the identification of
major pathogenic cell populations and pathways
• evaluate how a single cell characterization of local renal
immune responses can lead to identification of disease
amplification mechanisms
• describe how to identify and test novel disease biomarkers
2 0 1 4
PS
Strategies for Academic Success: The Roadmap From
FIT
PrM
Pd
PS
PM
Ed
Mentee to Mentor
1 7 ,
109 A
PM
PS
MONDAY
9:00 am
RISE Demonstration
Tim Parr
PM
n o v e m b e r
8:45 pm
The Value of Participating Registries
156 B
8:30 am
Stage Specific Systems Analysis of Lupus Nephritis: From Mice
to Men
Anne Davidson, MBBS
8:30 am
Physician Quality Reporting System (PQRS) – Reporting Made
Easy
Robert Warren, MD, PhD, MPH
9:00 am
Systems Analysis of the Immunoglobulin Gene Repertoire in
Nephritic Kidneys Suggests Local Antigenic Drive
Marcus R. Clark, MD
9:00 am
Health Insurance Portability and Accountability Act (HIPAA) – A
Guide to Compliance
MCS-P
9:30 am
Proteomic Analysis of Lupus Urines Leads to the Identification
of Potential Renal Biomarkers
Chandra Mohan, MD, PhD
9:30 am
The Fundamentals of Value-Based Modifier
MCS-P
2014 Program Book
73
scientific sessions
PM
Ballroom West
PS
The ACR Gout Management Guidelines: Have They
PS
PS
PM
PM
Gotten Us to Where We Want to Be?
Moderators: Dinesh Khanna, MD and N. Lawrence Edwards, MD
• describe the development and content of the recent ACR Gout
Guidelines
• examine the components of the guidelines that have
generated concern and controversy
• examine the historic success of guideline implementation and
which factors influence this success
8:30 am
An Overview of the 2012 ACR Gout Management Guidelines
John D. FitzGerald, MD, PhD
9:00 am
Strengths, Weakness and Controversies of the Gout Guidelines
Kenneth G. Saag, MD, MSc
n o v e m b e r
1 7 ,
MONDAY
2 0 1 4
9:30 am
The Trouble With Guidelines Implementation and What We
Can Do About It
Robert T. Keenan, MD, MPH
ACR/ARHP POSTER SESSION B, THIEVES’
MARKET POSTERS AND POSTER TOURS
8:30 am – 4:00 pm
(abstracts # 982 – 1793). Poster tours will be held 9:00 – 9:45
am and 10:15 – 11:00 am. Morning snacks will be available from
9:00 – 10:30 am.
PM
PS
Thieves’ Market Posters
TM 1. Friday Evening Consult...Vasculitis?
Manpreet Sethi, MBBS
TM 2. Numbness Matters
Nandita Gatla, MD
TM 3. Scary Salmonella
Yathish GC, MBBS, MD
TM 4. When Oral and Genital Ulcers Are Not Behçet’s...
Kim M. Wu, MD
TM 5. 47-Year-Old Woman With Fever and Anasarca
Kensuke Nakanishi, MD
TM 6. A Case of An Orbital Mass
Namrata Singh, MBBS
TM 7. Arthritis Mutilans in a Teenage Girl from Panama
Vidya Raman, MD
Guided Poster Tours
is required and is limited to scientific attendees. If you preregistered for a tour, you should have received a ticket with
your meeting materials. Once you have your ticket, check in
at the tour desk 15 minutes prior to the start of your tour to
9:00 – 9:45 am
Epidemiology and Health Services Research Poster Tour (313)
Tour Guide: Cheryl Barnabe, MD, MSc
Clinical Pain Syndromes Poster Tour (314)
Tour Guide: Daniel J. Claw, MD
Imaging of Rheumatic Diseases Poster Tour (315)
Tour Guide: Wolfgang A. Schmidt, MD
Pediatric Rheumatology: Clinical Aspects Poster Tour (316)
Tour Guide: Bryce A. Binstadt, MD, PhD
Tour Guide: Merete Lund Hetland, DMSc, MD, PhD
Pathogenesis, Animal Models and Genetics Poster Tour (318)
Tour Guide: Robert Lafyatis, MD
10:15 – 11:00 am
Pediatric Rheumatology: Clinical Aspects Poster Tour (319)
Tour Guide: Lisa F. Imundo, MD
Tour Guide: Vivian P. Bykerk, MD
Tour Guide: Grant H. Louie, MD, MHS
Spondyloarthropathies and Psoriatic Arthritis: Clinical Aspects
and Treatment Poster Tour (322)
Tour Guide: Robert D. Inman, MD
(323)
Tour Guide: Eliza Chakravarty, MD
Vasculitis Poster Tour (324)
Tour Guide: Kenneth J. Warrington, MD
74
2014 Program Book
scientific sessions
ACR SESSIONS
PS
153 B
Social Media Boot Camp: Blogging for Beginners
9:00 – 10:00 am
Moderator: Ronan Kavanagh, MD, MRCP
PM
104 B
• describe a blog and its relevance in professional social
engagement
• identify the challenges and opportunities of communicating
through blogs in a public environment
• evaluate appropriate content for blogging
• define self-hosting vs. writing for an established platform
• create a basic blog in WordPress
• produce strategies for basic blog promotion and building
readership
PS
Functional Genomics of Rheumatoid Arthritis: From
Genes to Function to Therapy
Moderator: Lindsey A. Criswell, MD, MPH
Speaker: Ranjeny Thomas, MBBS, MD
• review the molecular mechanisms whereby HLA-DRB1
contributes to the pathogenesis of rheumatoid arthritis
• appraise subtle differences in the structure of HLA-DR
molecules permitting the binding of specific autoantigens
• describe the rationale for contemporary approaches to
peptide specific immunotherapy for the treatment of
PS
9:00 am
Introduction
Ronan Kavanagh, MD, MRCP
PM
9:05 am
Why Blog: An Overview
Philip Gardiner, MD
102 A
Legislative Update: Chat with Congress
Moderator: David Goddard, MD
9:30 am
How to Blog
Paul Sufka, MD
PS
Prosthetic Device Infections, or Infection as a Threat
to the Bionic Man PM PS
Speaker: James E. Peacock Jr., MD
• define the utilization of prosthetic devices in musculoskeletal
diseases and the risk of infection associated with those
devices
• describe the pathogenesis of prosthetic device infection,
including the bacterial elaboration of extracellular glycocalyx
(biofilm) and how it impacts the choice and duration of
antibiotic therapy
• discuss the management strategies for infected joint
prostheses, including the impact of immunosuppressive
medications on the development and outcome of treatment
9:00 – 10:00 am
254 A
PM
2 0 1 4
PM
ARHP SESSION
1 7 ,
9:30 am
Legislative Update
William F. Harvey, MD, MSc
9:55 am
Question and Answer
MONDAY
9:00 am
Congressional Update
Speaker to be Determined
n o v e m b e r
• describe the latest developments in federal health policy
• discuss legislative initiatives currently before Congress
• appraise how legislative outcomes could affect the
rheumatology community
Ballroom East
PM
PS
ARHP Distinguished Lecturer: Maintaining Health and
Well-Being Despite Living with a Rheumatic Disease
Speaker: Monique A. Gignac, PhD
• describe factors beyond health symptoms and treatment that
are important in understanding the behaviors and perceptions
of patients with rheumatic diseases in living with and
managing their disease
• help patients find ways to maintain social participation in
diverse roles and activities in terms of physical health and
well-being
• develop strategies in combination with patients to promote
the maintenance of social participation and further promote
health and well-being
2014 Program Book
75
scientific sessions
EXHIBITS
159
10:00 am – 5:00 pm
*Musculoskeletal Ultrasound (220)
Speakers: Eugene Y. Kissin, MD and Amy M. Evangelisto, MD
Exhibit Hall A
Join your colleagues in the Exhibit Hall for morning and
afternoon refreshments from 10:00 – 11:00 am and 2:00 – 3:00
pm.
• demonstrate how to properly position the ultrasound
transducer to visualize targeted musculoskeletal structures
based on an understanding of the local bony landmarks
• differentiate tissue types on their ultrasound properties
• recognize the ultrasound appearance of some of the basic
musculoskeletal pathologies
(Booths #139 and #1401)
presentations will be held from 10:30 – 11:15 am, 12:30 – 1:15
pm and 2:30 – 3:15 pm. Innovation Theater B presentations
will be held from 11:30 am – 12:15 pm, 1:30 – 2:15 pm and
3:30 – 4:15 pm. For a complete listing of Innovation Theater
presentations, see
PS 238.
PM page
161
Renal Histopathology in Systemic Lupus
Erythematosus and Vasculitis (221)
Speaker: Anthony Chang, MD
• identify the pathologic changes that occur in lupus nephritis
• discuss the pathologic basis for the classification of lupus
nephritis and how it relates to clinical management
• describe the histological changes in the kidneys of patients
with vasculitis
ACR WORKSHOPS
10:30 am – 12:30 pm
n o v e m b e r
1 7 ,
MONDAY
2 0 1 4
154
Histopathology of Vasculitis (218)
Speakers: Allen Burke, MD and Fabio Tavora, MD, PhD
• describe histological features of normal blood vessels
• distinguish pathologic reactions to vascular injury
• identify histological features of major vasculitis syndromes
152
*Knee Braces, Foot Orthoses and Shoe Gear for
Managing Knee Osteoarthritis (219)
Speakers: Howard J. Hillstrom, PhD and Kelly D. Krohn, MD
• review the biomechanical rationale for the use of knee braces
and foot orthoses for knee osteoarthritis
• discuss the clinical data to support these modalities
• apply these modalities to their patients
ACR SESSIONS
11:00 am – Noon
PM
52 A
ACR Immunology Update: Innate Lymphoid Cells
Moderator: Leonard H. Sigal, MD
Speaker: Hergen Spits, MD, PhD
• provide an overview of human innate lymphoid cells subsets
• discuss development and plasticity of innate lymphoid cells
subsets
• discuss the possible roles of innate lymphoid cells in human
diseases
PS
PM
Ballroom West
ACR Knowledge Bowl: Final Round
Moderator: Rebecca L. Manno, MD, MHS
• identify key images that are important to recognize in clinical
practice
• describe factual information related to various rheumatic
diseases
• identify historical facts relevant to the field of rheumatology
Competing Teams:
Portlandumabs – Defending 2013 ACR Knowledge Bowl
Champions
Cailin H. Sibley, MD; Navid Mehraban, MD and Daniela Ghetie,
MD
Winners from the 2014 ACR Knowledge Bowl: Preliminary
Round
View the full list of competing 2014 Knowledge Bowl Teams on
page 41.
76
2014 Program Book
PS
scientific sessions
ARHP SESSIONS
ACR PLENARY SESSION II – DISCOVERY 2014
11:00 am – Noon
11:00 am – 12:30 pm
PM
259 A
PS
Evidence of the Benefits and Risks of Cannabis and
Cannabinoids for Treating Chronic Pain
Moderator: Kenneth N. Schikler, MD
Speaker: Daniel J. Clauw, MD
• summarize the research-based evidence for the benefits to
medicinal marijuana and cannabinoids for treating chronic
pain
• review the research-based evidence for the risks to medicinal
marijuana and cannabinoids
• enhance patient and provider education by using
contemporary scientific knowledge to clarify the appropriate
position of this class of drugs in the overall treatment
algorithms for chronic pain
PM
257 A
PS
Immunology Boot Camp II: The Basics of
Autoimmunity and Immunodeficiency
Moderator: Benjamin J Smith, PA-C
Moderator: Michael P. LaValley, PhD
• identify the ubiquity of ordinal data and contrast it with
continuous data
• review contingency table analysis of ordinal data
• describe common statistical models for ordinal outcome data
• interpret and report results generated by ordinal data
methods
11:00 am
Ordinal Data: Overview and Contingency Table Analysis
Todd A. Schwartz, DrPH
11:30 am
Statistical Modeling of Ordinal Data
Rebecca J. Cleveland, PhD
Background/Purpose: Cytosolic DNA sensors detect viral and
bacterial DNA, inducing inflammatory cytokines and type I IFNs
via the adaptor stimulator of interferon genes (STING) to clear
infection. The STING pathway also responds to endogenous DNA
from dying cells and contributes to autoimmune disease. We
have identified a potentially important role for cytosolic DNA
sensor pathways in bone by studying a mouse that develops
inflammatory polyarthritis and articular erosions in the setting
of DNA accrual. In this model, DNA accumulates in macrophages
due to deletion of the lysosomal endonuclease DNaseII and is
detected by cytosolic sensors that signal through STING. Type
I IFNs in DNaseII-/- mice lead to anemia-related embryonic
lethality; thus co-deletion of the type I IFN receptor is required
(DNaseII/IFN-IR double deficient, (DKO) mouse). We investigated
the impact of DNA and of the STING pathway in bone in this
model of autoimmune disease.
Methods: STING-/- mice were intercrossed with DKO mice to
generate STING/DNaseII/IFN-IR triple knock out (TKO) mice.
uCT was performed on TKO, DKO and control femurs from 6-16
month-old mice. Mesenchymal colony forming unit (CFU) assays
were used to determine the number of osteoblast precursor
cells in bone. uCT was performed on femurs from 6 month-old
STING-/- and littermate controls. Finally, RNA from wild type
(WT) osteoblasts was analyzed for the expression of cytosolic
DNA sensors. To determine the potential for osteoblasts to
respond directly to DNA, MC3T3 osteoblast-lineage cells were
transfected with poly(dA:dT) and RNA was analyzed by qPCR.
2 0 1 4
Stats Boot Camp: Statistical Analysis of Ordinal Data
11:00 am
1794. The Sting Pathway Regulates Bone Remodeling in a
Model of Autoimmune Disease
Rebecca Baum, University of Massachusetts Medical School,
Worcester, MA
1 7 ,
PS
Moderators: Eric L. Matteson, MD, MPH and Mary E. Cronin, MD
MONDAY
PM
254 A
ACR Plenary Session II: Discovery 2014
n o v e m b e r
• describe mechanisms of tolerance
• review the cellular changes responsible for autoimmunity
• describe the relevance of genetic predisposition for rheumatic
diseases
• recognize when the immune system fails to recognize threats
and mount an appropriate response
Exhibit Hall C
Results: Inflammatory cytokines in the DKO model would
be expected to induce bone loss in the axial skeleton, as
well as articular erosions. Paradoxically, we found that bone
accumulates in long bones, with significant replacement of the
marrow cavity by 16 months. CFU assays demonstrate increased
osteoblast precursor numbers and osteoid is also significantly
increased in DKO compared to controls (13,881 vs. 424 µm2,
p=0.02). Surprisingly, ectopic bone forms in DKO spleens, a site
of DNA accrual in macrophages. We thus sought to define the
contribution of cytosolic DNA sensor pathways to bone accrual.
STING deficiency almost completely abrogates both arthritis and
bone accrual in the spleen and long bones of DKO mice (BV/TV:
Het = 0.44%, DKO = 11.47%, TKO = 1.99%, p<0.02 compared to
DKO). STING also contributes to bone homeostasis, independent
of DNaseII deficiency, as revealed by uCT performed on femurs
from STING-/- and littermate controls (BV/TV: STING-/- = 1.39%,
WT = 0.62%, p=0.011). Furthermore, cytosolic DNA sensors are
2014 Program Book
77
scientific sessions
expressed in osteoblasts and expression of several sensors is
increased in osteoblasts upon transfection with a DNA ligand.
Conclusion: The STING pathway plays a role in bone remodeling
in situations of DNA accrual as well as in bone homeostasis.
Cytosolic DNA sensors are expressed in differentiating
osteoblasts and expression is upregulated by DNA. These
findings have relevance to SLE and other autoimmune diseases
in which DNA plays a pathogenic role. Discovery of new
pathways linking bone and the immune system may identify
new targets for the treatment of bone loss in inflammatory
autoimmune diseases.
Disclosures: R. Baum, None.
n o v e m b e r
1 7 ,
MONDAY
2 0 1 4
11:15 am
1795. Denosumab Restores Cortical Bone Loss at the Distal
Radius Associated with Aging and Reduces Wrist Fracture Risk:
Analyses from the Cross-Over Group in the Extension of the
Denosumab Pivotal Fracture Trial
JP Bilezikian, College of Physicians and Surgeons, Columbia
University, New York, NY and JP Brown, CHU de Québec
Research Centre and Laval University, Quebec City, QC
Background/Purpose: Cortical bone loss is a major determinant
of increased fracture risk. Denosumab (DMAb) has been shown
to increase BMD at sites of cortical bone, including the radius,
a skeletal site not responsive to most osteoporosis treatments.
Here, we evaluated changes over time in radius BMD and wrist
fracture incidence during 3 years of placebo (Pbo) and up
to 5 subsequent years of DMAb therapy in FREEDOM and its
Extension (EXT).
Methods: We evaluated 2207 women who received Pbo during
FREEDOM (3 years) and enrolled in the EXT to receive DMAb 60
mg Q6M (cross-over group); all women received daily calcium
and vitamin D. A subset of these women (n=115) participated in
a distal radius DXA substudy and were evaluated at baseline and
during FREEDOM and EXT. Analysis of mean percentage changes
in BMD over time from FREEDOM and EXT baselines consisted
of a repeated measure model. Wrist fracture rates (per 100
subject-years), rate ratios and 95% CI were computed.
Results: At FREEDOM baseline, the mean (SD) 1/3 radius T-score
was –2.53 (1.18). During FREEDOM, daily calcium and vitamin
D alone was associated with a progressive and significant loss
of BMD at the 1/3 radius (–1.2%); however, during EXT, DMAb
halted and reversed bone loss (Figure). With 5 years of DMAb
treatment, a significant gain in BMD (1.5% at EXT Year 5) was
observed, compared with EXT baseline. The wrist fracture rate
during the Pbo period in FREEDOM was 1.02 (0.80–1.29) per
100 subject-years. During the first 3 years of EXT, BMD recovered
to the original baseline levels in response to DMAb and the
wrist fracture rate remained comparable to the FREEDOM Pbo
rate (Table); with 2 additional years of DMAb treatment, BMD
increased further and the wrist fracture rate declined to levels
significantly lower than the FREEDOM Pbo rate (rate ratio=0.57,
95% CI=0.34–0.95; p=0.03).
78
2014 Program Book
Conclusion: In untreated women with postmenopausal
osteoporosis, cortical bone density at the radius declined
significantly. DMAb treatment for 3 years fully reversed this
bone loss and 2 additional years of treatment resulted in further
BMD gains that translated to significantly lower wrist fracture
rates, highlighting the clinical importance of reversing cortical
bone loss.
Disclosures: J. Bilezikian, NIH, Amgen Inc., NPS, 2, Columbia
University, 3, Merck, Amgen Inc., NPS, Lilly, Johnson&Johnson,
5, Elsevier Press, 7; J. Brown, Actavis, Amgen Inc., Eli Lilly, Merck,
Novartis, 2, Amgen Inc., Eli Lilly, 5, Amgen Inc., Eli Lilly, 8.
11:30 am
1796. Autotaxin Is Highly Expressed in Systemic Sclerosis (SSc)
Skin, Mediates Dermal Fibrosis Via IL-6 and Is a Target for SSc
Therapy
Flavia V. Castelino, Massachusetts General Hospital, Boston, MA
Background/Purpose: Autotaxin (ATX) is an enzyme present
in biological fluids that is responsible for the production of
the lipid mediator, lysophosphatidic acid (LPA). We previously
implicated LPA and its receptor, LPA1 in SSc pathogenesis.1
Here we studied the role of ATX in SSc dermal fibrosis using
the bleomycin (BLM) mouse model and skin biopsy samples
from SSc patients and healthy controls. We evaluated the role
of IL-6, a cytokine implicated in SSc, in mediating ATX-induced
fibrosis. Additionally, we investigated the therapeutic potential
of targeting ATX, by using a novel ATX inhibitor, PAT-048 in this
model.
Methods: BLM or saline (PBS) was administered subcutaneously
to C57Bl/6 mice daily for 3, 7, 14 and 28 days. 6mm dermal
punch biopsies were obtained and ATX levels were measured
by qPCR and ELISA. ATX inhibition with PAT-048 (20mg/kg
oral gavage daily) was assessed in the model. PAT-048 was
administered concurrently with BLM or PBS for 28 days, or
initiated at 7 or 14 days after BLM. Dermal thickness was
measured using H&E-stained sections. Collagen was visualized
by Masson’s trichrome stain and quantified by hydroxyproline
measurement. Skin IL-6 expression was evaluated by
immunohistochemistry (IHC). The effect of LPA-induced ATX
expression was tested on human dermal fibroblasts transfected
with IL-6 siRNA. Additionally, healthy and SSc dermal fibroblasts
were stimulated with LPA and IL-6 in vitro and IL-6 and ATX
induction were evaluated by ELISA, respectively. Skin ATX
expression was measured in SSc patients and healthy controls by
qPCR and IL-6 expression by IHC.
Results: ATX expression at both the mRNA and protein level
was increased at Day 3 after BLM injection (3-fold increase,
p=0.05) suggesting a role for ATX early in fibrosis. Treatment
with PAT-048 attenuated BLM-induced dermal fibrosis in all
treatment groups (50% reduction, Day 28, p=0.01) and reduced
IL-6 expression in the dermis. In vitro studies of human dermal
fibroblasts showed that LPA-induced ATX expression was
scientific sessions
attenuated with siRNA knock-down of IL-6 (65% reduction,
p<0.05). SSc fibroblasts demonstrated increased LPA-induced
IL-6 expression and increased IL-6-induced ATX expression,
compared to healthy fibroblasts. Furthermore, ATX expression
was increased in SSc skin (n=7) compared to healthy controls
(n=5; 3-fold increase, p=0.006) and IL-6 expression by IHC was
increased in SSc skin compared to healthy controls (n=3 per
group).
2 0 1 4
11:45 am
1797. One-Year Survival of Adults with Systemic Sclerosis
Following Lung Transplantation: A Nationwide Cohort Study
Elana J. Bernstein, Columbia University College of Physicians &
Surgeons, New York, NY
1 7 ,
Disclosures: F. V. Castelino, None.
Results: A total of 3763 adults were transplanted during the
study period and met inclusion criteria: 229 with SSc, 201
with PAH and 3333 with ILD (Table 1). The 1-year unadjusted
mortality rate following LTx per 100 person-years was 21.4
among adults with SSc, 19.0 among adults with PAH and 17.8
among adults with ILD. A diagnosis of SSc was associated with
a multivariable-adjusted 48% relative increase in the 1-year
mortality rate compared to a diagnosis of ILD (HR 1.48, 95% CI
1.01-2.17). However, a diagnosis of SSc was not associated with
a relative increase in the 1-year mortality rate compared to a
diagnosis of PAH (HR 0.85, 95% CI 0.50-1.44).
MONDAY
Reference: Castelino FV et al. Amelioration of dermal fibrosis
by genetic deletion or pharmacologic antagonism of LPA1 in a
mouse model of scleroderma. Arth Rheum, 2011; 63(5):1405-15.
Methods: We performed a retrospective cohort study of
adults who underwent double or single LTx in the United
States between May 4, 2005 (the date of implementation of
the lung allocation score) and September 14, 2012. Data were
provided by the United Network for Organ Sharing, a non-profit
organization that records data on all solid organ transplants
performed in the US. Subjects were included if they were at
least 18 years of age at the time of LTx; had a diagnosis of
SSc, ILD, or PAH; and were transplanted at a center that has
performed at least 1 LTx for SSc. Subjects were excluded if they
had received a heart-lung transplant; if they received a LTx from
a living donor; or if they had missing data on survival time. We
modeled diagnosis (SSc) as the independent binary variable of
interest in stratified Cox regression models where survival time
was the dependent variable, adjusting for recipient, donor and
procedural factors (Table 1). We used multiple imputation to
account for missing covariate data.
n o v e m b e r
Conclusion: We demonstrate that ATX has an important
role in SSc fibrosis. Pharmacologic inhibition of ATX with a
novel inhibitor, PAT-048, attenuated dermal fibrosis and IL-6
expression. Knock-down of IL-6 in fibroblasts in vitro abrogated
LPA-induced ATX expression, suggesting an autocrine loop for
ATX/LPA/IL-6 signaling. Both ATX and IL-6 are increased in SSc
skin compared to healthy controls and LPA-induced IL-6 and IL-6induced ATX expression are increased in SSc fibroblasts, further
supporting an ATX/LPA/IL-6 autocrine loop in SSc. Targeting
ATX may thus be an effective new therapeutic strategy for SSc
fibrosis.
Background/Purpose: Lung transplantation is a potentially
life-saving treatment for patients with systemic sclerosis (SSc)
who have developed end-stage lung disease due to interstitial
lung disease and/or pulmonary hypertension. However, many
transplant programs are hesitant to offer lung transplantation
(LTx) to those with SSc due to concerns about extra-pulmonary
involvement that might affect short- and long-term survival.
However, survival data for lung transplantation in SSc are sparse.
The primary aim of this study was to determine whether adults
with SSc have higher 1-year mortality rates after LTx compared
to those with interstitial lung disease (ILD) or pulmonary arterial
hypertension (PAH) not due to SSc. We hypothesized that adults
with SSc would have higher 1-year mortality rates after LTx than
those with ILD or PAH not due to SSc.
Conclusion: Adults with SSc had a 48% increased risk of death at
1 year following LTx compared to adults with ILD, but no increase
in risk of death at 1 year compared to adults with PAH. Rather
than denying SSc patients LTx because of their SSc diagnosis,
variables need to be identified that will enable risk stratification
of these patients prior to LTx, with particular attention to
modifiable risk factors.
2014 Program Book
79
scientific sessions
Table 1: Recipient Characteristics and Covariates
Recipient Characteristics
SSc
N = 229
PH
N = 201
ILD
N = 3333
Age, years
53 (44-59)
46 (34-57)
62 (56-66)
Female sex
135 (58.95%)
126 (62.69%)
941 (28.23%)
White
162 (70.74%)
161 (80.10%)
2782 (83.47%)
Black
38 (16.59%)
17 (8.46%)
199 (5.97%)
Hispanic
25 (10.92%)
17 (8.46%)
261 (7.83%)
Asian
3 (1.313%)
5 (2.49%)
67 (2.01%)
Other
1 (0.44%)
1 (0.50%)
24 (0.72%)
Race/Ethnicity
LAS score
44.31 (38.03-52.48) 36.90 (33.93-46.00) 45.36 (39.42-58.10)
Height, cm
168.97 (10.29)
169.59 (9.62)
Body mass index (kg/m2)
25.10 (4.21)
24.93 (4.36)
27.16 (3.99)
Steroid use
117 (52.00%)
N = 225
45 (23.20%)
N = 194
1741 (53.75%)
N = 3239
Pulmonary artery systolic 48 (37-66)
pressure, mmHg
N = 223
83 (68-98)
N = 194
39 (32-48)
N = 3206
Forced vital capacity,
%predicted
44 (34-60)
N = 225
73 (60-87)
N = 197
45 (36-57.5)
N = 3300
Creatinine, mg/dL
0.8 (0.7-1.0)
1.0 (0.8-1.2)
0.9 (0.7-1.0)
N = 3322
5 (2.49%)
50 (1.50%)
Extracorporeal membrane 11 (4.80%)
oxygenation
172.28 (9.56)
Mechanical ventilation
23 (10.04%)
6 (2.99%)
232 (6.96%)
Oxygen requirement, L/
min
5 (3-6)
N = 228
4 (2-6)
N = 200
4 (3-6)
N = 3310
n o v e m b e r
1 7 ,
MONDAY
2 0 1 4
Covariates adjusted for in Cox regression models
Recipient factors
Age; Sex; Race/Ethnicity; LAS score; Height; BMI; Steroid
use; Pulmonary artery systolic pressure; Forced vital
capacity; Creatinine; Extracorporeal membrane oxygenation;
Mechanical ventilation
Donor factors
Age; Sex; Height; Body mass index; PaO2 on FiO2 of 1.0;
Pulmonary infection; ≥ 20 Pack-years smoking; Heavy alcohol
use; Cause of death
Procedural factors
Ischemic time; Single vs. bilateral transplant; Transplant
center; Distance from donor hospital to transplant center;
Recipient-donor sex mismatch; CMV mismatch (D+/R-); ≤ 3
HLA mismatches
* Data presented as mean (SD), median (IQR) and frequency (percentage)
** LAS = lung allocation score; PaO2 = arterial oxygen tension; FiO2 = fraction of inspired
oxygen;
CMV = cytomegalovirus; D+ = donor positive; R- = recipient negative; HLA = human
leukocyte antigen
Disclosures: E. J. Bernstein, None.
Noon
1798. Interaction Between Innate Immunity and Anti-Ro52
Antibodies is Critical for the Induction of Sjögren’s Syndromelike Disease in Mice
Paulina Kaplonek and Umesh Deshmukh, Oklahoma Medical
Research Foundation, Oklahoma City, OK
Background/Purpose: Autoantibodies reactive with Ro52 are
present in almost 70% of Sjögren’s syndrome (SS) patients. This
study was undertaken to investigate the role of Ro52 induced
immune responses in the pathogenesis of SS in an experimental
mouse model system.
Methods: New Zealand Mixed (NZM) 2758 mice were
immunized with mouse Ro52, adsorbed on to alum adjuvant.
Control mice were injected either with Maltose binding
protein (MBP) or only with alum. Mice were monitored for
anti-Ro52 antibody production, sialoadenitis, serum cytokine
levels and pilocarpine induced salivation. Antibody binding
to salivary gland cells was analyzed in vivo and in vitro by
immunofluorescence. Sera from immunized mice were passively
transferred into untreated or alum injected NZM2758 mice.
80
2014 Program Book
Internalization of antibodies by live cells was investigated by
using the salivary gland cell line SCA9-15. Clinical data from the
Oklahoma pSS patient cohort that met the AECG classification
criteria for SS was analyzed for anti-Ro reactivity, minor labial
salivary gland biopsy focus scores and xerostomia.
Results: By day 30 post-immunization, Ro52 immunized mice
generated immunoprecipitating anti-Ro52 antibodies and they
had the maximum drop in saliva production. The glandular
dysfunction in these mice was significantly associated with the
level of anti-Ro52 antibody. Both Ro52 immunized and control
mice showed evidence for very mild sialoadenitis. However, only
Ro52 immunized mice had antibody deposition in their salivary
glands. Passive transfer of Ro52 immune sera induced salivary
gland dysfunction in the recipient mice, only if the recipients
were pre primed with alum. The levels of IL-1α and CXCL1 were
significantly upregulated in alum injected mice, indicative of
the inflammasome pathway activation. In vitro, antibodies
from Ro52 immune sera were internalized by SCA9-15 cells
and the antibodies recognized cytoplasmic Ro52. The antibody
internalization was inhibited by Cytochalasin D treatment,
indicating it to be an active uptake process. Amongst the 298
pSS patients in Oklahoma cohort, 28 patients (9.3%) were antiRo positive and had a focus score of 0; and 37 anti-Ro positive
patients (12%) had a focus score of >0 but <1. Several of these
patients have dry mouth and dry eyes
Conclusion: Our data show for the first time that antibodies
induced by Ro52 are capable of inducing salivary gland
dysfunction and this phenomenon is dependent on the
activation of innate immunity. The mouse model presented in
this study mimics a subset (22%) of pSS patients in our cohort,
who are biopsy negative (or have low focus scores) and are antiRo antibody positive. In this group of patients, in the absence
of sialoadenitis, it is possible that salivary gland dysfunction is
caused by autoantibodies. Our data also suggests that antibody
deposition within the salivary glands might be an important step
for the induction of glandular dysfunction. Overall this study
suggests that down modulation of autoantibody responses
should constitute a major therapeutic strategy for the treatment
of SS.
Disclosures: P. Kaplonek, None; U. Deshmukh, None.
12:15 pm
1799. Elevated Indoleamine-2,3-Dioxygenase (IDO) Activity and
Kynurinene-3-Monooxygenase (KMO) Expression in Interferon
Positive Primary Sjogrens Syndrome Patients Is Associated with
Increased CD25hiFoxP3+ regulatory Tcells: A Skew Towards
Neurotoxicity or an Attempt to Rescue?
Naomi I Maria, Erasmus Medical Center, Immunology,
Rotterdam, Netherlands
Background/Purpose: A role for indoleamine-2,3-dioxygenase
(IDO) in suppression of effector T-cell function and promotion of
regulatory T-cell (Treg) differentiation has been described. IDO
– the rate-limiting enzyme in tryptophan (TRP) catabolism – is
driven in part by type I and type II IFNs. Systemic overactivation
of IFN-signaling is evident in Primary Sjögrens syndrome
(pSS) and could shift the delicate regulatory balance towards
a more auto-reactive state in these patients. Interestingly
scientific sessions
aberrant systemic TRP catabolism, resulting in a shift from
neuroprotective towards neurotoxic downstream metabolites,
has been associated with mood disturbances as well as
neurophsychiatric consequences and possibly contributes to
symptoms of fatigue and depression in pSS. Here we investigate
the role of IDO and downstream TRP catabolism in pSS and
hypothesize an increase in Tregs, in concordance with increased
IDO-activity in IFNpositive pSS patients.
Methods: In a Cohort of 20 Healthy controls (HC), 18
IFNnegative and 21 IFNpositive pSS patients, diagnosed
according to the 2002 American-European criteria,
CD4+CD45RO+ T helper (Th) memory cell populations defined
by chemokine receptor expression: CD25hiFoxP3+ Tregs,
CCR6+CCR4+CXCR3-CCR10- Th17, CCR6+CCR4+CXCR3‑CCR10+
Th22, CCR6-CXCR3+CCR4- Th1 and CCR6-CXCR3‑CCR4+ Th2cells were analyzed by flow cytometry in peripheral blood
mononuclear cells (PBMCs). Analysis of TRP and Kynurenine
(KYN) were performed simultaneously in serum using HPLC.
CD14+ monocyte mRNA-expression of IDO1and downstream
enzymes was assessed using real-time quantitative PCR, to
investigate the direction of downstream TRP catabolism in pSS.
Noon – 2:00 pm
PM
PS
12:45 – 2:15 pm
*Adult Inflammatory Myopathy (041)
Speaker: Robert L. Wortmann, MD
• review the clinical manifestations of inflammatory myopathies
including important extra-muscle manifestations
• discuss diagnostic pearls for the evaluation of someone
suspected of having an inflammatory myopathy
• discuss the treatment paradigm for inflammatory myopathies
2 0 1 4
ARHP NETWORKING EVENT
This session is not eligible for CME credit.
1 7 ,
Disclosures: N. I. Maria, None.
Sit down with your colleagues over a complimentary lunch and
participate in open discussion on various research, practice and
clinical topics. Each roundtable discussion will be facilitated
by a rheumatology expert. All ARHP attendees are welcome to
participate in this event.
MONDAY
Conclusion: Here we find enhanced IDO activity in coherence
with increased CD25hiFoxP3+ Tregs and evidence for a shift
towards production of more neurotoxic metabolites – previously
associated with “sickness behavior” – in IFNpositive pSS. This
imbalance towards neurodegenerative effects might contribute
to increased fatigue and depressive symptoms in these patients.
However, whether this shift in Tregs reflects an immune rescuemechanism or increases “tolerance to self” remains unknown.
Intervening in these IFN and IDO-induced imbalances offers new
possibilities for therapeutic interventions.
ARHP Networking at Noon
n o v e m b e r
Results: Activity of IDO (p=0.0054) – as determined
by measuring levels of the KYN/TRP-ratio in sera – and
CD25hiFoxP3+ Tregs (p=0.039) were significantly increased
in IFNpositive pSS patients. In addition, CD25hiFoxP3+
Tregs significantly correlated with the KYN/TRP-ratio
(p=0.002;r=0.509) as well as the IFNscore (p=0.011;r=0.375).
Peripheral monocytes showed an upregulation of IDOexpression (p<0.0001) in IFNpositive pSS, also highly correlating
with the IFNscore (p<0.0001;r=0.816). Interestingly the
neuroprotective downstream enzymes KAT1 (p=0.0003), KAT3
(p=0.016) and KAT4 (p=0.04) were downregulated, whereas the
neurotoxic enzymes KMO (p=0.0057) and KYNU (p=0.0001) –
which convert KYN into the neutoxic metabolite Quinolinic acid
– were upregulated in these patients, suggesting a skew towards
neurotoxicity.
Commonwealth Ballroom
Pediatric Rheumatology for Adult Rheumatologists
(042)
Speaker: Daniel Lovell, MD, MPH
• identify how the evaluation of children with rheumatic
diseases may be different from that of adults
• identify the evaluation and treatment of arthralgia in children
• diagnose the various forms of arthritis that are unique to
children
• describe current treatment of chronic arthritis in children
Speaker: Dafna D. Gladman, MD
• discuss advances in diagnosis and classification of psoriatic
arthritis
• appraise if patients with psoriatic arthritis should be treated
aggressively
• choose treatment options for patients with psoriatic arthritis
2014 Program Book
81
scientific sessions
• describe recent trends in the use of biologics to improve
outcomes and utility
• describe strategies to reduce costs of biologics
• discuss emerging biologics, including biosimilars and their
advantage for the therapeutic algorithm
*Rheumatoid Arthritis: Challenging Cases (045)
Speaker: Stephen A. Paget, MD
therapies
Scleroderma Mimics (046)
n o v e m b e r
1 7 ,
MONDAY
2 0 1 4
Speaker: Faye N. Hant, DO, MSCR
• present an overview of scleroderma-like conditions
• review the clinical phenotypes and classification of
scleroderma
• create a differential diagnosis for conditions that may mimic
features of scleroderma
• discuss features of specific scleroderma mimics and strategies
to distinguish them
• explain potential diagnostic and initial management/
treatment of these conditions
*Still’s Disease and Autoinflammatory Syndromes
(047)
Speaker: John J. Cush, MD
• describe the clinical features of Still’s disease and other febrile
syndromes
• describe the immunogenetic mechanisms and treatment for
adult Still’s disease and related syndromes
*Systemic Lupus Erythematosus: Central Nervous
System (048)
Speaker: Cynthia Aranow, MD
• identify neuropsychiatric manifestations attributable to
• recognize the utility of diverse autoantibodies in the
diagnosis of neuropsychiatric syndromes of systemic lupus
erythematosus patients
82
2014 Program Book
• f ormulate a treatment plan in patients with neuropsychiatric
lupus
*Systemic Sclerosis: Disease Staging and Subsetting in
Clinical Practice (049)
Speaker: Robyn T. Domsic, MD, MPH
• use clinical and serologic classification systems of systemic
sclerosis to identify the natural history of clinical subsets
• explain the concept of disease staging in both diffuse and
limited cutaneous systemic sclerosis
• use knowledge of clinical/serologic classification and disease
staging to develop screening and management plans
Webster (Mezzanine)
Vasculitis Mimics (050)
Speaker: Peter A. Merkel, MD, MPH
• discuss the broad categories and specific entities that
constitute clinical mimics of vasculitis
• distinguish the subtleties of mimics of vasculitis including
common clinical situations of mimics in a patient with a
known diagnosis of vasculitis
• develop a methodology for clinically evaluating patients with
possible vasculitis with particular attention to differentiating
mimics from true vasculitis
ACR SESSIONS
1:00 – 2:00 pm
PM
PS
205 B
Classification Criteria for Gout
PM
PS
Moderators: Jasvinder A. Singh, MD, MPH and Nicola Dalbeth,
MBChB, MD
• recognize the limitations of existing classification criteria and
why new criteria are needed
• review the latest evidence related to various imaging
modalities and clinical parameters for classification of gout
• identify the key elements of the new proposed preliminary
gout classification criteria
1:00 pm
Gout Classification Criteria: Where Have We Been and Where
Do We Need to Go?
Tim L. Jansen, MD, PhD
1:10 pm
Key Clinical Considerations in Developing New Gout
Classification Criteria
William Taylor, PhD, MBChB
1:35 pm
The Proposed New Preliminary Gout Classification Criteria
Tuhina Neogi, MD, PhD
scientific sessions
PS
PM
• d
iscuss how cellular senescence impacts cell function and the
immune system
• determine how current research on families with telomere
syndromes informs biology of normal aging process and how
PS
it impacts the PM
immune system
107 B
Classification Criteria for Myositis
Moderators: Chester V. Oddis, MD and Lisa G Rider, MD
• discuss the history of and differences between criteria used in
myositis
• describe the new classification criteria for myositis
• appraise how to use the new classification criteria in clinical
settings and research
ACR WORKSHOPS
1:15 – 3:15 pm
1:00 pm
History of Classification Criteria for Idiopathic Inflammatory
Myopathies
Frederick W. Miller, MD, PhD
1:25 pm
New Classification Criteria for Idiopathic Inflammatory
Myopathies
Ingrid E. Lundberg, MD, PhD
152
1:50 pm
Panel Discussion
PM
Neonatal Lupus: From Bench to Bedside
Rheumatology on the Street
Moderator: Kristine M. Lohr, MD, MS
Speaker: Jonathan D. Graf, MD
PM
PS
Telomeres, Telomerase and the Aging Immune
System
Speaker: Jonathan Alder, PhD
2 0 1 4
• recognize typical active and structural lesions of
spondyloarthritis
• recognize complicated/subtle lesions of spondyloarthritis
• recognize lesions that may mimic spondyloarthritis
• recognize pitfalls in the interpretation of magnetic resonance
imaging in spondyloarthritis
Ballroom West
52 A
Magnetic Resonance Imaging in the Diagnosis and
Management of Spondyloarthritis: A Clinician’s Guide
(223)
Speaker: Walter P. Maksymowych, MD
PM
• summarize medical complications associated with certain
types of illicit drug use
• describe the rheumatic manifestations of cocaine use
• review an update of the clinical manifestations and
autoantibody profiles associated with levamisole toxicity
1 7 ,
159
MONDAY
Moderators: Elana J. Bernstein, MD, MSc and Rennie N. G.
Howard, MD
Speaker: Jill P. Buyon, MD
n o v e m b e r
• discuss indications and contraindications for joint aspirations
and injections
• identify and avoid common mistakes in joint injection
procedures
• practice common joint and soft tissue injections on upper and
lower extremities
Ballroom East
• identify pregnant women at risk for having babies affected
by neonatal lupus and describe the clinical manifestations of
neonatal lupus
• discuss the pathogenesis of heart block in neonatal lupus
and describe the diagnostic evaluation of heart block due to
neonatal lupus
• discuss the treatment of congenital
heart block
PS
*Joint Injection Techniques (222)
Speakers: Atul A. Deodhar, MD and Kenneth S. O’Rourke, MD
PS
161
Synovial Fluid Analysis and Crystal Identification (224)
Speakers: Brian F. Mandell, MD, PhD; Lan Chen, MD, PhD; and
Gilda M. Clayburne, MLT
• prepare synovial fluid samples for microscopic examination
• identify various components of synovial fluid
• identify crystals in synovial fluid
• describe current concepts of telomeres and telomerase
biology
2014 Program Book
83
scientific sessions
PM
ACR SESSIONS
52 A
2:30 – 4:00 pm
PM
PS
Clinical Challenges in Sjögren’s Syndrome:
Neurological Complications and Lymphoma Risk
Moderators: Shreyasee Amin, MD CM, MPH and Alan N. Baer,
MD
• describe the central and peripheral nervous system
manifestations of Sjögren’s syndrome
• recognize the different presenting manifestations of
lymphoma, including of mucosa-associated lymphoid tissue
(MALT) lymphoma, in patients with Sjögren’s syndrome
• outline the approach for evaluating patients with Sjögren’s
syndrome who have neurologic manifestations or symptoms
of lymphoma
3:30 pm
Lymphoma and Sjögren’s: What the Clinician Should Know
Elke Theander, MD, PhD
MONDAY
2 0 1 4
1 7 ,
3:00 pm
Neurological Complications of Sjögren’s Syndrome: Peripheral
Nervous System Manifestations
Julius Birnbaum, MD, MHS
n o v e m b e r
2:30 pm
Neurological Complications of Sjögren’s Syndrome: Central
Nervous System Manifestations
Julius Birnbaum, MD, MHS
PM
PS
Ballroom East
Forefronts in Lupus Nephritis
Moderator: George Stojan, MD
• recognize the pitfalls of current lupus nephritis treatment
guidelines
• discuss the emerging role of Rituxan
• challenge the dogma of the need for steroid use in lupus
nephritis
2:30 pm
Clinical Pearls and Pitfalls in Diagnosis and Management of
Lupus Nephritis
Michelle Petri, MD, MPH
2:45 pm
Guidelines for Lupus Nephritis—More Recommendations than
Data?
Derek M. Fine, MD
3:00 pm
The Parable of the Lost Sheep—The Rituximab Redemption
Liz Lightstone, MD, PhD
2014 Program Book
Insight into Lung Fibrosis
Moderators: John Varga, MD and Flavia V. Castelino, M.D.
205 B
84
PS
• review classification and biology of lung fibrosis
• recognize immune dysregulation in lung fibrosis
• review cell-based approaches to lung regeneration
2:30 pm
Insight into Lung Fibrosis
Timothy Blackwell, MD
3:00 pm
Immune Networks of Lung Fibrosis
Thomas Wynn, PhD
3:30 pm
Lung Regeneration and Cell-Based Therapies
Darrell Kotton, MD
2:30 – 4:00 pm
253 B
PM
PS
Epidemiology and Public Health II: Osteoarthritis,
Sedentary Behavior and More
Moderators: Jeffrey N. Katz, MD, MSc and Catherine Hill, MD,
MBBS
2:30 pm
1800. Objectively Measured Sedentary Behavior Is a Distinct
Risk Factor from Low Moderate-to-Vigorous Activity in
Predicting Subsequent Frailty: Evidence from Osteoarthritis
Initiative
Jing Song1, Lee A. Lindquist1, Rowland W. Chang1, Pamela A.
Semanik2, Linda S. Ehrlich-Jones3, Jungwha Lee1, Min-Woong
Sohn1 and Dorothy D. Dunlop1, 1Northwestern University
Feinberg School of Medicine, Chicago, IL, 2Rush University
Medical Center, Chicago, IL, 3Rehabilitation Institute of Chicago,
Chicago, IL
2:45 pm
1801. The Association of Knee Shape with Sex: The
Osteoarthritis Initiative
Barton L. Wise1, Lisa Kritikos1, Felix Liu2, Neeta Parimi2,
John A. Lynch2, Yuqing Zhang3 and Nancy E. Lane1, 1Center
for Musculoskeletal Health, UC Davis School of Medicine,
Sacramento, CA, 2University of California at San Francisco, San
Francisco, CA, 3Boston University School of Medicine, Boston,
MA
3:00 pm
1802. Are Outcomes after Total Knee Arthroplasty Worsening
over Time? a Time-Trends Study of Activity Limitation and Pain
Outcomes
Jasvinder A Singh1 and David Lewallen2, 1University of Alabama
and VA Medical Center, Birmingham, AL, 2Mayo Clinic college of
medicine, Rochester, MN
scientific sessions
3:15 pm
1803. Knee Osteoarthritis and All-Cause Mortality: The
Wuchuan Osteoarthritis Study
Qiang Liu1, Xu Tang Sr.2, Jingbo Niu3, Xu Wu2, Yan Ke4, Jian
Huang5, Rujun Li4, Hu Li4, Xin Zhi4, Kai Wang4, Zhengming Cao1
and Jianhao Lin2, 1Arthritis Institute, People’s Hospital, Peking
University, Beijing, China, 2Peking University Health Science
Center, Beijing, China, 3Boston University, Boston, MA, 4Peking
University People’s Hospital, Beijing, China, 5The Second
Affiliated Hospital of Inner Mongolia Medical University, Hohhot,
China
3:30 pm
1804. Increased Mortality in Ankylosing Spondylitis – Results
from a National Population Based Study
Sofia Exarchou1, Elisabeth Lie2, Johan Askling3, Helena Forsbladd’Elia4, Carl Turesson1, Lars Erik Kristensen5 and Lennart T.
Jacobsson2, 1Section of Rheumatology, Department of Clinical
Sciences, Malmö, Lund University, Malmö, Sweden, 2Sahlgrenska
Academy at University of Gothenburg, Gothenburg, Sweden,
3
Clinical Epidemiology Unit, Rheumatology Unit, Department
of Medicine Solna, Karolinska Institutet, Stockholm, Sweden,
4
Department of Rheumatology and Inflammation Research,
Sahlgrenska Academy at University of Gothenburg, Gothenburg,
Sweden, 5Lund University, Malmö, Sweden
2 0 1 4
Health Services Research: Improving Clinical Practice
3:45 pm
1811. The Burden of Depression on Healthcare Utilization in
a Population-Based Cohort of Patients with Systemic Lupus
Erythematosus
Alfredo Aguirre1, Gaobin Bao1, S. Sam Lim2 and Cristina
Drenkard1, 1Emory University, Atlanta, GA, 2Emory University
School of Medicine, Division of Rheumatology, Atlanta, GA
PS
1 7 ,
PS
160 B
3:30 pm
1810. Improper Use of Antinuclear Antibody (ANA) Test Can
Result in Misdiagnosis, Increased Patient Anxiety and Wasted
Health Care Resources
Sahar Eivaz Mohammadi1, Imam H Shaik1, Parag Chevli1,
Fernando Gonzalez-Ibarra1, Sohini Sarkar1, Saurav Acharya1,
Prerna Dogra1, Hesam Hekmatjou2, Maushmi Savjani2, Waheed
Abdul2 and Valentin Marian1, 1Jersey City Medical CenterBarnabas Health, Jersey City, NJ, 2St. George’s University SOM, St.
George’s, Grenada
MONDAY
PM
3:15 pm
1809. Is Team Care Better? a Comparison of Rheumatoid
Arthritis Disease Activity Among Patients Cared for in Practices
with Nurse Practitioners and Physicians Assistants Versus
Rheumatologist Only
DH Solomon1, Liana Fraenkel2, Bing Lu1, Erika Brown1, Peter Hsun
Tsao3, Elena Losina1, Jeffrey N. Katz1 and Asaf Bitton1, 1Brigham
and Women’s Hospital, Boston, MA, 2Yale University School of
Medicine, Veterans Affairs Connecticut Healthcare Systems, New
Haven, CT, 3Brigham and Women’s Hospital, Harvard Medical
School, Boston, MA
n o v e m b e r
3:45 pm
1805. Prevalence and Associating Factors with Atypical Femoral
Fractures: An Asian Single Center Based Case-Control Study
Dam Kim1, Yoon-Kyoung Sung1, Soo-Kyung Cho1, Minkyung Han1
and Yee-Suk Kim2, 1Clinical Research Center for Rheumatoid
Arthritis (CRCRA), Seoul, South Korea, 2Hanyang University
Hospital, Seoul, South Korea
National University of Singapore, Singapore, Singapore, 3Division
of Rheumatology, University Medicine Cluster, National
University Health System, Singapore, Singapore, 4Duke-NUS
Graduate Medical School, Singapore, Singapore, Singapore
PM
156 B
Moderators: Una Makris, MD and Elena Losina, PhD
Innate Immunity and Rheumatic Disease
Moderators: Philip L. Cohen, MD and Edward M. Behrens, MD
2:30 PM
1806. WITHDRAWN
2:45 pm
1807. Problems with Fee for Service Payments for Academic
Rheumatology Practices: A Need for Payment Reform:
Allen P. Anandarajah1 and Christopher T. Ritchlin2, 1Univ of
Rochester Medical Ctr, Rochester, NY, 2University of Rochester
Medical Center, Rochester, NY
3:00 pm
1808. Role of HLA-B*5801 Genetic Testing and a Safety
Programme When Initiating Allopurinol Therapy for Chronic
Gout Management: A Cost-Effectiveness Analysis
Di Dong1, Wei Chuen Tan-Koi2, Gim Gee Teng3, Eric Finkelstein4
and Cynthia Sung4, 1Duke-NUS Graduate Medical School,
Singapore, Singapore, 2Saw Swee Hock School of Public Health,
2:30 pm
1812. Investigation of the Sting/Interferon Pathway Activation
in a Novel Vasculopathy and Pulmonary Syndrome
Yin Liu1, Adriana Almeida de Jesus2, Bernadette Marrero1, Dan
Yang3, Gina A. Montealegre Sanchez2, Steve Brooks1, Zuoming
Deng2, Amy Paller4, Manfred Boehm3 and Raphaela GoldbachMansky2, 1NIAMS/NIH, Bethesda, MD, 2National Institute of
Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda,
MD, 3National Heart, Lung and Blood Institute, National
Institutes of Health, Bethesda, MD, 4Northwestern University
Feinberg School of Medicine, Chicago, IL
2:45 pm
1813. DNA Sensors Regulate Inflammation in a Model of
Autoimmune Arthritis
Rebecca Baum1, Shruti Sharma1, Sudesh Pawaria1, Susan
Carpenter2, Katherine A. Fitzgerald1, Ann Marshak-Rothstein1
2014 Program Book
85
scientific sessions
and Ellen M. Gravallese3, 1University of Massachusetts Medical
School, Worcester, MA, 2University of California, San Francisco,
San Francisco, CA, 3UMass Memorial Medical Center, Worcester,
MA
Boston, MA, 2Michael E. DeBakey VA Medical Center, Baylor
College of Medicine, Houston, TX, 3Tufts Medical Center, Boston,
MA, 4Center for Primary Care and Prevention, Memorial Hospital
of Rhode Island, Providence, RI
3:00 pm
1814. RNA-Containing Immune Complexes Shift Human
Neutrophils from Phagocytosing Cells to Efficient Releasers of
Oxidized DNA in a Process Requiring Crosstalk Between Tolllike Receptors and Fc Gamma Receptor IIa
Christian Lood1, Xizhang Sun1, Lena Tanaka1, Andrew Oberst2,
Jeffrey Ledbetter3 and Keith B. Elkon1, 1University of Washington,
Seattle, WA, 2Department of Immunology, University of
Washington, Seattle, WA, 3Division of Rheumatology, University
of Washington, Seattle, WA
2:45 pm
1819. WITHDRAWN
3:00 pm
1820. Discordance of Hip Pain with Radiographic Hip
Osteoarthritis: The Osteoarthritis Initiative
Chan Kim1, Michael C. Nevitt2, Pia M. Jungmann3, Irina Tolstykh4,
Nancy E. Lane5, Thomas M. Link4 and David T. Felson6, 1Boston
University, Boston, MA, 2UCSF (University of California, San
Francisco), San Francisco, CA, 3Technische Universitaet
Muenchen, Munich, Germany, 4University of California, San
Francisco, San Francisco, CA, 5Center for Musculoskeletal Health,
UC Davis School of Medicine, Sacramento, CA, 6University of
n o v e m b e r
1 7 ,
MONDAY
2 0 1 4
3:15 pm
1815. STAT3-Mediated Regulation of Mitochondrial Membrane
Potential Is Critical for NLRP3 Inflammasome Activation
Jehad H. Edwan1, Raphaela Goldbach-Mansky2 and Robert A.
Colbert3, 1NIAMS NIH, Bethesda, MD, 2NIH Building 10 Room
6D47B, Bethesda, MD, 3NIAMS/NIH, Bethesda, MD
3:15 pm
1821. The Co-Occurrence Patterns of MRI Lesions and Incident
Knee Osteoarthritis: The MOST Study
Jingbo Niu1, David T. Felson2, Tuhina Neogi2, Michael C. Nevitt3,
Cora E. Lewis4, James Torner5, Ali Guermazi2, Frank Roemer6
and Yuqing Zhang2, 1Boston University, Boston, MA, 2Boston
University School of Medicine, Boston, MA, 3UCSF (University
of California, San Francisco), San Francisco, CA, 4University of
Alabama, Birmingham, Birmingham, AL, 5University of Iowa,
Iowa City, IA, 6Klinikum Augsburg, Augsburg, Germany
3:30 pm
1816. Toll-like Receptor 4-Induced Interleukin-1 Defines the
Intestinal Microbiome and Mucosal Immune Response in
Arthritis-Prone IL-1 Receptor Antagonist Deficient Mice
Tom Ederveen1, Rebecca Rogier1, Jos Boekhorst1, Harm
Wopereis2, Johan Garssen2, Sacha van Hijum1, Fons A.J. van
de Loo1, Marije I. Koenders1, Wim B. van den Berg1 and Shahla
Abdollahi-Roodsaz1, 1Radboud university medical center,
Nijmegen, Netherlands, 2Danone Research, Wageningen,
Netherlands
3:30 pm
1822. Increasing Synovitis and Bone Marrow Lesions
Are Associated with Incident Joint Tenderness in Hand
Osteoarthritis
Ida K. Haugen1, Barbara Slatkowsky-Christensen1, Pernille
Boyesen1, Sølve Sesseng1, Désirée van der Heijde1 and Tore K.
Kvien2, 1Diakonhjemmet Hospital, Oslo, Norway, 2PsAID taskforce,
EULAR, Zurich, Switzerland
3:45 pm
1817. Connecting Two Pathways through Ca2+ Signaling: NLRP3
Inflammasome Activation Induced By a Hypermorphic PLCG2
Mutation
Jae Jin Chae1, Yong Hwan Park1, Chung Park2, Il-Young Hwang2,
Patrycja Hoffmann1, John Kehrl2, Ivona Aksentijevich1 and
Daniel L. Kastner1, 1National Human Genome Research Institute,
Bethesda, MD, 2National Institute of Allergy and Infectious
Diseases, Bethesda, MD
104 B
PM
3:45 pm
1823. Inflammation Is Associated with Erosive Progression
in Patients with Hand Osteoarthritis: A Prospective
Ultrasonography Study
Marion C. Kortekaas1, Wing Yee Kwok2, Monique Reijnierse2,
Theo Stijnen2 and Margreet Kloppenburg2, 1Flevoziekenhuis,
Almere-Stad, Netherlands, 2Leiden University Medical Center,
Leiden, Netherlands.
PS
Osteoarthritis – Clinical Aspects I: Imaging in
Osteoarthritis
Moderators: Grace H. Lo, MD, MSc and Leena Sharma, MD
2:30 pm
1818. Subchondral Bone Mineral Density Improves Prediction
of Knee Osteoarthritis Progression Compared with Clinical
Factors Alone: Data from the Osteoarthritis Initiative
Michael P. Lavalley1, Grace H. Lo2, Lori Lyn Price3, Jeffrey Driban3,
Charles Eaton4 and Timothy E. McAlindon3, 1Boston University,
86
2014 Program Book
PM
157 B
Aspects: Pediatric Systemic Lupus Erythematosus
PM
Ed
Pd
PS
PrM
FIT
Moderators: Mical Cidon, MD and Lisa F. Imundo, MD
PS
scientific sessions
2:30 pm
1824. A Randomized Double-Blind Placebo-Controlled Trial of
Vitamin D Supplementation in Juvenile-Onset Systemic Lupus
Erythematosus: Improvement in Disease Activity and Fatigue
Scores
Glauce Lima, Juliane Paupitz, Liliam Takayama, Eloisa Bonfa and
Rosa M R Pereira, Faculdade de Medicina da Universidade de
São Paulo, São Paulo, Brazil
3:45 pm
1829. Role of Fluorinated Steroids in Preventing the
Progression of Anti-SSA/Ro Associated Isolated Congenital
Heart Block to Disease Beyond the Conduction System
Ummara Shah1, Amit Saxena1, Sara Sahl1, Deborah Friedman2, Jill
P. Buyon1 and Peter M. Izmirly1, 1New York University School of
Valhalla, NY
Medicine, New York, NY, 2New York Medical College,
PS
PM
Quality Measures and Quality of Care
2 0 1 4
Moderators: Eric D. Newman, MD and Jinoos Yazdany, MD MPH
1 7 ,
153 B
MONDAY
3:00 pm
1826. A Renal Activity Index May Predict Histological Activity in
Lupus Nephritis in Children
Khalid Abulaban1, Michael Bennett1, Marisa Klein-Gitelman2,
Stacy P. Ardoin3, Kelly A. Rouster-Stevens4, Lori B. Tucker5, Kasha
Wiley6, Shannen Nelson7, Karen Onel8, Nora G. Singer9, Kathleen
M. O’Neil10, Elizabeth Brooks11, B Anne Eberhard12, Lawrence
K. Jung13, Lisa F. Imundo14, Tracey Wright15, David Witte16, Jun
Ying17, Prasad Devarajan1 and Hermine I. Brunner7, 1Cincinnati
Children’s Hospital Medical Center, Cincinnati, OH, 2Anne &
Robert H Lurie Children’s Hospital of Chicago, Chicago, IL, 3Ohio
State University College of Medicine, Columbus, OH, 4Emory
University School of Medicine, Atlanta, GA, 5BC Children’s
Hospital and University of British Columbia, Vancouver, BC,
6
Cincinnati Children’s Hospital Medical Center, c, OH, 7Cincinnati
Children’s Hospital Medical Center, Cincinnati, OH, 8University
of Chicago Hospitals, Chicago, IL, 9Division of Rheumatology,
MetroHealth Medical Center, Case Western Reserve University,
Cleveland, OH, 10Riley Hospital for Children, Indianapolis, IN,
11
Univ Hospitals of Cleveland, Cleveland, OH, 12Cohen Children’s
Medical Center, Lake Success, NY, 13Children’s National Medical
Center, Washington, DC, 14Columbia University Medical Center,
New York, NY, 15UT Southwestern Medical Center, Dallas, TX,
16
Cincinnati Children’s Hospital, Cincinnati, OH, 17University of
Cincinnati, Cincinnati, OH
3:30 pm
1828. Adverse Pregnancy Outcomes in Adolescents and Young
Women with Systemic Lupus Erythematosus: A National
Estimate
Nicole Ling, Isabel E. Allen, Erica F. Lawson and Emily von
Scheven, University of California, San Francisco, San Francisco,
CA
n o v e m b e r
2:45 pm
1825. Cognitive Performance Scores for the Pediatric
Automated Neuropsychological Assessment Metrics in
Childhood-Onset Systemic Lupus Erythematosus
Patricia Vega-Fernandez1, Shana Vanderburgh2, Deborah M.
Levy3, Frank A. Zelko4, Eyal Muscal5, Natasha M. Ruth6, Adam M.
Huber7, Marisa S. Klein-Gitelman8, Kasha Wiley9, Wenjie Zheng9,
Lori B. Tucker10, Tresa Roebuck-Spencer11, Jun Ying2 and Hermine
Brunner12, 1Cincinnati Children’s Hospital, Cincinnati, OH,
2
University of Cincinnati, Cincinnati, OH, 3The Hospital for Sick
Children and University of Toronto, Toronto, ON, 4Northwestern
University Feinberg School of Medicine, Chicago, IL, 5Texas
Children’s Hospital, Houston, TX, 6Medical University of South
Carolina, Charleston, SC, 7IWK Health Centre, Halifax, NS, 8Ann
& Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL,
9
Cincinnati Children’s Hospital Medical Center, Cincinnati, OH,
10
BC Children’s Hospital and University of British Columbia,
Vancouver, BC, 11University of Oklahoma, Norman, OK, 12PRCSG,
Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
3:15 pm
1827. Anti-Ro and Anti-La Antibodies in the General Pregnant
Population
Evelyn V. Rozenblyum1, Sharon Sukhdeo1, Edgar Jaeggi2,
Lisa Hornberger3, Philip Wyatt4, Carl A. Laskin5 and Earl D.
Silverman6, 1University of Toronto, Toronto, ON, 2The Hospital
for Sick Children, University of Toronto, Toronto, ON, 3Stollery
Children’s Hospital, Edmonton, ON, 4North York General Hospital,
Toronto, ON, 5University of Toronto and LifeQuest Centre for
Reproductive Medicine, Toronto, ON, 6The Hospital for Sick
Children, Toronto, ON
2:30 pm
1830. A Novel Population Care Model in Rheumatoid
Arthritis – Significant Improvement in Quality and Reduction
in Cost of Care
Eric D. Newman1, William T. Ayoub2, David M. Pugliese3, Chelsea
Cedeno1, Jason Brown1, Thomas M. Harrington1, Thomas P.
Olenginski1, Androniki Bili1, Alfred E. Denio1, Lisa L. Schroeder1,
Dennis Torretti1, Tarun Sharma1, Lyudmila Kirillova1, Susan
Mathew1, Jonida Cote1, Brian Oppermann2, Cynthia Sullivan2,
Shantanu Bishwal4, Brian DelVecchio3 and Howard Aylward2,
1
Geisinger Health System, Danville, PA, 2Geisinger Health System,
State College, PA, 3Geisinger Health System, Wilkes-Barre, PA,
4
Geisinger Health System, Wilkes Barre, PA
2:45 pm
1831. Monitoring Patients with Rheumatoid Arthritis in
Routine Care – Experiences from a Treat-to-Target Strategy
Using the Danbio Registry
Merete Lund Hetland1, Dorte Vendelbo Jensen2 and Niels
Steen Krogh3, 1DANBIO, Glostrup Hospital, Glostrup, Denmark,
2
DANBIO, Glostrup, Denmark, 3ZiteLab ApS, Copenhagen,
Denmark
2014 Program Book
87
scientific sessions
3:00 pm
1832. National Quality Forum Measure Achievement and Costs
in Rheumatoid Arthritis Patients in a Large Managed Care
Population
Roxanne Meyer1, Susan C. Bolge2, Joseph Tkacz3, Brenna Brady3
and Charles Ruetsch4, 1Janssen Scientific Affairs, Horsham, PA,
2
Janssen Scientific Affairs, LLC, Horsham, PA, 3Health Analytics,
LLC, Columbia, MD, 4Health Analytics LLC, Columbia, MD
3:15 pm
1833. Quality of Primary Care Management of Patients with
and without Rheumatoid Arthritis (RA)
Jessica Widdifield1, Claire Bombardier2, Jacqueline Young1, Noah
Ivers2, R. Liisa Jaakkimainen3, Sasha Bernatsky4, J. Michael
Paterson1, J. Carter Thorne5, Pooneh S.Akhavan6, Debra Butt1,
Vandana Ahluwalia7 and Karen Tu1, 1Institute for Clinical
Evaluative Sciences, Toronto, ON, 2University of Toronto, Toronto,
ON, 3Sunnybrook Health Sciences Centre, Toronto, ON, 4McGill
University Health Centre, Montreal, QC, 5Southlake Regional
Health Centre, Newmarket, Newmarket, ON, 6Mount Sinai
Hospital, Toronto, ON, 7William Osler Health Center, Brampton,
ON
n o v e m b e r
1 7 ,
MONDAY
2 0 1 4
3:30 pm
1834. Uptake of the American College of Rheumatology’s
(ACR) Rheumatology Clinical Registry (RCR): Quality Measure
Summary Data Natalie Fisk1, Melissa Francisco1, Jinoos Yazdany2 and Salahuddin
Kazi3, 1American College of Rheumatology, Atlanta, GA,
2
University of California, San Francisco, San Francisco, CA, 3UT
Southwestern Medical Center, Dallas, TX
3:45 pm
1835. Anti-Osteoporosis Medication Use after Hip or Vertebral
Fracture
Robert A. Overman1 and Chad L. Deal2, 1University of North
Carolina, Chapel Hill, NC, 2Cleveland Clinic, Cleveland, OH
210 B
PM
PS
Rheumatoid Arthritis – Clinical Aspects III:
Malignancies, Vaccinations, Pregnancy and Surgery
Moderators: Lin Brown, MD and Jennifer Barton, MD
2:30 pm
1836. Safety of Zoster Vaccination Administration in Rheumatic
Patients on Current Biologic Therapy
Stephen Lindsey1, Brandi Oufnac2 and Holly Walker2, 1Ochsner
Clinic Baton Rouge, Baton Rouge, LA, 2Ochsner Health Systems,
Baton Rouge, LA
2:45 pm
1837. First Results of a European Registries Collaborative
Project to Compare the Spectrum of Lymphomas Between
Different Exposure Groups in Rheumatoid Arthritis
Louise Mercer1, Xavier Mariette2, William Dixon1, Eva Baecklund3,
Karin Hellgren4, Lene Dreyer5, Merete Lund Hetland6, Lene
88
2014 Program Book
Mellemkjær7, Kimme Hyrich8, Anja Strangfeld9, Angela Zink10,
Helena Canhao11, Fernando Martins12, Victoria Hernández13,
Florence Tubach14, Jacques-Eric Gottenberg15, Jacques
Morel16, Jakub Zavada17, Piet van Riel18, Axel Finckh19, Florenzo
Iannone20, Johan Askling4 and Joachim Listing9, 1The University of
Manchester, Manchester, United Kingdom, 2Université Paris-Sud,
Le Kremlin Bicêtre, France, 3Uppsala University, Uppsala, Sweden,
4
Karolinska Institutet, Stockholm, Sweden, 5Copenhagen
University Hospital at Gentofte, Gentofte, Denmark, 6DANBIO,
Glostrup Hospital, Glostrup, Denmark, 7The Danish Cancer
Society, Copenhagen, Denmark, 8Arthritis Research UK Centre
for Epidemiology, The University of Manchester, Manchester,
United Kingdom, 9German Rheumatism Research Center,
Berlin, Germany, 10German Rheumatism Research Centre and
Charité University Medicine, Berlin, Germany, 11Instituto de
Medicina Molecular, Universidade de Lisboa, Lisbon, Portugal,
12
Instituto de Medicina, Universidade de Lisboa, Lisbon, Portugal,
13
BIOBADASER Registry, Madrid, Spain, 14Universite Paris Diderot,
Paris, France, 15Department of rheumatology CHU, Strasbourg,
France, 16Universite´ Montpellier, Montpellier, France, 17Charles
University, Prague, Czech Republic, 18Radboud University
Medical Centre, Nijmegen, Netherlands, 19University of Geneva,
Geneva, Switzerland, 20Reumatologia Universita e Policlinico di
Bari, Bari, Italy
3:00 pm
1838. No Increased Risk of Developing a First Invasive
Melanoma in Rheumatoid Arthritis Patients Treated with
Biologics: Results of a Collaborative Project of 11 European
Biologics Registers
Louise Mercer1, Johan Askling2, Pauline Raaschou2, William
Dixon1, Lene Dreyer3, Merete Lund Hetland4, Lene Mellemkjær5,
Anja Strangfeld6, Angela Zink7, Florenzo Iannone8, Axel Finckh9,
Jakub Zavada10, Helena Canhao11, Fernando Martins12, Xavier
Mariette13, Jacques Morel14, Jacques-Eric Gottenberg15, Adele
Green1, Victoria Hernández16, Florence Tubach17, Piet van
Riel18, Kimme Hyrich19 and Joachim Listing6, 1The University
of Manchester, Manchester, United Kingdom, 2Karolinska
Institutet, Stockholm, Sweden, 3Copenhagen University
Hospital at Gentofte, Gentofte, Denmark, 4DANBIO, Glostrup
Hospital, Glostrup, Denmark, 5The Danish Cancer Society,
Copenhagen, Denmark, 6German Rheumatism Research Center,
Berlin, Germany, 7German Rheumatism Research Centre and
Charité University Medicine, Berlin, Germany, 8Reumatologia
Universita e Policlinico di Bari, Bari, Italy, 9University of Geneva,
Geneva, Switzerland, 10Charles University, Prague, Czech
Republic, 11Instituto de Medicina Molecular, Universidade de
Lisboa, Lisbon, Portugal, 12Instituto de Medicina, Universidade
de Lisboa, Lisbon, Portugal, 13Université Paris-Sud, Le Kremlin
Bicêtre, France, 14Universite´ Montpellier, Montpellier, France,
15
Department of rheumatology CHU, Strasbourg, France,
16
BIOBADASER Registry, Madrid, Spain, 17Universite Paris Diderot,
Paris, France, 18Radboud University Medical Centre, Nijmegen,
Netherlands, 19Arthritis Research UK Centre for Epidemiology,
The University of Manchester, Manchester, United Kingdom
scientific sessions
3:15 pm
1839. Risk of Recurrent Non-Melanoma Skin Cancer with
Methotrexate and Anti-TNF Use in Rheumatoid Arthritis
Frank I Scott1, Ronac Mamtani1, Colleen Brensinger1, Kevin
Haynes2, Zelma ChiesaFuxench1, Huifeng Yun3, Jie Zhang4, Lang
Chen5, Fenglong Xie5, David Margolis1, James D. Lewis2 and
Jeffrey R. Curtis6, 1University of Pennsylvania, Philadelphia, PA,
2
Center for Clinical Epidemiology and Biostatistics, Perelman
School of Medicine, University of Pennsylvania, Philadelphia, PA,
3
University of Alabama at Birmingham School of Public Health,
Birmingham, AL, 4Univ. of Alabama at Birmingham, Birmingham,
AL, 5University of Alabama at Birmingham, Birmingham, AL, 6The
University of Alabama at Birmingham, Birmingham, AL
3:30 pm
1840. Pregnancy Outcomes Following Exposure to Abatacept
during Pregnancy
M Kumar1, L Ray1, S Vemuri2 and T Simon1, 1Bristol-Myers Squibb,
Hopewell, NJ, 2Bristol-Myers Squibb, Plainsboro, NJ
Moderators: Maarten Boers, MD, MSc, PhD and Mark C.
Genovese, MD
2:30 pm
1842. High Rates of Failure after Biological DMARD
Discontinuation While in Remission in a Japanese Multi-Center
Registry
Kazuki Yoshida1, Mitsumasa Kishimoto2, Helga Radner1, Kazuo
Matsui3, Masato Okada2, Yukihiko Saeki4, Daniel H. Solomon1 and
Shigeto Tohma5, 1Brigham and Women’s Hospital, Boston, MA,
2
St. Luke’s International Hospital, Tokyo, Japan, 3Kameda Medical
Center, Kamogawa, Japan, 4Osaka-Minami Medical Center, Osaka,
Japan, 5Sagamihara Hospital, National Hospital Organization,
Sagamihara, Japan
2:45 pm
1843. Randomised Controlled Non-Inferiority Study of Dose
Reduction and Withdrawal of Adalimumab and Etanercept in
Noortje van Herwaarden1, Aatke van der Maas1, Michiel
Minten1, Frank H.J. van den Hoogen2, Ronald F. van Vollenhoven3,
2 0 1 4
PS
1 7 ,
PM
and Gene Therapy III: Innovative Therapeutic
Strategies in Rheumatoid Arthritis
3:15 pm
1845. Tocilizumab Combination Therapy or Monotherapy
or Methotrexate Monotherapy in Methotrexate-Naive
Patients with Early Rheumatoid Arthritis: 2-Year Clinical and
Radiographic Results from a Randomized, Placebo-Controlled
Trial
Gerd Burmester1, William Rigby2, Ronald F. van Vollenhoven3,
Jonathan Kay4, Andrea Rubbert-Roth5, Ricardo Blanco6, Ariella
Kelman7, Sophie Dimonaco8 and Nina Mitchell8, 1CharitéUniversitätsmedizin Berlin, Free University and Humboldt
University of Berlin, Berlin, Germany, 2Geisel School of Medicine
at Dartmouth, Lebanon, NH, 3Karolinska Institute, Stockholm,
Sweden, 4UMass Memorial Medical Center, Worcester, MA,
5
University of Cologne, Cologne, Germany, 6Hospital Marques
de Valdecilla, Santander, Spain, 7Genentech, South San Francisco,
CA, 8Roche Products Ltd., Welwyn Garden City, United Kingdom
MONDAY
Exhibit Hall C
3:00 pm
1844. Identification of a Patient Phenotype Which Impacts
Response to Therapy in Rheumatoid Arthritis Clinical Trials:
Certolizumab Pegol Phase 4 Trial Data
Jeffrey R. Curtis1, Melvin Churchill2, Alan Kivitz3, Laura Gauer4,
Christopher Herrem4, David Carter5, Jeffrey Melin4 and Yusuf
Yazici6, 1The University of Alabama at Birmingham, Birmingham,
AL, 2Arthritis Center of Nebraska, Lincoln, NE, 3Altoona Arthritis
& Osteoporosis Center, Duncansville, PA, 4UCB Pharma, Smyrna,
GA, 5UCB Pharma, Brussels, Belgium, 6New York University
Hospital for Joint Diseases, New York, NY
n o v e m b e r
3:45 pm
1841. Eventual Joint Failure and Surgery Rates in Rheumatoid
Arthritis Remain High in Patients with Moderate Disease
Activity in the First 5 Years of Disease
Elena Nikiphorou1, Lewis Carpenter1, Sam Norton2, Josh Dixey3,
Patrick Kiely4, David Walsh5 and Adam Young6, 1University of
Hertfordshire, Hatfield, United Kingdom, 2King’s College London,
London, United Kingdom, 3New Cross Hospital, Wolverhampton,
United Kingdom, 4St. Georges Healthcare NHS Trust, London,
United Kingdom, 5University of Nottingham, Nottingham, United
Kingdom, 6ERAS, St Albans City Hospital, St Albans, United
Kingdom
Johannes W.J. Bijlsma4, Bart van den Bemt1 and Alfons A.
den Broeder1, 1Sint Maartenskliniek, Nijmegen, Netherlands,
2
Rheumatology Centre Sint Maartenskliniek and Radboud
university medical center, Ubbergen (Nijmegen), Netherlands,
3
Unit for clinical therapy research (ClinTrid), Karolinska Institute,
Stockholm, Sweden, 4University Medical Center Utrecht, Utrecht,
Netherlands
3:30 pm
1846. The Association Between Hydroxychloroquine Treatment
and Cardiovascular Morbidity Among Rheumatoid Arthritis
Patients
Michael Shapiro1 and Yair Levy2, 1Sackler Faculty of Medicine, Tel
Aviv University, Tel Aviv, Israel, 2Meir Medical Center, Kfar Saba,
Israel
3:45 pm
1847. Effect of Disease Duration on Clinical Outcomes in
Moderate Rheumatoid Arthritis Patients Treated with
Etanercept Plus Methotrexate
Josef S. Smolen1, David Collier2, Annette Szumski3, Heather
Jones3 and Lisa Marshall3, 1PsAID taskforce, EULAR, Zurich,
Switzerland, 2Amgen, Inc., Thousand Oaks, CA, 3Pfizer Inc.,
Collegeville, PA
2014 Program Book
89
scientific sessions
258 B
PM
PS
Spondyloarthropathies and Psoriatic Arthritis III –
Clinical Aspects of Psoriatic Arthritis
Moderators: Arthur Kavanaugh, MD and Enrique R. Soriano, MD,
MSc
n o v e m b e r
1 7 ,
MONDAY
2 0 1 4
2:30 pm
1848. Risk of Cancer in Patients with Severe Psoriatic Arthritis
Requiring Tumour-Necrosis Factor Alpha Inhibition
Karen M. Fagerli1, Louise K. Mercer2, Kath D. Watson2, Jonathon
Packham3, Deborah PM Symmons4, Kimme L. Hyrich5 and . On
behalf of the BSRBR6, 1Diakonhjemmet Hospital, Oslo, Norway,
2
Arthritis Research UK Centre for Epidemiology, University
of Manchester, Manchester, United Kingdom, 3Institute of
Science and Technology in Medicine, Keele, United Kingdom,
4
Arthritis Research UK Centre for Epidemiology, The University
of Manchester, Manchester, United Kingdom, 5Centre
Manchester, United Kingdom, 6British Society for Rheumatology,
2:45 pm
1849. Risk of Malignancy Among Medicare Psoriasis/Psoriatic
Arthritis Patients
Huifeng Yun1, Kevin L. Winthrop2, Lang Chen3, Wilson Smith3,
Benjamin Chan4, Fenglong Xie3, Allison Taylor3 and Jeffrey
R. Curtis3, 1University of Alabama at Birmingham School of
Public Health, Birmingham, AL, 2Oregon Health & Science
University, Portland, OR, 3University of Alabama at Birmingham,
Birmingham, AL, 4Oregon Health and Science University,
Portland, OR
3:00 pm
1850. The Incidence and Risk Factors for Psa in Patients with
Psoriasis – a Prospective Cohort Study
Lihi Eder1, Amir Haddad1, Hua Shen2, Cheryl Rosen1, Vinod
Chandran1, Richard J. Cook2 and Dafna D. Gladman3, 1University
of Toronto, Toronto Western Hospital, Toronto, ON, 2University
of Waterloo, Waterloo, ON, 3Toronto Western Research Institute,
Toronto Western Hospital, Toronto, ON
3:15 pm
1851. Serious Infection Events in the Psoriasis Longitudinal
Assessment and Registry Study: Cumulative Experience
Robert Kalb1, David Fiorentino2, Mark Lebwohl3, Craig Leonardi4,
John Toole5, Kavitha Goyal6, Steve Calabro6, Wayne Langholff7
and Steve Fakharzadeh8, 1SUNY at Buffalo, School of Medicine
and Biological Sciences, Buffalo, NY, 2Stanford University,
Redwood City, CA, 3Mount Sinai Medical Center, New York, NY,
4
Central Dermatology, St. Louis, MO, 5University of Manitoba,
Dermadvances Research, Winnipeg, MB, 6Janssen Services, LLC,
Horsham, PA, 7Janssen Research and Development, LLC, Spring
House, PA, 8Janssen Services, LLC, Spring House, PA
90
2014 Program Book
3:30 pm
1852. Increased Cardiovascular Risk in Patients Recently
Diagnosed with Psoriatic Arthritis: A Population-Based, Cohort
Study
Katelynn Wilton1, Floranne C. Ernste1, Cynthia S. Crowson2,
Eric L. Matteson2, Hilal Maradit Kremers2 and Marta SánchezMenéndez3, 1Mayo Clinic Rochester, Rochester, MN, 2Mayo Clinic,
Rochester, MN, 3Centro Medico de Asturias, Oviedo, Spain
3:45 pm
1853. Persistence and Predictors of Biologic TNFi Therapy
Among Biologic naïve Psoriatic Arthritis Patients in a US
Registry
Philip Mease1, David Collier2, Chitra Karki3, Guo Li4, Bojena
Bitman5 and Jeffrey D. Greenberg6, 1Swedish Medical Center,
Seattle, WA, 2Amgen, Inc., Thousand Oaks, CA, 3Corrona, LLC.,
Southborough, MA, 4Axio Research LLC, Seattle, WA, 5Amgen,
Inc., San Francisco, CA, 6New York University School of Medicine,
New York, NY
Ballroom West
PM
PS
and Treatment: Complications of Systemic Lupus
Erythematosus
Moderators: S. Sam Lim, MD, MPH and Iris Navarro-Millan, MD
2:30 pm
1854. Systemic Lupus Erythematosus Patients Have Increased
Risk of Short Term Adverse Events after Total Hip Arthroplasty
Jordan Roberts1, Lisa A. Mandl2, Edwin Su2, David J. Mayman2,
Mark P. Figgie2, Arielle Fein2, Yuo-Yu Lee2, Ummara Shah3 and
Susan M. Goodman2, 1Weill Cornell Medical College, New
York, NY, 2Hospital for Special Surgery, New York, NY, 3New York
University School of Medicine, NYC, NY
2:45 pm
1855. Not Keeping up with the Times: High Mortality and Early
Death Due to Disease in North American Natives with Systemic
Lupus Erythematosus (SLE)
Ripneet Puar1, Carol A. Hitchon1, David B. Robinson1, Hani
El-Gabalawy1, Navjot Dhindsa1 and Christine A. Peschken2,
1
University of Manitoba, Winnipeg, MB, 2University of Manitoba,
Canada, Winnipeg, MB
3:00 pm
1856. National Hospitalization Trends in Lupus Reveal Rising
Rates of Herpes Zoster and Declines in Pneumocystis Infections
Sara G. Murray, Gabriela Schmajuk, Laura Trupin, Lianne
S. Gensler and Jinoos Yazdany, University of California, San
3:15 pm
1857. Determinants of Annual Healthcare Utilization and
Overall Cost of Care in Individuals with Systemic Lupus
Erythematosus in a Large Insurance Claims Database:
Glucocorticoid Use
Shih-Yin Chen1, Chan-Bum Choi2, Qian Li3, Wei-Shi Yeh1, YuanChi Lee4, Amy H Kao1 and Matthew H. Liang5, 1Biogen Idec,
scientific sessions
Cambridge, MA, 2VA Healthcare System, Boston, MA, 3Evidera,
Lexington, MA, 4Formerly of Evidera, Lexington, MA, 5Harvard
3:30 pm
1858. Standardized Mortality Ratios for Cause-Specific Deaths
in Lupus Patients Followed Prospectively at a Single Centre
Lupus Clinic
Barry J. Sheane, Dominique Ibanez, Dafna D. Gladman and
Murray B. Urowitz, University of Toronto, Toronto Western
Hospital, Toronto, ON
3:45 pm
1859. Age-Specific Predictors of Mortality in SLE
Dominique Ibanez, Dafna D. Gladman and Murray B. Urowitz,
University of Toronto,
Toronto Western Hospital, Toronto, ON
PS
PM
107 B
Vasculitis II
Moderators: Robert F. Spiera, MD and Sebastian H. Unizony, MD
2 0 1 4
2014 Program Book
1 7 ,
3:00 pm
1862. The Association of Low-Density Granulocytes with
Disease Activity and Response to Treatment in ANCAAssociated Vasculitis
Peter C. Grayson1, Carmelo Carmona-Rivera1, Lijing Xu2, Noha
Lim2, Adam Asare2, Deborah J. Phippard2, Mariana J. Kaplan1,
3:30 pm
1864. Granulomatosis with Polyangiitis or Microscopic
Polyangiitis: Long-Term Outcomes of Comparing Azathioprine
Vs Methotrexate for Remission-Maintenance in 126 Patients
Xavier Puéchal1, Christian Pagnoux2, Elodie Perrodeau3,
Mohamed Hamidou4, Jean-Jacques Boffa5, Xavier Kyndt6,
François Lifermann7, Thomas Papo8, Dominique Merrien9,
Amar Smail10, Philippe Delaval11, Catherine Hanrotel-Saliou12,
Bernard Imbert13, Chahéra Khouatra14, Marc Lambert15, Charles
Leské16, Kim Heang Ly17, Edouard Pertuiset18, Pascal Roblot19,
Marc Ruivard20, Jean-François Subra21, Jean-Francois Viallard22,
Benjamin Terrier1, Pascal Cohen1, Luc Mouthon1, Philippe
Ravaud3 and Loïc Guillevin for the French Vasculitis Study
Group1, 1National Referral Center for Rare Systemic Autoimmune
Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes,
Paris, Paris, France, 2University of Toronto, Toronto, ON,
3
Epidemiology, Université Paris-Descartes, Paris, Paris, France,
4
CHU Hôtel Dieu, Nantes, Nantes, France, 5Hôpital Tenon, Paris,
Paris, France, 6CH, Valenciennes, Valenciennes, France, 7CH Côte
d’Argent, Dax, Dax, France, 8Bichat Hospital, Paris, Paris, France,
9
CH Compiègne-Noyon, Compiègne, France, 10CHU Amiens
Nord, Amiens, France, 11CHU Rennes Sud, Rennes, France, 12CHU
Cavale Blanche, Brest, Brest, France, 13CHU, Grenoble, Grenoble,
France, 14CHU Louis Pradel, Lyon, Lyon, France, 15Internal
Medicine University Lille Hospital, Lille, Lille, France, 16CH, Cholet,
Cholet, France, 17CHU Dupuytren, Limoges, Limoges, France,
18
René Dubos Hospital, Pontoise, France, 19CHU, Poitiers, Poitiers,
MONDAY
2:45 pm
1861. The Role of Macrophage Migration Inhibitory Factor
(MIF) and MIF Gene Polymorphisms in the Pathogenesis of
Granulomatosis with Polyangiitis
Antoine G. Sreih1, Rana Ezzeddine2, Juan Fan3, Lin Leng3, Simon
Carette4, David Cuthbertson5, Gary S. Hoffman6, Nader A.
Khalidi7, Carol A. Langford8, Carol McAlear9, Paul Monach10,
Philip Seo11, Ulrich Specks12, Steven R. Ytterberg12, Peter A.
Merkel13 and Richard Bucala14, 1The University of Pennsylvania,
Philadelphia, PA, 2Bristol-Myers Squibb, Wallingford, CT, 3Yale
University, New Haven, CT, 4University of Toronto, Toronto, ON,
5
University of South Florida, Tampa, FL, 6Center for Vasculitis
Care and Research, Cleveland Clinic Foundation, Cleveland,
OH, 7St. Joseph’s Hospital, McMaster University, Hamilton,
ON, 8Center for Vasculitis Care and Research, Cleveland Clinic,
Cleveland, OH, 9Vasculitis Center, University of Pennsylvania,
Philadelphia, PA, 10Boston University, Boston, MA, 11Johns
Hopkins Vasculitis Center, Johns Hopkins University, Baltimore,
MD, 12Mayo Clinic, Rochester, MN, 13Vasculitis Center, Division
of Rheumatology, University of Pennsylvania, Philadelphia, PA,
14
Yale University School of Med, New Haven, CT
3:15 pm
1863. CCX168, an Orally Administered C5aR Inhibitor for
Treatment of Patients with Antineutrophil Cytoplasmic
Antibody-Associated Vasculitis
Pirow Bekker1, David Jayne2, Annette Bruchfeld3, Matthias
Schaier4, Kazimierz Ciechanowski5, Lorraine Harper6, Michel
Jadoul7, Mårten Segelmark8, Daina Selga9, Istvan Szombati10,
Michael Venning11, Christian Hugo12, Paul L. van Daele13,
Ondrej Viklicky14, Antonia Potarca15 and Thomas J. Schall15,
1
Chemocentryx, Inc., Mountain View, CA, 2Addenbrookes
Hospital University of Cambridge, Cambridge, United Kingdom,
3
Karolinska Institute, Stockholm, Sweden, 4University of
Heidelberg, Heidelberg, Germany, 5Pomeranian Medical
University, Szczecin, Poland, 6University of Birmingham,
Birmingham, United Kingdom, 7Cliniques Saint-Luc, Brussels,
Belgium, 8Linkoping University, Linkoping, Sweden, 9Lund
University, Lund, Sweden, 10Budaclinic, Budapest, Hungary,
11
Manchester University, Manchester, United Kingdom,
12
Dresden University, Dresden, Germany, 13Erasmus Medical
Center, Immunology, Rotterdam, Netherlands, 14Instit of Clin
and Exp Med, Prague, Czech Republic, 15ChemoCentryx, Inc.,
Mountain View, CA
n o v e m b e r
2:30 pm
1860. Serum Calprotectin and Disease Relapse in ANCAAssociated Vasculitis
Juliana B Draibe1, Ruth J. Pepper1, Peter A. Merkel2, Alan D.
Salama1 and for The RAVE-ITN Investigators3, 1University College
London, London, United Kingdom, 2Vasculitis Center, University
of Pennsylvania, Philadelphia, PA, 3Immune Tolerance Network,
San Francisco, CA
Peter A. Merkel3 and Paul A. Monach4, 1National Institutes of
Health, Bethesda, MD, 2Immune Tolerance Network, Bethesda,
MD, 3Vasculitis Center, University of Pennsylvania, Philadelphia,
PA, 4Vasculitis Center, Boston University School of Medicine,
Boston, MA
91
scientific sessions
France, 20CHU Estaing, Clermont–Ferrand, Clermont–Ferrand,
France, 21CHU, Angers, Angers, France, 22Hôpital Haut-Lévêque,
Bordeaux, CHU Bordeaux, France
3:45 pm
1865. Increased Risk of Myocardial Infarction and
Cerebrovascular Accidents after Diagnosis of Granulomatosis
with Polyangiitis: A General Population-Based Cohort Study
Neda Amiri1, Natasha Dehghan1, Eric C. Sayre2, Kamran Shojania1
and J. Antonio Avina-Zubieta2, 1University of British Columbia,
Vancouver, BC, 2Arthritis Research Centre of Canada, Richmond,
BC
2:30 – 4:00 pm
102 A
PM
n o v e m b e r
1 7 ,
MONDAY
2 0 1 4
Moderators: Marisa S. Klein-Gitelman, MD, MPH and Bryce A.
Binstadt, MD, PhD
2:30 pm
1866. Birth Outcomes in Women with a History of Juvenile
Idiopathic Arthritis
Debbie Ehrmann Feldman1, Evelyne Vinet2, Sasha Bernatsky3,
Ciaran Duffy4, Elizabeth Hazel5, Marie-Pierre Sylvestre1, Garbis
Meshefedjian6 and Anick Bérard1, 1Université de Montréal,
Montréal, QC, 2McGill University Health Center, Montreal, QC,
3
McGill University, Montreal, QC, 4Children’s Hospital of Eastern
Ontario, Ottawa, ON, 5McGill University Health Center, Montreal,
QC, 6Public Health Department of Montreal, Montreal, QC
2:45 pm
1867. Mandibular Movement in Healthy Individuals from 4-17
Years of Age
Peter Stoustrup1, Kasper Dahl Kristensen2, Annelise Küseler3,
Thomas Klit Pedersen4 and Troels Herlin4, 1University of Aarhus,
Aarhus C, Denmark, 2Specialist Oral Health Center for Western
Norway, Rogaland Stavanger, Norway, 3Aarhus University, Aarhus,
Denmark, 4Aarhus University Hospital, Aarhus, Denmark
3:00 pm
1868. Can DAS 28 at 3 Months after the 1st Biologic Therapy
Predict Subsequent Sustainable Clinical Remission in
Polyarticular Juvenile Idiopathic Arthritis Patients?
Tomohiro Kubota1, Syuji Takei2, Tsuyoshi Yamatou3, Tomokazu
Nagakura4, Hiroyuki Imanaka3, Yukiko Nonaka3, Tomoko Takezaki3,
Harumi Akaike3 and Mio Matsuura5, 1Kagoshima University
Hospital, Kagoshima City, Japan, 2Kagoshima University,
Kagoshima, Japan, 3Kagoshima University Hospital, Kagoshima,
Japan, 4House of Meguminoseibo, Usuki, Japan, 5Kagoshima
University, Kagoshima-Shi, Japan
2014 Program Book
3:30 pm
1870. Children and Parent Satisfaction in the Pediatric
Rheumatology Clinic: Patient Orientated Quality Service
Measures
Jenny Tekano1, Lori B. Tucker2 and Audrea Chen3, 1BC Children’s
Hospital, Vancouver, BC, 2BC Children’s Hospital and University
of British Columbia, Vancouver, BC, 3research student, Vancouver,
BC
PS
ACR/ARHP Combined Abstract Session: Pediatric
FIT
PrM
Pd
PS
Ed
Rheumatology PM
92
3:15 pm
1869. Child Pain, Function and Psychological Outcomes in
an Intensive Interdisciplinary Pediatric Pain Rehabilitation
Program
Cara Hoffart, Rawni Anderson, Amy Chapman, Brandi Dorton,
Danielle Feltrop, Misty Wilson and Dustin Wallace, Children’s
Mercy Hospital, Kansas City, MO
3:45 pm
1871. Puberty and Disease Activity in JIA
Philomine A. van Pelt1, Aike.a. Kruize2, Anita C.S. HokkenKoelega3, Radboud JEM Dolhain4, Johannes WJ Bijlsma5 and
Nico M. Wulffraat5, 1Erasmus MC, Rotterdam, Netherlands,
2
University Medical Center Utrecht, Utrecht, Netherlands,
3
Erasmus Medical Center- Sophia Children’s Hospital, Rotterdam,
Netherlands, 4Erasmus MC University Medical Center Rotterdam,
Rotterdam, Netherlands, 5University Medical Centre Utrecht,
Utrecht, Netherlands
ARHP SESSIONS
2:30 – 4:00 pm
257 A
PM
PS
Alternative Medicine: Presenting the Evidence for
PS
PM
Rheumatic Conditions
Moderators: Deborah McCloskey, RN, BSN and Lisa Shelton, BSc,
BSN, RN
• evaluate the mounting evidence to support the use of
acupuncture for a variety of chronic pain conditions in
rheumatology
• describe the regulatory differences between dietary
supplements, medical foods and drug products
• discuss safety and efficacy data on dietary supplements and
medical foods utilized for rheumatic conditions
2:30 pm
Efficacy of Acupuncture for Treatment of Chronic Pain
Richard E. Harris, PhD
3:15 pm
Dietary Supplements in Rheumatology
James Torr, PharmD
PM
scientific sessions
PS
• e xpress the importance of positive affect experiences in
promoting resilience
• recognize how resilience can promote successful adaptation
to the stresses of chronic illness
254 A
Biomarkers in Rheumatic Care
Moderators: Jennifer L. Trizuto, MPT and Chokkalingam Siva, MD
• recognize what biomarkers are
• explain how biomarkers can be useful tools with diagnostic
and prognostic utility
• identify the obstacles in the validation of candidate
biomarkers
2:30 pm
Biomarkers in Rheumatic Care
Richard D. Brasington, MD
3:00 pm
Identifying Modifiable Biopsychosocial Pathways of Resilience
to Chronic Illness
Alex Zautra, PhD
3:00 pm
Biomarkers in the Assessment of Lupus Disease Activity
Chaim Putterman, MD
3:30 pm
Valued Life Activities and Psychological Well-Being
Patricia P. Katz, PhD
PS
PM
3:30 pm
Biomarkers in the Assessment of Vasculitis
Peter A. Merkel, MD, MPH
256
2:30 pm
Temperament and Affect Balance Style: Maximizing Strengths
to Promote Resilience
Kim Sibille, PhD
PM
ACR/ARHP WORKSHOPS
4:00 – 6:00 pm
Stats Boot Camp: A Call to Aims for Researchers!
An Interactive Session to Obtain Feedback on Your
Specific Aims Section
161
3:40 pm
Review of Attendees’ “In Progress” Specific Aims in Small
Breakout Groups Led by Speakers
Kelli D. Allen, PhD; Linda C. Li, PhD, PT
PS
PM
255
Thriving with Rheumatic Disease: Cultivating
Resilience
Moderator: Hazel L. Breland, PhD, OTR/L
• explain the importance of preserving valued life activities to
maintain psychological well-being
Dermatopathology of Rheumatic Diseases (225)
Speaker: Daniel Miller, MD
• identify what information can be gained from a skin biopsy in
• describe the importance of dermatopathology in clinical
decision making in patients with rheumatic diseases
• apply the knowledge gained to clinical practice
2:30 pm
How to Develop a Convincing Specific Aims Section
Kelli D. Allen, PhD
3:05 pm
Common Pitfalls of Specific Aims and How to Avoid Them
Linda C. Li, PhD, PT
2 0 1 4
1 7 ,
• recognize the importance of the Specific Aims section of a
research proposal
• describe the essential elements of a compelling Specific Aims
section
• develop Specific Aims that effectively “sell” a research idea
and form a partnership with reviewers
• enhance Specific Aims in current development based on direct
feedback given by experienced investigators during breakout
group review sessions
MONDAY
Moderator: Robert R. McLean, DSc, MPH
n o v e m b e r
PS
152
*Joint Injections (Knee, Ankle, Shoulder and Wrist)
(226)
Speakers: Jemima Albayda, MD and Pari Basharat, MD
• describe indications for lower extremity joint injection and
aspiration
• identify anatomic landmarks for injection of the knee and
ankle using joint prosthetics
• apply principles of joint aspiration and injection using ankle
and knee joint prosthetics
2014 Program Book
93
PM
Ed
scientific sessions
154
MDHAQ/RAPID3 and RHEUMDOC: Quantitative,
Standard, Scientific Summaries of Patient History and
Physical Exam, Toward Better Clinical Decisions and
Outcomes (227)
Speaker: Theodore Pincus, MD
• summarize the rationale for the use of MDHAQ/RAPID3 and
RHEUMDOC to help establish an “agenda” or “road map” for
the encounter
• proficiency in scoring RAPID3 and interpretation using
RHEUMDOC in using different levels of scores for clinical
decisions
• recognize how to use other components of MDHAQ beyond
RAPID3, including RADAI self-report joint count (rheumatoid
arthritis disease activity index), review of systems and recent
medical history and RHEUMDOC help improve doctor-patient
communication and save time for the doctor.
159
5:15 am
Guest Speaker
Ronald Laxer, MD
ACR SESSIONS
4:30 – 6:00 pm
204 A
Moderators: Marcy B. Bolster, MD and Kristine M. Lohr, MD, MS
• discuss examples of different career paths available to
rheumatologists
• explain the pros and cons of the various career paths in
rheumatology
4:30 pm
Basic Research
Ellen M. Gravallese, MD
Speakers: Janak R. Goyal, MD and Gurjit S. Kaeley, MBBS, MRCP
2 0 1 4
5:04 pm
Clinician Educator
Kenneth S. O’Rourke, MD
n o v e m b e r
1 7 ,
MONDAY
4:47 pm
Clinical Research
Jane E. Salmon, MD
• explain basic concepts of ultrasound physics
• assess how to perform a proper ultrasound examination
• identify various tissues in an ultrasound image
ACR SESSION
4:30 – 5:30 pm
PM
Pd
PS
PrM
5:21 pm
Private Practice
David G. Borenstein, MD
PS
Clinicopathologic Conference: A 17-Year-Old Young
PM
Ed
Woman with Chronic Ankle and Back Pain
Pd
PS
FIT
Moderators: Simon M. Helfgott, MD and Derrick J. Todd, MD,
PhD
• assess chronic ankle and back pain in adolescent patients
• determine the differences between inflammatory and noninflammatory joint pain
• synthesize clinical, radiologic and pathologic data in
formulating a diagnosis
4:30 pm
Case Presentation
Derrick J. Todd, MD, PhD
4:45 pm
Radiologic Findings
Barbara N. Weissman, MD
5:05 pm
Histologic Findings
Margaret Seton, MD
94
2014 Program Book
PS
Career Opportunities in Rheumatology: Making a
Choice
*Musculoskeletal Ultrasonography: Basic (228)
Ballroom East
PM
PrM
5:38
pm
FIT
Industry
Primal P. Kaur, MD
5:55 pm
PM
PS
Ballroom West
Curbside Consults – Ask the Experts
Moderators: Rula Hajj-Ali, MD, Rebecca L. Manno, MD, MHS and
N. Lawrence Edwards, MD
• compare the personal management approaches of selected
clinical problems with those of the presenters
• develop an approach to evaluating and managing patients
with a new diagnosis of granulomatosis with polyangiitis
• devise an approach to evaluating and managing patients with
cryoglobulinemic vasculitis
• describe therapeutic options for common but difficult
complications of the antiphospholipid syndrome
scientific sessions
4:30 pm
A New Diagnosis of Granulomatosis with Polyangiitis: How Do I
Treat This Patient?
Carol A. Langford, MD
5:00 pm
The Role of Wnt Signaling in Bone and Cartilage in
Osteoarthritis
Rik Lories, PhD, MD
5:00 pm
Cryoglobulinemic Vasculitis...Help!
Patrice Cacoub, MD
5:30 pm
Transforming Growth Factor Beta (TGF-ß), Bone Marrow
Mesenchymal Stem Cells and Osteoarthritis
Xu Cao, Phd
5:30 pm
Antiphospholipid Syndrome: How Do I Approach This Patient?
Robert Roubey, MD
PM
PS
Treating Pain Doesn’t Have to Be a Pain: Practical
PS
PrM
Pd
PS
PM
PM
Ed
Approaches to Pain Management
FIT
Moderators: Kerry Stone, MD and Rodney Tehrani, MD
160 B
Fibrotic Complications of Scleroderma
Moderators: Dinesh Khanna, MD and Virginia D. Steen, MD
• review the management of early skin involvement in systemic
scleroderma
• discuss the management of lung fibrosis in systemic
scleroderma
• explain the management of heart involvement in systemic
scleroderma
5:30 pm
Amplified Musculoskeletal Pain Syndrome
David D. Sherry, MD
2 0 1 4
PM
5:00 pm
Low Back Pain
Rajiv Dixit, MD
1 7 ,
5:30 pm
Primary Cardiac Involvement in Systemic Sclerosis –
Management Strategies
Yannick Allanore, MD, PhD
4:30 pm
Fibromyalgia
Don L. Goldenberg, MD
MONDAY
5:00 pm
Management of Interstitial Lung Disease – Whom to Treat
Philip J. Clements, MD, MPH
• develop a rational treatment approach to fibromyalgia
• develop a rational approach to the diagnosis and treatment of
low back pain
• describe the etiologies and diagnosis of amplified
musculoskeletal pain syndrome
• develop a multidisciplinary approach for the treatment of
amplified musculoskeletal pain syndrome
n o v e m b e r
4:30 pm
Skin Fibrosis in Systemic Sclerosis – Current Management
Strategies
Oliver Distler, MD
102 A
PS
PM
205 B
4:30 – 6:00 pm
PS
The Role of Bone in the Pathogenesis of
Osteoarthritis
Moderator: Richard F. Loeser, MD
• describe the relationship between bone marrow lesions and
pain and disease progression in osteoarthritis
• define the biological and mechanical factors that regulate
bone remodeling in osteoarthritis
• appraise how transforming growth factor beta in bone
activates mesenchymal stem cells that contribute to
osteoarthritis pathogenesis
4:30 pm
The Relationship of Bone Marrow Lesions to Pain and
Progression in Osteoarthritis
David T. Felson, MD, MPH
253 B
PM
PS
Epidemiology and Public Health III: Gout and
PS
PM
Moderators: Evelyne Vinet, MD and Dorothy D. Dunlop, PhD
4:30 pm
1872. Gout in Older Adult
Mara McAdams-DeMarco1, Anna Kottgen2, Bridget Burke3,
Andrew Law4, Josef Coresh1 and Alan N. Baer5, 1Johns Hopkins
Bloomberg School of Public Health, Baltimore, MD, 2University
Hospital Freiburg, Freiburg, Germany, 3Johns Hopkins University,
Baltimore, MD, 4Johns Hopkins, Baltimore, MD, 5Johns Hopkins
4:45 pm
1873. Food Sources of Protein and Risk of Incident Gout in the
Singapore Chinese Health Study
Gim Gee Teng1, An Pan2, Jian-Min Yuan3 and Woon-Puay
Koh4, 1Yong Loo Lin School of Medicine, National University
of Singapore, Singapore, Singapore, 2Saw Swee Hock School
2014 Program Book
95
scientific sessions
of Public Health, National University of Singapore, Singapore,
Singapore, 3Division of Cancer Control and Population Sciences,
University of Pittsburgh Cancer Institute and Department of
Epidemiology, University of Pittsburgh Graduate School of Public
Health, Pittsburgh, PA, 4Duke-NUS Graduate Medical School
Singapore, Singapore, Singapore
5:00 pm
1874. Obesity Paradox in Recurrent Gout – a Metrological
Clarification and Remedy
Uyen Sa D.T. Nguyen1, Qiong Louie-Gao1, Yuqing Zhang1, David T.
Felson1, Michael P. Lavalley2 and Hyon Choi3, 1Boston University
School of Medicine, Boston, MA, 2Boston University, Boston, MA,
3
Harvard Medical School, Boston, MA
n o v e m b e r
1 7 ,
MONDAY
2 0 1 4
5:15 pm
1875. Can Allopurinol Survival Impact Reverse Depending on
Patients’ Characteristics? a Propensity-Score-Based Subgroup
Analysis
Na Lu1, Hyon Choi2, Maureen Dubreuil3, Qiong Louie-Gao1 and
Yuqing Zhang1, 1Boston University School of Medicine, Boston,
MA, 2Harvard Medical School, Boston, MA, 3Boston University
Medical Center, Boston, MA
5:30 pm
1876. Influence of Alcohol Consumption on the Risk of SLE
Among Women in the Nurses’ Health Studies
Medha Barbhaiya, Bing Lu, Shun-Chiao Chang, Jeffrey A. Sparks,
Elizabeth W. Karlson and Karen H. Costenbader, Brigham and
Women’s Hospital, Harvard Medical School, Boston, MA
5:45 pm
1877. Pregnancy Outcomes in SLE: Before and after
Elizabeth V. Arkema1, Kristin Palmsten2, Christopher Sjöwall3,
Elisabet Svenungsson4, Jane E. Salmon5 and Julia F Simard6,
1
Karolinska Institutet, Stockholm, Sweden, 2University of
California, San Diego, La Jolla, CA, 3Linköping University,
Linköping, Sweden, 4Rheumatology Unit, Karolinska Institutet,
Stockholm, Sweden, 5Hospital for Special Surgery, New York, NY,
6
Stanford School of Medicine, Stanford, CA
104 B
PM
PS
and Specific Clinical Pain Syndromes II: Clinical
PS
PM
Perspectives
Moderators: Muhammad Yunus, MD and Lisa Suter, MD
4:30 pm
1878. A Combination of Celecoxib and Famciclovir Is Efficacious
in the Treatment of Fibromyalgia: Results of a Phase IIa
Randomized, Double-Blind, Placebo-Controlled Study
William Pridgen1, Carol Duffy2, Judith Gendreau3 and R
Michael Gendreau3, 1Innovative Med Concepts, Tuscaloosa, AL,
2
University of Alabama, Tuscaloosa, AL, 3Gendreau Consulting,
LLC, Poway, CA
96
2014 Program Book
4:45 pm
1879. The Efficacy of Pregabalin for Treating Fibromyalgia
Patients with Moderate or Severe Baseline Widespread Pain
Andrew Clair and Birol Emir, Pfizer Inc, New York, NY
5:00 pm
1880. Moderate Alcohol Consumption Is Associated with Lower
Risk (and severity) of Chronic Widespread Pain: Results from a
Population-Based Study
Gary J. Macfarlane and Marcus Beasley, University of Aberdeen,
Aberdeen, United Kingdom
5:15 pm
1881. Patients Who Fail Biologics Are More Likely to Have
Concomitant Fibromyalgia
Robert S. Katz1 and Jessica L. Polyak2, 1Rush Medical College,
Chicago, IL, 2Rheumatology Associates, Chicago, IL
5:30 pm
1882. Examination of Patients Newly Diagnosed with
Fibromyalgia: Use of Guideline-Recommended Therapies and
Opioids in Clinical Practice
Sonali N. Shah1, Rachel Halpern2, Joseph C. Cappelleri3, Elizabeth
T. Masters4, Andrew G. Clair1, Cori Blauer-Peterson2 and Damon
Van Voorhis5, 1Pfizer, Inc., New York, NY, 2Optum, Eden Prairie,
MN, 3Pfizer, Inc., Groton, CT, 4Pfizer Inc, New York, NY, 5Optum
Life Sciences, Eden Prairie, MN
5:45 PM
1883. WITHDRAWN
156 B
PM
PS
Genetics, Genomics and Proteomics I: Epigenetic
Mechanisms in Autoimmunity
Moderators: Patrick Gaffney, MD and Amr Sawalha, MD
4:30 pm
1884. Differential DNA Methylation Associated with
Rheumatoid Arthritis in Disease Discordant Monozygotic Twins
Amy Webster1, Flore Zufferey2, Darren Plant3, Anne Barton4,
Frances Williams2 and Jane Worthington5, 1Arthritis Research UK
Centre for Genetics and Genomics, The University of Manchester,
Manchester, United Kingdom, 2Dept Twin Research and Genetic
Epidemiology, Kings College London, London, United Kingdom,
3
NIHR Manchester Musculoskeletal Biomedical Research
Unit, Manchester Academy of Health Sciences, Manchester,
United Kingdom, 4Arthritis Research UK Centre for Genetics
and Genomics, University of Manchester, Manchester, United
Kingdom, 5The University of Manchester, Manchester, United
Kingdom
4:45 pm
1885. Integrative Omics Profiling Reveals Dysregulated Novel
Pathways Mediated By microRNAs and DNA Methylation in
Osteoarthritis
Kathleen M. Fisch1, Ryuichiro Akagi2, Oscar Alvarez-Garcia1,
Takeshi Teramura1, Yuta Muramatsu1, Masahiko Saito3, Stuart
scientific sessions
Duffy1, Shawn Grogan1, Takahisa Sasho4, Darryl D’Lima1, Andrew
I. Su1 and Martin K. Lotz1, 1The Scripps Research Institute, La
Jolla, CA, 2The Scripps Research Institute, San Diego, CA, 3Toho
University Sakura Medical Center, Sakura, Japan, 4Chiba
University School of Medicine, Chiba, Japan
Indianapolis, IN, 5Daiich Sankyo Co. Ltd, Tokyo, Japan, 6Daiichi
Sankyo Co. Ltd, Tokyo, Japan, 7University of California, San
Francisco, CCBR-Synarc, Newark, Tiburon, CA, 8Leiden University
Medical Center, Leiden, Netherlands, 9Keio University School of
Medicine, Tokyo, Japan
5:00 pm
1886. A Novel Monocyte-Specific Transcript Underlies
the Chromosome 21q22 Intergenic Genetic Association in
Ankylosing Spondylitis
Katelin Haynes, Tony Kenna, Evgeny Glazov, Matthew A. Brown
and Gethin Thomas, University of Queensland Diamantina
Institute, Brisbane, Australia
4:45 pm
1891. Early MRI Endpoints Provide a Valid Measure of
Structural Damage While Reducing Study Duration and
Participant Numbers in Rheumatoid Arthritis Clinical Trials
Joshua Baker1, Philip G. Conaghan2, Paul Emery3, Daniel
Baker4 and Mikkel Østergaard5, 1Philadelphia VA Medical
Center, Philadelphia, PA, 2University of Leeds and NIHR Leeds
Musculoskeletal Biomedical Research Unit, Leeds, United
Kingdom, 3NIHR-Leeds Musculoskeletal Biomedical Research
Unit and Leeds Institute of Rheumatic and Musculoskeletal
Medicine, University of Leeds, Leeds, United Kingdom, 4Janseen
R&D, Spring House, PA, 5Copenhagen Center for Arthritis
Research, Copenhagen University Hospital at Glostrup, Glostrup,
Denmark
5:15 pm
1887. Genome-Wide DNA Methylation Analysis of Twin Pairs
Discordant for Systemic Sclerosis Reveals Distinct Signatures in
Blood and Dermal Fibroblasts
Paula S. Ramos1, Rick Jordan2, James Lyons-Weiler2, Thomas A.
Medsger Jr.2 and Carol A. Feghali-Bostwick1, 1Medical University
of South Carolina, Charleston, SC, 2University of Pittsburgh,
Pittsburgh, PA
Imaging of Rheumatic Diseases: X-Ray, MRI and CT
Moderators: Charles Peterfy, MD, PhD and Orrin M. Troum, MD
4:30 pm
1890. Consistent Inhibition of Bone Destruction By Denosumab
in Important Subgroups of Japanese Patients with Rheumatoid
Arthritis
Naoki Ishiguro1, Yoshiya Tanaka2, Hisashi Yamanaka3, Toshiyuki
Yoneda4, Takeshi Ohira5, Naoki Okubo6, Harry K. Genant7, Desiree
van der Heijde8 and Tsutomu Takeuchi9, 1Nagoya University
Graduate School of Medicine, Nagoya, Japan, 2University of
Occupational and Environmental Health, Japan, Kitakyushu,
Japan, 3Institute of Rheumatology, Tokyo Women’s Medical
University, Tokyo, Japan, 4Indiana University School of Medicine,
2 0 1 4
PS
1 7 ,
PM
52 A
MONDAY
5:45 pm
1889. Rheumatoid Arthritis (RA)-Associated Risk Allele LBH
Alters the Function of a Differentially Methylated LBH Enhancer
Deepa Hammaker1, Gary S. Firestein2, Wei Wang3, John W.
Whitaker4 and Anna-Karin Ekwall5, 1University of California San
Diego, La Jolla, CA, 2University of California at San Diego School
of Medicine, La Jolla, CA, 3UCSD, La Jolla, CA, 4UCSD, San Diego,
CA, 5UC San Diego, La Jolla, CA
n o v e m b e r
5:30 pm
1888. PU.1, Mitf and Their Novel Co-Partner, Eomes, Set up
a Transcription Factor Network That Is Critical for Osteoclast
Differentiation
Heather Carey1, Sankha Ghosh1, Eason Hildreth III1, Jennifer
Cabrera1, Dias Kurmashev1, Wael N. Jarjour2, Ramiro Toribio1,
Sudarshana Sharma1 and Michael Ostrowski1, 1The Ohio State
University, Columbus, OH, 2The Ohio State University Wexner
Medical Center, Columbus, OH
5:00 pm
1892. In Vivo Visualization of Cortical Microchannels in
Metacarpal Bones in Patients with Cutaneous Psoriasis By
High Resolution Peripheral Computed tomography - Detecting
Cortical Pathologies before the Clinical Onset of Psoriatic
Arthritis
David Simon, Francesca Faustini, Arnd Kleyer, Judith Haschka,
David Werner, Axel J. Hueber, Michael Sticherling, Georg Schett
and Juergen Rech, University of Erlangen-Nuremberg, Erlangen,
Germany
5:15 pm
1893. Substantial Structural Lesions on MRI in the
Sacroiliac Joints of Patients with Non-Radiographic Axial
Spondyloarthritis Even in the Absence of MRI Inflammation
WP Maksymowych1, S Wichuk1, H Jones2, A Szumski2, L Marshall2,
J Bukowski2 and RG Lambert1, 1University of Alberta, Edmonton,
AB, 2Pfizer Inc., Collegeville, PA
5:30 pm
1894. Is It Worth to Include MRI of the Spine in the ASAS
Classification Criteria for Axial Spondyloarthritis
Manouk de Hooge1, Jean-Baptiste Pialat2, Antoine Feydy3,
Monique Reijnierse1, Pascal Claudepierre4, Alain Saraux5,
Maxime Dougados3 and Désirée van der Heijde1, 1Leiden
University Medical Center, Leiden, Netherlands, 2Hôpital
Edouard Herriot, Lyon, France, 3Descartes University, Cochin
Hospital, Paris, France, 4Henri Mondor Teaching Hospital, Creteil,
France, 5CHU de la Cavale Blanche, Brest Cedex, France
5:45 pm
1895. Sacroiliitis at Diagnosis in Children with Juvenile
Spondyloarthritis
Pamela Weiss1, Rui Xiao2 and Nancy Chauvin1, 1Children’s
Hospital of Philadelphia, Philadelphia, PA, 2University of
Pennsylvania, Philadelphia, PA
2014 Program Book
97
scientific sessions
157 B
PM
PS
Pediatric Rheumatology – Pathogenesis and Genetics
PM
Ed
Pd
PS
PrM
FIT
University of Pennsylvania, Philadelphia, PA, 2Alfred I. duPont
Hospital for Children, Wilmington, DE, 3The Children’s Hospital of
Philadelphia, Philadelphia, PA
Moderators: Karyl Barron, MD, PhD and Nora G. Singer, MD
n o v e m b e r
1 7 ,
MONDAY
2 0 1 4
4:30 pm
1896. Validation of a Novel IFN-Regulated Gene Score As
Biomarker in Chronic Atypical Neutrophilic Dermatosis with
Lipodystrophy and Elevated Temperature (CANDLE) Patients on
Baricitinib, a Janus Kinase 1 /2 Inhibitor, a Proof of Concept
Hanna Kim1, Steve Brooks2, Yin Liu1, Adriana Almeida de Jesus1,
Gina A. Montealegre Sanchez1, Dawn C. Chapelle1, Nicole
Plass1, Yan Huang1 and Raphaela Goldbach-Mansky1, 1National
Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH,
Bethesda, MD, 2NIAMS/NIH, Bethesda, MD
4:45 pm
1897. Circulating T-Helper Cell- Associated Cytokines and
Chemokines in Localized Scleroderma
Kathryn S. Torok1, Katherine Kurzinski2, Christina Kelsey3, Kelsey
Magee4, Jonathan Yabes4, Abbe N. Vallejo4, Thomas A. Medsger
Jr.4 and Carol A. Feghali-Bostwick5, 1Children’s Hospital of
Pittsburgh of UPMC, Pittsburgh, PA, 2Univ of Pittsburgh Med Ctr,
Pittsburgh, PA, 3University of Pittsburgh/UPMC, Pittsburgh, PA,
4
University of Pittsburgh, Pittsburgh, PA, 5Medical University of
South Carolina, Charleston, SC
5:00 pm
1898. Identification of “autoinflammatory interferonopathies”? a New Class of Autoinflammatory Conditions?
Adriana Almeida de Jesus1, Zuoming Deng1, Stephen Brooks2,
Yin Liu1, Hanna Kim1, Gina A. Montealegre Sanchez1, Dawn C.
Chapelle1, Yan Huang1, Philip Hashkes3, Gulnara Nasrullayeva4,
Maria Teresa Terreri5, Bita Arabshahi6, Marilynn G. Punaro7,
Lakshmi N. Moorthy8, Adam Reinhardt9, Clovis A. Silva10, Emilia I.
Sato11, Vibke Lilleby12, Thomas Fleisher13 and Raphaela GoldbachMansky1, 1National Institute of Arthritis and Musculoskeletal and
Skin Diseases, NIH, Bethesda, MD, 2NIAMS/NIH, Bethesda, MD,
3
Shaare Zedek Medical Center, Jerusalem, Israel, 4Azerbaijan
Medical University, Baku, Azerbaijan, 5University of Federal
De Sao Paulo, Sao Paulo, Brazil, 6Inova Fairfax Hospital for
Children, Fairfax, VA, 7University of Texas Southwestern
Medical Center, Dallas, TX, 8Robert Wood Johnson Medical
School-Rutgers University, New Brunswick, NJ, 9Children’s
Specialty Physicians, Omaha, NE, 10Faculdade de Medicina da
Universidade de São Paulo, São Paulo, Brazil, 11Escola Paulista
de Medicina – Universidade Federal de São Paulo, Sao Paulo,
Brazil, 12Department of Rheumatology, Oslo University Hospital,
Rikshospitalet, Oslo, Norway, 13National Institutes of Health,
Bethesda, MD
5:15 pm
1899. Blockade of Interleukin-33 Signaling Prevents Death in a
Mouse Model of Familial Hemophagocytic Lymphohistiocytosis
Julia Rood1, Portia Kreiger2, Erietta Stelekati1, E. John Wherry1
and Edward M. Behrens3, 1Perelman School of Medicine at the
98
2014 Program Book
5:30 pm
1900. HLA-DRB1*1101, Regulatory Variants of the MHC and
a Regulatory Region Near an Intergenic Long Noncoding RNA
on Chromosome 1 Are Risk Factors for Systemic Juvenile
Michael J. Ombrello1, Elaine F. Remmers2, Ioanna Tachmazidou3,
Alexei Grom4, Dirk Föll5, Alberto Martini6, Marco Gattorno7, Seza
Ozen8, Sampath Prahalad9, Andrew S. Zeft10, John F. Bohnsack11,
Norman T. Ilowite12, Jane L. Park13, Elizabeth D. Mellins13, Ricardo
A. G. Russo14, Claudio A. Len15, Sheila K. Feitosa de Oliveira16,
Rae SM Yeung17, Lucy R. Wedderburn18, Jordi Anton19, Tobias
Schwarz20, Buhm Han21, Richard H. Duerr22, Jean-Paul Achkar10,
M. Ilyas Kamboh22, Kenneth M. Kaufman23, Leah C. Kottyan4,
Dalila Pinto24, Stephen Scherer17, Marta E. Alarcón-Riquelme25,
Elisa Docampo Martinez26, Xavier Estivill27, Ahmet Gul28, Colleen
Satorius29, Paul I.W. de Bakker30, Soumya Raychaudhuri21,
Carl D. Langefeld31, Susan D. Thompson4, Eleftheria Zeggini3,
Wendy Thomson32, Daniel L. Kastner29, Patricia Woo33 and
International Childhood Arthritis Genetics (INCHARGE)
Consortium, 1National Institute of Arthritis Musculoskeletal
and Skin Diseases, National Institutes of Health, Bethesda, MD,
2
National Human Genome Research Institute, National Institutes
of Health, Bethesda, MD, 3The Wellcome Trust Sanger Institute,
Cambridge, United Kingdom, 4Cincinnati Children’s Hospital
Medical Center, Cincinnati, OH, 5University Children’s Hospital
Muenster, Muenster, Germany, 6University of Genova, Genova,
Italy, 7Instituto Giannina Gaslini, Genoa, Italy, 8Deptartment. of
Pediatric Rheumatology, Hacettepe University, Ankara, Turkey,
9
Emory University School of Medicine, Atlanta, GA, 10Cleveland
Clinic, Cleveland, OH, 11University of Utah, Salt Lake City, UT,
12
Albert Einstein College of Medicine, Bronx, NY, 13Stanford
University Medical Center, Stanford, CA, 14Hospital de Pediatria
Garrahan, Buenos Aires, Argentina, 15Universidade Federal
de São Paulo/Escola Paulista de Medicina, São Paulo, Brazil,
16
Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil,
17
The Hospital for Sick Children, Toronto, ON, 18University
College London (UCL) Institute of Child Health, London, United
Kingdom, 19Pediatric Rheumatology Unit. Hospital Sant Joan de
Déu. Universitat de Barcelona, Barcelona, Spain, 20University of
Wuerzburg, Wuerzburg, Germany, 21Broad Institute of MIT and
Harvard, Cambridge, MA, 22University of Pittsburgh, Pittsburgh,
PA, 23Cincinnati Children’s Hospital Medical Center and the
University of Cincinnati, Cincinnati, OH, 24Icahn School of
Medicine at Mount Sinai, New York, NY, 25Arthritis and Clinical
Immunology Program, Oklahoma Medical Research Foundation,
Oklahoma City, OK, 26GIGA-Université de Liège, LIege, Belgium,
27
Center for Genomic Regulation, Barcelona, Spain, 28Istanbul
Faculty of Medicine, Istanbul University, Istanbul, Turkey,
29
National Human Genome Research Institute, Bethesda, MD,
30
University Medical Center Utrecht, Utrecht, Netherlands,
31
Center for Public Health Genomics and Department of
Biostatistical Sciences, Wake Forest School of Medicine,
Winston-Salem, NC, 32Institute of Inflammation and Repair,
The University of Manchester, Manchester, United Kingdom,
33
University College London, London, United Kingdom
scientific sessions
5:45 pm
1901. Interferon-γ (IFNγ) in Macrophage Activation Syndrome
(MAS) Associated with Systemic Juvenile Idiopathic Arthritis
(sJIA). High Levels in Patients and a Role in a Murine MAS
Model
Claudia Bracaglia1, Ivan Caiello1, Kathy De Graaf2, Giovanni
D’Ario2, Florence Guilhot2, Walter Ferlin2, Lidia Meli1, Giusi
Prencipe1, Sergio Davì3, Grant Schulert4, Angelo Ravelli5, Alexei
Grom4, Cristina De Min2 and Fabrizio De Benedetti Sr.1, 1Division
of Rheumatology, Ospedale Pediatrico Bambino Gesù, IRCCS,
Rome, Italy, 2Novimmmune S.A., Plan-Les-Ouates, Geneva,
Switzerland, 3Istituto Giannina Gaslini, Genova, Italy, 4Cincinnati
Children’s Hospital Medical Center, Cincinnati, OH, 5Istituto
Giannina Gaslini and University of Genova, Genova, Italy
258 B
PM
PS
Rheumatoid Arthritis – Clinical Aspects IV: Promising
Biomarkers
Moderators: S. Louis Bridges Jr., MD, PhD and Kristen
Demoruelle, MD
1 7 ,
2 0 1 4
5:45 pm
1907. Clinical Evaluation of Anti-Aminoacyl tRNA Synthase
Antibodies in Rheumatoid Arthritis Patients
Masakazu Matsushita, Ken Yamaji, Naoto Tamura and Yoshinari
Takasaki, Juntendo University School of Medicine, Tokyo, Japan
MONDAY
4:45 pm
1903. Change in 14-3-3η Expression in Early RA Patients
Treated with DMARDs Corresponds with Change in DAS28 and
Good EULAR Responses
Dirkjan van Schaardenburg1, Mairead Murphy2, Yuan Gui2,
Samina Turk1, Walter P. Maksymowych3 and Anthony Marotta2,
1
Reade, Amsterdam, Netherlands, 2Augurex Life Sciences Corp.,
North Vancouver, BC, 3University of Alberta, Edmonton, AB
5:30 pm
1906. IL-6 Blockade Reduces Circulating N-Terminal Pro-Brain
Natriuretic Peptide Levels in Patients with Active Rheumatoid
Arthritis
Atsuma Nishiwaki1, Hitomi Kobayashi1, Yasuyuki Kobayashi2,
Isamu Yokoe1, Noboru Kitamura1, Hidetake Shiraiwa1, Takamasa
Nozaki1, Hirotake Inomata1, Natsumi Ikumi1, Kaita Sugiyama1,
Yousuke Nagasawa1 and Masami Takei3, 1Nihon University School
of Medicine, Tokyo, Japan, 2St.Marianna University School
of Medicine, Kawasaki, Japan, 3Nihon University School of
Medicine, Itabashi Tokyo, Japan
n o v e m b e r
4:30 pm
1902. Utility of Glyca, a Novel Inflammatory Marker, for
Assessment of Rheumatoid Arthritis Disease Activity
Michelle Ormseth1, Cecilia P. Chung1, Joseph F. Solus1, Annette
M. Oeser1, Margery A. Connelly2, Jim Otvos2 and C Michael
Stein1, 1Vanderbilt University, Nashville, TN, 2LipoScience, Inc.,
Raleigh, NC
5:15 pm
1905. Within-Day Variation and Influence of Physical Exercise
on Circulating Galectin-3 in Patients with Rheumatoid Arthritis
and Healthy Individuals
Saida Farah Issa1, Anne Friesgaard Christensen2, Tine
Lottenburger2, Kirsten Junker3, Hanne M. Lindegaard1, Kim
Hoerslev-Petersen4 and Peter Junker1, 1Department of
Rheumatology, Odense University Hospital, Odense, Denmark,
2
Department of Rheumatology, Vejle Hospital, Vejle, Denmark,
3
Institute of Molecular Medicine, Cardiovascular & Renal
Research, University of Southern Denmark, Odense, Denmark,
4
Research Unit at King Christian X Hospital for Rheumatic
Diseases, Graasten, Graasten, Denmark
Exhibit Hall C
PS
PM
and Gene Therapy IV: Safety of Biologics and Small
Molecules in Rheumatoid Arthritis – Cardiovascular
and Other Systems
Moderators: Gerd Burmester, MD and Alan K. Matsumoto, MD
5:00 pm
1904. Rheumatoid Factor Isotype Testing to Identify Individuals
in the Preclinical Period of Rheumatoid Arthritis
M. Kristen Demoruelle1, Anthony Kahr1, Mark C. Parish1, Marie L.
Feser1, Ryan W. Gan2, Jason R. Kolfenbach1, William R. Gilliland3,
Jess D. Edison3, Michael H. Weisman4, James R. O’Dell5, Ted
R. Mikuls6, Richard M. Keating7, Peter K. Gregersen8, Jane
H. Buckner9, Jill M. Norris2, V. Michael Holers1 and Kevin D.
Deane1, 1University of Colorado School of Medicine, Aurora, CO,
2
Colorado School of Public Health, Aurora, CO, 3Walter Reed
National Military Medical Center, Bethesda, MD, 4Cedars-Sinai
Medical Center, Los Angeles, CA, 5Veteran Affairs Nebraska
Western Iowa Health Care System and University of Nebraska
Medical Center, Omaha, NE, 6Omaha VA Medical Center and
University of Nebraska Medical Center, Omaha, NE, 7Scripps
Clinic, La Jolla, CA, 8Feinstein Institute for Medical Research,
Manhasset, NY, 9Benaroya Research Institute at Virginia Mason,
Seattle, WA
4:30 pm
1908. Pregnancy Outcomes in the Tofacitinib RA Safety
Database through April 2014
A. Marren1, Y. Chen1, D. Frazier2 and J. Geier3, 1Pfizer Inc,
Collegeville, PA, 2Pfizer Inc, Groton, CT, 3Pfizer Inc, New York, NY
4:45 pm
1909. Incidence of Congestive Heart Failure in Subjects with
Rheumatoid Arthritis Receiving Anti-Tumour Necrosis Factor
Drugs: Results from the British Society for Rheumatology
Biologics Register for Rheumatoid Arthritis
Alper van Sijl1, Mamas Mamas2, Mark Lunt3, . BSRBR Control
Centre Consortium4, Kath Watson5, Deborah P. Symmons4
and Kimme L. Hyrich6, 1Arthritis Research UK Centre for
Epidemiology, Centre for Musculoskeletal Research, Manchester
Academic Health Science Centre, University of Manchester,
Manchester, United Kingdom, 2Manchester Heart Centre,
Manchester Royal Infirmary, Oxford Road, Manchester, UK;
2014 Program Book
99
scientific sessions
Institute of Cardiovascular Sciences, University of Manchester,
Manchester, United Kingdom, 3University of Manchester,
Manchester, United Kingdom, 4Arthritis Research UK Centre
for Epidemiology, University of Manchester, Manchester,
United Kingdom, 5Arthritis Research UK Epidemiology Unit,
The University of Manchester, Manchester, United Kingdom,
6
Centre for Musculoskeletal Research, University of Manchester,
Manchester, United Kingdom
4:45 pm
1915. IL-17 Gene Transfer induces Myeloid Precursor Cells That
Initiate Epidermal Hyperplasia Independently of IL-23R+/CD4+
and γδ T Cells
Erika Suzuki, Ritu Sarin, Emanual Maverakis and Iannis E.
Adamopoulos, University of California at Davis, Sacramento, CA
5:00 pm
1916. Stromal Overexpression of Transmembrane TNF Induces
Spa-like Arthritis and Spondylitis in Mice
Leonie M. van Duivenvoorde1, Melissa N. van Tok1 and
Dominique L. Baeten2, 1Department of Clinical Immunology and
Rheumatology and Department of Experimental Immunology,
Academic Medical Centre/University of Amsterdam, Amsterdam,
Netherlands, 2Academic Medical Center / University of
Amsterdam, Amsterdam, Netherlands
5:00 pm
1910. Risk of Hypersensitivity Among Medicare Patients with
Rheumatoid Arthritis Who Were Taking Biologics
Huifeng Yun1, Fenglong Xie2, Lang Chen2, James Lewis3 and
Jeffrey R. Curtis2, 1University of Alabama at Birmingham School
of Public Health, Birmingham, AL, 2University of Alabama at
Birmingham, Birmingham, AL, 3University of Pennsylvania,
Philadelphia, PA
5:15 pm
1917. IL-23 Expression and Activation of Autophagy in
Synovium and PBMCs of HLA-B27 Positive Patients with
Barbara Neerinckx, Shea Carter and Rik Lories, KU Leuven,
Leuven, Belgium
n o v e m b e r
1 7 ,
MONDAY
2 0 1 4
5:15 pm
1911. Disease Modifying Anti-Rheumatic Drug Use and the Risk
of Incident Hyperlipidemia in Patients with Early Rheumatoid
Arthritis: A Retrospective Cohort Study
Rishi Desai, Wesley Eddings, Katherine Liao, DH Solomon and
Seoyoung C. Kim, Brigham and Women’s Hospital, Boston, MA
5:45 pm
1913. Rosuvastatin Induced Carotid Plaque Regression in
Patients with Inflammatory Joint Diseases
Silvia Rollefstad1, Eirik Ikdahl1, Jonny Hisdal2, Inge C. Olsen1,
Ingar Holme3, Hilde Berner Hammer1, Knut T. Smerud4, G
Kitas5, Terje R. Pedersen6, Tore K. Kvien7 and Anne Grete Semb1,
1
Diakonhjemmet Hospital, Oslo, Norway, 2Uslo University
Hospital-Aker, Oslo, Norway, 3Oslo University Hospital, Oslo,
Norway, 4Smerud Medical Research International AS, Oslo,
Norway, 5The Dudley Group of Hospitals NHS Foundation Trust,
Dudley, United Kingdom, 6University of Oslo, Oslo, Norway,
7
PsAID taskforce, EULAR, Zurich, Switzerland
153 B
PM
Spondyloarthropathies and Psoriatic Arthritis –
Pathogenesis, Etiology: From Genes to Cytokines
Moderators: Christopher T. Ritchlin, MD, MPH and Robert D.
Inman, MD
4:30 pm
1914. IL-17A Deficiency Promotes Periosteal Bone Formation in
a Model of Inflammatory Arthritis
Anita T. Shaw1, Yukiko Maeda1, Catherine Manning1 and Ellen
M. Gravallese2, 1University of Massachusetts Medical School,
Worcester, MA, 2UMass Memorial Medical Center, Worcester,
MA
100
5:30 pm
1918. IL23 Overexpression Demonstrates Gut-Joint
Inflammation Link and Increased Expression of
Spondyloarthopathy Associated Genes In Vivo
Donald Souza II, Boehringer Ingelheim Pharmaceuticals Inc.,
Ridgefield, CT
5:30 pm
1912. Tocilizumab Therapy for Rheumatoid Arthritis Patients
with Chronic Renal Insufficiency
Shunsuke Mori, NHO Kumamoto Saishunsou National Hospital,
Kumamoto, Japan
2014 Program Book
5:45 pm
1919. HLA-B27 Expression Shapes the Intestinal Microbiota
Mark Asquith1, Phoebe Lin1, Tejpal Gill2, Justine Debelius3, Patrick
Stauffer1, Sean Davin1, Gail Ackermann3, Robert A. Colbert2, Rob
Knight3 and James Rosenbaum4, 1Oregon Health and Science
University, Portland, OR, 2NIAMS/NIH, Bethesda, MD, 3University
of Colorado Boulder, Boulder, CO, 4Legacy Hospital, Portland, OR
210 B
PM
PS
and Treatment: Biomarkers in Systemic Lupus
Erythematosus
PS
Moderators: Diane L. Kamen, MD, MS and Anca D. Askanase,
MD
4:30 pm
1920. Predicting SLE Disease Activity in the Next Year Based on
Measures of Four Gene Transcripts and Two Proteins
Laurence S Magder1, Eric Zollars2, Jadwiga Bienkowska3, Chris
Stebbins4, Carrie Wager4, Linda Burkly4, Nicolas Wisniacki5, Ann
Ranger4 and Michelle Petri2, 1University of Maryland School of
Medicine, Baltimore, MD, 2Johns Hopkins University School of
Medicine, Baltimore, MD, 3Biogen Idec Inc., Cambridge, MA,
4
Biogen Idec, Cambridge, MA, 5Formerly with Biogen Idec,
Cambridge, MA
scientific sessions
4:45 pm
1921. The Deposition of Complement C4d Split Product on
Platelets and Erythrocytes Correlate with Disease Activity and
Improvement in Systemic Lupus Erythematosus
Joan T. Merrill1, Aikaterini Thanou1, Stan Kamp1, John Conklin2,
Derren Barken2 and Thierry Dervieux2, 1Oklahoma Medical
Research Foundation, Oklahoma City, OK, 2Exagen Diagnostics,
Inc., Vista, CA
5:00 pm
1922. Hydroxychloroquine Use Is Associated with Decreased
Soluble TNF Receptor Levels in SLE Patient Samples
Rufei Lu1, Adam Przebinda1, Melissa E. Munroe2, Joel M.
Guthridge2, Joan T. Merrill2 and Judith A. James2, 1University
of Oklahoma Health Sciences Center, Oklahoma City, OK,
2
Oklahoma Medical Research Foundation, Oklahoma City, OK
1 7 ,
MONDAY
2 0 1 4
5:30 pm
1924. Cell Bound Complement Activation Products Have Higher
Sensitivity Than Serum C3 and C4 Levels in Systemic Lupus
Erythematosus
Rosalind Ramsey-Goldman1, Richard Furie2, Chaim Putterman3,
Anka Askanase4, Jill P. Buyon5, Kenneth Kalunian6, W. Winn
Chatham7, E Massarotti8, Kyriakos A. Kirou9, A. Weinstein10, Puja
Chitkara11, Susan Manzi12, Joe Ahearn13, Leilani Wolover14, John
Conklin14, Tyler O’Malley14, Claudia Ibarra14, Derren Barken14
and Thierry Dervieux14, 1Northwestern University, Chicago, IL,
2
North Shore-LIJ Health System, Great Neck, NY, 3Albert Einstein
College of Medicine, Bronx, NY, 4Colombia University, New York,
NY, 5New York University School of Medicine, New York, NY,
6
UCSD School of Medicine, La Jolla, CA, 7University of Alabama
at Birmingham, Birmingham, AL, 8Brigham and Women’s
Hospital, Boston, MA, 9Hospital for Special Surgery, New York,
NY, 10Washington Hospital Center, Washington, DC, 11Sharp
Memorial Hospital, San Diego, CA, 12Division of Rheumatology,
University of Pittsburgh School of Medicine, Pittsburgh, PA,
13
West Penn Allegheny Health System, Pittsburgh, PA, 14Exagen
Diagnostics, Inc., Vista, CA
n o v e m b e r
5:15 pm
1923. Vitamin D Restores Lupus Myeloid Angiogenic Cell
Function Via Down-Regulation of IP-10/CXCL-10
John A. Reynolds1, David W. Ray2, Yvonne Alexander3 and Ian
N. Bruce4, 1Arthritis Research UK Centre for Epidemiology,
Centre for Musculoskeletal Research, Institute of Inflammation
and repair, Manchester Academic Health Science Centre, The
University of Manchester, United Kingdom, Manchester, United
Kingdom, 2Institute of Human Development, The University
of Manchester, Manchester, United Kingdom, 3Manchester
Metropolitan University, Manchester, United Kingdom,
4
Arthritis Research UK Centre for Epidemiology, Centre for
Musculoskeletal Research, Institute of Inflammation and repair,
Manchester Academic Health Science Centre, The University of
5:45 pm
1925. Determinants of Blood Hydroxychloroquine
Concentration Variations in Systemic Lupus Erythematosus
Patients
Moez Jallouli1, Lionel Galicier2, Olivier Aumaître3, Camille
Francès4, Véronique Le-Guern5, F. Lioté6, Amar Smail7, Nicolas
Limal8, L. Perard9, H. Desmurs-Clavel10, Du Boutin11, B. Asli12,
Jean Emmanuel Kahn13, Jacques Pourrat14, Laurent Sailler15, F.
Ackermann13, T. Papo16, Karim Sacre17, O. Fain18, J. Stirnemann18,
Patrice Cacoub1, Gaëlle Leroux1, Judith Cohen-Bittan1, Js Hulot19,
Zahir Amoura20, Jean-Charles Piette1 and Nathalie CostedoatChalumeau5, 1CHU Pitié-Salpêtrière, Paris, France, 2Hopital
St Louis, AP-HP, Paris, France, 3Division of internal Medicine,
Centre Hospitalier Universitaire, Hôpital Gabriel Montpied,
Clermont–Ferrand, Clermont–Ferrand, France, 4Hôpital Tenon,
Paris Cedex 20, France, 5Department of Internal Medicine,
Referral Center for Rare Autoimmune and Systemic Diseases,
Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France,
6
Hôpital Lariboisière, Université Paris-Diderot, Sorbonne ParisCité, Paris, France, 7CHU Amiens Nord, Amiens, France, 8Hôpital
Henri Mondor, APHP, Creteil, France, 9Hospices Civils de Lyon,
groupement Hospitalier Edouard Herriot, Lyon, France, 10Hospice
civils de Lyon, Lyon, France, 11Assistance Publique-Hôpitaux de
Paris, Hopital Pitié-Salpétrière, Paris, France, 12Hopital Saint
Louis, Université Paris Diderot, Sorbonne Paris Cité, Paris, France,
13
Hopital Foch, Suresnes, France, 14CHU Toulouse, Hopital
Rangueil, University of Paul Sabatier, Toulouse, France, 15CHU
Toulouse, Hopital Purpan, University of Paul Sabatier, Toulouse,
France, 16Hopital Bichat Claude Bernard, University of Paris
Diderot, Sorbonne Paris cité, Paris, France, 17University Paris-7,
INSERM U699, APHP, Bichat Hospital, Paris, France, 18Hopital
Jean Verdier, University Paris Nord, Sorbonne Paris Cité, Paris,
France, 19CHU Pitié-Salpêtrière, UPMC, University Paris 6, Paris,
France, 20Pitié-Salpêtrière Hospital (AP-HP), Paris, France
107 B
PS
PM
Raynaud’s – Clinical Aspects and Therapeutics II:
Approaches to Cardiac and Vascular Manifestations in
Systemic Sclerosis
Moderator: Robyn T. Domsic, MD, MPH and Laura K. Hummers,
MD
4:30 pm
1926. Nailfold Videocapillaroscopy Patterns Associated with
Calcinosis and Acro-Osteolysis in Systemic Sclerosis
Jerome Avouac1, Laetitia Morardet2, Maya Sammour3, Andre
Kahan2, Antoine Feydy3 and Yannick Allanore1, 1Paris Descartes
University, Rheumatology A Department and INSERM U1016,
Cochin Hospital, Paris, France, 2Paris Descartes University,
Rheumatology A department, Cochin Hospital, Paris, France,
3
Paris Descartes University, Radiology B department, Cochin
Hospital, Paris, France
2014 Program Book
101
scientific sessions
n o v e m b e r
1 7 ,
MONDAY
2 0 1 4
4:45 pm
1927. A Retrospective Look at the Recurrence of Digital Ulcers
in Patients with Scleroderma after Discontinuation of Oral
Treprostinil
Ami A. Shah1, Elena Schiopu2, Soumya Chatterjee3, Mary
Ellen Csuka4, Tracy Frech5, Avram Goldberg6, Robert F. Spiera7,
Stanford L. Peng8 and Virginia D. Steen9, 1Johns Hopkins
University School of Medicine, Baltimore, MD, 2University
of Michigan, Ann Arbor, MI, 3Cleveland Clinic, Cleveland, OH,
4
Medical College of Wisconsin, Milwaukee, WI, 5University of
Utah, Salt Lake City, UT, 6North Shore-LIJ Health System, Great
Neck, NY, 7Hospital for Special Surgery, New York, NY, 8Benaroya
Research Institute/Virginia Mason, Seattle, WA, 9Georgetown
University Medical Center, Washington, DC
5:00 pm
1928. A Multicenter, Prospective Cohort Study Using Nailfold
Videocapillaroscopy and Other Clinical Characteristics to
Determine the Risk of Developing New Digital Ulcers in
Patients with Systemic Sclerosis
Vanessa Smith1, Maurizio Cutolo2, Ariane Herrick3, Oliver
Distler4, Mike Becker5, Emma Beltran6, Patrick Carpentier7,
Clodoveo Ferri8, Murat Inanc9, Panayiotis Vlachoyiannopoulos10,
Harbajan Chadha-Boreham11, Emmanuelle Cottreel11, Thomas
Pfister11, Daniel Rosenberg11 and Juan Torres, on behalf of the
CAP study investigators12, 1Ghent University Hospital, Ghent,
Belgium, 2Research Laboratory and Academic Division of Clinical
Rheumatology, Department of Internal Medicine, University
of Genova, Genoa, Italy, 3Centre for Musculoskeletal Research,
University of Manchester, Manchester Academic Health Science
Centre, Manchester, United Kingdom, 4Zurich University Hospital,
Zurich, Switzerland, 5Charité University Hospital, Berlin, Germany,
6
Hospital La Fe, Valencia, Spain, 7La Tronche Hospital, Grenoble,
France, 8University of Modena & Reggio E, Moderna, Italy,
9
Division of Rheumatology, Department of Internal Medicine,
Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey,
10
School of Medicine, National University of Athens, Athens,
Greece, 11Actelion Pharmaceuticals Ltd, Allschwil, Switzerland,
12
Syntax for Science SL, Basel, Switzerland
5:15 pm
1929. Echocardiographic Phenomics for Novel Classification of
Cardiac Involvement in Systemic Sclerosis
Monique Hinchcliff, Vistasp Daruwalla, Lauren Beussink-Nelson,
Sofia Podlusky, Mary A. Carns, John Varga and Sanjiv J. Shah,
IL
5:45 pm
1931. Mycophenolate Mofetil (MMF) Use in Scleroderma
Patients with Pulmonary Hypertension: Observations from
the Pulmonary Hypertension Assessment and Recognition of
Outcomes in Scleroderma Cohort
Lesley Ann Saketkoo1, Matthew R. Lammi2, Aryeh Fischer3, Jerry
A. Molitor4 and Virginia D. Steen5, 1Louisiana State University
Health Sciences Center, New Orleans, LA, 2Louisiana State
University Health Sciences Center, Pulmonary and Critical
Medicine, New Orleans, LA, 3National Jewish Health, Denver,
CO, 4University of Minnesota, Minneapolis, MN, 5Georgetown
PS
University Medical Center, Washington, DC PM
4:30 – 6:00 pm
Antiphospholipid Syndrome (051)
Speaker: Doruk Erkan, MD
• review the spectrum of antiphospholipid syndrome
• explain the diagnostic utility of antiphospholipid antibody
tests
• discuss the management of persistently antiphospholipid
antibody-positive patients with different antiphospholipid
antibody-related clinical manifestation
*Behçet’s Syndrome (052)
Speaker: Yusuf Yazici, MD
• discuss the epidemiology, disease mechanisms and the
differential diagnosis of Behçet’s syndrome
• describe current approaches to the management of patients
with Behçet’s syndrome
5:30 pm
1930. The Value of Repeated Nailfold Capillaroscopy in
Raynaud’s Phenomenon in Daily Practice: A Follow-up Study in
the Netherlands
B. de Boer1, J. Meijs1, J. van Aken2, T.W.J. Huizinga1, A.a.
Schouffoer3 and J.K. de Vries-Bouwstra1, 1Leiden University
Medical Center, Leiden, Netherlands, 2Spaarne Ziekenhuis,
Hoofddorp, Netherlands, 3Haga Hospital, The Hague,
Netherlands
102
2014 Program Book
Immunodeficiency Syndromes (053)
• review the immunology and clinical manifestations of the
major immune deficiency syndromes that both adult and
pediatric rheumatologists might encounter
• discuss the diagnostic evaluation for someone suspected of
having an immune deficiency syndrome
• illustrate therapeutic options with cases
scientific sessions
*Infections with Biologics (054)
Speaker: Kathryn H. Dao, MD
• discuss the risk of infection related to inflammation and
disease
• discuss the risk factors for infection
• recognize the magnitude of risk imposed by steroids and
biologics
• determine the approach to risk reduction
*Myopathy: Issues in Diagnosis and Treatment (055)
Speaker: Rohit Aggarwal, MD, MS
• differentiate myositis mimics from idiopathic inflammatory
myopathies
• d escribe the importance of myositis antibodies and muscle
magnetic resonance imaging in diagnosis and prognosis
• review myositis diagnosis in difficult cases including review of
clinical features, muscle biopsy and electromyography
• review management of refractory myopathy including
management of extra-muscular manifestations especially
interstitial lung disease
Speaker: Lee S. Simon, MD
• examine the drug safety literature with greater expertise
• prescribe DMARDs with a broader and deeper knowledge of
potential toxicities
• discuss DMARD toxicities with their patients with greater
comfort
• manage potential DMARD toxicities with greater skill
*Systemic Lupus Erythematosus: Lupus Nephritis (059)
Speaker: Brad H. Rovin, MD
• review immunosuppressive therapy of lupus nephritis Classes
• discuss the use of renoprotective and anti-proteinuria
• discuss diagnosis and treatment of renal thrombotic
microangiopathy and podocytopathies
nephritis
Vasculitis – Factors That Influence Disease Patterns
(060)
Speaker: Gary S. Hoffman, MD
• identify emerging concepts regarding the pathophysiology of
inflammation and fibrosis in autoimmune lung disease
• recognize the appropriate use of diagnostic tests in the
evaluation of patients with rheumatic disorders and
autoimmune lung disease
• discuss the limits of traditional therapeutic options and
possible emerging therapies in managing autoimmune lung
disease
• review advances in diagnosis and staging of vasculitis and
updates on prognostic information of interest to clinicians and
patients
• review advances in therapeutic intervention (including
biologics) in the treatment of the systemic vasculitides such as
granulomatosis with polyangiitis, cryoglobulinemic vasculitis
and giant cell arteritis
• assess how to incorporate recent research data and practices
into providing clinical care in the community for patients with
vasculitis
Raynaud’s and Digital Ischemia (057)
Speaker: Fredrick M. Wigley, MD
ARHP SESSIONS
• discuss the current understanding of the pathogenesis of
Raynaud’s phenomenon
• classify type of Raynaud’s phenomenon and differentiate it
from mimickers
• describe the appropriate investigations for Raynaud’s
phenomenon and be aware of those patients at risk for the
development of an autoimmune rheumatic disease
• discuss current options and evidence for treatment of
Raynaud’s phenomenon, threatened digital ischemia and
digital ulcers
4:30 – 6:00 pm
254 A
PM
2 0 1 4
1 7 ,
MONDAY
*Pulmonary Manifestations of Rheumatic Disease
(056)
*Safety of Drugs Used to Treat Rheumatoid Arthritis
PS
PM
(058)
n o v e m b e r
PS
Best Practices of Total Knee Arthroplasty – From
Surgery to Rehabilitation
Moderator: Judy Foxworth, PhD, PT
• differentiate total knee arthroplasty prosthesis types and
surgical techniques
• evaluate predictors of success following total knee
arthroplasty
• implement best practices in a rehabilitation program for total
knee arthroplasty
2014 Program Book
103
scientific sessions
4:30 pm
Innovations in Total Knee Arthroplasty
Jason Lang, MD
5:00 pm
Diet and Nutritional Supplements in Rheumatoid Arthritis
Susanna Proudman, MBBS, PhD
5:00 pm
Predictors for Best Outcome After Total Knee Arthroplasty
Chad M. Brummett, MD
5:30 pm
Diet in Gout
Hyon Choi, MD, PhD
5:30 pm
Best Practice Rehabilitation Following Total Knee Arthroplasty
Sara R. Piva, PhD, PT
256
PM
255
2 0 1 4
1 7 ,
MONDAY
n o v e m b e r
The Emerging Demand for Medicinal Cannabis by
FIT
PrM
Pd
PS
Ed
Young Adults and Beyond PM
• summarize the research-based evidence for the benefits and
risks to medicinal cannabis on young adults
• evaluate environmental and psychosocial factors that may
drive a request for physician-approved medicinal cannabis by
young adults
• discuss the medicolegal implications for rheumatologists and
for patients in this era of increasing demand for medicinal
cannabis
From Inflammation to Atherosclerosis: The Case of
Inflammatory Rheumatic Diseases
• recognize the relative importance of immune mechanisms
in the onset of atherosclerosis among patients with
inflammatory rheumatic diseases
• review the generalizability of such mechanisms to people
without inflammatory rheumatic diseases
• evaluate the role of oxidative stress in non-autoimmune
diseases and autoimmune diseases on the incidence of
atherosclerosis
4:30 pm
A Prescription for Herbal Cannabis: Primum Non Nocere
Mary-Ann Fitzcharles, MBChB, MD
4:30 pm
Immunological Underpinnings of Atherosclerosis
5:00 pm
Atherosclerotic Cardiovascular Diseases and Oxidative Stress:
The Case of Crystalline Arthritis
Eswar Krishnan, MD
5:30 pm
Innate Immunity and Atherosclerosis in Inflammatory
Rheumatic Diseases
Mariana J. Kaplan, MD
PM
PS
257 A
Role of Nutrition in Rheumatic Diseases
Moderators: Susan J. Bartlett, PhD and Carole V. Dodge, OT, CHT
• summarize current scientific evidence underlying the role of
nutrition in rheumatic diseases
• discuss the role of diet and nutritional supplements in
managing rheumatoid arthritis care
• recognize how the intake of various foods and drinks may
affect patients with gout
4:30 pm
Role of Nutrition in Rheumatic Diseases- An Overview
Shivani Sahni, PhD
2014 Program Book
PS
Moderator: Lori B. Tucker, MD
PS
Moderator: Jasvinder A. Singh, MD, MPH
104
PM
5:15 pm
Medicolegal Considerations for Herbal Cannabis Use in
Rheumatology Practice
Peter A. Ste-Marie, BA, LLB
4:30 – 6:00 pm
109
PM
PS
Health Disparities/Social Determinants of
FIT
PrM
Pd
PS
PM
Ed
Health
Moderators: Jillian A. Rose, LCSW and Leigh F. Callahan, PhD
4:30 pm
1932. Increasing Access to Inflammatory Arthritis Education in
Rural and Remote Communities Using Telemedicine
Carol Kennedy1, Kelly Warmington2, Carol Flewelling1, Rachel
Shupak1, Angelo Papachristos3, Caroline Jones4, Dorcas Beaton5,
Sydney Brooks6 and Denise Linton1, 1St. Michael’s Hospital,
Toronto, ON, 2The Hospital for Sick Children, Toronto, ON, 3St
Michael’s Hospital, Toronto, ON, 4St. Michael’s Hospital, Aurora,
ON, 5Mobility Program Clinical Research Unit, Li Ka Shing
Knowledge Institute, St. Michaels Hospital, Toronto, ON, 6The
Arthritis Society, Ontario Division, Toronto, ON
4:45 pm
1933. Getting a Grip on Arthritis Online: Web-Based
Continuing Education Supports the Dissemination of Arthritis
Clinical Practice Guidelines Among Rural/Remote Primary Care
Providers
Sydney Lineker1, Mary Bell2, Lisa Fleet3, Elizabeth M. Badley4,
Vernon Curran3, Marlene Del Pino5, Fran Kirby3, Anne Lyddiatt6,
scientific sessions
Lynn Moore1, Karla Simmons3, Raquel Sweezie1, Peter
Tugwell7 and Ed Ziesmann1, 1The Arthritis Society, Toronto,
ON, 2Sunnybrook Health Sciences Ctr, Toronto, ON, 3Memorial
University, St. John’s, NF, 4Division of Health Care and Outcomes
Research, Toronto Western Research Institute; Dalla Lana School
of Public Health, University of Toronto, Toronto, ON, 5Health
Canada, Regina, SK, 6Patient Partners in Arthritis, Toronto, ON,
7
Institute of Population Hlth, Ottawa, ON
5:00 pm
1934. Examining Why Minority Women Are Risk Averse : A
Qualitative Study
Sonal Bhalla1, Kristin Mattocks2 and Liana Fraenkel3, 1YaleNew Haven Hospital, New Haven, CT, 2VA Central Western
Massachusetts Healthcare System, University of Massachusetts
Medical School, Leeds, MA, 3Yale University School of Medicine,
Veterans Affairs Connecticut Healthcare Systems, New Haven, CT
6:45 pm
The European End of the Tendon and Enthesis
George A. W. Bruyn, MD, PhD
7:00 pm
Sonographic Evaluation of the Enthesis and Enthesopathy
Maria-Antonietta d’Agostino, MD, PhD
7:15 pm
Ultrasound Assessment of Dactylitis
7:30 pm
Closing Statements
157 B
Antiphospholipid Syndrome Task Force Study Group
6:30 pm
Introduction – Past, Present and Future of Antiphospholipid
Syndrome Task Forces
Doruk Erkan, MD
5:15 pm
1935. Racial Disparities in Attitude Towards Treatment in Young
Women
Raluca Cozmuta1, Sonal Bhalla2 and Liana Fraenkel3, 1Yale
University School of Medicine, New Haven, CT, 2Yale University,
New Haven, CT, 3Yale University School of Medicine, Veterans
Affairs Connecticut Healthcare Systems, New Haven, CT
5:45 pm
1937. Model Examining Factors Related to Physicians’ Ratings
of Disease Activity in Patients with RA
Julia R. Ayeroff1, Sarah R. Ormseth2, David Hardy3, Michael R.
Irwin2, Michael H. Weisman4 and Perry M. Nicassio2, 1University
of Southern California, Los Angeles, CA, 2University of California,
Los Angeles, Los Angeles, CA, 3Loyola Marymount University, Los
Angeles, CA, 4Cedars-Sinai Medical Center, Los Angeles, CA
7:20 pm
2016 Antiphospholipid Syndrome Diagnostic and Classification
Criteria Task Force Update
MG Tektonidou, MD
7:30 pm
2013/2016 Antiphospholipid Syndrome Treatment Trends Task
Force Report/Update
Danieli Andrade, MD
ACR STUDY GROUPS
6:30 – 7:45 pm
Study Groups are non-CME activities open to all attendees.
109 A
ACR Musculoskeletal Ultrasound Study Group
6:30 pm
The American End of the Tendon and Enthesis
Ralf G. Thiele, MD
2 0 1 4
7:05 pm
2013 Antiphospholipid Syndrome Obstetric Diagnostics and
Treatment Task Force Report
Ware D. Branch, MD
1 7 ,
6:50 pm
2013 Antiphospholipid Syndrome Clinical Diagnostics Task
Force Report
Roger A. Levy, MD
MONDAY
5:30 pm
1936. Ageism, Fear and Competing Co-Morbidities – Why
Older Patients May Not Seek Care for Restricting Back Pain: A
Qualitative Study
Una Makris1, Robin Higashi2, Emily Marks2, Liana Fraenkel3,
Joanna Sale4 and CM Reid5, 1Dallas VA Medical Ctr, Dallas, TX, 2UT
Southwestern Medical Center, Dallas, TX, 3Yale University School
of Medicine, Veterans Affairs Connecticut Healthcare Systems,
New Haven, CT, 4University of Toronto, St. Michael’s Hospital,
Toronto, ON, 5Weill Cornell Medical College, New York City, NY
n o v e m b e r
6:35 pm
2013 Antiphospholipid Syndrome Laboratory Diagnostics and
Trends Task Force Report
Maria Laura Bertolaccini, MD, PhD
256
Capillaroscopy in Rheumatic Diseases Study Group
6:30 pm
Evaluation Tools for Microcirculation Analysis: Morphology
Versus Flow
Ariane L. Herrick, MD
6:50 pm
Capillaroscopy in Systemic Sclerosis: Clinical Applications
Vanessa Smith, MD, PhD
2014 Program Book
105
scientific sessions
7:05 pm
Capillaroscopy in Systemic Sclerosis: Basic Science
Maurizio Cutolo, MD
7:25 pm
Practical Issues in Videocapillaroscopy Including Scoring
Systems and Links with Other Diagnostic Tools
Alberto Sulli, MD
255
Childhood Vasculitis Study Group
2 0 1 4
1 7 ,
MONDAY
Degos Disease Study Group
6:30 pm
The Pathology of Degos
Cynthia Magro, MD
6:55 pm
Parvovirus Infection: Effects on Endothelium
Stanley J. Naides, MD
6:55 pm
Childhood Vasculitis in South Africa
Christiaan Scott, MD
7:20 pm
Formation of Degos Registry
J. Patrick Whelan, MD, PhD
259 A
n o v e m b e r
107 B
6:30 pm
Childhood Vasculitis in North American and Europe
Marinka Twilt, MD
7:20 pm
Childhood Vasculitis in India
Sathish Kumar
Clinical Anatomy Study Group
6:30 pm
Clinical Anatomy: An Unmet Need in Rheumatology Training
Robert A. Kalish, MD
6:45 pm
The Clinical Anatomy Program at Los Angeles County
Christine Evelyn, MD
7:00 pm
Ultrasonography as a Teaching Tool of Musculoskeletal
Anatomy
Karina D. Torralba, MD, MAppSc
7:15 pm
Development and Experience of the Mexican Group for the
Study of Clinical Anatomy (GMAC)
Pablo Villasenor Ovies, MD
7:30 pm
A Clinical Scholar’s Perspective
Richard S. Panush, MD
102 A
Crystal Study Group
6:30 pm
Introduction
Naomi Schlesinger, MD
6:35 pm
Forms of Monosodium Urate Crystal (MSUC) Deposits in Tissue
Eliseo Pascual, MD, PhD
106
7:10 pm
Potential Role of Uricosuric Agents in the Contemporary
Management of Gout
Peter A. Simkin, MD
2014 Program Book
104 B
Hypermobility Study Group
6:30 pm
Joint Hypermobility Syndrome and the Impact on Day to Day
Functioning in Children
Amanda Kirby, MBBS, MRCGP, PhD
6:55 pm
Joint Hypermobility and Autonomic Hyperactivity: Relevance
to Neurodevelopmental Disorders
Jessica Eccles, MB, BCh, MA, MSc, MRCPsych
7:20 pm
Dysautonomia and Fatigue in Hypermobility
Nelly Ninis, MRCP, MD
7:45 pm
Physical Therapy Management of Adolescents with
Postural Orthostatic Tachycardia Syndrome and Ehlers
Danlos Syndrome – Hypermobility Type
Jane Simmonds, MCSP, MMACP
160 B
Intestinal Lung Disease Study Group
6:30 pm
Emerging and Adjunctive Therapies for Intestinal Lung Disease
Due to Connective Tissue Disease: Lessons from Idiopathic
Pulmonary Fibrosis Trials
Aryeh Fischer, MD
7:00 pm
Appropriate Utilization of Imaging in Intestinal Lung Disease
Associated with Connective Tissue Disease
Rachna Madan, MD
scientific sessions
156 B
Macrophage Activation Syndrome Study Group
6:30 pm
The Genetics of Macrophage Activation Syndrome/
Haemophagocytic Lymphohistiocytosis in Adults
Lisa Filipovich, MD
6:55 pm
The Propensity to Develop Macrophage Activation Syndrome
in the Setting of Systemic Lupus Erythematosus
W. Winn Chatham, MD
7:20 pm
Macrophage Activation Syndrome Along the Spectrum of
Juvenile Idiopathic Arthritis and Adult-Onset Still’s-Disease
Peter A. Nigrovic, MD
153 B
Myositis Study Group
6:30 pm
Introduction
Ignacio Garcia-De La Torre, MD
6:30 pm
Introduction
Carla R. Scanzello, MD, PhD
6:35 pm
In-Vitro Models of Cartilage Injury and Post-Traumatic
Osteoarthritis
George Dodge, PhD
7:10 pm
Anterior Cruciate Ligament Injury and Osteoarthritis:
Biomarkers and Therapeutic Approaches
Richard Frobell, PT, PhD
6:30 pm
Is an “n of 1” Trail of Low Dose Prednisone and Methotrexate
More Definitive and Cost-Effective than an Extensive and
Expensive Evaluation to Meet Criteria?
Theodore Pincus, MD
6:55 pm
Criteria for Systemic Vasculitis: Diagnosis vs. Classification or
One and the Same?
Hasan Yazici, MD
7:20 pm
Criteria for Defining Rheumatoid Arthritis: Is New Always
Better?
Yusuf Yazici, MD
204 A
Veterans Affairs Rheumatology Study Group
6:30 pm
Utilization of Computerized Patient Record System Templates
to Capture Patient Outcomes During Clinical Practice
Mathilde Pioro, MD
2 0 1 4
Osteoarthritis Study Group
The “Why and How” of Disease Criteria Study Group
1 7 ,
257 A
254 A
MONDAY
7:10 pm
Novel Therapeuptic Approaches for Inclusion Body Myositis
Thomas E. Lloyd, MD, PhD
7:40 pm
Wrap-Up
Kristen Hayward, MD, MS
n o v e m b e r
6:35 pm
Update on the Pathogenesis of Inclusion Body Myositis
Steven A. Greenberg, MD
7:05 pm
Incorporating Active Learning Techniques into Your Teaching
Presentations
Kristen Hayward, MD, MS
6:55 pm
Opportunities for Participation in Veterans Affairs (VA)
Rheumatology Research Through Involvement in VA Disease
Specific Registries
Elizabeth Chang, MD
7:20 pm
Rheumatology Field Advisory Update: How to Use Available
Productivity Measures to Optimizing Veterans Affairs Practice
Grant W. Cannon, MD
151 A
Pediatric Rheumatologists Interested in Medial
Education Study Group
6:30 pm
Development of a Peer Review Process for Educational
Materials Submitted to Ouch My Leg!
Megan L. Curran, MD
2014 Program Book
107
scientific sessions
TUESDAY, NOVEMBER 18, 2014
8:00 am
Patient Access to Biologics in African League of Associations for
Rheumatology (AFLAR) Regions
Olufemi Adelowo, MD
ACR SESSIONS
7:30 – 8:30 am
205 B
8:10 am
Patient Access to Biologics in Asian Pacific League of
Association for Rheumatology (APLAR) Regions
Kevin Pile, MD
PS
PM
Glycosylation and Glycan Binding Proteins in Immune
Function
Speaker: Sean Ryan, PhD
8:20 am
Question and Answers
• identify roles for protein glycosylation in immune function
• identify roles for glycan binding molecules in immune function
• describe the importance of glycans and their binding partners
in health and diseasePS
ARHP SESSIONS
7:30 – 8:30 am
PM
254 A
Hepatitis C in 2014
Speaker: Raymond T. Chung, MD
• review the mechanisms contributing to involvement of the
central nervous system
• summarize the diagnostic criteria and screening tools used
to identify the presence of psychiatric and cognitive deficits
and whether they are due to active central nervous system
systemic lupus erythematosus or other factors
• recognize the range of cognitive changes and psychiatric
disorders found in systemic lupus erythematosus patients
PM
151 A
2 0 1 4
Patient Access to Biologics Across the Globe
1 8 ,
TUESDAY
PS
Moderator: Shawn Rose, MD, PhD
Speaker: Michelle Petri, MD, MPH
• describe the natural history of hepatitis C infection
• describe the extrahepatic manifestations of hepatitis C
infection
• discuss which patients are appropriate for therapy and how to
predict response to therapy
• describe available treatment regimens and novel/investigative
treatment regimens for hepatitis C infection
PS
n o v e m b e r
PM
Clinical Features of Central Nervous System Lupus
and Diagnosis of Cognitive Deficits and Psychiatric
Disorders
Ballroom West
PM
Ed
Moderators: Joseph Flood, MD and Maurizio Cutolo, MD
• discuss the access to biologics for patients in various regions
of the world
• locate the areas where patients’ access differs significantly
• identify potential solutions to overcome identified barriers to
providing biologics
7:30 am
Intro and Overview of International League of Associations for
Rheumatology (ILAR)
Joseph Flood, MD; Maurizio Cutolo, MD
7:40 am
Patient Access to Biologics in Pan American League of
Associations for Rheumatology (PANLAR) Regions
Carlos Pineda, MD, MSc
7:50 am
Patient Access to Biologics in The European League Against
Rheumatism (EULAR) Regions
Maurizio Cutolo, MD
Pd
PS
PrM
257 A
FIT
PM
PS
Muscle and Adipose Tissue in Rheumatic Diseases:
Location Is Everything
Moderator: Kelli D. Allen, PhD
Speaker: Jon T. Giles, MD, MPH
• differentiate between abnormal body composition
phenotypes (sarcopenia, overfat and sarcopenic obesity)
• summarize the relationships between muscle and adipose
tissue in rheumatoid arthritis
• evaluate the implications of fat and muscle distribution on
PS
PM
disease-associated outcomes in rheumatic diseases
7:45 – 9:15 am
108
2014 Program Book
scientific sessions
• r elate the pathogenesis of these syndromes to knowledge of
the various gene functions
• discuss the treatment rationale based on the pathogenesis
and to expand on practical issues in the management of these
patients
Speaker: Alana B. Levine, MD
• review classification criteria for antiphospholipid syndrome
• review non-criteria manifestations of antiphospholipid
syndrome
• discuss the management of obstetric antiphospholipid
syndrome, catastrophic antiphospholipid syndrome and
difficult cases posed by the audience
• review of current international research efforts in
antiphospholipid syndrome
*Rheumatoid Arthritis: Outcome Measures in Clinical
Practice (066)
Speaker: J. Timothy Harrington, MD
• discuss outcome measures used in rheumatoid arthritis
• integrate outcome measures into an office-based practice
Controversies in Sjögren’s Syndrome (062)
Safety of Drugs Used to Treat Rheumatoid Arthritis
PS
PM
(067)
Speaker: Frederick Vinino, MD
• identify the best approach to establish a diagnosis of Sjögren’s
syndrome
• differentiate among various causes of salivary and/or lacrimal
gland swelling
• discuss current treatment algorithms for dry eyes, dry mouth
and systemic manifestations
• identify risk factors and markers for lymphoma in Sjögren’s
syndrome patients
Speaker: Lee S. Simon, MD
• examine the drug safety literature with greater expertise
• prescribe DMARDs with a broader and deeper knowledge of
potential toxicities
• discuss DMARD toxicities with their patients with greater
comfort
• manage potential DMARD toxicities with greater skill
Systemic Lupus Erythematosus: Central Nervous
System (068)
Footwear in Orthoarthritis (063)
Speaker: Najia Shakoor, MD, MS
Speaker: Meggan Mackey, MD, MS
Speaker: Linda Russell, MD
• review the basic biology of bone as it relates to treatment
• examine the potential benefits and risks of antiresorptive
therapies
• discuss the potential benefits and risks of anabolic therapies
• review the current knowledge and understanding of how to
pick the best therapy for each patient and for how long to
treat each patient with osteoporosis
Systemic Sclerosis: Disease Staging and Subsetting in
Clinical Practice (069)
Speaker: Robyn T. Domsic, MD, MPH
PM
Ed
Pediatrics: Periodic Fevers in Children (065)
Pd
PS
PrM
2 0 1 4
Osteoporosis: Novel Treatments (064)
1 8 ,
TUESDAY
• identify neuropsychiatric manifestations attributable to
• recognize the utility of diverse autoantibodies in the
diagnosis of neuropsychiatric syndromes of systemic lupus
erythematosus patients
• formulate a treatment plan in patients with neuropsychiatric
lupus
n o v e m b e r
• establish the biomechanical pathophysiology of osteoarthritis
• discuss the impact of footwear choice on biomechanics of the
lower extremity
• discuss the impact of footwear choice on clinical conditions at
the knees and feet
FIT
• use clinical and serologic classification systems of systemic
sclerosis to identify the natural history of clinical subsets
• explain the concept of disease staging in both diffuse and
limited cutaneous systemic sclerosis
• use knowledge of clinical/serologic classification and disease
staging to develop screening and management plans
Speaker: Daniel L. Kastner, MD, PhD
• describe the differential diagnosis and expanding spectrum of
these syndromes
2014 Program Book
109
scientific sessions
• identify anatomic landmarks for injection of the knee and
ankle using joint prosthetics
• apply principles of joint aspiration and injection using ankle
and knee joint prosthetics
Vasculitis: Factors that Influence Disease Patterns
(070)
Speaker: Gary S. Hoffman, MD
• review advances in diagnosis and staging of vasculitis and
updates on prognostic information of interest to clinicians and
patients
• review advances in therapeutic intervention (including
biologics) in the treatment of the systemic vasculitides such as
granulomatosis with polyangiitis, cryoglobulinemic vasculitis
and giant cell arteritis
• assess how to incorporate recent research data and practices
into providing clinical care in the community for patients with
PS
PM
vasculitis
154
Speakers: Philip G. Conaghan, MD, PhD and Mikkel Ostergaard,
DMSc, MD, PhD
• recognize the most common types of magnetic resonance
images (as T1- and T2-weighted, fat-saturated, STIR and
contrast-enhanced) and the appearance of the most common
joint pathologies on these
• discuss the rationale and evidence for using magnetic
resonance imaging in clinical practice
• identify the advantages and disadvantages of dedicated
extremity magnetic resonance imaging
ACR/ARHP WORKSHOPS
7:45 – 9:45 am
ACR SESSIONS
8:30 – 10:00 am
PM
Bioenergetics and Energy Regulation
Moderator: Antonio La Cava, MD, PhD
• describe the relationship between metabolism and apoptosis
• recognize the interactions between metabolism and activation
of both the innate and adaptive immune response
• recognize the beneficial effects of reactive oxygen species
*Advanced Musculoskeletal Ultrasound: Image
Optimization and Pathology Recognition (229)
TUESDAY
2 0 1 4
Basic Statistical Concepts for the Medical Researcher
(230)
1 8 ,
n o v e m b e r
Speakers: Dorothy D. Dunlop, PhD and Jungwha Lee, PhD, MPH
• identify factors influencing sample size and power
• interpret confidence intervals, odds ratio and relative risk
• identify factors that confound study results
152
*Joint Injections (Knee, Ankle, Shoulder and Wrist)
(231)
Speakers: Jemima Albayda, MD and Pari Basharat, MD
• describe indications for lower extremity joint injection and
aspiration
110
8:30 am
Homeostatic Mechanisms of the Mitochondria
Richard Siegel, MD, PhD
• use practical knowledge of ultrasound technology to improve
image quality
• recognize common pathology patterns in musculoskeletal
ultrasound
161
2014 Program Book
PS
253 B
159
Magnetic Resonance Imaging of Peripheral Joints in
Rheumatology Practice (232)
9:15 am
Homeostatic Mechanisms of the Mitochondria
Navdeep S. Chandel, PhD
52 A
PM
PS
CARE: Maintenance of Certification Session Three of
Three – Rheumatoid Arthritis
program. Ten (10) rheumatoid arthritis questions will be covered
at this session. Attendance at the session(s) is not required to
participate in the online module.
Speaker: Jonathan Kay, MD
scientific sessions
knowledge
• review the diagnosis, management and treatment of
PM
102 A
PS
Pd
PS
PrM
FIT
Speaker: William Iobst, MD
153 B
• d iscuss the importance of direct observation for assessment
of clinical skills
• s ummarize the status of evaluation skills
• d
escribe strategies for direct observation and rater training
methods
PS
PM
104 B
Ed
Macrophages Gone Wild PM
Pd
PS
8:30 am
Differential Diagnosis of Polymyositis
Andrew L. Mammen, MD, PhD
9:15 am
Molecular Diagnosis of Adult-Onset Muscular Dystrophy and
Metabolic Myopathies
Anthony A. Amato, MD
PS
Educator: Direct Observation of Clinical Skills:
Educationally Indicated, Therapeutically Required
PM
PM
Ed
• d
escribe diagnostic features of a myopathy suggestive of a
muscular dystrophy or metabolic myopathy
• create an approach to the diagnosis of unusual forms of
myopathy that may mimic polymyositis
PrM
FIT
Moderators: Randy Q. Cron, MD, PhD and Karyl Barron, MD
PM
PS
Ballroom East
Myositis Mimics: Clinical and Molecular Diagnosis
Moderator: Alan N. Baer, MD
• review muscle diseases which may mimic adult-onset
polymyositis
8:30 am
Synovial Fibroblast Phenotypes After Activation Bv TNF/lL-17
Michael B. Brenner, MD
9:00 am
Dysfunctional High-Density Lipoprotein, Rheumatoid Arthritis
and Cardiovascular Disease
Subramaniam Pennathur, MD
9:30 am
Regulation of Osteoclasts During Inflammation
Julia F. Charles, MD, PhD
Exhibit Hall C
PM
2 0 1 4
9:30 am
Macrophage Activation Syndrome Independent of Systemic
Rayfel Schneider, MBBCh
• review functional differences among large numbers of
fibroblast-like synoviocytes and determine if the differences
are genetically determined
• describe how to use the blood level of high density
lipoprotein as a powerful determinant for predicting risk for
cardiovascular disease in patients with rheumatoid arthritis
• describe the role of innate immune receptors in osteoclast
development and how they relate to bone loss during
inflammation
1 8 ,
9:00 am
Diagnosis of Macrophage Activation Syndrome in the Age of
Biologics
Angelo Ravelli, MD
Moderator: Anne Davidson, MBBS
TUESDAY
8:30 am
Inside the World of a Killer: Understanding the Pathogenesis of
Macrophage Activation Syndrome
Edward M. Behrens, MD
Rheumatology Research Foundation Special Session:
Disease Targeted Research
n o v e m b e r
• review the pathophysiology of macrophage activation
syndrome
• recognize new classification criteria for macrophage activation
syndrome
• discuss macrophage activation syndrome outside of the
context of systemic juvenile idiopathic arthritis
PS
PM
PS
Risk and Risk Management of Cardiovascular Disease
in Patients with Rheumatoid Arthritis and Other
Systemic Rheumatic Diseases
• define the clinical aspects and epidemiology of cardiovascular
disease in systemic rheumatic diseases, particularly
• interpret mechanisms of cardiovascular disease in patients
with rheumatoid arthritis
• generate pragmatic guidance for the evaluation and
management of cardiovascular disease in patients with
2014 Program Book
111
scientific sessions
8:30 am
Epidemiology of Cardiovascular Disease in Rheumatoid
Arthritis and Other Rheumatic Diseases
Sherine E. Gabriel, MD, MSc
9:00 am
Cardio-Rheumatology: Approach to the Patient
Anne Grete Semb, MD, PhD
9:30 am
Which Tests Should Be Done and When?
Sharon Mulvagh, MD
ACR/ARHP POSTER SESSION C, LateBreaking and THIEVES’ MARKET POSTERS
AND POSTER TOURS
8:30 am – 4:00 pm
(abstracts # 1938 – 2780). Poster tours will be held 9:00 – 9:45
am and 10:15 – 11:00 am. Morning snacks will be available from
9:00 – 10:30 am.
Thieves’ Market Posters
TM 8. Acute Onset of Headaches, Dysarthria, Vision Changes in
a 17 y/o Male
Angela Bryan, MD
n o v e m b e r
1 8 ,
TUESDAY
2 0 1 4
TM 9. Discharged but Not Better for Long
Aixa Toledo-Garcia, MD
TM 10. Masquerader of Adult Still’s
Michael Thomas Avery, DO
TM 11. Refractory Knee Joint Swelling in a Patient With
Minyoung Her, MD
TM 12. The Thin Young Man -- Ed Oberle
Edward J. Oberle, MD
TM 13. Whispers of Disease
Rikitha Menezes, MD
Guided Poster Tours
is required and is limited to scientific attendees. If you preregistered for a tour, you should have received a ticket with your
112
2014 Program Book
meeting materials. Once you have your ticket, check in at
the tour desk 15 minutes prior to the start of your tour to
9:00 – 9:45 am
Osteoarthritis – Clinical Aspects Poster Tour (325)
Tour Guide: Grace H. Lo, MD, MSc
Quality Measures and Quality of Care Poster Tour (326)
Tour Guide: Gabriela Schmajuk, MD, MS
Tour Guide: Inmaculada Del Rincon, MD, MSc
Tour Guide: Joseph A. Markenson, MD
Spondyloarthropathies and Psoriatic Arthritis: Clinical Aspects
Tour Guide: Philip Mease, MD
Pathogenesis, Animal Models and Genetics (330)
Tour Guide: Laura K. Hummers, MD, ScM
10:15 – 11:00 am
Epidemiology and Health Services Research Poster Tour (331)
Tour Guide: Kaleb Michaud, PhD
Health Services Research Poster Tour (332)
Tour Guide: Salahuddin Kazi, MD, PhD
Rheumatoid Arthritis: Human Etiology and Pathogenesis Poster
Tour (333)
Tour Guide: David S. Pisetsky, MD, PhD
Tour Guide: Jonathan Kay, MD
Rheumatology 360 Poster Tour (335)
Tour Guide: Eric L. Matteson, MD
Spondyolarthropathies and Psoriatic Arthritis: Clinical Aspects
Tour Guide: John D. Reveille, MD
scientific sessions
ACR SESSIONS
ARHP SESSIONS
9:00 – 10:00 am
9:00 – 10:00 am
PS
PM
107 B
ACR-EULAR Polymyalgia Rheumatica Guidelines
PM
PM
PS
PS
204 A
PM
PS
Mycobacterium Infections in Immunocompromised
Patients
Moderators: Steven E. Carsons, MD and Andy Abril, MD
Moderator: Susan Richmond, MS, PA-C
• review the approach to polymyalgia, the relevant
investigations, differential diagnosis and overlap with other
conditions, classification criteria
• review Grading of Recommendations Assessment,
Development and Evaluation (GRADE) methodology and
available evidence for polymyalgia rheumatica therapies,
prognostic factors, values and preferences of patients and
professionals on polymyalgia rheumatica
• review ACR-EULAR polymyalgia rheumatica treatment
guidelines including glucocorticoids, disease modifiers,
biologic agents and future research agenda and clinical trials
• recognize the risk of non-tuberculosis mycobacterium
infection in immunosuppressed patients
• evaluate tuberculosis risk factors in immunosuppressed
patients and recognize the need to maintain vigilance for
tuberculosis during treatment with immunosuppressants
• review available screening tests, including the Tuberculin Skin
Test, Quantiferon-Gold and TB-spot
9:15 am
Mycobacterium Infections in Immunocompromised Patients
Kevin L. Winthrop, MD, MPH
9:00 am
Polymyalgia: What Does It Mean?
Bhaskar Dasgupta, MD
PM
9:20 am
Polymyalgia Rheumatica: Grading the Evidence
Christian Dejaco, MD, PhD
RheumChat
PM
PS
PS
PS
Rheumatology Research Foundation Oscar S. Gluck
Memorial Lectureship: Emerging Therapies in Bone
Diseases: Cellular Basis and Challenges
Moderator: Michael Maricic, MD
Speaker: Roland Baron, DDS, MD
• review the mechanisms regulating bone homeostasis and the
process of bone remodeling
• evaluate the effects of anti-resorptive and osteo-anabolic
drugs and the differences between them
• review the mode of action and anticipated effects of
molecules currently in development for the treatment of
osteoporosis
9:12 am
Jumping Across the Knowledge Gap: The Roles of Significance
and Innovation in Rheumatology Research
Marian T. Hannan, DSc, MPH
2 0 1 4
PM
9:00 am
Pain!
Sean Mackey, MD, PhD
1 8 ,
• review metabolic aspects of inflammation
• discuss metabolic pathways
TUESDAY
Metainflammation
Speaker: Gökhan S. Hotamisligil, PhD, MD
• describe the newest science and the oldest debates in the
field of pain research
• describe a potential means by which autoimmune disorders
may be cured
• discuss the intersection of research and clinical care in the
context of history, health policy and technology
n o v e m b e r
156 B
210 B
PS
157 B
9:40 am
Polymyalgia Rheumatica: Treatment Guidelines and Next Steps
Eric L. Matteson, MD, MPH
PM
9:00 am
Evaluating Tuberculosis Risk in Immunocompromised Patients
Lisa Shelton, BSc, BSN, RN
9:24 am
It’s Time that We Started to Talk About “Cure” in Severe
Autoimmune Disease
Troy R. Torgerson, MD, PhD
9:36 am
Did We Care More When We Knew Less?
Andrew A. Guccione, DPT, PhD
2014 Program Book
113
scientific sessions
259 A
PM
PS
Stats Boot Camp: The Prevalence Ratio as an
Alternative to the Odds Ratio for Cross-Sectional
Studies
159
• demonstrate how to properly position the ultrasound
transducer to visualize targeted musculoskeletal structures
based on an understanding of the local bony landmarks
• differentiate tissue types based on their ultrasound properties
• recognize the ultrasound appearance of some of the basic
musculoskeletal pathologies
Moderator: Alyssa B. Dufour, PhD
• review when to use the prevalence ratio and when to use the
odds ratio
• recognize with the regression models that can generate the
prevalence odds ratio
• explain the methodological issues that may arise when
estimating prevalence ratios
• analyze data using the prevalence ratio with popular
statistical packages
161
EXHIBITS
10:00 am – 2:30 pm
Exhibit Hall A
Join your colleagues in the Exhibit Hall for morning refreshments
from 10:00 – 11:00 am.
n o v e m b e r
1 8 ,
TUESDAY
2 0 1 4
(Booths #139 and #1401)
presentations will be held from 10:30 – 11:15 am and
12:30 – 1:15 pm. Innovation Theater B presentations will be held
from 11:30 am – 12:15 pm and 1:30 – 2:15 pm. For a complete
listing of Innovation
presentations, see page 238.
PS
PM Theater
ACR WORKSHOPS
10:30 am – 12:30 pm
114
2014 Program Book
Renal Histopathology in Systemic Lupus
Erythematosus and Vasculitis (234)
Speaker: Anthony Chang, MD
9:00 am
Regression Models for Prevalence Ratios
Kamil E. Barbour, PhD
9:30 am
Examples of the Prevalence Ratio vs. the Odds Ratio in
Rheumatology Research
Yvonne M. Golightly, PT, MS, PhD
Musculoskeletal Ultrasound (233)
Speakers: Eugene Y. Kissin, MD and Amy M. Evangelisto, MD
• identify the pathologic changes that occur in lupus nephritis
• discuss the pathologic basis for the classification of lupus
nephritis and how it relates to clinical management
• describe the histological changes in the kidneys of patients
with vasculitis
154
X-Ray Challenges in Rheumatic Diseases (235)
Speaker: Donald J. Flemming, MD
• describe the potential causes and exacerbating factors of the
disease
• discuss the appropriate use of laboratory testing and imaging
modalities
• design an efficacious, safe and cost-effective therapeutic
strategy
ACR SESSIONS
11:00 am – Noon
PM
253 B
PS
Mesenchymal Stem Cells: Biology and Use in
Rheumatic Diseases
Moderator: Dana P. Ascherman, MD
Speaker: Paolo Bianco, MD
• review the biology of MSCs and differences from
hematopoietic stem cells (HSCs)
• appraise anti-inflammatory versus remodeling properties
associated with MSCs
• define limitations in pre-clinical models, barriers in clinical
application
104 B
PM
PS
Protecting Bone Health in Pediatric Rheumatic
FIT
PrM
Pd
PS
Ed
Diseases PM
Moderators: Stacy P. Ardoin, MD, MS and Kelly A. RousterStevens, MD, MS
Speaker: Jon M. Burnham, MD, MSCE
scientific sessions
• evaluate threats to bone health in children with rheumatic
diseases
• review effects of rheumatic diseases and their therapies on
bone density, structure, strength and fracture risk
• describe best practices for bone health monitoring and
preventive measures, such as calcium and vitamin D
supplementation and bisphosphonate use
ARHP SESSIONS
11:00 am – Noon
PM
257 A
PS
Immunology Boot Camp III: Applying Principles of
Eth
PM
Immunology to Treatment Decisions
Moderator: Barbara A. Slusher, PA-C, MSW
• c ompare several biologic treatment options for active
• differentiate existing treatment options for systemic lupus
erythematosus when hydroxychloroquine is not enough
• discuss how psoriasis and psoriatic arthritis differ from
rheumatoid arthritis when anti-TNFs fail to control active
inflammation
• e xamine treatment considerations for refractory myopathies
255
PM
PS
Pathways to Resilience: Biopsychosocial Mechanisms
for the Generation of Positive Affect in Chronic Pain
PM
PS
Moderator: Donah Z. Crawford, BS, MA
PM
PS
Providing Evidence for Mid-Level Providers in
Rheumatology Practice
Moderator: Kori A. Dewing, DNP, ARNP
11:00 am – 12:30 pm
Exhibit Hall C
ACR Plenary Session III: Discovery 2014
Moderators: John Varga, MD and Mary K. Crow, MD
11:00 am
2781. Cost-Effectiveness of Adding Etanercept Vs. Sulfasalazine
and Hydroxychloroquine to Methotrexate Therapy: A
Randomized Noninferiority Trial
Nick Bansback, University of British Columbia, Vancouver, BC
Background/Purpose: To estimate the incremental costeffectiveness of etanercept plus methotrexate versus a
triple regimen of disease-modifying anti rheumatic drugs
(methotrexate, sulfasalazine and hydroxychloroquine) over 24
weeks and 48 weeks in patients with active rheumatoid arthritis
despite methotrexate therapy (RACAT).
Methods: In this double blind, noninferiority trial 353 patients
were randomized to etanercept plus methotrexate or a triple
regimen. After 24 weeks of treatment patients not achieving
a DAS28 improvement of 1.2 were switched in a blinded
fashion to the other therapy. Quality Adjusted Life Years
(QALYs) were estimated using US societal values from the
EQ-5D instrument which was measured every 24 weeks. Costs
of drugs, hospitalizations, procedures, tests, visits and lost
productivity were prospectively tracked and monetized from
a societal perspective in 2014 US dollars. Incremental costeffectiveness ratios were calculated using standard procedures
assuming an intent-to-treat analysis, with missing data analyzed
using multiple imputation and uncertainty assessed using
bootstrapping.
Results: Both strategies showed significant improvements in
EQ-5D, with etanercept providing marginally more accumulated
QALYs (0.358 vs 0.354 over 24 weeks and 0.742 vs 0.726 over 48
weeks for etanercept and triple regimen strategies respectively).
The etanercept strategy accumulated substantially higher drug
costs even considering the switches between treatments at 24
weeks ($11,286 vs $369 cumulative costs from 0 to 24 weeks
and $19,625 vs $3,721 cumulative costs from 0 to 48 weeks for
2014 Program Book
2 0 1 4
256
ACR PLENARY SESSION III – DISCOVERY 2014
1 8 ,
11:30 am
The Importance of Social Relations in Positive Emotion and
Resilience to Chronic Pain
Alex Zautra, PhD
11:15 am
The Role of Mid-level Providers in Rheumatology Care
Benjamin J. Smith, PA-C
TUESDAY
11:00 am
Mechanisms of Positive Emotion and Reward in Chronic Pain
Patrick Finan, PhD
11:00 am
Study Comparing Practices with and without Midlevel
Providers
Daniel H. Solomon, MD, MPH
n o v e m b e r
• discuss the state of the science on positive emotions and pain
• determine the mechanistic links between dopaminergic
neurotransmission, reward-related behaviors and coping with
chronic pain
• introduce the role of social relations in pain adaptation and
a promising new intervention in social intelligence that may
build social resourcefulness among patients with chronic pain
• explain the characteristics of rheumatology practices with and
without mid-level providers in the scope of the treat-to-target
concept
• discuss the research that has been done in regards to midlevel providers in rheumatology practice
• describe the role of a mid-level provider in rheumatology care
115
scientific sessions
etanercept and triple regimen respectively). The differences in
other health care and productivity costs across strategies were
negligible. The resultant incremental cost-effectiveness ratios
for etanercept vs. triple regimen were $2.7 million/QALY (95%CI
0.87 to ∞) gained over 24 weeks and $0.95 million/QALY (95%CI
0.41 to ∞) over 48 weeks.
Conclusion: This economic evaluation based on a prospective
tracking of resource use and QALY measurement in a blinded,
randomized trial demonstrates that the additional costs
associated with using etanercept prior to a triple regimen does
not provide good value for money at generally acceptable
willingness to pay thresholds. A limitation of the study is
its short time frame. However, even when considering the
long-term perspective, since the incremental benefits are so
small, even under the most optimistic scenarios imaginable,
etanercept has only a small probability of being cost-effective
compared to triple therapy. Given the opportunity cost
associated with all health care spending, adapting a triple
regimen prior to etanercept would free up scarce health dollars
for use on alternative health care interventions that provide
greater health benefits.
5 ACPAs were reverted to the germ line sequences and the
corresponding antibodies were also expressed for the above
tests.
Results: The relative frequencies of circulating plasmablasts
were significantly higher in RA patients than in healthy donors
( p = 0.0015). About 19.5% of circulating plasmablast-derived
recombinant antibodies from CCP-positive RA patients, but none
from the CCP-negative RA patient or healthy donors, specifically
recognized citrullinated RA autoantigens ( p = 0.0001). The
immunoglobulin genes encoding these ACPAs were highly
mutated with increased replacement/silent mutation ratios,
suggesting that the generation of ACPAs involved active antigen
selection. Interestingly, 63% of these ACPAs cross-reacted with
the outer membrane antigens and/or citrullinated enolase from
P. gingivalis. Germ-line reversions of some ACPAs completely
eliminated their reactivity to citrullinated RA autoantigens but
retained their reactivity to P. gingivalis antigens.
Conclusion: These results suggest that circulating plasmablasts
in RA patients produce ACPAs and this process may be, in part,
initiated by the anti-P. gingivalis immune responses.
Disclosures: S. Li, None.
11:30 am
2783. Effect of Synovitis, Effusion and Bone Marrow Lesions
on Development of Sensitization in Knee OA: The Multicenter
Osteoarthritis Study
Tuhina Neogi, Boston University School of Medicine, Boston, MA
n o v e m b e r
1 8 ,
TUESDAY
2 0 1 4
Disclosures: N. Bansback, None.
11:15 am
2782. Autoantibodies from Single Circulating Plasmablasts
React with Citrullinated Antigens and Porphyromonas
Gingivalis in Rheumatoid Arthritis
Song Li, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Anti-citrullinated protein antibodies
(ACPAs) are highly specific for rheumatoid arthritis (RA) and
also believed to play a pathogenic role in RA. Porphyromonas
gingivalis (P. gingivalis), a Gram negative oral pathogen
associated with periodontitis, has long been speculated as
a trigger for the anti-citrulline autoimmune responses in RA
patients. However, the detail relation between ACPA and P.
gingivalis is still unclear.
Methods: In this study, we made 195 recombinant monoclonal
antibodies from anti-cyclic citrullinated peptide (CCP)-positive
RA patients (N=6), 23 recombinant monoclonal antibodies
from CCP-negative RA patients (N=1) and 110 recombinant
monoclonal antibodies from healthy controls (N=4) using
a single cell-based antibody cloning approach. All the 7
RA patients satisfied the 2010 ACR classification criteria.
Monoclonal ACPAs were determined by commercial anti-CCP
test and fine specificity with 3 synthesized citrullinated peptides.
Cross-reactivity of ACPA to P. gingivalis was tested by ELISA
against P. gingivalis outer membrane protein and citrullinated
peptide from P. gingivalis enolase. Immunoglobulin genes of
116
2014 Program Book
Background/Purpose: Alterations in the peripheral and central
nervous systems including sensitization are thought to play
an important role in the pain experience in knee OA. While
sensitization could occur due to an underlying predisposition, it
is hypothesized that joint inflammation and/or tissue injury in
OA could provide sufficient peripheral nociceptive input to cause
sensitization. We previously reported that radiographic knee OA
severity or duration do not appear to be related to sensitization.
However, whether specific MRI lesions related to inflammation
(e.g., synovitis, effusion), or mechanical load or remodeling
related to noninflammatory tissue injury (e.g., bone marrow
lesions (BMLs)) are risk factors for development of sensitization
is not yet known.
Methods: The Multicenter Osteoarthritis (MOST) Study is a NIHfunded longitudinal cohort of persons with or at risk of knee OA.
Subjects had x-rays and MRIs (1.0 T) of each knee obtained at
each study visit and a standardized somatosensory evaluation of
mechanical temporal summation and pressure pain thresholds
(PPT) at the patella at 60- and 84-months. Temporal summation
was defined by increased pain during repeated mechanical
stimulation (1 Hz x 30-sec) with a 60g monofilament. PPT was
assessed with an algometer (1 cm2 tip, 0.5 Kg/sec) as the
point at which the subject felt the pressure change to slight
pain. Lower PPT indicates more sensitivity. Synovitis, effusion
and BMLs on MRIs were scored using WORMS (one knee per
person); these lesions were considered to be present if their
score was ≥1 in any subregion. In sensitivity analyses, we
assessed the sum of BML scores across all knee subregions as a
measure of BML burden. We assessed the relation of presence
of synovitis, effusion and BMLs at 60-mo to incident temporal
scientific sessions
summation in the same knee at 84-mo among those who did
not have temporal summation at 60-mo and to change in PPT
in the same knee between 60- and 84-mo in the whole sample
using logistic and linear regression, respectively, adjusted for
relevant potential confounders, including OA severity.
Results: There were 1111 subjects (mean age 66.9, mean
BMI 29.7, 62% female) in the whole sample. 22.6% developed
incident temporal summation at the 84-mo visit and the range
in change of PPT between the 60- and 84-mo visits was -7.35
to 7.15 kg/cm2. Presence of synovitis was associated with
a significant decrease in PPT (i.e., more sensitized) over 24
mo, while effusion was significantly associated with incident
temporal summation (Table). BML presence or burden were not
associated with temporal summation or PPT.
Conclusion: Inflammation, as evidenced by synovitis or effusion,
may drive the occurrence of sensitization in knee OA. In
contrast, BMLs do not appear to contribute to sensitization in
knee OA. Early targeting of inflammation in knee OA may be a
reasonable strategy to test for its ability to prevent occurrence
of sensitization, thereby reducing pain severity in knee OA.
Incident Temporal Summation
at 84-mo
(N=716)
Change in PPT (60- to 84-mo)
(N=1111)
Prevalence
of MRI
Lesion
Adjusted* OR
(95% CI)
Prevalence of
MRI Lesion
Presence of
synovitis
62%
1.12 (0.75, 1.66),
p=0.6
60%
-0.30 (-0.52, -0.08),
p=0.01
Presence of
effusion
67%
1.54 (1.01, 2.36),
p=0.04
66%
-0.04 (-0.28, 0.19),
p=0.7
Presence of
BMLs
79%
0.92 (0.56, 1.49),
p=0.7
79%
0.03 (-0.25, 0.31),
p=0.8
Sum of
BMLs (‘BML
burden’)
(per unit
increase)
Range: 0-19
1.00 (0.92, 1.07),
p=0.9
Range: 0-19
MRI Lesion
at 60-mo
Adjusted* Beta
(95% CI)
-0.01 (-0.05, 0.04),
p=0.8
Background/Purpose: Individuals with arthritis frequently
develop persistent pain despite adequate treatment of synovitis.
There is a need to better understand the mechanisms underlying
pain occurring with arthritis. Recently, it has been shown
that Toll-like receptor 4 (TLR4) mediates the transition from
acute to chronic pain in a murine model of arthritis. Rather
than developing persistent pain, animals deficient in TLR4
showed an attenuation of the late phase of pain. This receptor
is unique in signaling through both MyD88-dependent and
independent pathways. In order to further understand the role
of TLR signaling, we examined the development of arthritis and
persistent pain in mice deficient in these adaptor proteins.
Methods: Adult arthritic K/BxN mice were bled and the sera
pooled. 100μl of the pooled sera was injected into recipient
mice on Days 0 and 2. Clinical arthritis scores and mechanical
reactivity, using the up-down method of von Frey testing, were
assessed over a period of 28 days in male C57Bl/6, Tlr4-/-,
Noon
2785. Joint Specific Positional Differences in Coding and
Noncoding Transcriptome of Synovial Fibroblasts As a
Determinant of the Susceptibility of Synovial Joints to
Caroline Ospelt, Center of Experimental Rheumatology,
University Hospital Zurich, Zurich, Switzerland
2 0 1 4
Sarah Woller, UCSD, La Jolla, CA
Disclosures: S. Woller, None.
1 8 ,
11:45 am
2784. Contribution at the Spinal Level of Innate and Adaptive
Immunity to the Development of Persistent Post-Inflammatory
Mechanical Allodynia in Arthritic Mice
Conclusion: These results suggest that pain can persist after
resolution of inflammation. The innate and adaptive immune
systems appear to have distinct roles in the development of the
chronic pain state and this pain cannot be attributed solely to
increased TNF or IFNβ transcription.
TUESDAY
Disclosures: T. Neogi, None.
Results: As shown previously, WT mice develop a persistent
increase in mechanical reactivity that outlasts the period
of inflammation; the 50% withdrawal thresholds dropped
from 1.66 at baseline to 0.74 on day 28. In addition, Tlr4/- mice develop an initial increase in reactivity, which resolves
concurrent with inflammation (WT AUC 13.2 and TLR4
AUC 9.7, p<.05). MyD88 and TRIF play distinct roles in the
development of pain: mice lacking MyD88 do not develop
swelling or allodynia (AUC 2.6, p<0.01), while those deficient
in TRIF develop a prolonged allodynia (AUC 12.2), similar to WT
animals and outlasting the period of inflammation. NanoString™
nCounter™ analysis of 516 immune genes in the spinal cords
of WT and Tlr4-/- mice harvested on Day 10 of arthritis showed
differences in expression levels of IL2, RANKL, IFNβ and TNF
transcripts. Therefore, we also examined the development of
pain resulting from arthritis in Rag1-/-, Ifnar1-/- and Tnf-/- mice.
In the Tnf-/- mice there was an attenuated development of pain
(AUC 8.0, p<.001), the Rag1 (10.0, p<.05) mice developed pain,
which resolved with the resolution of inflammation similar to
Tlr4-/- mice and Ifnar1-/- mice developed pain that was not
different than the WT mice (AUC 12.2).
n o v e m b e r
*Analyses adjusted for age, sex, BMI, clinic site, race, catastrophizing, depressive symptoms,
widespread pain, KL grade
Triflps2, Myd88-/-, Tnf-/- and Ifnar1-/- mice. Spinal cords were
collected from WT and Tlr4-/- arthritic mice and changes in
gene expression were measured using nanoString™ nCounter™
analysis. Behavioral data were analyzed using repeated
measures ANOVAs and Duncan New Multiple Range post-hoc
analyses when appropriate.
Background/Purpose: The molecular mechanisms underlying
the topographic differences in the susceptibility of synovial
joints to develop rheumatoid arthritis (RA) are unknown.
Positional embryonic expression of Hox genes along proximaldistal and anterior-posterior body axes is critical for proper
limb development. Adult skin fibroblasts retain the positional
embryonic Hox code and exhibit major anatomic differences in
their transcriptome, defining their unique positional identities.
Synovial fibroblasts (SF) in the joints of RA patients drive joint
destruction and inflammation locally. We hypothesized that
SF from different joints show a joint specific, positional gene
expression pattern, which can predispose joints to develop
certain types of arthritides, like RA or osteoarthritis (OA).
Methods: SF were derived from knees, shoulders and
metacarpophalangeal joints (MCPs) of RA and OA patients (n=9
each) undergoing joint replacement surgery. SF were obtained
2014 Program Book
117
n o v e m b e r
1 8 ,
TUESDAY
2 0 1 4
scientific sessions
also from front paws, ankles and knees of wildtype (wt) and TNF
transgenic (TNFtg) mice (n=7 each). Total RNA was extracted
and RNA sequencing was performed with the Illumina HiSeq
2000 sequencing system followed by hierarchical clustering.
Functional annotation clustering of mRNAs was done using
Database for Annotation, Visualization and Integrated Discovery
(DAVID). Positionally expressed RNAs were validated by qPCR.
classified into clinical subgroups [Giant cell arteritis (GCA),
Takayasu’s arteritis (TAK), Focal Isolated Aortitis (FIA) or Other]
at the time of surgery using pre-defined criteria. Symptoms,
pathology, laboratory and imaging results were recorded at
surgery and over time using a standardized database. Patients
with FIA at surgery were followed for progression to systemic
disease and outcomes of clinical subgroups were compared.
Results: Unsupervised hierarchical cluster analysis showed
clustering of SF according to anatomic joint localization
rather than disease. The positional embryonic HOX code
was retained in SF, clearly differentiating between different
joints. Among the Hox cluster residing long noncoding RNAs,
HOTTIP was expressed in distal, MCP-derived SF and HOTAIR
in posterior, knee-derived SF. Several positionally expressed
mRNAs, e.g.HOXC8 and HOXD13, were differentially expressed
in MCP-derived RA and OA SF. DAVID analysis showed positional
enrichment of GOTERM limb development, anterior/posterior
patterning, cartilage development, extracellular region part,
cell adhesion, regulation of transcription. While some outliers
where found when clustering was based on mRNA expression,
clustering of SF into knee, shoulder and MCPs was perfect when
based on miR expression. For example, miR-24 was positionally
expressed in shoulder, miR-34c in MCP and miR-137 in kneederived SF, irrespective of disease. The positional expression of
these miRs was confirmed in wt and TNFtg mice. Interestingly,
miR-204 and miR-146a were positionally expressed in MCPs of
OA but not of RA patients. These miRs were indeed positional
also in wt mice but their MCP specific expression in humans
correlated to ankle specific expression in wt mice. In addition,
their expression was significantly changed in ankles of TNFtg
compared to wt mice.
Results: Of 7,551 patients who underwent thoracic aortic
surgery between 1996-2012, 196 patients with biopsy-proven
aortitis were identified for review. Median age at surgery was
69 years (range 15-88) and 67% were female. At the time of
surgery, 129 (65.8%) patients met criteria for FIA, 42 (21.4%)
for GCA, 14 (7.1%) for TAK and 11 (5.6%) for Other. A minimum
of 6 months of clinical follow-up was available for 73 FIA
patients. During follow-up (median 45 months, range 6-201
months), 14/73 (19.2%) FIA patients developed symptoms
of systemic disease, 17/40 (42.5%) developed elevated
inflammatory markers, 29/65 (44.6%) developed new vascular
lesions on imaging, 30/73 (41.1%) required a second vascular
surgery, 7(9.6%) dissected and 9 died (12.3%.) Ultimately
23 of 73 (31.5%) with FIA progressed to have features of a
systemic disease: 21 GCA, 1 TAK and 1 Other. When compared
to patients with known systemic disease at surgery, patients
with FIA were less likely to develop symptoms (p=0.01) but no
different with respect to development of elevated inflammatory
markers (p=0.19), new vascular lesions by imaging (p=0.92),
need for further vascular surgery (p=0.84), dissection (p=0.40)
or death (p=0.76) over time. Only 12 patients with FIA at
surgery received immunosuppressive therapy post-operatively.
Over time, 0/11 treated FIA patients with follow-up imaging
developed aneurysms, but 2 (18.2%) developed new stenoses.
Among the 54 untreated FIA patients with imaging available, 27
(50%) developed new lesions (23 aneurysms and 5 stenoses.)
Additional tissue obtained after subsequent surgery in 2
untreated FIA patients revealed persistent inflammation in the
distal aorta.
Conclusion: SF from joints of different anatomic sites exhibit
particularly different mRNA and miR expression patterns
suggesting that functionally unique subsets of SF populate
different joints. The existence of positionally imprinted “risk”
signatures of SF may account for the susceptibility of certain
synovial joints to develop RA in humans and mice and may have
major implications for synovial disease pathways operating early
in RA.
Disclosures: C. Ospelt, IMI BTCure, EuroTEAM, IAR, CABMM
start-up grant, 2.
12:15 pm
2786. Aortitis: Outcomes from a Cohort of 196 Patients
Alison Clifford, Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Idiopathic aortitis is a rare diagnosis that
may occur in the context of a primary systemic vasculitis, as part
of a systemic autoimmune disease, or in isolation. In patients
with focal isolated aortitis (FIA), surgery alone may be curative;
however, new vascular lesions have been reported to develop
in between 5-47% of cases. The risk of progression to systemic
disease and optimal management strategy for FIA patients is
uncertain.
Methods: Patients with biopsy-proven aortitis, diagnosed
following thoracic aortic surgery at the Cleveland Clinic between
1996 and 2012, were retrospectively reviewed. Patients were
Conclusion: Over time, nearly one third of patients classified
as FIA at the time of surgery progressed to have features of
a systemic autoimmune disease. Patients with FIA are less
likely to develop overt symptoms, but equally likely to develop
elevated inflammatory markers or new vascular lesions on
imaging when compared to GCA, TAK and Others. These
patients require regular clinical follow-up and serial imaging to
assess for progression.
Disclosures: A. Clifford, None.
PM
PS
12:45 – 2:15 pm
118
2014 Program Book
scientific sessions
Osteoarthritis: Update 2014 (075)
Speaker: Doruk Erkan, MD
Speaker: Joanne M. Jordan, MD, MPH
• review the spectrum of antiphospholipid syndrome
• explain the diagnostic utility of antiphospholipid antibody
tests
• discuss the management of persistently antiphospholipid
antibody-positive patients with different antiphospholipid
antibody-related clinical manifestation
• describe the pathogenesis of osteoarthritis including factors
that lead to its development and the underlying biology
responsible for the progression of osteoarthritis
• discuss advances in the management of osteoarthritis that
include non-pharmacologic interventions
• evaluate the potential benefits of new disease- or structuremodifying treatments for osteoarthritis
*Challenging Cases in Osteoporosis Management
(072)
Speaker: Kenneth G. Saag, MD, MSc
Speaker: Philip Mease, MD
• recognize bisphosphonate drug holidays
• discuss timing of use of various anti-osteoporosis therapies in
postmenopausal osteoporosis
• recognize current treatment approaches to steroid-induced
osteoporosis
• identify other forms of metabolic bone disease that present to
rheumatologists as low bone mass
• discuss advances in understanding of the pathogenesis of
psoriatic arthritis and implications for diagnosis and treatment
• learn the value of and how to accomplish a “treat-to-target”
approach to psoriatic arthritis in daily practice
• appraise the data on current and emerging treatments for
psoriatic arthritis, including ustekinumab, apremilast, IL-17
inhibitors and other emerging agents
PM
PS
Speaker: John S. Sundy, MD, PhD
*Systemic Lupus Erythematosus: Lupus Nephritis (078)
Speaker: Brad H. Rovin, MD
• review immunosuppressive therapy of lupus nephritis Classes
• discuss the use of renoprotective and anti-proteinuria
• discuss diagnosis and treatment of renal thrombotic
microangiopathy and podocytopathies
nephritis
2 0 1 4
• explain how to measure the relative efficacy of treatments
using effect sizes
• illustrate knowledge of data supporting efficacy of exercise,
bracing, glucosamine, intra-articular steroids and hyaluronic
acid in osteoarthritis
• identify pros and cons of treatments modifying knee
biomechanics for knee osteoarthritis including braces,
orthotics, the All Phases of Step-cycle system and others
• assess emerging treatments for osteoarthritis such as nerve
growth factor inhibitors and where they may fit in the
therapeutic armamentarium
• identify the challenge in the early diagnosis of
spondyloarthritis
• describe current treatment options for spondyloarthritis
1 8 ,
Non-Surgical Treatments for Osteoarthritis (074)
Speaker: David T. Felson, MD, MPH
Speaker: Robert D. Inman, MD
TUESDAY
Spondyloarthropathy: An Update (077)
n o v e m b e r
• discuss the pathogenesis and pathophysiology of acute and
chronic gout, including the distinctive treatment modalities
affecting patient outcomes
• appreciate the renal mechanisms underlying the
hyperuricemia of most gout patients and therapeutic
rationales applied to urate-lowering therapies
• c ritically assess current ACR recommendations for the
treatment of acute and chronic manifestations of gout
Temporal Arteritis (079)
Speaker: Robert F. Spiera, MD
• discuss current concepts in the diagnosis of temporal arteritis
including use of imaging modalities
• identify evolving concepts of the treatment of temporal
arteritis including the appropriate use of glucocorticoids and
the efficacy of “steroid sparing” agents
2014 Program Book
119
scientific sessions
PM
• d
escribe the relationship between temporal arteritis and
polymyalgia rheumatica
• outline current concepts of the pathogenesis of temporal
arteritis
253 B
New Regulatory T Cells
Moderators: George C. Tsokos, MD and Amit Golding, MD, PhD
Speaker: Harvey Cantor, MD
• describe the two major T cell subsets that mediate regulatory
activity
• summarize evidence for the contribution of Treg to selftolerance
• summarize evidence that defective Treg activity may
contribute to autoimmune disease
Vaccinations for Patients on Biologic Therapies (080)
Speaker: Kevin L. Winthrop, MD, MPH
• recognize the importance of appropriate vaccinations in
patients with autoimmune disease
• identify the different types of immunizations especially those
which are live viruses
• describe the effect of different classes of immunomodulatory
medications on vaccine efficacy and safety
PM
210 B
ACR SESSIONS
• identify the different types of specialized and general
connective tissues that may be of relevance for
musculoskeletal pain
• describe the alterations in connective tissue functioning found
in chronic low back pain and recognize the potential roles of
inflammatory and fibrotic pathways in alterations of these
connective tissues
• develop scientific rationale for why certain physical therapy
and exercise approaches may be beneficial for chronic low
back pain
PS
Clinical Issues Associated with the Use of
Methotrexate PM PS
Moderator: Mary E. Cronin, MD
• review the pharmacology of methotrexate
• discuss rational prescription of methotrexate as a solo agent
or in combination therapy
• identify side effects and their prevention and/or treatment
n o v e m b e r
1 8 ,
TUESDAY
2 0 1 4
1:00 pm
Clinical Issues Associated with the Use of Methotrexate
Joel M. Kremer, MD
ARHP SESSIONS
1:00 – 2:00 pm
1:30 pm
Clinical Issues Associated with the Use of Methotrexate
Michael E. Weinblatt, MD
Exhibit Hall C
PM
255
Hench Lectureship: Why Steroids Work in Some
Inflammatory Diseases but Not in Others
• review how inflammatory genes are activated through histone
acetylation
• appraise how corticosteroid suppress inflammation by
engaging histone deacetylase-2
• describe how oxidative stress induces corticosteroid resistance
by inactivating HDAC2
• review how this steroid resistance mechanism may be
reversed, leading to new therapeutic approaches
2014 Program Book
PM
PS
Etiology and Management of Peripheral Neuropathy
in Patients with Rheumatic Disease
Moderator: Jennifer L. Trizuto, MPT
Speaker: Charles E. Argoff, MD
PS
• describe the various causes for neuropathy
• evaluate the treatment options available for treatment of
neuropathy
• discuss neuropathic signs and symptoms in the context of
various rheumatic diseases
PS
Moderator: John M. Davis III, MD, MS
Speaker: Peter Barnes, DM, DSc
120
PS
Moderators: Tuhina Neogi, MD, PhD and Kerry Stone, MD
Speaker: Helene Langevin, MD
1:00 – 2:00 pm
Ballroom East
PS
Uncovering the Role of Connective Tissues in Chronic
Low Back Pain: From Bedside to Bench to Bedside
PM
PM
PS
PM
257 A
Pharmacotherapy: What’s New in Rheumatology
PM
PS
Moderator: Joan C. McTigue, PA-C, MS
Speaker: Susan Bruce, PharmD
• critique the evidence of triple therapy vs. early aggressive
biologic therapies for arthritis in light of treat-to-target
guidelines
scientific sessions
• e xplain the mechanism of action of the new kinase inhibitors
and recognize where the new oral agent tofacitinib fits in the
current armamentarium of therapies
• examine existing and emerging treatment options for systemic
lupus erythematosus
ACR STUDY GROUPS
1:00 – 2:00 pm
Study Groups are non-CME activities open to all attendees.
109 A
ACR-EULAR Study Group: Toward a New
Understanding of Myositis Through International
Collaboration
1:00 pm
Development of Transatlantic Registry Studies in Myositis
Ingrid E. Lundberg, MD, PhD
1:30 pm
New Insights into the Biology of Myositis
Ann M. Reed, MD
107 B
Autoantibodies in Diagnosis and Follow-Up of
Rheumatic Diseases Study Group
1:00 pm
IgG4-related Disease: Historical Background and Clinical
Spectrum
Hiroki Takahashi, MD
Biosimilars in Rheumatology: Update Study Group
1:00 pm
Introduction
Morton A. Scheinberg, MD, PhD
1:10 pm
Biosimilars in Asia: Where We Are
Arvind Chopra, DNB, MBBS, MD
1:35 pm
Biocopies and Biosimilars: Concerns and Risks
Jonathan Kay, MD
151 A
Closing the Gap – Psoriasis to Psoriatic Arthritis Study
Group
1:00 pm
Review the Current Evidence of Predictors of Psoriasis Patients
to Develop Psoriatic Arthritis
Joseph F. Merola, MD and Vinod Chandran, MBBS, MD, DM, PhD
1:24 pm
Identify Strategies to Detect Psoriatic Arthritis Earlier in Its
Disease Course (Clinical Presentation, Biomarkers, or Imaging)
Christopher T. Ritchlin, MD, MPH
2 0 1 4
1:00 pm
Epigenetics in Behçet’s Disease
Amr H. Sawalha, MD
157 B
1 8 ,
Behçet’s Disease Study Group
• assess epigenetic mechanisms and recent advances that
implicate dynamic epigenetic changes during the course of
Behçet’s disease
• discuss recent data related to oral health and its effect on
prognosis
• discuss epidemiology, genetic susceptibility factors and
potential non-genetic risk determinants
• review the existing data of biological treatment options and
management recommendations for Behçet’s disease patients
with severe ocular manifestations or treatment resistant
symptoms
1:45 pm
Biologics in the Treatment of Behçet’s Disease: Which and
When?
Ina Kotter, MD, PhD
TUESDAY
160 B
1:30 pm
Epidemiology of Behçet’s Disease
Alfred Mahr, MD, PhD
n o v e m b e r
1:30 pm
IgG4-related Disease: Pathophysiology and Diagnostic
Challenges
John H. Stone, MD, MPH
1:15 pm
Oral Health in Behçet’s Disease Pathogenesis
Haner Direskeneli, MD
1:36 pm
Optimization of Screening Methods for Psoriatic Arthritis
M. Elaine Husni, MD, MPH and Abrar A. Qureshi, MD, MPH
254 A
Global Musculoskeletal Health Initiatives Study
Group
1:00 pm
Need for Standardized Surveillance Tools for Prevalence and
Impact - Variations between International Surveys
Lyn March, MBBS, MSc, PhD
1:12 pm
Healthcare Quality Indicators to Enable Equity of Care
Ingemar F. Petersson, MD, PhD
2014 Program Book
121
scientific sessions
1:24 pm
Indicators of Equity of Care
Francis Guillemin, MD, PhD
1:36 pm
Measuring Musculoskeletal Disability in Developing Countries
Damian Hoy, BPhysio, PhD
1:40 pm
Study Design for Treating Temporomandibular Joint Arthritis in
Children with Juvenile Idiopathic Arthritis
Carol A. Wallace, MD
153 B
Latin American Study Group
1:48 pm
Round Table Discussion to Agree Core Questions for Health
Interview and Examination Surveys
Anthony D. Woolf, MBBS
1:00 pm
Education in Rheumatology
Carlo Vinicio-Caballero, MD
1:30 pm
Red de Excelencia en Artritis Latinoamerica
Loreto Massardo, MD
259 A
High-Resolution Peripheral Quantitative Computed
Tomography (HR-pQCT) Imaging in Arthritis Study
Group
204 A
Neuroendocrine Immunology Study Group
1:00 pm
Radiology Perspective on the Role of Magnetic Resonance
Imaging and High-Resolution Peripheral Quantitative
Computed Tomography in Trials and Clinical Practice
Charles G. Peterfy, MD, PhD
1:00 pm
Neuroendocrine Modulation of Pain
Leslie J. Crofford, MD
1:20 pm
Stress and Pain
John McBeth, PhD
1:12 pm
Multimodality Comparison: High-Resolution Peripheral
Quantitative Computed Tomography With Magnetic Resonance
Imaging and Ultrasound
Xiaojuan Li, PhD
n o v e m b e r
1 8 ,
TUESDAY
2 0 1 4
1:24 pm
High-Resolution Peripheral Quantitative Computed
Tomography in the Study of Psoriatic Arthritis
Stephanie Boutroy, PhD
1:36 pm
Reliability of High-Resolution Peripheral Quantitative
Computed Tomography and Use for Longitudinal Studies –
Erosion Assessment
Stephanie Finzel, MD
1:48 pm
Reliability of High-Resolution Peripheral Quantitative
Computed Tomography and Use for Longitudinal Studies –
Joint Space Assessment
Andrew J. Burghardt, BS
156 B
Juvenile Arthritis Workgroup (JAW) Study Group
1:00 pm
Treatment of Temporomandibular Joint Arthritis in Juvenile
Idiopathic Arthritis: What We Know and What We Don’t
Randy Q. Cron, MD, PhD
1:20 pm
A Scoring System for Evaluation of Temporomandibular Joint
Arthritis in Children with Juvenile Idiopathic Arthritis
Yoginder Vaid, MD
122
2014 Program Book
1:40 pm
Autonomic Mediators of Inflammation and Pain
Gary S. Firestein, MD
256
Pediatric Rheumatology Imaging Study Group
1:00 pm
The Enthesis in Children, Normal Anatomy and Pathologic
Findings
Johannes Roth, MD
1:20 pm
Frequency of Spinal Involvement in Children with Juvenile
Xenofon Baraliakos, MD
1:40 pm
Magnetic Resonance Imaging vs High-resolution Peripheral
Quantitative Computed Tomography for Erosions in Children
with Juvenile Idiopathic Arthritis
Stephanie Finzel, MD
104 B
Polymyalgia Rheumatica Study Group
1:00 pm
Update on Polymyalgia Rheumatica Guidelines
Bhaskar Dasgupta, MD
scientific sessions
1:20 pm
Prospective Study of Overlap in Inflammatory Diseases of the
Elderly
Eric L. Matteson, MD, MPH
154
Speakers: Philip G. Conaghan, MD, PhD and Mikkel Ostergaard,
DMSc, MD, PhD
1:40 pm
Glucocorticoid Receptors in Polymyalgia Rheumatica
Christian Dejaco, MD, PhD
• recognize the most common types of magnetic resonance
images (as T1- and T2-weighted, fat-saturated, STIR and
contrast-enhanced) and the appearance of the most common
joint pathologies on these
• discuss the rationale and evidence for using magnetic
resonance imaging in clinical practice
• identify the advantages and disadvantages of dedicated
extremity magnetic resonance imaging
102 A
Sjögren’s Syndrome Study Group
1:00 pm
Sjögren’s Cohort in India
Debashish Danda, DM
1:15 pm
Sjögren’s Cohorts in South America
Juan-Manuel Anaya, MD PhD
159
• explain basic concepts of ultrasound physics
• define how to perform a proper ultrasound examination
• identify various tissues in an ultrasound image
152
PS
ACR/ARHP WORKSHOPS
1:15 – 3:15 pm
• identify what information can be gained from a skin biopsy in
• describe the importance of dermatopathology in clinical
decision making in patients with rheumatic diseases
• apply the knowledge gained to clinical practice
2014 Program Book
2 0 1 4
Dermatopathology of Rheumatic Diseases (236)
Speaker: Daniel Miller, MD
• define the importance of using disease-activity measurement
tools in daily practice, the barriers which hinder routine
widespread use and how these barriers can be overcome in
nearly any practice setting
• review the practice of several of the most common and
well-recognized disease activity measurement tools used in
rheumatology care, including the Disease Activity Score for 28
Joints (DAS-28) and Clinical Disease Activity Index (CDAI) for
rheumatoid arthritis; the Psoriatic Arthritis Response Criteria
(PsARC) for psoriatic arthritis; measurements of spine and hip
flexibility as well as the Ankylosing Spondylitis Disease Activity
Score (AS-DAS) for spondyloarthropathies; and the modified
Rodnan skin score for systemic sclerosis
1 8 ,
161
Speaker: Arthur M. Mandelin II, MD, PhD
Facilitators: Barbara A. Slusher, PA-C, MSW and Kori A. Dewing,
DNP, ARNP
TUESDAY
The Rheumatologic Musculoskeletal Screening
Exam, with Emphasis on Objective Disease-Specific
Measurements (239)
n o v e m b e r
Musculoskeletal Ultrasonography: Basic (238)
Speakers: Janak R. Goyal, MD and Gurjit S. Kaeley, MBBS, MRCP
1:30 pm
The United Kingdom Sjögren’s Initiative
Wan-Fai Ng, MA, PhD, CCT
1:45 pm
Oklahoma Sjögren’s Cohort
Kathy Silvis, PhD
PM
Magnetic Resonance Imaging of Peripheral Joints in
Rheumatology Practice (237)
123
scientific sessions
ACR SESSION
52 A
2:00 – 2:30 pm
PM
PS
Ballroom West
ACR Business Meeting
This session is not eligible for CME credit.
Moderator: Joseph Flood, MD
• participate in a meeting with ACR leadership
• r ecognize ACR initiatives
• s ummarize what the ACR is doing to address various practice
issues and other issues
2013-2014 College Year in Review
Election of ACR Secretary
Election of ACR Board of Directors Members
Installation of 78th ACR President
ACR SESSIONS
2:30 – 4:00 pm
255
2 0 1 4
1 8 ,
TUESDAY
n o v e m b e r
Novel Regulatory Cell Subsets
Moderator: Jennifer H. Anolik, MD, PhD
• review the mechanisms by which immune cell subsets
regulate inflammatory responses
• recognize the role that mesenchymal stem cells play in
downmodulating immune responses
• recognize the role that antigen-presenting cell subsets play in
regulating immune responses
2:30 pm
Regulatory Roles of Mesenchymal Stem Cells
Arnold I. Caplan, PhD
3:00 pm
Regulatory B Cells
Claudia Mauri, PhD
3:30 pm
Regulatory Macrophages
James Hutchinson, MBBChir, PhD
PM
PS
210 B
PM
PS
Educator: Innovative Educators, Novel Techniques:
A Rheumatology Research Foundation Special
FIT
PrM
Pd
PS
PM
Ed
Session
Moderators: Sharon L. Kolasinski, MD and Deana M. Lazaro, MD
• discuss novel approaches to curriculum development for
medical students and residents in the musculoskeletal and
rheumatic diseases
• discuss new approaches to teaching in the rheumatic and
musculoskeletal diseases
• determine the unique and important roles of the clinician
scholar educator in medical education and training
2:30 pm
Development of Curricula in Metabolic Bone Disease
Juliet Aizer, MD, MPH
2:50 pm
Web-Based Learning Portfolios in Pediatric Rheumatology
Michal Jennifer Cidon, MD
3:10 pm
Development of Rheumatology Objective Structured Clinical
Examination (ROSCE) Stations With Follow-up Modules
Lisa G. Criscione-Schreiber, MD
3:30 pm
A Dynamic, Competency Based Learning Modules
Rodney Tehrani, MD
3:50 pm
Question and Answer
124
PS
PM
2014 Program Book
Psoriatic Arthritis: Skin, Entheses and Joints
Moderators: Rennie N. G. Howard, MD and Rebecca L. Manno,
MD, MHS
• describe the clinical manifestations of the variants of psoriasis
and discuss current treatment options for psoriasis
• describe the concept of the synovio-entheseal complex and its
role in psoriatic arthritis
• describe theories of the pathogenesis of psoriatic arthritis,
discuss the clinical manifestations and diagnosis of psoriatic
arthritis and develop a rational approach to the treatment of
psoriatic arthritis
2:30 pm
Psoriatic
Kenneth B. Gordon, MD
3:00 pm
The Synovio-Entheseal Complex
Dennis McGonagle, PhD
3:30 pm
Psoriatic Arthritis
Christopher T. Ritchlin, MD, MPH
2:30 – 4:00 pm
PM
Exhibit Hall C
ACR Late-Breaking Abstract Session
PS
scientific sessions
Ballroom East
PM
PS
2014 Rheumatology Research Foundation Edmond L.
Dubois, MD Memorial Lectureship
Moderators: Daniel J. Wallace, MD and Maureen A. McMahon,
MD
2:30 pm
Introductory Talk
Daniel J. Wallace, MD
2:45 pm
2787. Identification of Urinary Biomarkers for Lupus Nephritis
Carolina Landolt-Martincorena, MD
Carolina Landolt-Marticorena1, Stephenie Prokopec2, Heather
Reich3, James Scholey4, Carmen Avila-Casado3, Paul R. Fortin5,
Paul Boutros2 and Joan wither6, 1Toronto Western Hospital,
Toronto, ON, 2Ontario Institute for Cancer Research, Toronto,
ON, 3University Health Network, Toronto, ON, 4The Toronto
Western Hospital, Toronto, ON, 5Laval University, Division
of Rheumatology, Centre de Recherche du CHU de Québec
and Department of Medicine, Quebec City, QC, 6University of
Toronto, Toronto, ON
3:00 pm
2788. Preliminary Population- Based Incidence and Prevalence
Estimates of SLE: The California Lupus Surveillance Project
Maria Dall’Era1, Kurt Snipes2, Miriam Cisternas3, C. Gordon4
and Charles G. Helmick5, 1University of California, San Francisco,
San Francisco, CA, 2California Department of Public Health,
Sacramento, CA, 3MGC Data Services, San Diego, CA, 4Medical
School, Birmingham, United Kingdom, 5Centers for Disease
Control and Prevention, Atlanta, GA
3:45 pm
2791. Lung Cancer in SLE
Sasha Bernatsky1, Rosalind Ramsey-Goldman2, Michelle
Petri3, Murray B. Urowitz4, Dafna D. Gladman4, Edward H.
Yelin5, Christine Peschken6, John G. Hanly7, James E. Hansen8,
Jean-Francois Boivin1, Lawrence Joseph1, Patrice Chrétien
Raymer9, Mruganka Kale10, Ann E. Clarke11 and Systemic Lupus
International Collaborating Clinics (SLICC)12, 1McGill University,
Montreal, QC, 2Northwestern University, Chicago,
Biology and Pathology of Bone and Joint I: Bone
Remodeling in Inflammation and Arthritis
Moderators: Ellen M. Gravallese, MD and Julia F. Charles, MD,
PhD
2:30 pm
2792. Methotrexate Prevents Inflammatory Osteolysis By
Activation of the Adenosine a2A Receptor (A2AR)
Aranzazu Mediero1, Tuere Wilder1 and Bruce N. Cronstein2, 1NYU
School of Medicine, New York, NY, 2NYU School of Medicine,
Division of Rheumatology, New York, NY
2:45 pm
2793. BMP2 Requires TGF-Beta to Induce Osteophytes during
Experimental Osteoarthritis
Esmeralda Blaney Davidson1, Arjen Blom2, Arjan van Caam1, Elly
Vitters2, Miranda Bennink1, Wim van den Berg2, Fons van de Loo1
and Peter van der Kraan2, 1Radboud university medical center,
Nijmegen, Netherlands, 2Radboud University Medical Center,
Nijmegen, Netherlands
3:00 pm
2794. Deletion of the Inhibitory Receptor Motif, ITIM, on DCSTAMP Alters Osteoclast Differentiation and Function
Yahui Grace Chiu1, Edward M. Schwarz1, Dongge Li1, Yuexin
Xu1, Minsoo Kim1 and Christopher T. Ritchlin2, 1University of
Rochester, Rochester, NY, 2University of Rochester Medical
Center, Rochester, NY
3:15 pm
2795. Blockade of IL-6R Signaling by Sarilumab Suppressed
Circulating Markers of Bone Resorption and Synovial Damage
in Rheumatoid Arthritis Patients from a Phase 3, Randomized,
Double-Blind, Placebo-Controlled, International Study
Anita Boyapati1, Jérôme Msihid2, Emmanuelle Cousin2, Ling Cai3,
Janet van Adelsberg1, Jennifer D Hamilton1, Neil Graham1, Tanya
Momtahen4 and Stefano Fiore4, 1Regeneron Pharmaceuticals,
Inc., Tarrytown, NY, 2Sanofi R&D, France, Chilly-Mazarin, France,
3
Sanofi R&D, China, Beijing, China, 4Sanofi, Bridgewater, NJ
2 0 1 4
Stacy P. Ardoin1, Wael Jarjour2, Subha V. Raman2, Amanda Kibler2
and Tam Tran2, 1Ohio State University College of Medicine,
Columbus, OH, 2Ohio State University, Columbus, OH
PS
1 8 ,
3:30 pm
2790. CMR with Quantitative T2 Mapping in Patients with
Active SLE
PM
TUESDAY
Basmah Jalil1, Wilmer Sibbitt Jr2, Romy Cabacangun3, Clifford
Qualls3, Arthur Bankhurst4 and Roderick Fields5, 1University of
New Mexico, Albuquerque, NM, 2University of New Mexico HSC,
Albuquerque, NM, 3UNM, Albuquerque, NM, 4University of NM
Med Ctr, Albuquerque, NM, 5University of New Mexico School of
Medicine, Albuquerque, NM
102 A
n o v e m b e r
3:15 pm
2789. Medical Marijuana Related Outcomes in Patients with
IL, 3Johns Hopkins University School of Medicine, Baltimore,
MD, 4University of Toronto, Toronto Western Hospital, Toronto,
ON, 5University of California, San Francisco, San Francisco, CA,
6
University of Manitoba, Winnipeg, MB, 7Dalhousie University
and Capital Health, Halifax, NS, 8Yale University, New Haven, CT,
9
McGill University Health Centre, Montreal, QC, 10RI McGill Univ
Health Ctr, Montreal, QC, 11University of Calgary, Calgary, AB,
12
Systemic Lupus International Collaborating Clinics (SLICC), ON
3:30 pm
2796. A Novel Mouse Model of Osteochondromagenesis By
Deleting NFATc1 in Mesenchymal Progenitors and Postnatal
Chondrocytes
Xian-Peng Ge, Susan Y. Ritter, Julia F. Charles, Kelly Tsang and
Antonios O. Aliprantis, Brigham and Women’s Hospital, Harvard
2014 Program Book
125
scientific sessions
3:45 pm
2797. Anti-Citrullinated Proteins Antibodies Promotes
Osteoclastogenesis and Bone Destruction in Rheumatoid
Arthritis
Akilan Krishnamurthy1, Vijay Joshua1, Heidi Wähämaa1, Catia
Cerqueira1, Lars Klareskog2, Vivianne Malmström3, Jimmy
Ytterberg1 and Anca I Catrina1, 1Rheumatology Unit, Karolinska
University Hospital, Karolinska Institutet, Stockholm, Sweden,
2
Karolinska Institute, Stockholm, Sweden, 3Rheumatology Unit,
Karolinska University Hospital, Solna, Karolinska Institutet,
Stockholm, Sweden
107 B
PM
PS
Cytokines, Mediators, Cell-cell Adhesion, Cell
Trafficking and Angiogenesis I
Moderator: Shiva Shahrara, PhD
n o v e m b e r
1 8 ,
TUESDAY
2 0 1 4
2:30 pm
2798. C5orf30 a Novel Regulator of Inflammation and Tissue
Damage in Rheumatoid Arthritis
Munitta Muthana1, Sarah Hawtree1, Holly Davies1, Hannah
Roberts1, Sachin Khetan1, Mohammed Akil2, Fiona Wright1,
Barbara Ciani1, Ursula Fearon3, DJ Veale4 and Anthony G.
Wilson5, 1University of Sheffield, Sheffield, United Kingdom,
2
Rheumatology Department, Sheffield South Yorkshire, United
Kingdom, 3Translational Rheumatology Research Group, Dublin,
Ireland, 4St. Vincent’s University Hospital, Dublin, Ireland,
5
University College Dublin, Dublin, Ireland
2:45 pm
2799. The Differential Impact of Obesity on the Pathogenesis of
RA or Preclinical Models Is Contingent on the Disease Status Zhenlong Chen1, Seung-jae Kim1, Abdul Essani1, Michael V.
Volin2, Suncica Volkov1, William Swedler1, Shiva Arami1, Giamila
Fantuzzi1, Nadera J. Sweiss1 and Shiva Shahrara1, 1University of
Illinois at Chicago, Chicago, IL, 2Chicago College of Osteopathic
Medicine Midwestern University, Downers Grove, IL
3:00 pm
2800. Tofacitinib Regulates Synovial Angiogenesis in Psoriatic
Arthritis through Induction of Negative Feedback Inhibitors
Wei Gao, Jennifer McCormick, Carl Orr, Mary Connolly, Ursula
Fearon and Douglas J. Veale, Translational Rheumatology
Research Group, Dublin, Ireland
3:15 pm
2801. IL-38: A New Factor in Rheumatoid Arthritis Shinjiro Kaieda1, Katsuya Kanezaki2, Naomi Yoshida1, Yukiko
Kunitake1, Hiroaki Ida1 and Tomoaki Hoshino1, 1Kurume
University School of Medicine, Kurume, Japan, 2Nagata
orthopedic hospital, Omuta, Japan
3:30 pm
2802. Non-Canonical NF-Kappab Signaling Promotes
Angiogenesis in a Novel 3D Spheroid Model of Rheumatoid
Arthritis Synovial Inflammation
Chrissta X. Maracle1, Boy Helder1, Ae-Ri Noort1, Corine van der
126
2014 Program Book
Horst2 and Sander W. Tas1, 1Academic Medical Center, University
of Amsterdam, Amsterdam, Netherlands, 2Arthrogen BV,
Amsterdam, Netherlands
3:45 pm
2803. Methotrexate Impacts the Effects of Tofacitinib, but
Not Tocilizumab, on Clinically Relevant Biomarkers in Human
Primary Cell–Based BioMAP® Disease Models: Can We Utilize in
Vitro Models to Predict Clinical Outcomes?
Alison O’Mahony1, Ellen L. Berg1, Xitong Li1, Markus R. John2,
Kandeepan Ganeshalingam2 and Ernest H. Choy3, 1BioSeek,
South San Francisco, CA, 2F. Hoffmann-La Roche, Basel,
Switzerland, 3Cardiff University, Cardiff, United Kingdom
151 A
Miscellaneous Rheumatic and Inflammatory
PS
PM
Diseases/Innate Immunity and Rheumatic Disease:
Assessing Outcomes of Infections in Rheumatic
Disease
Moderators: Andy Abril, MD and John D. Carter, MD
2:30 pm
2804. Rituximab in IgG4-Related Disease: A Large Single-Center
Experience
Zachary Wallace, Mollie Carruthers and John H. Stone,
Massachusetts General Hospital, Boston, MA
2:45 pm
2805. IgG4-Related Disease: Baseline Features in 100 Patients
with Biopsy-Proven Disease
Zachary Wallace1, Vikram Deshpande1, Hamid Mattoo2, Vinay
Mahajan2, Mollie Carruthers1, Maria Kulikova1, Shiv Pillai1 and
John H. Stone1, 1Massachusetts General Hospital, Boston, MA,
2
Massachusetts General Hospital, Harvard Medical School,
Boston, MA
3:00 pm
2806. Characteristic Phenotype of Peripheral Blood
Lymphocytes in Patients with IgG4-Related Disease, Comparing
to Primary Sjögren’s Syndrome and Healthy Controls
Shintaro Hirata, Shingo Nakayamada, Satoshi Kubo, Maiko
Yoshikawa, Naoki Yunoue, Kazuhisa Nakano, Kunihiro Yamaoka,
Kazuyoshi Saito and Yoshiya Tanaka, University of Occupational
and Environmental Health, Japan, Kitakyushu, Japan
3:15 pm
2807. Comparison of Outcomes in Septic Arthritis Caused By
MRSA and MSSA
Deepa Panikkath1, Sian Yik Lim2, Swetha Gadwala3, Ragesh
Panikkath3 and Kenneth Nugent2, 1Texas Tech University of
Health Sciences, Lubbock, LUBBOCK, TX, 2Texas Tech University
Health Sciences Center, Lubbock, TX, 3Texas Tech University of
Health Sciences, Lubbock, TX
3:30 PM
2808. WITHDRAWN
scientific sessions
3:45 PM
2809. Human Papilloma Virus and Chlamydia Trachomatis
Infections in Rheumatoid Arthritis Under Anti-TNF Therapy
Mariana G Waisberg1, Ana C.M. Ribeiro2, Wellington M. Candido1,
Poliana B. Medeiros1, Cezar N. Matsuzaki1, Mariana C. Beldi1,
Maricy Tacla1, Helio H. Caiaffa-Filho1, Eloisa Bonfá1 and Clovis
A Silva3, 1Faculdade de Medicina da Universidade de São Paulo,
Sao Paulo, Brazil, 2University of Sao Paulo, Sao Paulo, Brazil,
3
Faculdade de Medicina da Universidade de São Paulo, São
Paulo, Brazil
258 B
PM
PS
Rheumatoid Arthritis – Clinical Aspects V: Mortality
and Other Outcomes
Moderators: Jennifer Barton, MD and Aryeh Fischer, MD
2:30 pm
2810. Reduced Mortality Risk in Rheumatoid Arthritis: Findings
from Two UK Inception Cohorts
Sam Norton1, Elena Nikiphorou2, Lewis Carpenter2, David Walsh3,
Patrick Kiely4, Josh Dixey5 and Adam Young6, 1King’s College
London, London, United Kingdom, 2University of Hertfordshire,
Hatfield, United Kingdom, 3University of Nottingham,
Nottingham, United Kingdom, 4St. Georges Healthcare NHS Trust,
London, United Kingdom, 5New Cross Hospital, Wolverhampton,
United Kingdom, 6ERAS, St Albans City Hospital, St Albans,
United Kingdom
104 B
PM
PS
Rheumatoid Arthritis – Human Etiology and
Pathogenesis I: Mechanisms of Joint Damage
Includes 2013 Lee C. Howley, Sr. Prize for Arthritis Research
Introductory Talk
Moderator: Miriam A. Shelef, MD, PhD and Bruce N. Cronstein,
MD
2 0 1 4
2:30 pm
2013 Lee C. Howley, Sr. Prize for Arthritis Research Introductory
Talk
Bruce N. Cronstein, MD
1 8 ,
3:15 pm
2813. Correlation of Morning Stiffness with Measures of
Higher Disease Activity in a Large US Registry Population of
Rheumatoid Arthritis Patients
Vibeke Strand1, Robert J. Holt2, Katherine C. Saunders3, Jeffery
D. Kent4, Ping Xu5, Amy Y. Grahn4, Marc Mason3 and Carol J.
Etzel3, 1Stanford University, Palo Alto, CA, 2University of Illinois –
Chicago, Chicago, IL, 3Corrona, LLC., Southborough, MA, 4Horizon
3:45 pm
2815. Better Functional Ability with Less Biologicals 2
years after Induction with Combination DMARD Therapy
versus methotrexate Monotherapy
T. Martijn Kuijper1, J.J. Luime1, P.H.P. de Jong1, A. H. Gerards2,
D. van Zeben3, I. Tchetverikov4, P.B.J. de Sonnaville5, M. van
Krugten6, B. Grillet7, J.M.W. Hazes8 and A.E.a.M. Weel9, 1Erasmus
University Medical Center, Rotterdam, Netherlands, 2Vlietland
Hospital, Schiedam, Netherlands, 3Sint Franciscus Gasthuis,
Rotterdam, Netherlands, 4Albert Schweitzer Hospital, Dordrecht,
Netherlands, 5Admiraal de Ruyter Ziekenhuis, Goes, Netherlands,
6
Admiraal de Ruyter Hospital, Vlissingen, Netherlands,
7
ZorgSaam Hospital, Terneuzen, Netherlands, 8Erasmus MC,
Rotterdam, Netherlands, 9MD, PhD, Rotterdam, Netherlands
TUESDAY
3:00 pm
2812. Is Rheumatoid Arthritis the Same Disease in Women
and Men?- Joint Damage in Patients with EARLY Rheumatoid
Arthritis at 10 YEARS after Diagnosis
Juha Asikainen1, Kalevi Kaarela2, Heidi Mäkinen3, Hannu
Kautiainen4, Pekka Hannonen5, Tuomas Rannio6 and Tuulikki
Sokka7, 1Jyvaskyla Central Hospital, Jyväskylä, Finland, 2Jyväskylä
Central Hospital, Jyväskylä, Finland, 3Tampere University
Hospital, Tampere, Finland, 4Medcare Oy, Äänekoski, Finland,
5
Jyväskylä Central Hospital, Jyvaskyla, Finland, 6Kuopio
University Hospital, Kuopio, Finland, 7Jyvaskyla Central Hospital,
Jyvaskyla, Finland
3:30 pm
2814. Time-to-Remission, Time-to-Relapse and Disease
Severity at the Time of Relapse in RA- Results from the Ontario
Best Practices Research Initiative (OBRI)
Bindee Kuriya1, Xiuying Li2, Binu Jacob2, Pooneh Akhavan3,
Jessica Widdifield1, Mark Tatangelo1, Janet E. Pope4, Edward
Keystone5 and Claire Bombardier6, 1University of Toronto,
Toronto, ON, 2University Health Network, Toronto General
Research Institute, Toronto, ON, 3Early Rheumatoid Arthritis
Program, Mount Sinai Hospital and University of Toronto,
Toronto, ON, 4Western University, London, ON, 5Mount Sinai
Hospital, University of Toronto, Toronto, ON, 6Institute for Work
& Health, Toronto, ON
n o v e m b e r
2:45 pm
2811. Improvements in Rheumatoid Arthritis Related Fatigue
Are Driven By Reductions in Pain, Not Disease Activity – Results
from the British Society for Rheumatology Biologics Register
for Rheumatoid Arthritis
Katie L Druce, Gareth T Jones, Gary J. Macfarlane and Neil Basu,
University of Aberdeen, Aberdeen, United Kingdom
Pharma, Inc., Deerfield, IL, 5Axio Research LLC, Seattle, WA
2:45 pm
2816. Distinctive DNA Methylome Signatures in Early
Rheumatoid Arthritis (RA) Synoviocytes Compared with
Longstanding (RA) and Other Inflammatory Arthritides
Rizi Ai1, John W. Whitaker2, David L. Boyle3, Paul Peter Tak4,
Danielle M. Gerlag5, Wei Wang6 and Gary S. Firestein3, 1UC
San Diego, La Jolla, CA, 2UCSD, San Diego, CA, 3University
of California at San Diego School of Medicine, La Jolla, CA,
4
Academic Medical Center / University of Amsterdam,
Department of Clinical Immunology and Rheumatology &
GlaxoSmithKline, Amsterdam, Netherlands, 5Academic Medical
Center/University of Amsterdam, Amsterdam, Netherlands,
6
UCSD, La Jolla, CA
2014 Program Book
127
scientific sessions
3:00 pm
2817. Histone Deacetylase One Contributes to the AutoAggressive Phenotype of Rheumatoid Arthritis
Sarah Hawtree1, Munitta Muthana1, J. Mark Wilkinson1, Anthony
G. Wilson1 and Mohammed Akil2, 1University of Sheffield,
Sheffield, United Kingdom, 2Rheumatology Department,
Sheffield South Yorkshire, United Kingdom
3:15 pm
2818. SH2 Domain-Containing Phosphatase 2 Promotes
Aggressiveness of Rheumatoid Fibroblast-like Synoviocytes
Stephanie M. Stanford1, German R. Aleman Muench1, Cristiano
Sacchetti1, Lifan Zeng2, David L. Boyle3, Gen-Sheng Feng4,
Zhong-Yin Zhang2, Maripat Corr3, Gary S. Firestein3 and Nunzio
Bottini1, 1La Jolla Institute for Allergy and Immunology, La Jolla,
CA, 2Indiana University School of Medicine, Indianapolis, IN,
3
University of California at San Diego School of Medicine, La Jolla,
CA, 4University of California at San Diego Division of Biological
Sciences, La Jolla, CA
3:30 pm
2819. The YAP Pathway Regulates Fibroblast-like Synoviocyte
Invasion
Beatrix Bartok, University of California, San Diego, La Jolla, CA
3:45 pm
2820. Dual Role for B Cells in Promoting Bone Erosion in
Rheumatoid Arthritis Via Effects on Osteoclast and Osteoblast
Differentiation
Nida Meednu, Hengwei Zhang, Teresa Owen, Lianping Xing and
Jennifer H. Anolik, University of Rochester, Rochester, NY
n o v e m b e r
1 8 ,
TUESDAY
2 0 1 4
253 B
128
PM
PS
and Gene Therapy V: Novel Therapies in Rheumatoid
Arthritis – Late in Development
Moderators: Jonathan Kay, MD and Joseph A. Markenson, MD
2:30 pm
2821. Efficacy and Safety/Tolerability of Mavrilimumab, a
Human GM-CSFRá Monoclonal Antibody in Patients with
Gerd Burmester1, Iain B. McInnes2, Joel M. Kremer3, Pedro
Miranda4, Mariusz Korkosz5, Jiri Vencovsky6, Andrea RubbertRoth7, Eduardo Mysler8, Sara Sandbach9, Matthew A. Sleeman9,
Alex Godwood9, David Close9 and Michael Weinblatt10, 1Charité
– University Medicine Berlin, Berlin, Germany, 2University of
Glasgow, Glasgow, United Kingdom, 3Albany Medical College
and the Center for Rheumatology, Albany, NY, 4Centro de
Estudios Reumatologicos, Santiago, Chile, 5Malopolskie Centrum
Medyczne, Krakow, Poland, 6Charles University Institute of
Rheumatology, Praha, Czech Republic, 7University of Cologne,
Koln, Germany, 8OMI, Buenos Aires, Argentina, 9MedImmune
Ltd, Cambridge, United Kingdom, 10Brigham & Women’s Hospital,
Harvard Medical School, Boston, MA
2014 Program Book
2:45 pm
2822. Safety and Efficacy of Baricitinib through 128 Weeks in
an Open-Label, Long-Term Extension Study in Patients with
Edward C. Keystone1, Peter C. Taylor2, Mark C Genovese3,
Douglas E. Schlichting4, Inmaculada De La Torre5, Scott D.
Beattie4 and Terence Rooney4, 1Mount Sinai Hospital, Toronto,
ON, 2University of Oxford, Oxford, United Kingdom, 3Stanford
University Medical Center, Palo Alto, CA, 4Eli Lilly and Company,
Indianapolis, IN, 5Eli Lilly and Company, Alcobendas, Spain
3:00 pm
2823. Comparable Efficacy with Sarilumab Plus Methotrexate
in Biologic-Experienced and Biologic-Naïve Patients with
Moderate-to-Severe Rheumatoid Arthritis from a Phase 3,
Randomized, Double-Blind, Placebo-Controlled, International
Study
Roy Fleischmann1, Dennis L. Decktor2, Chunpeng Fan3, Hubert
Van Hoogstraten3 and Mark C Genovese4, 1Metroplax Clinical
Research Center and University of Texas Southwestern Medical
Center, Dallas, TX, 2Regeneron Pharmaceuticals, Inc., Tarrytown,
NY, 3Sanofi, Bridgewater, NJ, 4Stanford University Medical Center,
Palo Alto, CA
3:15 pm
2824. A Profile of the Efficacy of Sarilumab Plus Methotrexate
in Rheumatoid Arthritis Patients: Results of a 52-Week,
Phase 3, Randomized, Double-Blind, Placebo-Controlled,
International Study
Arthur Kavanaugh1, Dennis L. Decktor2, Chunpeng Fan3, Janet
van Adelsberg2, Renata Martincova4 and Mark C. Genovese5,
1
University of California San Diego, La Jolla, CA, 2Regeneron
Pharmaceuticals, Inc., Tarrytown, NY, 3Sanofi, Bridgewater,
NJ, 4Sanofi Czech Republic, Prague, Czech Republic, 5Stanford
University Medical Center, Palo Alto, CA
3:30 pm
2825. A Randomized, Double-Blind, Phase 3 Equivalence Trial
Comparing the Etanercept Biosimilar, HD203, with Etanercept
(Enbrel®), in Combination with Methotrexate (MTX) in Patients
with Rheumatoid Arthritis (RA)
Sang-Cheol Bae1, Jinseok Kim2, Jung-Yoon Choe3, Won Park4,
So-Ra Lee5, Yongho Ahn6 and Yunjeong Seo5, 1Hanyang
University Hospital for Rheumatic Diseases, Seoul, South Korea,
2
Jeju National University, Jeju, Korea, South Korea, 3Catholic
University of Daegu School of Medicine, Daegu, South Korea,
4
Inha University Hospital, Incheon, South Korea, 5Hanwha
Chemical, Seoul, South Korea, 6Hanwha Chemical, Daejeon,
South Korea
3:45 pm
2826. A Phase 2b, Randomized, Double-Blind, Parallel-Group,
Placebo-Controlled, Dose-Finding, Multi-Center Study to
Evaluate the Safety and Efficacy of ASP015K in Moderate to
Severe Rheumatoid Arthritis Subjects Not on Concomitant
Methotrexate
Mark C. Genovese1, Maria Greenwald2, Christine Codding3,
Mario H. Cardiel4, Anna Zubrzycka-Sienkiewicz5, Alan J. Kivitz6,
scientific sessions
Steve Wisseh7, Kathyjo Shay8 and Jay P. Garg8, 1Stanford
University Medical Center, Palo Alto, CA, 2Desert Medical
Advances, PALM DESERT, CA, 3Health Research of Oklahoma,
Oklahoma City, OK, 4Centro de Investigacion Clinica de Morelia,
Morelia, Mexico, 5ARS Rheumatica sp. Zo.o, Reumatika,
Warszawa, Poland, 6Altoona Center for Clinical Research,
Duncansville, PA, 7Biocis, Chicago, IL, 8Astellas Pharma Global
Development, Northbrook, IL
Ballroom West
PM
PS
Spondyloarthropathies and Psoriatic Arthritis IV –
Clinical Aspects Axial Spondyloarthritis
Moderators: John D. Reveille, MD and Nigil Haroon, MD, PhD,
DM
2:30 pm
2827. Cervical Spine Fracture and Mortality in Ankylosing
Spondylitis
Katherine D. Wysham, Sara G. Murray, Nancy K. Hills, Edward
H. Yelin and Lianne S. Gensler, University of California, San
PM
PS
and Treatment: Novel Therapies for Systemic Lupus
Erythematosus
Moderators: Megan E. B. Clowse, MD, MPH and Kenneth C.
Kalunian, MD
2 0 1 4
2:30 pm
2833. SM101, a Novel Recombinant, Soluble, Human FcγIIB
Receptor, in the Treatment of Systemic Lupus Erythematosus:
Results of a Double-Blind, Placebo-Controlled Multicenter
Study
Sascha Tillmanns1, Claudia Kolligs1, David P. D’Cruz2, Andrea
Doria3, Eric Hachulla4, Reinhard E. Voll5, Michael Tansey1 and
Klaus Schollmeier1, 1SuppreMol GmbH, Martinsried, Germany,
2
Louise Coote Lupus Unit, Guy’s and St Thomas’ Hospital,
London, United Kingdom, 3University of Padova, Padova, Italy,
4
Lille University, Lille, France, 5University Hospital Freiburg,
Freiburg, Germany
1 8 ,
3:15 pm
2830. Progression to and Type of Orthopaedic Surgery in
Juvenile Vs. Adult-Onset Ankylosing Spondylitis
Deepak R. Jadon1, Gavin Shaddick2, Amelia Jobling2, Athimalaipet
V Ramanan3 and Raj Sengupta1, 1Royal National Hospital for
Rheumatic Diseases, Bath, United Kingdom, 2University of Bath,
Bath, United Kingdom, 3University of Bristol Hospital Trust,
Bristol, United Kingdom
205 B
TUESDAY
3:00 pm
2829. Spondyloarthritis Is Associated with Increased
Cardiovascular and Cerebrovascular Mortality
Nigil Haroon1, Nisha Nigil Haroon2, Ping Li3, Michael Paterson3
and Robert D. Inman4, 1Toronto Western Research Institute,
Toronto, ON, 2University of Toronto, Toronto, ON, 3Institute of
Clinical Evaluative Sciences, Toronto, ON, 4University of Toronto
and Toronto Western Hospital, Toronto, ON
3:45 pm
2832. The Effect of Co-Medication with Conventional Synthetic
Disease Modifying Anti-Rheumatic Drugs on TNF Inhibitor Drug
Survival in Patients with Ankylosing Spondylitis: Results from a
Nationwide Prospective Study
Elisabeth Lie1, Lars Erik Kristensen2, Helena Forsblad-d’Elia3,
Johan Askling4 and Lennart T. Jacobsson3, 1Diakonhjemmet
Hospital, Oslo, Norway, 2Lund University, Malmö, Sweden,
3
Sahlgrenska Academy at University of Gothenburg, Gothenburg,
Sweden, 4Karolinska Institutet, Stockholm, Sweden
n o v e m b e r
2:45 pm
2828. A Physically Demanding Job May Amplify the Effect of
Disease Activity on the Development of Syndesmophytes in
Patients with Ankylosing Spondylitis
Sofia Ramiro1, A.M. van Tubergen2, Robert Landewé3, Annelies
Boonen2, Carmen Stolwijk2, Maxime Dougados4, Filip Van den
Bosch5 and Desiree van der Heijde6, 1Amsterdam Rheumatology
Center/University of Amsterdam, Amsterdam, Netherlands,
2
Maastricht University Medical Center, Maastricht, Netherlands,
3
Academic Medical Center, University of Amsterdam,
Amsterdam, Netherlands, 4Université Paris René Descartes and
Hôpital Cochin, Paris, France, 5Ghent University Hospital, Ghent,
Belgium, 6Leiden University Medical Center, Leiden, Netherlands
3:30 pm
2831. Development of New Radiographic Vertebral Fractures
in Patients with Ankylosing Spondylitis during 4 Years of TNF-α
Blocking Therapy: Results from the Glas Cohort
Fiona Maas1, Anneke Spoorenberg1, Elisabeth Brouwer2,
Reinhard Bos3, Rizwana N. Chaudhry1, Freke Wink3, Hendrika
Bootsma4, Eveline van der Veer1 and Suzanne Arends4,
1
University Medical Center Groningen, Groningen, Netherlands,
2
University of Groningen, University Medical Center Groningen,
Groningen, Netherlands, 3Medical Center Leeuwarden,
Leeuwarden, Netherlands, 4University Medical Center Groningen,
University of Groningen, Groningen, Netherlands
2:45 pm
2834. Correlation of Laboratory and Clinical Parameters with
British Isles Lupus Assessment Group Response in an OpenLabel Extension Study of Epratuzumab in Systemic Lupus
Erythematosus
Richard A. Furie1, Michelle A. Petri2, Caroline Gordon3, Vibeke
Strand4, Catrinel Galateanu5, Sabine Bongardt6, Willem Koetse7
and Daniel J. Wallace8, 1North Shore – Long Island Jewish
Health System, Great Neck, NY, 2Division of Rheumatology,
Johns Hopkins University School of Medicine, Baltimore, MD,
3
Rheumatology Research Group, School of Immunity and
Infection, College of Medical and Dental Sciences, University of
Birmingham, Birmingham, United Kingdom, 4Biopharmaceutical
2014 Program Book
129
scientific sessions
Consultant, Portola Valley, CA, 5UCB Pharma, Brussels, Belgium,
6
UCB Pharma, Monheim, Germany, 7UCB Pharma, Raleigh, NC,
8
Cedars-Sinai Medical Center, Los Angeles, CA
3:00 pm
2835. A Phase 2, Multicenter, Randomized, Double-Blind,
Placebo-Controlled, Proof-of-Concept Study to Evaluate the
Efficacy and Safety of Sirukumab in Patients with Active Lupus
Nephritis
Cynthia Aranow1, R. van Vollenhoven2, Brad H. Rovin3, Carrie
Wagner4, Bei Zhou4, Robert Gordon4 and Benjamin Hsu4, 1The
Feinstein Institute, Manhasset, NY, 2The Karolinska Institute,
Stockholm, Sweden, 3Ohio State University Medical Center,
Columbus, OH, 4Janssen Research & Development, LLC., Spring
House, PA
n o v e m b e r
1 8 ,
TUESDAY
2 0 1 4
3:15 pm
2836. Effects of Blisibimod, an Inhibitor of B Cell Activating
Factor, on Patient Reported Outcomes and Disease Activity in
Patients with Systemic Lupus Erythematosus
Michelle Petri1, Renee S. Martin2, Colin Hislop2, Morton A.
Scheinberg3 and Richard Furie4, 1Johns Hopkins University
School of Medicine, Baltimore, MD, 2Anthera Pharmaceuticals
Inc, Hayward, CA, 3Rheumatology Hospital Abreu Sodre Pesquisa
Clínica, São Paulo, Brazil, 4North Shore – Long Island Jewish
Health System, Great Neck, NY
130
3:30 pm
2837. Induction of Clinical Remission By Low-Dose
Interleukin-2 in Refractory SLE
Jens Y. Humrich1, Caroline von Spee-Mayer1, Elise Siegert1,
Angelika Rose1, Tobias Alexander1, Falk Hiepe1, Andreas
Radbruch2, Gerd Burmester3 and Gabriela Riemekasten1,
1
Charité – University Hospital, Berlin, Germany, 2German
Rheumatism Research Centre Berlin (DRFZ), an institute of
the Leibniz Association, Berlin, Germany, 3Charité University
Medicine, Dept. Medicine/Rheumatology and Clinical
Immunology, Berlin, Germany
3:45 pm
2838. Exploratory Analysis of Pharmacokinetic Effects of
Atacicept in Patients with Moderate to Severe Systemic Lupus
Erythematosus
David Wofsy1, Caroline Gordon2, Yong Li3, Stephen D. Wax4
and David Isenberg5, 1Division of Rheumatology, University of
California, San Francisco, CA, 2Rheumatology Research Group,
School of Immunity and Infection, College of Medical and
Dental Sciences, University of Birmingham, Birmingham, United
Kingdom, 3R&D Global BioStatistics, EMD Serono, Billerica,
MA, 4Global Clinical Development Center – Immunology, EMD
Serono Inc, Rockland, MA, 5Centre for Rheumatology Research,
University College Hospital London, London, United Kingdom
2014 Program Book
156 B
PM
PS
Systemic Lupus Erythematosus – Human Etiology and
Pathogenesis II: Pathogenic Targets, Genetic Variants
and Apoptosis
Moderators: Gary S. Gilkeson, MD and Susan A. Boackle, MD
2:30 pm
2839. BCL-2 As a Potential Therapeutic Target in Human Lupus
Tubulointerstitial Inflammation
Kichul Ko1, Denisse Yanez1, Natalya Kaverina1, Vladimir M.
Liarski1, Yahui Peng2, Li Lan1, Stuart Perper3, Annette Schwartz3,
Liz O’connor3, Andrew Souers4, Steven Elmore4, Lisa Olson3,
Maryellen L. Giger1, Li Chun Wang3 and Marcus R. Clark1,
1
University of Chicago, Chicago, IL, 2Beijing Jiaotong University,
Beijing, China, 3AbbVie Inc, AbbVie Bioresearch Center,
Worcester, MA, 4AbbVie Inc, North Chicago, IL
2:45 pm
2840. Targeting the RhoA-Rock Pathway to Reverse T Cell
Dysfunction in SLE
Cristina T. Rozo, Laura Leuenberger, Kyriakos A. Kirou, Margaret
Robotham, Sanjay Gupta, Reena Khianey, Alessandra B. Pernis
and Jane E. Salmon, Hospital for Special Surgery, New York, NY
3:00 pm
2841. Identifying Novel Lupus Severity Risk Variants through
Identification of Alleles with High Ethnic Variability Worldwide
Belinda A. Waltman1, Kimberly E. Taylor1, Julio Molineros2, Sarah
French1, Joanne Nitiham1, Jennifer Kelly2, Adam Adler2, Judith
A. James2, Swapan Nath2, Marta Alarcon-Riquelme2 and Lindsey
A. Criswell1, 1University of California, San Francisco, Rosalind
Russell / Ephraim P. Engleman Rheumatology Research Center,
San Francisco, CA, 2Oklahoma Medical Research Foundation,
Oklahoma City, OK
3:15 pm
2842. An Anti CD123 Monoclonal Antibody (CSL362) Depletes
Plasmacytoid Dendritic Cells and Inhibits CpG Upregulated
IFNα Production and IFNα-Inducible Gene Expression in
Peripheral Blood Mononuclear Cells from Patients with
Shereen Oon1, Nicholas Wilson1 and Ian Wicks2, 1The University
of Melbourne, Melbourne, Australia, 2The Walter and Eliza Hall
Institute of Medical Research, Melbourne, Australia
3:30 pm
2843. SLE Patients Carrying a Disease-Associated PTPN22
R620W Variant Show Reduced Interferon-Inducing Capacity
Yaya Wang, David Ewart, Ami Yamamoto, Emily C. Baechler,
Parastoo Fazeli and Erik J. Peterson, University of Minnesota,
Minneapolis, MN
scientific sessions
3:45 pm
2844. Intracellular Complement C3 Is Exposed on the Cell
Surface upon Apoptosis Induction and Participates in the
Clearance of Apoptotic Cells By Phagocytes
Lucrezia Colonna1, Christian Lood1, YuFeng Peng1, Xizhang Sun1,
Lena Tanaka1, Sandip Panicker2 and Keith B. Elkon1, 1University of
Washington, Seattle, WA, 2True North Therapeutics, South San
Francisco, CA
PM
109 A
T Cell Biology and Targets in Autoimmune Disease
PS
Medicine, IFR100 ; Department of Internal Medicine and Clinical
Immunology, Dijon, France, 2INSERM UMR 1098, Besançon,
Dijon, France, 3Department of internal medicine and systemic
diseases, Dijon, France, 4Department of Geriatric Internal
Medicine, Dijon, France, 5Department of Internal Medicine,
Metz, France, 6Department of Internal Medicine, Besançon,
France, 7Department of Rheumatology, Dijon, France, 8University
Hospital Dijon, Dijon, France, 9INSERM UMR1098, Besançon,
France, 10INSERM UMR 1098, Besançon ; University of Burgundy,
Faculty of Medicine, IFR100 ; Department of Pathology, Dijon,
France
Moderators: Insoo Kang, MD and Andras Perl, MD, PhD
2:30 pm
2845. Altered Plasticity of Inflammatory CD4 T
Cells Contributing to Th17 Shift in Rheumatoid Arthritis
Jan Leipe, Fausto Pirronello, Simon Hermann, Matthias Witt,
Hendrik Schulze-Koops and Alla Skapenko, University of Munich,
Munich, Germany
2:45 pm
2846. CaMK4 Inhibition Ameliorates the Development of Th17
Driven Inflammatory Diseases By Preventing Recruitment of IL17 Producing Cells to Target Organs
Tomohiro Koga1, Kotaro Otomo2, Masayuki Mizui2, Nobuya
Yoshida2, José C. Crispin2, Atsushi Kawakami1 and George
C. Tsokos3, 1Department of Immunology and Rheumatology,
Nagasaki University Graduate School of Biomedical Sciences,
Nagasaki, Japan, 2Beth Israel Deaconess Medical Center, Harvard
Medical School, Boston, MA, 3Beth Israel Deaconess Medical
Center/Harvard Medical School, Boston, MA
Moderators: Tanaz A. Kermani, MD and Alfred Mahr, MD, PhD
2 0 1 4
2:30 pm
2851. The Relationship of ARMS2 Genotype with Idiopathic
Inflammatory Vasculitis
Christopher Mecoli1, Fan Wang2, Christopher Pappas3, Peter
C. Grayson4, David Cuthbertson5, Simon Carette6, Christian
Pagnoux6, Gary S. Hoffman7, Nader A. Khalidi8, Curry L. Koening9,
Carol A. Langford10, Carol McAlear11, Paul A. Monach12, Larry W.
Moreland13, Philip Seo14, Ulrich Specks15, Steven R. Ytterberg15,
Rui Feng1, Gregory Hageman3 and Peter A. Merkel11, 1University
of Pennsylvania, Philadelphia, PA, 2University of Pennsylvania,
Philadelphia, OK, 3University of Utah School of Medicine,
Salt Lake City, UT, 4National Institutes of Health, Bethesda,
MD, 5University of South Florida, Tampa, FL, 6University of
Toronto, Toronto, ON, 7Center for Vasculitis Care and Research,
Cleveland Clinic Foundation, Cleveland, OH, 8St. Joseph’s
Hospital, McMaster University, Hamilton, ON, 9University of
Utah, Salt Lake City, UT, 10Center for Vasculitis Care and Research,
Cleveland Clinic, Cleveland, OH, 11Vasculitis Center, University
of Pennsylvania, Philadelphia, PA, 12Vasculitis Center, Boston
University School of Medicine, Boston, MA, 13University of
Pittsburgh, Pittsburgh, PA, 14Johns Hopkins Vasculitis Center,
Johns Hopkins University, Baltimore, MD, 15Mayo Clinic,
Rochester, MN
1 8 ,
3:30 pm
2849. Involvement of CD8+ T Cells in the Pathogenesis of Giant
Cell Arteritis and Polymyalgia Rheumatica
Maxime Samson1, Sylvain Audia1, Malika Trad2, Marion Ciudad2,
Hervé Devilliers3, Alexandrine Gautheron2, Valérie Quipourt4,
Francois Maurier5, Nadine Meaux Ruault6, Patrick Manckoundia4,
Paul Ornetti7, Jean-Francis Maillefert8, Jean-François
Besancenot3, Christophe Ferrand9, Philippe Saas9, Laurent
Martin10, Nona Janikashvili2 and Bernard Bonnotte1, 1INSERM
UMR 1098, Besançon ; University of Burgundy, Faculty of
Vasculitis III
TUESDAY
3:15 pm
2848. T-Cell Signaling Defects Can be Corrected By
Manipulating ‘TCR Signal Fine-Tuning Molecules’ That
Are Altered Due to Increased Ubiquitination in Systemic
Autoimmune Disease
Julia Pinkhasov and Ram Raj Singh, UCLA, Los Angeles, CA
157 B
n o v e m b e r
3:00 pm
2847. Survivin Co-Ordinates Formation of Follicular T-Cells in
Maria Bokarewa1, Karin Andersson2, Malin Erlandsson2, Mattias
Svensson2, Nicola Cavallini3 and Mikael Brisslert2, 1University
of Goteborg, Goteborg, Sweden, 2University of Gothenburg,
Gothenburg, Sweden, 3University of Göteborg, Göteborg,
Sweden
3:45 pm
2850. MiR-125a Is Critical Regulator for Controlling
Autoimmunity in Multiple Autoimmune Diseases through
Stabilizing Treg Mediated Immune Homeostasis
Wan Pan1, Shu Zhu1, Dai Dai1, John Harley2 and Nan Shen1,
1
Institute of Health Sciences, Shanghai Institutes for Biological
Sciences (SIBS), Chinese Academy of Sciences (CAS) & Shanghai
Jiao Tong University School of Medicine (SJTUSM), Shanghai,
China, 2The Center for Autoimmune Genomics and Etiology
(CAGE), Cincinnati Children’s Hospital Medical Center, Cincinnati,
Ohio, UnitedPMStatesPSof America, Cincinnati, OH
2:45 pm
2852. Evaluation of KIR3DL1/KIR3DS1 Association with
Behçet’s Disease in Turkish Individuals
Burak Erer1, Elaine F. Remmers1, Masaki Takeuchi1, Colleen
Satorius1, Duran Ustek2, Ilknur Tugal-tutkun3, Emire Seyahi4,
Yilmaz Ozyazgan5, Ahmet Gul3, Daniel L. Kastner6 and Michael J.
2014 Program Book
131
scientific sessions
n o v e m b e r
1 8 ,
TUESDAY
2 0 1 4
Ombrello7, 1National Human Genome Research Institute,
National Institutes of Health, Bethesda, MD, 2Institute of
Experimental Medicine, Istanbul University, Istanbul, Turkey,
3
Istanbul Faculty of Medicine, Istanbul University, Istanbul,
Turkey, 4Cerrahpasa Medical Faculty, University of Istanbul,
Istanbul, Turkey, 5Cerrahpasa Medical Faculty, Istanbul University,
Istanbul, Turkey, 6National Human Genome Research Institute,
Bethesda, MD, 7National Institute of Arthritis Musculoskeletal
and Skin Diseases, National Institutes of Health, Bethesda, MD
132
3:00 pm
2853. Comparative Study of Infliximab Versus Adalimumab
in Patients with Refractory Uveitis Due to Behçet´s Disease.
Multicenter Study of 125 Cases
Leyre Riancho-Zarrabeitia1, Vanesa Calvo-Río1, Ricardo Blanco1,
Paz Rodríguez-Cundín1, Emma Beltrán2, Juan Sánchez Bursón
Sr.3, Marina Mesquida4, Alfredo Adan4, M. Victoria Hernández5,
Marisa Hernandez Grafella6, Elia Valls Pascual7, Lucía MartinezCosta8, Agusti Sellas-Fernandez9, Miguel Cordero-Coma10,
Manuel Díaz-Llopis11, Roberto Gallego11, Jose Luis García
Serrano12, Norberto Ortego-Centeno13, Jose M Herreras14,
Alejandro Fonollosa15, Angel M. Garcia-Aparicio16, Olga Maiz
Alonso17, Ana Blanco18, Ignacio Torre Salaberri19, Cruz FernándezEspartero20, Vega Jovani21, Diana Peiteado22, Esperanza Pato23,
Juan Cruz24, Carlos Férnandez Cid25, Elena Aurrecoechea26,
Miriam García-Arias27, Miguel Angel Caracuel-Ruiz28, Carlos
Alberto Montilla Morales29, Antonio Atanes-Sandoval30, Félix
Francisco31, Santos Insua32, Senen González-Suárez33, Maria
Amalia Sanchez Andrade34, Fernando Gamero35, Luis Francisco
Linares Ferrando36, Fredeswinda Romero37, A. Javier GarcíaGonzález38, Raquel Almodóvar González39, Enrique Minguez40,
Carmen Carrasco Cubero41, Alejandro Olive42, Julio Vázquez43,
Oscar Ruiz Moreno44, Fernando Jiménez-Zorzo44, Javier Manero44,
Santiago MuÑoz Fernandez45, Javier Rueda-Gotor1, Trinitario
Pina1, Montserrat Santos-Gómez1 and Miguel A. González-Gay1,
1
Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander.
Spain, Santander, Spain, 2Hospital General Universitario de
Valencia. Spain, Valencia, Spain, 3Rheumatology. Hospital
de Valme., Sevilla, Spain, 4Hospital Clinic. Barcelona. Spain,
Barcelona, Spain, 5Hospital Clinic, Barcelona, Barcelona, Spain,
6
Ophthalmology. Hospital General universitario de Valencia,
Valencia, Spain, 7Rheumatology. Hospital Peset, Valencia,
Spain, 8Ophthalmology. Hospital Peset, Valencia, Spain, 9H. Vall
d’Hebron, Barcelona, Spain, 10Hospital de León. Spain, León,
Spain, 11Hospital Universitario La Fe. Valencia. Spain, Valencia,
Spain, 12Ophthalmology. Hospital San Cecilio, Granada, Spain,
13
Systemic Autoimmune Diseases Unit, Hospital Clínico San
Cecilio, Granada, Spain, 14Ophthalmology. Hospital Universitario,
IOBA, Valladolid, Spain, 15Hospital de Cruces. Bilbao. Spain,
Bilbao, Spain, 16Virgen de la Salud Hospital, Toledo, Spain,
17
Hospital Universitario de Donostia. San Sebastián. Spain,
San Sebastián, Spain, 18Ophthalmology. Hospital Donosti, San
Sebastián, Spain, 19Hospital Universitario de Basurto. Bilbao.
Spain, Bilbao, Spain, 20Hospital Universitario de Móstoles.
Madrid. Spain, Madrid, Spain, 21Rheumatology. Hospital General
de Alicante, Alicante, Spain, 22Hospital La Paz – IdiPaz, Madrid,
Spain, 23Rheumatology. Hospital Clínico San Carlos, Madrid,
2014 Program Book
Spain, 24Rheumatology. Hospital de Pontevedra, Pontevedra,
Spain, 25Ophthalmology. Hospital de Pontevedra, Pontevedra,
Spain, 26Hospital Sierrallana. Torrelavega, Torrelavega, Spain,
27
Hospital Universitario de La Princesa. IIS La Princesa, Madrid,
Spain, 28H. Reina Sofia, Cordoba, Spain, 29Hospital Clínico
Universitario de Salamanca, Salamanca, Spain, 30Rheumatology
Division. C. Hospitalario Universitario A Coruña, A Coruña,
Spain, 31Hospital Doctor Negrín. Las Palmas de Gran Canaria.
Spain, Las Palmas de Gran Canaria, Spain, 32Rheumatology.
Hospital Universitario Santiago de Compostela, A Coruña,
Spain, 33Rheumatology. Hospital Cabueñes, Gijón, Spain,
34
Hosp. Lucus Augusti, Lugo, Spain, 35Rheumatology. Hospital
San Pedro Alcantara, Cáceres, Spain, 36Hospital Virgen de
la Arrixaca. Murcia. Spain, Murcia, Spain, 37Jiménez Díaz
Foundation University Hospital, Madrid, Spain, 38Instituto de
Investigación Hospital 12 de Octubre (I+12), Madrid, Spain,
39
Hospital Universitario Fundación Alcorcón, Madrid, Spain,
40
Ophthalmology. Hospital Clínico de Zaragoza, Zaragoza, Spain,
41
Hospital de Merida, Mérida, Spain, 42Germans Trias Pujol
Hospital, Barcelona, Spain, 43Rheumatology. Hospital de Ferrol,
A Coruña, Spain, 44Ophthalmology and Rheumatology. Hospital
Miguel Servet Zaragoza, Spain, Zaragoza, Spain, 45Sección de
Reumatología, Hospital Universitario Infanta Sofía, San Sebastián
de los Reyes, Madrid, Spain
3:15 PM
2854. Effect of Apremilast on Quality of Life and Physical
Function in Patients with Behçet’s Syndrome
Gulen Hatemi1, Melike Melikoglu1, Recep Tunc2, Cengiz Korkmaz3,
Banu Turgut Ozturk4, Cem Mat5, Peter A. Merkel6, Kenneth
Calamia7, Lilia Pineda8, Ziqi Liu8, Randall M. Stevens8, Hasan
Yazici1 and Yusuf Yazici9, 1Istanbul University, Cerrahpasa Medical
Faculty, Rheumatology, Istanbul, Turkey, 2Necmettin Erbakan
University, Meram Medical Faculty, Division of Rheumatology,
Konya, Turkey, 3EskiÅŸehir Osmangazi University, EskiÅŸehir,
Turkey, 4Selçuk University, Konya, Turkey, 5Istanbul University,
Cerrahpasa Medical Faculty, Dermatology, Istanbul, Turkey,
6
Vasculitis Center, Division of Rheumatology, University of
Pennsylvania, Philadelphia, PA, 7Mayo Clinic Health System in
Waycross, Waycross, GA, 8Celgene Corporation, Warren, NJ,
9
New York University School of Medicine, New York, NY
3:30 pm
2855. Efficacy and Safety of Rituximab Retreatment Regimen at
Clinical Relapse in Severe Cryoglobulinemic Vasculitis
Luca Quartuccio1, Francesca Zuliani2, Patrizia Scaini3, Marco
Lenzi4, Antonio Tavoni5, Marco Sebastiani6, Teresa Urraro7,
Francesco Saccardo8, Costanza Sbreglia9, Pietro Pioltelli10, Paolo
Fraticelli11, Davide Filippini12, Salvatore Scarpato13, Oreste
Perrella9, Armando Gabrielli14, Dario Roccatello15, Anna Linda
Zignego7, Clodoveo Ferri16, Stefano Bombardieri17, Maurizio
Pietrogrande18, Massimo Galli19, Giuseppe Monti8 and Salvatore
De Vita1, 1DSMB, University Hospital Santa Maria della
Misericordia, Udine, Italy, 2Rheumatology Clinic, University
Hospital of Udine, Udine, Italy, 3Nephrology, Spedali Civili
di Brescia, Brescia, Italy, 4University of Bologna, Bologna,
Italy, 5Rheumatology Clinic, University of Pisa, Pisa, Italy,
scientific sessions
6
Rheumatology Clinic, University of Modena and Reggio Emilia,
Modena, Italy, 7Center for Systemic Manifestations of Hepatitis
Viruses (MASVE), Department of Experimental and Clinical
Medicine, University of Florence, Florence, Italy, 8Internal
Medicine Unit, Saronno Hospital, Azienda Ospedaliera di Busto
Arsizio, Saronno (VA), Italy, 9Rheumatology Unit, AO Cotugno,
Naples, Italy, 10Hematology, S.Gerardo Hospital, Monza, Italy,
11
Istituto di Clinica Medica, Università Politecnica delle Marche,
Ancona, Italy, 12Rheumatology Unit, Ospedale Niguarda Ca’
Granda, Milan, Italy, 13Rheumatology Unit, M. Scarlato Hospital,
Scafati, Salerno, Italy, 14Università Politecnica delle Marche,
Ancona, Italy, 15UNIVERSITY OF TURIN (ITALY), TURIN, Italy, 16Univ
Modena Reggio Emilia, Modena, Italy, 17Rheumatology Unit,
University of Pisa, Pisa, Italy, 18Internal Medicine Unit, Policlinico
San Marco, Bergamo, Italy, 19Istituto di Malattie Infettive e
Tropicali, Università di Milano c/o Ospedale L. Sacco, Milano,
Italy
3:45 pm
2856. Update on Long-Term Outcomes after Reversible
Cerebral Vasoconstriction Syndrome (RCVS)
Seby John1, Aneesh Singhal2, Leonard H. Calabrese1, Ken Uchino1,
Tariq Hammad1, Stewart Tepper1, Mark Stillman1 and Rula A HajjAli1, 1Cleveland Clinic Foundation, Cleveland, OH, 2Massachusetts
General Hospital, Boston, MA
2:30 – 4:00 PM
PM
160 B
PS
ACR/ARHP Combined Abstract Session: Rehabilitation
PM
PS
3:30 pm
2861. Changes in Knee Kinematics from a 6-Week Hip and
Trunk Strengthening Program for Persons with Patellofemoral
Osteoarthritis
Lisa Hoglund1, Laura Pontiggia1, John Kelly IV2, Mark Arnott1,
Olumide Babalola1, Andrew Gushen1 and James Carey2,
1
University of the Sciences, Philadelphia, PA, 2University of
Pennsylvania, Philadelphia, PA
3:45 pm
2862. Satisfaction Following Total Knee Replacement: Journey
or Destination?
Jeffrey N. Katz1, Yan Dong1, Jamie E. Collins1, John Wright1,
David Dalury2, Kirk Kindsfater3 and Elena Losina1, 1Brigham
and Women’s Hospital, Boston, MA, 2Townson Orthopedics,
Maryland, Baltimore, MD, 3Orthopedic Center for the Rockies, Ft.
Collins, CO
1 8 ,
2 0 1 4
ARHP SESSIONS
2:30 – 4:00 pm
204 A
2:45 pm
2858. Education Effects on Outcome Expectations for Exercise
in Adults with Knee Osteoarthritis
Tressa Gamache, Lori Lyn Price, Jeffrey B. Driban, William F.
Harvey and Chenchen Wang, Tufts Medical Center, Boston, MA
TUESDAY
2:30 pm
2857. Restricting Back Pain Is Strongly Associated with
Disability in Community-Living Older Persons over the Course
of 13 Years
Una Makris1, Liana Fraenkel2, Ling Han3, Linda Leo-Summers3
and Thomas M. Gill4, 1Dallas VA Medical Ctr, Dallas, TX, 2Yale
University School of Medicine, Veterans Affairs Connecticut
Healthcare Systems, New Haven, CT, 3Department of Medicine,
New Haven, CT, 4Yale University, New Haven, CT
3:15 pm
2860. Randomised Comparison of the Effectiveness of a NonPharmacological Multidisciplinary Face-to-Face Group-Based
Treatment Program Vs. a Telephone-Delivered Treatment
Program on Daily Function in Patients with Generalized
Osteoarthritis
Nienke Cuperus1, Thomas Hoogeboom2, Clarinda Kersten1,
Leonie Rietveld1, Alfons den Broeder1, Thea Vliet Vlieland3 and
Cornelia H.M. van den Ende1, 1Sint Maartenskliniek, Nijmegen,
Netherlands, 2CAPHRI school for public health and primary care,
CCTR centre for Care Technology Research, Maastricht University,
Maastricht, Netherlands, 3Leiden University Medical Center,
Leiden, Netherlands
n o v e m b e r
Moderators: Nancy A. Baker, MPH and Daniel K. White, PT, ScD,
MSc
3:00 pm
2859. Randomized Controlled Trial of Postoperative Care
Navigation in Total Knee Arthroplasty Patients: Does One Size
Fit All?
Elena Losina, Jamie E. Collins, John Wright, Meghan E. Daigle,
Laurel Donnell-Fink, Doris Strnad, Vladislav Lerner, Stanley
Abrams and Jeffrey N. Katz, Brigham and Women’s Hospital,
Boston, MA
PM
PS
Brief Action Planning (BAP): A Motivational
Interviewing (MI) Technique to Enhance Patient SelfPrM
Pd
PS
PM
Ed
Management and Improve Outcomes
FIT
Moderator: Christine A. Stamatos, DNP, ANP-C
• explain how clinicians can efficiently, effectively engage their
patients for enhanced self-management of chronic illness and
improved outcomes
• describe the eight core competencies of Brief Action Planning
(BAP) and the four elements of the Spirit of Motivational
Interviewing (MI)
2014 Program Book
133
scientific sessions
• a pply the principles and practices of BAP and MI in routine
clinical work for enhanced patient self-management and
improved outcomes
2:30 pm
Brief Action Planning: Eight Core Competencies and the Spirit
of Motivational Interviewing
Steven Cole, MD
3:15 pm
Coping for Caregivers: Strength-Based Coping Strategies
for Family, Friends and Partners of Patients Living with
Neuropsychiatric Lupus
Liz Morasso, LCSW
PS
PM
153 B
Treatment Considerations in Chronic Pain
3:15 pm
How to Apply Brief Action Planning in Your Routine Clinical
Practice
Joseph Weiner, MD, PhD
256
PM
acute pain becomes chronic pain
• d
iscuss the latest research in treatment options for chronic
pain
• describe at least one new technique that may revolutionize
our management of persistent pain
Osteoporosis: Emerging Treatments Both
Pharmacological and Non-Pharmacological
2:30 pm
Recent Advances in the Diagnosis and Management of Chronic
Pain
Daniel J. Clauw, MD
• integrate new pharmacological treatment regiments for
osteoporosis
• evaluate current evidence supporting new treatment
paradigms for osteoporosis
• formulate rehabilitation recommendations for the treatment
of osteoporosis for those with rheumatic diseases
3:15 pm
Treatment Considerations in Chronic Pain
Sean Mackey, MD,
PM PhDPS
ACR WORKSHOPS
4:00 – 6:00 pm
n o v e m b e r
1 8 ,
TUESDAY
2 0 1 4
3:15 pm
Rehabilitation Techniques for the Treatment of Osteoporosis
Jennifer L. Trizuto, MPT
257 A
PM
PS
The Psychosocial Impact and Treatment Options
for Patients with Neuropsychiatric Lupus and Their
Caregivers
2:30 pm
Neuropsychiatric Lupus: Health-Related Quality of Life and
Treatment Options
John G. Hanly, MD
134
Moderator: Shawn Rose, MD, PhD
• identify the psychosocial quality of life indicators that are
frequently impacted by nervous system involvement in lupus
patients and to follow-through with a referral to a mental
health professional, where appropriate
• summarize the pharmacological and non-pharmacological
approaches currently in place to treat nervous system lupus
• recognize the psychological impact and lifestyle adjustments
experienced by family members, friends and partners of
patients with neuropsychiatric symptoms
• apply strength-based strategies to assist the caregivers of
patients with neuropsychiatric symptoms
2014 Program Book
PS
• d escribe the pathophysiologic mechanisms that occur when
PS
2:30 pm
Emerging Medicines for the Treatment of Osteoporosis
Barry Gruber, MD
PM
154
Getting Electronic Health Records Right (240)
Speaker: Salahuddin Kazi, MD
• describe the basic structure and capability of an electronic
health record
• e xplain the principles and design of rheumatology-specific
templates and order sets
• identify the key elements in current clinical processes and
workflow to help optimize the utilization of an electronic
health record
scientific sessions
152
managing osteoarthritis
• r ecommend specific exercise prescriptions for knee and hip
osteoarthritis may can be implemented in clinical practice
Systemic Sclerosis: How to Perform Skin Scores (241)
• review the usefulness and reasons to do a modified Rodman
skin score
• explain how to do a modified Rodman skin score
• demonstrate modified Rodman skin score under the
supervision of experts
159
4:30 pm
What Should I Eat to Help My Osteoarthritis?
Shivani Sahni, PhD
5:00 pm
Is There Evidence that Vitamins Can Help Osteoarthritis?
Timothy E. McAlindon, MD, MPH, MRCP
5:30 pm
Exercise for Osteoarthritis Management: Science in Action!
Ewa M. Roos, PT, PhD
*Ultrasound Injection Guidance (242)
Speaker: Gurjit S. Kaeley, MBBS, MRCP
• summarize the evidence for improved outcomes with
ultrasound guidance of joint injections
• describe methods to optimize needle visualization
• review best practices for maintaining aseptic technique and
probe positioning
• explain the anatomic approach for sonographically guided
injection of major joints
ACR SESSIONS
4:30 – 6:00 pm
PM
PS
160 B
Autophagy in Rheumatic Diseases
210 B
PM
PM
PS
PS
PM
Ed
Pd
PS
PrM
FIT
Moderators: Michael H. Weisman, MD and Arthur Kavanaugh,
MD
• identify important safety issues in the drug treatment of
rheumatic diseases
• integrate knowledge of new safety issues into their treatment
strategies
• review how to more fully advise patients about the safety
issues related to treatments for rheumatic diseases
• recognize evolutions at the FDA that will affect drug safety
monitoring and reporting
4:30 pm
Rheumatological Drugs in Pregnancy: Update on Fetal Safety
Gideon Koren, MD
4:50 pm
Update and Safety Issues of Recently Approved Agents for
Rheumatic Diseases
Nikolay P. Nikolov, MD
2 0 1 4
5:30 pm
Autophagy Pathways as Therapeutic Targets
Andras Perl, MD, PhD
Update on Safety Issues in the Treatment of
Rheumatic Diseases – From the FDA and Beyond
1 8 ,
5:00 pm
Autophagy and Autoimmune Diseases
PS
TUESDAY
4:30 pm
Autophagy-Inflammation-Cell Death Axis
Jenny Ting, PhD
PM
n o v e m b e r
• review the concept autophagy
• examine the role of autophagy in autoimmune diseases
• consider whether autophagy pathways are potential
therapeutic targets
52 A
5:15 pm
The Year in Review – Update on Safety Issues at the FDA for
the Last 12 Months
Janet W. Maynard, MD, MHS
4:30 – 6:00 pm
PM
PM
PS
Beyond Analgesics: State of the Evidence for
Nutrition, Vitamins and Exercise Prescriptions in
Osteoarthritis Management
Moderators: Shreyasee Amin, MD CM, MPH and David T. Felson,
MD, MPH
PS
104 B
Antiphospholipid Syndrome
Moderators: Roger A. Levy, MD and Joyce Rauch, PhD
• discuss the potential role for different nutrients in
osteoarthritis management
• describe the current evidence for specific vitamins in
2014 Program Book
135
scientific sessions
4:30 pm
2863. IgG Antiphospholipid Antibodies Enhance Stroke
Damage: An in Vivo Ischemia/Reperfusion Study
Charis Pericleous1, Valerie Taylor2, Lauren Bourke3, Daniel
Stuckey2, Jed Wingrove4, Mark Lythgoe2, Silvia S. Pierangeli5,
Anisur Rahman4, Ian Giles1 and Yiannis Ioannou6, 1Centre for
Rheumatology, University College London, London, United
Kingdom, 2Centre for Advanced Biomedical Imaging (CABI),
University College London, London, United Kingdom, 3Centre
for Rheumatology Research, University College London, London,
United Kingdom, 4University College London, London, United
Kingdom, 5University of Texas Medical Branch, Galveston, TX,
6
Centre for Rheumatology Research, University College Hospital
London, London, United Kingdom
n o v e m b e r
1 8 ,
TUESDAY
2 0 1 4
4:45 pm
2864. Markers of Thrombotic Events in Autoimmune Diseases:
Comparison of Antiphospholipid Score (aPL-S) and Global AntiPhospholipid Syndrome Score (GAPSS)
Kenji Oku, Olga Amengual, Ryo Hisada, Kazumasa Oomura,
Ikuma Nakagawa, Toshiyuki Watanabe, Toshiyuki Bohgaki,
Tetsuya Horita, Shinsuke Yasuda and Tatsuya Atsumi, Hokkaido
University Graduate School of Medicine, Sapporo, Japan
5:00 pm
2865. The Cellular Effects of ANTI-Factor Xa Antibodies Isolated
from Patients with Antiphospholipid Syndrome ARE Inhibited
By Factorxa Inhibitors, Hydroxychloroquine and Fluvastatin
Bahar Artim-Esen1, Natalia Smoktunowicz2, Vera M. Ripoll3,
Charis Pericleous3, Rachel Chambers2, Ian Mackie4, David
Isenberg5, Anisur Rahman6, Yiannis Ioannou5 and Ian Giles3,
1
Rheumatology Division, Department of Internal Medicine,
Istanbul Faculty of Medicine,Istanbul University, Istanbul, Turkey,
2
Respiratory Research Unit, University College London, London,
United Kingdom, 3Centre for Rheumatology, University College
London, London, United Kingdom, 4Haemostasis Research Unit,
University College London, London, United Kingdom, 5Centre
for Rheumatology Research, University College Hospital London,
London, United Kingdom, 6University College London, London,
United Kingdom
5:15 pm
2866. External Validation of the Global Anti-Phospholipid
Syndrome Score in Comparison to IgG Antibodies Directed
Against Domain I of ß2-Glycoprotein I. a Prospective
Multicentre Cohort Study
Stephane Zuily1, Bas De Laat2, Veronique Regnault3, Pierre
Kaminsky4, Hilde Kelchtermans5, Zakera Shums6, Roger Albesa6,
Gary L Norman6, Philip de Groot7, Anne-Christine Rat8, Jacques
Ninet9, Nadine Magy-Bertrand10, Jean-Louis Pasquali11, Marc
Lambert12, Bernard Lorcerie13, Thomas Lecompte14, Francis
Guillemin15 and Denis Wahl16, 1CHU de Nancy, Vascular Medicine
Division and Regional Competence Center For Rare Vascular
And Systemic Autoimmune Diseases, Nancy, F-54000, France;
Inserm, UMR_S 1116, Nancy, F-54000, France; Université de
Lorraine, Nancy, F-54000, France, Nancy, France, 2Biochemistry,
CARIM, Maastricht University, Maastricht, Netherlands,
136
2014 Program Book
3
Inserm, UMR_S 1116, Nancy, F-54000, France; Université
de Lorraine, Nancy, F-54000, France; CHU de Nancy, Contrat
d’interface, Nancy, F-54000, France, Nancy, France, 4CHU
Nancy, Vandoeuvre, France, 5Biochemistry, CARIM, Maastricht
University, The Netherlands; Synapse BV, Maastricht, The
Netherlands, Maastricht, Netherlands, 6INOVA Diagnostics, San
Diego, CA, 7Clinical Chemistry and Hematology, UMC Utrecht,
The Netherlands, Utrecht, Netherlands, 8University of Lorraine,
Nancy, France, 9Department of Nephrology and Internal
Medicine, Hôpital Edouard Herriot, Lyon, France, Lyon, France,
10
Bensançon University Hospital, Besançon, France, 11Nouvel
Hospital Civil, Strasbourg Cedex, France, 12Lille University
Hospital, Lille, France, 13Hopital Du Bocage, Service de Médecine
Interne et Immunologie Clinique, Dijon, France, 14Inserm,
UMR_S 1116, Nancy, F-54000, France; Université de Lorraine,
Nancy, F-54000, France; CHU de Nancy, Haematology Laboratory,
Nancy, F-54000, France; Division of Haematology, HUG, Geneva,
Switzerland (current address), Geneva, Switzerland, 15INSERM,
Centre d’Investigation Clinique – Epidémiologie Clinique (CIC-EC)
CIE6, Nancy, France, 16Nancy University Hospital and INSERM
U961, Vandoeuvre-Les-Nancy, France
5:30 pm
2867. Antiphospholipid Antibodies Promote the Release
of Neutrophil Extracellular Traps: a New Mechanism of
Thrombosis in the Antiphospholipid Syndrome
Srilakshmi Yalavarthi1, Levi F. Mazza1, Alexandra E. Morris1,
Carlos Núñez-Álvarez2, Diego Hernández2, Paula L. Bockenstedt1,
Antonio R. Cabral2 and Jason S. Knight1, 1University of Michigan,
Ann Arbor, MI, 2Instituto Nacional de Ciencias Medicas y
Nutricion, Mexico City, Mexico
5:45 pm
2868. Antiphospholipid Syndrome Alliance for Clinical Trials
and International Networking (APS ACTION) Clinical Database
and Repository Initial Analysis
Doruk Erkan1, Danieli Andrade2, Maria Tektonidou3, Amaia
Ugarte4, Alessandra Banzato5, Angela Tincani6, Pier-Luigi Meroni7,
Ricard Cervera8, Paul R. Fortin9, Roger A. Levy10 and On Behalf
of APS Action11, 1Hospital for Special Surgery, New York, NY,
2
University of São Paulo, São Paulo, Brazil, 3First Department
of Internal Medicine, Laikon Hospital, Athens University
Medical School, Athens, Greece, 4Hospital Universitario Cruces,
Bizkaia, Spain, 5Department of Cardiac Thoracic and Vascular
Sciences, University of Padua, Padua, Italy, 6Rheumatology and
Clinical Immunology, Spedali Civili and University of Brescia,
Brescia, Italy, 7University of Milan, Milano, Italy, 8Hospital Clinic,
Barcelona, Spain, 9Laval University, Division of Rheumatology,
Centre de Recherche du CHU de Québec and Department of
Medicine, Quebec City, QC, 10Universidade do Estado do Rio de
Janeiro, Rio de Janeiro, Brazil, 11APS ACTION, New York, NY
PM
109 A
B Cell Biology and Targets in Autoimmune Disease
Moderators: Jennifer H. Anolik, MD, PhD and Shaun Jackson, MD
PhD
4:30 pm
2869. TLR7 Influences Autoreactive B Cell Selection in the
Germinal Center
Weiqing Huang1, Megan Woods1, Alexis Boneparth2, Ramalingam
Bethunaickan1, Ranjit Sahu1 and Anne Davidson1, 1Feinstein
Institute for Medical Research, Manhasset, NY, 2Rutgers-Robert
Wood Johnson Medical School, New Brunswick, NJ
4:45 pm
2870. B Cell-Intrinsic Deletion of the Type 1 Interferon Receptor
Does Not Impact the Development of Murine Lupus
Shaun W. Jackson, Nicole Scharping, Socheath Khim and David
Rawlings, Seattle Children’s Research Institute, Seattle, WA
5:00 pm
2871. Break of Anergy in Human Autoreactive B Cells By T
Helper Signals Restores B Cell Receptor Signaling Capacity and
Is Dependent on Upregulation of CD45 Phosphatase Activity-a
Possible Novel Mechanism of Breech of B Cell Tolerance in
Rheumatic Diseases
Peter Szodoray1, Stephanie M. Stanford2, Nunzio Bottini2 and
Britt Nakken1, 1Institute of immunology, Rikshospitalet, Oslo
University Hospital, Oslo, Norway, 2La Jolla Institute for Allergy
and Immunology, La Jolla, CA
PM
PS
Cytokines, Mediators, Cell-Cell Adhesion, Cell
Trafficking and Angiogenesis II
Moderators: George D. Kalliolias, MD, PhD and Dana E. Orange,
MD, MS
4:30 pm
2875. Macrophage Expression of Hypoxia-Inducible Factor-2
Alpha Promotes Rheumatoid Arthritis Progression
Munitta Muthana1, William Jacob Hardy1, Sarah Hawtree1,
Fiona Wright1, Ursula Fearon2, DJ Veale3, Mauro Perretti4 and
Anthony G. Wilson5, 1University of Sheffield, Sheffield, United
Kingdom, 2Translational Rheumatology Research Group, Dublin,
Ireland, 3St. Vincent’s University Hospital, Dublin, Ireland, 4Barts
and the London School of Medicine, London, United Kingdom,
5
University College Dublin, Dublin, Ireland
4:45 pm
2876. Interleukin-10 Receptor Blockade during Lcmv Infection
Results in Macrophage Activation Syndrome-like Disease in
Mice
Lehn K. Weaver1 and Edward M. Behrens2, 1Children’s Hospital
of Philadelphia, Philadelphia, PA, 2Childrens Hospital of
Philadelphia, Philadelphia, PA
2 0 1 4
5:00 pm
2877. Novel Function of Tocilizumab As a Modulator of
Interleukin-27-Mediated Anti-Inflammatory Responses
Misato Hashizume1, Jun Kikuchi2, Keiko Yoshimoto2 and Tsutomu
Takeuchi2, 1Chugai Pharmaceutical Co., Ltd., Gotemba, Japan,
2
Keio University School of Medicine, Tokyo, Japan
1 8 ,
5:45 pm
2874. Pro-Inflammatory FcRL4+ Memory B Cells in Joints of RA
Patients: Immunoglobulin Gene Characteristics and Antigen
Specificity
Khaled Amara1, Lorraine Yeo2, Natalie Sippl1, Philip Titcombe1,
Andrew Filer3, Karim Raza3, Dagmar Scheel-Toellner2 and
107 B
TUESDAY
5:30 pm
2873. Epratuzumab Induces Broad Inhibition of B Cell Receptor
Proximal Signaling but Has Opposing Effects on Distal Signaling
in B Cell Subsets: A Profile of Effects on Functional Immune
Signaling By Single Cell Network Profiling
Alison Maloney1, Drew Hotson2, Stephen Rapecki1, Gianluca
Fossati1, Simon Lumb1, David Rosen2, Santosh Putta2, Nikil
Wale2, David Spellmeyer2, Alessandra Cesano2, Rachael Hawtin2
and Anthony Shock1, 1UCB Pharma, Slough, United Kingdom,
2
Nodality Inc., South San Francisco, CA
Vivianne Malmström4, 1Rheumatology Unit, Department of
Medicine, Karolinska University Hospital, Karolinska Institutet,
SE-17176 Solna, Stockholm, Sweden., Stockholm, Sweden,
2
Rheumatology Research Group, Centre for Translational
Inflammation Research, College of Medical and Dental Sciences,
University of Birmingham, Birmingham B15 2TT, UK, Birmingham,
United Kingdom, 3Rheumatology Research Group, MRC Centre
for Immune Regulation, School of Immunity and Infection,
University of Birmingham, Birmingham, United Kingdom,
4
Rheumatology Unit, Karolinska University Hospital, Solna,
Karolinska Institutet, Stockholm, Sweden
n o v e m b e r
5:15 pm
2872. B-Cell Autoepitope and Tetramer Analysis Reveals
Expansion of Apoptotic Autoantigen La and snRNP Reactive B
Cells in BXD2 Mice
Jennie Hamilton1, Jun Li1, Qi Wu1, PingAr Yang1, Bao Luo1,
Hao Li1, Troy Randall1, John Edwin Bradley1, Justin J. Taylor2,
John D. Mountz3 and Hui-Chen Hsu1, 1University of Alabama
at Birmingham, Birmingham, AL, 2Fred Hutchinson Cancer
Research Center, Seattle, WA, 3Birmingham VA Medical Center,
Birmingham, AL
scientific sessions
PS
5:15 pm
2878. G Protein Signaling Modulator 3 (GPSM3) Deficiency
Is Protective in Inflammatory Arthritis Models and Altered
GPSM3 Gene Products Correlate with Single Nucleotide
Polymorphisms in Humans
Teresa K. Tarrant1, D. Stephen Serafin1, Elizabeth Sugg1, Roman
Timoshchenko1, Matthew J. Billard1, David P. Siderovski2 and
Kristy Richards3, 1Thurston Arthritis Research Center, University
of North Carolina at Chapel Hill, Chapel Hill, NC, 2West Virginia
University School of Medicine, Morgantown, WV, 3Dept. of
Genetics, University of North Carolina at Chapel Hill, Chapel Hill,
NC
5:30 pm
2879. Epigallocatechin-3-Gallate (EGCG) Suppresses IL-1β2014 Program Book
137
scientific sessions
Induced IL-6 and IL-8 Synthesis By Selectively Inhibiting TAK1
Activation in Human Rheumatoid Arthritis Synovial Fibroblasts
Anil Singh1, Sharayah Riegsecker2, Sadiq Umar1 and Salahuddin
Ahmed1, 1Washington State University, Spokane, WA, 2University
of Toledo, Toledo, OH
5:45 pm
2880. Elevated Levels of Soluble Inflammatory Mediators and
Lupus-Specific Connective Tissue Disease Questionnaire Scores
Discern Unaffected First Degree Relatives of Lupus Patients
from Unaffected Individuals Not Related to Lupus Patients
Melissa E. Munroe1, Kendra A. Young2, Jennifer Fessler1, Dustin
Fife1, Diane L. Kamen3, Joel M. Guthridge1, Timothy B. Niewold4,
Michael H. Weisman5, Mariko L. Ishimori5, Daniel J. Wallace5,
David R. Karp6, John B. Harley7, Gary S. Gilkeson3, Jill M. Norris2
and Judith A. James1, 1Oklahoma Medical Research Foundation,
Oklahoma City, OK, 2Colorado School of Public Health, Aurora,
CO, 3Medical University of South Carolina, Charleston, SC, 4Mayo
Clinic, Rochester, MN, 5Cedars-Sinai Medical Center, Los Angeles,
CA, 6UT Southwestern Medical Center, Dallas, TX, 7Cincinnati
Children’s Hospital Medical Center; US Department of Veterans
Affairs Medical Center,
Cincinnati, OH
PS
PM
156 B
Education
PM
Ed
Pd
PS
PrM
FIT
n o v e m b e r
1 8 ,
TUESDAY
2 0 1 4
Moderators: Kenneth S. O’Rourke, MD and Deana M. Lazaro, MD
4:30 pm
2881. The Center of Excellence in Musculoskeletal Care and
Education: A Sustainable Interprofessional, Multidisciplinary
Programmatic Innovation Developed with the Department of
Veterans Affairs
Michael J. Battistone, Andrea M. Barker, Marissa Grotzke, Peter
Beck, Jeffery Berdan, Caroline Milne, JoAnn Rolando and Grant
W. Cannon, Salt Lake City VA and University of Utah, Salt Lake
City, UT
4:45 pm
2882. Using Decision-Based Learning to Highlight Rheumatic
Disease for Third-Year Medical Students
Karen Law1, J Richard Pittman1 and Chad Miller2, 1Emory
University School of Medicine, Atlanta, GA, 2Tulane University
Health Sciences Center School of Medicine, New Orleans, LA
5:00 pm
2883. Rheumatology-Specific Milestones for a Musculoskeletal
Radiology Curriculum
Michelle Newkirk1, Liem Mansfield1, Jay B. Higgs2 and Daniel
Battafarano1, 1San Antonio Military Medical Center, JBSA – Ft
Sam Houston, TX, 2San Antonio Military Medical Center, JBSA –
Fort Sam Houston, TX
138
2014 Program Book
5:15 pm
2884. Training the Rheumatologists of Tomorrow: The
Canadian Experience
Alfred Cividino1, Volodko Bakowsky2, Susan Barr3, Louis Bessette4,
Nader Khalidi5, Christian A. Pineau6, Janet E. Pope7, David
Robinson8, Kam Shojania9, Elaine Yacyshyn10, Lynne Lohfeld1
and Diane Crawshaw1, 1McMaster University, Hamilton, ON,
2
Dalhousie University, Halifax, NS, 3Heritage Medical Research
Bldg, Calgary, AB, 4Laval University, Québec, QC, 5Division of
Rheumatology, McMaster University, Hamilton, ON, 6McGill
University Health Center, Montreal, QC, 7St Joseph Health Care,
London, ON, 8University of Manitoba, Winnipeg, MB, 9University
of British Columbia, Vancouver, BC, 10University of Alberta,
Edmonton, AB
5:30 pm
2885. Clinical Training Opportunities in Two Innovative
Ambulatory Resources: The Primary Care Musculoskeletal
Clinic and Center of Excellence Multidisciplinary Clinic
Michael J. Battistone, Andrea M. Barker, Marissa Grotzke, Peter
Beck, Jeffery Berdan, Phillip Lawrence and Grant W. Cannon, Salt
Lake City VA and University of Utah, Salt Lake City, UT
5:45 pm
2886. Assessing Rheumatology Fellows’ Teaching Skills Using
the Objective Structured Teaching Exercise (OSTE)
Eli M. Miloslavsky1, Marcy B. Bolster1, Kenneth S. O’Rourke2 and
Lisa G. Criscione-Schreiber3, 1Massachusetts General Hospital,
Boston, MA, 2Wake Forest School of Medicine, Winston-Salem,
NC, 3Duke University Health System, Durham, NC
258 B
PM
PS
Epidemiology and Public Health IV: Rheumatoid
Arthritis Pathogenesis
Moderators: Cheryl Barnabe, MD, MSc and Yvonne C. Lee, MD,
MMSc
4:30 PM
2887. Post-Menopausal Factors and the Risk of Seropositive
and Seronegative Rheumatoid Arthritis Phenotypes: Results
from the Nurses’ Health Study
Camilla Bengtsson1, Susan Malspeis2, Jeffrey A. Sparks2, Karen
H. Costenbader2 and Elizabeth W. Karlson2, 1Karolinska Institutet,
Stockholm, Sweden, 2Brigham and Women’s Hospital, Harvard
4:45 pm
2888. Amount of Smoking, Duration of Smoking Cessation
and Their Interaction with Silica Exposure in the Risk
of Rheumatoid Arthritis: Results from the Swedish
Epidemiological Investigation of Rheumatoid Arthritis Study
Xia Jiang1, Camilla Bengtsson1, Henrik Källberg1, Lars Klareskog2
and Lars Alfredsson3, 1Karolinska Institutet, Stockholm, Sweden,
2
Karolinska University Hospital, Stockholm, Sweden, 3The
Institute of Environmental Medicine, Karolinska Institutet,
Stockholm, Sweden
scientific sessions
5:00 pm
2889. The Association Between Changes in Inflammation
and High Density Lipoprotein Cholesterol Efflux Capacity in
K P Liao1, Martin Playford2, Michelle A. Frits1, Christine K.
Iannaccone1, Jonathan S. Coblyn1, Michael E. Weinblatt1, Nancy
A. Shadick3 and Nehal N. Mehta4, 1Brigham and Women’s
Hospital, Boston, MA, 2National Heart, Blood and Lung
Institute, Bethesda, MD, 3Brigham and Women’s Hospital/
Harvard University, Cambridge, MA, 4University of Pennsylvania,
Philadelphia, PA
5:15 pm
2890. Does a Family History of RA Influence the Clinical
Presentation and Treatment Response in RA?
Thomas Frisell1, Saedis Saevarsdottir2 and Johan Askling3,
1
Clinical Epidemiology Unit, Dept of Medicine, Karolinska
Institutet, Stockholm, Sweden, 2Karolinska University Hospital
and Karolinska Institutet, Stockholm, Sweden, 3Rheumatology
Unit, Karolinska University Hospital, Stockholm, Sweden
PS
Osteoarthritis – Clinical Aspects II: Osteoarthritis Risk
Factors and Therapies
Moderators: Philip G. Conaghan, MD, PhD and Margreet
Kloppenburg, MD, PhD
2 0 1 4
PM
5:15 pm
2896. A Multi-Center Double-Blind, Randomized, Controlled
Trial (db-RCT) to Evaluate the Effectiveness and Safety of CoAdministered Traumeel® (Tr14) and Zeel® (Ze14) Intra‑articular
(IA) Injections Versus IA Placebo in Patients with Moderate-toSevere Pain Associated with OA of the Knee
Carlos Lozada1, Eve del Rio2, Donald Reitberg3, Robert Smith3,
Charles Kahn4 and Roland W. Moskowitz5, 1University of
Miami Miller School of Medicine, Miami, FL, Miami, FL, 2Rio
Pharmaceutical Services, LLC, Bridgewater, Afghanistan, 3Rio
Pharmaceutical Services, LLC, Bridgewater, NJ, 4South Florida
Rheumatology, Hollywood, FL, 5University Hospitals Case
Medical Center, Cleveland, OH
1 8 ,
153 B
5:00 pm
2895. Habitual Running Any Time in Life Is Not Detrimental and
May be Protective of Symptomatic Knee Osteoarthritis: Data
from the Osteoarthritis Initiative
Grace H. Lo1, Jeffrey B. Driban2, Andrea Kriska3, Kristi Storti3,
Timothy E. McAlindon2, Richard Souza4, Charles B. Eaton5, Nancy
J. Petersen6 and Maria E. Suarez-Almazor7, 1Michael E. DeBakey
VA Medical Center, Baylor College of Medicine, Houston, TX,
2
Tufts Medical Center, Boston, MA, 3University of Pittsburgh,
Pittsburgh, PA, 4University of California, San Francisco, San
Francisco, CA, 5Memorial Hospital of Rhode Island, Pawtucket,
RI, 6Baylor College of Medicine, Houston, TX, 7The University of
Texas, MD Anderson Cancer Center, Houston, TX
TUESDAY
5:45 pm
2892. The Relative Risk of Incident NON-Ischemic Heart
Failure in Prevalent Rheumatoid Arthritis
Ängla Mantel1, Marie Holmqvist2, Johan Askling3, Lars Lund4
and Daniel Andersson5, 1Clinical Epidemiology Unit, Dept of
Medicine, Karolinska Institutet, Solna, Sweden, 2Unit of Clinical
Epidemiology, Department of Medicine, Stockholm, Sweden,
3
Clinical Epidemiology Unit, Department of Medicine, Karolinska
Institutet, Stockholm, Sweden, 4Unit of Cardiology section for
Heart Failure. Department of Medicine, Stockholm, Sweden,
5
Unit of Cardiology Section for Heart Failure. Department of
Medicine, Stockholm, Sweden
4:45 pm
2894. Relationship of Dermal Advanced Glycation End Products
and Hand OA
Charles Eaton1, Jeffrey Driban2, Bing Lu3, Mary Roberts4
and Timothy E. McAlindon2, 1Center for Primary Care and
Prevention, Memorial Hospital of Rhode Island, Providence,
RI, 2Tufts Medical Center, Boston, MA, 3Brigham and Women’s
Hospital, Foxboro, MA, 4Center for Primary Care and Prevention,
Pawtucket, RI
n o v e m b e r
5:30 pm
2891. Inflammatory Genes Are Associated with Autoantibodies
in Rheumatoid Arthritis-Free Individuals Who Are at-Risk for
Future Disease
Ryan W. Gan1, Kendra A. Young1, M. Kristen Demoruelle2,
Michael H. Weisman3, Jane H. Buckner4, P. K. Gregersen5, Ted
R. Mikuls6, James R. O’Dell6, Richard M. Keating7, Elizabeth W.
Karlson8, Kevin D. Deane2, V. Michael Holers2 and Jill M. Norris1,
1
Colorado School of Public Health, Aurora, CO, 2University of
Colorado School of Medicine, Aurora, CO, 3Cedars-Sinai Medical
Center, Los Angeles, CA, 4Benaroya Research Institute at Virginia
Mason, Seattle, WA, 5Feinstein Institute Medical Research and
North Shore-Long Island Jewish Health System, Manhasset, NY,
6
Veteran Affairs Nebraska Western Iowa Health Care System
and University of Nebraska Medical Center, Omaha, NE, 7Scripps
Clinic, La Jolla, CA, 8Brigham and Women’s Hospital, Harvard
4:30 pm
2893. Genome-Wide Association Study of Osteoarthritis
Progression: Results from the Osteoarthritis Initiative
Michelle S. Yau1, Laura M. Yerges-Armstrong1, Youfang Liu2,
David J. Duggan3, Joanne M. Jordan2, Braxton D. Mitchell1,
Rebecca D. Jackson4 and Marc C. Hochberg1, 1University of
Maryland School of Medicine, Baltimore, MD, 2University
of North Carolina, Chapel Hill, NC, 3Translational Genomics
Research Institute, Phoenix, AZ, 4The Ohio State University,
Columbus, OH
5:30 pm
2897. Exercise Therapy and/or Manual Therapy for Hip or Knee
Osteoarthritis: 2-Year Follow-up of a Randomized Controlled
Trial
J. Haxby Abbott1, Cathy Chapple1, Daniel Pinto2, Alexis Wright3
and Jean-Claude Theis1, 1University of Otago, Dunedin, New
Zealand, 2Northwestern University, Chicago, IL, 3High Point
University, High Point, NC
2014 Program Book
139
scientific sessions
5:45 pm
2898. New Insights into the Primary Care Osteoarthritis
Consultation with Implications for Practice
Zoe Paskins, Tom Sanders, Peter Croft and Andrew Hassell, Keele
University, Keele, United Kingdom
205 B
PM
PS
Aspects: Miscellaneous Pediatric Rheumatic Diseases
PM
Ed
Pd
PS
PrM
FIT
Moderators: Andreas Reiff, MD and Lisa F. Imundo, MD
n o v e m b e r
1 8 ,
TUESDAY
2 0 1 4
4:30 pm
2899. High Dose Aspirin for Treating Kawasaki Disease –
Outdated Myth or Effective Aid?
Gil Amarilyo1, Yael Koren2, Dafna Brik Simon1, Maskit Bar-Meir3,
Hilla Bahat4, Mona Hanna Helou5, Amir Mendelson6, Yackov
Berkun7, Eli Eisenstein7, Yonatan butbul Aviel5, Galia Barkai8, Yoav
Bolkier8, Shai Padeh8, Philip J. Hashkes3, Riva Brik5, Liora Harel1
and Yosef Uziel6, 1Schneider Children’s Medical Center of Israel,
Petach Tikvah, Israel, 2Tel Aviv Sourasky Medical Center, Tel Aviv,
Israel, 3Shaare-Zedek Medical Center, Jerusalem, Israel, 4Assaf
Harofeh Medical Center, Zerifin, Israel, 5Rambam Medical Center,
Haifa, Israel, 6Meir Medical Center, Kfar Saba, Israel, 7Hadassah
Hebrew University Medical Center, Jerusalem, Israel, 8Sheba
Medical Center, Tel-Hashomer, Israel
140
4:45 pm
2900. Clinically Inactive Disease in Juvenile Dermatomyositis – a Proposed Revision to the Pediatric Rheumatology
International Trials Organisation Criteria
Beverley Almeida1, Raquel Campanilho-Marques2, Katie Arnold2,
Lucy R. Wedderburn3, Clarissa A Pilkington1 and Kiran Nistala4,
1
Great Ormond Street Hospital for Children NHS Trust, London,
United Kingdom, 2UCL Institute for Child Health, London,
United Kingdom, 3UCL, UCLH, GOSH NHS Trust, London, United
Kingdom, 4University College London, London, United Kingdom
5:15 pm
2902. The Health Status of Patients with Juvenile Idiopathic
Arthritis (JIA) Significantly Worsens after Transfer from
Pediatric to Adult Care
Kirsten Minden1, Jens Klotsche2, Martina Niewerth2, Angela
Zink3 and Gerd Horneff4, 1Charité University Medicine, Berlin,
Germany, 2German Rheumatism Research Center, Berlin,
Germany, 3German Rheumatism Research Centre and Charité
University Medicine, Berlin, Germany, 4Asklepios Klinik Sankt
Augustin, Sankt Augustin, Germany
5:30 pm
2903. Early Outcomes in Pediatric Antineutrophil Cytoplasmic
Antibody (ANCA) Associated Vasculitis (AAV)
Kimberly Morishita1, Susanne Benseler2, Rae S.M. Yeung3,
Thomas Mason II4, Dawn Wahezi5, Kenneth N. Schikler6, Erica
F. Lawson7, Susan Nielsen8, Sirirat Charuvanij9, Paul Dancey10,
Susan Shenoi11, Linda Wagner-Weiner12, Angelyne Sarmiento1,
David A. Cabral1 and For the PedVas Initiative1, 1BC Children’s
Hospital and University of British Columbia, Vancouver, BC,
2
Department of Pediatrics/University of Calgary, Calgary, AB,
3
The Hospital for Sick Children and University of Toronto,
Toronto, ON, 4Mayo Clinic, Rochester, MN, 5Children’s Hospital at
Montefiore, Bronx, NY, 6Univ of Louisville Schl of Med, Louisville,
KY, 7University of California, San Francisco, San Francisco,
CA, 8Rigshospitalet, Copenhagen, Denmark, 9Siriraj Hospital,
Bangkok, Thailand, 10Janeway Children’s Hospital, St. John’s, NL,
11
Seattle Childrens Hospital, Seattle, WA, 12University of Chicago
Hospital, Chicago, IL
5:45 pm
2904. Clinical and Radiological Features of Down’s Arthropathy
Charlene Foley, Orla Killeen and Emma Jane MacDermott, The
National Centre for Paediatric Rheumatology, Dublin, Ireland
PS
PM
151 A
Rheumatoid Arthritis – Animal Models II
Moderators: Harris R. Perlman, PhD and Thomas Pap, MD
5:00 pm
2901. Predictors of Relapse after Discontinuing Systemic
Treatment in Childhood Autoimmune Chronic Uveitis
Gabriele Simonini1, Claudia Bracaglia2, Marco Cattalini3, Andrea
Taddio4, Alice Brambilla1, Cinzia DeLibero5, Denise Pires Marafon6,
Roberto Caputo5 and Rolando Cimaz1, 1Anna Meyer Children’s
Hospital-University of Firenze, Florence, Italy, 2Division of
Rheumatology, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome,
Italy, 3Pediatric Immunology and Rheumatology Unit, Brescia,
Italy, 4Institute of Child Health, IRCCS Burlo Garofolo, University
of Trieste, Trieste, Italy, 5Anna Meyer Children’s Hospital,
Florence, Italy, 6Ospedale Pediatrico Bambino Gesù, IRCCS,
Roma, Italy
2014 Program Book
4:30 pm
2905. The IL-6/Th17 Axis Promotes Autoantibody-Associated
Autoimmune Valvular Carditis in Mice
Jennifer L. Auger, Brianna J. Engelson, Yaya Wang, Erik J.
Peterson and Bryce A. Binstadt, University of Minnesota,
Minneapolis, MN
4:45 pm
2906. Systemic Delivery of Short Hairpin RNA Targeting Calcium
Release-Activated Calcium Channel 3 Down-Regulates Severity
of Collagen-Induced Arthritis
Shuang Liu1, Takeshi Kiyoi2, Shohei Watanabe3 and Kazutaka
Maeyama1, 1Informational Biomedicine, Ehime University
Graduate School of Medicine, Toon-shi, Ehime, Japan,
2
Integrated Center for Sciences, Ehime University, Ehime, Japan,
3
Japan Community Health Care Organization Uwajima Hospital,
Ehime, Japan
scientific sessions
5:00 pm
2907. Loss of microRNA-146a Exacerbates Inflammatory
Arthritis
Victoria Saferding1, Antonia Puchner1, Eliana Goncalvesalves1,
Birgit Niederreiter1, Silvia Hayer1, Gernot Schabbauer2, Marije
Koenders3, Josef S. Smolen1, Kurt Redlich1 and Stephan Blueml1,
1
Medical University of Vienna, Vienna, Austria, 2Medical
University Vienna, Vienna, Austria, 3Radboud University
Nijmegen Medical Center, Nijmegen, Netherlands
5:15 pm
2908. Flip Deficiency in Dendritic Cells Promotes Spontaneous
Arthritis Mediated By Reduced Treg and Increased
Autoreactive CD4+t Cells
Qiquan Huang1, Harris R. Perlman1, Robert Birkett1, Renee E.
Doyle1, Deyu Fang1, G Kenneth.Haines2, William H. Robinson3,
Syamal K. Datta1, Hyewon Phee1 and Richard M. Pope4,
1
IL, 2Mount Sinai Hospital School of Medicine, New York, New
York, NY, 3VA Palo Alto Health Care System and Stanford
University, Palo Alto, CA, 4Northwestern University Feinberg
school of Medicine, Chicago, IL
5:30 pm
2909. Tolerogenic Splenic IDO+ Dendritic Cells from the Mice
Treated with Induced-Treg Cells Could Suppress CollagenInduced Arthritis
Jie Yang1, Huahua Fan2 and Hejian Zou1, 1Division of
Rheumatology, Huashan Hospital, Fudan University, Shanghai
200040, China, Shanghai, China, 2Blood Engineering Laboratory,
Shanghai Blood Center, Shanghai 200051, China, Shanghai,
China
Rheumatoid Arthritis – Clinical Aspects VI: Impact of
Treatment and Other Interventions
Moderators: Clifton O. Bingham, III, MD and Nancy A. Shadick,
MD, MPH
4:30 pm
2911. Clinical Outcomes of Early RA after 7 Years – Does T2T
Approach Overcome Delay of Therapy?
Tuulikki Sokka1, Hannu Kautiainen2, Tuomas Rannio3, Juha
Asikainen1 and Pekka Hannonen1, 1Jyvaskyla Central Hospital,
Jyväskylä, Finland, 2Medcare Oy, Äänekoski, Finland, 3Kuopio
University Hospital, Kuopio, Finland
5:15 pm
2914. The Clinical and Radiographic Course of Early
Undifferentiated Arthritis Under Treatment Is Not Dependent
on the Amount of Erosions at Diagnosis. Results from the Swiss
Prospective Observational Cohort
Ruediger Mueller1, Toni Kaegi1, Sarah Haile2 and Johannes
von Kempis3, 1Kantonsspital St. Gallen, St. Gallen, Switzerland,
2
University of Zurich, Switzerland, Zurich, Switzerland, 3St. Gallen
Hospital, CH- 9007 St.Gallen, Switzerland
2 0 1 4
PS
1 8 ,
PM
TUESDAY
Ballroom East
5:00 pm
2913. Does Corticosteroid Therapy at Disease Onset Influence
Disease Progression of RA? Results from the Swiss Prospective
Observational Cohort
Ruediger Mueller1, Nazim Reshiti2, Toni Kaegi1, Axel Finckh3,
Hendrik Schulze-Koops4, Michael H. Schiff5 and Johannes von
Kempis6, 1Kantonsspital St. Gallen, St. Gallen, Switzerland,
2
Division of Rheumatology, St. Gallen, Switzerland, 3Geneva
University Hospital, Geneva, Switzerland, 4University of Munich,
Munich, Germany, 5University of Colorado, Denver, CO, 6St.
Gallen Hospital, CH- 9007 St. Gallen, Switzerland
n o v e m b e r
5:45 pm
2910. Tofacitinib Facilitates the Expansion of Myeloid-Derived
Suppressor Cells and Ameliorates Arthritis in SKG Mice
Keisuke Nishimura, Jun Saegusa, Fumichika Matsuki, Kengo
Akashi, Goichi Kageyama and Akio Morinobu, Kobe University
Graduate School of Medicine, Kobe, Japan
4:45 pm
2912. Impact of Failure to Adhere to Treat-to-Target of
Rheumatoid Arthritis in Real World Practice: Data from the
International Rheumatoid Arthritis Biomarker Program
WP Maksymowych1, M. Østergaard2, O Elkayam3, R Landewé4,
J Homik5, C Thorne6, M Backhaus7, S Shaikh8, G Boire9, M
Larche10, B Combe11, T Schaeverbeke12, A Saraux13, G Ferraccioli14,
M Dougados15, C Barnabe16, M Govoni17, PP Tak18, D. van
Schaardenburg19, D van der Heijde20, R Dadashova1, E Hutchings1,
J Paschke1 and Oliver FitzGerald21, 1CaRE Arthritis, Edmonton,
AB, 2Copenhagen Center for Arthritis Research, Glostrup,
Denmark, 3Tel Aviv Sourasky Medical Center, Tel Aviv, Israel,
4
Amsterdam Rheumatology Center, Amsterdam, Netherlands,
5
University of Alberta, Edmonton, AB, 6Southlake Regional
Health Centre, Newmarket, ON, 7Charite University Hospital,
Berlin, Germany, 8Niagara Peninsula Arthritis Centre, Hamilton,
ON, 9CHUS-Sherbrooke University, Sherbrooke, QC, 10St Joseph’s
Healthcare Hamilton, Hamilton, ON, 11Hôpital Lapeyronie,
Montpellier, France, 12Bordeaux University Hospital, Bordeaux,
France, 13CHU Brest and EA 2216, UBO, Brest, France, 14Catholic
University of The Sacred Heart, Rome, Italy, 15Hopital Cochin,
Paris, France, 16University of Calgary, Calgary, AB, 17Universita di
Ferrara, Ferrara, Italy, 18Academic Medical Center, Amsterdam,
Netherlands, 19Jan van Breemen Research Institute, Amsterdam,
Netherlands, 20Leiden University Medical Center, Leiden,
Netherlands, 21St. Vincent’s University Hospital, Dublin, Ireland
5:30 pm
2915. Effects of Methotrexate on Anti-TNF Treatment in
Rheumatoid Arthritis: An in-Depth Analysis of a Prospective
Observational Study with Adalimumab
Marc Schmalzing1, Frank Behrens2, Eva C. Scharbatke1, Michaela
Koehm3, Bianca Wittig4, Gerd Greger5, Harald Burkhardt2 and
Hans-Peter Tony1, 1University of Würzburg, Würzburg, Germany,
2
Goethe-University Frankfurt, Frankfurt, Germany, 3Fraunhofer
2014 Program Book
141
scientific sessions
Institute for Molecular Biology and Applied Ecology IME,
Project Group Translational Medicine & Pharmacology TMP,
Frankfurt/Main, Germany, 4Abbvie Deutschland GmbH & Co.
KG, Wiesbaden, Germany, 5AbbVie GmbH & Co KG, Wiesbaden,
Germany
5:45 pm
2916. Effects of Exercise on Body Composition, Cardiovascular
Fitness, Muscle Strength and Cognition in Patients with
Rheumatoid Arthritis: A Randomised Controlled Trial of a
Patient-Specific Exercise Programme
Maha Azeez1, Ciara Clancy2, Tom O’Dwyer2, Fiona Wilson2 and
Gaye Cunnane1, 1St James’s Hospital and Trinity College Dublin,
Dublin, Ireland, 2Trinity College Dublin, Dublin, Ireland
157 B
PM
PS
Rheumatoid Arthritis – Human Etiology and
Pathogenesis II: Citrullination, Autoantibodies and
Genes
Moderators: Erik J. Peterson, MD and Jeremy Sokolove, MD
n o v e m b e r
1 8 ,
TUESDAY
2 0 1 4
4:30 pm
2917. Inhibition of PAD4 Activity and the Formation of
Neutrophil Extracellular Traps Via PTPN22, but Not Its
Rheumatoid Arthritis-Prone W620 Variant
I-Cheng Ho1, Hui-Hsin Chang1, Nishant Dwivedi1, Hsiao-Wei Tsao1
and Anthony Nicholas2, 1Brigham and Women’s Hospital, Boston,
MA, 2University of Alabama at Birmingham, Birmingham, AL
4:45 pm
2918. Fine-Mapping Major Histocompatibility Complex
Associations in ACPA-Positive Rheumatoid Arthritis Identified
Shared HLA Amino Acid Polymorphisms in Asian and European
Populations
Yukinori Okada1, Kwangwoo Kim2, Buhm Han3, Nisha E. Pillai4,
Rick T-H. Ong4, Woei-Yuh Saw4, Ma Luo5, Lei Jiang6, Jian Yin6, SoYoung Bang7, Hye-Soon Lee7, Matthew A. Brown8, Sang-Cheol
Bae9, Huji Xu10, Yik-Ying Teo4, Paul IW. de Bakker11 and Soumya
Raychaudhuri3, 1Tokyo Medical and Dental University, Tokyo,
Japan, 2Hanyang University Hospital for Rheumatic Diseases,
Seoul, South Korea, 3Brigham and Women’s Hospital, Harvard
Medical School, Boston, MA, 4National University of Singapore,
Singapore, Singapore, 5University of Manitoba, Winnipeg, MB,
6
The Second Military Medical University, Shanghai, China,
7
Hanyang University Guri Hospital, Guri, South Korea, 8University
of Queensland Diamantina Institute, Brisbane, Australia,
9
Department of Rheumatology, Hanyang University Hospital for
Rheumatic Diseases, Seoul, South Korea, 10Shanghai Changzheng
Hospital, Shanghai, China, 11University Medical Center Utrecht,
Utrecht, Netherlands
5:00 pm
2919. The Novel Rheumatoid Arthritis (RA) Risk Gene, LBH, Is
Regulated By TGFß and PDGF and Modulates Cell Growth in
Fibroblast-like Synoviocytes
Anna-Karin Ekwall1, Deepa Hammaker2, John W. Whitaker3,
William Bugbee4, Wei Wang5 and Gary S. Firestein6, 1UC San
142
2014 Program Book
Diego, La Jolla, CA, 2University of California San Diego, La Jolla,
CA, 3UCSD, San Diego, CA, 4Scripps Clinic, La Jolla, CA, 5UCSD,
La Jolla, CA, 6University of California at San Diego School of
Medicine, La Jolla, CA
5:15 PM
2920. WITHDRAWN
5:30 PM
2921. Contraceptive Factors Are Associated with Serum
Antibodies to Citrullinated Protein Antigens in Women at
Elevated Risk for Future Rheumatoid Arthritis
Sonia Khatter1, Mark C. Parish1, Marie L. Feser1, Jason R.
Kolfenbach1, Ryan W. Gan2, Michael H. Weisman3, James R.
O’Dell4, Ted R. Mikuls5, Richard M. Keating6, Peter K. Gregersen7,
Jane H. Buckner8, V. Michael Holers1, Kevin D. Deane1, Jill M.
Norris2 and M. Kristen Demoruelle1, 1University of Colorado
School of Medicine, Aurora, CO, 2Colorado School of Public
Health, Aurora, CO, 3Cedars-Sinai Medical Center, Los Angeles,
CA, 4Veteran Affairs Nebraska Western Iowa Health Care System
and University of Nebraska Medical Center, Omaha, NE, 5Omaha
VA Medical Center and University of Nebraska Medical Center,
Omaha, NE, 6Scripps Clinic, La Jolla, CA, 7Feinstein Institute for
Medical Research, Manhasset, NY, 8Benaroya Research Institute
at Virginia Mason, Seattle, WA
5:45 pm
2922. Association of Single Nucleotide Polymorphisms of PADI4
Gene with Susceptibility to Rheumatoid Arthritis-Related Lung
Disease
Seong-Wook Kang, Seung-Taek Song, Song Soo Kim, Ji Young Kim,
So Young Lee, Su-Jin Yoo, In-Seol Yoo, Jinhyun Kim and SeungCheol Shim, Chungnam National University School of Medicine,
Daejeon, South Korea
253 B
PS
PM
and Gene Therapy VI: Biomarkers and Predictors
of Rheumatoid Arthritis Disease Response and
Outcomes
Moderators: Stanley B. Cohen, MD and Duncan Porter, MD
4:30 pm
2923. Protein Quantification Using Mass Spectrometry
Methods to Predict Response to Abatacept and Methotrexate
Combination Therapy in Rheumatoid Arthritis
A Obry1, P Cosette1, T Lequerré2, Maria-Antonietta d’Agostino3, C
Gaillez4, M Le Bars5 and O Vittecoq2, 1UMR 6270 CNRS, PISSARO
Proteomic Facility, IRIB, Normandy University, University of
Rouen, Rouen, France, 2Rouen University Hospital, Rouen,
France, 3AP-HP Ambroise Paré Hospital, Boulogne-Billancourt,
France, 4Formerly of Bristol-Myers Squibb, Rueil-Malmaison,
France, 5Bristol-Myers Squibb, Rueil-Malmaison, France
scientific sessions
4:45 pm
2924. Clinical Utility of Random Anti-TNF Drug Level Testing
and Measurement of Anti-Drug Antibodies on Long-Term
Treatment Response in Rheumatoid Arthritis
Meghna Jani1, Hector Chinoy1, Richard B. Warren2, Christopher
E.M Griffiths2, Ann W. Morgan3, Anthony G. Wilson4, Kimme L.
Hyrich1, John Isaacs5, Darren Plant1 and Anne Barton6, 1Centre
Manchester, United Kingdom, 2Dermatology Centre, University
of Manchester, Manchester, United Kingdom, 3University of
Leeds, Leeds, United Kingdom, 4University College Dublin, Dublin,
Ireland, 5Institute of Cellular Medicine, University of Newcastle,
Newcastle, United Kingdom, 6NIHR Manchester Musculoskeletal
Biomedical Research Unit, Manchester Academic Health Science
Centre, Manchester, United Kingdom
5:00 pm
2925. Serum MMP-3 Predicts a Subgroup with No Radiographic
Progression in Rheumatoid Arthritis Patients with Low-Dose
Methotrexate (MTX) Monotherapy
Kazuko Shiozawa1, Takashi Yamane1, Miki Murata1, Chihiro
Tanaka1, Noriaki Yo1, Ryosuke Yoshihara1, Yasushi Tanaka1, Ken
Tsumiyama2 and Shunichi Shiozawa2, 1Kohnan Kakogawa Hospital,
Kakogawa, Japan, 2Kyushu University Beppu Hospital, Beppu,
Japan
102 A
Sjögren’s Syndrome I: Clinical Perspectives
Moderators: Arthur A. M. Bookman, MD and Stefano
Bombardieri, MD
4:30 pm
2929. Molecular Diagnostics for Patient Subsetting in Sjögren’s
Syndrome
John C. Hall1, Alan N. Baer1, Mi Y. Lam2, Lindsey A. Criswell3,
Antony Rosen1 and Livia Casciola Rosen1, 1Johns Hopkins
University School of Medicine, Baltimore, MD, 2University
of California San Francisco, San Francisco, CA, 3University of
California, San Francisco, Rosalind Russell / Ephraim P. Engleman
Rheumatology Research Center, San Francisco, CA
2 0 1 4
4:45 pm
2930. Precisely Quantified Fibrosis in Labial Salivary Glands
Predicts Sjögren’s Syndrome Classification in a Multiple
Regression Model
Kerry M. Leehan1, Michael Brown2, Courtney Montgomery2,
Astrid Rasmussen2, David M. Lewis1, Lida Radfar1, Donald U.
Stone1, Stephen Young1, R. Hal Scofield1, Kathy L. Sivils2 and A.
Darise Farris2, 1University of Oklahoma Health Sciences Center,
Oklahoma City, OK, 2Oklahoma Medical Research Foundation,
Oklahoma City, OK
1 8 ,
5:45 pm
2928. Serum IL-33 Level Is Increased in Rheumatoid Arthritis
and Predicts Response to Rituximab in Combination with High
Serum IgG Level and Autoantibody Positivity: An Open-Label,
Prospective, Multicentre Biological Trial
Jérémie Sellam1, Houria Chavez2, Stéphanie Rouanet3, Nathalie
Vernet3, Bineta Ly4, Sandrine Marion-Thore5, Bernard Combe6,
PS
TUESDAY
5:30 pm
2927. Baseline Serum Interferon Beta/Alpha Ratio Predicts
Response to Tumor Necrosis Factor Alpha Inhibition in
Priyanka Vashisht1, Jessica M. Dorschner2, Mark A. Jensen2,
Beverly Chrabot3, Theresa Wampler Muskardin2, Marlena Kern4,
Tetrad Investigators5, ABCoN Consortium6, S. Louis Bridges
Jr.7, P.K. Gregersen8 and Timothy B. Niewold2, 1University of
Nebraska Medical Center, Omaha, NE, 2Mayo Clinic, Rochester,
MN, 3University of Chicago, Chicago, IL, 4Feinstein Institute
for Medical Research, Manhasset, NY, 5AL, 6NY, 7University
of Alabama at Birmingham, Birmingham, AL, 8The Feinstein
Institute for Medical Research, Manhasset, NY
PM
n o v e m b e r
5:15 pm
2926. Calprotectin Serum Levels Reflect Residual Inflammatory
Activity in Patients with Rheumatoid Arthritis and Psoriatic
Arthritis on Clinical Remission or Low Disease Activity
Undergoing TNF-Antagonists Therapy
Jose Inciarte-Mundo1, M. Victoria Hernández1, Sonia CabreraVillalba1, Julio Ramirez1, Andrea Cuervo1, Virginia Ruiz-Esquide1,
Azucena González Navarro1, Jordi Yagüe2, Juan D. Cañete1 and
Raimon Sanmarti1, 1Hospital Clínic of Barcelona, Barcelona,
Spain, 2Hospital Clinic Barcelona, Barcelona, Spain
Jean Sibilia7, Jacques Tebib8, Gilles Chiocchia9, Maxime
Dougados10, Yassine Taoufik2 and Xavier Mariette11, 1AP-HP, SaintAntoine Hospital, Rheumatology Department and DHU i2B, Paris,
France, 2Hopital Bicetre, Université Paris Sud, AP-HP, Kremlin
Bicetre, France, 3Roche France, Boulogne-Billancourt, France,
4
Universite Paris-Sud, Kremlin Bicetre, France, 5Université
Versailles Saint-Quentin, Montigny le Bretonneux, France,
6
Hôpital Lapeyronie, Montpellier, France, 7University Hospital
of Strasbourg, Strasbourg, France, 8University Hospital Lyon,
Lyon, France, 9Université Versailles-Saint Quentin, Montigny le
Bretonneux, France, 10INSERM (U1153): Clinical Epidemiology
and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France., Paris,
France, 11Université Paris-Sud, Le Kremlin Bicêtre, France
5:00 pm
2931. Longitudinal Examination with Salivary Gland
Ultrasonography (SGUS) of Patients with Primary Sjögren’s
Syndrome: A Single Center Experience
Chiara Baldini1, Nicoletta Luciano1, Francesca Sernissi1, Daniela
Martini1, Francesco Ferro1, Marta Mosca2 and Stefano
Bombardieri2, 1Rheumatology Unit, Pisa, Italy, 2Rheumatology
Unit, University of Pisa, Pisa, Italy
5:15 pm
2932. Increased Risk of Deep Vein Thrombosis and Pulmonary
Embolism in Sjögren’s Syndrome: A General Population-Based
Cohort Study
Marko Yurkovich1, Hyon K Choi2, Eric C. Sayre3, Kamran Shojania1
and J. Antonio Avina-Zubieta3, 1University of British Columbia,
Vancouver, BC, 2Boston University School of Medicine, Boston,
MA, 3Arthritis Research Centre of Canada, Richmond, BC
2014 Program Book
143
scientific sessions
5:30 pm
2933. Metabolic Syndrome, Adipocytokines and Inflammation
in Sjögren’s Syndrome
Kristopherson Lustosa Augusto1, Eloisa Bonfá2, Rosa M. R.
Pereira1, Cleonice Bueno1, Vilma S. T. Viana3 and Sandra G.
Pasoto1, 1Faculdade de Medicina da Universidade de São Paulo,
Sao Paulo, Brazil, 2University of Sao Paulo, Sao Paulo, Brazil,
3
Faculdade de Medicina da Universidade de São Paulo, São
Paulo, Brazil
5:45 pm
2934. Abatacept reduces Circulating Effector Memory T-Helper
Cells in Patients with Primary Sjögren’s Syndrome
Gwenny Verstappen1, Wayel H. Abdulahad2, Petra M. Meiners1,
Suzanne Arends1, Silvia Beijer-Liefers1, Arjan Vissink1, Frans G.M.
Kroese1 and Hendrika Bootsma1, 1University Medical Center
Groningen, University of Groningen, Groningen, Netherlands,
2
University Medical Center Groningen, Groningen, Netherlands
Ballroom West
PM
PS
Spondyloarthropathies and Psoriatic Arthritis V –
Clinical Aspects and Treatment
Moderators: Filip Van den Bosch, MD, PhD and Robert B. M.
Landewé, MD, PhD
4:30 pm
2935. Attainment of Minimal Disease Activity Using
Methotrexate in Psoriatic Arthritis
n o v e m b e r
1 8 ,
TUESDAY
2 0 1 4
Barry J. Sheane, Arane Thavaneswaran, Dafna D. Gladman
and Vinod Chandran, University of Toronto, Toronto Western
Hospital, Toronto, ON
4:45 pm
2936. Is Ankylosing Spondylitis a Risk Factor for Cardiovascular
Diseases and How Does These Risks Compare to Those in
Rheumatoid Arthritis?
Johan Askling1, Lennart Jacobsson2 and Jonas Eriksson1, 1Clinical
Epidemiology Unit, Department of Medicine, Karolinska
Institutet, Stockholm, Sweden, 2Sahlrenska Academy,
Gothenburg, Sweden
5:00 pm
2937. Evaluation of Referral Models for Axial Spondyloarthritis
in Primary Care in the Spondyloarthritis Caught Early Cohort
Ozair Abawi, Rosaline van den Berg, Désirée van der Heijde and
Floris van Gaalen, Leiden University Medical Center, Leiden,
Netherlands
5:15 pm
2938. A Randomized, Double-Blind, Placebo-Controlled, 16Week Study of Subcutaneous Golimumab in Patients with
Active Nonradiographic Axial Spondyloarthritis
J Sieper1, D van der Heijde2, M Dougados3, W Maksymowych4, J
Boice5, G Bergman5, S Curtis5, A Tzontcheva5, S Huyck5 and HH
Weng5, 1University Clinic Benjamin Franklin, Berlin, Germany,
2
Leiden University Medical Center, Leiden, Netherlands, 3Paris-
144
2014 Program Book
Descartes University, Paris, France, 4University of Alberta,
Alberta, AK, 5Merck & Co., Inc., Whitehouse Station, NJ
5:30 pm
2939. Increased Diagnosis of Spondyloarthritis in Female
Patients Started in the Early Biologic Era
Nisha Nigil Haroon1, Ping Li2, Michael Paterson2 and Nigil
Haroon3, 1Department of Medicine, University of Toronto,
Toronto, ON, 2Institute of Clinical Evaluative Sciences, Toronto,
ON, 3Toronto Western Research Institute, Toronto, ON
5:45 pm
2940. Do Patients with Non-Radiographic Axial
Spondyloarthritis and Ankylosing Spondylitis Respond Similarly
Well to Nsaids? – a Prospective Study Including Magnetic
Resonance Imaging
Xenofon Baraliakos1, Uta Kiltz1, Frank Heldmann1, Heiner Appel2,
Friedrich Dybowski3, Manfred Igelmann4, Ludwig Kalthoff5,
Dietmar Krause6, Hans-Jürgen Menne7, Ertan Saracbasi8, Elmar
Schmitz-Bortz9 and Jürgen Braun1, 1Rheumazentrum Ruhrgebiet,
Herne, Germany, 2Rheumatology and Nephrology Practice,
Hamm, Germany, 3Rheumatology Practice, Herne, Germany,
4
Rheumatology Practice, Bochum, Germany, 5Rheumatology
practice, Herne, Germany, 6Rheumatology practice, Gladbeck,
Germany, 7Rheumatology practice, Dortmund, Germany,
8
Rheumatology practice, Oberhausen, Germany, 9Rheumatology
PS
PM
practice, Hattingen, Germany
4:30 – 6:00 pm
Adult Inflammatory Myopathy (081)
Speaker: Robert L. Wortmann, MD, MACR
• review the clinical manifestations of inflammatory myopathies
including important extra-muscle manifestations
• discuss diagnostic pearls for the evaluation of someone
suspected of having an inflammatory myopathy
• discuss the treatment paradigm for inflammatory myopathies
scientific sessions
• d escribe key elements of preclinical risk assessment and
Behçet’s Syndrome (082)
Speaker: Yusuf Yazici, MD
• discuss the epidemiology, disease mechanisms and the
differential diagnosis of Behçet’s syndrome
• describe current approaches to the management of patients
with Behçet’s syndrome
Calcium Crystal Arthritis (083)
PM
• d escribe the common clinical pictures of calcium
pyrophosphate disease and basic calcium phosphate arthritis
as well as appreciate unusual presentations
• d escribe currently available and emerging diagnostic
modalities to confirm suspected calcium crystal arthritis,
including ultrasound and novel techniques for BCP crystal
identification
• describe currently available therapies and understand the
rationale behind some promising new therapies for these
diseases
Pd
PS
PrM
Pulmonary Manifestations of Rheumatic Disease
(087)
PS
Speaker: Ann K. Rosenthal, MD
PM
Ed
Juvenile Dermatomyositis (084)
counseling for women who desire a future
pregnancy
• d
iscuss the impact of active maternal autoimmune disease
upon pregnancy outcomes.
• discuss the risk-to-benefit analysis of common anti rheumatic
and immunosuppressive medications during pregnancy
FIT
Speaker: Susan Kim, MD, MMSc
• differentiate myositis mimics from idiopathic inflammatory
myopathies
• d escribe the importance of myositis antibodies and muscle
magnetic resonance imaging in diagnosis and prognosis
• review myositis diagnosis in difficult cases including review of
clinical features, muscle biopsy and electromyography
• review management of refractory myopathy including
management of extra-muscular manifestations especially
interstitial lung disease
Pregnancy and Rheumatic Diseases (086)
Speaker: Eliza Chakravarty, MD, MS
• describe risk factors for adverse maternal and fetal outcomes
in systemic autoimmune diseases.
Rheumatoid Arthritis: Challenging Cases (089)
Speaker: Stephen A. Paget, MD
2 0 1 4
Speaker: Rohit Aggarwal, MD, MS
• discuss the current understanding of the pathogenesis of
Raynaud’s phenomenon
• classify type of Raynaud’s phenomenon and differentiate it
from mimics
• describe the appropriate investigations for Raynaud’s
phenomenon and be aware of those patients at risk for the
development of an autoimmune rheumatic disease
• discuss current options and evidence for treatment of
Raynaud’s phenomenon, threatened digital ischemia and
digital ulcers
1 8 ,
Myopathy: Issues in Diagnosis and Treatment (085)
Raynaud’s and Digital Ischemia (088)
Speaker: Fredrick M. Wigley, MD
TUESDAY
n o v e m b e r
• discuss what is known about the pathogenesis and
epidemiology of juvenile dermatomyositis
• discuss the approach to the evaluation of a patient referred
with possible juvenile dermatomyositis
• discuss different therapeutic approaches to the treatment of
juvenile dermatomyositis, ranging from mild to severe
• identify emerging concepts regarding the pathophysiology of
inflammation and fibrosis in autoimmune lung disease
• recognize the appropriate use of diagnostic tests in the
evaluation of patients with rheumatic disorders and
autoimmune lung disease
• discuss the limits of traditional therapeutic options and
possible emerging therapies in managing autoimmune lung
disease
therapies
Temporal Arteritis (090)
Speaker: Robert F. Spiera, MD
• discuss current concepts in the diagnosis of temporal arteritis
including use of imaging modalities
• identify evolving concepts of the treatment of temporal
arteritis including the appropriate use of glucocorticoids and
the efficacy of “steroid-sparing” agents
2014 Program Book
145
scientific sessions
• d
escribe the relationship between temporal arteritis and
polymyalgia rheumatica
• outline current concepts of the pathogenesis of temporal
arteritis
5:30 pm
Comparative Effectiveness Research and Optimization of
Patient Outcomes
ARHP SESSIONS
4:30 – 6:00 pm
255
PM
PS
Multidisciplinary Management of the Juvenile
FIT
PrM
Pd
PS
Ed
Idiopathic Arthritis Patient PM
Moderator: Michael Blakley, MD
• review how to perform the cursory history and physical exam
that may lead to the diagnosis of juvenile idiopathic arthritis
• facilitate and initiate the multidisciplinary management of a
child with juvenile idiopathic arthritis
• employ techniques to trouble shoot difficult juvenile
idiopathic arthritis cases
4:30 pm
Review of Seven Subtypes of Juvenile Idiopathic Arthritis
Peter Chira, MD, MS
4:55 pm
Nursing Management of the Juvenile Idiopathic Arthritis
Patient
Karla Jones, RN
5:45 pm
n o v e m b e r
1 8 ,
TUESDAY
2 0 1 4
5:20 pm
Physical and Occupational Therapy Management of the
Juvenile Idiopathic Arthritis Patient
Speaker to be determined
256
5:00 pm
Patient Advocacy, Patient Reported Outcomes and Social
Media
Seth Ginsberg
PM
PS
Patient-Reported Outcomes Data for Comparative
Effectiveness Research in Arthritis Care
Moderator: Jonathan Krant, MD, MPH
• review patient reported outcomes (PRO)
• review comparative effectiveness research (CER)
• recognize the differences between print and social media as
regards messaging and data capture
• translate PRO and CER into policy regarding quality metrics
and assessment of physician performance
4:30 pm
Introduction of Speakers and Overview of Rheumatology
Practice Management for Complex Diagnoses
Jonathan Krant, MD, MPH
257 A
PM
PS
State-of-the-Art Interventional Recommendations for
PS
PM
Chronic Low Back Pain
Moderators: David G. Borenstein, MD and Kimberly F. Kimpton,
PT
• evaluate the current evidence for the use of transcutaneous
electrical nerve stimulation for chronic low back pain
• discuss the benefits of physical therapy for chronic low back
pain
• r eview existing evidence for the efficacy of epidural steroid
injections and other interventional procedures for chronic
low back pain and spinal stenosis and delineate appropriate
patient selection
• identify clinical characteristics of chronic low back pain and
spinal stenosis that warrant referral for surgical evaluation, as
well as treatment to include standard and minimally invasive
surgical options
4:30 pm
Physical Therapy for Chronic Low Back Pain
Adam Goode, DPT, PT
5:00 pm
Interventional Pain Management for Chronic Low Back Pain
Chad M. Brummett, MD
5:30 pm
Surgical Considerations for Lumbar Stenosis and Chronic Low
Back Pain
Barton L. Sachs, MD, MBA
PS
PM
204 A
Successful Aging in Rheumatic Disease
Moderator: Patricia P. Katz, PhD
• recognize the traits that contribute to successful aging
• recommend interventions that can help patients successfully
age
• explain how rheumatic disease affects the aging process
4:30 pm
Successful Aging: What Does the Research Say?
Marian R. Stuart, PhD
5:15 pm
Successful Aging in Rheumatic Disease
Kim M. Huffman, MD, PhD
146
2014 Program Book
scientific sessions
of Medicine Beth Israel Deaconess Medical Center, Harvard
Medical School, Boston, MA, 3University of California, San
Francisco, San Francisco, CA, 4Hospital Special Surgery (HSS),
New York, NY, 5Hebrew SeniorLife & Boston Univ, Boston, MA
2:30 – 4:00 pm
PM
PS
254 A
5:45 pm
2946. The Association Between Accelerometer Monitored
Sedentary Behavior and Observed Physical Function Loss
Pamela Semanik1, Rowland W. Chang2, Jing Song2, Jungwha Lee2
and Dorothy D. Dunlop2, 1Rush University College of Nursing,
Chicago, IL, 2Northwestern University Feinberg School of
Medicine, Chicago, IL
Epidemiology/Public Health
Moderators: Kelli D. Allen, PhD and Uyen Sa D.T. Nguyen, DSc,
MPH
4:30 pm
2941. Physical Function Is Independently Associated with
Mortality Among Individuals with Knee and/or Hip OA: The
Johnston County Osteoarthritis Project
Rebecca Cleveland1, Todd Schwartz1, Jordan B. Renner2, Joanne
M. Jordan3 and Leigh F. Callahan4, 1University of North Carolina
at Chapel Hill, Chapel Hill, NC, 2University of North Carolina
Department of Radiology, Chapel Hill, NC, 3University of North
Carolina Dept of Epidemiology, Chapel Hill, NC, 4University of
North Carolina, Chapel Hill, NC
4:45 pm
2942. A Longitudinal Population-Based Study 1994-2010 of
Age, Period and Cohort Effects in the Prevalence of Arthritis:
The Effect of Improving Socioeconomic Status and Increasing
Obesity over Time
Elizabeth M. Badley1, Mayilee Canizares2, Anthony V. Perruccio2,
Sheilah. Hogg-Johnson2 and Monique A.M. Gignac2, 1Toronto
Western Research Institute, Toronto, ON, 2University of Toronto,
Toronto, ON
5:00 pm
2943. Severity of Foot Pain Is Linked to the Prevalence of
Depressive Symptoms: The Framingham Foot Study
Arunima Awale1, Alyssa B. Dufour2, Patricia P. Katz3, Virginia
A. Casey1 and Marian T. Hannan4, 1Hebrew SeniorLife, Boston,
MA, 2Hebrew SeniorLife, Harvard Medical School & Beth Israel
Deaconess Medical Center, Boston, MA, 3University of California,
San Francisco, CA, 4Institute for Aging Research, Hebrew
SeniorLife, Dept. of Medicine Beth Israel Deaconess Medical
Center, Harvard Medical School, Boston, MA
These symposia are both CME-accredited and non-CME
company-directed programs. For CME-accredited symposia,
the sponsoring organization is responsible for planning and
providing CME credit. All non-CME programs are wholly
sponsored and supported by commercial entities. Please visit the
organization’s exhibit booth, the industry-supported symposia
booth or see page 239 for more information.
WEDNESDAY, NOVEMBER 19, 2014
ACR SESSIONS
7:30 – 8:30 am
52 A
PM
PS
Co-Stimulation Pathways: Therapeutic Opportunities
for the Rheumatic Diseases
Moderators: Gregg J. Silverman, MD and Adam Mor, MD, PhD
Speaker: Vassiliki A. Boussiotis, MD, PhD
• examine the roles of co-receptor-mediated inhibitory
pathways for the immunosurveillance of cancer and the
development of autoimmune diseases, including rheumatoid
arthritis and lupus
• appraise the relative contributions of the CD28, CTLA4, PD-1,
ICOS and VISTA systems to immunoregulation
• review emerging data from therapeutic trials for the potential
utility of manipulating these signaling pathways
PM
1 9 ,
PS
Rheumatology Roundup: Highlights from the 2014
Annual Meeting
2 0 1 4
Ballroom East
WEDNESDAY
5:30 pm
2945. Foot Structure and Function Show Associations with
Lower Extremity Physical Function
Yvonne M. Golightly1, Marian T. Hannan2, Patricia P. Katz3,
Howard J. Hillstrom4, Alyssa B. Dufour5 and Joanne M. Jordan1,
1
University of North Carolina Dept of Epidemiology, Chapel
Hill, NC, 2Institute for Aging Research, Hebrew SeniorLife, Dept.
6:30 – 9:30 pm
n o v e m b e r
5:15 pm
2944. Sedentary Time Is an Independent Risk Factor for
Disability Onset Among Adults at Elevated Risk: Prospective
Cohort Study
Jungwha Lee1, Jing Song1, Barbara Ainsworth2, Rowland
W. Chang1, Linda S. Ehrlich-Jones3, Christine Pellegrini1,
Pamela Semanik4, Dorothy D. Dunlop1 and Leena Sharma5,
1
IL, 2Arizona State University, Phoenix, AZ, 3Rehabilitation
Institute of Chicago, Chicago, IL, 4Rush University, Chicago, IL,
5
Northwestern University, Chicago, IL
INDUSTRY-SUPPORTED SYMPOSIA
Speakers: John J. Cush, MD and Arthur Kavanaugh, MD
• list research highlights from the scientific presentations
• discuss the clinical impact of selected research reports
presented at the ACR meeting
• evaluate the therapeutic potential of selected clinical trials
presented at the meeting
2014 Program Book
147
scientific sessions
ARHP SESSIONS
• r eview the molecular and cellular pathways that link
complement activation to systemic autoimmunity
7:30 – 8:30 am
255
PM
PS
Physical and Occupational Therapy for Juvenile
Dermatomyositis: Treatment Planning and Case
FIT
PrM
Pd
PS
Ed
Presentations PM
Moderator: Sandra Mintz, BSN
• review the unique therapy needs of the juvenile
dermatomyositis population at all stages of the disease
process
• evaluate a patient with juvenile dermatomyositis
• formulate appropriate treatment plans for patients with
juvenile dermatomyositis
7:30 am
Juvenile Dermatomyositis Stages, Physical Therapy Evaluation
and Treatment
Jill R. Blitz, PT, DPT
8:00 am
Occupational Therapy Evaluation and Treatment for Juvenile
Dermatomyositis
Talitha Cox, MA, OTR/L
PS
PM
256
Rheumatic Manifestations of Malignancy
Moderator: Kori A. Dewing, DNP, ARNP
• review how patients can have a rheumatic disease as the
presenting feature of a hidden malignancy
• explain the clinical features of paraneoplastic rheumatic
disorders
• describe the evaluation and management of paraneoplastic
rheumatic disorders
n o v e m b e r
1 9 ,
WEDNESDAY
2 0 1 4
7:30 am
Rheumatic Disease as a Manifestation of Malignancy
David I. Daikh, MD, PhD
8:00 am
Vasculitis as a Manifestation of Malignancy
John H. Stone, MD, MPH
9:00 – 10:30 am
9:30 am
The Role of Complement in CD4⁺ T Cell Homeostasis and
Effector Function
Claudia Kemper, PhD
Ballroom East
PM
PS
Moving Toward Personalized Medicine for Systemic
Lupus Erythematosus Management: From Bench to
Bedside
Moderators: Shreyasee Amin, MD CM, MPH and Swamy
Venuturupalli, MD
• describe major subsets of lupus patients defined by cytokine,
autoantibody and genetic profiles
• recognize how this information may influence therapeutic
strategies and responses
• describe emerging biomarkers that may help with disease
monitoring and treatment decisions
9:00 am
Defining Biological Subsets in Systemic Lupus Erythematosus:
Progress Toward Personalized Therapy
Timothy B. Niewold, MD
9:30 am
Influence of Biomarkers, Race and Ethnicity on Disease
Severity and Treatment Response in Systemic Lupus
Erythematosus
PM
PS
253 B
Complement in Rheumatic Disease
Moderators: Susan A. Boackle, MD and Leendert A. Trouw, PhD
• review current evidence that supports a key role for
complement and its receptors in regulating T-cell function
• review the repertoire of complement-mediated effector
responses in autoimmunity
2014 Program Book
9:15 am
Immune-Mediated Membranolytic Pathways: Key to
Felipe Andrade, MD, PhD
10:00 am
Improving Return on Investment: Molecular Analysis of the
Kidney Biopsy for Lupus Nephritis
Brad H. Rovin, MD
ACR SESSIONS
PM
148
9:00 am
Effector Pathways Linking Complement Activation to Systemic
Lupus Erythematosus
Susan A. Boackle, MD
Ballroom West
PS
Primary Angiitis of the Central Nervous System and
Its Mimics
Moderators: Elana J. Bernstein, MD, MSc and Rula Hajj-Ali, MD
• formulate a diagnostic approach to primary angiitis of the
central nervous system and describe “best practices” in the
management of primary angiitis of the central nervous system
• discuss the pathophysiology, clinical manifestations,
diagnosis and treatment of the reversible cerebrovascular
scientific sessions
vasoconstriction syndromes
• d escribe non-atherosclerotic cerebral vasculopathies that can
mimic primary angiitis of the central nervous systems
9:00 am
Primary Angiitis of the Central Nervous System
Leonard H. Calabrese, DO
9:30 am
Reversible Cerebrovascular Vasoconstriction Syndromes
Aneesh Singhal, MD
10:00 am
Non-Atherosclerotic Central Nervous System Vasculopathies
Cenk Ayata, MD
9:00 – 10:30 am
160 B
PM
PS
Biology and Pathology of Bone and Joint II: Cartilage
Biology and Synovial Activation
Moderators: Anne-Marie Malfait, MD, PhD and Antonios O.
Aliprantis, MD, PhD
9:00 am
2947. Adenosine a2A Receptor As a Potential New Therapeutic
Target for the Prevention/Treatment of Osteoarthritis
Carmen Corciulo1, Aranzazu Mediero1, Tuere Wilder1 and Bruce
N. Cronstein2, 1NYU School of Medicine, New York, NY, 2NYU
School of Medicine, Division of Rheumatology, New York, NY
9:15 am
2948. S100 Proteins Induce Canonical Wnt Signaling, Which
Causes Increased Expression of MMPs in the Synovium
Martijn H. van den Bosch1, Arjen B. Blom1, R. Pelle Hoek1, Rik F.
Schelbergen1, Sylvia W. Suen1, Anke E. van Erp1, Wim B. van den
Berg1, Peter M. van der Kraan1 and Peter L. van Lent2, 1Radboud
university medical center, Nijmegen, Netherlands, 2Experimental
Rheumatology, Radboud University, Nijmegen, Netherlands
10:00 am
2951. Syndecan-4 Regulates Chondrocyte Phenotype and
Cartilage Homeostasis Via the WNT Signaling Pathway
Charlotte Kimberley Clarke1, Annelena Held1, Richard Stange2,
Uwe Hansen2, Lars Godmann2, Jessica Bertrand2, Thomas
Pap3, Giovanna Nalesso4, Frank Echtermeyer5, Francesco
Dell’Accio6 and Joanna Sherwood4, 1Institute of Experimental
Musculoskeletal Medicine (IEMM), Muenster, 48149, Germany,
2
University Hospital Münster, Münster, Germany, 3University
Hospital Muenster, Muenster, Germany, 4Queen Mary University
London, London, United Kingdom, 5University Hospital Hannover,
Hanover, Germany, 6William Harvey Research Institute, Barts
and the London Queen Mary’s School of Medicine and Dentistry,
Centre for Experimental Medicine and Rheumatology, London,
United Kingdom
10:15 am
2952. S100A9 Inhibitor Paquinimod (ABR-215757) reduces
Joint Destruction in Experimental Osteoarthritis and Blocks
Activating Effects of S100A9 in OA Synovium
Peter L. van Lent1, Rik Schelbergen1, Arjen B. Blom1, Tomas
Leanderson2, Helena Eriksson3 and Wim B. van den Berg1,
1
Radboud university medical center, Nijmegen, Netherlands,
2
Lund University, Lund, Sweden, 3Active Biotech AB, Lund,
Sweden
153 B
PM
PS
Genetics, Genomics and Proteomics II: Genetics of
Autoimmunity
Moderators: Lindsey A. Criswell, MD, MPH and Patrick Gaffney,
MD
1 9 ,
2 0 1 4
2014 Program Book
WEDNESDAY
9:00 am
2953. International Immunochip Study in the Idiopathic
Inflammatory Myopathies Identifies Novel Susceptibility Loci
and Confirms HLA As Strongest Genetic Risk Factor
Simon Rothwell1, Robert G. Cooper2, Ingrid E. Lundberg3,
Frederick W. Miller4, Peter K. Gregersen5, Jiri Vencovsky6, Katalin
Danko7, Lucy R Wedderburn8, Vidya Limaye9, Albert Selva
O’Callaghan10, Michael G. Hanna11, Pedro Machado11, Lauren
M. Pachman12, Ann M. Reed13, Lisa G. Rider4, Joanna Cobb1,
Hazel Platt14, Øyvind Molberg15, Olivier Benveniste16, Pernille
Mathiesen17, Timothy Radstake18, Andrea Doria19, Jan De
Bleecker20, Boel De Paepe20, Britta Maurer21, William E. Ollier14,
n o v e m b e r
9:30 am
2949. Activation of AMP-Activated Protein Kinase (AMPK) By
Berberine Limits Both Surgical Knee Instability-Induced and
Aging-Related Osteoarthritis in Mice
Ru Bryan1, Xianling Zhao2, Yun Wang3, Han Sol Lee2, Hyunje
Kim4, Alifah Akasdi2 and Robert Terkeltaub5, 1VA Medical Center/
University of California San Diego, San Diego, CA, 2VAMC, San
Diego, CA, 3VA Medical Ctr/UCSD, San Diego, CA, 4Yeungnam
University, Daegu, South Korea, 5VA Medical Ctr/University of
California San Diego, San Diego, CA
9:45 am
2950. Synovial Macrophages Promote TGF-β Activation after
Intra-Articular Injections of Oxidized LDL in Naïve Murine
Knee Joints, Preventing Production of Pro-Inflammatory
Factors S100A8/9, Chemokines and Aggrecanase-Induced NeoEpitopes
Wouter de Munter, Peter M. van der Kraan, Wim B. van den
Berg and Peter L. van Lent, Radboud university medical center,
Nijmegen, Netherlands
149
scientific sessions
Leonid Padyukov3, Terrance P. O’Hanlon4, Annette Lee22, Hector
Seldin7 and Lindsey A. Criswell1, 1University of California, San
Chinoy and Janine Lamb , Centre for Genetics and Genomics,
Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology
Arthritis Research UK, University of Manchester, Manchester,
Research Center, San Francisco, CA, 2Johns Hopkins University
United Kingdom, University of Liverpool, Liverpool, United
School of Medicine, Baltimore, MD, 3Feinstein Institute for
Kingdom, 3Rheumatology Unit, Karolinska University Hospital,
Medical Research, Manhasset, NY, 4Genentech, Inc., South
Solna, Karolinska Institutet, Stockholm, Sweden, Environmental
San Francisco, CA, 5Division of Rheumatology, University of
Autoimmunity Group, NIEHS, NIH, Bethesda, MD, The Feinstein
Pittsburgh School of Medicine, Pittsburgh, PA, 6University of
Institute for Medical Research, Manhasset, NY, Institute of
Pittsburgh, Pittsburgh, PA, 7University of California, Davis, Davis,
Rheumatology and Department of Rheumatology, 1st Faculty of
CA
1
14 1
2
4
5
6
Medicine, Charles University in Prague, Prague, Czech Republic,
7
9:45 am
UK Centre for Adolescent Rheumatology, University College
2956. Identification of Autoimmune Functional Variants Under
London, London, United Kingdom, 9Royal Adelaide Hospital,
Positive Selection in the Gullah African American Population of
University of Debrecen, Debrecan, Hungary, 8Arthritis Research
Adelaide, Australia, Vall d’Hebron General Hospital, Barcelona,
South Carolina
Spain, 11MRC Centre for Neuromuscular Diseases, UCL Institute
Paula S. Ramos1, Satria Sajuthi2, Jasmin Divers2, Yiqi Huang3, Uma
of Neurology, London, United Kingdom, 12Ann & Robert H. Lurie
Nayak3, Wei-Min Chen3, Kelly J. Hunt1, Diane L. Kamen1, Gary
Children’s Hospital of Chicago Research Center, Chicago, IL,
S. Gilkeson1, Jyotika K. Fernandes1, Ida J. Spruill1, W. Timothy
10
Mayo Clinic, Rochester, MN, Centre for Integrated Genomic
Garvey4, Michèle M. Sale3 and Carl D. Langefeld2, 1Medical
Medical Research, University of Manchester, Manchester, United
University of South Carolina, Charleston, SC, 2Wake Forest
Kingdom, Department of Rheumatology, Oslo University
School of Medicine, Winston-Salem, NC, 3University of Virginia,
Hospital Rikshospitalet, Oslo, Norway, 16Pitié-Salpêtrière
Charlottesville, VA, 4University of Alabama at Birmingham,
Hospital, APHP, Paris, France, Paediatric Department, Holbaek
Birmingham, AL
13
14
15
17
University Hospital, Holbaek, Denmark, 18University Medical
Center Utrecht, Utrecht, Netherlands, 19University of Padova,
10:00 am
Padova, Italy, 20University of Ghent, Ghent, Belgium, 21Division
2957. The Rheumatoid Arthritis -Risk Locus CCR6 and Its SNP-
of Rheumatology, University Hospital Zurich, Zurich, Switzerland,
Dependent Response to Estrogen: A Possible Genomic Link
Between Sex Hormones and the IL-17 Inflammatory Pathway
Feinstein Institute Med Rsch, Manhasset, NY
22
Ming-Fen Ho, Richard M. Weinshilboum, Liewei Wang and Tim
Bongartz, Mayo Clinic, Rochester, MN
9:15 am
2954. The Amino Acid Positions 11, 13 and 26 of HLADR Beta Chain 1 Explain the Majority of the Association
10:15 am
Between Systemic Lupus Erythematosus and the Major
2958. Polygenic Analysis of Transport, Metabolism and
Histocompatibility Complex Locus
Immune Related Genomic Compartments in Serum Urate and
Kwangwoo Kim , So-Young Bang , Hye-Soon Lee , Yukinori
Gout
Okada3, Woei-Yuh Saw4, Paul IW. de Bakker5, Yik-Ying Teo6,
Eli A. Stahl1, Tony R. Merriman2, Amanda Dobbyn3, David
Soumya Raychaudhuri and Sang-Cheol Bae , Brigham and
B. Mount4, Peter Kraft5 and Hyon Choi6, 1Mt Sinai School of
Women’s Hospital, Harvard Medical School, Boston, MA,
Medicine, New York City, NY, 2University of Otago, Dunedin, New
1
2
2
7
2 1
Hanyang University Hospital for Rheumatic Diseases, Seoul,
n o v e m b e r
1 9 ,
WEDNESDAY
2 0 1 4
2
Zealand, 3Icahn School of Medicine at Mount Sinai, New York,
South Korea, Broad Institute, Cambridge, MA, National
NY, 4Brigham and Women’s Hospital, Boston, MA, 5Program in
University of Singapore, Singapore, Singapore, University
Molecular and Genetic Epidemiology, Harvard School of Public
Medical Center Utrecht, Utrecht, Netherlands, 6Genome
Health, Boston, MA, 6Harvard Medical School, Boston, MA
3
4
5
Institute of Singapore, Agency for Science, Technology and
Research, Singapore, Singapore, 7Broad Institute of MIT and
104 B
PM
PS
Harvard, Cambridge, MA
Metabolic and Crystal Arthropathies II: Mechanisms
of Disease
9:30 am
Moderators: Nicola Dalbeth, MBChB, MD and Alexander So, MD
2955. The Impact of Northern European Ancestry and
9:00 am
Susceptibility Loci on the Risk of Lupus Nephritis
Sarah French1, Kimberly E. Taylor1, Sharon A. Chung1, Joanne
Nitiham1, Michelle Petri2, Peter K. Gregersen3, Ward Ortmann4,
Annette T. Lee , Timothy W. Behrens , Susan Manzi , F. Yesim
3
4
5
Demirci , M. Ilyas Kamboh , Robert R. Graham , Michael F.
6
150
2014 Program Book
6
4
2959. Twenty-Eight Loci That Influence Serum Urate Levels:
Analysis of Association with Gout
Tony R. Merriman1, Marilyn E. Merriman1, Ruth Topless1, Sara
Altaf1, Grant Montgomery2, Christopher Franklin3, Gregory T.
Jones1, Andre M. van Rij1, Douglas HN White4, Lisa K. Stamp5,
scientific sessions
Nicola Dalbeth3 and Amanda Phipps-Green1, 1University of
an der Technischen Universität Dresden, Dresden, Germany,
Otago, Dunedin, New Zealand, Queensland Institute of Medical
19
Research, Brisbane, Australia, University of Auckland, Auckland,
of Auckland, Auckland, New Zealand, 21Université Paris Diderot,
New Zealand, Waikato Clinical School, Waikato Hospital,
Paris, France, 22CHUV, Lausanne, Switzerland
2
3
4
University of Otago, Christchurch, New Zealand, 20University
Hamilton, New Zealand, 5University of Otago, Christchurch, New
Zealand
10:00 am
9:15 am
Acid Homeostasis and Its Activity May be Altered in Gout
2960. Urate Genetic Loci and the Risk of Incident Cases of
Patients and in Drug-Induced Hyperuricemia
Confirmed Gout in Two Prospective Cohort Studies
Philip K. Tan, Sha Liu and Jeffrey N. Miner, Ardea Biosciences,
Hyon K Choi1, Gary Curhan2, Ying Bao3, Eli A. Stahl4, Peter Kraft5,
Inc., San Diego, CA
2963. The URAT1 Uric Acid Transporter Is Important in Uric
Robert M. Plenge3, Yuqing Zhang1 and Tony R. Merriman6,
Boston University School of Medicine, Boston, MA, 2Harvard
10:15 am
Medical School, Boston, MA, Brigham and Women’s Hospital,
2964. Association Analysis of Apolipoprotein B and Very Low-
1
3
Boston, MA, 4Mt Sinai School of Medicine, New York City, NY,
Density Lipoprotein with Hyperuricemia and Gout
5
Program in Molecular and Genetic Epidemiology, Harvard
Humaira Rasheed1, Angela Hsu1, Nicola Dalbeth2, Lisa K. Stamp3,
School of Public Health, Boston, MA, 6University of Otago,
Sally McCormick1 and Tony R. Merriman1, 1University of Otago,
Dunedin, New Zealand
Dunedin, New Zealand, 2University of Auckland, Auckland, New
Zealand, 3University of Otago, Christchurch, New Zealand
9:30 am
2961. Conditional Analysis of 30 Serum Urate Loci Identifies 25
Additional Independent Effects
Eli Stahl , Hyon Choi , Murray Cadzow , Tanya Flynn , Ruth
1
2
3
3
Topless3 and Tony R. Merriman3, 1Mt Sinai School of Medicine,
New York City, NY, 2Harvard Medical School, Boston, MA,
University of Otago, Dunedin, New Zealand
PM
107 B
PS
Pain: Basic and Clinical Aspects II/Orthopedics, Low
PS
PM
Back Pain and Rehabilitation
Moderators: Yvonne C. Lee, MD, MMSc and M. Elaine Husni, MD,
MPH
3
9:00 am
2965. Effects of Anti-NGF Strategies in Two Animal Models of
9:45 am
2962. Association of the Toll-like Receptor 4 (TLR4) Gene with
Gout
Kannangara , Kenneth Williams , Linda Bradbury , Matthew
3
4
Brown5, Catherine Hill6, Susan Lester7, Maureen Rischmueller8,
Malcolm Smith6, Mariano Andrés9, Thomas Bardin10, Michael
Doherty11, Matthijs Janssen12, Tim Jansen13, Leo Joosten13,
Fernando Perez-Ruiz , Timothy Radstake , Philip L. Riches ,
14
15
16
Ed Roddy17, Anne-Kathrin Tausche18, Lisa K. Stamp19, Nicola
Dalbeth , Frederic Lioté , Alex So , Cushla McKinney and
20
21
22
1
South Wales, Sydney, Australia, 4The University of Queensland,
United Kingdom, 2Array BioPharma, Boulder, CO
9:15 am
2966. Genome-Wide Association Analysis of Pain Reduction in
Rheumatoid Arthritis Patients Treated with TNF Inhibitors
Marieke J.H. Coenen1, Maša Umicevic-Mirkov1, Sophine
B. Krintel2, Julia Johansen3, Corinne Miceli-Richard4, Henrik
Kallberg5, Hans Scheffer1, Wietske Kievit1, Mart A. van de
Laar6, Piet L.C.M. van Riel1, X. Mariette7, Saedis Saevarsdottir8,
Institute, Brisbane, Australia, 6Queen Elizabeth Hospital,
1
Adelaide, Australia, Queen Elizabeth Hospital, Woodville
2
7
South, Australia, 8The Queen Elizabeth Hospital, SA, Australia,
Hospital General Universitario de Alicante, Alicante, Spain,
9
Hôpital Lariboisière, Paris, France, City Hospital, Nottingham,
10
11
United Kingdom, 12Rijnstate Hospital, Arnhem, Netherlands,
Radboud University Medical Center, Nijmegen, Netherlands,
13
Hospital De Cruces, Baracaldo, Spain, 15University Medical
14
Center Utrecht, Utrecht, Netherlands, 16University of Edinburgh,
Edinburgh, United Kingdom, Keele University, Staffordshire,
17
Radboud university medical center, Nijmegen, Netherlands,
Copenhagen University Hospital at Glostrup, Glostrup,
2 0 1 4
Merete Lund Hetland9, Sita Vermeulen1 and Cornelis A. Albers1,
1 9 ,
Brisbane, Australia, 5University of Queensland Diamantina
WEDNESDAY
St. Vincent’s Hospital, Sydney, Australia, University of New
3
Research UK Pain Centre, University of Nottingham, Nottingham,
n o v e m b e r
Tony R. Merriman1, 1University of Otago, Dunedin, New Zealand,
2
Lilian Ngozi Nwosu1, Paul Mapp1, Karyn Bouhana2, Steven
Andrews2, Victoria Chapman1 and David Walsh1, 1Arthritis
Humaira Rasheed1, Ruth Topless1, Richard Day2, Diluk
3
Osteoarthritis (OA)
Denmark, 3University of Copenhagen, Frederiksberg, Denmark,
Université Paris-Sud 11, Bicêtre Hospital,, Kremlin Bicêtre,
4
France, 5Karolinska University Hospital, Karolinska Institutet,
Stockholm, Sweden, 6University Twente & Medisch Spectrum
Twente, Enschede, Netherlands, 7Paris-Sud University, Paris,
France, 8Karolinska University Hospital and Karolinska Institutet,
Stockholm, Sweden, 9DANBIO, Center for Rheumatology and
Spine Diseases, Glostrup Univ Hospital, Glostrup, Denmark
United Kingdom, 18Universitätsklinikum Carl Gustav Carus
2014 Program Book
151
scientific sessions
9:30 am
9:15 am
2967. Patient Reported Pain By the Paindetect Questionnaire
2972. Elevations of Certain Memory-Effector T Cell and
Reveals Multimodal Elements to Pain Perception in
Inflammatory Monocyte Subpopulations in Rheumatoid
Arthritis Are Associated with the Presence of Subclinical
Saqa Ahmed1, Tejal Magan1, Mario Vargas1, Abiola Harrison1 and
Coronary Artery Atherosclerosis
Nidhi Sofat , St George’s, University of London, London, United
Robert Winchester1, Jon T. Giles1, Simona Nativ2, Hui-Zhu Zhang1,
Kingdom, St. George’s University of London, London, United
Kendall Downer1 and Joan Bathon1, 1Columbia University, New
Kingdom
York, NY, 2Morristown Medical Center, Morristown, NJ
2 1
2
9:45 am
9:30 am
2968. Improvement Following Total Knee Replacement (TKR)
2973. The Multi-Biomarker Disease Activity Score As a
Surgery: Exploring Preoperative Symptoms and Change in
Predictor of Radiographic Progression in a Registry of Patients
Preoperative Symptoms
Ernest R. Vina , Michael J. Hannon and C. Kent Kwoh ,
Eric H. Sasso1, George Wu1, CC Hwang1, Michael E. Weinblatt2,
University of Pittsburgh and VA Healthcare System, Pittsburgh,
Nancy A. Shadick2, Claire Alexander1 and Oscar Segurado1,
1
2
3
1
PA, University of Pittsburgh School of Medicine, Pittsburgh, PA,
2
Crescendo Bioscience Inc., South San Francisco, CA, 2Brigham
1
and Women’s Hospital, Boston, MA
University of Arizona, Tucson, AZ
3
10:00 am
2969. Mortality after Knee Replacement Surgery for
9:45 am
Osteoarthritis in a Population-Based Propensity-Score Matched
2974. Multi-Biomarker Disease Activity Score Is Associated
Cohort
with Power Doppler Ultrasound in Patients with Rheumatoid
Devyani Misra , Tuhina Neogi , Na Lu , David T. Felson , Thomas
Arthritis in Low Disease Activity State
Einhorn1, Hyon Choi2, Jessica Maxwell3 and Yuqing Zhang1,
Margaret H. Ma1, Toby Garrood2, Wanying Li3, Nadine A.
Boston University School of Medicine, Boston, MA, Harvard
Defranoux3, Gabrielle H. Kingsley4, Andrew P. Cope5 and David L.
Medical School, Boston, MA, 3Boston University, Boston, MA
Scott6, 1King’s College Hospital, London, United Kingdom, 2Guy’s
1
1
1
1
1
2
and St. Thomas’ Foundation Hospital NHS Trust, London, United
10:15 am
Kingdom, 3Crescendo Bioscience Inc., South San Francisco, CA,
2970. Psoriatic Arthritis is Associated with Heterotopic
4
Kings College London, London, United Kingdom, 5King’s College
Ossification after Total Hip Arthroplasty
London, London, United Kingdom, 6King’s College London,
Mario Cedillo , Arielle Fein , Susan M. Goodman , Rebecca Zhu ,
1
2
2
2
Department of Rheumatology, London, United Kingdom
Mark P. Figgie2, Michael Alexiades2, Jayme C. Burket2 and Lisa A.
Mandl2, 1Weill Cornell Medical College, New York, NY, 2Hospital
10:00 am
for Special Surgery, New York, NY
2975. Residual Large Joint Synovitis By Power Doppler
258 B
PM
PS
Rheumatoid Arthritis – Clinical Aspects VII: New
Aspects of Monitoring Disease
n o v e m b e r
1 9 ,
WEDNESDAY
2 0 1 4
Moderators: Merete Lund Hetland, DMSc, MD, PhD and Barbara
Goldstein, MD, MMSc
9:00 am
2971. Patient’s Self-Monitoring Via Smartphone: The
Compass Study Correlation Between Patient Self-Assessment
of Rheumatoid Arthritis Disease Activity Via Smartphone
Technology and Physicians’ Validated Scores
Ruediger Mueller1, Ulrich Walker2, Diego Kyburz3, Robert Theiler4,
with Established Rheumatoid Arthritis
Yu Xiao Guo1, Manjari Lahiri2 and Peter Cheung2, 1Yong Loo Lin
School of Medicine, National University of Singapore, Singapore,
Singapore, 2Division of Rheumatology, National University
Hospital, Singapore, Singapore
10:15 am
2976. Lung Ultrasound Screening for Interstitial Lung Disease
in Rheumatoid Arthritis. Comparison with Usual Detection
Algorithms in Clinical Practice
Marco Antivalle, Michel Chevallard, Michele Battellino,
Adrian Forster5, Fabiana Ganz6 and Patrick Dufner6, 1Kantonspital
MariaChiara Ditto, Valentina Varisco, Federica Rigamonti,
St. Gallen, St. Gallen, Switzerland, 2Department of Rheumatology,
Alessandra Mutti, Fabiola Atzeni, Alberto Batticciotto and
Basel University, Basel, Switzerland, 3University Hospital, Basel,
Piercarlo Sarzi-Puttini, L. Sacco University Hospital, Milano, Italy
Switzerland, 4Triemli spital, Zurich, Switzerland, 5Spital Thurgau
AG, Diessenhofen, Switzerland, 6Abbvie AG, Baar, Switzerland
152
Ultrasonography Is Associated with Higher Disease Activity
and Significant Impact of Disease in Multi-Ethnic Asian Patients
2014 Program Book
scientific sessions
PS
PM
157 B
9:45 am
Sjögren’s Syndrome II: Insights Into Pathophysiology
2980. Genome-Wide DNA Methylation Analysis of CD19+ B
Cells in Primary Sjögren’s Syndrome
Gunnel Nordmark1, Juliana Imgenberg-Kreuz2, Jonas Carlsson
Moderators: Alan N. Baer, MD and Kathy L. Sivils, PhD
Almlöf2, Jessica Nordlund2, Roald Omdal3, Katrine B. Norheim3,
9:00 am
Maija-Leena Eloranta4, Lars Rönnblom4 and Johanna K. Sandling2,
2977. Distinct Serum Protein Signature and Novel Biomarkers
1
of primary Sjögren’s Syndrome Revealed by comprehensive
University, Uppsala, Sweden, 2Molecular Medicine and Science
High-Throughput Proteomic Analysis
for Life Laboratory, Department of Medical Sciences, Uppsala
Rheumatology, Department of Medical Sciences, Uppsala
University, Uppsala, Sweden, 3Clinical Immunology Unit,
Ayumi Nishikawa , Katsuya Suzuki , Yoshiaki Kassai , Yuumi
1
1
2
Gotou , Takahiro Miyazaki , Maiko Takiguchi , Masaru Takeshita ,
Department of Internal Medicine, Stavanger University Hospital,
Atsuko Murota1, Rimpei Morita5, Akihiko Yoshimura5 and
Stavanger, Norway, 4Department of Medical Sciences, SciLife Lab,
Tsutomu Takeuchi1, 1Keio University School of Medicine, Tokyo,
Rheumatology, Uppsala University, Uppsala, Sweden, Uppsala,
Japan, Takeda Pharmaceutical Company Limited, Kanagawa,
Sweden
3
2
4
1
2
Japan, 3Takeda Pharmaceutical Company Limited, Tokyo, Tokyo,
10:00 am
Japan, 4Takeda Pharmaceutical Company Limited, Tokyo, Japan,
5
2981. Prognostic Value of the Complex P2X7 Receptor-
School of Medicine, Tokyo, Japan
Inflammasome in Patients with Primary Sjögren’s Syndrome at
9:15 am
Chiara Baldini1, Eleonora Santini2, Chiara Rossi2, Francesca
2978. Characterization of the Sjögren’s Syndrome Intergenic
Sernissi1, Daniela Martini1, Alessia Gallo3, Valentina Donati2,
Non-Coding RNA 1 (SSINCR1)
Nicoletta Luciano1, Francesco Ferro1, Illias Alevizos3, Anna
Department of Microbiology and Immunology, Keio University
Lymphoma Risk
John A. Ice , He Li , Indra Adrianto , Mikhail G. Dozmorov , Astrid
Solini2 and Stefano Bombardieri2, 1Rheumatology Unit, Pisa,
Rasmussen , Graham B. Wiley , Jennifer A. Kelly , Kimberly
Italy, 2Rheumatology Unit, University of Pisa, Pisa, Italy, 3NIDCR,
1
1
1
1
1
1
1
Bethesda, MD
S. Hefner2, Donald U. Stone3, Raj Gopalakrishnan4, David M.
Lewis , Stephen Young , Michael D. Rohrer , Juan-Manuel Anaya ,
3
3
4
5
Swamy Venuturupalli6, Barbara M. Segal7, Nelson L. Rhodus4,
10:15 am
Lida Radfar3, Michael H. Weisman8, Judith A. James1, Courtney
2982. Identification of Whole Blood Gene Expression Signature
in Primary Sjögren’s Syndrome Associated Lymphoma
G. Montgomery1, R. Hal Scofield9, Patrick M. Gaffney1, Linda F.
Thompson , A. Darise Farris , Susan Kovats , Jonathan D. Wren ,
Shereen Al-Ali1, Simon Cockell2, Andrew Skelton3, Katherine
Kathy L. Sivils and Christopher J. Lessard , Oklahoma Medical
James2, Jessica Tarn2, David Young3, Bridget Griffiths4, Simon
Research Foundation, Oklahoma City, OK, Hefner Eye Care and
Bowman5, James Locke2 and Wan-Fai Ng2, 1University of Basrah,
Optical Center, Oklahoma City, OK, 3University of Oklahoma
Basrah, Iraq, 2Newcastle University, Newcastle upon Tyne,
Health Sciences Center, Oklahoma City, OK, University of
United Kingdom, 3Newcastle University, Newcastle Upon Tyne,
Minnesota, Minneapolis, MN, Center for Autoimmune Diseases
United Kingdom, 4Freeman Hospital, Newcastle Upon Tyne,
Research (CREA), Universidad del Rosario., Bogota, Colombia,
United Kingdom, 5University Hospital Birmingham, Birmingham,
1
10
1
3
1
1 1
2
4
5
Cedars-Sinai Medical Center, West Hollywood, CA, 7Hennepin
6
County Medical Center, Minneapolis, MN, Cedars-Sinai Medical
United Kingdom
8
Research Foun, Oklahoma City, OK
PM
PS
Spondyloarthropathies and Psoriatic Arthritis VI –
Imaging and Biomarkers
Collaborate in Driving the Systemic IFN Signature and Amplify
the Pathogenic Loop: Potential New Targets for Therapy in
Primary Sjögren’s Syndrome
Naomi I Maria1, Cornelia G. van Helden-Meeuwsen1, Eline C.
Steenwijk1, Arne S. IJpma2, Wouter Beumer1, Zana Brkic1, Virgil A.
Dalm1, Paul L. van Daele1, P. Martin van Hagen1, Peter J. van der
2 0 1 4
9:30 am
2979. Nucleic Acid Sensing Receptors TLR7, RIG-I and MDA5
1 9 ,
Moderators: Robert Inman, MD and Juergen Braun, MD
WEDNESDAY
Medical Center, Oklahoma City, OK, 10Oklahoma Medical
205 B
n o v e m b e r
Center, Los Angeles, CA, 9US Department of Veterans Affairs
9:00 am
2983. Infliximab Added to Naproxen Does Not Increase
Frequency of New Fatty Lesions on MRI of the Sacroiliac Joints
and of the Spine As Compared to Naproxen Alone in Early Axial
Spondyloarthritis
Denis Poddubnyy and Joachim Sieper, Charité
Universitätsmedizin Berlin, Berlin, Germany
Spek , Hemmo A. Drexhage and Marjan A. Versnel , Erasmus
2
1
1 1
Medical Center, Immunology, Rotterdam, Netherlands, 2Erasmus
Medical Center, Bioinformatics, Rotterdam, Netherlands
2014 Program Book
153
scientific sessions
9:15 am
Germany, 3Department of Pathology Ghent University Hospital,
2984. Degenerative Changes of the Spine on MRI in Patients
Ghent, Belgium, 4University Children’s Hospital Muenster,
with Inflammatory Back Pain
Muenster, Germany
F. de Bruin1, Marc Olivier Treyvaud2, Antoine Feydy2, Maxime
Dougados3, Laure Gossec4, J.L Bloem1, Désirée van der Heijde1
and Monique Reijnierse , Leiden University Medical Center,
1 1
Leiden, Netherlands, 2Paris Descartes University, Radiology B
department, Cochin Hospital, Paris, France, 3Descartes University,
Cochin Hospital, Paris, France, 4UPMC Paris 06 University, GRC
08, Paris France and Pitié Salpétrière Hospital Paris France, Paris,
France
2985. Autoantibodies to 14-3-3η Are Novel Biomarkers
Associated with Inflammation and Radiographic Progression in
Joel A. Block1 and Meenakshi Jolly1, 1Rush University Medical
Center, Chicago, IL, 2Department of internal medicine and
Murphy and Anthony Marotta , University of Alberta,
9:15 am
BC
2990. Risk Factors for Posterior Reversible Encephalopathy
9:45 am
Center Study
Syndrome in Systemic Lupus Erythematosus Patients: A Single
2986. Fat Metaplasia on MRI of the Sacroiliac Joints Is a Lead
Javier Merayo-Chalico1, Elia Apodaca2, Ana Barrera-Vargas1,
Indicator of Radiographic Progression in the Spine of Patients
Jorge Alcocer-Varela1 and Diana Gómez-Martín1, 1Instituto
with Ankylosing Spondylitis
Nacional de Ciencias Médicas y Nutrición Salvador Zubirán,
Mexico City, Mexico, 2Instituto Nacional de Ciencias Médicas y
WP Maksymowych , S Wichuk , P Chiowchanwisawakit , RG
1
1
2
Lambert1 and Sj Pedersen3, 1University of Alberta, Edmonton, AB,
Mahidol University, Bangkok, Thailand, Copenhagen Center for
2
Nutrición, Mexico City, Mexico
3
Arthritis Research, Copenhagen, Denmark
9:30 am
2991. Anti-Ribosomal P Antibody Is a Key Autoantibody
Associated with Complications of NP-SLE with High-Levels of
10:00 am
CSF IL-8
2987. Value of Color Doppler Ultrasound Assessment of
Sacroiliac Joints in Patients with Inflammatory Chronic Low
Hidenaga Kawasumi1, Takahisa Gono1, Yasushi Kawaguchi1,
Back Pain
Yasuhiro Katsumata1, Hisae Ichida1, Akiko Tochimoto1, Masanori
Maximiliano Bravo1, Leandro Ferreyra Garrott1, David A. Navarta1,
Hanaoka1, Yuko Okamoto1, Sayuri Kataoka1 and Hisashi
Emmanuel Bertiller , Ricardo Garcia-Monaco , Santiago Ruta ,
Yamanaka2, 1Tokyo Women’s Medical University, Tokyo, Japan,
Javier Rosa3 and Enrique Soriano1, 1Rheumatology Unit, Internal
2
1
2
1
Medical Services, Hospital Italiano de Buenos Aires, Buenos
2 0 1 4
systemic diseases, Dijon, France
2 1
Edmonton, AB, 2Augurex Life Sciences Corp., North Vancouver,
1 9 ,
9:00 am
Disease Activity in Lupus
2
WEDNESDAY
Moderators: Dafna D. Gladman, MD and Stacy P. Ardoin, MD, MS
David Giangreco1, Hervé Devilliers2, Narender Annapureddy1,
WP Maksymowych1, Stephanie Wichuk1, RG Lambert1, Mairead
n o v e m b e r
PS
PM
Systemic
Lupus
Erythematosus – Clinical Aspects and
Treatment: Central Nervous System and Other Clinical
Aspects
2989. Lupus Impact Tracker Is Responsive to Changes in
9:30 am
Aires, Argentina, 2Radiology and Imagenology Department,
Hospital italiano de Buenos Aires, Buenos Aires, Argentina,
Institute of Rheumatology, Tokyo Women’s Medical University,
Tokyo, Japan
9:45 am
3
2992. Usefulness of Diagnostic Biomarker for Neuropsychiatric
de Buenos Aires, Buenos Aires, Argentina
Systemic Lupus Erythematosus By Anti-Microtubule Associated
10:15 am
Yusuke Yamada, Department of Internal Medicine and
Rheumatology Unit, Internal Medicine Service, Hospital Italiano
2988. Calgranulin Levels Are Elevated in Spondyloarthritis and
Reflect the Presence of Acute Microscopic Gut Inflammation
Heleen Cypers1, Gaëlle Varkas1, Liesbet Van Praet1, Johannes
Roth2, Thomas Vogl2, Claude Cuvelier3, Dirk Föll4, Miha
Lavric4, Filip van Den Bosch1 and Dirk Elewaut1, 1Department
of Rheumatology Ghent University Hospital, Ghent, Belgium,
Institute of Immunology University of Muenster, Muenster,
2
154
52 A
2014 Program Book
Protein 2 Antibody in Cerebrospinal Fluid
Rheumatology, Juntendo University Faculty of Medicine, Tokyo,
Japan
10:00 am
2993. MRI in Neuropsychiatric Lupus: Correlations with the
1999 ACR Case Definitions
Minyoung Her1, Dongyook Kim1, Na young Park1, Seong-Kyu Kim2,
Lee Sung Won3 and Lee sang Yeob3, 1Inje University, Pusan
scientific sessions
Paik Hospital, Busan, South Korea, Busan, South Korea, 2Catholic
9:45 am
University of Daegu, Daegu, South Korea, Daegu, South Korea,
2998. Screening for Interstitial Lung Disease in Systemic
Dong-A university, Busan, South Korea, Pusan, South Korea
3
Sclerosis: Performance of High-Resolution Computed
Tomography with Limited Number of Slices – a Prospective
10:15 am
Study
2994. WITHDRAWN
Thomas Frauenfelder1, Anna Winklehner1, Thi Dan Linh Nguyen1,
Rucsandra Dobrota2, Stephan Baumüller1, Britta Maurer3 and
Oliver Distler3, 1Institute of Diagnostic and Interventional
151 A
PM
Raynaud’s
–PSClinical Aspects and Therapeutics III:
Updates in Predictors and Outcomes in Systemic
Sclerosis
Radiology, University Hospital Zurich, Zurich, Switzerland,
Department of Internal Medicine and Rheumatology,
2
Dr.I.Cantacuzino Hospital, Carol Davila University of Medicine
and Pharmacy, Bucharest, Romania, 3Division of Rheumatology,
University Hospital Zurich, Zurich, Switzerland
Moderators: Laura K. Hummers, MD, ScM and Sindu R. Johnson,
MD, PhD
10:00 am
2999. Development of a Composite Index for Clinical Trials in
9:00 am
2995. Surrogate Measures of Extent of Interstitial Lung Disease
As Measured By Quantitative Radiographic Analysis in Patients
with Systemic Sclerosis
Elizabeth Volkmann , Donald Tashkin , Chi-hong Tseng , Kim
1
2
1
Hyun1, Jonathan Goldin1, Philip J. Clements3, Daniel E. Furst1,
Dinesh Khanna4, Eric Kleerup1, Michael Roth1 and Robert
Elashoff , University of California, Los Angeles, David Geffen
5 1
School of Medicine, Los Angeles, CA, University of California
2
at Los Angeles, Los Angeles, CA, 3University of California, Los
Angeles, Department of Medicine, Los Angeles, CA, 4University
of Michigan Health System, Ann Arbor, MI, University of
5
California, Los Angeles, Los Angeles, CA
Early Diffuse Cutaneous Systemic sclerosis—the Combined
Response Index in Systemic Sclerosis
Dinesh Khanna1, Veronica Berrocal2, Edward Giannini3, Maureen
Mayes4, Peter A. Merkel5, Jeffrey Siegel6, James R. Seibold7,
Murray Baron8, Philip J. Clements9, Yannick Allanore10, Virginia
D. Steen11, Christopher P. Denton12, Oliver Distler13, Sindhu
R. Johnson14, Marco Matucci-Cerinic15, Lazlo Czirjak16, Janet
E. Pope17, Susanna Proudman18, Weng Kee Wong19, Athol U.
Wells20 and Daniel E. Furst9, 1University of Michigan Scleroderma
Program, Ann Arbor, MI, 2University of Michigan, Ann Arbor, MI,
Childrens Hosp Med Ctr, Cincinnati, OH, 4University of TX Health
3
Science Center -Houston, Houston, TX, 5Boston University School
of Medicine, Boston, MA, 6Genentech, South San Francisco, CA,
Scleroderma Research Consultants LLC, Avon, CT, 8Lady David
7
9:15 am
2996. Intestinal Pseudo-Obstruction in Patients with Systemic
Sclerosis: An Analysis of the Nationwide Inpatient Sample
Antonia Valenzuela1, Shufeng Li1, Laren Becker1, Nielsen
Fernandez-Becker1, Dinesh Khanna2, Linda Nguyen1 and Lorinda
Chung , Stanford University School of Medicine, Palo Alto, CA,
1 1
University of Michigan Health System, Ann Arbor, MI
2
Institute for Medical Research and Jewish General Hospital,
Montreal, QC, 9University of California, Los Angeles, Department
of Medicine, Los Angeles, CA, 10Department of Rheumatology,
University Paris Descartes and Cochin Hospital, Paris, France,
Georgetown University Medical Center, Washington, DC, 12UCL
11
Medical School Royal Free Campus, London, United Kingdom,
University Hospital Zurich, Zurich, Switzerland, 14Division of
13
Rheumatology, Toronto Western Hospital, University Health
Mortality Risk Stratification Tool for Early Diffuse Systemic
4
5
Denton and Thomas A. Medsger Jr. , University of Pittsburgh,
6
1 1
Pittsburgh, PA, 2Royal Free and University College Medical
School, London, United Kingdom, 3University of Pittsburgh,
of Pécs, Pécs, Hungary, 17Western University, London, ON,
Royal Adelaide Hospital, Adelaide, Australia, 19UCLA Fielding
18
School of Public Health, Los Angeles, CA, 20Department of
Radiology, London, United Kingdom
10:15 am
Graduate School of Public Health, Pittsburgh, PA, 4University of
3000. Comparison of Systemic Sclerosis Subsets As Predictors
Pittsburgh and Center for Health Equity Research and Promotion,
of Mortality and Morbidity
VA Pittsburgh Healthcare, Pittsburgh, PA, 5The University of
Hebah Alhajeri1, Marie Hudson1, Canadian Scleroderma
Arizona Arthritis Center, Tucson, AZ, 6Centre for Rheumatology,
Royal Free and University College Medical School, London,
United Kingdom
2 0 1 4
R. Wisniewski , Michael J. Fine , C. Kent Kwoh , Christopher P.
3
Hospital, Mount Sinai Hospital and University of Toronto,
Toronto, ON, 15University of Florence, Florence, Italy, 16University
1 9 ,
Sclerosis Patients
Robyn T. Domsic1, Svetlana I. Nihtyanova2, Mary Lucas1, Stephen
Network Pulmonary Hypertension Programme, Toronto General
WEDNESDAY
2997. Development and External Validation of a Five-Year
n o v e m b e r
9:30 am
Research Group CSRG1 and Murray Baron2, 1McGill University,
Montreal, QC, 2Lady David Institute for Medical Research and
Jewish General Hospital, Montreal, QC
2014 Program Book
155
scientific sessions
156 B
PM
8-Isoprostane Inhibits the Pro-Angiogenic Effect of Vascular
Moderators: Sandeep K. Agarwal, MD, PhD and Romy
Christmann, MD, PhD
Pei-Suen Tsou1, George Zakhem2, Beatrix Balogh2, M. Asif Amin3,
9:00 am
3001. Targeting IL-6 By Both Passive or Active Immunization
Strategies Prevents Inflammation-Driven Skin Fibrosis
Jerome Avouac1, Lucille Desallais2, Maxime Fréchet3, Muriel
Elhai3, Jean François Zagury2 and Yannick Allanore1, 1Paris
Descartes University, Rheumatology A Department and
INSERM U1016, Cochin Hospital, Paris, France, 2Chaire de
Bioinformatique, Laboratoire Génomique, Bioinformatique
et Applications, EA 4627, Conservatoire National des Arts et
Métiers, Paris, France, 3INSERM U1016, Cochin Institute, Paris,
France
n o v e m b e r
1 9 ,
WEDNESDAY
2 0 1 4
9:15 am
3002. Anti-Fibrotic Effects of a Newly Discovered HGF Receptor
Carboxy-Terminal Fragment in Systemic Sclerosis
Yuichiro Shirai1, Ilia Atanelishvili2, Tanjina Akter1, Richard
Silver3 and Galina Bogatkevich1, 1Medical University of South
Carolina, Charleston, SC, 2Medical University of South Carolina,
Charleston,USA, Charleston, SC, 3Medical University of South
Carolina, Charleston, SC
3006. Activation of the Thromboxane A2 Receptor By
Endothelial Growth Factor in Scleroderma
Phillip Campbell3, Gautam Edhayan3, Ray A. Ohara3, Elena
Schiopu3, Dinesh Khanna1, Alisa E. Koch4 and David A. Fox3,
University of Michigan Scleroderma Program, Ann Arbor, MI,
1
University of Michigan Medical School, Ann Arbor, MI, 3Division
2
of Rheumatology, University of Michigan Medical Center, Ann
Arbor, MI, 4Department of Veteran’s Affairs and University of
Michigan, Ann Arbor, MI
ARHP SESSIONS
9:00 – 10:30 am
256
PM
PS
Exercise Adherence in Arthritis: The Role of
Technology
Moderator: Jennifer M. Hootman, PhD
• identify established barriers to/risk factors of poor exercise
adherence
• discuss the prevalence of aerobic and strength exercise in
arthritis
9:30 am
3003. Am80 Ameliorates Bleomycin-Induced Dermal Fibrosis
By Suppressing the Pro-Fibrotic Phenotype of Fibroblasts,
Endothelial Cells and Immune Cells
Tetsuo Toyama1, Yoshihide Asano1, Takehiro Takahashi1, Ryosuke
Saigusa1, Yohei Ichimura1, Takashi Taniguchi1, Shinji Noda1,
Kaname Akamata1, Shinichi Sato1, Takafumi Kadono1 and Koichi
Shudo2, 1University of Tokyo Graduate School of Medicine, Tokyo,
Japan, 2Reseach Foundation ITSUU Laboratory, Tokyo, Japan
• review the measurement of activity adherence and challenges
9:45 am
3004. Autoantibody-Mediated Raynaud’s Phenomenon:
Animal Model and Human Disease
Dana P. Ascherman1, Yunjuan Zang2, Laisel Martinez1, Judith
Pignac-Kobinger2, Irina Fernandez2 and Eric L. Greidinger2,
1
Miami VAMC, Miami, FL, 2University of Miami, Miami, FL
10:00 am
3005. Essential Role for Alternately Spliced Tenascin C and TLR4
Signaling in Persistent Organ Fibrosis
Swati Bhattacharyya1, Wenxia Wang1, Luisa Morales-Nebreda1,
Katja Lakota1, Robert Lafyatis2, Monique E. Hinchcliff1, GR Scott
Budinger1, Zenshiro Tamaki1 and John Varga3, 1Northwestern
University, Feinberg School of Medicine, Chicago, IL, 2Boston
University School of Medicine, Boston, MA, 3Northwestern
9:30 am
University Feinberg School of Medicine, Chicago, IL
156
10:15 am
PS
Raynaud’s – Pathogenesis, Animal Models and
Genetics II
2014 Program Book
and opportunities in the field
• describe the innovative use of technology to promote
adherence and the evidence to support it
9:00 am
Barriers to Exercise Adherence: Challenges and Opportunities
to Foster Adherence
Julie J. Keysor, PhD, PT
Exercise Adherence in Arthritis: Can We Improve It with
Technology?
Kristin Baker, PhD
10:00 am
Environmental Barriers to Physical Activity in Arthritis
Molly Vaughn, PhD
scientific sessions
PS
PM
255
Francisco Rodríguez-Salvanés1, Lorena Vega1, Santos Castañeda1
Nothing About Us without Us: Engaging Patients in
Rheumatology Research PM PS
and Javier P Gisbert3, 1Hospital Universitario de La Princesa,
Moderator: Janet L. Poole, OTR, PhD
Díaz, Madrid, Spain, 3Hospital Universitario de La Princesa. IIS La
• evaluate and apply best practices for engaging patients in the
research process, from the investigator perspective, including
specific examples of successes and challenges
• describe the patient experience as a member of the research
team
• review the funding agency perspective regarding expectations
and best practices for patient engagement on the research
team
IISP, Madrid, Spain, 2Hospital Universitario Fundación Jiménez
Princesa, Madrid, Spain
9:30 AM
3009. Stem Cell Augmentation for Cardiovascular Risk in
Nidhi Garg1, Ashit Syngle2 and Pawan Krishan1, 1Punjabi
University Patiala, India, Patiala, India, 2Healing Touch City Clinic,
Fortis Multispeciality Hospital, Chandigarh, India
9:45 am
9:00 am
Patient Engagement from the Researcher Perspective
Monique A. Gignac, PhD
3010. The Development and Evaluation of a Self-Monitoring
and Patient-Initiated Follow-up Service for People with
Rheumatoid or Psoriatic Arthritis on Methotrexate
Hayley McBain1, Michael Shipley2, Abigail Olaleye2, Samantha
9:25 am
The Patient Experience: A Research Team Member
Amye L. Leong, MBA
Moore3, Shashi Hirani4 and Stanton Newman4, 1East London
Foundation Trust, London, United Kingdom, 2University College
Hospital London, London, United Kingdom, 3University College
London, London, United Kingdom, 4City University London,
9:50 am
Funding Agency Perspective on Patient Engagement
Suzanne Schrandt, JD
10:00 am
3011. Ambulatory Gait Analysis in Clinical Practice: Single or
10:15 am
Dual Task Conditions?
Panel Discussion
Bernard Auvinet1, Claude Touzard2 and Vincent Goëb3, 1Polyclinic,
ARHP CONCURRENT ABSTRACT SESSIONS
LAVAL, France, 2Hospital of Laval, LAVAL, France, 3Amiens
University Hospital, Amiens, France
9:00 – 10:30 AM
PM
PS
257 A
Clinical Practice/Patient Care
Moderator: Marian T. Hannan, DSc, MPH
9:00 am
Daniel White1, Tuhina Neogi2, W. Jack Rejeski3, Michael Walkup3,
Cora E. Lewis4, Michael Nevitt5, Capri Foy3 and David T. Felson2,
Winston-Salem, NC, 4The University of Alabama at Birmingham,
Birmingham, AL, 5UCSF, San Francisco, CA
9:15 am
3008. High Prevalence of Subclinical Ultrasonographic
Enthesopathy and Synovitis in Patients with Inflammatory
Bowel Disease without Clinical Signs or Symptoms of
Spondyloarthritis
Tel-Aviv Medical Center, Sackler Faculty of Medicine, Tel-Aviv
2
University, Tel-Aviv, Israel
PM
PS
259 A
Innovations in Rheumatologic Care
PM
Ed
Pd
PS
PrM
Moderators: Carol M. Greco, PhD and Elizabeth M. Badley, PhD
FIT
2 0 1 4
School of Medicine, Boston, MA, 3Wake Forest University,
N. Ablin1, 1Tel Aviv Sourasky Medical Center, Tel Aviv, Israel,
1 9 ,
Boston Univ School of Med, Boston, MA, 2Boston University
1
Dysfunction Among Patients at a Tertiary Rheumatology Clinic
Sharon Nesher Peleg1, Ori Elkayam2, Bruria Yahini1 and Jacob
WEDNESDAY
Among Those at High Risk?
3012. Needs Assessment Survey – Evaluation of Sexual
n o v e m b e r
3007. Can Knee Pain be Prevented through Diet and Exercise
10:15 am
9:00 am
3013. The Reserve Capacity Model in Patients with
Rheumatoid Arthritis: Understanding the Relationship of
Socioeconomic Status, Psychosocial Resources, Mood and Pain
Desiree Azizoddin1, Taylor Draper1, Sarah Ormseth1, Perry
M. Nicassio1, Michael R. Irwin1, Michael Weisman2 and Hilary
Wilson1, 1University of California, Los Angeles, Los Angeles, CA,
Cedars-Sinai Medical Center, Los Angeles, CA
2
Esther Vicente1, Silvia Pérez-Esteban2, María Chaparro1,
2014 Program Book
157
scientific sessions
9:15 am
Reade, Amsterdam, the Netherlands, Amsterdam, Netherlands,
3014. Does the Order or Amount of Risk-Benefit Information
3
Presented Influence patients’ Perceived Value of a Proposed
4
New Medication?
of Southern Denmark, Odense, Denmark, 6University of Lorraine,
Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands,
Glasgow Caledonian University, Glasgow, Scotland, 5University
Liana Fraenkel1, Richard Street2, Harjinder Chowdhary3, Sarah
Nancy, France, 7INSERM, Centre d’Investigation Clinique –
Swift and Ellen Peters , Yale University School of Medicine,
Epidémiologie Clinique (CIC-EC) CIE6, Nancy, France, 8Istituto
Veterans Affairs Connecticut Healthcare Systems, New Haven, CT,
Ortopedico Rizzoli, Bologna, Italy, 9Basurto University Hospital,
3
4 1
Bilbao, Spain, 10Diakonhjemmet Hospital, Oslo, Norway
Texas A&M University, College Station, TX, Yale University, New
2
3
Haven, CT, 4Ohio State University, Columbus, OH
ACR SESSION
9:30 am
11:00 am – Noon
3015. Evaluation of the effuc Educational Needs Assessment
PM
Tool (ENAT) Focused Patient Education on Health Outcomes in
Patients with Rheumatoid Arthritis – a Randomised Controlled
PS
Exhibit Hall C
Inflammation and Atherothrombosis
Trial
Moderators: Swamy Venuturupalli, MD and Anne Bass, MD
Adewale O. Adebajo1, Dawn Johnson2, Hardware Bernadette3,
Speaker: Paul M. Ridker, MD, MPH
Claire Hale4 and Mwidimi Ndosi4, 1University of Sheffield,
Sheffield, United Kingdom, 2Barnsley Hospital NHS Foundation
• discuss the immune mechanisms responsible for
Trust, Barnsley, United Kingdom, Barnsley Hospital NHS
3
atherothrombosis
Foundation Trust, Baarnsley, United Kingdom, 4University of
Leeds, Leeds, United Kingdom
• explain the use of statins to prevent venous thromboembolic
9:45 am
• r eview the recent AHA/ACC guidelines for statin
events
3016. Measuring the Impact of an Early RA Support and
Education Program Using a Program Evaluation with Patient
ACR SESSIONS
Identified Outcomes
11:00 am – 12:30 pm
Adena Batterman1, Kathryn Klingenstein1, Roberta Horton1, Linda
Leff1, Theodore R. Fields2 and Vivian P. Bykerk1, 1Hospital for
Special Surgery, New York, NY, 2Hospital for Special Surgery Weill
Cornell Medical College, New York, NY
• review the role of proteomics-based profiling in rheumatic
Clinical Service for Patients with Hip or Knee Osteoarthritis
J. Haxby Abbott , Helen Harcombe , Chris Crane , Liam Hutton ,
1
1
2
2
Kirsten Stout , Cathy Chapple and David Gwynne-Jones ,
2
1
1
University of Otago, Dunedin, New Zealand, 2Southern District
1
2 0 1 4
Health Board, Dunedin, New Zealand
1 9 ,
WEDNESDAY
Advances in Molecular Profiling and Relevance to
Autoimmune Disease
3017. Program Evaluation of ‘the Joint Clinic’: An Innovative
n o v e m b e r
PS
Moderator: Dana P. Ascherman, MD
10:00 am
10:15 am
3018. Testing of a Newly Developed Computerized Animated
Activity Questionnaire for Assessing Activity Limitations in
Patients with Hip and Knee Osteoarthritis.
Wilfred FH Peter1, Mick Loos1, Henrica de Vet1, Maarten Boers1,
Jaap Harlaar1, Leo D. Roorda2, Rudolf Poolman3, Vanessa
Scholtes3, Jan Bogaard1, Hilda Buitelaar1, Martijn P.M. Steultjens4,
Ewa M. Roos5, Anne-Christine Rat6, Francis Guillemin7, Maria
158
PM
52 A
disease with respect to biomarker development, delineation
of pathogenesis
• describe metabolomics and its relationship to human
autoimmune/rheumatic disease
• a cknowledge differences between metabolomics and
proteomics
• d emonstrate the utility versus limitations of molecular
profiling
11:00 am
Proteomics – Composite Signaling Molecule Profiles
William H. Robinson, MD, PhD
11:30 am
Grazia Benedetti8, Antonio Escobar Martinez9, Nina Østerås10 and
Proteomics 2 – Assessment of Post-Translationally Modified
Caroline Terwee1, 1VU University Medical Center, Amsterdam,
Target Molecules
Netherlands, 2Amsterdam Rehabilitation Research Center |
Paul Eggleton, PhD
2014 Program Book
scientific sessions
Noon
11:00 am
Metabolomics – Relevance to Autoimmune Disease
Accommodations Work: Evidence for People with Arthritis
Stephen Young, BSc, PhD
Linda C. Batiste, JD
PM
Ballroom East
PS
Non-Radiographic Axial Spondyloarthritis: The
Controversy of Diagnosis and Optimal Treatment
Moderators: Alan N. Baer, MD and Grant H. Louie, MD, MHS
11:30 am
Overview of Arthritis-Attributable Work Limitation in U.S.
Adults
Kristina A. Theis, MPH
Noon
• describe the concept of non-radiographic axial
The Meaning and Importance of Work
spondyloarthritis
Nancy A. Baker, MPH, OTR, OTR/L
• explain the natural history of non-radiographic axial
spondyloarthritis
• discuss differential treatment response in non-radiographic
axial spondyloarthritis and ankylosing spondylitis
11:00 am
Non-Radiographic Axial Spondyloarthritis: A Primer
Michael M. Ward, MD
INDUSTRY-SUPPORTED POST MEETING
SYMPOSIA
1:00 – 4:00 pm
For CME-accredited symposia, the sponsoring organization
is responsible for planning and providing CME credit. Please
visit the organization’s exhibit booth, the industry-supported
symposia booth or see page 239 for more information.
11:30 am
Does Non-Radiographic Axial Spondyloarthritis Represent PreRadiographic Axial Spondyloarthritis?
Maxime Dougados, MD, PhD
Noon
Are Treatment Responses in Non-Radiographic Axial
Spondyloarthritis Similar Axial Spondyloarthritis?
Jürgen Braun, MD
ARHP SESSION
11:00 am – 12:30 pm
PM
255
PS
Work and Worker Health: Easy Accommodations
Keep People with Arthritis Employed
Moderator: Julie J. Keysor, PhD, PT
WEDNESDAY
n o v e m b e r
• describe the prevalence and impact of arthritis-attributable
work limitations in U.S. adults
1 9 ,
• discuss justification for the importance of working for people
with arthritis’ health and well-being
2 0 1 4
• share information with participants on the Job
Accommodation Network and how this resource can be used
to facilitate workers remaining in the workforce
• explain necessary steps for disclosing and/or requesting legally
protected accommodations
2014 Program Book
159
ACR POSTER INDICES
SUNDAY, NOVEMBER 16, 2014
16.
Differential Assay Reactivity of IgA Anti-B2glycoprotein
I Antibodies: Implications for Clinical Interpretation of
Antiphospholipid Antibody Testing
17.
Antiphospholipid Syndrome Following Infection: A
Systematic Review of Case Reports
18.
The Effect of Clinically Significant Antiphospholipid
Antibody Positivity on Organ Damage in Systemic Lupus
Erythematosus
Antiphospholipid Syndrome
1.
Lymphocyte Proliferation to a Cross-Reactive Gut
Commensal Candidate in Antiphospholipid Syndrome
2.
Thrombocytopenia in Primary Antiphospholipid Syndrome
Is Related to Arterial Thrombosis
3.
Is There an Association Between Persistently High Positive
Antiphospholipid Antibody Profile and Organ Damage
Accrual in Lupus Patients?
4.
Detection of Anti-Beta2glycoprotein I Domain 1
Antibodies By an Automated Chemiluminescence Assay
in a Cohort of 400 Clinically Characterized Consecutive
Routine Samples
Antiphospholipid-Associated Nephropathy Is a Risk for
Developing Arterial Thromboses in Patients with Systemic
Lupus Erythematosus
5.
Performance Evaluation and Clinical Associations of
the Aphl ELISA Compared to Criteria Antiphospholipid
Immunoassays in Lupus Patients
6.
Beneficial Effects of in Vivo Ubiquinol Supplementation
on Athero-Thrombosis Prevention in Antiphospholipid
Syndrome Patients
7.
8.
Safety and Efficacy of New Oral Direct Inhibitors of
Thrombin and Factor Xa in Antiphospholipid Syndrome
9.
A Risk-Stratified Perioperative Management Strategy for
Antiphospholipid Antibody Positive Patients Undergoing
Kidney Transplantation
10.
11.
12.
160
Antiphospholipid Antibodies and Neuropsychiatric Events
in Pediatric Patients
Sustained Moderate Intensity Levels of Oral Anticoagulant
Therapy and the Rate of Recurrent Thrombosis in Patients
with Primary Antiphospholipid Syndrome
Non-Criteria Antiphospholipid Antibodies in Obstetrical
“seronegative Anti-Phospholipid syndrome”
Biology and Pathology of Bone and Joint: Osteoclasts, Osteoblasts
and Bone Remodeling
19.
Adenosine Receptors Stimulate Bone Regeneration
20.
High Systemic LDL Cholesterol Levels during Experimental
Osteoarthritis Lead to Increased Synovial Activation and
Ectopic Bone Formation at End-Stage Osteoarthritis,
While Excessive Levels Accelerate Development of Joint
Pathology Already at Early-Stage O
21.
Mendelian Randomization Analysis to Examine for Causal
Relationships Between Serum Urate Levels and Bone
Mineral Density
22.
Adenosine a2A Receptor (A2AR) Stimulation Inhibits
Osteoclast Differentiation and Promotes Osteoblast
Formation By Regulation of Axon Guidance Proteins
23.
Activation of EPAC1/2 Is Essential for Osteoclast
Formation By Modulating NFkB Nuclear Translocation and
Actin Cytoskeleton Rearrangements
24.
Netrin1 Is Highly Expressed and Required in Inflammatory
Infiltrates in Wear Particle-Induced Osteolysis
25.
DC-STAMP Modulates Osteoblast Differentiation and
Regulates Bone Repair
26.
Functional Osteoclasts Differentiate Spontaneously from
the Rheumatoid Joint
27.
CD115+ Osteoclast Precursors Arise before Clinical Onset
of Arthritis and Are Regulated By Proinflammatory
Cytokines
28.
Evidence for Receptor Activator of NF-Kb (RANK)Independent Bone Erosion in the Cherubism Mouse
Model of Inflammatory Arthritis
13.
Eculizumab in Antiphospholipid Antibody Syndrome
14.
Rivaroxaban Use in Patients with Antiphospholipid
Syndrome Patients and Previous Poor Anticoagulation
Control with Vitamin K Antagonists
29.
Impaired Bone Healing in Patients Suffering from
Rheumatoid Arthritis - Anti-Inflammatory Therapy As
Confounder
15.
Performance of an Automated Chemiluminescence
Assay for Anti-Cardiolipin and Anti-Beta2glycoprotein
I Antibodies Detection in a Cohort of 400 Clinically
Characterized Consecutive Routine Samples
30.
Inhibiting Autocrine Interleukin-6 (IL-6) Trans-Signalling
in Human CD14+VE Monocultures Reduces Osteoclast
Differentiation
2014 Program Book
ACR POSTER INDICES
31.
Interaction of FGF-8 and TNF-a in the Regulation of BMPInduced Osteoblast Differentiation
46.
Xanthine Oxidase Inhibitors and Risk of Type 2 Diabetes in
Patients with Gout
32.
Regulation of Senescence and Inflammatory Mediators By
N- and C-Terminal Parathyroid Hormone-Related Protein
in Osteoarthritic Human Osteoblasts
47.
The Risk of Aplastic Anemia and Pancytopenia with
Colchicine: A Retrospective Study of Integrated Health
System Database
33.
Stimulation of the Adenosine a2A receptor (A2AR)
Regulates the Expression of Netrin1 and Their Receptors
(Unc5b, DCC) and Inhibits Osteoclast Differentiation and
Inflammatory Bone Destruction
48.
Osteoporotic Women at High Risk for Fractures Despite
Two Years of Oral Bisphosphonate Therapy: Analysis Using
the Canadian Multicentre Osteoporosis Study
49.
34.
Pro-Nerve Growth Factor (ProNGF) Stimulates Bone
Growth By Stimulating Osteoblasts and Inhibiting
Osteoclast Differentiation, an Explanation for Anti-NGFMediated Osteonecrosis; Prongf Is a Novel Therapeutic
Target for Treatment of Osteonecrosis and Charc
Long-Term Oral Bisphosphonate Use for Osteoporosis
Among Older Women – US and Canadian Perspective
50.
Incidence and Risk Factors for Osteoporotic Vertebral
Fracture in Low-Income Community-Dwelling Elderly: A
Population-Based Prospective Cohort Study in Brazil. the
São Paulo Ageing & Health (SPAH) Study
51.
High Incidence of Non-Vertebral Osteoporotic Fracture
and Hip Fracture in Brazilian Low-Income CommunityDwelling Elderly: A Population-Based Prospective Cohort
Analysis from the São Paulo Ageing & Health (SPAH) Study
52.
Visceral Fat Measured By Dual-Energy X-Ray
Absorptiometry Is Associated with Increased Risk of
Non-Spine Fractures in Nonobese Elderly Women: a
Population-Based Prospective Cohort Analysis from the
São Paulo Ageing & Health (SPAH) Study
53.
Spine-Hip Diagnostic Discordance in the United Arab
Emirates
54.
Concordance with the National Osteoporosis Foundation
Treatment Guidelines After DXA Result Notification
55.
Validation of the Diagnosis of Avascular Necrosis of Bone
in Administrative Data
56.
High Prevalence of Cervical Malignant and Premalignant
Lesions Among Women with Rheumatoid and Psoriatic
Arthritis
57.
Risk of Hospitalized Infection in a Psoriasis/Psoriatic
Arthritis Cohort
58.
What Does the Patient Global Assessment Mean for
Patients with Psoriatic Arthritis? A Post-Hoc Analysis of
223 Patients with Psoriatic Arthritis
59.
Assessing Dietary Habits in a Large Cohort of Rheumatoid
Arthritis and Psoriatic Arthritis Patients: Results of the
Spanish Imid Consortium
60.
Epidemiology of Polymyalgia Rheumatica in Korea
61.
Advocating for Pediatric Rheumatology Care in the
Mid-Canadian Provinces: Large Geographic Area,
Large Pediatric Population, Low Number of Pediatric
Rheumatologists and Allied Health Workers Identified
As Unique Challenges
35.
Hydrogen Sulfide Inhibits Human Osteoclast
Differentiation in Vitro By Triggering Sustained
Antioxidant Response and Inhibiting the RANKL/OPG
Ratio
36.
The Use of Three-Dimensionally Printed β-Tricalcium
Phosphate/Hydroxyapatite to Further Understand
the Regulation of Adenosine Receptors in Osteoclast
Formation and Promotion in Bone Regeneration
37.
Regulation of Osteoclast and T Cell Differentiation By DCSTAMP and TRAF3
38.
39.
Angiopoietin-like 4 Is over-Expressed in Rheumatoid
Arthritis: A Potential Role in Pathological Bone Resorption
Human CD14+ Monocytes Stimulated with a Combination
of TNFα and IL-6 Differentiate into Osteoclast-like Cells
with Bone-Resorption Activity
Epidemiology and Public Health: Osteoporosis, Non-Inflammatory
Arthritis and More
40.
Prevalence of Spondyloarthritis (ASAS Criteria) in FirstDegree Relatives of Patients with Ankylosing Spondylitis
41.
The Impact of Ankylosing Spondylitis on Work
Impairment: Data from the Scotland Registry for
42.
The Prevalence of Ankylosing Spondylitis in Sweden – a
Nationwide Register Study
43.
Deaths Associated with Ankylosing Spondylitis in France
from 1969 to 2009
44.
Physical Function, Hyperuricemia and Gout in Older
Adults
45.
Body Mass Index Across the Lifespan and Lifetime
Incidence of Gout in Men
2014 Program Book
161
ACR POSTER INDICES
62.
Severe Spine Osteoarthritis in Older Men Is Associated
with the Risk of Incident Fragility Fracture
77.
Epigenome Profiling Reveals Robust Hypomethylation of
Interferon Signature Genes in Lupus Neutrophils
63.
Spine Osteoarthritis Is Associated with All Cause Mortality
in Older Men
78.
64.
Effect of Family Support on Short-and Intermediate
Term Pain and Function Outcomes after Knee or Hip
Replacement
a HPLC-SRM-MS Based Method for the Detection and
Quantification of Methotrexate Used at Doses in Clinical
Practice for Patients with Rheumatological Disease in
Urine
79.
PECAM-1 GENE Polymorphisms and Soluble PECAM-1
LEVEL in Rheumatoid Arthritis and Systemic LUPUS
Erythematosus Patients Is There a Link with Clinical
Atherosclerotic Events?
80.
Cellular Responses of IL6 Inhibition (Tocilizumab) in
Rheumatoid Arthritis Using High-Accuracy Tandem Mass
Spectrometry
81.
Elevated Peripheral Blood Leukocyte Inflammatory Gene
Expression in Radiographic Progressors with Symptomatic
Knee Osteoarthritis: NYU and OAI Cohorts
82.
HLA-DPB1*04:01 Confers Risk for PR3-ANCA Positive
ANCA-Associated Vasculitis (AAV), but Protects Against
MPO-ANCA Positive AAV, in a Japanese Population
83.
Whole Exome Sequencing Analysis Performed on a Patient
with Fibroblastic Rheumatism
84.
Amerindian Ancestry Influences Polyautoimmunity
85.
Protective Association of HLA-DRB1*13:02 Against MPOANCA Positive ANCA-Associated Vasculitis in a Japanese
Population
86.
Association of Leukocyte Immunoglobulin-like Receptor
A3 (LILRA3) with Systemic Sclerosis
87.
Association of TRIM21 (RO52) Polymorphisms with
Systemic Lupus Erythematosus in a Japanese Population
88.
Microbiomes of Inflammatory and Non-Inflammatory
Thoracic Aortic Aneurysms
89.
Global miRNA Expression Profiling in Peripheral Blood
and Synovial Fluid Mononuclear Cells of Patients with
Enthesitis Related Arthritis
90.
Genetic Variants in IL-6, IL-10, C5-TRAF1 and FCRL3 and
Progression of Joint Damage in Rheumatoid Arthritis; A
Study on Six Cohorts
91.
Quantitative Proteomics Using Dimethyl Isotope Labeling
for Comparison of Fresh Frozen Versus Formalin-Fixed,
Paraffin-Embedded Tissue for Lupus Nephritis
92.
Long Noncoding RNA Nron Regulates the Activity of NFAT5
through Ubiquitin-Independent Proteasome Pathway in
65.
Impact of Dropout and Total Knee Replacement on Joint
Space Narrowing Estimation: Data from Osteoarthritis
Initiaive
66.
Association of Knee Osteoarthritis and Limitations in
Physical Function in a Rural Chinese Population: The
Wuchuan OA Study
67.
Effects of Exercise on Depressive Symptoms in Adults with
Arthritis: A Systematic Review with Meta-Analysis
68.
Physical Inactivity to Activity Associated with Less Decline
in Physical Function
69.
Assessment of Exercise Status in Routine Care Using
Patient Reported Outcomes: Initiating Exercise Is
Associated with Better Outcomes Than No Exercise
70.
The Odds of Work Disability, Unemployment and
Depending on Living Allowances Are More Influenced
By the Number of Morbidities Than By the Presence of a
Musculoskeletal Disease
71.
Prevalence of Pain Reporting in Different Ethnic Groups in
the UK: Results from a Large Biobank
72.
The Association Between Doctor-Diagnosed Arthritis
and Falls and Fall Injuries Among Middle-Aged and Older
Adults
73.
Frequency and Risk Factors for Recurrent Falls in
Community-Dwelling Elderly: A Population-Based
Prospective Cohort Study in Brazil. the São Paulo Ageing &
Health (SPAH) Study
Genetics, Genomics and Proteomics I
162
74.
Influence of the Polymorphism IL1ß (-511 A/C) and IL6
(- 174 G/C) on the Activity, Radiographic Damage and
Clinical Forms of Patients with Psoriatic Arthritis (PSA)
75.
Robust Identification of Anti-TNF Non-Responders in RA
from Blood
76.
Identification of Synovial Genes and Pathways Associated
with Disease Progression in a Cohort of Early Symptomatic
Osteoarthritis Patients Using a Transcriptomic Approach
2014 Program Book
ACR POSTER INDICES
93.
Protein Profiling of Secretome Human Cartilage to Identify
Potential EARLY Specific Biomarkers in Osteoarthritis
Health Services Research
94.
Possible Effects of Medicare-Only Insurance Coverage on
the Use of Biologics in Patients with RA
95.
Comparison of Patient Characteristics, Healthcare
Costs, and Biologic Persistence Between Patients with
Rheumatoid Arthritis Initiating First- or Second-Line
Subcutaneous Abatacept, Adalimumab, or Etanercept
96.
97.
Comparison of Cardiovascular Risk Factor Management in
Patients with RA and Matched Non-RA Patients
Identification of Tuberculosis in Rheumatoid Arthritis
Patients Initiating Therapy with Biologic or Non-Biologic
Disease-Modifying Anti-Rheumatic Drugs Using Health
Insurance Claims Data
108.
Patient Reported Outcomes Following Total Knee
Arthroplasty in Rheumatoid Arthritis and Osteoarthritis
109.
Knee Arthroscopy in an International Training Centre: An
Audit of Safety and Impact on Work Days
110.Use of Smartphones in Collecting Patient Reported
Outcomes: Can Passively-Collected Behavior Determine
Rheumatic Disease Activity? Early Results from a NationWide Pilot Study
111.
Low Rates of Bone Mineral Density Testing in Medicare
Beneficiaries with Breast Cancer Starting Aromatase
Inhibitor Therapy
112.
Relationship Between Rheumatology Physician Supply
and Travel Distances to Rheumatologists for Medicare
Beneficiaries in the United States
113.
Dermatologic Rheumatism: Our Experience with a
Multidisciplinary Dermatology/Rheumatology Clinic
114.
Treat-to-Target (T2T) and Measuring Outcomes in RA Care:
a 2014 Longitudinal Survey of US Rheumatologists
115.
Biologic Dmards Modify the Association Between Patient
Expectations and Outcomes of Total Knee Replacement in
98.
Costs of Musculoskeletal Diseases in the United States,
1996-2011: Population Growth, Population Aging, Health
Care Utilization, or Prices?
99.
Impact of Comorbidities on Health Resource Utilization in
Patients with Spa
100.
Evaluation of Real World Experience with Non-Biologic
DMARD in the Treatment of RA: Data from an Electronic
Health Record Database
116.
Is Socioeconomic Status at Diagnosis Associated with
Long-Term Direct Medical Costs in Systemic Sclerosis? a
General Population-Based Cohort Study
101.
Country of Residence and Its Wealth Determine Disease
Activity Levels in RA: Results from Multi-National Study
Across 17 Countries (COMORA)
117.
Predictors of Gout Flares in a US Managed Care Setting
118.
Difficult to Treat Gouty Arthritis Associated with Poor
Health Related Quality of Life and High Resource
Utilization: Post- Hoc Analysis
102.
Real-World Utilization, Patient Characteristics and
Persistency of Certolizumab Pegol Vs Other Anti-TNFs
for the Treatment of Rheumatoid Arthritis in the United
Kingdom
Imaging of Rheumatic Diseases: Ultrasound
103.
Rheumatology e-Consult Services: a Rheumatology
Workforce Management Model
119.
Sonographic Evaluation of the Fifth Metatarsophalangeal
Joint Erosion in Rheumatoid Arthritis
104.
Reasons for Leaving an Academic Career in Research
Among Rheumatologists in the United States
120.
105.
Resource Use and Health Related Quality of Life Burden
of Gout Exacerbated By Common Comorbidities: Results
from the 2012-2013 National Health and Wellness Survey
Can We Use Ultrasound to Identify Rheumatoid
Arthritis Patients in Remission Who Cannot Taper Their
Medication?
121.
Predictors of Persistence of Power Doppler Ultrasound
Synovitis in Rheumatoid Arthritis Patients in Clinical
Remission
Patient Reported Outcomes Following Upper Extremity
Arthroplasties in RA -a Report from the Swedish National
Register of Rheuma Surgery (RAKIR)
122.
The Use of Ultrasound to Detect Residual Joint
Inflammation in Patients with Rheumatoid Arthritis in
Clinical Disease Remission
107.Use of Internet in Adolescents and Young Adults with JIA
123.
Combination with Joint Power Doppler Signals with AntiCitrullinated Peptide Antibody Predicts Joint Destruction
in Rheumatoid Arthritis
106.
2014 Program Book
163
ACR POSTER INDICES
124.Ultrasound Power Doppler Findings in the Wrists and
Hands Joints of Anti-CCP Antibody Positive Individuals
with Non-Specific Musculoskeletal Symptoms and the
Development of Inflammatory Arthritis
125.
PD Signal Detected By Ultrasonography Relates to Joint
Destruction in Rheumatoid Arthritis Under Biologics
Therapy in Real World
126.
Asymptomatic Versus Symptomatic Ankle Joints in
Rheumatoid Arthritis: A High Resolution B-Mode and
Power Doppler Ultrasound Study
127.
Metacarpophalangeal Cartilage Loss in Rheumatoid
Arthritis. a Simple and Fast Ultrasonographic Assessment
Comparing Patients and Healthy Controls
128.
A Rapid 4- Joint Ultrasonographic Score to Daily
Monitoring Disease Activity in Patients with Rheumatoid
Arthritis: Validity and Sensitivity to Change
129.
130.
Inter-Rater Reliability of the US-7 Score in a Population
of Volunteers: Is a Post-Hoc Analysis of Still Images
Comparable to the Dynamic Analysis? Results from the
German “Rheuma-Truck” Cohort
131.
Detection of Synovitis and Erosions with an Automated
Ultrasound System: Data from a Prospective Cohort with
Early and Established RA
132.
133.
134.
Do Ultrasound (PDUS) and DAS28 Measure Different
Aspects of Disease Activity? Analyses from the First
Prospective International Phase IIIb Study of PDUS
Response in Abatacept-Treated Patients with Rheumatoid
Arthritis (RA)
On-Demand Ultrasonography Assessment in the Most
Affected Joint Is Efficient for Management of RA Patients
in Daily Practice
Histopathological Correlation of Ultrasound-Defined
Active Synovitis in Patients with Rheumatoid Arthritis in
Clinical Remission. Preliminary Results
135.
Comparison of the Ultrasonography Images and Synovial
Pathology of the Joints in Patients with Rheumatoid
Arthritis Treated with Biological Agents
136.
Serum Calprotectin (S100A8/9) Is an Independent
Predictor of Ultrasound Synovitis in Patients with
137.
164
Seven Joints Ultrasound Scoring System May be Useful
and Effective in Assessing Disease Activity in Patients with
Rheumatoid Arthritis in the State of Remission in Daily
Clinical Practice
Evaluation of Metalloproteinase-3 As a Soluble Biomarker
of Synovitis Using Weighted Joint Counts Assessed
Clinically and on Ultrasound Imaging
2014 Program Book
138.
Can Ultrasonography of Peripheral Entheses Play a Role
in the Diagnosis and Understanding of Diffuse Idiopathic
Skeletal Hyperostosis (DISH)?
139.Ultrasound Enthesitis in Primary Care Psoriasis Patients
with Musculoskeletal Complaints
140.
Are Entheses Ultrasound Findings Similar in Axial Spa
Patients and in Athletes?
141.
Prevalence of Subclinical Enthesopathy in Asymptomatic
First Degree Relatives of Patients with Spondyloarthritis
142.
Prevalence of Subclinical Entheseal Involvement in
Patients with Paediatric Inflammatory Bowel Disease: An
Ultrasonographic Study
143.
Detailed Anatomical Distribution of Synovial Inflammation
Revealed By Ultrasound in Patients with Blau Syndrome
144.
Sonographic Differentiation of Heel Pain: Focal
Degenerative Versus Systemic Inflammatory Enthesitis
145.
A Cut-Off Value Analysis By Ultrasound for the Diagnosis
of Giant Cell Arteritis (GCA)
146.Ultrasonographic Evaluation of Joint and Tendon
Involvement in Patients with Early Systemic Lupus
Erythematosus (SLE) in Comparison with Early
Rheumatoid Arthritis (RA)
147.US Lung Examination in SSc Patients: A Comparison of
Two Different Scoring Systems
148.
Value of Ultrasonography Parotid Glands in Patients with
Suspected Primary Sjögren’s Syndrome
149.
Automated Digital Analysis of Major Salivary Gland
Ultrasound Images
150.Ultrasonographic Evaluation of Major Salivary Glands in
Primary Sjögren’s Syndrome: Comparison of Two Scoring
Systems and Diagnostic Value of Sonoelastography
151.
Sonographic Measurements Can be Misleading for
Diagnosing Carpal Tunel Syndrome in Patients with
152.
Subclinical Synovial Inflammation in Gout
153.
Musculoskeletal Ultrasound of Finger and Foot Joints
in a Population of Volunteers: Is Osteoarthritis an
Underestimated Problem? Results from the German
“Rheuma-Truck” Cohort
154.
Cimt in Individuals with Rheumatoid Arthritis Compared
to Individuals with Type2 Diabetes
ACR POSTER INDICES
Metabolic and Crystal Arthropathies: Clinical Aspects
171.
High-Protein Diet (Atkins Diet) and Uric Acid Response
155.
Cost-Effectiveness Analysis of HLA-B5801 Genotyping
in the Treatment of Gout Patients with Chronic Renal
Insufficiency in Korea
172.
Sleep Apnea and Risk of Incident Gout: A PopulationBased Body-Mass Index Matched Cohort Study
156.
Colchicine and the Risk of Acute Cardiovascular (CV)
Events Among Gout Patients: The New York Department
of Veterans Affairs Retrospective Cohort Study
173.
Self-Management Education for Patients with Gout: A
Review of Existing Resources
174.
Long Term Safety and Efficacy of Canakinumab Liquid
Formulation in Acute Gouty Arthritis Patients: Results
from a 36 Week Extension Study
Efficacy and Safety of Canakinumab in Acute Gouty
Arthritis Patients with Chronic Kidney Disease Stage
Greater Than or Equal to 3: A Post-Hoc Analysis of 12Week Data
157.
158.
159.
160.
Can We Diagnose Acute Gout without Joint Aspiration?
Results of a Prospective Study of 112 Patients Presenting
with Acute Arthritis
Performance of Joint Ultrasonography in the Diagnosis of
Suspected Acute Crystal Arthritis : Results of a Prospective
Study of 112 Patients
176.
Canakinumab in Frequently Flaring Gouty Arthritis
Patients, Contraindicated, Intolerant or Unresponsive to
non-Steriodal Anti-Inflammatory drugs and/or Colchicine:
Safety and Efficacy Results from Long Term Follow-up
Comparative Cardiovascular (CV) Risk and Outcomes
Among Patients with Gout, Osteoarthritis (OA), or Both
177.
Increase in Thyroid Stimulating Hormone (TSH) Levels in
Patients with Gout Treated with Inhibitors of XanthineOxido-Reductase
All Men with Gout Should be Screened for Erectile
Dysfunction
178.
The Effect of Initiating Pharmacologic Insulin on Serum
Uric Acid Levels in Patients with Diabetes
179.
Effect of Allopurinol on All-Cause Mortality in Adults
with Incident Gout: Propensity Score Matched Landmark
Analysis
180.
Analytical Comparison Between Point of Care Uric Acid
Testing Meters
181.
Adherence to Treatment Recommendations of Gout: A
Patient Survey in China
182.
Effect of Urate-Lowering Therapy on Radiographic
Changes in Gout Patients
183.
Musculoskeletal Ultrasound Reveals Calcific Deposition
Arthropathy in Seronegative Inflammatory Arthritis
Patients
161.Ultrasonographic Measurement of Renal and Carotid
Artery Resistive Indices and Diastolic Function of the
Heart in Gout Patients
162.
Development of Preliminary Remission Criteria for Gout
Using Delphi and 1000Minds Consensus Exercises
163.
Is the Rate of Skin Reactions to Febuxostat Increased in
Patients with a History of Skin Intolerance to Allopurinol?
a Retrospective, Hospital-Based Study Involving 101
Patients Consecutively Treated with Allopurinol and
Febuxostat
164.
Gouty Patients with History of Adverse Reaction to
Allopurinol Are Not at Higher Risk of Reaction to
Febuxostat
165.
Prevalence of Gout in the Adult Population of France in
2013
166.
Risk Factors for Gout Attack Recurrence during UrateLowering Allopurinol Treatment
167.
Target Serum Urate: Do Patients Know Their Goal?
168.
Positive Association Between Tomato Consumption and
Serum Urate: Investigating an Anecdotal Trigger of Gout
Flares
169.
170.
175.
Is Gout a Coronary Heart Disease Risk Equivalent, Similar
to Diabetes?
Increased Risk of Skin Reactions with Gout Medications:
An Analysis of VA Databases
184.Ultrasound Versus X-Rays Versus Synovial Fluid Analysis
for the Diagnosis of Calcium Pyrophosphate Dihydrate
Deposition Disease: Is It CPPD? Ask US!
185.
Distribution of Haemochromatosis Arthropathy. High
Ankle and Mid Foot Prevalence; A Diagnostic Clue ?
Orthopedics, Low Back Pain and Rehabilitation
186.
The Association Between Low Back Pain and Radiographic
Features: A Systematic Review with Meta-Analysis
187.
Revision Arthroplasty in Rheumatoid and Osteoarthritis:
Does Methotrexate Decrease Radiographic Lucency in RA
Patients?
2014 Program Book
165
ACR POSTER INDICES
188.
Time Trends in Total Ankle Arthroplasty in the U.S.: A
Study of the Nationwide Inpatient Sample
189.
Sex Differences in Characteristics, Utilization and
Outcomes of Patient Undergoing Total Elbow
Arthroplasty: A Study of the U.S. Nationwide Inpatient
Sample
190.
Hospital Volume Predicts Outcomes and Complications
after Total Shoulder Arthroplasty
191.Utilization and Outcomes Following Total Shoulder
Arthroplasty in Elderly and Non-Elderly Patients
192.
Title: Use of Non-Traditional Modalities for Pain
Management after Knee or Hip Joint Replacement
Risk Factors for Increased Extrusion of the Meniscus Body
in Subjects Free of Radiographic Knee Osteoarthritis:
6-Year MRI Data from the Osteoarthritis Initiative
207.
Changes in Knee Compartment Distriubtion of Cartilage
Loss and Bone Marrow Lesions over 7 Years: The MOST
Study
208.
Correlates of Knee Bone Marrow Lesions in Younger
Adults
209.
Physical Performance and Obesity Measures Are
Associated with Tibial Cartilage Volume and Explains the
Sex Difference in Cartilage Volume
210.
Preliminary Assessment of Predictive Validity of Cartilage
Thickness MRI Biomarkers in Knee OA - the Fnih OA
Biomarkers Consortium
211.
Association Between Baseline External Knee Adduction
and Flexion Moments during Gait and Medial
Tibiofemoral Cartilage Thickness Loss over Two Years in
Persons with Knee Osteoarthritis (OA)
193.
Pre-Operative Pain and Function: Profiles of Patients
Selected for Total Knee Replacement Among Surgeons in
the United States
194.
Differences in Total Knee Replacement Outcomes Based
on Age
195.
Dependence on Walking Aids and Patient-Reported
Outcomes after Total Knee Arthroplasty
212.
Relation of Shoe Stability to Risk of Knee Cartilage
Damage: The Multicenter Osteoarthritis Study
196.
Dependence on Walking Aids Is Associated with Pain and
Mobility Limitation after Total Hip Arthroplasty
213.
197.
Differences in Total Hip Replacement Outcomes Based on
Age
Foot Center of Pressure in Knee Osteoarthritis (OA) and
Its Association with Knee Load Reduction with Barefoot
Walking
214.
Knee Instability and Advanced Function Decline in Persons
with Knee Osteoarthritis
215.
External Hip Adduction Moment and Progression of
Medial Tibiofemoral Cartilage Damage and Bone Marrow
Lesions in Persons with Knee Osteoarthritis
216.
Hip Adiposity, Not Local Knee Adiposity, Is Associated with
Knee Pain Independent of Radiographic Osteoarthritis
Severity
217.
The Relationship of Quadriceps and Hamstrings
Intramuscular Fat and Lean Muscle with Power in Women
with Knee Osteoarthritis
218.
Surface Area and Fatty Infiltration of Vastus Medialis
Measured By Magnetic Resonance Imaging Are Risk
Factors for the Progression of Knee Osteoarthritis and
Discriminate Two Osteoarthritis Phenotypes
219.
DXA Body Composition, Sarcopenia and Knee and Hip
Osteoarthritis: Results from the Khoala Cohort
204.Ultrasonographic Predictors for Clinical and Radiological
Progression in Knee Osteoarthritis after 2 Years Follow up
220.
Lower Extremity Presarcopenia Is Associated with the
Severity of Knee Pain
205.
221.
An Analysis of Age-Related Loss of Skeletal Muscle
Mass and Its Significance on Osteoarthritis in a Korean
Population
198.
Implant Survival and Patient-Reported Outcomes after
Total Hip Arthroplasty in Young Patients with JIA
199.
Increasing Complexity of Patients Undergoing Primary
Total Hip Arthroplasty in the U.S
Osteoarthritis - Clinical Aspects: Imaging and Biomechanics
166
206.
200.
Leg Length Inequality and Hip Osteoarthritis
201.
Measures of Hip Morphology Are Related to Development
of Incident Radiographic Hip Osteoarthritis over 6 to
13 Year Follow-up: The Johnston County Osteoarthritis
Project
202.
Is Schuss View Alone Enough for the Diagnosis of
Femorotibial Osteoarthritis ? the Khoala Cohort Study
203.
Predictors of Radiographic Progression of Interphalangeal
Finger Joints in Erosive Osteoarthritis: A Prospective Study
Natural History and Clinical Significance of Meniscal Tears
over 8 Years in a Largely Non-Osteoarthritic Cohort
2014 Program Book
ACR POSTER INDICES
222.
OA Phenotypes Rather Than Disease Stage Drive
Structural Progression – Identification of Structural
Progressors from 2 Phase III Randomized Clinical studies
with Symptomatic Knee OA
Osteoporosis and Metabolic Bone Disease - Clinical Aspects and
Pathogenesis: Osteoporosis: Pathogenesis, Epidemiology and
Diagnosis
223.
224.
225.
226.
Risk Factors for Clinical Vertebral Fractures in Japanese
Men and Women with Rheumatoid Arthritis: Results from
a Large Prospective Observational Cohort Study
Is the Protective Effect of Obesity Against Hip Fracture
Due to Changes of Proximal Femur Shape?
Association Between Lean Mass and Hip Bone Mineral
Density
Improved Prediction of Hip Fracture Using the Health
Assessment Questionnaire-Disability Index and FRAX®
in Japanese Patients with Rheumatoid Arthritis: A
Prospective Observational Study
238.
RANKL and OPG Gene Polymorphisms: Association
with Vertebral Fractures and Bone Mineral Density in
Premenopausal Systemic Lupus Erythematosus
239.
Does Adjusting BMI for Lean Mass Deficits Affect
Calculated Fracture Risk Using FRAX in Rheumatoid
Arthritis?
240.
An Observational Study on the Influence of Glucocorticoid
Exposure on Bone
Pain: Basic and Clinical Aspects
241.
Reduced Estimated Glomerular Filtration Rate Was
Improved after Cessation of NSAID and Switching
to Tramadol Hydrochloride/Acetaminophen Tablets
(UltracetTM) in Patients with Chronic Musculoskeletal
Pain
242.
WOMAC Pain Score Reflects Preceding Daily Pain Ratings
in Knee Osteoarthritis Interventional Randomized Clinical
Trials
227.
Increasing Fat-Mass May Reverse Bone Loss As Detected
By DXA Scan
243.
Safety of Solumatrix Diclofenac in Adults with
Osteoarthritis: Results of a 12-Month, Phase 3 Study
228.
Is Adult Hypophosphatasia a Cardiovascular Risk Factor?
244.
229.
Correlates of Heel Bone Mass in Young Adults: The Role
of Cholesterol over 20 Years from Childhood to Early
Adulthood
Onset, Magnitude, and Durability of Pain Relief in Patients
with Knee OA Receiving a Fixed-Dose Combination Tablet
of Enteric-Coated (EC) Naproxen Plus Immediate-Release
(IR) Esomeprazole Magnesium Versus Celecoxib and
Placebo: Pooled Results from Two Ran
230.
Risk Factors That Predict Poor Bone Health in Those Aged
over 75 Years - a Cross Sectional Study
245.
WITHDRAWN
246.
Neuropathic PAIN in Patients with Ankylosing Spondylitis
231.
Factors Predicting Fracture in the over-75s: An
Observational Case-Control Study
247.
Cognitive Task Related Hypoperfusion of Frontal Gyrus in
Patients with Chronic Fatigue
Significance of Serum Srankl and Osteoprotegerin
Concentration in Patients with Rheumatoid Arthritis
248.
Is the Basdai Score Driven By Pain in Ankylosing
Spondylitis Patients Treated with Anti-TNF?
249.
A Phase 3 Open-Label Trial of Low-Dose Solumatrix
Diclofenac in Patients with Osteoarthritis Pain: Impact of
Long-Term Administration on Patient-Reported Outcomes
250.
Early Gout Pain Response at 28 Hours Predicts Response
at 5 Days on Both Patient Pain and Physician Global
Assessment
251.
Chronic Fatigue Is Associated with Hypoperfusion of
Parahippocampal Gyrus
252.
Preliminary Validation of the Michigan Body Map
253.
Evaluating Neuropathic Complaints By DN4 and Lanss
Scales after Local Corticosteroid Therapy in Carpal Tunnel
Syndrome
232.
233.
Significance of Serum Marker Levels of Wnt/ß-Catenin
Signaling Pathway in Patients with Systemic Autoimmune
Diseases Under Glucocorticoid Therapy; A Prospective
Study
234.
The Decrease in Prescription of Anti-Osteoporotic Drugs
Has No Impact on Hip Fracture Incidence
235.
Lower P1NP Serum Levels: a Predictive Marker of Bone
Loss after One-Year Follow-up in premenopausal SLE
Patients
236.
Risk Factors for Prevalent and Progressive Bone Deficits
Among Adult Men and Women with Cystic Fibrosis
237.
Analysis of Vitamin D Receptor Gene Polymorphisms and
Bone Mineral Density in a Population of Women with
Rheumatoid Arthritis in Use of Steroid
2014 Program Book
167
ACR POSTER INDICES
254.
The Effect of Milnacipran on Pain in Rheumatoid Arthritis
Patients with Widespread Pain: a Randomized Blinded
Crossover Trial
255.
Pain As Predictor of Organ Involvement in Fabry Disease
256.
Characteristics of Pain in Fabry Disease
257.
Quality of Life Assessment of Adults Patients with
X-Linked Hypophosphoremia
258.
Pain Characteristics Among Patients with Rheumatoid
Arthritis in the Context of Patient-Physician Discordance
in Disease Activity Assessments
Development of Pediatric Item Banks to Measure Pain
Behavior in the Patient Reported Outcomes Measurement
Information System
259.
260.
Validation of the Dutch-Flemish Promis Physical
Functioning Item Bank in Patients with Chronic Pain
261.
Validation of the Dutch-Flemish Promis Pain Behavior and
Pain Interference Item Banks in Patients with Chronic Pain
262.
Longitudinal Assessment of Promis Pediatric Item Banks in
Children with Chronic Musculoskeletal Pain
263.
Nutraceutical Products and Pain or Non-Pain Medications
Use in Patients with Knee Osteoarthritis
264.
Efficacy and Safety of Cannabinoid Treatments in the
Rheumatic Diseases: A Systematic Review of Randomized
Controlled Trials
265.
Prevalence of Medicinal Marijuana Use Among 1000
Rheumatology Patients Attending a Community-Based
Rheumatology Clinic: A Prospective Cross-Sectional Study
266.
An Examination of the Interaction of Opioid Use, Pain, and
Depression
267.
Selective and Peripheral-Specific Trk Inhibitor Shows
Potent Analgesic Effect Comparable to Morphine in Rat
Osteoarthritis Model without CNS Toxicity
268.
The Effect of Treatment with Resiniferatoxin and Capsaicin
on Dynamic Weight Bearing Measures and Evoked Pain
Responses in a Chronic Inflammatory Arthritis Murine
Model
Pediatric Rheumatology - Clinical and Therapeutic Aspects: Juvenile
168
269.
Discontinuation of Concomitant Medication for EnthesitisRelated Arthritis during 52 Weeks of Treatment with
Adalimumab
270.
Disease Burden Is Comparable in Children with EnthesitisRelated Arthritis and Polyarticular Juvenile Idiopathic
Arthritis
2014 Program Book
271.
Predicting Treatment Response to Etanercept in Juvenile
Idiopathic Arthritis: Results from the British Society for
Paediatric and Adolescent Rheumatology Etanercept
Cohort Study (BSPAR-ETN)
272.
Factors Associated with Choice of First Biologic Among
Children with Juvenile Idiopathic Arthritis: A Combined
Analysis from 2 UK Paediatric Biologic Registers
273.
Long-Term Safety and Effectiveness of Adalimumab in
Children with Moderately to Severely Active Polyarticular
or Polyarticular-Course Juvenile Idiopathic Arthritis
274.
Treatment Prescribing Patterns in a Cohort of Patients
with Juvenile Idiopathic Arthritis (JIA). Data from the
Childhood Arthritis Prospective Study
275.
Environmental Risk Factors and Development of Juvenile
276.
Growth during Tocilizumab Therapy for PolyarticularCourse Juvenile Idiopathic Arthritis: 2-Year Data from a
Phase 3 Clinical Trial
277.
Nearly 20% of Children ARE NOT Correctly Classified
According to Current ILAR Classification in a Printo
Dataset of More THAN 12,000 Juvenile Idiopathic Arthritis
Patients
278.
Is It Worth Allowing the Presence of Morning Stiffness in
the Definition of Inactive Disease in Juvenile Idiopathic
Arthritis?
279.
Focus on Patient Reported Outcomes in Juvenile
Idiopathic Arthritis: There Is Room to Improve Care
280.
Biologic Treatment of Adult Patients with Juvenile
Idiopathic Arthritis Followed in the National Registry
281.
Retrospective Review of Immobilization Vs. Immediate
Resumption of Activity in Patients with Oligoarticular
Juvenile Idiopathic Arthritis and Corticosteroid Knee
Injections
282.
Pharmacovigilance in Juvenile Idiopathic Arthritis Patients
(PHARMACHILD) Treated with Biologic Agents and/or
Methotrexate. Consolidated Baseline Characteristics from
Pharmachild and Other National Registries
283.
Agreement Between Enthesitis Evaluation By Manual
Palpation and Dolorimetry in Juvenile Spondyloarthritis
284.
Single Hub and Access Point for Paediatric Rheumatology
in Europe (SHARE)– Evidence Based Recommendations for
Diagnosis and Treatment of Juvenile Idiopathic Arthritis
285.
Drug Safety in Treatment of Juvenile Idiopathic Arthritis
(JIA): Biologic Therapy Compared with MTX
ACR POSTER INDICES
286.Using the 2011 ACR Recommendations for the Treatment
of Juvenile Idiopathic Arthritis (JIA) to Evaluate a Single
Centre Treatment Pathway: A Feasibility Study
303.
Predicting Chronic Pain in Children with Juvenile
Idiopathic Arthritis: Results from the Childhood Arthritis
Prospective Study
287.
Role of Joint Status in Decreased Accelerometer-Assessed
Daily Physical Activity in Juvenile Idiopathic Arthritis
304.
Juvenile Rheumatoid Arthritis and Future Risk for
Cardiovascular Disease; A Multicenter Population-Based
Study
288.
Establishing Clinical Meaning and Defining Important
Differences in Patient Reported Outcome Measures
of Physical Function, Fatigue and Pain Interference in
289.
290.
Patient-Reported Outcomes in Children with Moderately
to Severely Active Polyarticular or Polyarticular-Course
Juvenile Idiopathic Arthritis Who Are Prescribed and
Treated with Adalimumab
Patterns of Active Joint Involvement in JIA
Pediatric Rheumatology - Pathogenesis and Genetics
305.Understanding the Molecular Pathogenesis of and
Response to Canakinumab Treatment in TNF ReceptorAssociated Periodic Syndrome By Gene Expression
Profiling of Whole Blood from Patients
306.
Association of Kawasaki Disease with Tropospheric Winds
in Central Chile: Is Wind-Borne Desert Dust a Risk Factor?
307.
Sibling Exposure and Risk of Juvenile Idiopathic Arthritis
308.
Tenascin-C, a TLR4 Ligand Levels in Enthesitis Related
Arthritis Category of Juvenile Idiopathic Arthritis: CrossSectional and Longitudinal Study
309.
Clinical Significance of Cytokine Profile with Interleukin-18
and -6 in Systemic Juvenile Idiopathic Arthritis
291.
Development of a Serious Game Designed for Children
with Juvenile Idiopathic Arthritis
292.
Flares in Children with JIA: Results from the Reacch-out
Cohort
293.
Long Term Functional Outcome and Quality of Life of
Patients with Refractory Juvenile Idiopathic Arthritis
Treated with Etanercept: Results of the Dutch Arthritis
and Biologicals in Children Register
310.
294.
Long-Term Pharmacokinetics of Body Surface AreaAdjusted Doses of Golimumab Following Repeated
Subcutaneous Administrations in Pediatric Patients with
Polyarticular Juvenile Idiopathic Arthritis
Differential Expression of microRNA in Monocytes from
Children with Systemic Juvenile Idiopathic Arthritis:
Implications for Polarized Phenotype
311.
Intra-Articular Corticosteroid Injections in Juvenile
Idiopathic Arthritis: Results from a UK Prospective
Collaborative Study
Inhibition of Natural Killer (NK) Cell Cytotoxicity By
Interleukin-6 (IL-6): Implications for the Pathogenesis of
312.
Countermeasures Against Methotrexate Intolerance in
Juvenile Idiopathic Arthritis Instituted By Parents Show
No Effect
Mutations in the MTHFR Gene Are Not Associated with
Methotrexate Intolerance in Patients with Juvenile
313.
Elevated Cardiovascular Disease Burden and Inflammatory
Biomarker Levels in Adults with Juvenile Idiopathic
Arthritis
314.
Next Generation Sequencing Reveals Restriction of the
Treg Cell Repertoire and an Abundance of Shared Synovial
Treg Clonotypes in JIA
295.
296.
297.
S100 Proteins in Oligoarticular Juvenile Idiopathic Arthritis
298.
Long-Term Impact of Juvenile Idiopathic Arthritis in the
Greek adults’ Psychosocial Life
299.
A Controlled Trial of Intra-Articular Corticosteroids with or
without Methotrexate in Oligoarticular Juvenile Idiopathic
Arthritis
315.
NLRC4-Related Macrophage Activation Syndrome (NLRC4MAS): A Novel Primary Autoinflammatory Syndrome
Caused By Activating Mutations in NLRC4
300.
Patient-Reported Joint Count in Juvenile Idiopathic
Arthritis: The Reliability of a Mannequin Format
316.
301.
Pregnancies in Females with Juvenile Idiopathic Arthritis
(JIA) Who Were Exposed to Biologics and/or Methotrexate
– Results from a Biologic Register
Cytokines in Systemic Juvenile Idiopathic Arthritis and
Macrophage Activation Syndrome: Tipping the Balance
Between Interleukin-18 and Interferon-Gamma
317.
Myeloid Related Proteins 8 and 14 (MRP 8/14) - Potential
Biomarkers of Disease Activity of Arthritis in Children with
Trisomy 21
302.
Qualitative Assessment of Important Long-Term
Outcomes in Juvenile Idiopathic Arthritis
2014 Program Book
169
ACR POSTER INDICES
318.
HLA-B27 Subtypes in Enthesitis Related Arthritis Category
of Juvenile Idiopathic Arthritis
334.
Inflammatory Arthritis in K/BxN Mice Is Associated with
Abnormal HDL Function
319.
Systemic Juvenile Idiopathic Arthritis and Exposure to Fine
Particulate Air Pollution
335.
Interleukin-33 Suppresses Experimental Arthritis through
Promoting Foxp3⁺ Regulatory T-Cells and Type-2 Immune
Responses in Mice
320.
Autoantibodies in Juvenile Systemic Sclerosis
336.
321.
Mutations of Familial Hemophagocytic
Lymphohistiocytosis (FHL) Related Genes and
Abnormalities of Cytotoxicity function tests in Patients
with Macrophage Activation Syndrome (MAS) Occurring
in Systemic Juvenile Idiopathic Arthritis (sJIA)
The Additive Inflammatory in Vivo and in Vitro Effects of
Thymic Stromal Lymphopoietin (TSLP) and IL-7 in Arthritis
Underscore the Therapeutic Rationale for blockade of
Their Common Receptor Subunit
337.
Effect of Etanercept on Endothelial Dysfunction in Rat
Adjuvant-Induced Arthritis
338.
Bombina Variegate peptide8/Prokineticin 2: A Novel
Arthritis-Inducible Chemokine
Toll-like Receptor Dependent Autoantigens and Vesicles
from P.Gingivalis in Animal Models of RA to Modulate
Collagen and Collagen Antibody Induced Arthritis
Rheumatoid Arthritis - Animal Models
322.
Superior Therapeutic Efficacy of a Novel Oral Small
Molecule Retinoic Acid Receptor-Related Orphan Receptor
Gamma T [Rorgt] Inverse Agonist Inv-17: A Promising Safe
& Efficacious Treatment for Rheumatoid Arthritis
323.
Anti-Inflammatory Marine Compound, Lyy-B2,
Ameliorates Rheumatoid Arthritis through Inhibition of
Osteoclast Differentiation
324.
340.
Role of Beta-Catenin Signaling to Control Dendritic Cell
Function in Collagen-Induced Arthritis
341.
Death Receptor 3 Causes Vascular Dysfunction in a Murine
Model of Rheumatoid Arthritis
342.
Vascular Permeability As an Imaging Biomarker for
Chronic Inflammatory Arthritis: A Dynamic Contrast
Enhanced Magnetic Resonance Imaging Study
343.
The Caspase 8/RIPK3 Signaling Axis Has Opposing Roles
in Myeloid and Dendritic Cells during Progression of a
Murine Model of Acute Inflammatory Arthritis
344.
Reduced Macrophages in the Synovium Contribute
to the Effective Treatment of Spontanneous Arthritis
Observeded in Human TNF-Transgenic Mice
325.
Tadalafil Decreases Joint Inflammation in TNF-Tg Mice By
Restoring Passive Lymphatic Transport
326.
IL-1 Receptor Antagonis (IL-1Ra)-Fc Ameliorate
Autoimmune Arthritis By Regulation of the Th17 Cells/
Treg Balance and Arthrogenic Cytokine Activation
327.
AMPK Activation in Inflammatory Arthritis
328.
Etanercept, Abatacept and Anakinra Treatment
Ameliorates Inflammation and Pain in a Novel MonoArthritic Multi-Flare Model of Streptococcal Cell Wall
Induced Arthritis: Further Characterization in a Rodent
Model of Collagen Induced Arthritis
345.
A Low Salt Diet Ameliorates Clinical Manifestations in
Collagen-Induced Arthritis
346.
A Novel, Small Molecule Cyclin-Dependent Kinase 4/6
Inhibitor As the New Option for Treatment of Rheumatoid
Arthritis
Treatment of Collagen Induced Artritis with Human
Embrionic Stem Cell-Derived Multipotent Mesenchymal
Stromal Cells (hESC-MSC)
347.
Salt Aggravates Arthritis By Th17 Polarization
329.
330.
170
Regulation of TNF-α-Mediated Activation of Rheumatoid
Synovial Fibroblasts By Transcription Factor Snail
339.
Prolactin Reduces Bone Erosion in Adjuvant-Induced
Arthritis
331.
WITHDRAWN
332.
Improvement of the Stability of RNA Aptamers Against
Interleukin-17A
333.
Deletion of the Prolactin Receptor Aggravates the Course
of Antigen-Induced Arthritis
2014 Program Book
Rheumatoid Arthritis - Clinical Aspects: Novel Biomarkers and Other
Measurements of Disease Activity
348.
Smoking Status Is Associated with Inflammatory Cytokine
Profile and Disease Activity: Decreased Inflammation and
Disease Improvement with Smoking Cessation?
349.
Galectin-3 in the Systemic Circulation Is Increased in
Newly Diagnosed Rheumatoid Arthritis and Is Associated
with Anti-CCP and Bone Marrow Edema
ACR POSTER INDICES
350.
Rho-Associated Protein Kinase (ROCK) Activity Is Elevated
in Rheumatoid Arthritis (RA) Patients and May be
Responsive to RA Therapies
364.
In Early Rheumatoid Arthritis, the Multi-Biomarker
Disease Activity Score at Different Time-Points Is
Predictive of Subsequent Radiographic Progression
351.
Doctor, Will My Fatigue be Better If I’m in Remission? an
Exploratory Analysis of 1284 Rheumatoid Arthritis (RA)
Patients Indicates Fatigue Is the Only Aspect of PatientPerceived Impact to Remain Significant in ACR/EULAR
Boolean Remission
365.
Differential Relative Contribution of Individual
Components on DAS28 over Time: An Analysis from the
Prospective, Observational, Biological Treatment Registry
Across Canada
352.
Remaining Pain in Spite of Suppressed Inflammation in
Early Rheumatoid Arthritis – Long-Term Strongly Increased
Risk for Widespread Pain and Fatigue
366.
Soluble 4-1BB Is a Marker of Joint Involvement and
Disease Activity in Rheumatoid Arthritis
367.
In Early Rheumatoid Arthritis Patients with NonResponse to Methotrexate Monotherapy the Change in
Multi-Biomarker Disease Activity Score Is Differentially
Associated with Subsequent Response to Non-Biological
Versus Biological Therapy
368.
Serum C1M Level Predicts Disease Progression and Early
Treatment Efficacy in Rheumatoid Arthritis
Validation of Snapshot, a Rheumatoid Arthritis
Assessment Tool, Against CDAI, DAS28 (ESR), and DAS28
(CRP) in Canadian Patients with Rheumatoid Arthritis
353.
Sensitivity of Unique Multidimensional Health
Assessment Questionnaire Items Compared to Items on
Both the HAQ and MDHAQ in Patients with RA and SLE
354.
Increased Vascular Wall Inflammation in Patients with
Active Rheumatoid Arthritis As Measured By an 18F-FDGPET/CT Scan
355.
356.
357.
358.
359.
Increased Left Ventricular Mass Index and Decreased
Ejection Fraction Are Associated with Disease Activity in
Rheumatoid Arthritis Patients without Cardiac Symptoms;
Comparison Between Non-Biologic and Biologic Dmards
Treatment Groups, Using a Cardiac Mag
369.
370.
Double Positivity of RA Serologies More Prevalent Yet
Associated with Clinical Response in Ethnic Minority
Patients with Rheumatoid Arthritis
371.
The Impact of Missing Anti-Citrullinated Protein Antibody
(ACPA) on Outcomes in Early Rheumatoid Arthritis: From
the Canadian Early Arthritis Cohort
372.
Diagnostic Accuracy and Associated Costs of Rheumatoid
Factor Testing in Primary Care: A Population-Based Cohort
Study in Spain
373.
Parity and Severity of ACPA-Positive/Negative
Rheumatoid Arthritis. Results from the Swedish EIRA
Study
Biomarkers of Cardiac Dysfunction and Inflammation
in Plasma Predict Occult Coronary Plaque Burden and
Composition in Rheumatoid Arthritis
374.
14-3-3η Cit:Arg Antibody Ratios: Are We Overlooking
the Prognostic Utility of Citrullinated Antibodies By Only
Looking at Titers?
IL-33 and Soluble ST2 Levels As Novel Predictors for
Remission and Progression of Carotid Plaque in Early
Rheumatoid Arthritis: A Prospective Study
375.
Evaluation of RAPID3 with Minimal Joint Count and ACR/
EULAR Provisional Remission Definitions As Predictors
of Future Good Radiographic + Functional Outcome in a
Double-Blind, Phase 3, Randomized Controlled Trial of
Tocilizumab
The Rheumatoid Arthritis Impact of Disease Score Is
Associated with Disease Activity By Clinical, Laboratory
and Ultrasonographic Measures: Validation in an
inception Cohort of DMARD naïve Patients with
Development and Validation of a Diagnostic BeadBased Multiplex Autoantibody Assay:Screening for
Autoantibodies to Detect “Seronegative” Rheumatoid
Arthritis
360.
88% of Recent Onset Polyarthritis Patients Are Positive for
14-3-3η Markers and 14-3-3η Auto-Antibodies Inform a
Favourable Prognosis
361.
Citrullinated 14-3-3η Antibodies Are Specific for Early and
Established RA and Are Complementary to ACPA
376.Using the Multi-Biomarker Disease Activity Score As a
Complementary Inclusion Criterion for Clinical Trials in
Rheumatoid Arthritis May Enhance Recruitment
362.
14-3-3η Early RA Biomarkers: Does Seronegative RA Exist?
377.
363.
Increased Prevalence of Plasma Anti-Nuclear, Anti-SSA,
and Connective Tissue Disease Associated Antibodies in
African American Patients with Rheumatoid Arthritis
Fatigue Fluctuates Substantially over Time in Rheumatoid
Arthritis Patients Despite Stable Disease Activity during
Treatment with Biological Agents
378.
The Use of Week 12 CDAI, RAPID3 and DAS28(CRP)
Responses to Predict Optimal Response to Methotrexate
2014 Program Book
171
ACR POSTER INDICES
395.
Could Osteoprotegerin and TNF-Related ApoptosisInducing Ligand Assessments Help Us to Manage Early
Rheumatoid Arthritis? Results from the Espoir Cohort
In Palindromic Rheumatism, Older Age, Shorter Interval
Between Attacks and Positive Anti-CCP Antibodies May
Predict Progression to RA
396.
Disease Activity Scoring: Comparing Patient and Physician
Global Assessment of Disease Activity in Rheumatoid
Arthritis
381.
Distribution and Clinical Significance of Anti-Heterogenic
Nuclear Ribonucleoprotein A2 Antibody in Connective
Tissue Diseases
397.
Th9 Lymphocytes in Rheumatoid Arthritis
398.
382.
What Is More Predictive of Achieving Remission at 12
Months: The Percentage of Baseline Improvement or the
Actual Disease State Achieved at 6 Months?
Anti-Rheumatic Therapy Decreases Syndecan-1 Shedding
in Rheumatoid Arthritis (RA)
399.
Lipid Concentrations and Particle Sizes in Drug Naive
How Low Is Low Disease Activity? an Analysis from a
Prospective, Observational Registry
400.
Clinical Utility of 14-3-3η in the Evaluation of
Inflammatory Arthritis
401.
Association of Anti-Thyroid Autoantibodies with
Fibromyalgia in Rheumatoid Arthritis
402.
Can GP88 (Progranulin) be Used As a Biomarker for
the Diagnosis and Therapy Evaluation of Rheumatoid
Arthritis?
403.
Metaflammation, PEDF and Chemerin: Potential Systemic
Factors Which Link Obesity to Response to Therapy in
Early Rheumatoid Arthritis
404.
The Relationship Between Disease Activity and Levels of
HMGB1 in Patients with Rheumatoid Arthritis
405.
14-3-3η: A Mechanistic Biomarker That Supports the
Concept of “Uncoupling” of Inflammation and Joint
Damage
406.
The Utility of HLA-DR Genotypification As a
Complementary Tool to Discriminate Undifferentiated and
Rheumatoid Arthritis Patients in Early Arthritis
407.
Serum 14-3-3η Protein Supplements Traditional
Rheumatoid Arthritis Biomarkers
408.
14-3-3η Auto-Antibody Positivity Informs Better Clinical
Outcomes in RA
409.
Soluble CD163 Is a Marker of Disease Activity in Early
Rheumatoid Arthritis and Reflects TNFα Levels
410.
Vascular Endothelial Function Changes during Treatment
in Patients with Rheumatoid Arthritis
411.
ABCB1 and ABCG2 Drug-Efflux Transporters Function
and Its Association with Disease Activity in a Cohort of
412.
Determinants of Radiological Progression in Rheumatoid
Arthritis: Relationship with Serum Levels of OPG, RANKL
and DKK-1
379.
What Level of Disease Activity at 6 Months Predicts
Achieving or Sustaining Remission at 12 Months?
380.
383.
384.Using Patient Reported Outcome Measures to Classify
Disease Activity States in Rheumatoid Arthritis: A
Comparison of Patient Activity Score (PAS) and Routine
Assessment of Patient Index Data (RAPID)
385.
386.
Association of Pharmacogenetic Markers with Treatment
Response in Patients with Rheumatoid Arthritis
387.
Levels of IgG Autoantibodies to Oxidation-Associated
MDA Neo-Determinants Are a Biomarker for Systemic
Inflammation and Disease Activity in SLE and RA
388.
Soluble TREM-1 Is a Biomarker of Anti-CCP-Positive,
DMARD-Naive Early Rheumatoid Arthritis
389.
High 11B-HSD1 Activity Is Associated with Progression
to Rheumatoid Arthritis in Patients with a New Onset of
390.
Prevalence and Correlates of Patient-Physician
Discordance in Early Rheumatoid Arthritis
391.
Self-Assessment Tool of Rheumatoid Arthritis Disease
Activity: Handgrip Strength Measured By a Smartphone
Connected to a Dynamometer
392.
172
Validation of a Prognostic Model to Predict Structural
Damage Assessed By X-Ray in Patients with RA Using MRI
Data from a Clinical Trial
Neuroendocrine Hormone and Metabolic Peptide Levels
in the Earliest Phases of Rheumatoid Arthritis – Do Free
Fatty Acids Play a Role?
393.
Influence of Body Mass Index on Disease Activity and
Radiographic Joint Damage in Rheumatoid Arthritis : A
Systematic Review and Meta-Analysis
394.
Very Low or High Body Mass Index Negatively Affects
patients’ Ability to Achieve Sustained Remission in Early
RA in a Multicenter Canadian Cohort
2014 Program Book
ACR POSTER INDICES
413.
Association of Antinuclear Antibodies with Lung Disease,
Malignancy and Joint Replacement in Rheumatoid
Arthritis
414.
Relationship Between Range of Motion of Joints in
Upper Limbs and Physical Function in Patients with LongStanding Rheumatoid Arthritis: Multicenter Prospective
Cohort Study for Evaluation of Joint Surgery on Physical
Function
415.
a Dual-Center, Double Blind Randomized Study for a
New Scientific Approach in Assessment of Tender Joints
in Inflammatory Arthritis Using the Smart Joint Assessor
Glove Device (Smart JAG Device)
416.Using Patient Reported Outcome Measures to Classify
Disease Activity States in Rheumatoid Arthritis: A
Comparison of Patient-Derived Versions of Clinical Disease
Activity Index (CDAI), Simplified Disease Activity Index
(SDAI) and Disease Activity Score 28
Normal Scores of “0” (floor effects) Are Seen in 33-83%
417.
of Patients with Rheumatoid Arthritis (RA) on 8 HAQ
Activities Which Also Are Found on the MDHAQ, but in
Fewer Than 32% of Patients on 2 Unique MDHAQ Complex
Activities “Walk 2 Miles or 3 Kilometers,
418.
419.
Prevalence of Morning Stiffness in a US Registry
Population of Rheumatoid Arthritis Patients
Comparative Dynamics of Rheumatoid Arthritis Disease
Activity and Disease Severity Measures Using Rarbis, Ciras
and DAS28 in a Population Based Cohort of Patients with
RA
426.
Exploring the DAS: What Is the Level of Agreement in
the Classification of Remission and Low Disease Activity
(LDA) Among the Various Versions of the Disease Activity
Score (DAS) and Their Correlation? an Analysis from a
Prospective, Observational Registr
427.
Multimedia Patient Education Tool for Patients with
428.
Patient-Physician Discordance of Disease Activity
Assessments Predicts Inadequate Treatment Response in
429.
Investigation of MRI Bone Changes in Early-Stage RA
Patients Achieved in Sustained Clinical Good Response:
Sub-Analysis from Nagasaki University Early Arthritis
Cohort
430.
Minimally Important Difference in the European Quality
of Life-Five Dimensions in Patients with Rheumatoid
Arthritis
431.
Joint Dermal Temperature Specifically Identifies the
Individual RA Patient Most Likely to Develop Radiographic
Change on Sharp Score; An Exam in Less Than a Minute
Can Predict Who Specifically Needs Biologic Therapy
432.
Rheumatoid Arthritis-Associated Interstitial Lung Disease:
Risk Factors for Disease Progression
Rheumatoid Arthritis - Human Etiology and Pathogenesis
433.
Less Is More: The Shorter Physical Function Measure
Promis-PF10a Outperforms HAQ in an Ethnically Diverse,
Urban Rheumatoid Arthritis Clinic Population
Bronchiectasis: A Model for Chronic Bacterial Infection
Inducing Autoimmunity in Rheumatoid Arthritis
434.
Characterization of Lung Inflammation in the Lungs of
421.
Prediction of Remission By Patients and Physicians: Does
the Doctor Know Best?
435.
422.
Correlation of RAPID3, DAS28 and CDAI in Disease Activity
and Effects of Education Level and Co-Morbid Diseases on
This Assesment in RA
Smoking Functions As a Negative Regulator of IGF-1 Levels
and Adipokine Network in Patients with Rheumatoid
Arthritis
436.
Increasing Cartilage Turnover in Smokers Developing
Rheumatoid Arthritis Is Associated with High Disease
Activity in Early Disease
437.
Anti-Citrullinated Heat Shock Protein 90 Antibodies
Identified in Bronchoalveolar Lavage Fluid Are a Marker of
Lung-Specific Immune Responses
438.
Distinct Profiles of Proinflammatory Macrophages in
Rheumatoid Arthritis and Coronary Artery Disease
439.
The Anti-IL-6 Antibody Sirukumab Inhibits Vascular
Inflammation in a Human Surrogate Model of
Atherosclerosis
420.
423.
Circulating Anti-Citrullinated Peptide Antibodies and
Cytokines As Biomarkers of Response to DiseaseModifying Antirheumatic Drugs Therapy in Early
424.
The Comparison Between Physical and Ultrasound
Joint Examination for the Hand Joints in Patients with
425.
Beyond Disease Activity: Patient Global Scores Also
Reflect Treatment Expectations and Emotional Reactions
to Living with Rheumatoid Arthritis
2014 Program Book
173
ACR POSTER INDICES
440.
441.
Arthritis Associated Autoantibodies in Non-Rheumatoid
Arthritis Patients with Mucosal Inflammation
442.
Anti-Carbamylated Protein Antibody Levels Are Elevated
in Seropositive Rheumatoid Arthritis and Correlate with
Anti-Sa/Citrullinated Vimentin Antibody Levels
443.
456.
AAA-Atpase p97 Regulates Autophagy-Associated Cell
Death in Arthritis
Rheumatoid Arthritis - Small Molecules, Biologics and Gene
Therapy: Safety of Biologics and Small Molecules in Rheumatoid
Arthritis
457.
First Confirmation Data of Long Term Safety for
Tocilizumab in Real-World Setting; 3 Year Follow-up
Postmarketing Surveillance of 5573 Patients with
Rheumatoid Arthritis in Japan
Sputum Anti-Citrullinated Protein Antibodies in Patients
with Long Standing Rheumatoid Arthritis
458.
Meta-Analysis of Serious Infections with Tofacitinib and
Biological Treatment in Rheumatoid Arthritis Clinical Trials
444.
Evidence for Citrullination of the Nuclear Transciption
Factor Inhibitor of DNA Binding 1 (Id1) in Rheumatoid
Arthritis
459.
Evaluation of the Effect of Tofacitinib on Measured
Glomerular Filtration Rate in Patients with Active
445.
Differing Specificities of Anticitrullinated Peptide/Protein
Antibodies in Palindromic Rheumatism and Rheumatoid
Arthritis: A Case-Control Study
460.
Analysis of Non-Melanoma Skin Cancer Across the
Tofacitinib Rheumatoid Arthritis Clinical Program
446.
Immunoglobulin a Antibodies to Cyclic Citrullinated
Protein Predominate in Individuals at-Risk for Future
Rheumatoid Factor Isotypes in Relation to Antibodies
Against Citrullinated Peptides in Individuals before Onset
of Rheumatoid Arthritis
461.
Comprehensive Summary of the Efficacy and Safety of
Tofacitinib 5mg Twice Daily in Patients with Rheumatoid
Arthritis and an Inadequate Response to DiseaseModifying Antirheumatic Drugs
462.
Infections and Gastrointestinal Side Effects in a
Comparison of Rheumatoid Arthritis Therapies
463.
Golimumab 5-Year Safety: an Analysis of Pooled Data
from the Long Term Extensions of Randomized, DoubleBlind, Placebo-Controlled Studies in Rheumatoid Arthritis,
Psoriatic Arthritis, and Ankylosing Spondylitis
464.
Analysis of Pooled Data from Two Randomized Controlled
Trials and Their Open-Label Extensions: Long-Term Safety
in Rheumatoid Arthritis before and after Certolizumab
Pegol Dose Increase/Decrease
465.
18-Month Worldwide Post-Marketing Surveillance
Experience of Tofacitinib
466.
Should Anti-Tnfa treatment of RA be Stopped before
Orthopedic Surgery?
467.
Evaluation of the Rabbit Risk Score for Serious Infections
in a UK Anti-TNF Treatment Cohort
447.
174
Comparison of C-Reactive Protein (CRP) and Erythrocyte
Sedimentation Rate (ESR) with Estimated Glomerular
Filtration Rate (eGFR) in Patients with Rheumatoid
Arthritis (RA)
448.
Citrulline-Specific Autoimmunity Resides in Quiescent
Circulating Memory B Cells in Rheumatoid Arthritis
449.
Citrullinated-Vimentin-Specific Regulatory T-Cell
Responses Associate with ACPA Positive Individuals with
Non-Specific Musculoskeletal Symptoms
450.
The Mucosal Anti-Citrullinated Protein Antibody Response
in Pre-Clinical Rheumatoid Arthritis
451.
The Association of Fine Specificities of Anti-Citrullinated
Protein Antibodies (ACPA) with disease Severity in
African-Americans with RA
452.
The Use of Multiplex Bead Array to Follow the Effect of
Rituximab on IgG and IgA Serum Autoantibody Responses
to Citrullinated Epitopes in Patients with Rheumatoid
Arthritis
453.
In a Periodontal Disease Cohort without RA,
Indeterminate or Low-Positive Anti-CCP-2 Antibodies Are
Associated with Multiple Distinct ACPA
468.
Identification of Baseline Risk Factors for Adverse Events
in Certolizumab Pegol Treated Rheumatoid Arthritis
Patients
454.
The Specificity of Anti-Carbamylated Protein Antibodies
for Rheumatoid Arthritis in a Setting of Early Arthritis
469.
Safety of Rituximab in Patients with Chronic Inflammatory
Arthritis. Seven-Year Follow-up Observational Study
455.
Clinical and Tissue Specificity of Antibodies Against
Carbamylated Proteins in Patients with Rheumatoid
Arthritis
470.
Safety Profile of Biologic Agents for Rheumatoid Arhtisitis
Treatment after the Complication with MethotrexateRelated Lymphoproliferative Disorder
2014 Program Book
ACR POSTER INDICES
471.
Improving of Safety in Treatment with Biologics during
First Seven-Years Experiences; Long-Term Results from
Observational Cohort Study of Clinical Practice Using
Multicenter Registry in Japan
472.
Abatacept Can be Used Safely for RA Patients with
Interstitial Lung Disease
473.
Complications of Varicella Zona Virus Infections Are More
Frequent in Patients Treated with Biologic Drugs When
Combined with Steroids
487.
Assessment of Lipid Changes in Patients with Early
Rheumatoid Arthritis Treated with Tofacitinib or
Methotrexate over 24 Months
488.
Increases in Serum Cholesterol with Baricitinib Treatment
Are Associated with Favorable Changes in Apolipoprotein
Content and with Improvement in DAS28-CRP in Patients
489.
Rosuvastatin Improves Arterial Stiffness in Patients with
Inflammatory Joint Diseases
474.
Assessment of 12-Month Efficacy and Safety of 168
Certolizumabpegol Rheumatoid Arthritis Treated Patients
from a Multicenter Retrospective National Study in Spain
490.
A Randomised Controlled Trial Evaluating the Effect
of Humira upon Endothelial Function in ACPA Positive
Rheumatoid Arthritis – an Interim Analysis
475.
Risk Analysis of a First Adverse Event and Recurrent
Infections during Biological Therapy in Chronic
491.
Do Patients with Congestive Heart Failure Treated with
Biologics for RA Have a Lower Risk of Fatal Outcome of
Serious Infections?
476.
Medium-Term Safety of TNF-Alpha Inhibitors in
Rheumatoid Arthritis: A Meta-Analysis of Randomized
Controlled Trials
492.
Patient-Reported Outcomes from a Canadian Study of
Patients Taking Methotrexate and Etanercept
477.
Leflunomide Use Is Not Associated with an Increased Risk
of Lung Disease in Rheumatoid Arthritis: A Meta-Analysis
of Randomised Controlled Trials
493.
Efficacy and Safety of Tofacitinib Following Inadequate
Response to Nonbiologic DMARD or Biologic DMARD
494.
Estimation of Cost per Effectively Treated Patients with
Biologic Disease Modifying Anti-Rheumatic Drugs in US
Veterans with Rheumatoid Arthritis
495.
Discontinuation of Biologics in Patients with Rheumatoid
Arthritis after Achieving Low-Activity Disease Status
496.
Efficacy and Safety of Induction Therapy for Rheumatoid
Arthritis with Simultaneous Administration of
Methotrexate and Low-Dose Tacrolimus: A Retrospective
Study
497.
Efficacy and Safety Study of a Sequential Therapy of
Tocilizumab and, If Initially Inadequately Responded
to Tocilizumab, Followed By Rituximab in Patients with
Rheumatoid Arthritis and Inadequate Response to
Traditional Disease Modifying Anti-Rheumatic Drugs
498.
Patient Experience with Initiation of SQ and Oral MTX
499.
Biologic Discontinuation in Rheumatoid Arthritis:
Experience from a Canadian Clinic
500.
Prediction of Successful Dose Reduction or
Discontinuation of Adalimumab or Etanercept Using
Serum Drug Levels and Antidrug Antibody Measurement
501.
Bio-naïve Patients with Rheumatoid Arthritis Benefit
More from Abatacept Treatment Compared to Those Who
Are Inadequate Responders to Other Biologics – Results
from the National Swedish Rheumatology Quality Register
478.
479.
Adverse Events and Infections in Patients with
Rheumatoid Arthritis Treated with Conventional Drugs or
Biologic Agents: A Real World Study
Long Term Safety of Intravenous Golimumab and
Comparison with Subcutaneous Golimumab in
Rheumatoid Arthritis: Results through 2 Years
480.
Serious Infection Risk By Treatments and Types in Patients
with RA
481.
Efficacy and Safety of Etanercept in Rheumatoid Arthritis
Patients over 75 Years Old
482.
Incidence of Opportunistic Infections in Rheumatoid
Arthritis Treated with Biological Agents
483.
Risk of HBV Reactivation in Rheumatoid Arthritis Patients
Undergoing Treatment with Newer Biological Dmards,
Tocilizumab and Abatacept: A Single-Center Real Life
Experience
484.
Reactivation of Hepatitis B Virus in Patients with
Rheumatoid Arthritis after Anti-TNF Therapy
485.
Incidence of Clinical and Serological Lupus-like Disease
during Anti-Tnfα-Treatment – a Two-Year Prospective
Study in an Interdisciplinary Patient Cohort
486.
Tofacitinib Improves Arterial Stiffness Despite upRegulating Serum Cholesterol with Chronic Cardiovascular
Disease in Methotrexate-Resistant Active Rheumatoid
Arthritis Patients. a Cohort Study
2014 Program Book
175
ACR POSTER INDICES
502.
Tocilizumab Use in Patients with Rheumatoid Arthritis
Having Failed One Previous Anti-TNF Agent: Comparison
with Adalimumab, Etanercept and Infliximab
518.
Risk of Infection Associated with Subsequent Biologic Use
Following Rituximab—Results from a National RA Patient
Registry
503.
Does a Higher Dose of Folic Acid Reduce Adverse Effects
of Methotrexate in Rheumatoid Arthritis? a Randomized
Controlled Trial
519.
Patterns of Tocilizumab Use and Safety in Patients
with Rheumatoid Arthritis: Interim Results from a
Multinational Observational Study
504.
Abatacept after Rituximab in Rheumatoid Arthritis.
a Pan-European Collaboration of RA Registries
505.
A Structured Approach for Comparative BenefitRisk Assessment of Rituximab for the Treatment of
520.
Genetic Variant and High Levels of CCL11 in Serum Are
Associated with the Occurrence of Lymphoma and Disease
Activity in Primary Sjögren’s Syndrome Patients (pSS)
506.
Trial of Six Weeks Interval of Tocilizumab Infusion in
521.
CXCL13 Serum Levels Is Associated with Lymphoma, High
B Cells Markers and Diseases activity in Primary Sjögren ’s
Syndrome Patients
507.
Efficacy and Safety of Adalimumab Therapy in Japanese
522.
Whole Blood microRNA Signature for Primary Sjögren’s
Syndrome-Related Lymphoma
508.
Relationship Between NK Cell Count and Important Safety
Events in Rheumatoid Arthritis Patients Treated with
Tofacitinib
523.
Serum CXCL4 Is Increased in Patients with Primary
Sjögren’s Syndrome and Is Associated with Features of
Microvascular Impairment
509.
Etanercept Have Better Drug Survival Than Monoclonal
Antibodies in Rheumatoid Arthritis: Results of Single
Center Hur-BIO Registry
524.
Distinct Patterns of DNA Methylation in Labial Salivary
Gland Tissue Based on Sjögren’s Syndrome Disease Status
510.
Similar Short Term Survival on Drug for Patients with
Rheumatoid Arthritis Treated with Subcutaneous and
Intravenous Abatacept - Results from the National
Swedish Rheumatology Quality Register
525.
The Genetic Basis of Sjögren’s Syndrome (SS) Clinical
Manifestations from Genome-Wide Association Analysis
of Subphenotype Extremes in an International Cohort
526.
A Descriptive and Comparative Study of the Transcriptome
from Salivary Exosomes of Sjögren’s Syndrome Patients
Using RNA-Seq
527.
Salivary Expression of S100A7/Psoriasin and Oral Damage
in Primary Sjögren’s Syndrome and Overlapping Disorders
528.
Calcium-Calcineurin-NFAT Signaling Pathway Regulates
AQP5 Expression in Primary Salivary Gland Acinar Cells
511.
512.
176
First and Second Line Continuation Rates of Non
Anti-TNF-α Biological DMARD for the Treatment of
Effect and Safety of Concomitant Methotrexate and
Tacrolimus on Clinical Response of Abatacept in
Rheumatoid Arthritis Patients with Prior Use of Biological
Dmards
Sjögren’s Syndrome: Pathophysiology
513.
Analysis of Shoulder Joint Destruction in Rheumatoid
Arthritis Patients Treated with Biologics
529.
IP3R3 Deficit Underlies the Loss of Fluid Secretion in
Salivary Glands from Sjögren’s Syndrome Patients
514.
Methotrexate Reduces the Frequency of Prediabetes in
Patients with Rheumatoid Arthritis or Psoriatic Arthritis
530.
Downregulation of Microrna-183 in Sjögren’s Syndrome
Minor Salivary Glands. Implications in Control of Ezrin
Expression and Salivary Gland Function
515.
Dosing of Intravenous Tocilizumab in a Real-World
Setting—Analyses from a US RA Registry
531.
Expression of Indoleamine 2,3 Dioxygenase-1 and -2 in
Focal Sialoadenitis of Patients with Sjögren’s Syndrome
516.
The Safety and Treatment Efficacy of Abatacept
in Rheumatoid Arthritis Patients with Pulmonary
Complications: From the Tsurumai Biologics
Communication Registry (TBCR) Multicenter Study
532.
Adipose Tissue Is Prominent in Salivary Glands of
Sjögren’s Syndrome Patients and Appears to Influence the
Autoimmune Microenvironment in These Organs
517.
Real-World Use of Tocilizumab in Rheumatoid Arthritis
Patients in Canada: Interim Results
533.
Predictive Significance of CCL21 and CXCL13 Levels in
the Minor Salivary Glands of Patients with Sjögren’s
Syndrome
2014 Program Book
ACR POSTER INDICES
548.
Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is
Associated with Long-Term (52-Week) Improvement in
Measures of Disease Activity in Patients with Psoriatic
Arthritis: Results from 3 Phase 3, Randomized, Controlled
Trials
549.
Reliability and Construct Validity of the Psoriasis Symptom
Inventory in Subjects with Psoriatic Arthritis
550.
Secukinumab, an Anti–Interleukin-17A Monoclonal
Antibody, Improves Physical Function, Quality of Life
and Work Productivity in Patients with Active Psoriatic
Arthritis: Results from a Phase 3, Randomized, Controlled
Trial
551.
Predictors Associated with Rheumatologist Referral Time
in Patients with Ankylosing Spondylitis
552.
Secukinumab, a Monoclonal Antibody to Interleukin-17A,
Significantly Improves Physical Function and Quality of
Life in Subjects with Active Ankylosing Spondylitis: Results
of a Phase 3 Randomized, Placebo-Controlled Trial with
Intravenous Loading and Subc
Sustained Improvement in Physical Function, HealthRelated Quality of Life, and Work Productivity with
Adalimumab Treatment in Non-Radiographic Axial
Spondyloarthritis
553.
Efficacy and Safety of Ustekinumab in Psoriatic
Arthritis Patients with Spondylitis and Peripheral Joint
Involvement: Results from a Phase 3, Multicenter, DoubleBlind, Placebo-Controlled Study
Comparison of Baseline Extra-Articular Manifestations,
Comorbidities, and Long-Term Safety in Patients Treated
with Adalimumab for Ankylosing Spondylitis and NonRadiographic Axial Spondyloarthritis
554.
Myocardial Infarction Risk with Diclofenac Use in
Spondyloarthropathy Versus Non-Inflammatory Low Back
Pain
540.
Two Years Sacroiliac Radiographic Progression Rate and
Influence of Baseline Markers of Inflammation in Recent
Onset Spondyloarthritis
555.Urinary Excretion of Type II Collagen C-Telopeptide and
Glucosyl-Galactosyl-Pyridinoline As Prognostic Biomarkers
in Early Spondyloarthritis
541.
Collagen II Neo-Epitopes in Spondyloarthritis.
556.
542.
Predictors for Cardiovascular Events in Patients with
Psoriatic Arthritis – a Cohort Study
Defining Flare in Spondyloarthritis : Thresholds of Disease
Activity Variations
557.
Translation and Cross-Cultural Adaptation of the ASAS
Health Index and the environmental Item Set into 15
Languages
558.
Therapeutic Response in Adalimumab-Treated Patients
with Non-Radiographic Axial Spondyloarthritis Is Similar
Regardless of Body Mass Index
534.
Serum Biomarkers of Inflammation and Fibrosis in
Advancing Diagnosis, Prognosis and Treatment of Anti-Ro
Associated Congenital Heart Block
535.
WITHDRAWN
Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and
Treatment I
536.
Secukinumab, a Monoclonal Antibody to Interleukin-17A,
Significantly Improves Signs and Symptoms of Active
Ankylosing Spondylitis: Results of a Phase 3, Randomized,
Placebo-Controlled Trial with Subcutaneous Loading and
Maintenance Dosing
537.
Secukinumab, a Human Anti–Interleukin-17A Monoclonal
Antibody, Significantly Reduces Psoriasis Burden in
Patients with Psoriatic Arthritis: Results from a Phase 3
Randomized Controlled Trial
538.
539.
543.
544.
Disease Activity and Clinical Response Early in the Course
of Treatment Predict Long-Term Outcomes in Axial
Spondyloarthritis Patients Treated with Certolizumab
Pegol
Observed Incidence Rates of Uveitis over 96 Weeks of
Certolizumab Pegol Treatment in Patients with Axial
Spondyloarthritis
559.Ultra Sonographic Evaluation of the Anterior Chest Wall in
Spondyloarthritis. a Prospective Study
545.
Long-Term Safety and Efficacy of Certolizumab Pegol over
96 Weeks in Patients with Psoriatic Arthritis with and
without Prior Tumor Necrosis Factor Inhibitor Exposure
560.
High Sensitivity of the ASAS Classification Criteria
in Patients with HLA-B27 Positive Undifferentiated
Spondyloarthritis with Onset of Disease after Age 45
546.
Psoriatic Arthritis Mutilans: Characteristics and
Radiographic Progression
561.
A Psychometric Analysis of Outcome Measures in Trials of
Peripheral Spondyloarthritis
547.
Comparison of Clinical and Imaging Characteristics of Axial
Psoriatic Arthritis and Axial Spondyloarthritis
562.
Clinical Response and Remission in Patients with NonRadiographic Axial Spondyloarthritis after Three Years of
Adalimumab Therapy
2014 Program Book
177
ACR POSTER INDICES
563.
Evaluation of Clinical Parameters and Quality of Life in
Smokers with Ankylosing Spondylitis: Results from the
Scotland Registry for Ankylosing Spondylitis
579.
Patients with Ankylosing Spondylitis Do Not Adapt to
Their Disease: Evidence from the ‘then Test’ in Patients
Treated with TNF-Inhibitors
564.
Cardiovascular Events in Ankylosing Spondylitis. an
Updated Meta-Analysis
580.
MRI Is Often Negative in Clinically Suspected NonRadiographic Axial Spondyloarthritis
565.
Effect of Certolizumab Pegol over 96 Weeks of Treatment
on Inflammation of Spine and Sacroiliac Joints Measured
By Magnetic Resonance Imaging in Patients with Axial
Spondyloarthritis
581.
Evaluation of the Nonsteroidal Anti-Inflammatory DrugSparing Effect of Etanercept in Axial Spondyloarthritis:
Results of a Multicenter, Randomized, Double-Blind,
Placebo-Controlled Trial
566.
Structural Progression of the Spine Measured By X-Ray
in Patients with Axial Spondyloarthritis Treated with
Certolizumab Pegol over 96 Weeks, Including Ankylosing
Spondylitis and Non-Radiographic Axial Spondyloarthritis
582.
Non-Steroidal Anti-Inflammatory Drugs in Axial
Spondyloarthritis: A Cochrane Review
583.
What Is the Correlation of Individual HAQ and Basdai
Questions with Disease Activity Measures in Ankylosing
Spondylitis? Implications for Instrument Reduction
584.
Flare in Spondyloarthritis: Proposal of a Meaningful
Change in Symptomatic Outcome Measures in Axial
Spondyloarthritis
585.
Optimism Levels Are Moderate and Similar in Patients
with Axial Spondyloarthritis and Chronic Low Back Pain,
and Are Related to Mental Quality of Life but Not Physical
Quality of Life. a Cross Sectional Study of 277 Patients
586.
Helplessness in Coping Is Associated with Worse Patient
Reported Outcomes Among Patients with Ankylosing
Spondylitis: A Longitudinal Multi-Country Cohort Study
587.
Clinical Characteristics of Nonradiographic Axial
Spondyloarthritis in Korea: A Comparison with Ankylosing
Spondylitis
588.
Blacks with As Have Greater Disease Severity Than Whites
589.
Patients with Nr-Axspa Show a Statistically Higher Disease
Burden in Clinical Practice Compared with Patients with
Radiographic Axial Spa
590.
Factors Associated with a Poor Functional Prognosis in
Early Inflammatory Back Pain: Results from the DESIR
Cohort
591.
The Fat Spondyloarthritis Spine Score (FASSS)
Independently Predicts Radiographic Progression in
592.
Clinical and Psychological Correlates of Sleep Difficulties
in Patients with Spondyloarthropathies Compared to
567.Use of Monotherapy Anti-Tnf Agents in Ankylosing
Spondylitis Patients from the rhumadata® Registry: 8-Year
Comparative Effectiveness of Adalimumab, Etanercept
and Infliximab
568.
Secondary Amyloidosis Complicating Spondyloarthritis:
Still Present after All These Years
569.
Better Outcomes in Ankylosing Spondylitis: The
Synergistic Association Between Exercise and Tumor
Necrosis Factor Inhibitors
570.
Sleep Disturbances in Korean Patients with Ankylosing
Spondylitis Are Associated with Increased Disease Activity
571.Unraveling the Familial Tendency for Ankylosing
Spondylitis in Korea
572.
573.
178
Objective Evaluation of Physical Functioning after TNFi
Therapy in Ankylosing Spondylitis Patients; A Selection of
Three Feasible Performance-Based Tests
Three-Year Course and Prediction of Physical Functioning
in Ankylosing Spondylitis Patients Treated with TNFInhibitors
574.
Do Extra-Articular Manifestations Influence Outcome in
Ankylosing Spondylitis? a 12 Year Follow-up Study
575.
Disease Activity Strongly Influences Work Productivity
and Physical Health Related Quality of Life in Early Axial
Spondyloarthritis: Data from the SPACE-Cohort
576.
Dikkopf-1 (Dkk-1) Serum Levels in Axial Spondyloarthritis
(axSpA) Are Related to Disease Duration
577.
A Substantial Decrease in Work Productivity and Physical
Health-Related Quality of Life in Chronic Back Pain of
Recent Onset: Data from the SPACE-Cohort
593.
The Clinimetric Outcomes of Two Bath Ankylosing
Spondyltis Metrology Indices in Treatment with TNF-á
Blockers
578.
Female Patients but Not Male Patients with Ankylosing
Spondylitis Are at Increased Risk of Developing Ischemic
Heart Disease: A Population-Based Cohort Study
594.
Do Bone Marrow Edema Lesions in the Sacroiliac Joint
Change into Fatty Lesions over a 1-Year Period in Patients
with Axial Spondyloarthritis or Possible Spondyloarthritis
2014 Program Book
ACR POSTER INDICES
595.
Radiographic Sacroiliitis Progression in an Early Axial
Spondyloarthritis Cohort
596.
Clinical Value of ASDAS Index in Spanish Patients with
597.
Inflammatory Burden in Recent-Onset Axial
Spondyloarthritis
598.
Anti-Drug Antibodies As a Predictor for the
Discontinuation of Anti-TNF Agents in Patients with
Spondyloarthrtis
599.
Is There Any Gender Specific Difference in the Cut Off
Values of Ankylosing Spondylitis Disease Activity Score
(ASDAS) in Patients with Axial Spondyloarthritis?
600.
Differing Patterns of Axial Spondyloarthritis in Females
and Males
601.
Combined Hip Abduction Angle Measured By Using
Iphone Compass Application; A Novel Measurement Tool
to Asses Hip Mobility
602.
A Phase 3, Randomized, Controlled Trial of Apremilast,
an Oral Phosphodiesterase 4 Inhibitor, for Treatment of
Psoriatic Arthritis: Long-Term (52-Week) Improvements in
Physical Function
Spondylarthropathies and Psoriatic Arthritis - Pathogenesis, Etiology
611.
Autophagy and Unfolded Protein Response: A Fine
Balance That Can Influence the Pathogenesis of
Ankylosing Spondylitis and Inflammatory Bowel Disease
612.
Association of Platelet Endothelial Cell Adhesion
Molecule-1 and beta1 Integrin Gene Polymorphisms with
Uveitis Development in Ankylosing Spondylitis
613.
The Amount of Free Heavy Chain and β2-Microglobulin in
the Cytoplasm of B*2705 Ankylosing Spondylitis Patients
Compared to B*2705 and B*2709 Healthy Subjects
Does Not Support the UPR Theory. Influence of ERAP1
Polymorphisms
614.
The Association of PPM1A with Inflammasome Activation
in Ankylosing Spondylitis
615.
Analysis of the Gut Transcriptome in HLA-B27 Transgenic
Rats By RNA-Seq Reveals Prominent Interferon and IL-23/
IL-17 Axis Signatures
616.
In Situ Analysis of Mechanisms of New Bone Formation
in Zygapophyseal Joints from Patients with Ankylosing
Spondylitis
617.
Shared HLA Class I and II Alleles in Susceptibility to
Ankylosing Spondylitis Among Three Ethnic Groups
618.
A Gender Bias in Gut Microbiota of SKG Mice Colonized
with a Limited Bacterial Consortium Associated with
Severity of Spondyloarthritis and Ileitis Triggered By BetaGlucan
619.
Effect of ERAP1 Knockdown on Conformation of HLA-B27
and Other HLA Class I Molecules in Human Monocytic
Cells
603.
Periostin May Have a Role in Ankylosing Spondylitis and It
Is Associated with Wnt Signalling Pathway Regulators
604.
Characterisation of Mucosal-Associated Invariant T (MAIT)
Cells in Ankylosing Spondylitis Patients
605.
Decreased Frequencies of Circulating Follicular Helper
T Cell Counterparts and Plasmablasts in Ankylosing
Spondylitis Patients Naïve for TNF Blockers
620.
Innate Immune Stimulation Triggers Altered IL-1a/b
Gene Expression and Experimental Spondyloarthritis in
HLA-B27/huβ2m Transgenic Rats
606.
The Immunological Basis of the Sex-Bias in Ankylosing
Spondylitis: Th17 Expansion Is Restricted to Male Patients
and Correlates with Sex-Related Alteration in Vitamin D
Metabolism
621.
ERAP1 Knockdown Affects HLA-B27 Misfolding and
Endoplasmic Reticulum Stress in HLA-B27 Transgenic Rat
Macrophages
607.
The HLA-B27 Peptidome in Vivo in Transgenic Rats
622.
Gut Microbiota Variations Correlate with Disease Activity
in Spondyloarthritis (SpA) and Rheumatoid Arthritis (RA)
608.
Identification of Novel Autoantibodies in Patients with
Ankylosing Spondylitis Using Human Protein Microarray
623.
Epigenetic Studies in Maternally Versus Paternally
Transmitted Psoriatic Disease
609.
Induced Pluripotent Stem Cells (iPSCs) As a Tool for
Unraveling the Role of Different Cell Types in the Disease
Process of Spondyloarthritis Pathogenesis
624.
Genome-Wide Methylome Investigation Reveals New
Candidate Genes Associated with Arthritis Mutilans
610.
Functional Implications of the Endoplasmic Reticulum
Aminopeptidase 2 (ERAP2) Association with Ankylosing
Spondylitis and Crohn’s Disease: Impact on the Unfolded
Protein Response
625.
Fine-Mapping Major Histocompatibility Complex
Associations Identified Contribution of Multiple Class
I and II HLA Genes on Risk of Psoriasis and Its Clinical
Subtypes
2014 Program Book
179
ACR POSTER INDICES
626.
The Impact of the Interaction Between Human Leukocyte
Antigen Alleles and Obesity on Psoriatic Arthritis Risk
644.
HM-0523, a Novel Syk Inhibitor Blocks Glomerulonephritis
and Extends Life Spans in Lupus Prone MRL/Lpr Mice
627.
HLA Markers for Disease Severity Are Associated with a
Higher Burden of Atherosclerosis in Patients with Psoriatic
Disease
645.
The Combination of Metformin and 2-Deoxy-D-Glucose
Normalizes CD4 T Cell Metabolism and Functions, and
Reverse Disease in Murine Models of Lupus
628.
The Predictive Value of Cardiovascular and Metabolic
Biomarkers for Progression of Atherosclerosis in Psoriatic
Disease
646.
ONO-4059 - a Highly Potent and Dual Oral Inhibitor of
Bruton’s Tyrosine Kinase (Btk) and Tec Kinase: Improves
Anti-Nuclear Antibodies–mediated SLE in Mice
629.
Biomarkers of Chondrocyte Activity Are Increased in
Psoriasis Arthritis and Spondyloarthritis
647.
Helminthes Derivative for Treating Lupus and Colitis in
Mice Models
630.
Biomarkers of Bone Remodeling Are Elevated in Psoriatic
Arthritis
648.
631.
Joint and Bone Related Pathways Discriminate Psoriatic
Arthritis Lesional Skin from Psoriasis vulgaris Lesional Skin
Influenza A (H1N1) Virus Infection Triggers Severe
Pulmonary Inflammation in Lupus-Prone Mice Following
Viral Clearance
649.
IL-23 Mediates Psoriasis-like Inflammation in the SKG
Mouse Model of Spondyloarthropathy
Enhance Translatability Using Multi-Modality Disease
Evaluation Approach in Lupus Model
650.
Immunological and Clinical Relationships of Synovial IL17+ T Cells in Psoriatic Arthritis
Decreased Severity of Pristane Induced Lupus in miR155
Deficient Mice
651.
Inhibiting Tweak (TNF-like weak inducer of apoptosis)
Signaling Improves Blood Brain Barrier Integrity
and Protects from Neuronal Damage in Murine
Neuropsychiatric Lupus
652.
Identification of Eat-2 As a Lupus Susceptibility Gene in
New Zealand Black (NZB) Mice That Regulates Dendritic
Cell Function
632.
633.
Systemic Lupus Erythematosus - Animal Models
634.
635.
636.
Liposomal-Glucocorticoids: A Novel Approach to the
Therapy of SLE
653.
Dermal Injury Promotes Nephritis Flare in Lupus-Prone
NZM2328 Mice
637.
Decreased Inflammatory Dendritic Cells in Lupus-Prone
Estrogen Receptor Alpha Knockout (ERαKO) Mice
Correlate with Increased Survival
654.
Type I Interferon Induces the Depletion and Dysfunction
of Endothelial Progenitor Cells in Gld. ApoE-/- C57BL/6
Mice
638.
Commensal Microbiota Influence Systemic Autoimmune
Responses
655.
Hydroxycholorquine Is Cardioprotective in an In Vivo Rat
Model of Myocardial Ischaemic Reperfusion Injury
639.
Lack of Response Gene to Complement-32 Impairs Th17
Differentiation and Attenuates Lupus-like Chronic Graft
Versus Host Disease
656.
Breach of B Cell Tolerance in New Zealand Black
Chromosome 1 Congenic Mice
657.
640.
A Peptide Mimic Inhibits the Cross Reaction of Anti-DNA
Antibodies with Glomerular Antigens
Distinct Contributions of C1q and C3 in Preventing
Immunogenicity of Apoptotic Cells in Lupus
658.
641.
Peptidylarginine Deiminase Inhibition Mitigates NET
Formation and Protects Against Kidney, Skin, and Vascular
Disease in Lupus-Prone MRL/Lpr Mice
17β Estradiol Regulates VCAM-1 Expression during
Glomerulonephritis
659.
Breakdown of Tolerance at the Tissue Level in Systemic
Autoimmunity: Role of Tissue-Resident Dendritic Cells
660.
Microthrombotic Renal Vascular Lesions Are Associated
to Increased Renal Inflammatory Infiltration in a Mouse
Model of Lupus Nephritis
642.
643.
180
Characterization of CD4+ T Cell Response and Effects of
Regulatory T Cells in Pristane Induced Lupus (PIL)
Mir-663 Impairs the Effects of Bone Marrow-Derived
Mesenchymal Stem Cells on MRL/Lpr Mice
Treatment with a Glycolipid Ameliorates Lupus Dermatitis
and Expands Skin ãä T Cells That Promote the Migration
of Langerhans Dendritic Cells
The Effect of TNF Inhibition on the Autoreactive B Cell
Repertoire in SLE Prone Mice
2014 Program Book
ACR POSTER INDICES
661.
Dysfunction of Glycosphingolipid Metabolism in Lupus
Nephritis
678.
The Effectiveness of Tacrolimus for Minor Flares of the
662.
Interferon Regulatory Factor-5 Promotes Disease in the
MRL/Lpr Mouse Model of Lupus
679.
Hydroxychloroquine Dosing and Disease Activity in a Large
Multi-Racial Lupus Cohort
663.
STAT3 Inhibition Delays the Onset of Lupus Nephritis in
MRL/Lpr Mice
680.
Influence of Antimalarial doesn´t Modify the Outcome of
Cytopenias in Systemic Lupus Erythematosus
664.
The Pathogenesis of Neuropsychiatric Systemic Lupus
Erythematosus Is Dependent on Brain Intrinsic Factors
681.
Hydroxychloroquine Use Is Associated Independently with
Improved Quality of Life in Systemic Lupus Erythematosus
682.
Impact of Patient’s Priorities on the Management of
683.
Impact of Lupus on Work Productivity in Patients and
Caregivers: Findings from a Cross-Sectional Online Survey
in the United States
Systemic Lupus Erythematosus - Clinical Aspects and Treatment:
Treatment and Management Studies
665.
Safety and Efficiency of Low-Dose Interleukin-2 Treatment
in Systemic Lupus Erythematosus
666.
Approach to Discriminate Treatment Impact in Both
Moderate and Severe SLE
684.
Effects of Current Therapies for Lupus on Disease Activity
and Renal Flares
667.
24-Month Outcomes Associated with Belimumab in
Patients with Systemic Lupus Erythematosus in Clinical
Practice Settings
685.
Successful Withdrawal and Discontinuation of
Immunosuppressants in Lupus Patients: Outcomes and
Predictors
668.
Evolution of Patients with Systemic Lupus Erythematous
Treated with Belimumab in Clinical Practice Settings
686.
669.
Predicted Chronic Exposure and Dose Selection for
Belimumab Administered Subcutaneously to SLE Patients
Clinicians Approaches to the Management of Background
Therapy in SLE Patients in Clinical Remission: Results of an
International Survey
687.
670.
Decreased Disease Activity and Corticosteroid Usage and
No Renal Flares during Belimumab Treatment in Patients
with Systemic Lupus Erythematosus
Effect of Corticosteroid Use By Dose on the Risk of
Developing Organ Damage over Time in Systemic Lupus
Erythematosus—the Hopkins Lupus Cohort
688.
Corticosteroids in Early Treatment Pathways in SLE
671.
Belimumab Reduces the Frequency of Flares in Patients
with Refractory SLE: DATA from Clinical Practice Setting
689.
672.
Favorable Response to Belimumab in Pediatric-Onset
Prednisone, Disease Activity and Hypertension
Independently Predict Cataracts in Systemic Lupus
Erythematosus (SLE)
690.
673.
A Comparison of Rheumatoid Arthritis and Systemic Lupus
Erythematosus Trial Design: Ways to Improve Positive
Trials in Systemic Lupus Erythematosus
Lupus Patients Requiring First Corticosteroid Intervention
Late in Disease Course - a Phenotypic Description
691.
Prevalence of Subclinical Echocardiographic Abnormalities
in Patients with Systemic Lupus Erythematosus (SLE)
692.
Circulating Anti-Ro/SSA Antibodies Are Associated with
the Presence of Severe Mitral Regurgitation in Systemic
Lupus Erythematosus
693.
Acute Myocarditis in Patients with Systemic Lupus
Erythematosus: Experience from Affiliated Hospitals of
Catholic University of Korea
694.
Lupus Myocarditis: Clinical, Echocardiographic and
Magnetic Resonance Characteristics
695.
Osteonecrosis in Patients with Systemic Lupus
Erythematosus: Risk Factors and Clinical Outcome
674.
A Novel Strategy to Identify and Evaluate Approved
Drugs and Treatments for Repositioning As Therapies for
Systemic Lupus Erythematosus (SLE)
675.Use of Rituximab in Systemic Lupus Erythematosus: A
Single Center Experience
676.
677.
Response to Rituximab in Patients with Refractory
Systemic Lupus Erythematosus (SLE): Results from a
National Multicentre Register
Pharmacokinetics, Safety, and Biological Activity of
Intravenously or Subcutaneously Administered Tabalumab
in Subjects with Rheumatoid Arthritis or Systemic Lupus
Erythematosus
2014 Program Book
181
ACR POSTER INDICES
714.
The Validity of Patient and Physician Global Disease
Activity Assessments of Systemic Lupus Erythematosus:
Results from the Lupus Activity Scoring Tool (LAST)
As Compared to the Selena Sledai (SS) Modification
Multicentre Study
715.
The REAL Life with Lupus Study: Developing a Patient
Reported Outcome Measure for Use in Clinical Trials and
Clinical Care
Osteonecrosis in Systemic Lupus Erythematosus:
Prevalence, Patterns and Outcomes
716.
Simple Disease Assessment for People with Lupus
Erythematosus
700.
Decreased Lung Diffusion Capacity in Asymptomatic
Patients with Systemic Lupus Erythematosus Does Not
Predict Future Lung Disease
717.
Comparison of Responsiveness of Lupus Impact Tracker
with Lupus Quality of Life to Selena Responder Index
718.
701.
How Important Is Physical Activity for Patients with
Systemic Lupus Erythematodes? -Results of Lula-Study
Safety of Gardasil® Vaccine in Systemic Lupus
Erythematosu, Trial Update
719.
702.
Protein Losing Enteropathy in Systemic Lupus
Erythematosus
Target Modulation of a Type I Interferon (IFN) Gene
Signature with Sifalimumab or Anifrolumab in Systemic
Lupus Erythematosus (SLE) Patients in Two Open Label
Phase 2 Japanese Trials
703.
Autoimmune Hepatitis in Systemic Lupus Erythematosus
696.
Clinical Characteristics and Outcome of Intestinal
Pseudo-Obstruction in Patients with Systemic Lupus
Erythematosus
697.
Venous and Arterial Thrombosis in SLE: Differences in
Natural History
698.
Grip Strength Identifies Increased Physical Disability in
Women with Systemic Lupus Erythematosus
699.
704.Utility and Associated Risk of Pulmonary Embolism CT
Scans in the Michigan Lupus Cohort
182
Systemic Sclerosis, Fibrosing Syndromes and Raynaud’s - Clinical
Aspects and Therapeutics: Systemic Sclerosis Measures and
Outcomes
705.
Lupus Chest Pain in the Emergency Department: a
Common Diagnostic Dilemma
720.
Measures of Disease Status in Systemic Sclerosis:
Systematic Review
706.
Humoral Immunodeficiency in Patients Presenting with
Clinical Features of Systemic Lupus Erythematosus
721.
Muscle Disease in Systemic Sclerosis Is Associated with an
Increased Risk for Cardiac Involvement
707.
Characteristics of Lupus Patients with Interstitial Lung
Disease and Relationship with Jo-1 Antibody
722.
Prediction of Improvement in Skin Fibrosis in Diffuse
Cutaneous Systemic Sclerosis
708.
Determining Risk Factors That Increase Hospitalizations in
Patients with Systemic Lupus Erythematosis
723.
709.
Impact of Sleep Disorders in Quality of Life, Pain and
Disease Activity Using Actigraphy and Pittsburgh Sleep
Quality Index (PSQI)in Female with Systemic Lupus
Ertyhematosus (SLE).
Early Mortality in Australian, Canadian and Spanish
Scleroderma Patients: Rationale for Establishing a MultiNational Inception Cohort of Patients with Systemic
Sclerosis
724.
Moderate Decline in Forced Vital Capacity is Associated
with a Poor Outcome in Systemic Sclerosis Patients
725.
Reduced Diffusing Capacity of Carbon Monoxide Is
Independently Associated with Worse Subclinical
Left Ventricular Function on Speckle-Tracking
Echocardiography in Systemic Sclerosis
726.
Risk of Ischemic Stroke in Patients with Systemic Sclerosis:
A Systematic Review and Meta-Analysis
727.
International Classification of Functioning, Disability,
and Health (ICF) Core Sets for Connective Tissue Disease
Interstitial Lung Disease (CTD-ILD) and Idiopathic
Pulmonary Fibrosis (IPF) – a Necessary Map to Health
Care Provision in the Era of ICD-11
710.
Splenectomy in Systemic LUPUS Erythematosus and
AUTOIMMUNE Hematological Diseases. a Comparative
Analysis
711.
Is the Disease-Specific Lupusqol Sensitive to Changes of
Disease Activity in SLE Patients after Treatment of a Flare?
712.
Mapping the Disease-Specific Lupusqol to the SF-6D
713.
Lupuspro Is Responsive to Changes in Disease Activity
over Time
2014 Program Book
ACR POSTER INDICES
728.
Prediction and Impact of Attacks of Raynaud’s
Phenomenon, As Judged By Patient perception
Systemic Sclerosis, Fibrosing Syndromes and Raynaud’s Pathogenesis, Animal Models and Genetics
729.
A Dilated Esophagus Is an Independent Risk Factor for
Interstitial Lung Disease in SSc
744.
Integrin Inhibitor Modulates Pulmonary Fibrosis in the
Reactive Oxygen Species Murine Model of Systemic
Sclerosis
730.
Prediction of Cardiac and Vascular Events in Systemic
Sclerosis: Input from Endothelin-1 Type a Receptor
Antibodies
745.
Genetic Susceptibility Loci of Idiopathic Interstitial
Pneumonitis Do Not Represent Risk for Systemic Sclerosis
731.
Performance of the Old ACR and the New ACR-EULAR
Systemic Sclerosis Classification Criteria in Patients with
Limited Cutaneous Disease: Effect on the Ascertainment
of Severe Pulmonary Arterial Hypertension
746.
Elevated Pentraxin 3 in Patients with Systemic Sclerosis:
Associations with Vascular Manifestations and Defective
Vasculogenesis
732.
Predictors of Inpatient Mortality in Patients with Systemic
Sclerosis: A Case Control Study
747.
Systemic Sclerosis Patients with Antitopoisomerase
Antibodies Showed Significant Association with CCR6
Polymorphisms
733.
Impact of Geographic Variation on the Risk of Digital
Ulcers Development in Systemic Sclerosis: A Brazilian
Multicenter Registry
748.
Increased Expression of Chemerin in Endothelial Cells Due
to Fli1 Deficiency May Contribute to the Development of
Digital Ulcers in Systemic Sclerosis
734.
Lower Socioeconomic Status, Male Gender and Diffuse
Scleroderma Are Associated with Worse Survival in the
Pulmonary Hypertension Assessment and Recognition of
Outcomes in Scleroderma Cohort
749.
Progranulin Overproduction Due to Fli1 Deficiency
Contributes to the Resistance of Dermal Fibroblasts to
Tumor Necrosis Factor a in Systemic Sclerosis
735.
Sarcopenia in Systemic Sclerosis: Prevalence and
Association with Functional Parameters and Quality of
Life
750.
Molecular Characterization of Systemic Sclerosis
Esophageal Pathology Identifies Inflammatory and
Proliferative Signatures with Few Fibrotic Markers
736.
Serum Galectin-3 Levels in Early Diffuse Systemic Sclerosis
and the Relationship to Skin Score and Skin Score Change
751.
Dissecting the Heterogeneity of Skin Gene Expression
Patterns in Systemic Sclerosis
737.
Reliability of Nailfold Capillary Density Measurement As a
Possible Outcome Measure for Systemic Sclerosis-Related
Microangiopathy
Troponin T as a Diagnostic and Prognostic Biomarker of
Primary Cardiac Involvement in Systemic Sclerosis
752.
Potential Roles of Toll-like Receptor 4 in the Murine
Models of Systemic Sclerosis
753.
Identification of IL12RB1 As a Novel Systemic Sclerosis
Susceptibility Locus
738.
739.
740.
741.
742.
743.
Lack of Association Between Esophageal Symptoms and
Abnormal Findings in High-Resolution Manometry in a
Mexican Mestizo Cohort with Systemic Sclerosis (SSc)
754.
The Global miRNA Whole Blood Profile in Systemic
Sclerosis and Its Correlation with Serum Cytokine Levels
755.
Right Ventricular Diastolic Impairment Is Common in
Systemic Sclerosis and Is a Marker of Several Organ-Target
Damage of the Disease
Increased Degradation of BMPR2 in a TGFβ Dependent
Transgenic Mouse Model of Scleroderma with
Susceptibility to Pulmonary Arterial Hypertension
756.
Abnormal Right Ventricular Longitudinal Strain Detected
in Systemic Sclerosis Patients Prior to Abnormalities in
Conventional Measures of Right Ventricular Size and
Function
Nucleosome, a Basic Repeating Unit of Chromatin, in
Patients with Systemic Sclerosis: Possible Association with
Immunological Abnormalities Via Abnormal Activation of
T and B Cells
757.
Precision of Ultrasound Skin Thickness Measurements:
Influence of Examiner and Ultrasound Transducer
Distinctive Patterns of Telomere Shortening and Apoptosis
in Limited and Diffuse cutaneous Systemic Sclerosis
758.
Outcome of Patients with Systemic Sclerosis Admitted to
the Intensive Care Unit
Assessment of mRNA Gene Expression Based on Forearm
Skin Score in Systemic Sclerosis Patients
759.
The Anti-Fibrotic Effect of Endostatin-Derived Peptide Is
Mediated By Urokinase
2014 Program Book
183
ACR POSTER INDICES
760.Use of Multiplex Cytokine Analysis of Dermal Blister Fluid
to Assess Local Inflammatory and Immune Activity in
Systemic Sclerosis
761.
762.
763.
764.
765.
766.
HLA-DRB1 Alleles in Susceptibility to Giant Cell Arteritis:
Literature Review and Meta-Analysis
776.
A Candidate Gene Approach Identifies IL33 as a Novel
Genetic Risk Factor for GCA
777.
Influence of the IL17A Locus in Giant Cell Arteritis
Susceptibility
778.
PTPN22 rs2476601 and Susceptibility to Biopsy Proven
Giant Cell Arteritis (GCA) in an Australian Sample
779.
ERG and FLI1 in Systemic Sclerosis-Associated Pulmonary
Complications
Toll-like Receptor 2 Agonism Induces Inflammation,
Angiogenesis and Cell Migration in Giant Cell Arteritis
780.
Gene-Gene Interaction of IRF5 and BLK Polymorphisms in
US and Spanish Cohorts of Systemic Sclerosis (SSc)
Novel Roles for Zyxin in the Pathogenesis of Giant Cell
Arteritis
781.
Rho Kinase (ROCK) Activity in Aortitis: Comparison of
Giant Cell Arteritis (GCA), Takayasu Arteritis (TA) and
Isolated Aortitis (IA)
782.
Temporal Artery Microbiome in Giant Cell Arteritis
783.
Increased Migration and Proliferation Potential
Characterize Vascular Smooth Muscle Cells from Patients
with Giant Cell Arteritis
784.
Novel Inhibitory Effects of Mast Cells in Aortitis Involves
Aortic Expression of Suppressor of Cytokine Signaling-1
785.
Incidence, Prevalence and Survival of Biopsy-Proven Giant
Cell Arteritis in Northern Italy
786.
The Incidence and Mortality Rates of Giant Cell Arteritis in
Southern Norway Are Lower Than Previous Reported
787.
Cardiovascular Risk Factors and Incident Giant Cell
Arteritis
788.
Fast-Track Diagnostic Procedure for Giant Cell Arteritis
789.
Association Between Histological Features and Clinical
Features of Patients with Biopsy Positive Giant Cell
Arteritis
790.
Correlations Between Histopathological Findings and
Clinical Manifestations in a Large Monocentric Cohort of
Patients with Biopsy-Proven Giant Cell Arteritis
791.
Comparison of Clinical Manifestations in Different
Histological Subsets of Biopsy-Proven Giant Cell Arteritis
792.
Is Temporal Artery Biopsy the Gold Standard for the
Diagnosis of Giant Cell Arteritis?
793.
Preliminary Analysis of Histological Findings in Diagnosis
of Giant Cell Arteritis Biopsy Positive Patients
Specific Autoantibody Profiles and Disease Subgroups
Correlate with Circulating Micro-RNA in Systemic Sclerosis
IQGAP1 Enhances Contractility of Scleroderma Lung
Fibroblasts and Promotes Bleomycin-Induced Pulmonary
Fibrosis
Caveolin-1 and Peroxisome Proliferator-Activated
Receptor Gamma Co-Regulate the Differentiation of
Monocytes to Adipocytes and Myofibroblasts in Vivo and
in Vitro
Endothelial Fli1 Deficiency Delays Wound Healing Due
to Impaired Anastomosis of Newly Formed Vessels – a
Possible Mechanism of Refractory Skin Ulcers in Systemic
Sclerosis
The Impact of Plasmacytoid Dendiritc Cells (pDCs) on
Fibrosis in bleomycin–induced Murine Model of Systemic
Sclerosis (SSc)
768.
Transforming Growth Factor Beta Induces anti Angio and
Vasculo-Genesis Phenotype in Dermal Fibroblasts through
Secretion of Pigment Epithelium Derived Factor
770.
771.
772.
773.
774.
184
775.
767.
769.
Vasculitis
Anti-Fibrotic Effects of an Investigational Drug: BisOxetanyl Sulfoxide
Detection of Proteins in Lung Tissues of Patients with
Systemic Sclerosis Using Tissue Microarrays
Development of a Bifluorescent Lineage Tracker Reporter
Mouse Strain to Analyze the Phenotypic Conversion of
Endothelial Cells into Myofibroblasts in Vivo. Application
to Study the Synergistic Effects of Endothelin-1 on TGF-β1Induced Endothelial-to-Mesen
RNA-Seq and Mir-Seq Analysis of SSc Skin Across Intrinsic
Gene Expression Subsets Shows Differential Expression of
Non-Coding RNAs Regulating SSc Gene Expression
Functional Autoantibodies from Patients with Systemic
Sclerosis Reactive to Angiotensin II Type 1 and
Endothelin-1 Type a Receptor Induce Inflammatory
Lymphocyte Infiltration into Lungs of Mice
Endothelin-1 Synergistically Increases TGF-β-Induced
Hif1α Expression Under Normoxic Conditions during
Endothelial-to-Mesenchymal Transition in Murine
Endothelial Cells. a Novel Mechanism for the Fibrogenic
Effects of Endothelin
2014 Program Book
ACR POSTER INDICES
794.
795.
Color Doppler Ultrasonography Findings in Giant
Cell Arteritis and Their Relationship with Clinical
Manifestations
High Interobserver Agreement on Ultrasonographic
Findings in Patients with Large Vessel Vasculitis
796.
Early Halo Sign Features on Ultrasound Examination of
Treated Patients with Giant Cell Arteritis
797.
PET/CT for the Diagnosis of Giant Cell Arteritis: A
Prospective Study
798.
Frequency and Predictive Variables of Relapses in Patients
with Biopsy-Proven Giant Cell Arteritis
799.
Peripheral Arterial Disease in Patients with Giant Cell
Arteritis: A Systematic Review and Meta-Analysis
800.
Hospitalization Rates and Utilization Among Patients with
Giant Cell Arteritis: A Population-Based Study from 1987
to 2012
801.
Venothromboembolism in Large Vessel Vasculitis
802.
Inpatient Complications in Patients with Giant Cell
Arteritis: Increased Risk of Thromboembolism, Delirium
and Adrenal Insufficiency
803.
Corticosteroid-Related Adverse Events in Patients with
Giant Cell Arteritis: A Claims-Based Analysis
804.
Vasculitis and Inflammatory Bowel Diseases: A Study of 32
Patients with Both Conditions and Systematic Review of
the Literature
805.
Takayasu Arteritis and Ulcerative Colitis –High
Concurrence Ratio and Genetic Overlap
806.
Association of a Single Nucleotide Polymorphism (SNP) in
IL-12B Region with Clinical Features and Peripheral T Cell
Profiles of Patients with Takayasu Arteritis
807.
Serum Cytokine Profiles in Takayasu’s Arteritis: A Search
for a Biomarker
808.
Biomarkers of Disease Activity in Vasculitis
809.
Risk Factors for Severe Ischemic Complications in Takayasu
Arteritis: A French Multicenter Retrospective Cohort of
182 Patients
810.
Damage Assessment in Takyasu Arteritis Using Takayasu
Arteritis Damage Score (TADS)
811.
Biologics in Takayasu Arteritis: Preliminary Data from the
French Registry
812.
Prognosis of Clinically Inactive Takayasu’s Arteritis
813.
Long-Term Outcomes of Takayasu’s Arteritis Patients with
Renal Artery Involvement
814.
Tocilizumab in Giant Cell Arteritis: Multicenter Open-Label
MONDAY, NOVEMBER 17, 2014
B cell Biology and Targets in Autoimmune Disease: Rheumatoid
Arthritis and Related Diseases
982.
Identification of Potential SERUM Autoantibody
Biomarkers in Rheumatic Diseases Using a New
Generation of Protein Arrays
983.
Identification of Annexin A2 As an Autoantigen in
Rheumatoid Arthritis and in Lyme Arthritis
984.
Apolipoprotein B Is a Target of T and B Cell Responses in a
Subgroup of Patients with Lyme Disease
985.
Labial Salivary Gland Antibody-Secreting Cell Specificity
and Characteristics in Sjögren’s Patients
986.
Integrated Comprehensive Analysis of Immune Cell
Subsets and Serum Protein Profile Identifies the Role
of Pre-Germinal Center B Cells in Sjögren’s Syndrome
Pathogenesis
987.
Novel Auto-Antigen in Aortic Aneurysms of Large Vessel
Vasculitis
988.
Serum CXCL13 As a Biomarker of Disease Activity and
Severity in Rheumatoid Arthritis: Comparison with Acute
Phase Reactants and the Autoantibody Profile
989.
Fcgamma Receptor IIb Facilitates Rapid Internalisation
of Rituximab (type 1 anti-CD20 antibody) in B Cells from
Patients with RA and SLE and Contributes to Less Efficient
B Cell Lysis Than Type 2 Anti-CD20 Antibodies, in Vitro
990.
WITHDRAWN
991.
The Alternative CD20 Transcript Variant Is Not a Factor
for Resistance to Rituximab in Patients with Rheumatoid
Arthritis
992.
Differential Antigen-Presenting B-Cell Phenotype from
Synovial Microenvironment of Rheumatoid Arthritis and
Psoriatic Arthritis Patients
993.
Anti-Citrullinated Proteins Antibodies Promote Synovial
Fibroblast Migration in Rheumatoid Arthritis
2014 Program Book
185
ACR POSTER INDICES
994.
995.
IL-7 Modulates B Cell Immunoglobulin Isotype Production
and Increases B Cell Activating Factor of the Tumor
Necrosis Factor Family (BAFF) in Synovial Fibroblasts
from Osteoarthritis (OA) and Rheumatoid Arthritis (RA)
Patients
Rheumatoid Arthritis Patients Have Alterations in
Inherently Autoreactive 9G4+ B-Cell Subpopulations in
Peripheral Blood
996.
Memory B Cell Subtype Modulation in Patients with
997.
Explore Translational Pharmacokinetics/
Pharmacodynamics Response/Efficacy Relationship of a
Novel Bruton’s Tyrosine Kinase Inhibitor in Rat CollagenInduced Arthritis Model
998.
β2 Adrenoceptor Signal Is Augmented in B Cells in the
Course of Arthritis to Increase IL-10
999.
Microrna-155 As an Epigenetic Regulator of B-Cell
Activation in Rheumatoid Arthritis: In Vivo and in Vitro
Evidences
1000.
Pathogenic Role of CXC Chemokine receptor 3-Positive B
Cells in Bone Destruction of Rheumatoid Arthritis
Biology and Pathology of Bone and Joint: Cartilage, Synovium and
Osteoarthritis
1001.
Fibroblast-like Synoviocytes Inhibit Wnt Signaling Pathway
By Secreting Dockcop-1
1002.
Global Transcriptome Analysis in Osteoarthritic Cartilage
Reveals Significant Differential Gene Expression and
Associations with Histologic Disease Progression
1003.
Proteomic Analysis of Connexin 43 Reveals Novel
Interactors Related to Osteoarthritis
1004.
Elevated Levels of BMP2 Compensate for Loss of TGF-Beta
in Articular Cartilage during Experimental Osteoarthritis
1005.
Histone Lysine Demethylase KDM6A Mediates Joint
Destruction in Osteoarthritic Knees By Epigenetic
Disturbance of SOX9 Promoter and Histone H3K27
1006.
Interleukin-4 As Promising, Anti-Inflammatory Transgene
for Gene Therapeutic Application in Joint Diseases
1007.
Markedly Increased Mesenchymal Stem Cell Activity in
MRI Bone Marrow Lesions Compared with Non-Involved
Bone in Osteoarthritic Hips
1008.
Autophagy Activation Protects from Mitochondrial
Dysfunction in Human Chondrocytes
1009.
186
Regeneration of Articular Cartilage in Situ with Bone
Marrow-Derived Mesenchymal Stem Cells
2014 Program Book
1010.
Catecholaminergic-to-Cholinergic Transition of
Sympathetic Nerve Fibers in Arthritis and in a Co-Culture
System of Sympathetic Ganglia in Vitro
1011.
Fibroblast Growth Factor-2 and Its Receptor Antagonists
in Osteoarthritis
1012.
Role of High Glucose Environment on Chondrocyte
Activation and Characterization of Diabetic Osteoarthritic
Cartilage: Toward Pathophysiological Delineation of
Diabetes Mellitus-Related Osteoarthritis
1013.
Mitochondrial Function Is Impaired in Human Knee
Osteoarthritic (OA) Chondrocytes and Improved By
Pharmacologic AMPK Activation Via SIRT1 and PGC-1α
1014.
Harpagide, a Low Molecular Weight Natural Product,
Suppresses IL-1â-Induced IL-6 Expression By Blocking the
Activation of p38 MAPK and Transcription Factors CEBPâ
and AP-1 in Primary Human Osteoarthritis Chondrocytes
1015.
Mir-9/MCPIP1 Axis Mediated Regulation of IL-6
Expression in Osteoarthritis Chondrocytes
1016.
Reduced Expression of Circadian Rhythm Genes in Human
Osteoarthritis Cartilage: NR1D1 Suppression Alters
Chondrocyte Response to IL-1β Stimulation
1017.
BMP9-Induced pSmad1/5/8 Signaling and Chondrocyte
Hypertrophy Are Effectively Inhibited By TGFβ1
1018.
Monolayer Culture Induced the Expression of ZyxinRelated Protein 1 (ZRP-1), αvβ3 integrin Complex and
Leptin in Human Articular Chondrocytes
1019.
Targeting the Bone-Driven Metabolic OA Phenotype By a
Novel Dual Amylin Calcitonin Receptor Agonist, KBP-056
1020.
Changes in Peripheral Blood Immune Cell Composition in
Osteoarthritis
1021.
Transthyretin and Amyloid in Cartilage Aging and
Osteoarthritis
1022.
Fibroblast-like Synovial Cells and Monocytes Team up
in the Organization and the Dynamic Modelling of the
Synovial Tissue
1023.
Chronic PTHrP Treatment Promotes Hypertrophic
Differentiation and Inflammatory Gene Expression in
Chondrocytes
1024.
Racial Differences in Biochemical Knee Cartilage
Composition Between African American and Caucasian
American Women with MR-Based T2 Relaxation Time
Measurements – Data from the Osteoarthritis Initiative
1025.
Leptin Production By Osteoarthritis Synovial Fibroblasts:
Stimulation By Glucocorticoids and Mineralocorticoids
through the Glucocorticoid Receptor and GILZ
(Glucocorticoid-Induced Leucine Zipper) Protein
ACR POSTER INDICES
1026.
Monosodium Urate Monohydrate Crystals Induces
the Expression of Ihh and MMP-13 in ATDC5 Cells:
Implications in Osteoarthritis (OA) Development.
Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and
Angiogenesis
1027.
Hematopoietic Cell Kinase (HCK) As a Novel Regulator of
Fibroblast-like Synoviocyte Function in RA
1028.
ADAM-10 Plays Monocyte Migration and Adhesion in
Rheumatoid Arthritis Synovial Fibroblasts
1029.
Anandamide and Related Eicosanoids Decrease the
Production of Pro-Inflammatory Cytokines in Synovial
Fibroblasts By a COX-2 Dependent Mechanism:
Involvement of Calcium and TRP Channels
1042.
IL-1β and TNF-α Promote Monocyte Viability through the
Induction of GM-CSF Expression By Rheumatoid Arthritis
Synovial Fibroblasts
1043.
Identification of Putative Biomarkers and Molecular
Mechanisms Associated with Adverse Tissue Reactions to
Metal-on-Metal and Modular Neck Hip Implants
1044.
Novel Compound Cytokine Release Inhibitory Drug 3
(CRID3) Inhibits the NLRP3 Inflammasome in Rheumatoid
Arthritis
1045.
Tertiary Lymphoid Organ Developmental Program:
Diversgent Paradigm of Lymphoid Organogenesis
1046.
Modulatory Effect of Adiponectin on Apoptosis and
Proliferation of Synovial Fibroblasts from Rheumatoid
Arthritis Patients
1047.
Type I and II Interferon Signatures in Sjögren’s Syndrome:
Contributions in Distinct Clinical Phenotypes and Sjögren’s
Related Lymphomagenesis
1030.
ABT-122, a Novel Dual Variable Domain (DVD)-IgTM,
Targeting TNF and IL-17, Inhibits Peripheral Blood
Mononuclear Cell Production of GM-CSF and Decreases
Lymphocyte Expression of CXCR4 in Healthy Subjects
1031.
Induction of Pro-Apoptotic Noxa Expression By Ursolic
Acid Sensitizes Rheumatoid Arthritis Synovial Fibroblasts
to Apoptosis: A Role of Mir-181a
1048.
Oncostatin M Suppresses Activation of IL-17/Th17 Via
Suppressor of Cytokine signaling3 (SOCS3) Regulation in
CD4+ T Cells
1032.
Neutralization of IL-17 Ameliorated Kidney Pathology
Associated with Immune-Complex Mediated Autoimmune
Glomerulonephritis
1049.
Bioactive TGF-β Is Present on Bovine Milk-Derived
Exosomes: Consequences for Patients?
1050.
1033.
Stat3 Promotes IL-10 Expression in SLE T Cells through
Trans-activation and Chromatin Remodeling
A Role for Purinergic Receptor Signalling in Basic Calcium
Phosphate Crystal-Induced Inflammation
1034.
Therapeutic Potential of Targeting Sialic Acid Modified
Receptors in Osteoarthritis
Epidemiology and Public Health: Rheumatoid Arthritis and
Systemic Lupus Erythematosus Outcomes
1035.
TNF-á Modulates the Expression of Circadian Clock Genes
Via Calcium Signaling in Rheumatoid Synovial Cells
1051.
Rates of Renal Remission with Immunosuppressives in
Lupus Nephritis: A Systematic Review and Network MetaAnalysis
1036.
Synergism Between GM-CSF and IL-17 Causes Enhanced
Joint Pathology Via the Production of IL-6 and IL-23
1052.
Time Trends in Comorbidities Among Patients with
Rheumatoid Arthritis Compared to the General Population
1037.
Anti-MDA5 Antibody Associated Myositis Compared to
DM Patient: A Distinct Muscular Pattern Associated with a
shared IFN Signature
1053.
Co-Morbidity Is Associated with Disease Severity in Early
1038.
Macrophage-Fibroblast Crosstalk Pathways Amplify RA
Joint Pathology
1054.
Rheumatoid Factor, Not ACPA, Is Associated with Disease
Activity in Rheumatoid Arthritis
1039.
Interleukin-20 Is Triggered By TLR Ligands and Associates
with Rheumatoid Arthritis Disease Activity
1055.
Identifying Flare in Rheumatoid Arthritis (RA):
Performance of the Flare-Assessment in RA (FLARE)
Questionnaire in a US Population
1040.
Dysregulated Serum Interleukin 16 Concentration
Associated with Clinical Disease Activity in Patients
with Rheumatoid Arthritis Is Efficiently Corrected By
Immunological Intervention
1056.
Factors Associated with Impairment on Quality of Life in
Early or Established RA Patients
1041.
Imaging the Role of Chemoattractants in Inflammatory
Arthritis
1057.
Work-Related Behavior and Experiences in Patients with
2014 Program Book
187
ACR POSTER INDICES
Levels of Fatigue Are Dependent on Country of Residence
in Rheumatoid Arthritis: An Analysis Among 3920 Patients
from 17 Countries
1075.
1059.
Patients with RA from Wealthier Countries Perform Better
on Clinical Disease Activity Measures, but Tend to Show
Worse Person Reported Outcomes
1076.U.S. Geographic Trends in the Distribution and Treatment
Practices of Juvenile Systemic Lupus Erythematosus: An
Analysis of the Childhood Arthritis and Rheumatology
Research Alliance Registry
1060.
Musculoskeletal Surgeries and Procedures in Patients with
RA: Results from a UK Retrospective Study
1077.
A Real-World Characterization of US Patients with
“Moderate-to-Severe” Systemic Lupus Erythematosus
1061.
How Does Rheumatoid Arthritis Disease Activity Affect
Development of Upper Cervical Lesions? a Retrospective
Study of Cervical Spine X-Rays Combined with a Cohort
Study in Rheumatoid Arthritis Patients
1078.
Work-Related Behavior and Experiences in Patients with
1079.
Prevalence of Cardiac Arrhythmias in Systemic Lupus
Erythematosus
1080.
Stroke Risks Among U.S. Medicaid Recipients with
Systemic Lupus Erythematosus, 2000-2006: Racial and
Ethnic Variation
1081.
Prediction of Mortality Risk Related to Cerebrovascular
Accidents in Patients with Systemic Lupus Erythematosus
(SLE) vs Anti-Phospho-Lipid-Antibody (aPL) syndrome
1082.
Risk of Intra Cranial Hemorrhage among Patients with
Anti-Phospho-Lipid-Antibody (aPL) syndrome vs Systemic
Lupus Erythematosus (SLE) in Stroke Population: A
Nationwide Analysis
1062.
1063.
Impact of Obesity on 1 Year Outcomes: Results from the
Meteor Foundation International Rheumatoid Arthritis
Cohort
Management of Hyperlipidemia Among Patients with
Rheumatoid Arthritis in the Primary Care Setting
1064.Unique Profile of Cardiovascular Risk Factors in
Rheumatoid Arthritis High-Risk Populations with
Insufficient Risk Control
1065.
Characteristics of Rheumatoid Arthritis Patients with and
without Cardiovascular Diseases - Data from the Ontario
Best Practice Research Initiative (OBRI)
1066.
Factors Associated with Recording of Rheumatoid Arthritis
on Death Certificate
1067.
Mortality Trends in Rheumatoid Arthritis during the
Biologic Era, 1998 to 2011
1068.
Smoking-Related Mortality in Rheumatoid Arthritis: A
Retrospective Cohort Study Using Electronic Medical
Records
1069.
Impact of Rheumatoid Arthritis on the Mortality of
Patients Who Develop Cancer: A Population-Based Study
Mortality Risk in Patients with Rheumatoid Arthritis Who
Develop Non–Hodgkin′s Lymphoma
1070.
188
Risk of High-Grade Cervical Dysplasia and Cervical Cancer
in Women with Systemic Lupus Erythematosus on
Immunosuppressive Drugs
1058.
1071.
What Is the Impact of Chronic Systemic Inflammation
Such As Rheumatoid Arthritis on Mortality Following
Cancer?
1072.
Sex Ratio of Offspring Born to Women with Lupus and
1073.
Prescription Medication Trends in Medicaid-Enrolled
Pregnant Women with Rheumatoid Arthritis, Psoriasis,
and Systemic Lupus Erythematosus
1074.
A Meta-Analysis of the Risk of Venous Thromboembolism
in Inflammatory Rheumatic Diseases
2014 Program Book
Epidemiology and Public Health (ARHP)
1083.
The Relation of Step Length to MRI Features of
Osteoarthritis in the Patellofemoral Joint: The MOST
Study
1084.
Obesity Is a Risk Factor for Depression in Systemic Lupus
Erythematosus (SLE)
1085.
Trajectories and Predictors of Physical Activity over Two
Years in Rheumatoid Arthritis
1086.
The Effect of Foot Pain on Mobility Disability in Older
Adults: The Framingham Foot Study
1087.
The Prevalence of Knee Arthritis and Associated SelfReported Limitation of Activity in Chinese Populations
1088.
Socioeconomic Disparities in Health Outcomes Among
Individuals with, or at Risk for, Osteoarthritis from the
United States: Data from the Osteoarthritis Initiative
1089.
Trajectories of Disability over Time Among Patients with
Systemic Sclerosis
1090.
Association of Objectively Measured Physical Activity and
Metabolic Syndrome Among Adults with Osteoarthritis in
the United States
ACR POSTER INDICES
1091.
Skeletal Muscle Fat and Its Association with Physical
Function and Physical Activity in Adults with Rheumatoid
Arthritis
1092.
Does Arthritis Status Predict Starting or Stopping Work
over a 2-Year Period?
Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical
Pain Syndromes: Clinical Focus
1109.
Impact of Age on Symptom Severity and Disease
Management at Fibromyalgia Diagnosis
1110.
The Comparative Efficacy of Kinesio Taping and
Local Injection Therapy in Patients with Subacromial
Impingement Syndrome
1111.
The Effect of High Intensity Laser Therapy in the
Management of Myofascial Pain Syndrome of the
Trapezius: A Double Blind, Placebo-Controlled Study
1093.
Female Sexual Function in Fibromyalgia
1112.
1094.
Work Productivity and Healthcare Utilization in Patients
with Fibromyalgia and Comorbid Depression Taking
Antidepressant Medication
Cognitive Symptoms in Fibromyalgia Patients Compared
with Rheumatoid Arthritis Patients
1113.
Mayor Trocanter Painful Syndrome. Treatment with
Hyaluronic Acid Versus Triamcinolone Acetonide
Injections. a Comparative Study
1114.
Clinical Effectiveness of Exercise and Corticosteroid
Injection for Subacromial Impingement Syndrome: A
Randomised Controlled Trial
1115.
The Effects of Mulligan’s Mobilization with Movement
Techniques in Patients with Lateral Epicondylitis
1116.
Mindfulness Is Associated with Sleep Quality Among
Patients with Fibromyalgia
1117.
Fibromyalgia Patients Taking Opioids Have Low SelfEfficacy and High Pain Catastrophizing but No Reduction in
Pain or Improvement in Activity
1095.
Treatment of Fibromyalgia with Neurostimulation: A
Randomized, Double-Blinded, Sham-Controlled Trial
1096.
Fibromyalgia Patients Who Have More Symptoms at Their
Initial Office Visit Tend to Have a Worse Clinical Course
1097.
Can We Help Identify Learning Disabilities in Fibromyalgia
Patients?
1098.
Clinical Efficacy of the High-Concentration Capsaicin Patch
for the Treatment of Carpal Tunnel Syndrome
1099.
Which Stresses Bother Fibromyalgia Patients Most?
1100.
System Review: The Most Common Symptoms of
Fibromyalgia Patients Other Than Pain, Fatigue, Insomnia,
and Cognitive Dysfunction
1118.
Olecranon Bursitis Is Often Hemorrhagic and Responds to
Steroid Injections
1101.
Numbness and Tingling: Neurological Symptoms in
Fibromyalgia
1119.
Comparison High Intensity Laser Therapy and Wrist Splint
in the Treatment of Lateral Epicondylitis
1102.
Anxiety in Fibromyalgia Patients
1120.
1103.
Analgesic and Anti-Hyperalgesic Effects of Deep Dry
Needling Therapy in Fibromyalgia Patients
The Relationship Between Tender Points and Disease
Severity in Patients with Fibromyalgia
1104.Utility of the 2010 ACR Diagnostic Criteria for Fibromyalgia
for Pediatric Patients with Juvenile Fibromyalgia
The Effectiveness of Mirror Therapy in Patients with
1105.
Adhesive Capsulitis
1106.
1107.
Most Patients Diagnosed with Fibromyalgia By Physicians
Do Not Have Fibromyalgia: The 2012 National Health
Interview Survey Fibromyalgia Study
Genetics, Genomics and Proteomics II
1121.
The mtDNA Haplogroups Influence the DNA Methylome
of Articular Chondrocytes
1122.
Transmitocondrial Cybrids: A Tool to Study the Role of
mtDNA Haplogroups in OA Pathogenesis
1123.
Impact of Genes Modulating Serum Low-Density
Lipoprotein Cholesterol Levels on Progression of Joint
Destruction in Japanese Patients with Rheumatoid
Arthritis
1124.
Genome-Wide Profiling of DNA from Cartilage Reveals
Regions Differently Methylated in Osteoarthritis Patients
1125.
The Mitochondrial Genome Influences the Risk of Incident
Knee OA. DATA from the Osteoarthritis Initiative
A Strong Association Between Memory Loss and Word
Finding Difficulties in Fibromyalgia
1108.Understanding Baseline Clinical Characteristics May be
of Use in Considering the Response to Pregabalin in FM
Patients with Comorbid Depression
2014 Program Book
189
ACR POSTER INDICES
1126.
Quantitative Proteomics (iTRAQ) Reveals Putative
Biomarkers in Pre-Radiological Osteoarthritis
1127.
Mass Spectrometry Imaging Revealed Potential Lipid
Chondrogenic Biomarkers for Cell-Based Therapy in
Cartilage
1128.
Regulation of PIWIL4 By Histone Modifications in
1129.
FCGR2A Polymorphism and Response to Anti-TNF
Treatment in Rheumatoid Arthritis
1130.
IRF8 Gene Contributes to Disease Susceptibility and
Interacts with NF-KB By Modulating Interferon Signature
in Patients with Systemic Sclerosis
1131.
Identification of Genetic Variants Associated with
Response to Adalimumab Plus Methotrexate in Patients
with Early Rheumatoid Arthritis
1132.
A Novel Epigenetic Mark, Histone H1 Fucosylation,
Orchestrates Macrophage Differentiation and Plasticity
By Remodeling the Enhancer Landscape in Rheumatoid
Arthritis
1133.
1134.
1135.
1136.
1137.
1138.
1139.
1140.
190
Health Services Research (ACR)
1141.
Comparisons of Quality of Life, Resource Use and Physical
Functioning in RA Patients Classified As High, Moderate or
Low Risk for Rapid Radiographic Progression
1142.
Healthcare Costs Associated with Serious Infections
Among Biologic-Naïve Rheumatoid Arthritis Patients
Initiating First-Line Biologic Treatment
1143.
Preferences of Biologic Treatment Characteristics Among
Rheumatoid Arthritis Patients Who Are Current Biologic
Therapy Users
1144.
Economic Implications for Policies Regarding Triple
Therapy Use in Patients with Rheumatoid Arthritis
1145.
Evaluation of Biologic Treatment Patterns, Clinical
Outcomes, and Healthcare Resource Utilization PostTumor Necrosis Factor Inhibitor Discontinuation in
1146.
Cost-Effectiveness of Adalimumab for Rheumatoid
Arthritis in Germany
1147.
Economic Implications of Flares Among Patients with Early
1148.
Evaluation of a Methodological Approach to Determine
Timing of Rheumatoid Arthritis Disease Onset Using
Administrative Claims Data
1149.
Novel Adherence Measures for Infusible Therapeutic
Agents in Rheumatoid Arthritis
1150.
Marked Differences in Euro-Qol-5-Dimensions Preference
Sets Based on Hypothetical or Experience Based Valuation
1151.
Multiway Transcriptomic Analysis of Monocyte-Derived
Dendritic Cells Discriminates Effects of Disease and of
HLA-B27 in Spondyloarthritis
Barriers and Facilitators of a Career in Research Among
Rheumatologists in the United States
1152.
Vasoactive Intestinal Peptide (VIP) Genetic Variants
Determine VIP Serum Levels and Could be Used As a
Prognosis Biomarker
Euroqol-5-Dimensions Utility Gain in Rheumatoid
Arthritis, Treated with Abatacept, Rituximab, Tocilizumab
or Tumor Necrosis Factor Inhibitors
1153.
TACR1 rs3771863 Single Nucleotide Polymorphism Is a
Genetic Risk Factor for Sicca Syndrome in Fibromyalgia
Patients
Area of Residence and Socio-Economic Factors
Significantly Affect Access to Biological Therapy for
Rheumatoid Arthritis Patients in Romania
1154.
Increasing Discrepancies Between Physician Assessment
of Disease Activity and Patient Global Health in Germany
Between 2000 and 2012
Economic Impact of Frequent Gout Flares in a Managed
Care Setting
Genetic Variants Influencing Joint Damage in Mexican
Americans and European Americans with Rheumatoid
Arthritis
Role of NOD2 Pathway in Sarcoidosis Cases with
Characteristics of Blau Syndrome
Genes Involved in Cartilage Synthesis and Risk to Knee
Osteoarthritis
Transcriptional Heterogeneity of the SLC2A9 Gene
Encoding the GLUT9 Urate Transporter
Association of Polymorphisms on OPG, RANK and RANKL
with ACPA Presence and Erosions: Results of a MetaAnalysis on 1570 Rheumatoid Arthritis Patients from 3
French Cohorts
2014 Program Book
1155.
1156.
Satisfaction with Rural Rheumatology Telehealth Service
1157.
Delay in Diagnosis from Onset of Symptoms By More Than
One Year in 31% of Patients with Different Rheumatic
Diseases in Australia
ACR POSTER INDICES
1158.
A Patient Survey Study of Zoledronic Acid Utilization and
Factors Associated with Persistence
1159.
Long-Term Quality of Life, Productivity Impairment,
Disease Severity and Health Care Costs in Relation to
Functional Impairment in Ankylosing Spondylitis Patients
in the Czech Republic
1160.
Annual Real-Practice Costs of Biologics for 200 Cases with
Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing
Spondylitis Treated By Tight Control and Treat to Target
Strategy Permitting Dose Reduction
1172.
Assessing the Validity and Reliability of a Novel MRI SemiAutomated Algorithm for Quantifying Bone Loss in the
Hand
1173.
Magnetic Resonance Imaging of Inflammatory Severity
and Cartilage Damage of Finger Joints in Rheumatoid
Arthritis
1174.
Evaluating MRI-Detected Tenosynovitis of the Hand and
Wrist in Early Arthritis
1175.
Association of Hand MRI Findings with the Level of Plasma
Cytokines in Patients with Newly Diagnosed Rheumatoid
Arthritis
1161.
The Price of a Positive Test: Is It Worth the Cost?
1162.
Patterns of Use of Long-Term (> 5 Years) Oral
Bisphophonate Prescription Among Primary Care
Providers and Rheumatologists for the Treatment of
Osteopenia and Osteoporosis in a Veteran Population
1176.
Feasibility and Clinical Implication of Radiocarpal Cartilage
T1ρ MR Imaging in Rheumatoid Arthritis
1177.
Predictors of Cholesterol and Lifestyle Discussions in
Rheumatoid Arthritis Visits: Impact of Perceived RA
Control and Comparison with Other Prevention Topics
Evaluation of a Simplified Version of the Rheumatoid
Arthritis Magnetic Resonance Imaging Score (RAMRIS)
Comprising 5 Joints (RAMRIS5)
1178.
Inequity: Level of Education Is Associated with Access to
Biologic Dmards Even in a Country with Highly Developed
Social Welfare (Norway)
Novel Quantification of MRI Provides a More Sensitive
Outcome Measure Than Ramris
1179.
Evaluation of Symptom Control Among Treated Gout
Patients in the United States, United Kingdom, and
Germany
Efficacy of Tocilizumab in Patients with Rheumatoid
Arthritis: Sequential Evaluation Using Whole-Body
Magnetic Resonance Imaging
1180.
Dynamic Magnetic Resonance Imaging in the Assessment
of the Response to Certolizumab Pegol in Rheumatoid
Arthritis Patients: Results from a Phase IIIb Randomized
Study
1181.
Effects of Tofacitinib on Bone Marrow Edema, Synovitis,
and Erosive Damage in Methotrexate-Naïve Patients with
Early Active Rheumatoid Arthritis (Duration ≤2 Years):
Results of an Exploratory Phase 2 MRI Study
1182.
Do Patients with Active RA Also Have Inflamed
Atherosclerotic Plaques on PET-MRI?
1183.
Validation of the Omeract Psoriatic Arthritis Magnetic
Resonance Imaging Score for the Hand and Foot in a
Randomized Placebo-Controlled Trial
1184.
Subclinical Inflammation in Psoriatic Patients with No
History of Psoriatic Arthritis: An Assessment By Magnetic
Resonance Imaging
Feature of Fatty Deposition in Sacroiliac Joints in
Ankylosing Spondylitis Patients Seen By MRI
1163.
1164.
1165.
Health Services Research (ARHP)
1166.
5 Year Budget Impact Analysis of Biosimilar Infliximab for
the Treatment of Rheumatoid Arthritis in UK, Italy, France
and Germany
1167.
A Description and Comparison of Treatments for Low Back
Pain in the United States
1168.Usng an Advanced Clinician Practitioner in Arthritis Care
Trained Physiotherapist and a Standardized Electronic
Medical Record Triage Assessment Tool to Detect
Inflammatory Arthritis and Initiate Dmards Earlier in a
Community Rheumatology Office Setting
Imaging of Rheumatic Diseases: Magnetic Resonance Imaging (MRI)
1169.
1185.
Hippocampal Atrophy Is Associated with Anti-NR2
Antibodies in Patients with Systemic Lupus Erythematosus
and Primary Sjögren’s Syndrome
1186.
Prevalence of MRI Spinal Lesions Typical for Axial
Spondyloarthritis in Patients with Inflammatory Back Pain
1170.
Neurological Complications during Anti-TNF Therapy: A
Prospective Imaging and Electrophysiological Study
1187.
1171.
Diffusion–weighted Magnetic Resonance Imaging (MRI)
of Wrist and Hands in Patients with Rheumatoid arthritis
–reproducibility and Correlation with Conventional MRI
Scoring of Spinal Lesions Compatible with Axial
Spondyloarthritis on MRI in Clinical Practice By Local
Radiologist or Rheumatologist in Desir; Comparison with
Central Reading
2014 Program Book
191
ACR POSTER INDICES
1188.
Reproducibility of Magnetic Resonance Imaging Diffusion
Weighted Imaging in Axial Spondyloarthritis Patients and
Healthy Subjects
1203.
NK/NKT Cells from Early and Definite Systemic Sclerosis
Patients Show Different Immunological Responses after
IL-2 Stimulation
1189.
Conventional Magnetic Resonance Imaging (MR) and
Hybrid 18F-Fluoride Positron Emission Tomography MRI
(18F-F- PET/MRI) of the Spine and the Sacroiliac Joints – a
Detailed Description of Pathologic Signals in Patients with
Active Ankylosing Spondylitis
1204.
Oral Administration of Nano-Emulsion Curcumin in Mice
Suppresses Inflammatory-Induced NFkB Signaling and
Macrophage Migration
1205.
Osteoarthritis-like Changes Are Present in the Tibia and
Femur 1 Year Following ACL Reconstruction
Expression of Lectin-like Transcript 1, the Ligand for
CD161, in Rheumatoid Arthritis
1206.
Low Dose Colchicine Anti-Inflammatory Effects Are
Transduced By AMP-Activated Protein Kinase (AMPK)
1207.
Novel Role of Liver X Receptor Alpha (LXRα) in the
Attenuation of TLR Signalling: Implications in Congenital
Heart Block
1208.
Cholesterol Loading Induces Neutrophil Extracellular
Traps, and Atorvastatin Attenuates This Effect
1209.
Anti-Scavenger Receptor Autoantibodies Disrupted
Marginal Zone Macrophage Integrity Via Bruton’s Tyrosine
Kinase
1210.
The Role of the Transcription Factor cAMP Responsive
Element Binding Protein 1 in Lipopolysaccharide-Induced
Tolerance
1211.
Gene Expression Profile in Muscle Tissue before and after
Immunosuppressive Treatment in Patients with Myositis
1212.
Behcets Disease in Females Due to Mutation in NEMO,
the NF-Kb Essential Modulator
1213.
Absence of Hormone Responsive Estrogen Receptor Alpha
Reduces the Activation of Plasmacytoid Dendritic Cells in
Lupus Prone Mice
1190.
1191.
The Kimriss Bone Marrow Lesion Score in Patients with
Osteoarthritis of the Knee Correlates with WOMAC Pain
Status Using Target-Lesion Based Scoring Methodology;
Data from the Osteoarthritis Initiative
1192.
Erosions Detected By Magnet Resonance Imaging in
Patients with Juvenile Idiopathic Arthritis (JIA) Are True
Erosions As Visualized By Computed Tomography
1193.
Diagnostic value of Contrast-Enhanced MR-Angiography in
diagnosing large Vessel Vasculitis
Innate Immunity and Rheumatic Disease: Signaling Mechanisms
1194.
1195.
1196.
1197.
Activation of the nlrp3 Inflammasome By an Endogenous
TLR2 Ligand in Rheumatoid Arthritis
Inflammation Develops in a Toll-like Receptor
9-Independent Manner in Experimental Arthritis and
Febuxostat Inhibits Monosodium Urate Crystal-Induced IL1beta Secretion and Cell Death Via ROS- and Intracellular
ATP-Dependent Pathways
1198.
Prolactin Is Locally Produced in the Synovium of Patients
with Inflammatory Arthritic Diseases and Promotes
Macrophage Activation
1199.
Alarmins S100A8/S100A9 Aggravate Osteophyte
Formation in Experimental Osteoarthritis and Predict
Osteophyte Progression in EARLY Human Osteoarthritis in
the Dutch Check Cohort
1200.
192
Cofilin-1 Is a ROS Sensor in Regulating the NLRP3
Inflammasome
Plasma Levels of Pattern Recognition Molecules of the
Lectin Pathway Are Altered in SLE Patients
1201.
Hypoxia Modulates Peptidyl Arginine Deiminase 4 Activity
and Neutrophil Extracellular Trap Formation
1202.
Type I Interferon Promotes Inflammatory Cytokine
Production By Inhibiting Mir-146a Maturation in SLE
2014 Program Book
Metabolic and Crystal Arthropathies: Mechanisms of Disease
1214.
Oxidative Stress from Use of Allopurinol - Is There a
Reason for Patients with Gout to Take Vitamin C?
1215.
Circulating Mediators of Bone Remodeling in Patients with
Tophaceous Gout
1216.
The Relationship Between Serum Homocysteine, Uric
Acid and Renal Function in Chronic Gouty Patients: 2 Year
Follow-up Results
1217.
The Random Urine Uric Acid to Creatinine Ratio As a
Predictor of 24-Hour Urine Uric Acid Excretion in Gout
Patients
1218.
The Reduction of Serum Uric Acid Level Might Prevent
Atherosclerosis in Mice
ACR POSTER INDICES
1236.
IgG4 Immunostaining Is Common but Not Specific in
Orbitbal Inflammatory Diseases
1237.
Retroperitoneal Fibrosis and IgG4 Disease: Response
to Immunosuppressive Therapy - a Single Centre
Retrospective Study
Serum Uric Acid As an Independent Risk Factor on
Progression of Chronic Kidney Disease in Gout Patients
with Uric Acid Lowering Agent
1238.
Proportion of Peripheral Plasmacytoid Dendritic Cells and
Plasmablasts Reflects Disease Activity in IgG4-related
Disease
Suppressive Effect of Butyrate on Monosodium Urate
(MSU) Crystal-Induced IL-1beta Production Is Mediated
Via Inhibition of Class I Histone Deacetylases
1239.
Is Lymphocytic Sialadenitis IgG4-Related?
1240.
Efficacy of Anakinra in Refractory Adult-Onset Still´s
Disease: Multicenter Study of 41 Patients
1241.
Efficacy of Tocilizumab Therapy in Korean Patients with
Adults Onset Still’s Disease: Multicenter Retrospective
Study of 20 Cases
1242.
Switching Biologic Agents in Refractory Adult-Onset Still’s
Disease: Efficacy and Safety in a Cohort of 20 Patients at a
Single Referral Center
1243.
Macrophage Activation Syndrome Complicating Adult
Onset Still’s Disease - Single Center Experience and
Literature Review
1244.
The Prevalence of Malignancy in Adult-Onset Still’s
Disease
1245.
Long Term Outcome of Infliximab in Severe and Refractory
Systemic Sarcoidosis: Report of 16 Cases
1246.
Assessment of Protective Factors of Bone Mineral Density
in a New Orleans Sarcoidosis Population
1247.
The Prevalence of Sacroiliitis and Spondyloarthritis in
Patients with Sarcoidosis
1248.
Serologic and Clinical Overlap Between Sarcoidosis and
the Rheumatic Autoimmume Diseases
1219.
Lack of Gene-Diuretic Interactions on Risk of Incident
Gout: The Nurses’ Health Study and Health Professionals
Follow-up Study
1220.
Higher Inflammatory Response in Elderly Patients during
Gout Attack
1221.
1222.
1223.
1224.
Enhancement of Proinflammatory Cytokine Production By
Uric Acid in Human Cells Via Down Regulation of IL-1Ra
Pegloticase for Tophus Debulking: Comparison of
Dual Energy Computerized Tomography (DECT),
Musculoskeletal Ultrasound (MSK-US) and Topographic
Caliper Measurement for Assessing Debulking Rate
1225.
1226.
Clinical Presentation and Cytokine Production
Abnormalities in a Cohort of Patients Carrying NLRP12
GENE Variants
Studying Patients with Autoinflammatory Diseases: The
Past, Present, and a Perspective for the Future
1227.
Cryopyrinopathy with a Myeloid-Specific NLRP3 Mutation
1228.
Involvement of the IFN-Õ Pathway in a Patient with
Candle Syndrome Carrying a Novel Variant of PSMB8
Gene
1229.
Is NOD2-Associated Autoinflammatory Disease Remotely
Related to Familial Mediterranean Fever or Continuum of
It?
1230.
Efficacy of Interleukin-1 Targeting Drugs in Familial
Mediterranean Fever Patients
1249.
Efficacy of Tocilizumab in Patients with Uveitis Refractory
to Other Biologic Drugs: A Multicenter Study on 31 Cases
1231.
Evidence Based Recommendations for Genetic Diagnosis
of Familial Mediterranean Fever
1250.
1232.
Canakinumab Therapy in Patients with Familial
Mediterranean Fever
Golimumab As an Alternative Therapy in Patients with
Uveitis Refractory to Other Anti-TNFα Drugs. Multicenter
Study of 29 Cases
1251.
Efficacy of Certolizumab in Patients with Refractory
Uveitis to Other Biologic Therapy. Study of 7 Cases
1252.
Intravenous Methylprednisolone Pulse Therapy in Severe
Inflammatory Eye Disease. a Multicenter Study
1253.
Anakinra – a Promising New Therapy for Idiopathic
Recurrent Pericarditis
1233.
Tocilizumab (TCZ) in the Treatment of AA Amyloidosis in
Patients with Familial Mediterranean Fever
1234.
Periodic Fever Syndromes in an Academic Medical Center
1235.
Recovery of Renal Function after Corticosteroid Therapy
for IgG4-Related Kidney Disease
2014 Program Book
193
ACR POSTER INDICES
1254.
Anakinra for the Management of Resistant Idiopathic
Recurrent Pericarditis in Adults
Muscle Biology, Myositis and Myopathies: Myositis Autoantibodies
and Disease Phenotype
Study of Autoantibodies in a cohort of Mexican patients
with idiopathic inflammatory myopathies
1269.
Epidemiology and Characteristics of Antisynthetase
Syndrome in the African Descent Population of
Martinique
1255.
Pathogenic Role of Tyrosyl–Transfer RNA Synthetase in
Anti-Synthetase Syndrome
1270.
Distinctive Muscle Histopathological Features of AntiSynthetase Syndrome
1256.
Clinical and Temporal Characterization of Anti-Jo-1
Positive Anti-Synthetase Syndrome: Preliminary Results of
an International Multicentre Study
1271.
Myocarditis in Antisynthetase Syndrome
1272.
Myositis-Specific and Myositis Associated Autoantibodies
in Indian Patients with Inflammatory Myositis
1273.
Assessment of the Effect of Rituximab in the Treatment
of Interstitial Lung Disease associated with the
Antisynthetase Syndrome
1257.
1258.
A New Multianalyte Assay for Detection of
Dermatomyositis-Specific Autoantibodies Undetectable
By Commercially Available Immunoassays
Enzyme-Linked Immunosorbent Assays for Detection of
Anti-Transcriptional Intermediary Factor-1 Gamma and
Anti-Mi-2 Autoantibodies in Dermatomyositis: Utility and
Crossreactivity
1259.
A Multi-Center Study for Validation of a New Assay for
Anti-Melanoma Differentiation-Associated Gene 5 (MDA5)
Autoantibody
1260.
The Early Use of Cyclosporine Is Beneficial for Long-Term
Prognosis in Patients of Polymyositis/DermatomyositisAssociated Interstitial Lung Disease with Anti- Synthetase
Antibodies
1261.
Pulmonary Arterial Hypertension in Patients with AntiPM-Scl Antibody
1262.
Mechanisms of Muscular Necrosis in Auto-Immune
Myopathies Associated with Anti-Signal Recognition
Particle and Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme
a Reductase Antibodies: Pathogenic Role of AutoAntibodies
1263.
Evidence for the Involvement of NK Cells in
Antisynthetase Syndrome
1264.
Analysis of Clinical Manifestations and Myositis-Specific
Autoantibodies Associated with Severity of Physical
Dysfunction after Treatment for Polymyositis and
Dermatomyositis
1265.
Diabetes and Atorvastatin Are Potential Risk Factors for
Statin-Associated Myopathy with Autoantibodies Against
3-Hydroxy-3-Methylglutaryl-Coenzyme a Reductase
1266.
Anti-MDA5 Is Associated with Rapidly-Progressive
Interstitial Lung Disease and Poor Survival in U.S. Patients
with Amyopathic and Myopathic Dermatomyositis
1267.
194
1268.
Are Anti-SRP Auto-Antibodies Specific for Myositis?
2014 Program Book
Osteoarthritis - Clinical Aspects: Epidemiology and Pathogenesis
1274.
Patients with Osteoarthritis Do NOT Have Increased Risk
of Cardiovascular Disease in Ullensaker Community in
Norway
1275.
Association Between Cardiometabolic Disorders and Hand
Osteoarthritis Severity: A Cross-Sectional and Longitudinal
Study
1276.
Hyperglycemia and Risk of Osteoarthritis
1277.
Retinal Arteriolar Narrowing and Incidence of Knee
Replacement for Osteoarthritis: A Prospective Cohort
Study
1278.
Association of Low Birth Weight and Preterm Birth
with the Incidence of Knee and Hip Arthroplasty for
Osteoarthritis
1279.
Pre-Operative Musculoskeletal Comorbidities Limit
Improvement in Functional Outcomes and Hip Pain in
Total Hip Arthroplasty Patients
1280.
Relationship of Buckling and Knee Injury to Pain
Exacerbation in Knee Osteoarthritis: A Web-Based CaseCrossover Stud
1281.
Knee Pain and a Prior Injury Are Associated with Increased
Risk of a New Knee Injury: Data from the Osteoarthritis
Initiative
1282.
Systemic Pain Modulation Is Related to Body Perception in
People with Knee Osteoarthritis
1283.
WITHDRAWN
1284.
Sensitivity to Change of Patient Preference Outcome
Measures for Pain in Trials of Patients with Knee
Osteoarthritis
ACR POSTER INDICES
1300.
Subclinical Right Ventricle Systolic Dysfunction By TwoDimensional Speckle-Tracking Echocardiography in
Childhood-Onset Systemic Lupus Erythematosus Patients
1301.
Trabecular Bone Impairment Assessed By HR-pQCT
in Juvenile-Onset Systemic Lupus Erythematous with
Vertebral Fractures
1302.
The Psychological Impact on Health-Related Quality of Life
in Childhood-Onset Lupus
1303.
Accuracy of Laboratory Measures and Clinical Renal
Activity Indices for Reflecting Biopsy-Proven Lupus
Nephritis (LN) Activity
Classification of Osteoarthritis Phenotypes By
Metabolomics Analysis
1304.
Development of an Index to Non-Invasively Quantify
Lupus Nephritis Chronicity in Children
1290.
Knee Osteoarthritis Progression Is Predictable By Genetic
Polymorphisms. Results from a Multicenter Association
Study
1305.
Adiposity and Adipokines Are Associated with Insulin
Resistance in Pediatric Systemic Lupus Erythematosus
1291.
Relationships Between Inflammation, Disease Severity
and Synovial Fluid Calcium Crystals Detected By Scanning
Electronic Microscopy in Early Osteoarthritis
1306.
Outcome of Lupus Nephritis in Children Less Than 12 Years
Old from North-India
1307.
Synovitis Characteristics and Associated IntraArticular Pathology in a Cohort of Patients Undergoing
Meniscectomy for Meniscal Tear
Monitoring of Mid-Interval Plasma Levels of
Mycophenolic Acid in Pediatric Lupus Nephritis Patients
1308.
Identification of an Inflammation-Driven Phenotype of
Osteoarthritis By Quantification of Synovial Inflammation
Ex Vivo and in Serum from Patients
Antinucleosome Antibodies As Potential Diagnostic and
Prognostic Biomarkers in Childhood Onset Systemic Lupus
Erythematosus
1309.
Does Anti-C1q Antibody Have Diagnostic and
Prognostic Roles in Childhood – Onset Systemic Lupus
Erythematosus?
Pediatric Rheumatology - Clinical and Therapeutic Aspects: Pediatric
Lupus, Scleroderma and Myositis
1310.
Predicting Macrophage Activation Syndrome in Pediatric
Systemic Lupus Erythematosus Patients at Diagnosis
1311.
Lupus Nephritis in Mexican Children
1312.
Features, Treatment and Outcome of Macrophage
Activation Syndrome in Pediatric Systemic Lupus
Erythematosus
1313.
Comorbidity Patterns in Children with Juvenile Idiopathic
Arthritis and Systemic Lupus Erythematosus: The
Childhood Arthritis and Rheumatology Research Alliance
Registry
1314.
Comparison of the Utility and Validity of Three Scoring
Tools to Detect Skin Disease in Patients with Juvenile
Dermatomyositis
1315.
Cross-Sectional Evaluation of Hydroxychloroquine (HCQ)
Therapy in Children with Juvenile Dermatomyositis (JDM)
Enrolled in the Childhood Arthritis and Rheumatology
Research Alliance (CARRA) Registry
1285.
Prevalence of Risk Factors for Gastrointestinal Side Effects
of Drugs for the Treatment of Pain in Rheumatic Diseases
and the Provision of Gastroprotective Treatment – Results
of a Large Non-Intervention Study
1286.
The Natural Course of Physical Function in People
with Symptomatic Knee Osteoarthritis: Data from the
Osteoarthritis Initiative
1287.
Patient Perspective of the Main Health Concerns and
Needs of Living with Hand Osteoarthritis
1288.
Older Adults with Osteoarthritis Do Not Have an
Increased Risk of Cognitive Impairment
1289.
1292.
1293.
1294.
Gender Differences in the Lupus Nephritis Biomarkers in
Children
1295.
Childhood-Onset Systemic Lupus Erythematosus: ShortTerm Treatment Response Rates in Proliferative Lupus
Nephritis
1296.
Pulse- Pediatric Update on Lupus in South Africa:
Epidemiology and Management
1297.
Safety and Efficacy of Rituximab in Pediatric Lupus and
Other Rheumatic Diseases
1298.
1299.
Macrophage Activation Macrophage Activation
Syndrome: A Severe and Frequent Manifestation of
Acute Pancreatitis in Childhood-Onset Compared to Adult
Systemic Lupus Erythematosus Patients
A Cross-Sectional Study of Mental Health Symptoms and
Mental Health Care in Pediatric SLE/MCTD Patients and
Their Peers
2014 Program Book
195
ACR POSTER INDICES
1316.
1317.
1318.
Anti-p155/140 Autoantibodies and Selected Features
at Illness Onset Are Associated with a Chronic Course
of Illness in the Juvenile Idiopathic Inflammatory
Myopathies
The Efficacy of a Multidisciplinary Intervention Strategy
for the Treatment of Benign Joint Hypermobility
Syndrome (BJHS) in Childhood: A Randomized, Single
Center Parallel Group Trial
1331.
Factors Associated with Pain in Children with
Hypermobility - a Pilot Study
Illness Onset Features and Misdiagnosis in Juvenile
Idiopathic Inflammatory Myopathies (JIIM) Differ Among
Clinical and Autoantibody (Ab) Subgroups
Psychology/Social Sciences (ARHP)
Safety of Rituximab in Treating Pediatric Rheumatic
disease
1320.
1322.
1323.
1324.
1332.
Analysis of Risk Factors for Thrombosis in Pediatric
From Social Support to Information Sharing, How Are
Persons with Rheumatoid Arthritis Using Disease-Specific
Facebook Communities? a Content Analysis
1333.
A Pilot Study to Evaluate the Feasibility of Conducting
Juvenile Localized Scleroderma Comparative Effectiveness
Treatment Studies
Bridging the Social Support Needs Gap for African
American Women with Systemic Lupus Erythematosus
through the Chronic Disease Self-Management Program
1334.
Cardiopulmonary Involvement in Juvenile Systemic
Sclerosis: Development of Recommendations for
Screening and Investigation
Social Support and Suicidal Ideation in Systemic Lupus
Erythematosus: Georgians Organized Against Lupus
Cohort
1335.
Gastrointestinal Involvement in Juvenile Systemic
Sclerosis: Development of Recommendations for
Screening and Investigation
Early Birds Versus Night Owls: Morning/Evening
Preference and Its Association with Sleep Problems,
Fatigue, and Emotional Well-Being Among RA Patients
1336.
Associations of Physical and Mental Factors with Outcome
Expectations for Exercise in a Clinical Trial
Predictors of Disease Relapse in Juvenile Localized
Scleroderma
1337.
Mindfulness Is Associated with Symptom Severity and
Pain Impact in Patients with Fibromyalgia
1338.
Correlates of Body Image Dissatisfaction in Patients with
Limited and Diffuse Systemic Sclerosis
1339.
Is Psychological Status Related to Symptom Experience in
Behçet’s Syndrome?
1325.
Single Hub and Access Point for Pediatric Rheumatology
in Europe (SHARE): Evidence Based Recommendations
for Diagnosis and Treatment of Juvenile Localized
Scleroderma and Juvenile Systemic Sclerosis
1326.
Transition of Care and Long-Term Outcomes of Juvenile
Systemic Sclerosis during Adulthood: Results from a
French Single-Center Case-Control Study
1327.
Decreased CD3-CD16CD56+ Natural Killer Cell Counts Are
Associated with Disease Activity in Children with Orbital
Myositis
1328.
Modulation of Natural IgM-Autoantibodies to Oxidative
Stress-Related Neo-Epitopes on Apoptotic Cells in
Newborns of Mothers with Anti-Ro Autoimmunity
1329.
Pediatrics (ARHP)
1330.
1319.
1321.
196
A Hybrid Conjoint Analysis Model Is Proposed As the
Definition of Minimal, Moderate and Major Clinical
Improvement in Juvenile Dermatomyositis Clinical Trials
Comparison of Clinical and Serological Features of
Childhood Sjögren Syndrome Based on the Presence or
Absence of Parotitis
2014 Program Book
1340.
Choosing Subserologies Wisely: An Opportunity for
Rheumatologic Healthcare Resource Savings
1341.
Choosing Not so Wisely: The Tale of Antinuclear Antibody
Testing
1342.
Improving Serologic Testing for Antiphospholipid
Antibodies in Patients with Systemic Lupus Erythematosus
1343.
A Quality Improvement Initiative to Improve
Pneumococcal Vaccination Rates in Immunosuppressed
Patients
1344.
Electronic Medical Record-Based Best Practice Alert Used
By Clinical Staff Improved Pneumococcal Vaccination and
Documentation Among Immunosuppressed Rheumatoid
Arthritis Patients
ACR POSTER INDICES
1345.
Improving Pneumococcal Immunization Rates for Patients
on Immunosuppressant Medications at an Academic
Rheumatology Clinic
1346.
Leveraging Electronic Health Records to Improve
Vaccination Rates for Patients with Rheumatoid Arthritis
1347.Understanding Vaccination Rates Among Patients with
1348.
Improvement in Herpes Zoster Vaccination and
Documentation for Rheumatoid Arthritis Patients Using
Electronic Medical Record
1361.
Rheumatologists’ Attitudes on Cardiovascular Risk and
Lipid Screening in Patients with Rheumatoid Arthritis at
an Academic Medical Center
Rheumatoid Arthritis - Clinical Aspects: Comorbidities,
Treatment Outcomes and Mortality
1362.
Impact of Rapid Attainment of Stringent Measures of
Efficacy in Rheumatoid Arthritis on Patient-Reported
Outcomes
1363.
Psychosocial Comorbidities Are Independently Associated
with Subclinical Atherosclerosis in Rheumatoid Arthritis
1364.
Accelerated Diastolic Dysfunction in Premenopausal
Women with Rheumatoid Arthritis
1349.
A Decision Support Tool to Improve Herpes Zoster
Vaccination Rates Among Patients Starting Biologic
Medications
1350.
Practice What You Preach? Suboptimal Guideline
Adherence By Rheumatologists in Patients with
1365.
ARE Erosions a Disappearing Feature in Rheumatoid
Arthritis (RA)?Joint Damage in Patients with EARLY RA at
10 YEARS after Diagnosis
1351.
Assessment of ACR Endorsed Quality Indicators in
Rheumatoid Arthritis Patients – a Quality Improvement
Initiative
1366.
Outcomes of Interstitial Lung Disease Associated with
Rheumatoid Arthritis in High Volume Referral Centers
1367.
1352.
Rheumatoid Arthritis (RA) Disease Activity Assessment
and Population Management Processes Used By Clinician
Rheumatologists
Cardiovascular Morbidity and Associated Risk Factors in
Spanish Patients with Chronic Inflammatory Rheumatic
Diseases Attending Rheumatology Clinics
1368.
Are Tender Joints Better Than Synovitis to Predict
Structural Damage in Rheumatoid Arthritis?
1369.
Improving the Measurement of Disease Activity for
Patients with Rheumatoid Arthritis: Validation of an
Electronic Version of the Routine Assessment of Patient
Index Data (RAPID 3)
Predictors of Deterioration in Subjective Cognition:
Results from a Rheumatoid Arthritis (RA) Observational
Cohort Study
1370.
The Association of Body Mass Index (BMI) and
Radiographic Progression of Joint Disease in Rheumatoid
Arthritis (RA)
1355.
Population Management of Rheumatoid Arthritis (RA) in
Rheumatology Practices: A Quality Improvement Project
1371.
Impact of Metabolic Syndrome (MetS) on Rheumatoid
Arthritis Disease Activity
1356.
Collaboration Between a Third Party Payer and
Community Rheumatologists to Create a Clinical Pathway
for the Treatment of Rheumatoid Arthritis to Assure
Proper Use of Biologics and Quality of Care
1372.
Prevalence of Cardiovascular Disease in US Veterans with
Rheumatoid Arthritis and Hepatitis C Infection
1373.
1357.
Improving Compliance for Tuberculosis Screening for
Patients on Biologics in Rheumatology Clinics
Physical Function of Patients with RA Varies Importantly
Across Countries, and These Differences Are Not
Attributed to GDP: Results from Multi-National Study with
17 Countries
1358.
A Systematic Analysis of the Safety of Prescribing AntiRheumatic Immunosuppressive and Biologic Drugs in
Pregnant Women
1374.
1359.
Care of Women with Rheumatological Conditions during
Family Planning and Pregnancy
A Comparison of the Risk for Cardiovascular Event in
Patients with Rheumatoid Arthritis Treated with Biologic
Disease Modifiers and Patients Treated with Methotrexate
Only
1375.
1360.
Monitoring Methotrexate and Leflunomide Treatment for
Liver Toxicity: the Kaiser Permanente Experience
Educational Level and Not Ethnicity an Important
Determinant of Disease Progression in Patients with
1353.
1354.
Integrating Collection of Rheumatoid Arthritis Disease
Activity and Physical Function Scores into an Academic
Rheumatology Practice to Improve Quality of Care
2014 Program Book
197
ACR POSTER INDICES
1376.
Angiographic Pattern Among Rheumatoid Arthritis
Patients Who Are Hospitalized Due to Acute Coronary
Syndrome
1377.
Anti-Citrullinated Peptide Antibody Titers and the
Prevalence of Interstitial Lung Disease in Patients with
and without Rheumatoid Arthritis
1378.
198
The Impact of Rheumatoid Arthritis Activity and
Medications on Pregnancy Outcomes
1393.
Periodontal Disease and Its Impact on Structural Joint
Damage in a Rheumatoid Arthritis Peruvian Population
1394.
Low Vitamin D Level Is Not Associated with Increased Risk
of Cardiovascular Disease in Rheumatoid Arthritis Patients
1395.
Disease Activity Is Associated with Insulin Resistance in
1396.
Assessment of Pulmonary Function in Rheumatoid
Arthritis Patients Attending Rheumatology Clinics in
Nairobi,Kenya
1397.
Impact of Corticosteroid Use on Remission Sustainability
and Infection Rates Among Rheumatoid Arthritis Patients
in Remission While on Infliximab: Treatment Implications
Based on a Real-World Canadian Population
1379.
Studies on Ageing and the Severity of Radiographic Joint
Damage in Rheumatoid Arthritis
1380.
Patient Global Impression of Change for Patient
Reported Outcomes in Rheumatoid Arthritis: Impact of
Comorbidities
1381.
Subaxial Cervical Spine Involvement in Symptomatic
Rheumatoid Arthritis Patients: Comparison with Cervical
Spondylosis
1398.
Spontaneous Regression of Methotrexate (MTX)-Related
Lymphoproliferative Disorder Correlates with Lymphocyte
Restoration after MTX Withdrawal
1382.
The Longitudinal Course of Fatigue in Rheumatoid
Arthritis – Results from the Norfolk Arthritis Register
1399.
Proteinase K-like Serine Protease PCSK9 Influence on the
Dyslipidemia and Endothelial Dysfunction Observed in
1383.
Disease Characteristics and RA Development in
Undifferentiated Arthritis: A 2-Year Follow-up Study of 413
Patients with Arthritis of Less Than 16 Weeks Duration
1400.
Risk of Venous Thromboembolic Events in Patients with
Rheumatoid Arthritis: A Meta-Analysis of Observational
Studies
1384.
Fibromyalgia and Its Effect on Treatment Response in
Early Rheumatoid Arthritis Patients
1401.
1385.
What Discriminates Best Flares in Rheumatoid Arthritis
(RA)? a Subanalysis of the Strass Treatment Tapering in RA
Study
Higher-Order Neuropsychological Deficits Are Frequent
and Occur Early in RA and SLE: The Impact of Basic
Processing Abilities on Psychological Well-Being
1402.
Parameters of Periodontitis Correlate with AntiCitrullinated Protein Antibodies and P. Gingivalis Antibody
Titers in Patients with Early or Chronic Rheumatoid
Arthritis
1403.
Psychosocial Impact of Rheumatoid Arthritis Patients on
Their Family Members
1404.
Presence and Significance of Anti-CCP Antibody in Patients
with Interstitial Lung Disease with and without Clinically
Apparent Rheumatoid Arthritis
1405.
Five-Year Changes in Myocardial Structure and Function in
1406.
Comorbidity in Rheumatoid Arthritis. It Is Feasible to
Record Concomitant Medical Conditions and MultiMorbidity in Observational Research Studies. Can This be
Extended to Routine Clinical Settings?
1407.
Low HAQ and Pain Predict Patient Perceived Remission in
Rheumatoid Arthritis Patients Receiving MTX or Anti-TNFAlpha Treatment
1408.
Inflammatory Biomarkers, Sleep Quantity and Sleep
Quality in Rheumatoid Arthritis
1386.
Disease Flares during 10 Year Follow-up in Patients with
Rheumatoid Arthritis Are Associated with Joint Damage
Progression and Disability
1387.
Radiographic Progression Differs Between Trajectory
Clusters Defined By DAS28 Scores in Early Rheumatoid
Arthritis
1388.
Prevalence and Predictive Factors of Drug-Free and
Sustained Remission in Patients with Early Arthritis
1389.
Osteophytes Increase the Ambiguity of Clinical Evaluation
of Joint Swelling in Rheumatoid Arthritis
1390.
Heterogeneity in Cardiovascular Risk Factors, Event Rates
and RA Disease Characteristics Among Patients with
Rheumatoid Arthritis Across 10 Countries - Implications
for CV Risk Assessment
1391.
Weight Loss and Risk of Death in Rheumatoid Arthritis
1392.
Predictors of Long-Term Changes in Body Mass Index in
2014 Program Book
ACR POSTER INDICES
1409.
Pregnancy Outcomes after Exposure to Certolizumab
Pegol: Updated Results from Safety Surveillance
1426.
Periodontal disease and Clinical Activity of Rheumatoid
Arthritis Patients
1410.
Low Rates of Cardiovascular Risk Factor Modification
Among High-Risk Rheumatoid Arthritis Patients: Barrier to
Cardiovascular Prevention Strategies?
1427.
Low Prevalence of Sarcopenic Obesity in Rheumatoid
Arthritis Patients with Moderate Clinical Activity
1411.
Psychological Distress over Time in Early Rheumatoid
Arthritis: Results from a Longitudinal Study in an Early
Arthritis Cohort
1428.
Comparison of Application of the European Society
Cardiology, Adult Treatment Panel III, and ACC/AHA
Guidelines for Cardiovascular Disease Prevention in a
French Cohort of Rheumatoid Arthritis
1412.
Sarcopenia and Its Impact on Disability in Rheumatoid
Arthritis, a Pilot Study
1429.
Systemic Inflammation in Alzheimer’s Disease: Relevance
to Patients with Rheumatoid Arthritis
1413.
The Prevalence of Renal Impairment in Patients with
1430.
1414.
Investigation of the Association Between
Gastroesophageal Reflux Disease and Clinical Factors in
1431.
IMPACT of Initiative to Control Cardiovascular Risk Factors
in Collaboration with LOCAL Doctors in Patients with
Influence of Radiographic Joint Damage in Mortality Risk
in a Cohort of Rheumatoid Arthritis Patients: A 20 Years
Survival Study
1415.
Differential Gender Impact in the Quality of Life of
Patients with Rheumatoid Arthritis. Comprehensive
Study Including Clinical, Comorbidity and Psicho-Social
Variables.
1432.
Mortality Ratio of Rheumatoid Arthritis Under Biological
Treatment
1433.
Clinical Characterization of Subclinical Rheumatoid
Arthritis-Associated Interstitial Lung Disease
Analysis of Cardiac Involvement in Patients with Amyloid
a (AA) Amyloidosis Due to Rheumatoidarthritis
1434.
The Longitudinal Association Between Inflammation and
Blood Pressure in Rheumatoid Arthritis
Red Cell Distribution Width: A Measure for Cardiovascular
Risk in Rheumatoid Arthritis Patients?
1435.
Changes in the Types and Prognoses of Infections
Complicated in RA Patients during the Last 15 Years, in
Japan.
1416.
1417.
1418.
Prevalence of Vitamin D Deficiency in Rheumatoid
Arthritis
1436.
1419.
Rituximab Use in Patients with Rheumatoid ArthritisAssociated Interstitial Lung Disease and Other Connective
Tissue Disease-Associated Interstitial Lung Disease: A
Single Center Experience
Impact of Depression on Clinical and Social Outcomes in
Patients with Rheumatoid Arthritis: Comparative Study in
Germany and Brazil
1437.
Cholesterol Efflux Capacity of HDL and Coronary
Atherosclerosis in Rheumatoid Arthritis
Non-Use of Glucocorticoid and Osteoarthritis Absence As
Predictors of Clinical Remission in AR
1438.
Association Between Chronic Inflammatory Conditions
and Anti Cyclic Citrullinated Peptide Antibodies in Patients
with Early Rheumatoid Arthritis
1439.
Miscarriage in Rheumatoid Arthritis – Association with
Disease Characteristics and Medication Use
1440.
Asymptomatic Carotid Plaques in RA Patients Are
Associated with Increased HDL Function
1441.
Accelerated Aging in DMARD and Treatment Naive Early
Rheumatoid Arthritis Patients Measured By a Stem Cell
Assay Is Associated with Increased LDL and Is Linked to
Impaired Cardiopulmonary Function
1442.
The 2013 ACC/AHA Cardiovascular Risk Prediction Model
and Coronary Atherosclerosis in Patients with Rheumatoid
Arthritis
1420.
1421.
Preclinical Interstitial Lung Disease in Early Rheumatoid
Arthritis
1422.
Demographic Differences in Health Related Information
Technology Use Among Patients with Rheumatic Diseases
1423.
Cardiovascular Risk Estimation in Rheumatoid Arthritis:
What Is Missing in Traditional Risk Estimators?
1424.
Bone Erosions in Patients with RA: Exploring the Impact of
the Anatomy of Interest on the Relationship Between MRI
and X-Ray Erosion Detection
1425.
Screening Behavior and Prevalence of Hepatitis C Virus in
Mexico
2014 Program Book
199
ACR POSTER INDICES
1443.
Increased Occurence of Carotid and Femoral Plaques,
but Not Increased Arterial Stiffness of Hypertrophy, in
Classical Risk Factor-Free Patients with Rheumatoid
Arthritis
Clinical Practice/Patient Care (ARHP)
1444.
1445.
The Vocational Experiences of Young People with Juvenile
Idiopathic Arthritis and the Role of the Multidisciplinary
Team Supporting Positive Employment Outcomes
Improving Osteoarthritis Outcomes Utilizing a
Multidisciplinary Model of Care; Experience in a Diverse
Multicultural Urban Teaching Hospital
1446.Utility of Ultrasound in the Nuffield Orthopaedic Centre
Emergency Rheumatology Clinic: Survey of Clinical
Effectiveness
1447.
Implementing American College of Rheumatology (ACR)
Quality Indicators for Rheumatoid Arthritis (RA) in the
United Arab Emirates (UAE)
1448.
A Questionnaire Assessment of Knowledge about
Methotrexate of Patients with Rheumatoid Arthritis
1449.
WITHDRAWN
1450.
Spironolactone As a Novel DMARD in Rheumatoid
Arthritis
1451.Use of Analgesics in Patients with Knee and/or Hip
Osteoarthritis: Results from the Amsterdam Osteoarthritis
Cohort
1452.
1453.
Timing of Decisions to Adjust Disease Modifying AntiRheumatic Drug (DMARD) Therapy for Rheumatoid
Arthritis (RA) Patients with Active Disease in a Usual
Practice Setting
Gastrointestinal Risk Factors and Treatment Patterns of
Rheumatoid Arthritis Versus Osteoarthritis Patients in
Korea
1457.
Stem Cell Growth Factor Expression in Rheumatoid
Arthritis
1458.
Functional Phenotype of Synovial Monocytes Modulating
Inflammatory T-Cell Response in Rheumatoid Arthritis
1459.
IL-22 Secreted By NKp44+NK Cells Promote the
Proliferation of Synovium in Patients with Rheumatoid
Arthritis By Activation of STAT3
1460.
Midkine, a Growth Factor, May Play a Pathophysiological
Role in Patients with Rheumatoid Arthritis
1461.
Quantitave Analysis of Cadherin-11 and Beta-Catenin
Signaling during Proliferation of Rheumatoid ArthritisDerived Synovial Fibroblast Cells
1462.
Cadherin-11 mRNA Expression in the Peripheral Blood
of Rheumatoid Arthritis Patients As a Marker of Active
Polyarthritis
1463.
Dickkopf-1 Perpetuated Synovial Fibroblast Activation and
Synovial Angiogenesis in Rheumatoid Arthritis
1464.
Numbers of Circulating CD4 Positive CD28null T Cells Are
Increased in Patients with Rheumatoid Arthritis and Are
Associated with Rheumatoid Factor Positivity but Not
Subclinical Cardiovascular Disease
1465.
Follicular Helper T Cells Control Autoimmunity through IL21/IL-21 Receptor Interaction in RA Patients
1466.
Patients with Active Rheumatoid Arthritis Display an
Expanded Population of GM-CSF Expressing Peripheral B
Cells
1467.
Do G-CSF and Neutrophils Contribute to the
Pathophysiology of Rheumatoid Arthritis?
1468.
Mechanism of Effectiveness of IL-6 Blockade for Reduction
of SAA Production and Amyloid a Deposition in AA
Amyloidosis Patients with RA
1469.
Methotrexate Treatment Reduces Serum IL-6 Level By
Decreasing a CD14brightCD16+ Intermediate Non-Classical
Subset of Monocytes in RA Patients
1470.
Malondialdehyde-Acetaldehyde Adducts (MAA) and AntiMalondialdehyde-Acetaldehyde Antibody in Rheumatoid
Arthritis
1471.
TNFα Influences the Status of B and T Cells By Acting
on BCR and TCR Pathways Via RasGRP1 and RasGRP3
Proteins
1472.
Synovial Fluid from Rheumatoid Arthritis Patients
Modulates the Immunophenotype and Viability of
Monocytes
200
1454.
Quantitative and Qualitative Tracking of Expanded CD4+ T
Cell Clones in Rheumatoid Arthritis Patients
1455.
Ex Vivo-Expanded, but Not in Vitro-Induced, Human
Regulatory T Cells Are Suitable for Cell Therapy in
Rheumatological Autoimmune Diseases Thanks to Stable
FOXP3 Demethylation
1456.
Foxp3+ Regulatory T Cells in Peripheral Blood and Synovial
Fluid of Patients with RA: A Comparative Phenotypic
Analysis
2014 Program Book
ACR POSTER INDICES
1487.
A Phase 1 Dose-Ranging Repeated-Dose Trial of Parenteral
Staphylococcal Protein A (PRTX-100) in Patients with
Active Rheumatoid Arthritis on Methotrexate or
Leflunamide Therapy
1488.
Clinical Efficacy of Add-on Iguratimod Therapy in Patients
with Active Rheumatoid Arthritis Despite of Methotrexate
~a Multicenter Registry Study~
1489.
Influences of Disease Activity at the Initiation of
Iguratimod, a Small Molecule Antirheumatic Drug, on
Efficacy of Iguratimod in Patients with Rheumatoid
Arthritis –a Multicenter Registry Study-
1490.
Therapy: Novel Therapies, Biosimilars, Strategies and Mechanisms in
Can Tumor Necrosis Factor Inhibitors Protect Rheumatoid
Arthritis Patients from Osteoporosis? Impact of Tumor
Necrosis Factor Inhibitors on Bone Mineral Density and
Bone Remodeling Markers
1491.
Pharmacokinetics, Bioavailability and Safety of a
Modified-Release Once-Daily Formulation of Tofacitinib in
Healthy Volunteers
Discovery and Characterization of COVA322, a Clinical
Stage Bispecific TNF/IL-17A Inhibitor for the Treatment of
Inflammatory Diseases
1492.
Impact of Clinical Remission on Physical Function in
Patients with Rheumatoid Arthritis Treated with ALX0061: Post-Hoc Analysis of Phase I/II Data
Safety and Tolerability of NNC01140006, an Anti-IL-21
Monoclonal Antibody, at Multiple s.c. Dose Levels in
1493.
Dose Selection of GLPG0634, a Selective JAK1 Inhibitor,
for Rheumatoid Arthritis Phase 2B Studies: PK/PD and
Exposure-DAS28 Modeling Approach
A Phase 1 Study of FPA008, an Anti-Colony Stimulating
Factor 1 Receptor (anti-CSF1R) Antibody in Healthy
Volunteers and Subjects with Rheumatoid Arthritis (RA):
Preliminary Results
1494.
Phase 1 and Phase 2 Data Confirm That GLPG0634, a
Selective JAK1 Inhibitor, Has a Low Potential for DrugDrug Interactions
Treatment of Rheumatoid Arthritis Patients with the
JAK1-Selective Inhibitor GLPG0634 Reverses an ArthritisSpecific Blood Gene Signature to Healthy State
1495.
Preclinical and Clinical Phase I Profile of MK-8457,
a Selective Spleen Tyrosine Kinase and Zeta-ChainAssociated Protein Kinase 70 Inhibitor, Developed for the
Treatment of Rheumatoid Arthritis
1496.
Exposure-Response Analysis for Mavrilimumab Phase2b
Study in RA Patients with Informative Dropout
1497.
Efficacy and Safety of Iguratimod for Rheumatoid Arthritis
1498.
ALX-0061, an Anti-IL-6R Nanobody® for use in Rheumatoid
Arthritis, Demonstrates a Different in Vitro Profile As
Compared to Tocilizumab
1499.
Characterization of ABT-494, a Second Generation Jak1
Selective Inhibitor
1500.
Preclinical and Clinical Characterization of MK-8457,
a Selective Spleen Tyrosine Kinase and Zeta-ChainAssociated Protein Kinase 70 Inhibitor, in Normotensive
and Hypertensive Cardiovascular Models
1473.
Manocept-Cy3 Localizes CD206 + Macrophages in Synovial
Tissue and Fluid from Rheumatoid Arthritis Patients
Differentially Compared to Controls
1474.
Anti-Peptidyl Arginine Deiminase 4 Antibodies in AfricanAmericans with Rheumatoid Arthritis and Radiographic
Scores
1475.
Porphyromonas Gingivalis and Bone Turnover Biomarkers
1476.
a Dose Response Relationship Between Shared Epitope
and ACPA Level: But Not All SE Alleles Are Created Equal
1477.
Overweight and Obesity Are Associated with Reduced
Risk of Rheumatoid Arthritis in Men, but Not in Women
1478.
1479.
1480.
1481.
1482.
Response of Patient Reported Symptoms of Stiffness
and Pain during the Day from Adding Low-Dose DelayedRelease (DR) Prednisone to Stable DMARD Therapy over
12 Weeks in Patients with Moderate Rheumatoid Arthritis
(RA)
1483.
Efficacy and Safety of Baricitinib in Japanese Rheumatoid
Arthritis Patients during a 52 Week Extension Phase
1484.
Discovery of ARN-4079 - a Potent, Orally Available Dual
Target Inhibitor of Janus Kinase 3 (JAK3) and Interleukin-2
Inducible T-Cell Kinase (ITK) for Rheumatoid Arthritis
1485.
Analysis of Patient-Reported Outcomes during Treatment
with Mavrilimumab, a Human Monoclonal Antibody
Targeting GM-CSFRá, in the Randomized Phase 2b Earth
Explorer 1 Study
1486.
Rapid Onset of Clinical Benefit Is Associated with a
Reduction in Validated Biomarkers of Disease in Patients
with Rheumatoid Arthritis Treated with Mavrilimumab, a
Human Monoclonal Antibody Targeting GM-CSFRá
2014 Program Book
201
ACR POSTER INDICES
1517.
A Phase I Trial Comparing PF-05280586 (A Potential
Biosimilar) and Rituximab in Subjects with Active
Analysis of Gene Expression Fluctuation with Abatacept
Highlights the Involvement of the Proteasome Pathway
As a Mechanism of Action of Abatacept in Rheumatoid
Arthritis
1518.
Disentangling the Effects of Tocilizumab on Neutrophil
Survival and Function
1503.
Demonstration of Functional Similarity Comparing
Adalimumab to Biosimilar Candidate ABP 501
1519.
1504.
Pharmacokinetic Equivalence of ABP 501 Relative to
Adalimumab: Results from a Randomized, Single-Blind,
Single-Dose, Parallel Group Study in Healthy Subjects
Implementation of an Acid Dissociation Procedure for
Immunogenicity Detection in Patients Treated with ANTITNF Drugs
1520.
Gene Expression Analyses of Abatacept- and AdalimumabTreated Patients from the Ample Trial
1505.
The Biosimilar Landscape: A Systematic Review of Its
Current Status
1521.
1506.
Incidence of Adverse Events in Patients Treated with
Intended Copies of Biologic Therapeutic Agents in
Colombia and Mexico
Sustained Improvements in Magnetic Resonance Imaging
Outcomes with Abatacept Following the Withdrawal of All
Treatment in Patients with Early Rheumatoid Arthritis
1522.
Impact of Sarilumab on Health Related Quality of Life
(HRQoL), Fatigue, and Sleep in Rheumatoid Arthritis
Patients at Week 24 - Results of a Phase 3, Randomized,
Double-Blind, Placebo-Controlled, Multi-Center Study
1523.
Follow-up Data on the Rheumatoid Arthritis Comparison
of Active Therapies Trial: Observational Cohort
1524.
Rituximab Done! What’s Next in RA?
1525.
Cumulative Clinical Response in Rheumatoid Arthritis
Patients with Rituximab Repeated Courses after Failure
to Tumor Necrosis Factor Inhibitors in Routine Clinical
Practice
1526.
Sustained Clinical Efficacy after Multiple Courses
of Rituximab in Rheumatoid Arthritis Patients with
Inadequate Response to Tumor Necrosis Factor Inhibitors:
3-Year Data
1527.
Efficacy of Biologic Treatments in Early Active Rheumatoid
Arthritis: An Indirect Comparison
1528.
Efficacy and Safety of MK-8457, a Novel SYK Inhibitor
for the Treatment of Rheumatoid Arthritis in Two
Randomized, Controlled, Phase 2 Studies
1529.
Evaluation of the Pharmacokinetics and Safety of the
Interactions Between the Anti-Interleukin-6 Monoclonal
Antibody Sirukumab and Cytochrome P450 Activities in
1530.
Autologous Tolerogenic Dendritic Cells for Rheumatoid
and Inflammatory Arthritis
The Impact on Anti-Citrullinated Protein Antibody
Isotypes and Epitope Fine Specificity in Patients with Early
RA Treated with Abatacept and Methotrexate
1531.
CUT-Off LEVEL of Adalimumab and Prevalence of
Antibodies ANTI-Adalimumab in Patients with Ankylosing
Spondylitis: Results from a LOCAL Registry
TNF-Alpha Inhibitors Normalizes Melanocortin Receptor
Subtype 2, 3 and 4 Expression in CD8+, CD14+ and CD19+
Leukocyte Subsets in Rheumatoid Arthritis
1532.
Efficacy of the Subcutaneous Formulation of Abatacept/
Orencia in Rheumatoid Arthritis, a Single-Center Italian
Experience
1501.
Immunogenicity Assessment of PF-06438179, a Potential
Biosimilar to Infliximab, in Healthy Volunteers
1502.
1507.
1508.
1509.
A Randomized, Double-Blind, Three-Arm, Parallel Group,
Single-Dose Study to Compare the Pharmacokinetics,
Safety, and Tolerability of Three Formulations of
Infliximab (CT-P13, EU-sourced Infliximab and US-sourced
Infliximab) in Healthy Volunteers
1510.
Blockade of TLR5 Ligation Is a Novel Strategy for RA
Therapy
1511.
COVA322: A Clinical Stage Bispecific TNF/IL-17A Inhibitor
for the Treatment of Inflammatory Diseases
1512.
Therapeutic Efficacy of a Novel Oral Small Molecule
Macrophage Migration Inhibitory Factor [MIF] Inhibitor:
A Promising Safe & Efficacious Treatment for Rheumatoid
Arthritis
1513.
1514.
1515.
1516.
202
Patient Perspectives on the Introduction of Subsequent
Entry Biologics in Canada
Impact of Anti-Drug Antibody on Efficacy and Safety
over Week 24 in Both CT-P10 and Innovator Rituximab
Treatment Groups
Selection of Vagus Nerve Stimulation Parameters for a
First-in-Human Study in Rheumatoid Arthritis: A Unique
Translational Medicine Challenge
An Analysis of in-Vitro Cytokine Inhibition Profiles of
Tofacitinib and Other Janus Kinase Inhibitors at ClinicallyMeaningful Concentrations
2014 Program Book
ACR POSTER INDICES
1533.
Study of One Vial (400mg) per Body Infusion of
Tocilizumab in Patients with Active Rheumatoid Arthritis
1547.
Endocrine Co-Morbidities in Patients with Psoriatic
Arthritis: A Population-Based Study
1534.
Disease Severity and Treatment of Rheumatoid Arthritis:
A Comparative Study Between Sudan and Sweden
1548.
Treatment Effect of Ustekinumab on Fatigue in Patients
with Psoriatic Arthritis: Results from a Phase 3 Clinical
Trial
1549.
The Swedish Early Psoriatic Arhtritis (SWEPSA) Registry
5-Yeear Follow-up: Slow Radiographic Progression with
Highest Scores in Male Feet and in Patients with Baseline
X-Ray Abnormalities
1550.
Prevalence of Enthesitis and Dactylitis, Impact on Disease
Severity and Evolution over 12 Months in Psa Patients
Treated with Anti-TNF in a Real-World Setting
1551.
Correlation of Individual HAQ Questions with Disease
Activity Measures in Psoriatic Arthritis: Implications for
Instrument Reduction
1552.
Sustained Improvements in Workplace and Household
Productivity and Social Participation with Certolizumab
Pegol over 96 Weeks in Patients with Psoriatic Arthritis
1553.
Relation Between Number of Previous Anti TNF Agents
and Clinical Response in Rheumatoid Arthritis Patients
Treated with Rituximab
Disease Activity and Clinical Response Early in the Course
of Treatment Predict Long-Term Outcomes in Psoriatic
Arthritis Patients Treated with Certolizumab Pegol
1554.
Treatment Patterns of Biologics Used in Rheumatoid
Arthritis and Ankylosing Spondylitis in the US Veterans
Population
Early and Sustained Modified Psarc Response in Psoriatic
Arthritis Patients Treated with Ustekinumab: Results from
2 Phase 3 Studies
1555.
An Indirect Comparison and Cost per Responder Analysis
of Adalimumab, Methotrexate (MTX) and Apremilast
in the Treatment of MTX-naïve Psoriatic Arthritis (PsA)
Patients
1556.
Integrated Safety of Ustekinumab in Psoriatic Arthritis:
2 Year Follow-up from the Psoriatic Arthritis Clinical
Development Program
1535.Use of Rituximab Compared to Anti-Tnf Agents As Second
and Third Line Therapy in Patients with Rheumatoid
Arthritis: A Report from the rhumadata® Clinical Database
and registry
1536.
Comparing Abatacept to Adalimumab, Etanercept
and Infliximab As First Line Agents in Patients with
Rheumatoid Arthritis. Experience from the Rhumadata®
Clinical Database and Registry
1537.
Clinical Characteristics of RA Patients Newly Prescribed
Tofacitinib Citrate (tofacitinib) in the United States after
Food and Drug Administration Approval: Results from the
Corrona US Rheumatoid Arthritis Registry
1538.
Sustained Clinical Benefit with Multiple Courses of
Rituximab in Second Line for All Rheumatoid Arthtritis
Patients Irrespective to the Inhibitor of Tumour Necrosis
Factor Previously Used
1539.
1540.
1541.
Distinct Regulation of T Helper Cell Differentiation By
Biologic DMARD Therapy in Rheumatoid Arthritis
Treatment II
1542.
Predicting Successful Long-Term Treatment with Tumour
Necrosis Factor-Alpha Inhibitors in Patients with Psoriatic
Arthritis
1557.
Clinical Response in Subjects with Psoriatic Arthritis
Following One Year of Treatment with Brodalumab, an
Anti-Interleukin-17 Receptor Antibody
1543.
Associated with Long-Term (52-Week) Improvement in
the Signs and Symptoms of Psoriatic Arthritis in DMARDNaive Patients: Results from a Phase 3, Randomized,
Controlled Trial
1558.
Evaluation of Extreme Enthesitis and/or Patient-Related
Outcome Score As Potential Surrogates for Fibromyalgia
and As Potential Confounding Factors of Anti-TNF
Response
1544.
Economic and Comorbidity Burden Among Moderate-toSevere Psoriasis Patients Comorbid with Psoriatic Arthritis
1559.
1545.
Better Performance of the Leeds and Sparcc Enthesitis
Indices Compared to the Mases in Patients with Peripheral
Spondyloarthritis during Treatment with Adalimumab
Long Term Improvements in Physical Function Are
Associated with Improvements in Dactylitis, Enthesitis,
Tender and Swollen Joint Counts, and Psoriasis
Skin Involvement: Results from a Phase 3 Study of
Ustekinumab in Psoriatic Arthritis Patients
1560.
Rheumatoid Factor Status Is a Predictor of Osteoporosis in
Patients with Psoriatic Arthritis
1546.
Risk of Non Melanoma Skin Cancer Among Medicare
Psoriasis/Psoriasis Arthritis Patients
2014 Program Book
203
ACR POSTER INDICES
1561.
Apremilast, an Oral Phosphodiesterase 4 Inhibitor,
and the Impact of Baseline Weight and BMI on ACR20
and HAQ-DI Response: Pooled Results from 3 Phase 3,
Randomized, Controlled Trials
Value and Prediction of Minimal Disease Activity in
1578.
Abatacept Improves Synovitis As Assessed By Magnetic
Resonance Imaging (MRI) in Psoriatic Arthritis Preliminary Analysis from a Single Centre, PlaceboControlled, Crossover Study
1579.
Change in Weight from Baseline with Apremilast, an Oral
Phosphodiesterase 4 Inhibitor: Pooled Results from 3
Phase 3, Randomized, Controlled Trials
1580.
Gender Differences in Disease Activity Accounting for
Inflammatory Biomarkers in a Psoriatic Arthritis Routine
Care Cohort
1562.
Psoriasis Longitudinal Assessment and Registry: Global
Update upon Full Enrollment
1563.
Malignancies in the Psoriasis Longitudinal Assessment
and Registry Study: Cumulative Experience
1564.
Long-Term (104-Week) Safety Profile of Apremilast, an
Oral Phosphodiesterase 4 Inhibitor, in Patients with
Psoriatic Arthritis: Results from a Phase 3, Randomized,
Controlled Trial and Open-Label Extension
1565.
Associated with Improvement of Pain, Fatigue, and
Disability in Patients with Psoriatic Arthritis: Results from
3 Phase 3, Randomized, Controlled Trials
1581.
Inflammatory Back Pain in Psoriasis and Psoriatic Arthritis
Is Suggestive of Undiagnosed Spondyloarthropathies
1582.
The Efficacy and Safety of Biological Disease Modifying
Anti-Rheumatic Drugs and Apremilast in the Treatment of
Psoriatic Arthritis: A Systematic Review and Meta-Analysis
Cumulative Inflammatory Burden Is Independently
Associated with Increased Arterial Stiffness in Patients
with Psoriatic Arthritis
1583.
The Spectrum of Autoimmune Ophthalmic Manifestations
in Psoriatic Disease
Screening for Psa in Primary Care Psoriasis Patients with
Musculoskeletal Complaints with PEST, PASE & Earp
1584.
Joint Damage Is Not Associated with Smoking Status in
Evaluation of the Patient Acceptable Symptom State in
1585.
Persistence of Biologic Therapy in Psoriatic Disease:
Results from the Psoriasis Longitudinal Assessment and
Registry
Presence of Swollen and Tender Joints in Patients Fulfilling
Minimal Disease Activity Criteria
1586.
Quantitative Proteomic Analysis of Synovial Fluid and Skin
Identifies Putative Psoriatic Arthritis Biomarkers
1570.
Relationship Between Psoriatic Arthritis Severity,
Duration, and Comorbidities
1587.
The Economic Impact of Psoriatic Arthritis in Toronto,
Ontario
1571.
Musculoskeletal Complaints and Psoriatic Arthritis in
Primary Care Patients with Psoriasis
1588.
Resistance Training in Patients with Psoriatic Arthritis
Improves Function, Disease Activity and Quality of Life
1572.
Associated with Long-Term (52-Week) Improvements
in Enthesitis and Dactylitis in Patients with Psoriatic
Arthritis: Results from a Phase 3, Randomized, Controlled
Trial
1589.
Risk of Opportunistic Infection and Herpes Zoster
Infection in a Psoriasis/Psoriatic Arthritis Cohort
1590.
Associated with Long-Term (104-Week) Improvements in
Patients with Psoriatic Arthritis: Results from a Phase 3,
Randomized, Controlled Trial
1591.
Exploring the Association of Serum Paraoxonase and
Arylesterase Activities with Cardiovascular Risk in
Psoriasis and Psoriatic Arthritis
1592.
Ability of Clinical Variables to Predict Radiographic
Damage in Psoriatic Arthritis
1593.
Neutrophil-Lymphocyte Ratio As a Marker of Disease
Activity in Psoriatic Arthritis
1566.
1567.
1568.
1569.
1573.
Norwegian Psoriatic Arthritis Patients Are More Obese
Than Rheumatoid Arthritis and Axial Spondyloarthropathy
Patients
1574.University Students with Psoriatic Nail Changes Have a
Greater Number of Tender Enthesial Points Than Those
with Normal Nails
1575.
1576.
204
1577.
The Association Between Obesity and Disease Phenotype
in Psoriatic Arthritis
Reversal of Damage in Psoriatic Arthritis
2014 Program Book
ACR POSTER INDICES
1594.
Persistence of Low Disease Activity after Tumor Necrosis
Factor Inhibitor Withdrawal in Patients with Psoriatic
Arthritis
1595.
Economic Evaluation of Sequencing Strategies in the
Treatment of Psoriatic Arthritis in the United States
1596.
Clinical Characteristics and Outcome of Golimumab
Treatment Differs Between Bio-naïve and Patients
Previously Exposed to Biologicals. Nationwide Results
on Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA),
Ankylosing Spondylitis (AS) and Other Spondyl
1597.
Work Productivity Improvement Associated with
Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in
Patients with Psoriatic Arthritis: Results of a Phase 3,
Randomized, Controlled Trial
1608.
Erythrocyte C4d and Antibodies to Anti-C1q Are
Associated with Proteinuria in Lupus Nephritis
1609.
Dissection of the Type I Interferon Response in Systemic
Lupus Erythematosus : Serum IFNα Is Elevated in Lupus
Nephritis and Correlates with IFN Score; IFNβ Is Elevated
in Mucocutaneous Disease
1610.
New Autoantigens Associated with Lupus Nephritis
1611.
Modular Transcriptional Neutrophil Signature As
Predictive of Nephritis and of Its Severity in SLE Patients
1612.
Deficient Repair of DNA Double-Strand Breaks and
Increased Apoptosis in Patients with Lupus Nephritis
1613.
Circulating microRNAs As Candidate Biomarkers of
Diagnosis in Systemic Lupus Erythematosus
1598.
Serum Fetuin-a, Intercellular Adhesion Molecule -1 and
Interleukin -18 Levels in Ankylosing Spondylitis and
Psoriatic Arthritis
1614.
Functional Analysis of Interferon Responsiveness in PBMC
from SLE Donors Identifies Subgroups with Higher and
Lower Disease Activity
1599.
Comparison of Rheumatoid Arthritis, Ankylosing
Spondylitis, and Psoriatic Arthritis Pregnancies: Disease
Activity, Treatment, and Outcomes
1615.
MiR-127-3p As a Novel Regulator of Type I Interferon
Signaling Pathway in SLE
1600.
Is There a Role for Inflammasome Activation in PsA
Pathogenesis and Its Comorbidities?
1616.
Functional Profiling of PBMC from SLE Patients Versus
Healthy Controls Identifies Subgroups with DiseaseAssociated Dysfunctional Signaling
1601.
Are There Gender Specific Differences in Patient
Characteristics at Initiation of Biologic Treatment in
Ankylosing Spondylitis and Psoriatic Arthritis?
1617.
Single Cell Interferon Signatures in Lupus Patient
Monocytes Reveal a Differential Impact of Interferon
Signaling Between Monocyte Subtypes
1602.
Th9 Cells in Inflammatory Cascades of Autoimmune
Arthritis
1618.
1603.
Effect of Methotrexate on the Immunogenicity of TNF
Inhibitors in Spondyloarthritis Patients
Suppression of IFN-α Production from Systemic Lupus
Erythematosus Immune Complexes Via C1 Complex
Enzymatic Properties
1619.
Systemic Lupus Erythematosus - Human Etiology and Pathogenesis:
Autoimmune Disease Transition, Disease Subsets and Prediction of
Flares, Cytokines and Autoantibodies
Interferon Dysregulation in an Academic SLE Cohort Is
Associated with Distinct Signaling Differences in Blood
Neutrophils Versus PBMCs
1620.
IFN-γ (Th1), IL4 (Th2), and IL5 (Th2) Are Elevated in PreClinical SLE and Predict Transition to Classified Disease
Prior to Appearance of Autoantibodies or Clinical Criteria
Antibody to Malondialdehyde-Acetaldehyde Adducts
(MAA) As a Potential Biomarker of Inflammation in
Systemic Lupus Erythrematosus (SLE)
1621.
A Shift Towards Trans-Signalling Explains Relatively Low
CRP Despite an Active Interleukin-6 (IL-6)/IL-6-Receptor
(IL-6R) System in SLE
1622.
Th1 and Th2 Cytokines Are Associated with Cerebral
Atrophy in Systemic Lupus Erythematosus
1623.
Increased CD95 (Fas) Expression on Naive B Cells Is
Associated with a Switch to Double Negative and Plasma
Cells in the Peripheral Blood, and Correlates with Disease
Activity in Systemic Lupus Erythematosus
1624.
The Role of B Lymphocyte Stimulator in Monocyte
Subpopulation Differentiation in SLE
1604.
1605.
Elevated Regulatory Mediators and Interferon Gamma
Associated Responses, but Not Interferon Alpha, BLyS or
IP-10, Accompany High-Titer Anti-Ro Autoantibodies in
Asymptomatic Mothers of Children with Neonatal Lupus
1606.
Profiling a Broad Range of Autoantibodies in Healthy and
Systemic Lupus Erythematosis Revealed Autoantibody
Patterns Associated with Autoantibody Transition and
Disease Activity
1607.
B Cell and Neutrophil-Related Transcripts Predict and
Characterize a Lupus Flare
2014 Program Book
205
ACR POSTER INDICES
1641.
Baseline Factors That Predict High BLyS Levels in Patients
with Systemic Lupus Erythematosus (SLE) and High
Disease Activit
1642.
A Prospective Study of Vitamin D Effects on T Cells
Phenotype in Patients with Systemic Lupus Erythematosus
Treated with Different Regimens of Supplementation for
Two Years
1643.
Role of Inflammasome Activation in Systemic Lupus
Erthematosus: Are Innate Immune Cells Activated?
1644.
1628.Upregulation of Myxovirus Resistance Protein 1
in Patients with Neuropsychiatric Systemic Lupus
Erythematosus
Mycophenolic Acid and Ribavirin Induces Cytoplasmic
Autoimmunogenic Rods and Rings Structures in Vivo
1645.
Interferon Gene Signature Expression and Serological
Differences in Japanese and Non-Japanese SLE Patients
1629.
Added Value of the Determination of Anti-Ribosomal
and Anti-Ku Antibodies for Diagnosis of Systemic Lupus
Erythematosus
1646.
1630.
A Novel NMR Biomarker of Inflammation (GlycA) Is
Elevated in Systemic Lupus Erythematosus
Molecular, Cellular and Histopathologic Assessment of
Baseline Characteristics of Sixteen Subjects with Discoid
Lupus Erythematosus Prior to Treatment with AMG 811
(anti-IFNγ)
1625.
Interferon Stimulates Transglutaminase Activity on
Human Monocytes and Their Microparticles
1626.
Autoantibodies Against High Mobility Group Box 1
(HMGB1) in Patients with SLE
Biomarker, Translational and Nephritis Studies
1627.
1631.
Cell Bound Complement Activation Products and Their
Relationship to Disease Activity and Quality of Life
Measures in Systemic Lupus Erythematosus
1632.
Is Liopxin A4 a Biomarker for Systemic Lupus
Erythematosus?
1633.
Galectin-3-Binding Protein Is Associated with Disease
Activity, but Not with Atherosclerosis in SLE Patients
1634.
Thrombophilia Associated with DFS70 Antibodies
1635.
Association Between Carrying at Least One
Apolipoprotein1 Variant Allele and Hypertension in Lupus
Patients with Normal Renal Function
1636.
Disease Phenotype Is Associated with TH1, TH2 and
TH17 Cytokines in Childhood-Onset Systemic Lupus
Erythematosus
1637.
LACK of Association of ANTI CCP and Arthritis in SLE
1638.
Anti-Dense Fine Speckled 70 Antibodies: Long-Term
Followup Study of Clinical Associations in a US Laboratory
Patient Population
1639.
Serum Anti-Müllerian Hormone Levels in SLE Patients.
the Disease Severity and Cyclophosphamide Reduce the
Ovarian Reserve
1640.
206
The Global Antiphospholipid Syndrome Score (GAPSS)
Differentiates Between Transient Ischemic Attack and
Stroke in Patients with Antiphospholipid Antibodies
Cyclophosphamide Diminishes Plasmablasts and
Transitional B Cells and Suppresses Autocrine Production
of B Cell Activating Factor of Tumor Necrosis Factor Family
(BAFF) in These Cells in Patients with Systemic Lupus
Erythematosus
2014 Program Book
1647.
Relationship Between Apom/S1P Levels and
Atherosclerosis in Women with Systemic Lupus
Erythematosus
1648.Urinary T Cells and Macrophages Strongly Reflect the
Disease Activity, Kidney Function, and the Histopathologic
Classification in Patients with Lupus Nephritis
1649.
High Specificity of Skin Immunoglobulin Deposits for
diagnosing SLE in Patients with Lupus Nephritis
1650.
Prevalence and Prognostic Implications of IgG4 in
Membranous Lupus Nephritis
1651.
Association of Glomerular Macrophage Phenotypes and
Urine Soluble CD163 with Disease Activity in Human
Lupus Nephritis
1652.
Biomarkers of Lupus Nephritis and Ethnic Disparities in
1653.
Serum Cystatin C As a Biomarker for Clinical Practice in
Patients with Lupus Nephritis
1654.
Thrombotic Microangiopathy and Poor Renal Outcome in
Lupus Patients Is Not Associated with Antiphospholipid
Syndrome and/or Other Lupus Conventional Features
1655.
Lupus Nephritis: Clinicopathological Correlation in 126
Biopsies
1656.
Rate of Histological Transformation to Higher Grade
Nephritis in Class II Mesangial Proliferative Lupus
Glomerulonephritis
1657.
Does Advanced Age Influence the Type of Renal Injury and
the Prognosis of Lupus Nephritis?
ACR POSTER INDICES
1658.
Renal Thrombotic Microangiopathy in Systemic Lupus
Erythematosus: Novel Risk Factors and Clinical Outcomes
1659.
The Clinical Relevance of a Repeat Biopsy in Lupus
Nephritis (LN) Flares
1660.
A Systematic Review and Network Meta-Analysis of
Cyclophosphamide and Mycophenolate Mofetil in Lupus
Nephritis
1661.
Are Repeat Renal Biopsies Important in Managing Lupus
Nephritis Flares?
1662.
Lupus Nephritis Patients Who Stopped Maintenance
Immunosuppressive Therapy without Relapse
1663.
Influence of Ethnicity on Efficacy of Current
Immunosuppressive Protocols in Proliferative Lupus
Nephritis
1664.
Novel Risk Factors for Systemic Lupus Erythematosus
(SLE) Flares in Patients with End-Stage Renal Disease: Is
SLE in Patients with End-Stage Renal Disease a “sleeping
beauty”?
1675.
Regional Implantation of Adipose Tissue-Derived Cells
Induces a Prompt Healing of Long-Lasting Indolent Digital
Ulcers in Patients with Systemic Sclerosis
1676.
Physical Therapy for Systemic Sclerosis: Systematic Review
and Meta-Analysis
1677.
Association of Gastrointestinal Symptoms with
Immunosuppressant Use in the Prospective Registry of
Early Systemic Sclerosis Cohort
1678.
Initial Therapy with an Endothelin Receptor Antagonist
Is Associated with Worse Outcomes in Patients with
Systemic Sclerosis and Pulmonary Arterial Hypertension:
Observations from the Pulmonary Hypertension
Assessment and Recognition of Outcomes in Sclero
1679.
A Double Blind Randomized Control Trial of Oral Tadalafil
in Interstitial Lung Disease of Scleroderma
1680.
An Indirect Comparisons Analysis of Medications Used for
Treatment of Raynaud’s Phenomenon
1681.
Heart Transplantation in 6 Patients with Systemic Sclerosis
and a Primary Cardiac Involvement
1682.
Mycophenolate Mofetil Versus Azathioprine in
Scleroderma-Associated Interstitial Lung Disease: Results
from the Australian Scleroderma Cohort Study
Botulinum Toxin-a for the Treatment of Severe Raynaud
Phenomenon
1665.
Efficacy Versus Safety of Prednisone in Lupus Nephritis
Since 1988
1666.
The Relevance of Urinary Podocyte Number and Urinary
Podocalyxin Level with Response to Treatment and 1 Year
Renal Prognosis in Systemic Lupus Erythematosus
1667.
‘Probability of 3 and 6 Month Complete Response in
Lupus Nephritis’
1684.
Treatment of Scleroderma Associated Lung Disease with
Mycophenolate Mofetil: A Community-Based Study
1668.
Identifying Patient Perceptions of Medication Decision
Making Barriers in Minorities with Lupus Nephritis
1685.
Effects of Mycophenolate Mofetil on Pulmonary Lung
Function in Interstitial Lung Disease of Systemic Sclerosis
1669.
Validation of a Machine Learning Lupus Nephritis Decision
Support Tool to Predict Complete Response to Therapy
1686.
DUAL Energy Computed Tomography for the Evaluation of
Calcinosis in Systemic Sclerosis
1670.
Characterization of Patients with Lupus Nephritis
Included in a Large Cohort from the Spanish Society of
Rheumatology Registry of Patients with Systemic Lupus
Erythematosus
1687.
Key Role of Cardiac Biomarkers in the Assessment of
Systemic Sclerosis: Contribution of High Sensitivity Cardiac
Troponin
1688.
1671.
Renal Relapses Are Common in Lupus Nephritis
1672.
Facilitating the Medication Decision-Making process—
What Do Patients with Lupus Nephritis Say?
Early Detection of Left Ventricular Morphological,
Functional Abnormalities and Myocardial Characteristics
in Systemic Sclerosis without Cardiac Symptoms Using
Cardiac Magnetic Resonance Imaging: A Preliminary
Report
1673.
Disease Specific Quality of Life in Patients with Lupus
Nephritis
1689.
Microhaemorrages and Giant Capillaries in Nailfold
Videocapillariscopies Are Able to Accurately Predict
Disease Activity Level in Systemic Sclerosis
Systemic Sclerosis, Fibrosing Syndromes and Raynaud’s - Clinical
Aspects and Therapeutics: Systemic Sclerosis, Diagnostic and
Therapeutic Aspects
1690.
Improvement of Digital Ulcerative Disease in Patients with
Systemic Sclerosis Is Associated with Better Functional
Prognosis
1674.
1683.
Long-Term Efficacy of Rituximab in Systemic Sclerosis
2014 Program Book
207
ACR POSTER INDICES
1691.
1692.
Systemic Sclerosis Patients with Pulmonary Hypertension
Have a Lower Change in End Tidal Carbon Dioxide
Following Three Minutes of Step Exercise Than Systemic
Sclerosis Patients without Pulmonary Hypertension: A
Cross-Sectional Study
The Additive Value of Nailfold Videocapillaroscopy
Patterns to Disease-Specific Autoantibodies in
Discrimination of Patients with Systemic Sclerosis at Risk
for Severe Organ Involvement
The Lectin Pathway of Complement – a Potential Role in
the Pathogenesis and Disease Manifestations of Systemic
Sclerosis
1706.
Prevention of SU5416-Induced Pulmonary Hypertension in
a TGFβ Dependent Genetic Mouse Model of Scleroderma
Using the Endothelin Receptor Antagonist Macitentan
1707.
High Oxidative Stress in Fibrotic and Non-Fibrotic Skin of
Patients with Systemic Sclerosis
1693.
Progressive Disease in Systemic Sclerosis after One Year
of Follow-up; Results of a Standardized Multidisciplinary
Health Care Program
1708.
The Pathogenic Role of Immune Complexes Containing
Scleroderma-Specific Autoantibodies in the Inductor
Phase of the Disease
1694.
A Feasibility Study of Subjective and Objective
Assessment of Sublingual Abnormalities in Systemic
Sclerosis
1709.
WITHDRAWN
1710.
Endothelin-1 Is a Downstream Mediator of Profibrotic
Effects by Transforming Growth Factor-β1 in Systemic
Sclerosis Skin Fibroblasts
1711.
The Relationship Between Vascular Biomarkers and
Disease Characteristics in Systemic Sclerosis: Elevated
MCP-1 Is Associated with Predominantly Fibrotic
Manifestations
1712.
Monocytic Angiotensin and Endothelin Receptor
Imbalance Determines Secretion of the Profibrotic
Chemokine Ligand CCL18
1713.
Increased Number of CD206+cells in Peripheral Blood and
Skin of Systemic Sclerosis Patients
1714.
IL-6 Trans-Signalling Activates M2 Macrophage
Polarisation and Mediates Fibrotic Response in
Scleroderma
1715.
Serum Levels of CD163/Tweak Predict Risk of Digital
Ulcers in Patients with Systemic Sclerosis
1716.
MHC Class I and Class II Genes Influence Systemic Sclerosis
Susceptibility, Clinical Presentation and Autoantibody
Profile in a Mexican Admixed Population
1717.
Antiphospholipid Antibodies in Systemic Sclerosis:
Prevalence and Clinical Significance?
Endothelial to Mesenchymal Transition Contributes to
the Development of Pulmonary Vasculopathy in Systemic
Sclerosis PAH
1718.
An Association of Anti-PM/Scl Antibody Reactivity with
Risk of Malignancy in Scleroderma
B Cell Subsets Homeostasis and Functional Properties Are
Altered in a Murine Model of Systemic Sclerosis
1719.
Periostin May Promote Productin of Extracellular Matrix
By Modulating TGF-β Signaling in Human Skin Fibroblasts
1720.
GATA6 Deficiency Activates UPR Pathways in Endothelial
Cells during the Development of Pulmonary Arterial
Hypertension
1721.
Investigating the SCF/c-Kit Pathway in Scleroderma
Fibrosis
1695.
Validation of Vesmeter As a Diagnostic Tool of
Scleroderma
1696.
Left Atrial Area Measurement Is Useful for Evaluating
Left Ventricular Diastolic Dysfunction Coexisting with
Pulmonary Arterial Hypertension Associated with
Systemic Sclerosis
1697.
High Frequency Skin Ultrasound Detects Subclinical
Diffuse Dermal Involvement in Patients with Limited
Cutaneous Systemic Sclerosis
1698.
1699.
Peripheral Blood Eosinophil Counts Increase in Patients
with Systemic Sclerosis and Associated with Its Disease
Severity
Endothelial and Platelet Microparticles As Potential Novel
Biomarkers of Peripheral Microvascular Dysfunction in
Systemic Sclerosis and Primary Raynaud’s Phenomenon
1700.
Laser Speckle Contrast Analysis in the Follow-up of Digital
Ulcers in Systemic Sclerosis Patients
1701.
Short-Term Effects of Iloprost on Micro-Vessels
Hemodynamics in Systemic Sclerosis Patients Evaluated By
Laser Doppler Flowmetry
1702.
1703.
Systemic Sclerosis, Fibrosing Syndromes and Raynaud’s Pathogenesis, Animal Models and Genetics
1704.
208
1705.
CXCL4 Promotes Fibrosis By Increasing Expression of
Extracellular Matrix Modifying Factors and By Facilitating
Epithelial/Endothelial Mesenchymal Transition
2014 Program Book
ACR POSTER INDICES
1722.
1723.
1724.
1725.
1726.
1727.
1728.
1729.
1739.
Immunomodulatory Properties of CD271+ and CD271Synovial Mesenchymal Cells
1740.
Predicting the Evolution of Inflammatory Arthritis in
ACPA-Positive Individuals: Can T-Cell Subsets Model Help?
1741.
Loss of IRF5 Ameliorates Tissue Fibrosis in a Murine
Model of Systemic Sclerosis
Anti-TNFα Treatment Increases IL-17A+ and IL-22+ T Cells
in Spondyloarthritis Regardless of Concomittant Gut
Inflammation
1742.
The SYK Inhibitor Fostamatinib Limits Tissue Damage and
Fibrosis in a Bleomycin-Induced Scleroderma MOUSE
MODEL
Depletion of Reactive Oxygen Species Biases T Cells to
Proinflammatory Cytokine Production in Rheumatoid
Arthritis
1743.
Therapeutic Efficacy of Mesenchymal Stem Cells in Diffuse
Murine Hypochlorite-Induced Systemic Sclerosis
Antigen-Specificity Regulates Peripheral Homeostasis of
Regulatory T Cells
1744.
CD4+ T Cell Subpopulations in Blood and Synovial Fluid
Defined By Differential Expression of Integrins
1745.
Bromodomain Inhibitor JQ1 Modulates Collagen
Processing and Ameliorates Bleomycin Induced Dermal
Fibrosis in Mice
Memory Stem T Cells Are Selectively Enriched in Patients
with Rheumatoid Arthritis, Contract upon Anti-TNF
Treatment, and May Provide a Long-Term Reservoir of
Arthritogenic Lymphocytes
1746.
Adenosine A2A Receptor (A2AR) Promotes Collagen Type
3 Expression Via β-Catenin Activation
Involvement of IL-17-Producing MAIT Cells in the
Pathogenesis of Rheumatoid Arthritis
1747.
WITHDRAWN
TLR4 and TLR7 Are Required for Gadolinium Based
Contrast Agent Induction of Dermal and Pulmonary
Fibrosis in an Adenine-Induced Model of Chronic Renal
Failure
Identification of the Microbiome As a Potential Trigger of
Systemic Sclerosis By Metagenomic RNA-Sequencing of
Skin Biopsies
Poly(ADP-ribose) Polymerase-1 (PARP-1) Suppresses the
Profibrotic Effects of Transforming Growth Factor â in
Systemic Sclerosis
1730.
Identification of Novel Scleroderma –associated Antigens
and Development of an Autoantibody Assay Panel
Enabling Their Subsequent Validation
1748.
CCR6+CD4+ Cells Are Counterparts of Follicular T-Cells
Supporting Autoantibody Production in Rheumatoid
Arthritis
1731.
Translocation of IGFBP-5 to the Nucleus and Its Interaction
with Nucleolin Do Not Dictate Its Fibrotic Effects
1749.
Molecular Mechanisms Underlying 1,25(OH)2D3Mediated Suppression of Th17 Cell Activity
1732.
Attenuation of Sclerodermatous Graft Versus Host Disease
(sclGVHD) in IL4RA Receptor-Deficient Mice
1750.
The Effect of a Pro-Inflammatory Milieu on Tregalizumab
(BT-061)-Induced Regulatory T-Cell Activity
1751.
CD4 Aptamer-RORγt shRNA Chimera Inhibits IL-17
Synthesis By Human CD4+ T cells
T cell Biology in Rheumatoid Arthritis and Other Arthritis
1733.
Immunomodulatory Effects of Dietary Non-Digestible
Oligosaccharides in T Cell-Mediated Autoimmune Arthritis
1752.
CD30 As a Target of Aptamers and Delivery Portal for
Aptamer-shRNA to Block Th17 Cells
1734.
IL-22 Plays a Significant Role in the Initiation and
Augmentation of Th17-Dependent Experimental Arthritis
1753.
1735.
T–cell Tolerance Induction By the Glycosylated Type II
Collagen Peptide-Based Vaccination in Murine Arthritis
Human T-Cells Express RANKL in Response to Combination
of ZAP-70, Calcineurin and Voltage-Gated K+-Channel
Signaling Following Co-Ligation of the Adhesion Molecule
CD2 and the T-Cell Receptor Complex
1736.
Immune Related Adverse Events Associated with AntiCTLA-4 Antibodies: Systematic Review and Meta-Analysis
1737.
Altered Phenotype and Function of Senescent Regulatory
T Cells in Rheumatoid Arthritis
1738.
Prominent Role of CCR6+ T Helper Cells in the
Pathogenesis of ACPA+ Patients with Early RA
Vasculitis
1754.
Peripheral CD5+ b-Cells in ANCA-Associated Vasculitis
1755.
Proteomic Analysis of ANCA Vasculitis Serum Reveals
Broad Neutrophil Activation, Angiogenesis, and Selective
Inflammatory Pathway Activation
2014 Program Book
209
ACR POSTER INDICES
1756.
Molecular Diagnosis Reveals a Surprising Prevalence of
Limited Gpa Among Patients with Orbital Inflammatory
Diseases
1773.
Otolaryngologic Lesions Are Not Rare and Closely Related
with Pachymeningitis and Cranial Neuropathy in MPOANCA Associated Vasculitis
1757.
An Analysis of the Incidence and Characteristics of ANCA
Positive Vasculitis before and after the Christchurch
Earthquake
1774.
Granulomatosis with Polyangiitis (Wegener’s): Endoscopic
Management of Tracheobronchial Stenosis - Results from
a Multicenter Experience in 47 Patients
1758.
Environmental Risk Factors for Granulomatous Polyangiitis
(GPA): Southern Hemisphere Similar to Northern
Hemisphere
1775.
Predicting Relapse in Patients with Granulomatosis with
Polyangiitis - the Potential Use of Monitoring in Vitro
ANCA Production
1759.
Analysis of Employment, Work Disability and Quality of
Life of Patients with ANCA-Associated Vasculitis
1776.
Factors Predictive of ANCA-Associated Vasculitis Relapse
in Patients Given Rituximab-Maintenance Therapy
1777.
Staphylococcus Aureus Nasal Carriage and Relapses,
Bvas, ANCA-Positivity and Cotrimoxazole Use in ANCAAssociated Vasculitis
1778.
Rituximab Versus Azathioprine for ANCA-Associated
Vasculitis Maintenance Therapy: Impact in Health-Related
Quality of Life
1779.
Plasmapheresis Therapy in ANCA-Associated Vasculitides:
A Single-Center Retrospective Analysis of Renal Outcome
and Mortality
1780.
Outcomes of Triple Therapy (Plasma Exchange,
Cyclophosphamide and Systemic Corticosteroid) for
Anti-Neutrophil Cytoplasm Antibody (ANCA)-Associated
Vasculitis
1781.
Long-Term Outcomes Among Patients with Renal Disease
Secondary to ANCA-Associated Vasculitis: Temporal
Trends over 25 Years
1782.
Long-Term Follow-up of Non-HBV Polyarteritis Nodosa
and Microscopic Polyangiitis with Poor-Prognosis Factors
1783.
The Importance of Histopathological Classification of
ANCA-Associated Glomerulonephritis in Renal Function
and Renal Survival
1784.
Prognostic Factors for Interstitial Lung Disease with
Microscopic Polyangiitis
1785.
Survival of Microscopic Polyangiitis (MPA) Patients with
and without Pulmonary Fibrosis (PF)
1786.
Vasculitis As Underlying Cause of Death in the United
States: 1999 – 2010
1787.
HLA-DRB1*01 Is Associated with Henoch- Schönlein
Purpura in the Spanish Population
1788.
Association of HLA-B*41 with Henoch-Schönlein Purpura
in Spanish Individuals Irrespective of the HLA-DRB1 Status
1789.
Are EULAR/Printo/PRES Classification Criteria Appropriate
for Classification of IgA Vasculitis in Adults?
1760.United Kingdom & Ireland Vasculitis Registry – CrossSectional Data on the First 1085 Patients
1761.
Standardisation of Disease Assesment in Systemic
Vasculitis: Use of a Novel Web-Based Software Training
Application
1762.
The Muscle Biopsy Is a Useful and Noninvasive Procedure
in Diagnosing Systemic Vasculitis Affecting Small-toMedium-Sized Vessels: A Prospective Evaluation
1763.
Tobacco Differentially Affects the Clinical-Biological
Phenotype of ANCA-Associated Vasculitides at Diagnosis
1764.
Clinical and Other Differences Observed Between Cocaine
Induced and Non-Cocaine Induced Anti-Neutrophil
Cytoplasmic Antibody Positive Vasculitis
1765.
1766.
1767.
1768.
210
Comparison of Clinical Characteristics of Anti-Neutrophil
Cytoplasmic Antibody-Associated Vasculitis By the
Serotype Specificity to Myeloperoxidase and Proteinase-3
Comparison of Clinicopathologically- and SerologicallyBased Classification Systems for ANCA-Associated
Vasculitis
Granulomatosis with Polyangiitis (Wegener’s) According
to Geographic Origin and Ethnicity: Clinical-Biological
Presentation and Outcome
Cardiac Involvement in Granulomatosis with Polyangiitis:
A Magnetic Resonance Imaging Study of 31 Consecutive
Patients
1769.
Abdominal Visceral Adipose Tissue Measured By DXA As a
Novel Surrogate Marker of Cardiovascular Risk in Primary
Necrotizing Vasculitides
1770.
Increased Risk of Chronic Obstructive Pulmonary
Disease in Granulomatosis with Polyangiitis: A General
Population-Based Study
1771.
Arterial Thrombotic Events in Systemic Vasculitis
1772.
Venous Thromboembolic Events in Eosinophilic
Granulomatosis with Polyangiitis (EGPA)
2014 Program Book
ACR POSTER INDICES
1790.
Follow up of an Unselected IgA Vasculitis (HenochSchönlein Purpura) Population at Single Rheumatology
Center
1949.
Defective PTEN Regulation and Function Contributes
to B Cell Hyper-Responsiveness in Systemic Lupus
Erythematosus
1791.
Applicability of the 2006 European League Against
Rheumatism (EULAR) Criteria for the Classification of
Henoch-Schönlein Purpura. an Analysis Based on 766
Patients with Cutaneous Vasculitis
1950.
Circulating CD19+CD38+CD43+ B Cell Subset in SLE
Patients Have More Cell Cycle Related Genes Than Healthy
Controls
1792.
Clinical-Biological and Pathological Spectrum and
Outcome of IgA Vasculitis in Adults: A French Study
1951.
A Novel CD27(-) Spleen Tyrosine Kinase (Syk) Bright
Memory B-Cell Subset Is Expanded in SLE
1793.
Efficacy and Safety of IFN-Alpha in Induction and
Maintenance of Remission in Patients with Eosinophilic
Granulomatosis with Polyangiitis (EGPA). Single Center
Observational Study
1952.
Elucidation of Molecular Mechanisms of Breg Induction in
Autoimmune Diseases
1953.
Circulating Plasmablasts from Patients with Systemic
Lupus Erythematosus Produce Autoantibodies Reactive to
Epstein-Barr Virus
1954.
Successfull Long-Term Depletion of Memory Plasma Cells
Requires a Combined Depletion of Plasma Cells and Their
Precurors in NZB/W Mice
1955.
Disparity in Internalisation of Monoclonal Antibodies
Targeting B Cell Antigens and Regulation By Fc Gamma
Receptor IIb: Implications for Targeted Therapy in SLE
1956.
Increased IL-6 Production By Effector B Cells in Giant Cell
Arteritis and Polymyalgia Rheumatica
TUESDAY, NOVEMBER 18, 2014
B cell Biology and Targets in Autoimmune Disease: Systemic Lupus
Erythematosus and Related Diseases
1938.
Effects of Mesenchymal Stem Cells on Human B Cell
Proliferation
1939.
Development of Cell–Based Enzyme–Linked
Immunosorbent Assay for the Quantification of Anti–M–
type phospholipase–a–receptor Antibodies and Its Clinical
Usefulness in Patients with Membranous Nephropathy
1940.
1941.
A Novel Murine Model of B Cell-Mediated Glomerular
Injury Is Mediated By Cytokines
Neuropsychiatric Lupus Is Substantially Unaffected By
B-Cell Deficiency
Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and
Angiogenesis
1957.
Dysregulation of CC Chemokines at Microvascular
Endothelial Cells of Blood and Lymphatic Vessels Under
Inflammatory Conditions
1942.
Regulation of the Responses of Human B Cell Subsets to
Innate Immune Signals By Epratuzumab, a Humanized
Monoclonal Antibody Targeting CD22
1958.
Pyrrolopyrimidine Derivatives That Inhibit Binding of BAFF
to Its Receptor, BR3, Are Drug Candidates for Primary
1943.
In Vivo Effects of Epratuzumab, a Monoclonal Antibody
Targeting Human CD22, on B Cell Function in Human CD22
Knock-in (Huki) Mice
1959.
Interaction of PDE4 and β-Arrestin Reverses AntiInflammatory Effects of Catecholamine-Producing Cells in
Chronic Arthritis Via Adrenoceptor Switching from Gαs to
GαI Signalling
1944.
Targeting CD22 with Epratuzumab Impacts Cytokine
Production By B Cells
1960.
NF-κB-Inducing Kinase (NIK) Is Expressed in Synovial
Endothelial Cells in Early Arthritis Patients and Correlates
with Local Disease Activity and Systemic Markers of
Inflammation
1961.
Chemokine-like Receptor 1 (CMKLR1) is Expressed on
Synoviocytes and Proinflammatory Monocytes in Arthritis
and is Predominantly Regulated By β arrestin 2 and G
Protein Coupled Receptor Kinase (GRK) 6
1962.
Inflammatory Properties of Inhibitor of DNA Binding 1 As
a Unique Fibroblast Derived Nuclear Protein
1945.
Pharmacodynamic Effects of the CD22-Targeted
Monoclonal Antibody Epratuzumab on B Cells in Patients
with Systemic Lupus Erythematosus
1946.
CD22 Is Required for Formation of Memory B Cell
Precursors within Germinal Centers
1947.
Prolactin Promotes Survival of Immature B Cells from
MRL/Lpr Mice
1948.
A Dual Role for IFN-γ in Development of Peripheral B Cells
in Lupus-Prone MRL/Lpr Mice
2014 Program Book
211
ACR POSTER INDICES
212
1963.
Hierarchical Role of PI3K/Akt/mTOR Signaling Cascade on:
Tissue Inflammation, Organization and Angiogenesis in
Autoimmune Arthritis
1978.
Role of Monocytes Subsets in the Pathology of
Rheumatoid Arthritis: Involvement in Endothelial
Dysfunction and Proinflammatory Profile
1964.
Changes in Soluble CD18 Reflect Latency in the Immune
System and Predict Radiographic Progression in Early
1979.
Pseudostarvation By AMPK Activator Therapy Is
Associated with Reduced Disease Activity and
Downregulation of Pro-Inflammatory Responses in
1965.
Characterization of the Thyroid Hormone System in
1980.
1966.
CTLA4-Ig (abatacept) Modulate in Vitro the ICAM1 and
VEGFR-2 Expression in Human Endothelial Cells
Thrombospondin-1 Is Elevetad in the Plasma of Patients
with Antiphospholipid Syndrome and Is Correlated with
Soluble Fas Ligand and Free Active TGF-B levels
1967.
Transforming Growth Factor Beta Is a Major Regulator
of Micro-RNA Synthesis in Rheumatoid Arthritis Synovial
Fibroblasts
1968.
Highly activated IL-23/Th17 axis and JAK2/STAT3 signal
pathway in PBMC of active AS patients involve in
pathogenesis of AS
1969.
Neurotrophin Receptor p75 (CD271) Defines a
Distinct Synovial Fibroblast Subset in Rheumatoid
and Osteoarthritic Synovial Tissues with Enhanced
Proinflammatory Potential
1970.
TH17 Inflammatory Responses Occur in a Subset of
Patients with Erythema Migrans or Lyme Arthritis, but Are
Not Predominant Responses in Joints
1971.
The Role of the Proinflammatory Mediator High-Mobility
Group Box Protein 1 (HMGB1) in Anti-Collagen-AntibodyInduced Arthritis Is Dependent on Vascular Endothelial
Growth Factor (VEGF)
Education (ACR)
1981.
A Qualitative Analysis of Methotrexate Injection Videos
on Youtube
1982.
Final Year Medical Students Prefer E-Reading Content
to Interactive Case-Based Quizzes in a Pediatric
Rheumatology E-Learning Module
1983.
Improving Resident Confidence with the Musculoskeletal
Exam through a Rheumatology-Dedicated Musculoskeletal
Workshop
1984.
Implementation and Performance of an Objective
Structured Clinical Examination (OSCE) in a National
Certification Process of Trainees in Rheumatology. Two
Years of Experience
1985.
Rheumatology Learning Management System
1986.
Ambulatory Rheumatology Curriculum: Effect of
Multimodal Curriculum Enhancement
1972.
Analysis of Anakinra in Primary Human Cell Systems
Reveals an in Vitro Signature for Skin-Related Side Effects
1987.
Simulation in Continuing Education: Improving EvidenceBased Decisions for Rheumatoid Arthritis Management
1973.
Ectopic Lymphoid Neogenesis Is Strongly Associated with
Activation of the IL-23/IL-17 Pathway in Rheumatoid
Synovitis
1988.
Process Outcomes and Community-Wide Efficacy of the
Amigo Inter-Institutional Mentoring Initiative within
Pediatric Rheumatology
1974.
Sex Steroids, Interleukin-1, and Interleukin-10 Inhibit
interferon–gamma (IFN-γ) Induced B Cell Activating Factor
of the Tumor Necrosis Factor Family (BAFF) in Human
Synovial Fibroblasts
1989.
Application of an Experiential Learning Framework for
Clinician Scholar Educator Training in a Rheumatology
Fellowship
1975.
Profiling 14-3-3η in Human Primary Cell Based BioMAP®
Disease Models Reveals a Unique Pro-Inflammatory
Phenotypic Signature Consistent with RA-Inflammation
Biology
1990.
Pilot Musculoskeletal Workshop for Internal Medicine
Residents
1991.
Integration of Nailfold Capillary Microscopy and
Dermoscopy into the Rheumatology Fellows Curriculum
1992.
Resident’s Guide to Rheumatology Mobile Application: An
International Needs Assessment
1993.
Does Psychological Safety Impact Learning Environments
Among Rheumatology Fellows: Findings from Veterans
Affairs Learners’ Perception Survey
1976.
Elevation and Functional Activity of Interferon Omega in
Human Systemic Lupus Erythematosus
1977.
The Proangiogenic Function of the Epigenetic Regulator
EZH2 in Synovial Tissue Is Mediated By Fibroblasts in
2014 Program Book
ACR POSTER INDICES
1994.
Incorporation of Musculoskeletal Ultrasound Curriculum
and 6-Month Assessment of Knowledge Retention into
the 2nd Year of Medical Student Training
1995.
Design and Implementation of a Clinical Teaching Tool for
Approach to Children with Suspected New Rheumatologic
Diagnosis
1996.
Improvement in Basic Bone Health Knowledge Among
VA Primary Care Practitioners during a Focused
Musculoskeletal Mini-Residency
1997.
Structured Integrative Rheumatology Modules (SIRM)
1998.
pGALS Training Increases Kenyan Pediatric Residents’
Confidence in Performing a Musculoskeletal Exam
1999.
Internal Medicine Resident Confidence in Rheumatologic
and Musculoskeletal Diseases: A Needs Assessment
Survey
2000.
The Effect of a Rheumatology Ambulatory Rotation for
Medical Residents on Documentation of Musculoskeletal
Complaints
2001.
The Musculoskeletal Mini-Residency Collaborative
Network: A National Department of Veterans Affairs
Interdisciplinary and Interprofessional Educational
Innovation for Primary Care Providers
2011.
What Do State Legislators Think about Arthritis? Results
of Focus Groups with State Legislators
2012.
Moving Social Media Beyond Health Education and into
Patient Engagement
2013.
Quality Appraisal of Educational Websites on
Osteoporosis and Bone Health
Epidemiology and Public Health (ACR): Rheumatoid Arthritis
Pathogenesis and Treatment
2014.
Performance of Self-Reported Measures for Periodontitis
in Rheumatoid Arthritis and Osteoarthritis
2015.
Fine Particulate Air Pollution and Systemic Autoimmune
Rheumatic Disease in Two Canadian Provinces
2016.
Occupation and Risk of Developing Rheumatoid Arthritis
2017.
Fish Consumption and Risk of Rheumatoid Arthritis
Among Women in Large Prospective Cohorts
2018.
Do Mediterranean or Vegetarian Diets Influence Risk of
Rheumatoid Arthritis?
2019.
Antibodies to Citrullinated Clusterin, Filaggrin, Vimentin,
and Fibrinogen Are Associated with Blood Pressure in
First-Degree Relatives of Rheumatoid Arthritis Patients:
The Studies of the Etiology of Rheumatoid Arthritis
2020.
Circulating Carotenoids and Subsequent Risk of
2002.
Implementation of a Collaborative Rheumatology and
Physiatry Musculoskeletal Ultrasound Training Program
2003.
Pilot Study of a Web-Based Module on Gout
2004.
Osteoporosis Screening and Fracture Risk Assessment Tool
Usage Among House Staff
2021.
The Association Between Rheumatoid Factor and
Cardiovascular Disease in Healthy Adults
2005.
Osteoporosis
2022.
First Nations Persons Have an Increased Risk of
Developing Rheumatoid Arthritis with an Early Onset
Age but Are Seen Less Frequently By Rheumatologists: A
Population Based Study
2023.
Prevalence of Inflammatory Arthritis Conditions in the
First Nations Population of Alberta
2024.
Prevalence of Rheumatoid Arthritis in French West Indies,
an African Ancestry Population. the Eppra Study
2025.
Factors Associated with Time to Diagnosis from Symptom
Onset in Early Rheumatoid Arthritis Patients
2026.
Treatment Delays and Worse Outcomes Associated with
Lower Socioeconomic Status in Rheumatoid Arthritis
2027.
Higher Educational Level Correlates with Retarded Onset
and Less Severe Disease in Rheumatoid Arthritis Patients
Education (ARHP): Education/Community Programs
2006.
Multiple Joint Osteoarthritis: Patient Preferences for a
Generic Exercise and Self-Management Programme
2007.Using Photovoice Techniques to Empower Lupus Patients
and Create Public Awareness: A Program Evaluation
2008.
Personalized Risk Education for Rheumatoid Arthritis
Improves Self-Perceived Risk Accuracy and Risk Factor
Knowledge in First-Degree Relatives
2009.
Development of Multimedia Patient Education Tools
(MM-PtET) for Osteoarthritis (OA), Osteoporosis (OP) and
Rheumatoid Arthritis Patients (RA)
2010.
Reaching out to Physical Therapists: Results of a Survey
on Physical Therapists Preferences for Learning about
Evidence-Based Community Programs
2014 Program Book
213
ACR POSTER INDICES
2028.
Effect of Age at Rheumatoid Arthritis Onset on Clinical,
Radiographic, and Functional Outcomes: The Espoir
Cohort
2029.
Treatment Patterns of Multimorbid Rheumatoid Arthritis
Patients: Results from an International Cross-Sectional
Study
2030.
Predicting Failure of Conventional Disease Modifying
Antirheumatic Drugs in Treatment Naive Early
Rheumatoid Arthritis Patients: A Single Centre Inception
Prognostic Factor Cohort Study
2031.
Early Adherence to Methotrexate in Rheumatoid Arthritis
(RA) Is High: a Prospective Longitudinal Study of New
Users
2032.
Psychological Factors Predict Adherence to Methotrexate
(MTX) in Rheumatoid Arthritis (RA); Findings from a
Systematic Review of Rates, Predictors and Associations
with Patient Outcomes
2033.
Patient Factors Associated with Oral Glucocorticoid
Prescribing Patterns in UK Primary Care for Patients with
2034.
A Treat-to-Target Strategy Preserves Work Capacity in
Early Rheumatoid Arthritis (RA)
2035.
Joint Distribution and Outcome in 350 Patients with
Monoarthritis of Less Than 16 Weeks Duration: Data from
a Multicenter Longitudinal Observational Study in Eastern
Norway
2036.
Biologic Disease-Modifying Antirheumatic Drugs and Risk
of High-Grade Cervical Dysplasia and Cervical Cancer in
Women with RA
2041.
Performance of a Two-Step Latent Tuberculosis Screening
Algorithm in Patients with Rheumatoid Arthritis, Psoriatic
Arthritis or Ankylosing Spondylitis Prior to Treatment
with Tumor Necrosis Alpha Inhibitors: Prospective
Observational Data from the Biorx.S
2042.
Tuberculin Conversion in Patients with Autoimmune
Arthropathies Receiving Biologic Therapy
2043.
How Correct Are the Assumptions Made for Tuberculosis
Screening Algorythms before TNF-Alpha Antagonists?
2044.
Systematic Review of the Effect of Anti-Rheumatic
Therapies upon Vaccine Immunogenicity
Epidemiology and Public Health (ARHP)
2045.
Interaction Effects Between Genes and Blood Lead Level
on a Composite Score of Multiple Joint Symptoms: The
Johnston County Osteoarthritis Project
2046.
Perceived Discrimination in Individuals with Radiographic
Knee and Hip Osteoarthritis
2047.
No Association of Serum Uric Acid with Hip Fracture Risk
in Older Men and Women from the Framingham Original
Cohort
2048.
Disability in Discretionary Valued Life Activities and SelfEfficacy Explain a Significant Portion of RA Patients’ Global
Assessments
2049.
Fatigue Is a Risk Factor for Subsequent Functional Decline
in SLE
2050.
Knee Arthritis Is Positively Associated with Physical
Impairment: Conclusion Based on Physical Examinations
from a Cross-Sectional Study of 17708 Chinese Residents
Modification of Effects of Household Income and
Homeownership By Block Group Poverty on Health
Outcomes in a Cohort of African Americans with
2037.
Incidence and Prevalence of Myasthenia Gravis in
Rheumatoid Arthritis Patients with and without
Treatment Compared with the General Population
2051.
2038.
Respiratory Cause Mortality Was Significantly Predicted
By Incident Rheumatoid Arthritis (RA) and Higher Pre-RA
Levels (0.50+ SD) of Soluble Interleukin-2 Receptor Alpha
(sIL-2Rá): Results of a 21-Year Community-Based Cohort
Survival Analysis
2052.
Foot and Ankle Characteristics Associated with Falls in
Adults with Rheumatoid Arthritis
2053.
Among Persons Assayed with Lower Serum Interleukin-1
Beta (IL-1β) Levels, Serum Androstenedione (Δ4A)
and Testosterone (T) Were Significantly Lower in a
Community-Based Cohort of Rheumatoid Arthritis MultiYears before Clinical Onset (Pre-RA) Than in Non-
Mortality Decreases in Patients with Rheumatoid
Arthritis: a 15-Year Prospective Cohort Study
2054.
Physical and Mental Functioning in Patients with
Established Rheumatoid Arthritis over an 11-Year Followup Period: The Role of Specific Comorbidities
2039.
2040.
Opportunistic Infections in Patients Treated with Biologic
Drug Therapy
Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical
Pain Syndromes: Research Focus
2055.
214
2014 Program Book
Are There Immunological Abnormalities in Fibromyalgia
Patients: Flow Cytometry Analysis
ACR POSTER INDICES
2056.
Fibromyalgia Symptoms Beyond the Pain and Its Impact
on the Patient
2076.
Predictive Modeling of a Fibromyalgia Diagnosis:
Increasing the Accuracy Using Real World Data
2057.
Electrophysiological Evaluation of Autonomic Nervous
System and Cutaneous Silent Period in Patients with
Fibromyalgia Syndrome
2077.
A New Tender Point on the Plantar Arch in Primary
Juvenile Fibromyalgia: A Potential Point to be Considered
2058.
The Impact of Environmental Stress on Pain in
Fibromyalgia Patients
2078.
A Proposed Simple 3-Variable Index for Identification of
Fibromyalgia, Analogous to Classification Criteria for RA
and SLE
2059.
Muscle Tension Is Increased in Fibromyalgia
2079.
The Association Between Straight Neck and Fibromyalgia
2060.
Do Fibromyalgia Patients Have a Distinct Sleep Signature?
2080.
Carryover Effects in Crossover Design Studies in
Fibromyalgia and Other Pain Conditions
2081.
Ehlers-Danlos Hypermobile (EDS-HT) Patients and Postural
Instability : Another Clue to Explain Pain and Fatigue ?
2061.Unexpectedly High Prevalence of Immunoglobulin
Deficiency in Fibromyalgia
2062.
WITHDRAWN
2082.
2063.
Analysis of the Fibromyalgia Rapid Screening Tool Spanish
Version to Detect Fibromyalgia in Primary Health Care
Centers
Presence of Acrocyanosis in Patients with Joint
Hypermobility
2083.
Evaporative Dry-Eye Disease and Aqueous Deficient DryEye Disease Associated with Fibromyalgia
Assessment of the Spanish Version of the American
College Rheumatology Preliminary Diagnostic Criteria for
Fibromyalgia
Genetics, Genomics and Proteomics
2064.
2065.
A Cross-Sectional Analysis of Psychological Symptoms,
Sleep Quality, and Functional Balance in Fibromyalgia
2066.Ultra Orthodox Religious Orientation Associated
with Reduced Rates of Pain, Anxiety and Fatigue in a
Population Based Study
2067.Understanding the Factors Influencing Time to Diagnosis
in Fibromyalgia
2068.
Joint Hypermobility Syndrome and Postural Orthostatic
Tachycardia Syndrome (HyPOTS)
2069.
Investigation of the Effects of Physical Exercise on the
Control Mechanisms of Cutaneous Circulation in Patients
with Fibromyalgia Syndrome
2070.
2071.
Elevated Serum Leptin Concentrations in a Subset of
Fibromyalgia Patients with High Inflammatory Markers
Chronic Widespread Pain Versus Multi-Site Pain: Does the
Distribution Matter?
2084.
Are Genetic Markers Associated with Myocardial
Infarction in Patients with Early Rheumatoid Arthritis?
2085.
Association of Circulating Mirnas with Spinal Involvement
in Patients with Axial Spondyloarthritis
2086.
Replication of PTPRC As Genetic Biomarker of Response to
TNF Inhibitors in Patients with Rheumatoid Arthritis
2087.
Defective Regulation of L1 Endogenous Retroelements
in Primary Sjögren’s Syndrome and Systemic Lupus
Erythematosus: Role of Methylating Enzymes
2088.
Association of TNFAIP3 Gene Polymorphisms with the
Risk for RA and Prediction of Therapy Outcome of TNFαBlocker Treatment
The APOL1 Gene Is Not Associated with Lupus Nephritis in
Individuals with Enriched Amerindian Ancestry
2089.
2090.
Contribution of MTHFR Gene Polymorphisms in Sjögren’s
Syndrome Related Lymphomagenesis
2091.
Plasma Microparticle Protein Features Distinctively
Classify Systemic Lupus Erythematosus and Systemic
Sclerosis and Their Clinical Phenotype
2092.
Proteomic Phenotyping of Rheumatoid Arthritis Disease
Activity
2093.
Improvement of Rituximab Response Prediction in
Rheumatoid Arthritis Via Correction for PrednisoneRelated Suppression of Type I Interferon Response Gene
Expression
2072.Ultrasound Assessment of Both Hands in Fibromyalgia
Patients: What Could We Detect?
2073.
Is Susceptibility to Fibromyalgia a Trait?
2074.
Hypervigilance and FMS
2075.
The Lumbar Spine in Fibromyalgia
2014 Program Book
215
ACR POSTER INDICES
2110.
WITHDRAWN
2111.
Overcoming Barriers to Acute Patient Access: Is There a
Need for Urgent Care Clinics in Rheumatology Practices?
2112.
Assessment of RA Heterogeneity in Two Independent
Cohorts of Patients
Patterns of Medication Use Before, During, and After
Pregnancy Among Women with Systematic Lupus
Erythematosus: A Population-Based Study
2113.
Identification of Diagnostic and Activity Metabolomic
Urine Biomarkers in Six Immune-Mediated Inflammatory
Diseases
The Number of Morbidities Drives the Health Care
Expenditures and Presence of a Musculoskeletal Condition
Is Additionally Accountable for Higher Costs
2114.
Genetic Variants of the NLRP3 Inflammasome Are
Associated with Stroke in Patients with Rheumatoid
Arthritis
Comorbidity Characteristics of Patients Starting FirstLine Acute Gout Agents - Colchicine, NSAID, and
Corticosteroids
2115.
Serum C-X-C Motif Chemokine 10 (CXCL10) Is Elevated in
Psoriasis Patients Prior to Psoriatic Arthritis Onset
Inflammatory Arthritis Treatment Outcomes at a First
Nations Reserve Rheumatology Specialty Clinic
2116.
Activation of NFkβ Pathways in Sjögren’s Syndrome
Related Lymphomagenesis-Role of the His159Tyr
Mutation of the BAFF-R Receptor
Hospitalization Rates and Utilization Among Rheumatoid
Arthritis Patients: A Population-Based Study from 1987 to
2012
2117.
Association Between Depression and High Utilization of
Emergency Department in Patients with Systemic Lupus
Erythematosus from the Southeastern United States: The
Goal Cohort
2118.
Lower Socioeconomic Status at Disease Onset Is
Associated with Higher Health Care Costs in Patients with
Systemic Lupus Erythematosus: A General PopulationBased Cohort Study
2119.
Off Work Days Decreased RATE in Muskuloeskeletal
Disease Patients: Usefulness of the EARLY Intervention
Program
2120.
Societal Preferences for Rheumatoid Arthritis Treatments.
Evidence from a Discrete Choice Experiment
2121.
Real-World Cost Comparison of Urate Lowering Therapies
in Patients with Gout and Moderate to Severe Chronic
Kidney Disease
2122.
Variation in the Prescribing Practices of Biologic Dmards
2123.
Characterization of Social Stigma in Rheumatic Diseases
and Correlation with Quality of Life and Medication
Adherence
Significant State-Level Variation in Source of Biologic Drug
Coverage Among Beneficiaries with Rheumatoid Arthritis
2124.
Characteristics of Medicare Beneficiaries Travelling Long
Distances to Visit a Rheumatologist
2108.
Anxiety in Caregivers of Patients with Chronic Rheumatic
Conditions
2125.
Burden of Illness in Refractory Gouty Arthritis: A One-Year
Prospective Multinational, Observational Study
2109.
Are Patient Ratings of Providers and Health Plans
Associated with Technical Quality of Care in SLE?
2094.
2095.
2096.
2097.
2098.
2099.
2100.
Deep Sequencing Reveals Differential RNA Expression
during Malignant Transformation in Major Salivary Glands
in a Mouse Model of Sjögren’s Syndrome
Two Novel Serum Urate Levels Associated Genetic Loci
Identified By GWAS in European Were Confirmed in
Chinese Han Population
2101.
Epigenetic Study of Advanced Ankylosis in Patients with
2102.
A Tissue-Specific Lincrna in the TRAF1-C5 Risk Locus As a
Putative Cis-Regulator, Bridging Genetics and Disease
Health Services Research
2103.
Benefits of Early Onset of DAS28 (CRP) <2.6 on Physical
Functioning, Quality of Life and Resource Use Among RA
Patients in a Clinical Practice Setting
2104.
Effectiveness of a Workplace Integrated Care Intervention
on Work Productivity in Workers with Rheumatoid
Arthritis
2105.
Nonsurgical Treatment Patterns in Patients with Chronic
Spinal Cord Injury
2106.
Surgical Compared with Nonsurgical Management of
Fractures in Men with Chronic Spinal Cord Injury
2107.
216
2014 Program Book
ACR POSTER INDICES
Imaging of Rheumatic Diseases: Various Imaging Techniques
2141.
Sensitivity to Change of Joint Space Width Measurements
in Hand Osteoarthritis in a Two Year Follow-up Study
2126.
The Utility of Digital Activity Fluorescence Optical Imaging
in Quantifying Hand and Wrist Inflammation in Rheumatic
Diseases
2142.
Sensitivity and Precision of Automated Osteophyte
Volumetric Measurement in Knee Osteoarthritis over Four
Years
2127.
Subclinical Arthritis Is Detected By Macrophage Targeting
and Positron Emission Tomography (PET) in Early RA
Patients in Clinical Remission
2143.
Cortical Breaks and Bone Erosions in the Hand Joints: A
Cadaver Study Comparing Conventional Radiography with
High-Resolution and Micro-Computed Tomography
2128.
Effectiveness of 18f-Fluoro-Dexoxyglucose Positron
Emission Tomography for the Diagnosis of Polymyalgialike Illness
2144.
Cuantification of Hand Bone Mineral Density By
Radiogrammetry and Dual X-Ray Absorptiometry in Early
Arthritis Patients
2129.
Sensitivity and Specificity of the “Green Nail” Sign in
Fluorescence Optical Imaging in Psoriatic Arthritis
2145.
2130.
Bone Microstructure in Patients with Cutaneous Psoriasis
and No History of Psoriatic Arthritis Shows Bone Anabolic
Changes at a Greater Extent Than in Healthy Controls
Diagnostic Performance and Disease Activity Assessment
By FDG-PET in Large-Vessel Vasculitis: A Systematic
Literature Review and Meta-Analysis
2146.
Optimal Hand Position for Reliable Volumetric Joint Space
Width Measurements Using High-Resolution Peripheral
Quantitative Computed Tomography
2147.
Automatically Extracted Quantitative Biomarkers for
Assessing Connective Tissue Disease Using Nailfold
Capillaroscopy
2148.
Dual Energy CT Scanning: Variable Sensitivity for Gout
in Non-Tophaceous and Tophaceous Disease and in
Individual Erosions
2131.
The Impact of Patient-Reported Flares on Radiographic
Progression in Rheumatoid Arthritis Patients with LowDisease Activity: Secondary Analyses from a Randomized
Trial
2132.
What Is Associated with X- Ray Progression at 5 Years
in Rheumatoid Arthritis (RA) Patients in Low Disease
Activity?
2133.
Efficacy of Tocilizumab Therapy in Patients with
Rheumatoid Arthritis Based on FDG-PET/CT
2149.
2134.
Baseline Scintigraphic Detection of TNFá As a Predictor
of Therapy Response after Treatment with Certolizumab
Pegol in Rheumatoid Arthritis and Spondyloarthritis
Patients
Relationship Between the Magnitude of Bone Formation
in the Anterior Vertebral Corners, As Assessed through
18F-Fluoride Uptake, and Lumbar Spine Bone Mineral
Density in Patients with Ankylosing Spondylitis
2150.
The Craniocervical Junction in Ankylosing Spondylitis: A
Computed Tomography Based Study
Patients with Moderate Disease Activity in the
First 5 Years of Rheumatoid Arthritis Still Progress
Radiographically Despite Conventional Disease Modifying
Therapy
Infections, Infection-related Biomarkers and Impact of Biologic
Therapies
2135.
2136.
2137.
Rheumatoid Arthritis Erosion Detection and Measurement
in Longitudinal Datasets Using High-Resolution Peripheral
Quantitative Computed Tomography
Linear Extrapolation of Missing Radiographic Progression
Scores Does Not Spuriously overestimate overall
Radiographic Progression in Rheumatoid Arthritis
2138.
Radiological Outcomes after Two Years of Remission
Steered Treatment in Early Arthritis Patients
2139.
Predictors of Radiologic Disease Progression during the
Rheumatoid Arthritis Comparison of Active Therapies Trial
2140.
Agreement Among FDG-PET/CT, Ultrasound and Physical
Examination in Patients with Inflammatory Arthritis
2151.
Abatacept Related Infections: No Association with
Gammaglobulin Reduction
2152.
Frequency of Postoperative Deep Infection in Patients
Clinical Characteristics and Outcomes in Synovial Fluid
Culture ̵ Negative Septic Arthritis
2153.
2154.
Risk for Developing Adult T-Cell Leukemia in Patients with
Human T Lymphotropic Virus Type-I Carrier Receiving
Immunosuppressive Therapy
2155.
Chikungunya Fever in Patients Under Biologics
2156.
Persistent Arthralgia Following Chikungunya Fever
.
2014 Program Book
217
ACR POSTER INDICES
2174.
MicroRNA-146a in Salivary Gland Epithelial Cells Inhibits
Co-Stimulatory Molecule CD80 Expression and Increases
Autoreactive T Cell Activation in Sjögren’s Syndrome
2175.
Macrophages from the Synovium of Active Rheumatoid
Arthritis Exhibit an Activin a- Dependent ProInflammatory Profile
Human T-Lymphotropic Virus Type 1 Biomarkers in
2176.
Macrophages-Mediated Response to Uric Acid Crystals Is
Modulated By Their Functional Polarization
2160.
WITHDRAWN
2177.
2161.
Interest of Systematic Lyme Serology in Context of Recent
Onset Arthritis
Class a Scavenger Receptor SR-a Exacerbated Synovial
Fibroblasts-Mediated Inflammation in Rheumatoid
Arthritis
2178.
Extensive Natural Killer Cell Receptor Phenotyping on NK
and T Cells Discloses Differences in RA and Psa, Potentially
Mirroring Diverse Immunoregulatory Functions
2179.
The Monocyte-Phagocyte System in Gout: Enhanced
Inflammasome Activity and Expansion of CD14++CD16+
Monocytes in Patients with Gout
2180.
Macrophage Depletion Ameliorates Nephritis Induced By
Pathogenic Antibodies
2181.
Investigating Myeloid and Plasmacytoid Dendritic Cell
Activation within the Synovium and Peripheral Blood of
2182.
Investigating the Roles of Factor H-Related Proteins
in Systemic Lupus Erythematosus (SLE) and Other
Autoimmune Diseases
2183.
Release of Enzymatically Active Peptidyl Arginine
Deiminases (PADs) By Neutrophils Allows Generation of
Citrullinated Extracellular Autoantigens in the Synovial
Fluid of Patients with Rheumatoid Arthritis
2184.
Selective Consumption of C2 Component in HCV Patients
2185.
Alterations in B Cell Complement Processing Related to a
Lupus-Associated Variant in Complement Receptor 2
2157.
Tuberculosis Reactivation Risk in Patients Treated
with Tumor Necrosis Factor Alpha Inhibitors: A Turkish
Experience with Higher Mortality and Different
Background Diseases
2158.
Severe Neutropenia in Patients with Rheumatic Diseases
at a Tertiary Care Hospital in South Korea
2159.
2162.
Immunological Abnormalities in Adult Patients with
Parvovirus B19 Infection : A study of 23 Cases
2163.
Genetic Variants of TNFAIP3 in Patients with HCV
Related Lymphoma Are Associated with the Presence of
Rheumatoid Factor (RF)
Innate Immunity and Rheumatic Disease: Mediators, Cells and
Receptors
2164.
218
Self-Phospholipids Regulate Inflammation Via Activation
of CD1d-Restricted T-cells and Induction of ‘antiinflammatory’ Myeloid-Derived Suppressor Cells (MDSC)
2165.
Myeloid-Derived Suppressor Cells in Rheumatoid Arthritis:
Friend or Foe?
2166.
Bim Suppresses the Development of Glomerulonephritis
By Inhibiting M2 Polarization
2167.
Snapin Is Critical for Cathepsin D Activation and the
Normal Lysosomal Function
2168.
Extramedullary Myelopoiesis Drives Persistent Toll-like
Receptor-Mediated Inflammation
2169.
Targeting ITGAM+ Cells Successfully Treats a Model of
Anti-RNP-Associated Pulmonary Hypertension
2170.
Human Tolerogenic Dendritic Cells Generated with Protein
Kinase C Inhibitor Are Optimal for Regulatory T Cell
Induction-a Comparative Study
2171.
Polymorphisms in the FCN1 Gene Coding for M-Ficolin Are
Associated with Disease Activity, Radiographic Damage
and Are the Strongest Predictors of DAS28 Remission in
180 DMARD naïve Early Rheumatoid Arthritis Patients
2186.
Clinical and Immunologic Correlates in Cocaine Users with
Serum Anti-Neutrophil Cytoplasmic Antibodies
2187.
Revisiting RS3PE after Twenty Five Years: A Systematic
Review of 250 Cases
2188.
Incidence and Mortality of Relapsing Polychondritis in the
United Kingdom: A Population-Based Cohort Study
2172.
PTPN22 Promotes TLR-Induced Amelioration of Arthritis
2189.
Multicentric Reticulohistiocytosis- Case Series from a
Tertiary Care Center
2173.
Role of Natural Killer Cells and Gamma Delta T Cells in
Enthesitis Related Arthritis Category of Juvenile Idiopathic
Arthritis
2190.
Features of Interstitial Lung Disease Associated with
Connective Tissue Disease in a Spanish Southwest Cohort
2014 Program Book
ACR POSTER INDICES
2191.
Intravenous Sodium Thiosulfate for Treatment of
Refractory Calcinosis in Rheumatic Disease
2192.
Successful Therapy with Intravenous Sodium Thiosulfate
for Adult Dermatomyositis Associated Calcinosis
2193.
Prevalence of Raynaud’s Phenomenon and Nailfold
Capillaroscopic Abnormalities in Fabry’s Disease: A CrossSectional Study
2194.
Blue Digit Syndrome: The Rheumatologist’s Perspective
2195.
Eculizumab Treatment of Malignant Atrophic Papulosis
(Köhlmeier-Degos Disease): World Experience to Date
2196.
Treprostinil Use in Malignant Atrophic Papulosis
(Köhlmeier-Degos Disease): Review of Worldwide
Experience to Date
2209.
Novel Biomarkers of Extracellular Matrix Remodeling in
Inflammatory Bowel Disease: Different Patterns of Gut
Injury in UC and CD
Muscle Biology, Myositis and Myopathies: Immunological Aspects of
Inflammatory Myopathy
2210.
Redefining Dermatomyositis: Description of
New Diagnostic Criteria That Differentiate Pure
Dermatomyositis from Overlap Myositis with
Dermatomyositis Features
2211.
Epidemiologic and Clinical Features of Patients with Adult
and Juvenile Dermatomyositis, Polymyositis and Inclusion
Body Myositis from Myovision, a National Myositis
Patient Registry
2212.
Serum Adipokines in Dermatomyositis: Correlation with
Risk Factors Associated to Cardiovascular Diseases and
Metabolic Syndrome
2213.
Gene Expression Profiling of T Helper Subsets in Blood
and Affected Muscle Tissues Reveals Differential
Activation Pathways in Patients with Juvenile and Adult
Dermatomyositis
2214.
Power Doppler Ultrasonography for Detection of
Abnormal Fascial Vascularity: A Potential Early Diagnostic
Tool in Fasciitis of Dermatomyositis
2215.
Clinical Characteristics and Prognosis of Malignancies
Associated with Active Myositis
2216.
Muscle Type I Interferon Gene Expression May Predict
Therapeutic Responses to Rituximab in Myositis Patients
2197.
Malignant Atrophic Papulosis (MAP) Complicating
Connective Tissue Diseases (CTDs)
2198.
The Aromatase Inhibitor Induced Musculoskeletal
Syndrome: Is There a Potential Role of Osteoporosis
Therapy and Menopause Timing?
2199.
Intravenous Immunoglobulin Therapy for Secondary
Hemophagocytic Lymphohistiocytosis : A Retrospective
2200.
Elevated Serum Ferritin Levels in Adult Inpatients As a
Predictor of in-Hospital Mortality and Association with
2201.
Haematological Complications in Rheumatic Diseases: Not
Only Lymphomas
2202.
Pilot Study of Tocilizumab in Patients with ErdheimChester Disease
2217.Ultrasonography Analysis of Carotid Parameters in
Patients with Idiopathic Inflammatory Myopaties:
Correlation with Demographic Profile and Disease Activity
2203.
Adalimumab Therapy Improves Insulin Sensitivity in NonDiabetic Psoriatic Patients: A 6-Month Prospective Study
2218.
2204.
New Onset Vitiligo Under Biological Agents: A Case Series
Endoplasmic Reticulum (ER) Stress-Induced Mitochondrial
Dysfunction and Atrophy Can be Prevented By
Pharmacological Upregulation of Heat Shock Protein 70
(HSP) in Cultured Murine Myotubes
2205.
Management of Asymptomatic Coccidioidomycosis in
Patients with Rheumatic Disease
2219.
2206.
The Incidence of Zoster in Patients with Cutaneous
Lupus Erythematosus and Dermatomyositis Is Increased
Compared to the Average U.S. Population
Contribution of Tripartite Motif Proteins Modulating
Membrane Repair to the Pathogenesis of AutoimmuneMediated Myositis
2220.
Overexpression of Ankyrin Repeat Domain Containing
Protein 1 Gene (ANKRD1) in Polymyositis Muscle Biopsies
Is Correlated to Hypoxia
2221.
Reduction of Ovarian Reserve in Adult Patients with
Dermatomyositis
2222.
Predictors of Myositis Treatments Received and
Associated Treatment Responses in Myovision, a National
Myositis Patient Registry
2207.
2208.
Decreased Bone Mineral Density in Patients with EhlerDanlos Syndrome
Ovarian Reserve Alterations in Premenopausal Women
with Rheumatoid Arthritis, Behcet’s Disease and
Spondyloarthritis – Impact on Anti-Muellerian Hormone
Levels
2014 Program Book
219
ACR POSTER INDICES
2223.
High Prevalence of Hepatitis C Virus Infection in a
Japanese Inclusion Body Myositis Cohort
2224.
Increased Immune Complex Levels in Children with
Juvenile Dermatomyositis Are Not Associated with Levels
of Von Willebrand Factor Antigen, C4, Duration of Illness,
Disease Activity Score, or the Absolute NK Count
2225.
Does Previous Corticosteroid Treatment Affect the
Inflammatory Infiltrate Found in Polymyositis Muscle
Biopsies?
2226.
Systemic Treatment for Clinically Amyopathic
Dermatomyositis
2227.
Physical Impairment in Patients with Idiopathic
Inflammatory Myopathies Is Predicted By the American
College of Rheumatology Functional Status Measure
2228.
Has MRI an Added Value over Serum Creatine Kinase
Measurement in Myositis?
2229.
How Often Are Clinically Amyopathic Dermatomyositis
Patients Truly Amyopathic?
2237.
Interleukin-1 Dual-Variable Domain Immunoglobulin
Reduces Multiple Inflammatory Markers in Knee
Osteoarthritis Patients
2238.
Exploratory Six Month Phase IIa Study of a Potential
Disease Modifying Drug in Patients with OA of the Knee
2239.
Efficacy of Ketoprofen Lysine Salt in Reducing
Inflammation and Pain in Primary Osteoarthritis of
the Hand: Preliminary Results of a Retrospective and
Prospective Clinical Trial
2240.
An Exploratory 4-Week Study of a P2X3 Antagonist AF-219
in the Treatment of Patients with Osteoarthritis (OA) of
the Knee
2241.
Intermittent Analgesic Use and Risk of Pain Exacerbation
in Knee Osteoarthritis: A Web Based Case-Crossover Study
2242.
Effects of Intraarticular (IA) Corticosteroid Injections on
Bone Markers and Endogenous Cortisol in Patients with
Knee Osteoarthritis (OA): A Randomized, Double-Blind,
Placebo Controlled Trial
2243.
Comparison Between Two Diclofenac Diethylamine Gel
Formulations, 1.16% Vs 2.32%: Is It Only Increasing the
Strength of the Active Ingredient Enough?
2244.
Osteoarthritis
2245.
Characteristics of Conventional Footwear and Their
Association with Reductions in Knee Loading with a
Flexible Footwear Intervention
2246.
Reduction of Knee Osteoarthritis Symptoms in a Cohort of
Bariatric Surgery Patients
2247.
Bariatric Surgery Improves Quality of Life in Patients with
Osteoarthritis and Obesity Compared to Non-Surgical
Weight Loss
2248.
Clinical Outcomes, Neuropathic Pain and Patient
Satisfaction over a 15 Year Period Following Primary Tka:
A Repeat-Cross-Sectional Analysis
2249.
Criteria for Clinically Important Worsening in Knee and
Hip Osteoarthritis
2250.
The Effects of Treatment on Disease Symptoms and
Progression of Structural Changes in Knee Osteoarthritis
Participants from the Osteoarthritis Initiative Progression
Cohort
2251.
Kneeling Disability Associated with the Treatment of
Osteoarthritis: Analysis of a Copcord Study in Mexico
2252.
Autoimmune Thyroid Disease Is Associated with a Higher
Frequency of Spinal Degenerative Disc Disease
Osteoarthritis - Clinical Aspects: Therapeutics
2230.
Treatment of Symptomatic Knee Osteoarthritis with Oral
Salmon Calcitonin: Results from Two Phase 3 Randomized
Clinical Trials
2231.
Combined Chondroitin Sulfate and Glucosamine Is
Comparable to Celecoxib for Painful Knee Osteoarthritis.
Results from a Multicenter, Randomized, Double-Blind,
PHASE IV NON-Inferiority TRIAL
2232.
220
Cost-Effectiveness of Glucosamine, Chondroitin Sulfate,
Their Combination, Celecoxib,Non-Selective Non-Steroidal
Anti-Inflammatory Drugs, and Placebo in Treating Knee
Osteoarthritis
2233.
A PHASE 2, Multicenter, Randomized, Double-Blind,
Placebo-Controlled, Parallel-Group, Efficacy Study of
Apremilast (CC-10004) in Subjects with Erosive Hand
Osteoarthritis
2234.
Safety and Efficacy of Liposome Intra-Articular Injection in
Moderate Knee Osteoarthritis. a Prospective Randomized
Double-Blinded Study
2235.
Cost-Effectiveness of Long-Term Opioid Use in the
Treatment of Knee Osteoarthritis in Older Patients with
Multiple Comorbidities
2236.
Plant–Derived Products Are Effective for Treatment of OA
Pain and Safer Than Other Active Therapies
2014 Program Book
ACR POSTER INDICES
Osteoporosis and Metabolic Bone Disease - Clinical Aspects and
Pathogenesis: Osteoporosis: Treatment, Safety, and Long Term
Outcomes
2253.
Effect of Teriparatide in Patients with Osteoporosis with
Prior Vertebral Fracture
2254.
Changes in Subject Characteristics in the Denosumab
Pivotal Fracture Trial and Its Extension for up to 8 Years
2255.
Vertebral Cortical Bone Mass and Structure Significantly
Improved with Romosozumab Compared with
Teriparatide: HR-QCT Analyses of Postmenopausal
Women with Low BMD from a Phase 2 Study
2268.
Odanacatib Anti-Fracture Efficacy and Safety in
Postmenopausal Women with Osteoporosis: Results from
the Phase III Long-Term Odanacatib Fracture Trial
Pediatric Rheumatology - Clinical and Therapeutic Aspects:
Systemic Juvenile Idiopathic Arthritis, Spondyloarthropathy and
Miscellaneous Pediatric Rheumatic Diseases
2269.
Efficacy and Safety of High Dose Infliximab in the
Treatment of Uveitis in Pediatric Patients
2270.
Changes in Cerebral Blood Flow Velocity in Patients with
Familial Mediterranean Fever
2256.
Effects of Pre-Dosage Alendronate Treatment on Bone
Metabolic Indices and Bone Mineral Density in Patients
Treated with Glucocorticoids: A Prospective Study
2271.
Symptom and Treatment Characteristics of Juvenile
Primary Fibromyalgia Syndrome: Are Males and Females
Created Equal?
2257.
How Does Non-Compliance to Prolia ® (DENOSUMAB)
Impact the Change in Bone Mineral Density (BMD) in
Osteoporotic Patients?
2272.
Assessment of Transition Readiness in Adolescents and
Young Adults with Rheumatic and Other Chronic Health
Conditions
2258.
WITHDRAWN
2273.
2259.
Changes in serum Soluble RANKL and Osteoprotegerin
Levels after Teriparatide Administration in Rheumatic
Disease Patients with Glucocorticoid-Induced
Osteoporosis
Does a Standardized Multidisciplinary Approach Improve
Outcomes for Children with NMDA Receptor Antibody
Encephalitis? : A Preliminary Assessment of a Single
Center Experience
2274.
TNF Inhibitors Provide Long-Term Clinical Benefits in 6
Patients with Early-Onset Sarcoidosis
2275.
Immunization Status and Barriers in Childhood Rheumatic
Diseases
2276.
Consensus Statement on the Transition Process from
Pediatric Care to Adult Care in Patients with Chronic
Inflammatory Rheumatic Diseases with Childhood-Onset
2260.
Effects of Daily Teriparatide on the Spine and Femoral
Strength Assessed By Finite Element Analysis of Clinical
Computed Tomography in Rheumatoid Arthritis Patients
2261.
A Meta-Anlaysis of Bisphosphonate and Parathyroid
Hormone (PTH) Use in Osteoporosis
2262.
Raloxifene for Osteoporosis in Postmenopausal Women
with Rheumatic Diseases
2277.
Inpatient Pediatric Rheumatic Diseases: Characteristics,
Cost and Trends
2263.
Continued Zoledronic Acid Use in a Large Healthcare
System
2278.
Orbital Pseudotumor As the Presenting Symptom of
Pediatric ANCA-Associated Vasculitis
2264.
Denosumab for Long-Term Glucocorticoid Users Who
Have Inadequate Response to the Bisphosphonates: A
12-Month Randomized Control Trial
2279.
Evidence Based Recommendations for Diagnosis and
Management of Tumor Necrosis Factor Receptor-1
Associated Periodic Syndrome (TRAPS)
2265.
Comparative Effects of Raloxifene and Bisphosphonate
on Bone Mineral Density and Osteoporotic Fracture
Outcomes in Rheumatoid Arthritis Patients
2280.
Evidence Based Recommendations for the Management
of Cryopyrin Associated Periodic Syndromes (CAPS)
2266.
Risk Factors for Treatment Failure in Osteoporotic Patients
2281.
Dissecting the Heterogeneity of Macrophage Activation
Syndrome
2267.
Percentage of Women Achieving Non-Osteoporotic BMD
T-Scores at the Spine and Hip over 8 Years of Denosumab
Treatment
2282.
Evidence Based Recommendatinos for Diagnosis and
Management of Mevalonate Kinase Deficiency (MKD)
2283.
Steroid-Sparing Effect of Anakinra (Kineret®) in the
Treatment of Patients with Severe Cryopyrin-Associated
Periodic Syndrome
2014 Program Book
221
ACR POSTER INDICES
2284.
Joint Involvement in Pediatric Crohn’s Disease Is Related
to Higher Disease Activity and Worse Quality of Life
2300.
Biologic Treatment in Systemic Juvenile Idiopathic
Arthritis: Single Center Experience
2285.
Safety and Efficacy of Rilonacept in Patients with
Deficiency of Interleukin-1 Receptor Antagonist (DIRA)
2301.
The New Proposal Classification Criteria for Juvenile
Spondyloarthropaties
2286.
Food Allergy and Celiac Disease in Children with Juvenile
2302.
Classification of Juvenile Spondyloarthropathies According
to ASAS Criteria
2287.
Cartilage Thickness and Bone Health in Children with
2303.
Clinical Observation on Ankylosing Spondylitis Patients
with Different Phenotypes
2288.
The Research in Arthritis in Canadian Children
Emphasizing Outcomes (ReACCh Out) Cohort:
Independent Risk Factors and Medication Use in New
Onset Uveitis in Juvenile Idiopathic Arthritis
2304.
Positive HLA-B27 in Juvenile Spondyloarthritis Is
Associated to Early Sacroiliitis and Progression to
2289.
Accuracy of the Use of Administrative Diagnostic Codes to
Identify Pediatric in-Patient Musculoskeletal Conditions in
an African Tertiary Hospital
2290.
2291.
Canakinumab in Biologic-naïve Versus Previously BiologicExposed Systemic Juvenile Idiopathic Arthritis Patients:
Efficacy Results from a 12 Week Pooled Post Hoc Analysis
2292.
Demographic, Clinical and Treatment Characteristics
of the Childhood Arthritis and Rheumatology Research
Alliance Registry Systemic JIA Cohort
2293.
Preliminary Results from the Childhood Arthritis and
Rheumatology Research Alliance Systemic JIA Consensus
Treatment Plans Pilot Study
2294.
The Presentation and Initial Treatment of Systemic
Juvenile Idiopathic Arthritis According to Observational
Data from the United States and the United Kingdom
2295.
A Pharmacometric Based Analysis of the Occurrence
of Selected Safety Events of Special Interest and
Canakinumab Exposure in Systemic Juvenile Idiopathic
Arthritis Patients
Improving Screening for Hyperlipidemia in Patients with
Rheumatoid Arthritis at an Academic Rheumatology
Practice
2306.
Quality of Care for Cardiovascular Prevention in RA:
Compliance with Diabetes Screening Guidelines
2307.
Cardiovascular Disease Prevention in Rheumatic disease:
Assessing Screening in a Primary Care Setting
2308.
Quality of Care for Cardiovascular Disease Prevention in
RA: Compliance Lipid Screening Guidelines
2309.
A Novel Approach to Assess Wait-Times to
Rheumatologists
2310.
Improving Access to Health Care in Rheumatology
Practices through Initiation of an Outpatient Urgent Care
Clinic, a Paradigm Shift
2311.
Tele-Rheumatology: Despite Improved Access Could There
be a Potential Delay in Care without a Skilled “Presenter”?
2312.Use of Physician Extenders to Improve Quality and
Efficiency of Clinical Visits
2296.
Tocilizumab Therapy in Children with Systemic Juvenile
Idiopathic Arthritis. DATA from Russian Register of Sjia
2313.
Best Practices for Best Practice Alerts: Evaluation of a Best
Practice Alert to Detect Chronic Glucocorticoid Use
2297.
Efficacy of Canakinumab in Patients with Systemic
Juvenile Idiopathic Arthritis (SJIA) using JADAS Criteria an Analysis of 12-Week Pooled Data
2314.
Dexa Testing in Long-Term Steroid Use
2315.
Glucocorticoid Induced Osteoporosis Screening and
Treatment in a Cohort of Male Patients with Underlying
Rheumatologic Diagnosis in a Tertiary Care Setting
2316.
Adherence to Denosumab in a Large Healthcare System
2317.
Towards Reliable Implementation and Optimal Use of
Medication Decision Aid Cards for Shared Decision Making
in Juvenile Idiopathic Arthritis
2298.
2299.
222
Race and Other Risk Markers of Uveitis in a Prospective
Cohort of Children with Juvenile Idiopathic Arthritis
2305.
Canakinumab Treatment Shows Maintained Efficacy in
Systemic Juvenile Idiopathic Arthritis (SJIA) Patients at
Individual Patient Level: An Analysis of 12 Week Pooled
Data
M-Ficolin and Masp-2 As Inflammatory Markers in
Oligoarticular and Systemic Juvenile Idiopathic Arthritis
2014 Program Book
ACR POSTER INDICES
2318.
Increasing Rates of Remission in Juvenile Idiopathic
Arthritis through a Quality Improvement Learning
Network – the Pediatric Rheumatology Care and
Outcomes Improvement Network
2334.Understanding the Experiences of Rural CommunityDwelling Older Adults in Using a New DVD-Delivered
Otago Exercise Programme
2319.
Standardizing and Documenting Patient Education and
Disease Indices in Childhood-Onset Systemic Lupus
Erythematosus
Research Methodology (ARHP)
2320.
Initial Benchmarking of the Quality of Medical Care of
Childhood-Onset Systemic Lupus Erythematosus
2321.
Quality Improvement in the Identification of Crystals from
Synovial Fluid: Hospital Laboratory Versus Rheumatology
Department Evaluation
2322.
Aim for Better Gout Control: A Retrospective Analysis of
Preventable Hospital Admissions for Gout
2323.
WITHDRAWN
2324.
Only 30% Rheumatologists Collect Basdai in Patients
with Axial Spa in Daily Practice: The Potential Role of a
Consensual Meeting to Improve It
2335.
Reliability and Validity of the Arthritis Helplessness Index
in Systemic Sclerosis
2336.
Evaluating the Use of Video-Stimulated Recall to Research
the Osteoarthritis Consultation in Primary Care: Reaching
Parts Other Methods don’t Reach
2337.
The Cost and Effectiveness of Various Recruitment
Strategies in a Mind Body Clinical Trial Among Older
Adults with Knee Osteoarthritis
2338.
Cost-Effectiveness and Yield of Different Recruitment
Strategies Utilized in an Exercise Trial of Fibromyalgia
Patients
Rheumatoid Arthritis - Animal Models
2339.
Detecting Inflammation in Vivo Using Activatable
Fluorescence Contrast Agents in Inflammatory Arthritis
2340.
Human Osteoclasts Are Mobilized in Erosive Arthritis of
Epstein-Barr Virus-Infected Humanized NOD/Shi-Scid/IL2Rγnull Mice
Rehabilitation Sciences (ARHP)
2325.
A Systematic Review of the Educational Approach of
Occupational Therapy for Rheumatoid Arthritis
2326.
Investigation of Parameters Used to Test Quadriceps
Muscle Power Using Isokinetic Dynamometer in Arthritis
2341.
The Combination Therapy of Cell Cycle Regulation Therapy
Combined and TNF Blockade Ameliorated the Established
Arthritis
2327.
Delivering ESCAPE-Pain (Enabling Self-Management and
Coping of Arthritic Pain through Exercise ) - an Online
Guide for Healthcare Professionals
2342.
Redox Regulation of a New Autoimmune Mouse Model,
Glucose-6-Phosphate Isomerase Peptide Induced Arthritis
in Mice
2328.
The Physical and Psychosocial Effects of Exercise on
Chronic Hip and Knee Pain: A Cochrane Review with MetaAnalysis
2343.
Therapeutic Effects of Mesenchymal Stem Cells, AntiTumor Necrosis Factor and Anti-CD20 Treatment on
Collagen Induced Arthritis
2329.
Course and Outcome of Rehabilitation Care in Different
Rheumatological Diagnosis Groups. a Descriptive Study
Using the STAR-Etic Registry
2344.
Amelioration of Collagen-Induced Arthritis By WaterSoluble Fullerene C60(OH)36 Nanoparticles through the
Inhibition of Angiogenesis
2345.
Anti-IL-6 Receptor Antibody Prevents Deterioration in
Bone Structure in a Mouse Model of Collagen-Induced
Arthritis
2346.
Specific Overexpression of FPR2 (FPRL-1) on Th1 Cells
in GPI-Induced Arthritis and Patients with Rheumatoid
Arthritis
2347.
Therapeutic Effect of a Novel Histone Deacetylase 6
Inhibitor, CKD-L, on Collagen Induced Arthritis and
Peripheral Blood Mononuclear Cells from Patients with
2330.
Construct Validity of the Adult Myopathy Assessment Tool
in Individuals with Inclusion Body Myositis
2331.
People’s Views, Beliefs and Experiences of Exercise
for Chronic Hip and Knee Pain: Cochrane Review with
Qualitative Synthesis
2332.Use of Wrist Hand Orthoses during Hand Function
Skills and Functional Tasks By Adults with and without
2333.
The Natural Use of Activity Pacing in Daily Life Does Not
Result in Lower Symptoms in Osteoarthritis
2014 Program Book
223
ACR POSTER INDICES
2348.
Activatory Fc Gamma Receptor IV Plays a Crucial Role in
Pathogenesis of Experimental Immune Complex Mediated
Chronic Arthritis
2363.
Leucine-Rich Alpha-2 Glycoprotein Is a Potential Disease
Activity Marker Under IL-6 Suppression in Autoimmune
Arthritis
2349.
Early Sympathectomy Inhibits Egress of Lymphocytes in
Control and Arthritic Animals and Ameliorates Arthritic
Disease
2364.
PET-CT Imaging of Joints: A Quantitative Tool for
Developing Novel Anti-Inflammatory Drugs
2350.
A Humanized Monoclonal Antibody Raised Against a
Heat Shock Protein Epitope Suppresses Autoimmune
Inflammatory Diseases By Skewing the Immune System
Selectively Towards an Anti-Inflammatory Response
Rheumatoid Arthritis - Clinical Aspects: Impact of Various
Interventions and Therapeutic Approaches
2351.
2352.
RORγt Expressing Foxp3+ Regulatory T Cells Regulates the
Development of Autoimmune Arthritis in Mice
Comparison of the Effects of a Pharmaceutical Industry
Decision Guide and Decision Aids on Patient Choice to
Intensify Rheumatoid Arthritis Therapy with Etanercept
2366.
Effectiveness, Tolerability, and Safety of Subcutaneous
Methotrexate in Early Rheumatoid Arthritis: Clinical Data
from the St. Gallen Cohort
2367.
Physician Awareness of Suboptimal Patient Adherence
to MTX: Results from a Large U.S. Rheumatoid Arthritis
Registry
2353.
The Nitric Oxide Receptor Soluble Guanylyl Cyclase
Is Found in Lymphatic Vessels of Arthritic Mice and
Inhibition Alters Lymphatic Pulse
2368.
2354.
Efficacy of a Novel Orally Bioavailable JAK1 Selective
Compound in a Preclinical Rat Collagen-Induced Arthritis
Model
Impact of Physicians’ Adherence to Treat-to-Target
Strategy on Outcomes in Early Rheumatoid Arthritis
2369.
Apremilast, a Novel Phosphodiesterase 4 Inhibitor, and
Methotrexate Independently Prevent Inflammation in
Vivo and in Vitro
Management of Perioperative Tumor Necrosis
-á Inhibitors in Rheumatoid Arthritis Undergoing
Arthroplasty: A Systematic Review and Meta-Analysis
2370.
Management of Perioperative Tumor Necrosis Factor
α Inhibitors in Rheumatoid Arthritis Undergoing
Arthroplasty: A Systematic Review and Meta-Analysis
2371.
Efficacy of First Line Biological Monotherapy in RA: Data
from the Czech Registry Attra
2372.
Fatigue and Related Factors in Patients with Rheumatoid
Arthritis Treated with Tocilizumab in Daily Clinical Setting
2373.
Compliance in the Rheumatoid Arthritis Comparison of
Active Therapies Trial: Triple Vs Etanercept
2355.
2356.
2357.
Toluenesulfonylamido-Chalcone,
4-(p-toluenesulfonylamido)-4-Hydroxychalcone (TSAHC)
Suppresses Inflammatory Response and Joint Destruction
in an Experimental Arthritic Mice and Fibroblast-like
Synoviocytes
Vascular Adhesion Molecule-1 Overexpression in
Collagen-Induced Arthritis: Modeling Vascular Dysfunction
2358.
The Role of Dendritic Cells during Inflammatory Arthritis
2359.
CGEN-15001, a Novel Immunomodulatory Fusion Protein
of the B7 Family Induces Immune Tolerance and Shows
Efficacy in Mouse Models of Rheumatoid Arthritis and
Psoriasis
2360.
Glucocorticoids and Vascular Function in Arthritis: Benefic
or Deleterious Effects? Study in Rat
2361.
the Role of CD146 in the Therapeutic Potential of
Mesenchymal Stem Cells in Favor of CD146+ Cells for
Experimental Arthritis
2362.
224
Ligand of Glucocorticoid-Induced Tumor Necrosis Factor
Receptor Enhances Th17 Cells Response in CollagenInduced Arthritis Via P38 MAPK and STAT3 Pathway
2365.
Enhanced Efficacy of Dexamethose with Synovial
Fibroblast Targeted Micelles in a Collagen-Induced
Arthritis Mouse Model
2014 Program Book
2374.Use of Hydroxychloroquine Associated with Improved
Lipid Profile in Rheumatoid Arthritis Patients
2375.
Should Physician Reduce patients’ Glucocorticoids to
Offset the Risk of Serious Infection Event Among RA
Patients Who Switched from Non-Biologic Dmards and
Glucocorticoid to Biologics?
2376.
Safety of Rapid Rituximab Infusion in Rheumatoid
Arthritis in a Single Community Practice
2377.
A Pilot Randomized Controlled Trial of a Tailored Smoking
Cessation Intervention for Rheumatoid Arthritis Patients
2378.
Ethnic Minorities with Rheumatoid Arthritis Achieve
a Meaningful Clinical Response at 12 Months Despite
Infrequent Use of Biologic Therapies
ACR POSTER INDICES
2379.
Minimal Radiographic Progression in RA Patients
Receiving Routine Care in the Espoir Early Arthritis Cohort:
Similar Prognosis According to 6 Different Remission
Criteria
2380.
Durability of First Biologic Is Not Influenced By Initial/
Early DAS28
2396.
Treat to Target in Routine Clinical Practice
2397.
Improvement of Fatigue in Patients with Rheumatoid
Arthritis Treated with Biologics: Relationship with Sleep
Disorders, Depression and Clinical Efficacy. a Prospective,
Multicenter Study
2398.
Continued Participation in a 10-Year Tight Control Treatto-Target Study in Rheumatoid Arthritis: Why Keep
Patients Doing Their BeSt?
2399.
Non-Adherence to Disease-Modifying Anti-Rheumatic
Drugs in Patients with Rheumatoid Arthritis: An Italian
Survey
2400.
Comparing a Tapering Strategy to the Standard Dosing
Regimen of TNF Inhibitors in Patients with Rheumatoid
Arthritis in Remission or with Low Disease Activity
2401.
Interrupted and Delayed Care in First Nation Patients with
Rheumatoid Arthritis: The Best Target for Therapy?
2402.
Evaluation of Perceived Self-Efficacy, Learned Helplessness
and Functional Capacity in Patients with Rheumatoid
Arthritis
2403.
From Early Arthritis Clinic to Remission Clinic: Short-Term
Outcome and Ultrasonographic-Synovitis Dynamics in
Rheumatoid Arthritis Patients in DMARD-Induced SDAIRemission during Drug-Free Follow-up
2404.
RA Patients with Inadequate Response to Oral MTX
Maintain Satisfactory Disease Control and Durable LongTerm Response When Switched to SC MTX Monotherapy
2405.
Determinants and Impact of Early Initiation of DiseaseModifying Anti-Rheumatic Drug Therapy in Rheumatoid
Arthritis
Quality of Patient- Clinician Communication in a Diverse
Cohort of Adults with Rheumatoid Arthritis
2406.
Sustained Rheumatoid Arthritis Remission and Low
Disease Activity: Analysis of 13 Years of Follow up in
Clinical Practice
Primary Non-Adherence, Associated Clinical Outcomes
and Healthcare Resource Utilization Among Rheumatoid
Arthritis Patients Prescribed Injectable Biologics
2407.
Early Treatment in Rheumatoid Arthritis and Its Effect on
Patient Outcomes
2408.
Frequency of Rheumatoid Arthritis Flares in Clinical
Practice: Analysis of a Monocentric Cohort of Patients in
Stable Remission or Low Disease Activity
2409.
Omega-3 Fatty Acids and Mediterranean Diet As
Complimentary Therapies for Rheumatoid Arthritis
2410.
Working Status and Improvements in Work Productivity
over Time in an Early Rheumatoid Arthritis (ERA) Cohort
2381.
Adherence to a Treat-to-Target (T2T) Strategy in Early
Rheumatoid Arthritis. Is It Feasible in Daily Clinical
Practice?
2382.
Adherence to Dmards in the First Six Months of Treatment
in Early Arthritis Patients; Comparing Three Adherence
Measures
2383.
The 12-Years Retention Rate of the First-Line TNF-Inhibitor
in the Treatment of Rheumatoid Arthritis: Real-Life Data
from a Local Registry
2384.
Factors Associated with Methotrexate Treatment
Duration, Including Subcutaneous Use, in Patients with
Rheumatoid Arthritis: Observations from the VA Database
2385.
Reasons for Non-Vaccination in Rheumatoid Arthritis and
Spondyloarthritis Patients
2386.
Patients’ Interpretations of Rheumatoid Arthritis Model
Disease States in a Safety-Net Rheumatology Clinic
2387.
Relation Between Disease Activity Indices and Their
Individual Components and Radiographic Progression in
Rheumatoid Arthritis: A Systematic Literature Review
2388.
DMARD Use after an Initial Acute MI Is Associated with
Reduced Risk of a Recurrent Event and Mortality
2389.
2390.
2391.
MRI Osteitis at Baseline Predicts the Development of
Rapid Radiographic Progression at 1 Year Toward Patients
with Early-Stage Rheumatoid Arthritis
2392.
Anti-Carbamylated Antibodies (anti-CarPA) Are Associated
with Long Term Disability and Increased Disease Activity
in Patients with Early Inflammatory Arthritis: Results from
the Norfolk Arthritis Register (NOAR)
2393.
Similar Improvements in Physical Function, Quality of
Life and Work Productivity Among Rheumatoid Arthritis
Patients Treated with 2 Different Doses of Methotrexate
in Combination with Adalimumab
2394.
2395.Understanding Patient Preferences Associated with the
Use of Therapies for Rheumatoid Arthritis: Results of a
Conjoint Analysis
Sustained Remission Improves Physical Function in RA
Patients Treated with Tumor Necrosis Factor Inhibitor
2014 Program Book
225
ACR POSTER INDICES
Assessing Treatment Durability of Infliximab in the
Management of Psoriatic Arthritis and Rheumatoid
Arthritis Patients in a Canadian Setting
Regime of Use of Rituximab in Patients with Rheumatoid
Arthritis in Daily Clinical Practice
2427.
Attainment of Low Disease Activity Is Predictive of
Maintenance of Disease Control upon Adalimumab
Discontinuation for Two Years Following Combination
Therapy in Japanese Patients with Early Rheumatoid
Arthritis
2413.
Similar Response Rates to Anti-Tumor Necrosis Factor and
Non- Anti-Tumor Necrosis Factor Biologic Therapies in
Ethnic Minority Patients at 6 Months
2428.
Comparative Study of Rheumatoid Arthritis Disease
Activity Indices in Two Populations of Meteor Database
2429.
2414.
Etanercept in Mono Therapy or in Combination with
MTX: Results from a Sub Analysis of a German NonInterventional Study
Seasonal Changes May Influence Activity of Rheumatoid
Arthritis
2415.
Characteristics of Rheumatoid Arthritis Patients Not
Receiving Early Initiation of Disease Modifying Therapy
2430.
Serological and Clinical Characteristics of a Large
Collection of Incomplete Lupus Erythematosus Patients
2416.
Do Patterns of Joint Swelling or Tenderness in Rheumatoid
Arthritis Patients Impact Disease Activity Outcomes and
Pain? Implications for Clinical Practice
2431.
Tai Chi and Yoga Are Effective for Improving Physical
Function in Adults with Rheumatoid Arthritis- a MetaAnalysis
2417.
Is Remission Really Achievable in EARLY Rheumatoid
Arthritis?
2432.
Nutritional Assessment in Patients with Systemic Lupus
Erythematosus and Systemic Sclerosis
2418.
Treatment Pattern and Direct Cost of Biologics for
Rheumatoid Arthritis Patients: A Real-World Analysis of
Nationwide Japanese Claims Data
2433.
Efficacy of Ketoprofen Vs Ibuprofen and Diclofenac for
Treating Pain in Patients with Rheumatoid Arthritis: A
2419.
Efficacy of Biologic Medications in Active Rheumatoid
Arthritis: A Systematic Review
2434.
Gait Instability in the Elderly: A New Dedicated outPatients Consultation
2420.
Quality Assessment of Controlled Trials Evaluating Chinese
Herbal Medicine in Patients with Rheumatoid Arthritis: a
Systematic Review
2435.
‘It’s like the Worst Toothache You’ve Ever Had’ – How
Persons with Rheumatoid Arthritis Describe and Manage
Pain in Daily Life
2421.
Patient Treatment Goals in Rheumatoid Arthritis: Results
of Focus Groups Among Rheumatologists, English and
Spanish-Speaking Patients
2436.
Analytical and Clinical Evaluation of an Immunoassay for
Estimating Immunogenicity of Infliximab and Etanercept
in Indian Population
2422.
A Tailored Approach to Reduce Dose of TNF Inhibitors
Is Equally Effective, but Substantially Less Costly Than
Standard Dosing in Patients with Rheumatoid Arthritis
over One and Two Years: A Prospective Cohort Study
2437.
Why Doesn’t Participation in Activity Increase Following
Hip or Knee Replacement?
2438.
2423.
Prevalence of Subclinical Synovitis Detected By
Ultrasound in Rheumatoid Arthritis and Psoriatic Arthritis
Patients Receiving Anti-TNF-α Therapy with Extended
Interval of Administration
A Multi-Centre Survey of Tolerability Problems for
Patients on Regular Methotrexate
2439.
Knee Joint Pathology in Patients with Rheumatoid
Arthritis and Osteoarthritis Using a Validated Ultrasound
Scoring System: A Cross Sectional Study
2424.
Comparison of Medication Use in Rheumatoid Arthritis
Patients Between University and Private Settings – Results
from Ontario Best Practice Research Initiative
2440.
Factors Influencing Health Related Quality of Life (HRQOL) for Korean Patients with Rheumatoid Arthritis
2425.
Rheumatoid Arthritis Stable Follow up Visits – 3 Month
Versus 6 Month Intervals
2441.
Prevalence and Determinants of Treatment Adherence
Among Patients with Rheumatoid Arthritis
2426.
Comparison of Patient Self-Reported and Physician
Reported Rheumatoid Arthritis Medication Use - Results
from the Ontario Best Practices Research Initiative
2442.
Aligning Ethics with Digital Health Technologies and
Shared Decision-Making: Interview Accounts of Patients
and Clinicians
2411.
2412.
226
2014 Program Book
Clinical Practice/Patent Care (ARHP)
ACR POSTER INDICES
2443.
A New Meta-Analysis on Safety of Ketoprofen Vs
Ibuprofen and Diclofenac: Risk and Benefit of Nsaids
Beyond Efficacy Meta-Analysis
2459.
Osteoprotegerin CGA Haplotype Protection Against
Cerebrovascular Complications in Anti-CCP Negative
2444.
Pharmacist-Developed Letters May Enhance Success in
Obtaining Insurer Approval for Off-Label Use of Biologics
2460.
Phospho-STAT1/3 and Gene Expression Measurement
in Circulating CD4+ T Cells As Diagnostic Tools in Early
Autoantibody-Negative Rheumatoid Arthritis
2461.
Osteprotegerin Concentrations Are Independently Related
to Established Cardiovascular Disease in Rheumatoid
Arthritis
2462.
Centrosomal Protein 70kDa Is Down-Regulated By Decoy
Receptor 3 in Specifically Rheumatoid Synovial Fibroblasts
2463.
Stromal Cell Markers Are Differentially Expressed in the
Synovial Tissue of Patients with Early Arthritis
2464.
Anti-Arthritic Effect of Tubastatin A, a Novel Histone
Deacetylases-6 Inhibitor, Is Mediated By Stabilization of
IkB Via Suppression of Ubiquitin-Proteasome Pathway
2465.
Cyclic Phosphatidic Acid (cPA) Suppresses MMP-3, a
Disintegrin and Metalloproteinase with Thrombospondin
Motifs(ADAMTS)-4, -5 and Stimulates HAS2 Expression in
Inflammatory Rheumatoid Synovial Fibroblasts Induced
with IL-1β and/or TNF-α
2466.
Increased Risk of Rheumatoid Arthritis (RA) Among
Shared Epitope-Negative (SE-) Mothers with Shared
Epitope-Positive (SE+) Children
2445.
2446.
A Distinct Profile of Circulating Microparticles Is
Associated with Disease Features in Rheumatoid Arthritis
Patients and Impairs Endothelial Functionality in Vitro
DNA Methylation Profiles That Distinguish Rheumatoid
Arthritis from Osteoarthritis in Fibroblast-like
Synoviocytes Can be Detected in Immune Cells from
Peripheral Blood
2447.
The Role of TET3-Mediated DNA Demethylation By ProInflammatory Cytokines in Rheumatoid Arthritis
2448.
DNA Methylation Analysis of Lymph Node Stromal Cells of
2449.
Microrna-346 Regulation of Follicular Helper T Cells Is
Involved in the Pathogenesis of rheumatoid Arthritis
Disease
2450.
Downregulation of Mirna-196a and Its Downstream
HOXC8 Target Gene in Rheumatoid Arthritis Synovial
Fibroblasts
2451.
Mir-155 Expression Correlates with Clinical Disease
Activity and Has Effector Function in Rheumatoid Arthritis
Therapy: Therapeutic Strategies, Biomarkers and Predictors of
Outcomes in Rheumatoid Arthritis
2452.
Protective Effect of the IL33 rs3939286 Gene
Polymorphism in the Development of Subclinical
Atherosclerosis in Patients with Rheumatoid Arthritis
2467.
2453.
High-Density Genotyping of Risk Loci in African Americans
with RA
Effectiveness and Safety of Tocilizumab in Biologics Naïve
RA Patients - Interim Analysis of PMS for Investigating
Success in Achieving Clinical and Functional Remission
and Sustaining Efficacy with Tocilizumab in Biologics-Naïve
RA Patients Study
2454.
Genetic Influences on Rheumatoid Arthritis in AfricanAmericans
2468.
2455.
IL-6 Proximal Promoter SNP rs18000795 Genotype
Strongly Correlates with Synovial Fibroblast IL-6
Expression
Stringent Criteria for Low Disease Activity and Remission
after 12 Months of Treatment, and after Treatment
Withdrawal, with Abatacept Monotherapy, Abatacept
with Methotrexate or Methotrexate Alone in Early
2469.
The Efficacy and Safety of Tocilizumab Subcutaneous
Q2W and Following Escalation from Q2W to QW Therapy
in Combination with Traditional Dmards in Patients with
Moderate to Severe Rheumatoid Arthritis at 96 Weeks
2470.
Treatment Strategy for Maximizating the Effect of
Adalimumab in Japanese Patients with Rheumatoid
Arthritis : Retrospective Analyses of Data Collected from
the Patient Treated with Adalimumab in Routine Clinical
Practice in Hamamatsu Area
2456.
Associations of Toll-like Receptor (TLR)-4 Single Nucleotide
Polymorphisms and Rheumatoid Arthritis Disease
Progression
2457.
Anti-Major Histocompatibility Complex Class I-Related
Chain a (MICA) Antibodies in Rheumatoid Arthritis
Patients with Interstitial Lung Disease
2458.
Targeting IL-6, JAK or SYK? : An Analysis of Transcriptome
Alteration in Peripheral Blood By RA Treatments
2014 Program Book
227
ACR POSTER INDICES
2471.
Effect of Teriparatide in Patients with Osteoporosis and
2472.
The First, Multicenter, Double-Blind, Randomized,
Parallel-Group Study of Certolizumab Pegol in Early
Rheumatoid Arthritis Demonstrates Inhibition of Joint
Damage Progression
2473.
Post-Marketing Surveillance of Efficacy and Safety of
Tacrolimus Add-on Therapy in Japanese Rheumatoid
Arthritis Patients Who Failed to Show an Adequate
Response to Biological Dmards : Interim Analysis
2486.
Patient-Reported Outcomes Following 12 Months
of Therapy with Abatacept (Plus Methotrexate or as
Monotherapy) or Methotrexate and up to 6 Months after
Treatment Withdrawal in Patients with Early Rheumatoid
Arthritis
2487.
Effects of Tofacitinib on Health Care Resource Utilization
and Work Productivity in US Patients with Rheumatoid
Arthritis
2488.
Relationship Between Different Clinical Measurements
and Patient-Reported Outcomes
Analysis of Early Neutropenia, Clinical Response, and
Serious Infection Events in Patients Receiving Tofacitinib
for Rheumatoid Arthritis
2489.
2474.
Efficacy and Tolerability of Subcutaneous Methotrexate
for Inflammatory Arthritis: A Retrospective Observational
Cohort Study
2475.
Multiple Approaches for Implementation of Long-Term
Efficacy: Interpretation of Certolizumab Pegol Data in
Rheumatoid Arthritis Case Study
2476.
WITHDRAWN
2477.
Integrating Treatment Goals of Physicians, Patients, and
Payers during Treatment with Golimumab in Patients with
2478.
Assessment of Structural Benefits of SC Abatacept Using
MRI in Patients with RA Who Have Failed 1 or 2 TNFs
and Correlated with Clinical Outcomes As Measured By
DAS28(ESR)
2491.
Prognostic Factors for IV Abatacept Retention in Patients
Who Have Received at Least One Prior Biologic Agent:
2-Year Results from a Prospective, International, RealWorld Study
2492.
Does Body Mass Index Impact Long-Term Retention with
Abatacept in Patients with RA Who Have Received at
Least One Prior Biologic Agent? 2-Year Results from a
Real-World, International, Prospective Study
2493.
Prediction of Remission and Low Disease Activity in
DMARD-Refractory Patients with RA Treated with
Golimumab
2494.
Persistence on Single Disease Modifying Anti-Rheumatic
Drug Therapy in US Veterans with Rheumatoid Arthritis Is
Extremely Rare
2495.
Impact of Golimumab on Physical Function and
Employability of Patients with Rheumatoid Arthritis:
5-Year Data from 3 Phase III Clinical Trials
2496.
Predictors of ACR/EULAR Boolean and SDAI Remission
in Patients with Established Rheumatoid Arthritis
Treated with Anti-TNF: An Analysis from the Prospective,
Observational, Biological Treatment Registry Across
Canada
2497.
Correlation Between Time to Switch and Clinical Response
Amplitude to Rituximab in Second Line Treatment in
Rheumatoid Arthritis Patients with Treatment Failure to
Tumor Necrosis Factor Inhibitors: 3-Year Data from Repeat
Observational Study
2498.
Characteristics of Responding Versus Non-Responding
Moderate Rheumatoid Arthritis Patients Treated with
Etanercept Plus Methotrexate
Analysis of the Clinical Sustained Response after
Retreatment with a Lower Dose of Rituximab in Patients
with Chronic Inflammatory Arthropathies
2479.Utility of Adjustment of Administration Interval in
Tocilizumab in Rheumatoid Arthritis
2480.
Is there a Difference in the Effectiveness in the Treatment
of Rheumatoid Arthritis with Rituximab when Using a
Dose of 1 or 2 Grams per Cycle? a Systematic Review
2481.
Which Factors Influence the Prescription of Tocilizumab
Alone or in Combination with DMARDs in Rheumatoid
Arthritis Patients in a Real Life Setting?: An Interim
Analysis of Safety and Efficacy at 6 Months
2482.Use of Biologic Therapy As Monotherapy in Patients with
228
2490.
2483.
Treatment Adjustment Strategy after Achieving Remission
or Low Disease Activity in Rheumatoid Arthritis : A
2484.
Adding an Initial Six-Month Course of Infliximab to an
Active Combination Treatment Is Cost Saving in WorkingAged Early Rheumatoid Arthritis Patients
2485.
Predictors of Drug-Free Remission Following Treatment
with Abatacept (in Combination with Methotrexate or as
Monotherapy) in Early Rheumatoid Arthritis
2014 Program Book
ACR POSTER INDICES
2499.
Early Response Indicator early Predicts Clinical Response
to Certolizumab in Rheumatoid Arthritis Patients
2514.
Biological Treatment for Rheumatoid Arthritis (RA): A
Fifteen Years Multicentric Overview
2500.
Genetic Variation in the TLR5 Locus Is Associated with
Anti-TNF Response Among Rheumatoid Arthritis Patients
2515.
Serum Survivin in Early Rheumatoid Arthritis
2501.
Indirect Comparison of Tocilizumab and Tofacitinib in
2516.
Reasons and Risk Factor for Discontinuation of Biologic
Agents in Rheumatoid Arthritis Patients
2502.
Ten Year Follow-up Results of Four Dynamic Treat
to Target Strategies in Patients with ACPA Negative
2517.
Long-Term Clinical, Structural, and Functional
Consequences of Not Adopting Treatment in MTX
Suboptimal Responders
2503.
Early Response to Full-Dose Etanercept-Plus-Methotrexate
Induction Therapy Predicts Sustained Remission with
Reduced-Dose Combination Therapy in Early Rheumatoid
Arthritis Patients
2518.
What Is the Level of Agreement Between Disease Activity
Indices and Response Criteria Among Rheumatoid
Arthritis Patients Treated with TNF Inhibitors?
Are Patients with Rheumatoid Arthritis Initiating a TNF
Biologic Comparable to Patients Initiating a Non TNF?
2519.
2504.
Impact of Concomitant Methotrexate on the Enhanced
Clinical Efficacy of Abatacept after 24 Weeks in
2520.
Patient, Genetic and Disease Factors Influence the
Response to the Disease Modifying Anti-Rheumatic Drug
Leflunomide
2505.
Long-Term Treatment with Tocilizumab (TCZ) Strongly
Suppresses Joint Destruction in Biologic-naïve
Patients with Rheumatoid Arthritis (RA) Regardless of
Inflammation Status
2521.
Analysis on Predictors for Long-Term Clinical Efficacies of
Golimumab in Patients with Rheumatoid Arthritis
2522.
Effect of Infliximab Dose Increase in Rheumatoid Arthritis
at Different Trough Concentrations
2523.
Are Biologic Agents Effective on the Treatment of
Secondary Amyloidosis: A Multicenter Report on Turkish
Rheumatoid Arthritis and Ankylosing Spondylitis Patients
2506.
Decrease in the Number of Peripheral Leukocytes and
Neutrophils and Increase of the Percentage of Eosinophils
at 4 Week Predict the DAS28-ESR Remission at 24 Weeks
after Administration of Tocilizumab
2507.
Is There an Autoinflammatory Component in Rheumatoid
Arthritis Associated with Better Response to Anakinra
(Kineret®)?
2524.
Smoking and Response to Rituximab in Anti-CCP Positive
and Negative Rheumatoid Arthritis – Results from an
International European Collaboration
2508.
Tocilizumab Serum Trough Levels and Its Relationship with
Disease Activity and Drug Dosage in Rheumatoid Arthritis
Patients
2525.
Infliximab Versus Conventional Combination Treatment
and Work Loss in Early RA over 7 Years: A Randomized
Trial
2509.
ADAM-10 As a Tocilizumab Treatment Predictive Factor in
2526.
2510.
Good Response to Methotrexate (MTX) and/or MTX Plus
Adallimumab (ADA): 3 Yrs Study Results in Patients with
Efficacy of Biological Therapies in Rheumatoid Arthritis:
Graphical Modeling of DAS28 Components’ Evolution over
Time
2527.
Predictors of Discontinuation of Biologic DMARD Therapy
Due to Remission in Patients with Rheumatoid Arthritis in
a National Registry
The Effect of Biological Agents on Work in Patients with
Chronic Inflammatory Arthritides: A Meta-Analysis of
Randomized Controlled Trials and Controlled Cohorts
2528.
Golimumab Therapy Retention Rates in Patients with
Rheumatoid Arthritis and Seronegative Spondyloarthritis:
Data from the Italian Lorhen Registry
Efficacy Meta-Analysis of Randomized Controlled Trials
(RCTs) of Biologics in Methotrexate-Naive Patients with
2529.
Efficacy of Infliximab, Adalimumab, and Tocilizumab Can
be Improved Under the Baseline ADAMTS5 Selection
2530.
PRE.MARK-TNF Test Based on Iga-Specific Autoantigens
Predicts Therapy Response in Rheumatoid Arthritis
Patients Treated with TNFα Inhibitors
2511.
2512.
2513.
The Monitoring of Infliximab Levels at Early Stages Can
Predict the Development of Anti-Infliximab Antibodies in
a Cohort of Rheumatoid Arthritis Patients Treated with
Infliximab
2014 Program Book
229
ACR POSTER INDICES
Sjögren’s Syndrome: Clinical Science
2531.
Risk of Venous Thromboembolism in Patients with
Sjögren’s Syndrome: A Systematic Review and MetaAnalysis
2532.
Characteristics of Primary Sjögren Syndrome in the Black
Population of Martinique
2533.Utility of the American-European Consensus Group
and American College of Rheumatology Classification
Criteria for Sjögren’s Syndrome in Patients with Systemic
Autoimmune Diseases in the Clinical Setting
2534.
Ocular Surface Temperature in Early Sjögren’s Syndrome
and Established Disease
2535.
Performance of the Ocular Staining Score (OSS) Vs. the
Van Bijsterveld Score in the Assessment of Sjögren’s
Syndrome-Related Keratoconjunctivitis Sicca
2536.
The Sjögren’s Syndrome Responder Index, a Data-Driven
Combined Endpoint, Could Detect Biologics Efficacy
2537.
Diagnostic Accuracies of Sialography and Salivary
Ultrasonography in Sjögren’s Syndrome Patients: A MetaAnalysis
2538.Ultrasound-Guided Core Needle Biopsy of the Major
Salivary Glands Is a Safe and Useful Diagnostic Tool in
the Evaluation of Suspected or Established Sjögren’s
Syndrome
230
2539.
Antibodies to Human Interferon-Inducible Protein-16
Are Present in Primary Sjögren’s Syndrome and Systemic
Lupus, but Are Rare in Dermatomyositis
2540.
Sjö™, an Advanced Diagnostic Panel for Detection of
Sjögren’s Syndrome Autoantibodies
2541.
Autoantibodies in Pediatric Sjögren’s Patients
2542.
La Positive, Ro60 Negative Subset of Primary Sjögren’s
Syndrome Is a Reality
2543.
Anti-Ro/SSA Positive Incomplete Sjögren’s Syndrome
2544.
How Does a Younger Age at the Onset of Sjögren’s
Syndrome (pSS) Influence the Clinical Presentation and
the Clinical Course of the Disease?
2545.
Risk of Cervical Root and Incisal Caries in Patients with
2546.
Metabolic Disorders Causing Fatigue in Sjögren’s
Syndrome
2547.
The Impact of Primary Sjögren’s Syndrome on Female
Sexual Function
2014 Program Book
2548.
Primary Sjögren’s Syndrome Is Associated with Significant
Cognitive Dysfunction
2549.
Renal Involvement in Primary Sjögren’s Syndrome: A
Multicenter French Study of 95 Biopsy Proven Cases
2550.
Impaired Speckle Tracking As a Marker of Subclinical Left
Ventricular Dysfunction in Patients Affected By Primary
2551.
Presence of Germinal Centers at Baseline Is Associated
with Clinical Response of Glandular Essdai Domain after
Abatacept Treatment in Primary Sjögren’s Syndrome
2552.
Effectiveness and Safety of Low-Dose Cyclosporine a in
Patients with Primary Sjögren’s Syndrome (pSS) with
Articular Involvement – Results of a Pilot Study
Treatment III
2553.
Compromised Volumetric Bone Density, Bone
Microarchitecture and Bone Strength in Patients with
Ankylosing Spondylitis: High-Resolution Peripheral
Quantitative Computerized Tomography (HRpQCT) Based
Study
2554.
Do TNF Alpha Inhibitors Have an NSAID Sparing Effect in
Real Life in Early Axial Spa? Results from the DESIR Cohort
2555.
The Effect of Co-Medication with Conventional Synthetic
(cs)Dmards on Achieving Low Disease Activity While
Persisting on Adalimumab Therapy in Patients with
Ankylosing Spondylitis/ Axial Spondylarthritis (AS)–
Analysis from the Czech Biologics Registry At
2556.
Is the Degree of NSAID Treatment in Early Axial
Spondyloarthritis a Reflection of the physician’s Diagnosic
Confidence? Results from the DESIR Cohort
2557.
Are We over-Treating with Nsaids Our Early Axial Spa
Patients? Results from the DESIR Cohort
2558.
Etanercept Increases Bone Mineral Density in Ankylosing
Spondylitis, but Does Not Prevent Vertebral Fractures
2559.
Vitamin D insufficiency and Deficiency in Two European
Cohorts of Patients with Inflammatory Rheumatic
Disorders
2560.
Sustained Improvements in Workplace and
Household Productivity and Social Participation with
Certolizumab Pegol over 96 Weeks in Patients with Axial
Spondyloarthritis, Including Ankylosing Spondylitis and
Non-Radiographic Axial Spondyloarthritis
2561.
Low Cardio-Respiratory Fitness Is Associated with
Increased Arterial Stiffness in Patients with Ankylosing
Spondylitis
ACR POSTER INDICES
2562.
The Comparative One-Year Drug Survival Rate of Tumor
Necrosis Factor Inhibitors in Patients with Rheumatoid
arthritis and ankylosing spondylitis; results from Turkbio
Registry
2577.
The Ankylosing Spondylitis Disease Activity Score More
Closely Reflects MRI Parameters of Sacroiliitis Than the
Bath Ankylosing Spondylitis Disease Activity Index in
Patients with Non-Radiographic Axial Spondyloarthritis
2563.
The Distribution of Inflammatory Lesions in the Anterior
and Posterior Structures of the Spine in Patients with
Active Ankylosing Spondylitis and the Effect of TNF-αBlockade
2578.
Disease Activity Is the Major Determinant of Quality of
Life and Physical Function in Patients with Early Axial
Spondyloarthritis. Results from the Esperanza Cohort.
2579.
2564.
Ileocolonoscopic Findings in the Korean Patients with
How Should We Calculate the ASDAS If the Conventional
C-Reactive Protein Is below the Limit of Detection? – an
Analysis in the DESIR Cohort
2565.
The Effect of DMARD Co-Therapy on the Clinical
Efficacy of Anti-TNF Medications in Patients with Axial
Spondyloarthritis
2580.
A Comparison of Baseline Characteristics and Real-Life
Effectiveness of Anti-TNF Therapy in Non-Radiographic
Axial Spondyloarthritis Versus Ankylosing Spondylitis – a
Single Center Cohort Study
2566.
Spinal Mobility in the Cervical and the Lumbar Spine
Correlates with Magnetic Resonance Imaging Findings in
Vascular Endothelial Growth Factor and C-Reactive Protein
Serum Levels Lack Predictive Value for Radiographic and
Magnetic Resonance Imaging Outcomes in Patients with
Active Ankylosing Spondylitis Treated with the Tumor
Necrosis Factor-Inhibitor Golimumab
2581.
Clinically Active Non-Radiographic Axial Spondyloarthritis
Patients Who Initially Have a Negative MRI and Normal
CRP May Develop a Positive MRI or Elevated CRP at a
Later Timepoint
2582.
Serum Levels of Bone Morphogenetic Protein-7 and
Sclerostin Are Elevated in Ankylosing Spondylitis, but Not
Linked with Structural Damage
2567.
2568.
2569.
Routine Assessment of Patient Index Data (RAPID3)
Provides Similar Information Compared to Ankylosing
Spondylitis Specific Indices: Analyses of the DESIR French
Cohort
Profiles of Switches in Patient with Ankylosing Spondylitis:
Comparing Adalimumab, Etanercept, Infliximab,
Golimumab and Certolizumab
2570.
Validation of Modified Disease Activity and Functional
Status Questionnaires in Spondyloarthritis
2571.
Disease Activity and Risk of Cardiovascular Disease in
Patients with Ankylosing Spondylitis with High and Low
Body Mass Index
2572.
Recognition of Spondyloarthritis By General Practitioners
in Daily Practice and the Effect of Education on This; A
Study with Standardized Patients
2573.
Preferences of Patients with Spondyloarthritis for the
Items of the ASAS Health Index : A Best Worst Scaling
2574.
Do Patients with Axial Spondyloarthritis (AxSpA) Perform
Enough Physical Activity? a Cross-Sectional Study of 207
Patients
2575.
Validation of the RAPID-3 Questionnaire in a Cohort of
Patients with Axial Spondyloarthritis
2576.
Diffusing Weight Magnetic Resonance Imaging May
Suggest the Treatment Strategy in Ankylosing Spondylitis
2583.Unexpected High Prevalence of Cardiac Disease in Patients
2584.
Smoking Is Not Associated with Response to TNF Blockers
in Patients with Axial Spondyloarthritis
2585.
Association of Smoking with Acute Phase Reactants and
Molecules Involved in Bone Formation in Patients with
2586.
Which Characteristics of Inflammatory Back Pain
(CBP) Forecast the Presence of Sacroiliitis on Magnetic
Resonance Imaging (MRI)? Results from the Esperanza
Cohort
2587.
Predictors of Treatment Response to Tumor Necrosis
Factor-Alpha Blockers in Spondyloarthritis: Systematic
Review and Meta-Analysis
2588.
Which Characteristics of Inflammatory Back Pain (CBP)
Forecast the Presence of HLA-B27? Results from the
Esperanza Cohort
2589.
EULAR Recommendations for the Use of Imaging in
Spondyloarthritis in Clinical Practice
2590.
Comparison of Radiographic Damage Score in Ankylosing
Spondylitis According to Tumor Necrosis Factor Inhibitor:
Observation Study of Korean Spondyloarthropathy
Registry (OSKAR) Data
2591.
Effects of Self-Management Model on the Disease-Related
Knowledge, Joint Function and Quality of Life in Patients
2014 Program Book
231
ACR POSTER INDICES
2592.
Assessment of Spondyloarthritis International Society
Endorsed Recommendations for Early Referral of Patients
Suspected for Axial Spondyloarthritis
2607.
Fatigue in Ankylosing Spondylitis: A Multivariable Analysis
Implicates Inflammation As the Key Determinant of
Disability
2593.
Patients with Non-Radiographic Axial Spondyloarthritis
and Ankylosing Spondylitis Demonstrate the Same Clinical
Disease Course over Two Years: Results from the Gespic
Cohort
2608.
Do You Assess Gastro-Intestinal Auto-Antibodies and
Symptoms in Patients with Spondyloarthritis?
2609.
Treating Axial-Spa to Target: Prevalence of Ankylosing
Spondylitis Disease Activity Score (ASDAS) Inactive
Disease in a Cohort of Patients Treated with Anti-TNFα
Agents
2610.
The Role of IL-20 in the Pathogenesis of Ankylosing
Spondylitis with Peripheral Joint Involvement
2611.
Short Term Efficacy of Tumor Necrosis Factor Inhibitors in
Patients with non–radiographic Axial Spondylarthritis and
ankylosing Spondylitis; Results from Turkbio Registry
2612.
Different Performance of the Major Disease Activity
Measures ASDAS and Basdai in Patients with Axial
Spondyloarthritis Treated with Non-Steroidal AntiInflammatory Agents – Results from a Prospective Study
2613.
Positive Spine MRI for Inflammation Predicts Radiographic
Progression in Patients with Ankylosing Spondylitis
2614.
Reliability of Electronic Patient Self-Assessment of Swollen
and Tender Joints in Psoriatic Arthritis: A Comparison
Study with B-Mode Ultrasonography, Physician and Nurse
Assessments
2615.
Preliminary Assessment of a Multi-Biomarker Disease
Activity Test for Axial Spondyloarthritis
2594.
Differences in Localization and Activity of the Entheseal
Involvement Between Non-Radiographic and Radiographic
Axial Spondyloarthritis By the Ultrasound Assessment
2595.Using Iphone Compass Application for the Assessment of
Cervical Rotation in Patients with Ankylosing Spondylitis
2596.
2597.
Impact of Repeating Imaging of the Sacro-Iliac Joints over
One Year on the Classification According the ASAS Axial
Spa Criteria of Patients
2598.
Disease Characteristics Associated with the Presence of
Dactylitis in Patients with EARLY Spondyloarthritis: Results
from Esperenza Cohort
2599.
232
Similarities and Differences Between Axial and
Peripheral Predominant Forms in patients with Early
Spondyloarthritis (SpA): Results from the Esperanza
Cohort.
Do Patients Diagnosed As Axial Spondyloarthritis (AxSpA)
Who Have Primary Inefficacy to Anti-TNF Really Have
AxSpA? a Five-Year Follow-up Study of 27 Patients with
Primary Inefficacy to Anti-TNF
2600.
Gender-Attributable Differences in Outcome of Ankylosing
Spondylitis: Long-Term Results from the Outcome in
Ankylosing Spondylitis International Study
2616.
2601.
Serum Biomarkers Associated with Changes in ASDAS and
MRI Following Treatment of Ankylosing Spondylitis with
Golimumab
Comparison of Characteristics of Ankylosing Spondylitis in
Association with Familial Mediterranean Fever with Those
of Typical Ankylosing Spondylitis
2617.
2602.
Prevalence of Subclinical Atherosclerosis in Patients
with Spondyloarthritis without Clinically Evident
Cardiovascular Disease Using Carotid Intima-Media
Thickness
No Evidence of Accelerated Atheromatosis, Increased
Arterial Stiffness or Hypertrophy in Ankylosing
Spondylitis: A Systematic Case-Control Study
2618.
2603.
Short-Term Non-Steroidal Anti-Inflammatory Drug (NSAID)
Use Induces Subclinical-Kidney-Injury in Spondyloarthritis
Patients: Urinary Biomarker Study
Impact of Ustekinumab on Active Inflammation and
Post-Inflammatory Structural Changes As Detected By
Magnetic Resonance Imaging in Patients with Active
Ankylosing Spondylitis: Results of a 28-Week, Prospective,
Open-Label, Proof-of-Concept Study
2604.
Ankylosing Spondylitis and Non- Radiographic Axial
Spondyloarthritis : the Same Syndrome or Different
Diseases? Analysis from Esperanza Cohort
2605.
Profiling Ankylosing Spondylitis Patients Likely to Respond
to NSAID Treatment
2606.
How to Classify Spondyloarthritis after a Two Year
Follow up? Results from the French Recent onset
spondyloarthritis Cohort
2014 Program Book
Epidemiology, Women’s Health, Cardiovascular and CNS
2619.
Low Socioeconomic Status (SES) As Measured By
Education Is (not) Associated with Worse Outcome in SLE:
Data from the 1000 Canadian Faces of Lupus
2620.
Mortality and Survival in Systemic Lupus Erythematosus
Patients: Trends in a Spanish Cohort from 1985 to 2013
2621.
Health-Related Quality of Life in Patients with Systemic
Lupus Erythematosus
ACR POSTER INDICES
2622.
“Systemic LUPUS Erythematosus in Spanish Males”
2623.
Treatment Patterns and Resource Utilization of Systemic
Lupus Erythematosus Patients Newly Initiating Standard
of Care: United States Commercial and Medicare
Supplemental Claims Analysis
2624.
Impact of Provider Specialty on the Diagnosis and
Management of Systemic Lupus Erythematosus in the
American Indian/Alaska Native Population
2639.
Coronary-Artery Atherosclerosis in Males with Systemic
Lupus Erythematosus
2640.
Prevalence and Predictors of ECG Cardiovascular
Abnormalities in Lupus Patients
2641.
Cardiac Magnetic Resonance Imaging in Systemic Lupus
Erythematosus
2642.
Risk of Cardiovascular Events in Patients with Cutaneous
Lupus Erythematosus: A Population-Based Study
2643.
Angiogenic and Antiangiogenic Factors in Patients with
2625.
Work Productivity in Systemic Lupus Erythematosus:
Relationship with Clinical Features
2626.
Relationship of Socio-Demographic and Disease Factors
with Loss-to-Follow-up and Appointment Noncompliance
in Indigent Patients with Systemic Lupus Erythematosus
2644.
2627.
Comparison of Disease Characteristics and Organ Damage
in Patients with Juvenile and Adult-Onset Systemic Lupus
Erythematosus in Large Cohort from Turkey
Carotid Intima-Media Thickness and Plaque in Mexican
Mestizos with Systemic Lupus Erythematosus: A CaseControl Study
2645.
2628.
Risk of Cancer Is Not Increased in Patients with Cutaneous
Lupus Erythematosus: A Population-Based Study
Long-Term Efficacy and Safety of Pulse Cyclophosphamide
for Neuropsychiatric Systemic Lupus Erythematosus: A
Two-Centre Experience
2646.
2629.
Childhood-Onset and Adult-Onset Systemic Lupus
Erythematosus: Distinctions in an Underserved Ethnic
Minority Cohort
Mood Disor

2014 ACR/ARHP Program Book

Transcription

Similar documents

Do you have joint pain? It could be Rheumatoid Arthritis.

Rheumatoid Arthritis - Arthritis New Zealand

Biologics in Rheumatoid arthritis… Where are we 15 years later?

Olbas Analgesic Salve Sales Sheet

THERAPY in RHEUMATOLOGY

pain killer suggestions

Seronegative Spondyloarthropathies

Why do we struggle with the diagnosis?

SELENA-SLEDAI* A TOOL TO ASSESS DISEASE ACTIVITY IN